<SEC-DOCUMENT>0000950170-23-005832.txt : 20230302
<SEC-HEADER>0000950170-23-005832.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302161648
ACCESSION NUMBER:		0000950170-23-005832
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Longboard Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001832168
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				845009619
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40192
		FILM NUMBER:		23699152

	BUSINESS ADDRESS:	
		STREET 1:		4275 EXECUTIVE SQUARE
		STREET 2:		SUITE 950
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		619-592-9775

	MAIL ADDRESS:	
		STREET 1:		4275 EXECUTIVE SQUARE
		STREET 2:		SUITE 950
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lbph-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-02T14:53:22.5983+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:lbph="http://www.longboardpharma.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9966dab8-f3b5-4022-bcb9-d2650d18a5da" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_56ed215b-7913-48c7-bad3-4df734060549">P3Y</ix:nonNumeric><ix:nonNumeric id="F_4dfc8584-5325-43eb-b80f-dcd0108315f4" name="dei:AmendmentFlag" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d">false</ix:nonNumeric><ix:nonNumeric id="F_2c59c8cc-00ea-404f-95e9-edc59dc884a5" name="dei:EntityCentralIndexKey" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d">0001832168</ix:nonNumeric><ix:nonFraction id="F_7074996f-aa33-408c-a854-e306fcd2dcfc" name="us-gaap:CommitmentsAndContingencies" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_3a5bd633-6fb2-4428-91ac-efb4e0c66392" name="dei:CurrentFiscalYearEndDate" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d">--12-31</ix:nonNumeric><ix:nonNumeric id="F_c1171003-0a4e-4fc3-897f-9cf0a00e25b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_6490df2c-634d-4037-be30-74e94250a14c">P1Y</ix:nonNumeric><ix:nonNumeric id="F_65bc4d84-441c-43ae-adc4-890075daa0a2" name="dei:DocumentFiscalPeriodFocus" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d">FY</ix:nonNumeric><ix:nonFraction id="F_75379c9c-6922-449b-9b8b-dd32eeaad626" name="us-gaap:CommitmentsAndContingencies" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lbph-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_a6fbcb62-1dd5-47e8-a5f0-a9811e2e702b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_396dcdce-0d58-40b6-bfc6-6c19ad7ef2d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_542f2c4a-2e6b-42f0-8322-3069af427f7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db5b19d0-862e-49e9-b69a-8b019f65a709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41221969-e7b7-45c7-916d-09ca02aa8b4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_288ded8c-213e-400a-8676-efb385f835af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b4cba7f-1def-41a7-8c96-7470a5736a61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6490df2c-634d-4037-be30-74e94250a14c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8a21ac0-4ab6-4676-b445-ba6f8022ca4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1515ae5b-ea8a-4cfb-8646-520a57119b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fb4ce3e-c646-46e9-a87a-ec14ffdb12ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d29e8ef9-ee88-456f-b2dd-f017a70b32f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56ed215b-7913-48c7-bad3-4df734060549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_408b138b-5567-4c0d-8740-e0f77b39b6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9519f058-65b9-4a77-993f-c530aca0ec5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b846d527-268f-4a88-a431-c7de28a3105b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31b36330-7551-4a6c-b015-e29fcadaa3ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c17c66e-3873-4eff-9ad7-cbee76e03837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_708a2984-e296-43ff-8866-08ed7b02f589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f6a227c-60ec-49a6-8cdd-04c84137d99d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba895260-3a97-4fca-9f2e-da37a4f7379e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_341fea9a-781e-4a09-8de8-80cfcb42280e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_974c0b74-b247-493a-a244-61954bd74ea0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35559507-1949-4257-b3c7-aa78f7685bfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c2552fb-8de3-4abb-af54-8eaa29d393c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74af52ba-c383-42f9-b16d-f0ae6869106e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c36fe1a1-d21f-4b74-a586-0129d93b4a19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8ccaab1-2bd3-458a-8b03-8557b629abff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0e46809-eb85-4065-bb2f-e5ee4eca223d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1cb02383-4a83-4256-897d-6beb9cf7f359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dff02006-cd88-4a9f-b084-06afef117c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b72f156f-3735-4e2b-85b3-f2d14f32ace8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7408153-655c-4c91-a796-44b1c9e2b6bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_351fd3fe-1bac-41ec-aaee-86835367c6a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2387a101-f4f7-41ac-81ac-f6f8c20ae797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3f38f3c-0e13-4518-80d3-a72bb118157d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8180cb1-d339-43ce-8382-ffb65f743b36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_543a9b51-1efa-42be-8dd4-628dbc709107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53dd140c-ac6e-4f56-8b33-5aa2379a8262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f4f6d27-b781-451e-928f-7197f0c3b0a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a865a91f-b26b-471a-990b-888ae5f1a037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9891fa5-a5a6-46ca-ab8f-679aad15f810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e02f99d-7c5e-4870-8e5b-0f199407f23f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40404be9-80f7-4dc1-b501-800029d9ebce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8be4e204-080b-4434-8ee1-a698bdb48ced"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f18a6a6-d98f-4e05-b791-6e86ed836955"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe3381e4-0776-4a65-882e-c5998ec43929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e2350c3-4151-47e7-8025-d36e129778e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7cb4cfe-7014-4ddf-b9bf-2f0c02907348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3eeb2093-348a-4291-bc28-b0dd5ac681be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5c63294-9633-482f-83e8-25fa79adec30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bac860ed-4260-4d2b-aaa0-2cf0b6ff87f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_605c1392-d2f6-4361-a5a7-62e125b3d648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_701bf585-2e81-4356-a0ca-8b96a608fa6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c563b15e-dc26-4b32-8128-0eb744b0ea45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27e2ac14-7028-40bd-adb2-ee9d7609e0b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e460be53-bb93-4714-a2f3-98129e137c72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:VotingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5f0dc44-7d37-4e54-8447-edb5ba753a90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7302ab2c-5265-4951-b1f5-570da21cd701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_316ea6c1-7da7-4c8b-98b3-6abc844f5486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cac615bb-7672-44e1-90ae-9ae47c52b057"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70566aaa-8ddd-488f-8329-70945439bec9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e064b44-0ba6-4451-b69e-017e6f114799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_092f0ada-7a1d-48a7-a337-44d3d7397cba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6f25d12-90a1-4bda-b22f-fb58f13cbf4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a38ddbe-fed7-4742-ab7b-2216e168c7ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f36635ab-29c5-4e22-a6be-fcbab49127d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53b98a5d-b6cc-435d-a362-2f3c9ec191b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa63f794-52c0-4d53-92d9-a98e8d59cf61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa114e73-9d3e-4367-b67d-0376849d85a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48d2c5e1-2f02-4441-bec9-1183eabb3c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ffd1420-ee39-450c-bf5c-212f9be25ac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f66a237-edb9-4f7a-a43e-d837a3fc0485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_097b4d4d-1926-4a4a-8cc2-59de0584c1ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cec91faf-30a3-4e32-832f-b145d4c6a42a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:NonVotingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be512020-51df-4a10-b5c1-f8941f57b2b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c34bb4d2-986f-4c99-8052-d48376f6db2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77aa498b-d2ae-4aea-ba96-b80a84ca1ab4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b7a9061-a201-4231-855f-78dd8445bc9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a748f73-8881-44ab-8a19-7b222ef02cd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1282f9df-89a7-4f4e-9c7a-cb95e8ead303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d4f20c8-e119-4763-a167-6957a1d2975c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f374945-0780-451f-9899-e3095382578c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8814bdd7-1687-482a-bc89-42533bc5d148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45ad8322-a85c-453a-9600-e04bab154cf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76c0819f-9885-4686-b0fe-6c11ff7e48b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15377397-0660-4b11-971f-4f76f43bcec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78f4b339-ebd9-40c0-a799-bb28950ec2e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2da7e87-edb0-45d0-b6f2-541ed90e5347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd718034-3502-4331-8733-465c9d758bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_115b4147-e78e-43dc-81da-9e776c6fefa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1111d63f-8f4d-4079-a133-a11d3aa8b573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_355af628-daf1-4971-8c16-cbb53131df03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46857555-d570-4cd4-ae8b-3c59794bbe00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_997cf810-2610-4985-8384-a99e8aea8da6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e8da0f5-7411-4acd-b359-d2226605885a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5baa7a2f-9417-41f3-897c-6e8e7fb9c734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f3ce05b-630d-43cb-8922-6a4a7d3fe473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_379bd6b7-5319-4b15-8167-d1c5f35d5101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001832168</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Securities"><xbrli:measure>lbph:Securities</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e990f497-5e08-4c9a-9233-67ed6280fe2d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6afaab35-7c35-4451-a2c4-f3e27d3cd6ea" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1013e482-47bb-4c7f-bea5-2790b4302567" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7068c631-35dd-4ff9-a6a3-b4de2e74db78" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4657c7e6-cf56-47ff-b150-1fc89e2b2c35" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e641f589-f7e4-403c-95f4-be4f6d795390" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-40192</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1ab7fe3d-3df5-4265-ae21-8347140c70a4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1cca0e1d-4102-4958-a7b9-5db20d3f0290" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_351c3cfa-f374-49b1-adcf-d07143e07fdc" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84-5009619</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f3c80a4-c4b6-4c44-8d5f-9de8c96022a8" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4275 Executive Square</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e370db2-a75d-4d04-ba60-32515068821b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 950</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3edd3577-5ab3-49b6-a1fe-f95ff912ba43" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1a201417-67c4-430d-99ff-6a533f29e3b2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5555366c-e091-453f-bbf8-8164062a9c29" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92037</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2d795a85-8b2f-4434-a988-637221dd2381" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">619</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4e5ff524-ce44-4ceb-91a9-da8681de1c26" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">592-9775 </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_232357ba-2726-4952-9cf1-cc95594fbee2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d71c57c-43da-4e8c-8ec9-5a17e9f69db0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LBPH</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e472eb73-4046-41ab-9b95-e03a04db05e0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa902150-edba-46e5-a4f5-a56bdfc466b0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5bfa1f27-4241-4536-b9cf-1d3946709dac" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_17b986a8-5c40-4d40-8745-1efc6107201f" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_073754b8-fe1e-4444-86c9-1e76a087feed" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d7398aec-8a24-41eb-9944-caa869285dc1" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0283d1b1-ee23-4928-9ba1-a2988a399d6c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_df8cf9e3-bba0-4f41-9c17-e4bda8cb4dc4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f805dd30-dc70-4c5e-8708-c6c0b10bf008" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16551218-d242-4cdc-820d-6ba646c9c303" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on June 30, 2022, was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10e95754-e313-4b05-b6af-04671528fa60" contextRef="C_b8a21ac0-4ab6-4676-b445-ba6f8022ca4b" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">52,100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 28, 2023, the registrant had </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f831739-33b5-4969-af92-f6dae53984ef" contextRef="C_77aa498b-d2ae-4aea-ba96-b80a84ca1ab4" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">22,965,350</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, $0.0001 par value per share, outstanding, comprised of 19,335,950 shares of voting common stock, $0.0001 par value per share and 3,629,400 shares of non-voting common stock, $0.0001 par value per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2479afd-9781-490b-82a3-61d295677b3f" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the registrant's Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in May 2023, which will be filed with the Securities and Exchange Commission on or before May 2, 2023.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.259%;"></td>
    <td style="width:16.657%;"></td>
    <td style="width:12.204%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:13.343%;"></td>
    <td style="width:25.537%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Firm Id:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a000d2e8-9790-4635-b0f7-58cb8cb3f1b3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Name:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b01ecaf7-cb8c-4824-b6f1-d90e8475c31b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KPMG LLP</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor Location:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c09360da-5f72-497f-97a9-d350e8215d2b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Diego, CA</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:1pt solid;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.093%;"></td>
    <td style="width:82.824%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#special_note_regarding_forward"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY RISK FACTORS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#disclosures_regarding_foreign_juris"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item16_form10ksummary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="special_note_regarding_forward"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIAL NOTE REGARDING </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K (this Annual Report) contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements, which speak only as of the date they are made and are not guarantees of future performance. In some cases, you can identify forward-looking statements by words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or the negative or plural of these words or other comparable terminology. These forward-looking statements generally relate to future events or our future financial or operating results and may include, but are not limited to, statements about:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our plans to research, develop and commercialize our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the initiation, progress, success, cost and timing of our clinical trials and product development activities;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability and timing to advance our product candidates into, and to successfully initiate, conduct, enroll and complete, clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the performance of third parties in connection with the development and manufacture of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size and growth of the potential markets for our product candidates and our ability to serve those markets;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential scope, duration and value of our intellectual property rights;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability, and the ability of our licensors, to obtain, maintain, defend and enforce intellectual property rights protecting our product candidates, and our ability to develop and commercialize our product candidates without infringing the proprietary rights of third parties;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit and retain key personnel;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effects on our operations of general political and economic conditions, including the COVID-19 pandemic, the invasion of Ukraine by Russia, economic slowdowns, recessions or market corrections, inflation, rising interest rates and tightening of credit markets resulting from the pandemic, the conflict in Ukraine or another cause; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other risks and uncertainties, including those described under Part II, Item 1A, &#x201c;Risk Factors&#x201d; of this Annual Report.</span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any forward-looking statements in this Annual Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A, &#x201c;Risk Factors&#x201d; of this Annual Report. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context otherwise indicates, references in this Annual Report to the terms &#x201c;Longboard&#x201d;, the &#x201c;Company&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d;, and &#x201c;us&#x201d; refer to Longboard Pharmaceuticals, Inc. and references to our &#x201c;common stock&#x201d; refers to our voting common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="summary_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUMMARY OF RISKS AS</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SOCIATED WITH OUR BUSINESS</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the risks that we face. Additional discussion of the risks listed in this summary, as well as other risks that we face, are set forth under Part I, Item 1A, &#x201c;Risk Factors&#x201d; in this Annual Report. Some of the material risks associated with our business include the following:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited operating history, and we have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. The effects of macroeconomic conditions and geopolitical events, including economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets caused by COVID-19 or another pandemic, the conflict in Ukraine or otherwise, may limit our access to capital. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are early in our development efforts and have only one product candidate, LP352, in early clinical development. All of our other product candidates are in the preclinical or research stage. If we are unable to advance our product candidates in clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical and preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of prior clinical trials and early preclinical studies and clinical trials of our product candidates are not necessarily predictive of future results.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have multiple product candidates in our pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The regulatory approval processes of the U.S. Food and Drug Administration (FDA) and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we estimate, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 has impacted and could continue to adversely impact our business. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. Our stock market price may be negatively affected if our principal stockholders and management sell some or all of their stock.</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We depend on intellectual property licensed from third parties, including Arena Pharmaceuticals, Inc. (Arena), and the failure by us or our licensors to protect the licensed intellectual property or the termination of our license could result in the loss of significant rights, which would harm our business. </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PAR</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of world-class GPCR research. Arena was purchased by Pfizer, Inc. (Pfizer) on March 11, 2022 and is now a wholly-owned subsidiary of Pfizer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently focused on developing the following product candidates in our pipeline:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352, an oral, centrally acting, 5-hydroxytryptamine 2C receptor subtype (5-HT2C) superagonist, currently in a Phase 1b/2a clinical trial (the PACIFIC Study) expected to evaluate 50 participants ages 12 to 65 years old with developmental and epileptic encephalopathies (DEEs), which may include Dravet syndrome, Lennox-Gastaut syndrome (LGS), tuberous sclerosis complex (TSC), CDKL5 deficiency disorder (CDD), SCN2A-related disorders, among others, with study enrollment expected to be completed in the first half of 2023 and topline data expected in the second half of 2023; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator, for which we anticipate initiating a Phase 1 clinical study in healthy volunteers in the first half of 2023 and anticipate topline single ascending dose (SAD) data in the second half of 2023.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352, our most advanced product candidate, is a potential best-in-class serotonin receptor agonist anti-seizure medication (ASM) for DEEs. LP352 has shown no measurable impact on 5-HT2B and 5-HT2A receptor subtypes in preclinical studies to date. 5-HT2B and 5-HT2A receptor agonism have been associated with significant adverse side effects, including valvular heart disease and pulmonary arterial hypertension in the case of the 5-HT2B receptor, and euphoria, hallucination, and dissociation in the case of the 5-HT2A receptor. LP352 has the potential to be a clinically differentiated 5-HT2C superagonist for patients with DEEs, a group of severe early-childhood onset epilepsies characterized by refractory seizures and developmental delay and/or regression. Certain compounds in the 5-HT2C agonist class, including FINTEPLA and lorcaserin, have been shown to produce clinical benefit in epilepsy patients, although the side effect profiles of available non-selective 5-HT2 therapies may limit their use due to their activity on receptor subtypes 5-HT2B and/or 5-HT2A. We believe LP352&#x2019;s potential for high selectivity and novel chemistry may reduce seizures and lead to differentiated non-seizure outcomes in DEE patients, as well as overcome the known or perceived safety limitations of available drugs in the 5-HT2 class.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also developing LP659, a centrally acting, S1P1,5 receptor modulator for which aberrant modulation has been shown to be involved in a wide range of neurological diseases. Based on its novel chemistry, potential for high selectivity for specific subtypes of GPCRs and favorable blood-brain-barrier penetration, we believe LP659 has the potential to address multiple inflammatory neurological conditions. LP659 was designed by Arena to have more optimized pharmacology and pharmacokinetics (PK) for its intended S1P receptor subtypes, compared to other known compounds. We believe this potential selectivity and specificity could result in a superior profile in the clinic compared to drugs that may not fully engage the intended GPCR target, may cause off-target activity, or may be associated with other undesirable effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates are targeted towards specific GPCRs. GPCRs mediate cell-to-cell communication in humans, and approximately 40% of prescription drugs currently on the market target mainly GPCRs, making GPCRs a highly validated class of drug targets. Our GPCR product candidates are designed to increase the likelihood of the desired pharmacology and PK and minimize the risk of off-target effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides an overview of our product candidates currently in development:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img8619836_0.jpg" alt="img8619836_0.jpg" style="width:720px;height:250px;" />&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing LP352, an oral, centrally acting, 5-HT2C superagonist for DEEs and other epileptic disorders. LP352 is the only 5-HT2C receptor agonist being dose optimized specifically for DEEs, a group of severe early-childhood onset epilepsies characterized by refractory seizures and developmental delay and/or regression. These diseases are often progressive and resistant to treatment. DEEs encompass a diverse range of over 25 syndromes, of which only four currently have FDA-approved therapies. We believe that LP352 could be a treatment for individuals with DEEs where no options are available and a potentially safer, more efficacious, easy to add-on treatment option for individuals with syndromes where current therapies are inadequate.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following diagram illustrates the current DEE landscape:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img8619836_1.jpg" alt="img8619836_1.jpg" style="width:720px;height:366px;" />&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 selectively targets the 5-HT2C receptor, which has been shown to upregulate the release of gamma-aminobutyric acid (GABA), a principal neurotransmitter in the brain. This release of GABA increases the threshold for neuronal hyperexcitability, and decreases the likelihood of seizure occurrences. We believe LP352 has the mechanistic potential to reduce seizures in a broad number of DEEs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We initiated our first clinical trial in patients with DEEs (the PACIFIC Study) in the first quarter of 2022. We plan to evaluate 50 patients, ages 12 to 65 years old, with a range of DEEs, across sites in the United States and Australia. Topline data is expected in the second half of 2023. In addition, we have conducted multiple Phase 1 clinical trials in healthy volunteers with LP352, and will continue to conduct such trials to further explore the potential of LP352.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP659</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing LP659, a centrally acting, S1P1,5 receptor modulator for inflammatory neurological conditions. LP659 was designed for optimized pharmacology, PK and engagement of S1P1,5, which may lead to improved efficacy and safety. LP659 was designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which may be associated with more serious, off-target cardiac, pulmonary, and cancer-related effects. Aberrant S1P receptor modulation has been shown to be involved in a wide range of neurological diseases, including multiple sclerosis, lupus, Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease. Preclinical data demonstrated an initial dose-dependent decrease in disease progression over 17 days in a mouse model of demyelinating disease. LP659 rapidly reduced circulating lymphocytes, which returned to baseline after its clearance. We believe LP659 has high oral bioavailability with a direct impact on CNS glial cell S1P receptors. We anticipate initiating a Phase 1 clinical trial in healthy volunteers for LP659 in the first half of 2023. Topline SAD data is expected in the second half of 2023.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Company History and Team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were established in January 2020 as Arena Neuroscience, Inc., a wholly owned subsidiary of Arena, based in San Diego, California. We changed our name to Longboard Pharmaceuticals, Inc. and launched as an independent company in October 2020. Building on Arena&#x2019;s 20-year history in discovering, developing and optimizing GPCR therapies, we believe we are well positioned to execute our clinical development programs. Our current product candidates LP352 and LP659 were designed by Arena to have distinct chemistry and therapeutic profiles from Arena&#x2019;s other product candidates with similar mechanisms of actions. Namely, LP352 was designed to be centrally acting and a more specific and selective 5-HT2C subtype receptor agonist than lorcaserin, and LP659 was designed to be a centrally acting S1P1,5 receptor modulator with differentiated selectivity and blood brain penetration compared to etrasimod (an S1P1 receptor modulator that is Arena's lead product candidate and the subject of an New Drug Application (NDA) submission accepted for review in December of 2022 following Arena's acquisition by Pfizer Inc. (Pfizer)).</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a License Agreement (Arena License Agreement) with Arena, pursuant to which Arena granted us an exclusive, royalty bearing, sublicensable, worldwide license to develop and commercialize LP352, LP659, LP143 and certain 5-HT2A compounds (pharmaceutical products containing any such product candidates, the Licensed Products). In January 2022, we amended the Arena License Agreement to add an additional program, and in September 2022 we further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to develop therapies targeting well-characterized receptor pathways with optimized pharmacology and PK properties to transform the lives of patients with neurological diseases, initially focused on rare neurological diseases. Key elements of our strategy to achieve this goal include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Advance our lead program LP352 through clinical development and approval in DEEs. There are only treatment options for four out of the over 25 DEEs, currently. Additionally, existing treatment options for these rare neurological diseases have significant limitations, and, if approved, we believe LP352 would represent a potential therapeutic advancement for patients. </span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Continue preclinical development of LP659, an S1P1,5 receptor modulator, across a range of neurological diseases and progress into clinical development. We expect to initiate a Phase 1 clinical study in healthy volunteers in the first half of 2023 and anticipate topline SAD data in the second half of 2023. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identify additional product candidates, including those that we currently hold rights to, and expand current candidates into additional neurological diseases. We see potential for our current product candidates to be evaluated in clinical trials outside of their initial indications and will evaluate additional indications to maximize the potential of our pipeline. We also plan to continue to identify and develop additional novel product candidates that align with our strategy.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Explore strategic collaborations to maximize the value of our product candidates. We plan to explore collaborations opportunistically to maximize the value of our pipeline. We intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LP352, an oral, centrally acting, 5-HT2C superagonist</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing LP352, an oral, centrally acting, 5-HT2C superagonist for DEEs and other epileptic disorders. LP352 is designed to selectively target 5-HT2C, which has been shown to upregulate the release of GABA, a principal inhibitory neurotransmitter in the brain. The release of GABA increases the threshold for neuronal hyperexcitability and decreases the likelihood of seizure occurrence. We believe LP352 has the mechanistic potential to reduce the frequency of seizures in Dravet syndrome and LGS as well as a broader epilepsy population. We have conducted multiple clinical trials in healthy volunteers with LP352. We initiated the PACIFIC Study in patients with DEEs in the first quarter of 2022 and expect to have topline data in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Background on Epilepsy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Epilepsy covers a broad range of disorders and is characterized by spontaneous and recurrent seizures, or bursts of neuronal hyperactivity. Seizures are caused by a disrupted balance between excitatory and inhibitory signaling at the synaptic level. Excitatory synaptic activity is normally regulated by inhibitory interneurons, but disruptions to this regulatory process can result in hyperexcitability. Common aberrations include mutations to ion channels or neurotransmitter genes or proteins that regulate signaling, such as GABA, and disruptions lead to the signaling aberrations characteristic of epileptic disorders. For example, Dravet syndrome is characterized by mutations in the sodium ion channel, the ion channel critical for the generation and propagation of action potentials in neurons, and which ordinarily plays a crucial role in inhibitory signaling.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview of the Forms of Epilepsy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Epilepsy spans all age groups and in many cases is debilitating, with a large portion of patients resistant to pharmacologic treatment, underscoring a large unmet need. Epilepsy is currently estimated to affect up to 1.2% percent of the U.S. population or approximately 3.4 million individuals, with roughly 150,000 new cases diagnosed each year. We are initially focused on DEEs, which are a group of severe early childhood-onset epilepsies characterized by refractory seizures and developmental delay and/or regression and include Dravet syndrome and LGS, among others, but the 5-HT2C pathway has been implicated in a broader set of epilepsies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dravet Syndrome - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dravet syndrome is an early childhood-onset CNS disease that results in severe epileptic seizures typically occurring within the first year after birth. Incidence for Dravet syndrome is approximately 1:15,000 in the United States, and 90% of the associated mutations are de novo (not passed from a parent). Mortality rate for Dravet syndrome patients is higher than general epilepsy patients, with a rate of 15-20% by adulthood. The disease is genetically linked, with 70% to 85% of cases characterized by mutations in the SCN1A gene. Mutations cause defects in the function of the sodium ion channel. Seizures due to Dravet syndrome are typically difficult to control and require life-long treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lennox Gastaut Syndrome - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LGS is a severe form of childhood-onset epilepsy with prevalence of approximately 1:7,000 in the United States. The age of onset is typically between three and five years and affected children typically experience cognitive dysfunction, leading to developmental and behavioral problems. LGS is characterized by multiple seizure types, with the most common associated seizures being tonic and atonic seizures. Seizures due to LGS are difficult to control and generally require life-long treatment. The pathophysiology of LGS is less known than Dravet syndrome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Tuberous Sclerosis Complex (TSC) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- TSC is a genetic disorder that causes tumors to form in many different organs, primarily in the brain, eyes, heart, kidney, skin and lungs. The aspects of TSC that most strongly impact quality of life are generally associated with the brain: seizures, developmental delay, intellectual disability and autism. Current estimates place TSC-affected births at 1:6,000 in the United States. Nearly 1 million people worldwide are estimated to have TSC, with approximately 50,000 in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CDKL5 Deficiency Disorder (CDD)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2013; CDD is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene, and this can manifest in a broad range of clinical symptoms and severity. The hallmarks are early-onset, intractable epilepsy and neurodevelopmental delay impacting cognitive, motor, speech, and visual function. Although rare, the occurrence is believed to be approximately 1:40,000 -60,000 live births in the United States, making it one of the most common forms of genetic epilepsy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Current Treatment Paradigm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEEs are commonly treated with multiple combinations of anti-epileptic drugs (AEDs) though physician preference for administered therapies differs across different epilepsy types. Currently available AEDs have limited long-term efficacy with many patients cycling through multiple lines of treatment to try to optimize efficacy. Non-pharmaceutical therapies for epilepsy patients include a ketogenic diet, vagus nerve stimulation (VNS), and surgery for some patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table is illustrative of the typical treatment paradigm for DEEs:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img8619836_2.jpg" alt="img8619836_2.jpg" style="width:720px;height:288px;" /></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dravet syndrome and LGS are two types of epilepsies that are difficult to treat given that most patients are refractory to antiseizure medications. The seizures for a vast majority of these patients remain uncontrolled and patients typically require multiple lines of treatment. FDA approved drugs in Dravet syndrome include Epidiolex</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (cannabidol), FINTEPLA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (fenfluramine) and DIACOMIT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (stiripentol). Epidiolex is also approved in LGS and TSC. Ztalmy is approved for CDD. Despite these treatments being available, we believe a significant unmet medical need remains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Background on GABA and Neurotransmission</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GABA is a principal neurotransmitter in the brain and binds to receptors inside and outside the synaptic gap. GABA plays key roles in neuronal inhibition, and reduction of GABA levels has been shown to result in a decline of this inhibition. Lack of GABA-mediated inhibition subsequently leads to the chronic activation of post-synaptic neurons characteristic of seizures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5-HT2 Receptors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5-HT receptors, or serotonin receptors, are widely expressed in neural networks. Serotonin plays a key role in modulating neurotransmission, as agents elevating extracellular serotonin levels have been shown to inhibit focal and generalized seizures while agents reducing serotonin levels have been shown to lower the threshold for seizures. To date, 14 receptor subtypes of 5-HT receptors have been characterized and are grouped into seven classes. The two main classes are 5-HT1 and 5-HT2. 5-HT2 receptors are G-coupled membrane proteins that are distinguished by their function of increasing intracellular calcium levels (Ca2+) and activation of protein kinase C. Three subtypes exist: 5-HT2A, 5-HT2B and 5-HT2C, with the 5-HT2A and 5-HT2C receptor subtypes primarily expressed in the CNS and 5-HT2B primarily expressed in the peripheral nervous system. All subtypes have been shown to modulate neurotransmission, though the 5-HT2B receptor has been implicated with valvular heart disease and pulmonary arterial hypertension and the 5-HT2A receptor subtype has been implicated with hallucinations and mild to severe anxiety.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5-HT2C is one of the many binding sites for serotonin and is expressed on GABAergic, glutamatergic, and dopaminergic neurons. Multiple preclinical studies have suggested that 5-HT2C plays an important role in the inhibition of seizures. For example, in a knockout mouse model, mice missing the 5-HT2C receptor subtype were shown to have a lower threshold for seizures and experienced spontaneous convulsions. Preclinical models suggest that activation of 5-HT2C regulates GABA and glutamate pathophysiology seen in seizure disorders. Excitatory glutamate release is directly and indirectly regulated by 5-HT actions on GABA interneurons and pyramidal neurons. Research proposes that neuronal hyperexcitability occurs during the transition to seizure when excitatory glutamatergic activity increases while inhibitory GABAergic synaptic input is weakened. It is thought that 5-HT2C agonists, acting on GABA interneurons, inhibit excitatory glutamatergic activity, thereby decreasing neuronal action potential firing and downstream electrical activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This downstream electrical activity is illustrated in the below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img8619836_3.jpg" alt="img8619836_3.jpg" style="width:443px;height:384px;" />&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 5-HT2 class and 5-HT2C subtype have additionally been shown in the clinic to reduce seizure frequencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FINTEPLA (fenfluramine) - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FINTEPLA, a 5-HT2 receptor agonist with activity on 5-HT2A, 5-HT2B and 5-HT2C receptors, was initially developed as monotherapy treatment for adult obesity as well as in combination with phentermine (fen-phen). Later, however, reports were published documenting cases of valvular heart disease and pulmonary arterial hypertension, causing the drug to be pulled from the market in 1997. More recently, Zogenix, Inc. (Zogenix) began developing fenfluramine for Dravet syndrome, LGS, and other rare epilepsies using lower doses of fenfluramine. In June 2020, the FDA approved fenfluramine for the treatment of seizures associated with Dravet syndrome. Approval was based on data from two randomized, double-blinded, placebo-controlled Phase 3 clinical trials, as well as safety data from an open-label extension trial in which patients received FINTEPLA for up to three years. Patients administered the therapy demonstrated significant reductions in monthly convulsive seizure frequency compared to placebo. However, the FDA placed a boxed warning in FINTEPLA&#x2019;s label noting an association between serotonergic drugs with 5-HT2B agonist activity, including fenfluramine, and valvular heart disease and pulmonary arterial hypertension. FINTEPLA is available only through a restricted distribution program called the FINTEPLA REMS program, in which prescribers and patients must be enrolled. Cardiac monitoring via echocardiogram is required pretreatment, during treatment and after treatment with FINTEPLA. In June 2022, the FDA approved fenfluramine for the treatment of seizures associated with LGS. Zogenix was acquired by UCB in June 2022 for approximately $1.9 billion.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lorcaserin</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> - Lorcaserin, a 5-HT2C agonist, was discovered by Arena, approved by the FDA for weight management, and marketed as BELVIQ by Eisai Inc. Lorcaserin was withdrawn from the market at the request of the FDA following the FDA&#x2019;s analysis of the CAMELLIA-TIMI 61 clinical trial, for which patients in the lorcaserin group demonstrated a numerically higher but not a statistically significantly higher rate of total cancer diagnoses (7.7% vs 7.1% placebo). Based on the results of this clinical trial, the FDA concluded that the risks of lorcaserin outweigh the benefits, and requested that lorcaserin be withdrawn from the market for the approved indication of weight management in February 2020. The FDA authorized an expanded access program for patients with Dravet syndrome to continue to receive lorcaserin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lorcaserin has demonstrated the potential to reduce seizures in patients with Dravet syndrome and refractory epilepsies. A National Institutes of Health funded study conducted at the University of California, San Francisco showed that several 5-HT receptor modulating compounds, including lorcaserin, reduced seizure-like activity in a zebrafish model of Dravet syndrome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lorcaserin has been tested in a small study of &#x201c;off-label&#x201d; use in five children who each had an SCN1A (sodium channel) gene mutation or a clinical diagnosis of Dravet syndrome, and failed at least two medications. Lorcaserin was initially dosed at 2.5 mg at bedtime and gradually increased weekly as needed to a maximum dose of 10 mg twice a day or 0.3 mg/kg/day, whichever occurred</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">first. One patient was initially seizure-free for three weeks, one patient was seizure-free for two weeks, and a third patient had one to two seizure-free days per week. All five patients exhibited a reduction in the total number of seizures after three months on treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A follow-up retrospective study conducted in 35 lorcaserin-treated refractory epilepsy patients found a 50% reduction in mean monthly frequency of seizures in LGS patients (n = 9), a 43% reduction in patients with Dravet syndrome (n = 20), and a 23% reduction in patients with other epilepsies (n = 6). Overall, the study demonstrated a 47.7% median percentage reduction in mean monthly frequency of motor seizures from baseline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2020, following consultation with the FDA, Eisai Inc. initiated a Phase 3 clinical trial of lorcaserin in patients with Dravet syndrome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 in Epilepsies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 is an oral, centrally acting, 5-HT2C superagonist. A superagonist displays higher receptor signaling output than the natural agonist. As a 5-HT2C superagonist, LP352 is designed to modulate GABA inhibition and as a result, suppress the hyperexcitability that is characteristic of seizures. Based on its potential mechanism of action, we believe that LP352 has the potential to reduce the frequency of seizures in Dravet syndrome, LGS, and across a broad range of refractory epilepsies. 5-HT2C agonism has shown clinical benefit in epilepsy patients, however, currently available 5-HT2 agonists have been associated with significant adverse events (AEs). LP352 was discovered at Arena, and was developed to be the next-generation to lorcaserin. LP352 has novel chemistry and attributes, and was designed with the goal of being a safer, more effective 5-HT2C superagonist. We hold worldwide rights to LP352 through the Arena License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 has demonstrated selectivity on the 5-HT2C receptor subtype with no detected activity on the 5-HT2B and 5-HT2A receptor subtypes in in vitro preclinical studies, as shown in the following table:</span><img src="img8619836_4.jpg" alt="img8619836_4.jpg" style="width:720px;height:405px;" /></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The above table is for illustrative purposes only and is not a head-to-head comparison. These data were generated from different studies, and caution should be exercised when comparing data across studies. However, each of these studies followed the same basic protocol using HEK293 cells expressing recombinant human 5-HT2 receptors, and receptor densities in all of the functional assays were determined by [</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I]-2,5-Dimethoxy-4-iodoamphetamine, or DOI, radioligand binding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A superagonist is a compound that is capable of producing a higher receptor response than the endogenous agonist. We have shown LP352 to be a superagonist in a dynamic mass redistribution assay measuring a holistic integrated cellular response to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lorcaserin, serotonin and LP352. This assay demonstrated that, as the concentration of LP352 increases, the cellular response is greater than the endogenous ligand serotonin and considerably more than lorcaserin. The results of this assay are demonstrated below.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img8619836_5.jpg" alt="img8619836_5.jpg" style="width:392px;height:371px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 Clinical Development Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 Clinical Trial SAD-MAD</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 was evaluated in a multi-part Phase 1 clinical trial in healthy volunteers. This was a randomized, double-blind, placebo-controlled, parallel-group trial that included a SAD portion (with and without food effect) and a MAD portion (with and without dose titration). Safety and tolerability were evaluated throughout the clinical trial, and blood sampling and urine samples for PK analysis were also collected. LP352 was administered as a capsule formulation. The Phase 1 clinical trial enrolled 83 healthy participants. Doses ranging from 1 mg to 24 mg were evaluated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SAD Results - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352 was observed to be generally well-tolerated, and AEs were consistent with events observed with other centrally acting 5-HT2C agonists. Headache was the dose limiting AE, and mild to moderate headache was the most common treatment-emergent AE. There were no serious adverse events (SAEs) reported, and no participants dropped out due to AEs. In the SAD and food effect portions of the clinical trial, LP352 demonstrated favorable PK and pharmacodynamic effects (with target plasma exposure (minimum serum concentration) measured based on prolactin levels), including dose-dependent PK properties with proportional increases in AUC and Cmax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MAD Results - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Five doses including the maximum planned dose were evaluated. The majority of AEs were mild to moderate, with the most common being headache. AEs were generally consistent with CNS effects and expected effects of serotonergic drugs. A single SAE of anxiety was reported at the maximum planned dose two days after the last dose of study drug and subsequently resolved. LP352 demonstrated dose- and exposure-dependent increases of prolactin, suggesting proof of central 5-HT2C receptor engagement, as well as dose-dependent increases in exposure (Cmax and AUCtau). The safety and tolerability of titrating LP352 was also examined.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Phase 1 Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we announced topline data from cohorts 1 and 2 of a Phase 1 clinical trial assessing CNS PK/PD parameters in healthy adult male and female participants. In these cohorts LP352 exhibited a strong correlation between plasma and cerebrospinal fluid (CSF) PK concentration, which increased in a dose-dependent and consistent manner. In these cohorts LP352 also demonstrated early quantitative electroencephalogram (qEEG) changes and sustained effects on qEEG activity after continuous dosing in a dose-dependent manner indicating receptor engagement, and favorable safety and tolerability results were observed, with AEs generally consistent with previous clinical studies.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting and plan to conduct additional Phase 1 clinical trials with LP352 to further characterize and differentiate LP352.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The PACIFIC Study - a Phase 1b/2a Clinical Trial of LP352 in Patients with DEEs</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The PACIFIC Study is a Phase 1b/2a safety, tolerability and exploratory efficacy clinical trial of LP352. This is a randomized double-blind placebo-controlled trial. We plan to enroll 50 participants ages 12-65 with a variety of treatment resistant motor seizures and seizure disorders that fall into the category of DEEs. The PACIFIC Study was initiated in the first quarter of 2022, with completion of enrollment expected in the first half of 2023 and topline data expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img8619836_6.jpg" alt="img8619836_6.jpg" style="width:720px;height:405px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LP659, a centrally acting, S1P1,5 modulator</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing LP659, a centrally acting, S1P1,5 receptor modulator for inflammatory neurological conditions. LP659 was designed to have optimized pharmacology, PK and engagement of S1P1,5, which may lead to improved efficacy and safety. LP659 was designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which may be associated with more serious, off-target cardiac, pulmonary, and cancer-related effects. Aberrant S1P receptor modulation has been shown to be involved in a wide range of neurological diseases, including multiple sclerosis, Lupus, Parkinson&#x2019;s disease and Alzheimer&#x2019;s disease. Preclinical data in a mouse model of demyelinating disease demonstrated that LP659 treatment produced a dose-dependent decrease in disease progression over 17 days. LP659 rapidly reduced circulating lymphocytes, which returned to baseline after its clearance. In a PK/PD study to assess LP659 effects on lymphocytes in rats, male rats were given a 0.00 (vehicle control), 0.300 or 1.00 mg/kg oral dose of LP659 (n=3 per dosing group). Fingolimod, the positive control for blood lymphopenia, was given as an oral dose (n=4) at 1.00 mg/kg to a separate group of rats. Blood samples were collected at 0, 1, 3, 5, 8, 16, 24, 32, 48 and 72 hours post-dose for blood lymphocyte and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">plasma drug concentration measurements. LP659 at both doses demonstrated a rapid reduction in lymphocytes which returned to baseline, whereas no return to baseline was observed for fingolimod over the study duration.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img8619836_7.jpg" alt="img8619836_7.jpg" style="width:477px;height:403px;" />&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A study of CNS distribution of LP659 was conducted in rats. Male rats were dosed orally with LP659 at 1.00 mg/kg for six consecutive days. On Day 6, plasma, brain and cerebrospinal fluid samples were taken at 0, 1, 3, 5, 8, and 24 hours post-last dose (n = 3 per time point). The maximum plasma concentration of LP659 was 551 ng/mL at 3.00 hours post-dose. The maximum brain concentration of LP659 was 947 ng/mL at 8.00 hours post-dose. The mean brain to plasma ratios of LP659 at 0, 1, 3, 5, 8, and 24 hours post-last dose were 2.87, 1.25, 1.17, 1.68, 1.98, and 2.94, respectively. We believe LP659 has high oral bioavailability with a direct impact on CNS glial cell S1P receptors. We anticipate initiating a Phase 1 clinical study in healthy volunteers in the first half of 2023 and expect topline SAD data in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S1P Receptors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S1P receptors are expressed broadly in the CNS. By limiting lymphocyte circulation, S1P receptor modulators exert anti-inflammatory effects. Multiple S1P receptor modulators have been approved for the treatment of relapsing forms of multiple sclerosis. There are five known receptor types: S1P1, S1P2, S1P3, S1P4 and S1P5. S1P1, S1P2 and S1P3 receptors are expressed broadly, S1P4 is primarily expressed in immune system cells, and S1P5 is expressed primarily in the spleen and CNS. Astrocytes are the most abundant cells in the human CNS and preferentially express S1P3 and S1P1 and express S1P2 at low levels. Oligodendrocytes, oligodendrocyte precursor cells (OPC), neurons, and microglia are other brain cells that express S1P.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The various brain cell types are illustrated in the below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img8619836_8.jpg" alt="img8619836_8.jpg" style="width:459px;height:393px;" />&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">LP659 in Neurological Diseases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP659 acts as a S1P1 and S1P5 receptor subtypes modulator with no observed impact on S1P2 or S1P3 and has been selectively developed to cross the blood-brain barrier and target neurological diseases. In addition to its receptor subtype selectivity, LP659 has demonstrated rapid onset and offset of action (in preclinical models), with a low half-maximal inhibitory concentration in plasma (IC50 approximately 25 ng/ml in rat) to inhibit entrance of lymphocytes into blood. A single dose of LP659 causes rapid depletion of circulating lymphocytes and rapid recovery, paralleling elimination of LP659 from plasma. The S1P receptor has been well-validated in slowing the progression of neurodegeneration, notably in multiple sclerosis, for which disease area the FDA has approved four S1P receptor modulators. LP659 was designed to avoid the negative effects connected to the receptor subtypes 2 and 3, which may be associated with more serious, off-target cardiac, pulmonary, and cancer-related effects. While initial studies have shown that LP659 is efficacious in reducing the development and severity of disease in a widely accepted model of demyelinating disease (e.g., multiple sclerosis), we have not finalized a target indication as we see potential for a selective S1P1 receptor modulator to treat a spectrum of inflammatory neurological conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Compounds</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a license to certain compounds including LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, and compounds targeting the 5-HT2A receptor, including nelotanserin. We are not currently developing any of these compounds.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement with Arena</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Arena License Agreement was originally entered into in October 2020 and amended in January 2022 and again in September 2022. Pursuant to the Arena License Agreement, Arena granted us an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to LP352 for any use in humans, LP659 for the treatment of developmental, degenerative and autoimmune disease, disorders or conditions of the CNS or peripheral nervous system in humans and LP143 and certain 5-HT2A compounds for the treatment of CNS indications (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder) in humans (pharmaceutical products containing any such compounds, Licensed Products). Arena further granted us a covenant not to sue under any patents or certain information of Arena with respect to each Licensed Product in its respective field. Arena retained the exclusive right to use the licensed intellectual property to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop, make or use intermediates, pro-drugs and metabolites related to the LP352, LP659, LP143 and 5-HT2A compounds to exploit Arena&#x2019;s etrasimod, lorcaserin, olorinab, or temanogrel products, in any dosage strength or formulation, and we granted Arena a covenant not to sue with respect to such activities under certain of our intellectual property related to such compounds and the Licensed Products. We will assign to Arena new intellectual property developed by us related to such compounds. We have sole responsibility over development, regulatory and commercialization activities for the Licensed Products in the applicable fields, as well as commercial manufacture and supply therefor. In September 2022, we provided Arena a right of first negotiation, for a specified period of time, to acquire certain development and commercial rights to LP659 products subject to Arena and we mutually agreeing on terms. This right of first negotiation is triggered by our announcing Phase 2 clinical results relating to an LP659 product for an indication that was not in the original field of the license or if we otherwise intend to commence discussions or negotiations to license or partner rights to LP659 in such field.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the rights granted to us under the Arena License Agreement, we will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by us, our affiliates or our sublicensees, subject to standard reductions. Our royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed to us under the Arena License Agreement covering the manufacture, use or sale of such product in such country, which we expect to run in most jurisdictions until 2036 for LP352, until 2029 for LP659 and 2030 for LP143 without taking into account patent term adjustments or extensions regimes of any country, or any additional term of exclusivity we might obtain by virtue of later filed patent applications. We also will owe Arena up to two $25.0 million commercial sales milestones if nelotanserin products (which are among the licensed 5-HT2A compounds) are developed and achieve annual net sales of $100.0 million and $500.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may unilaterally terminate the Arena License Agreement for any reason with a specified prior notice period, and Arena may terminate the Arena License Agreement if we challenge any of the licensed patents. Either party may terminate the Arena License Agreement in the event of the other party&#x2019;s insolvency or for the other party&#x2019;s uncured material breach of the Arena License Agreement. Absent early termination, the Arena License Agreement will automatically expire upon the expiration of all our payment obligations under the Arena License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty Purchase Agreement with Arena</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a Royalty Purchase Agreement with Arena and 356 Royalty Inc., a wholly owned subsidiary of Arena (356 Royalty), pursuant to which we purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, in all countries and territories of the world owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd. (Eisai) pursuant to a Transaction Agreement dated December 28, 2016, as amended (Transaction Agreement), by and among 356 Royalty and Eisai, for an upfront payment of approximately $0.1 million. Under the Transaction Agreement, the royalty rates range from 9.5% on annual global net sales less than or equal to $175.0 million, 13.5% on annual global net sales greater than $175.0 million but less than or equal to $500.0 million and 18.5% on annual global net sales greater than $500 million. In addition, we purchased the right to receive a payment of $25.0 million, which will be payable upon the achievement of annual net sales of $250.0 million. Lorcaserin is currently in a Phase 3 clinical trial for Dravet syndrome.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Services Agreement with Arena</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a Services Agreement with Arena (Services Agreement) under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for us. The initial term of the Services Agreement was through December 31, 2021, and it then automatically renews for successive one-year terms. Neither party provided notice of non-renewal as of December 31, 2022. Each party may also terminate the Services Agreement for any reason, subject to specified notice periods. During 2022, we significantly reduced our activities under the Services Agreement, including as a result of our having hired employees or contracted with third parties with the requisite expertise, and we are no longer dependent on such services from Arena.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates and other discoveries, inventions, trade secrets and know-how that are critical to our business operations. Our success also depends in part on our ability to operate without infringing the proprietary rights of others, and in part, on our ability to prevent others from infringing our proprietary rights. A comprehensive discussion on risks relating to intellectual property is provided under the section of this prospectus entitled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 1, 2023, we held an exclusive, worldwide license to issued and pending patent claims for compositions of matter and certain methods of treatment using LP352 in several jurisdictions, including issued patents in the United States, Europe (17</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries), China, Japan, India, Russia, South Korea, Australia, Mexico, New Zealand, and Israel, and pending applications in Brazil, Canada, and Macao. The terms of these patents (and applications, if issued) are capable of continuing into 2036, without taking into account any patent term adjustment or extension regimes of any country (e.g., up to five additional years in certain jurisdictions if maximum PTE or SPC applies) or any additional term of exclusivity we might obtain by virtue of later filed patent applications. For example, we exclusively license pending patent claims directed to methods of dosing LP352 in a later patent application having a term capable of continuing into 2043 in certain jurisdictions, without taking into account any applicable patent term adjustment or extension.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 1, 2023, we held an exclusive, worldwide license to issued and pending patent claims for compositions of matter and certain methods of treatment using LP659 in several jurisdictions, including issued patents in the United States, Europe (39 countries), Brazil, China, Japan, Canada, Russia, South Korea, Australia, Mexico, South Africa, New Zealand, Singapore, Israel. The terms of these patents (and applications, if issued) are capable of continuing into 2029, without taking into account any patent term adjustment or extension regimes of any country (e.g., up to five additional years in certain jurisdictions if maximum PTE or SPC applies) or any additional term of exclusivity we might obtain by virtue of later filed patent applications. For example, we exclusively license patent claims for compositions of matter and certain methods of treatment using salt and crystalline forms of LP659 in several jurisdictions, including issued patents in the United States and 10 countries in Europe. The terms of these patents are capable of continuing into 2031 in certain jurisdictions, without taking into account any patent term adjustment or extension.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patent protection, we rely on trade secret protection, trademark protection and know-how to expand our proprietary position around our chemistry, technology and other discoveries and inventions that we consider important to our business. We are a party to a license agreement with Arena under which we are granted intellectual property rights to know-how that are important to our business. We have licensed know-how related to the Licensed Products (including LP352, LP659, LP143 and certain 5-HT2A compounds) in all countries around the world from Arena. The Arena License Agreement imposes various development, regulatory and/or commercial diligence obligations, payment of royalties, including a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by our company, its affiliates or its sublicensees, subject to standard reductions, and other obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to protect our intellectual property by having confidentiality terms in our agreements with companies with whom we share proprietary and confidential information in the course of business discussions, and by having confidentiality terms in our agreements with our employees, consultants, scientific advisors, clinical investigators and other contractors and also by requiring our employees, commercial contractors, and certain consultants and investigators, to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in our employ.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales and Marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of any of our approved products. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely for the foreseeable future, on third parties for the manufacturing of our product candidates for preclinical and clinical testing, as well as for commercial manufacture of any products that we may commercialize. We expect to initially obtain our supplies from manufacturers on a purchase order basis without long-term supply arrangements in place. We do not currently have arrangements in place for redundant supply for active pharmaceutical ingredients (APIs) and drug product. For all of our product candidates, we intend to identify and qualify manufacturers to provide the APIs and drug product prior to submission of an NDA to the FDA or other marketing authorization applications to other regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All our product candidates are compounds of low molecular weight, generally called small molecules. They can be manufactured from readily available starting materials in reliable and reproducible processes that we expect will be amenable to scale-up and will not require specialized equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical industry is characterized by rapidly advancing competition and a strong emphasis on proprietary drugs. We face competition with respect to our current product candidates and will face competition with respect to any other product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEEs are commonly treated with multiple combinations of AEDs though physician preference for administered therapies differs across different epilepsy types. Pharmaceutical companies, such as Lundbeck, Pfizer, and UCB have approved AEDs for the treatment of epilepsies. There are also non-pharmaceutical therapies for epilepsy patients, such as a ketogenic diet, VNS, and surgery for some patients. FINTEPLA (fenfluramine) was approved by the FDA for the treatment of seizures associated with Dravet syndrome in June 2020 and LGS in June 2022 (both include REMS programs). Epidiolex (cannabidiol) was approved by the FDA for the treatment of seizures associated with Dravet syndrome and LGS in 2018, and the treatment of seizures associated with TSC in 2020, and DIACOMIT (stiripentol) was approved by the FDA in 2018 for seizures associated with Dravet syndrome. Lorcaserin is also in a Phase 3 clinical trial for the treatment of seizures associated with Dravet syndrome. In addition, other companies are developing therapeutics for the treatment of epilepsies, including alternative approaches such as gene therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the S1P receptor modulator space, there are four drugs that have been approved by the FDA for the treatment of certain indications in multiple sclerosis: fingolimod, ozanimod, siponimod and ponesimod. There are multiple additional S1P receptor modulators in development for additional therapeutic indications beyond multiple sclerosis, including in other neurological diseases. There are also numerous other drugs and product candidates in development for indications for which we might develop our product candidates.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Additional potential competitors include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. More established companies may have a competitive advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts, relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key competitive factors affecting the success of our product candidates are likely to be their efficacy and safety, the scope and limitations of marketing approval, success of regulatory approval, successful protection of our intellectual property, and the availability of funding and reimbursement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other drugs, non-pharmaceutical therapies and alternative approaches to indications we may pursue for our drug candidates will compete with us both in the U.S. and elsewhere in the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation and Product Approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a pharmaceutical company that operates in the United States, we are subject to extensive regulation. Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products such as those we are developing. Product candidates that we develop must be approved by the FDA, before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country specific regulation remains essential in many respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Drug Development Process</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (FDCA), and its implementing regulations. A new drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies in accordance with the FDA&#x2019;s Good Laboratory Practice (GLP) regulations and other applicable regulations;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with applicable regulations, including the FDA&#x2019;s good clinical practice (GCP) regulations to establish the safety and efficacy of the proposed drug for its proposed indication; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an NDA after completion of all pivotal trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#x2019;s current good manufacturing practice (cGMP) requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA to assess compliance with GCP regulations; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA advisory committee review, if applicable; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States. </span></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before testing any compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies, to assess the potential safety and activity of the drug candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Clinical trials involve the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#x2019;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject inclusion and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1. The drug is initially administered to healthy human participants and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion, the side effects associated with increasing doses and if possible, to gain early evidence of effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases or conditions and to determine dosage </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">tolerance, optimal dosage and dosing schedule. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3. The drug is administered to an expanded patient population to further evaluate dosage and clinical efficacy at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall benefit/risk ratio of the product and provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Post-approval studies, or Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected AEs or any finding from tests in laboratory animals that suggests a significant risk for human participants. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Review and Approval Processes</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Pediatric Research Equity Act (PREA) requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data need to be collected before the pediatric clinical trials begin. The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. Unless otherwise required by regulation, the PREA does not apply to any drug for an indication for which orphan designation has been granted. However, if only one indication for a product has orphan designation, a pediatric assessment may still be required for any applications to market that same product for the non-orphan indication(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the Prescription Drug User Fee Act (PDUFA) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#x201c;filing&#x201d; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#x201c;filing&#x201d; decision after the application is submitted. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, strength, quality and purity. The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and typically follows the advisory committee&#x2019;s recommendations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical sites to assure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application has ended and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may detail required additional clinical data and/or (an) additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. For example, the FDA may require Phase 4 testing, which involves clinical trials designed to further assess a drug safety and effectiveness, and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also determine that a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the orphan product has exclusivity. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the product candidate may be eligible for priority review. With regard to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it is designed to treat a serious condition, and if approved, would provide a significant improvement in the treatment, diagnosis or prevention of a serious condition compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the predicted clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required clinical trials, or if such trials fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor may seek FDA designation of a drug candidate as a &#x201c;breakthrough therapy&#x201d; if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will expedite the development and review of such drug. Breakthrough therapy designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, such designations or shortened review periods may not provide a material commercial advantage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term stability of the drug product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters, or untitled letters; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical holds on clinical studies; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA-approved labeling.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Patent Term Restoration and Marketing Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of non-patent market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">DEA Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The CSA establishes registration, security, recordkeeping, reporting, storage, distribution and other requirements administered by the DEA. The DEA is concerned with the control of handlers of controlled substances, and with the equipment and raw materials used in their manufacture and packaging, in order to prevent loss and diversion into illicit channels of commerce. The DEA regulates controlled substances as Schedule I, II, III, IV or V substances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule I substances by definition have no established medicinal use, and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual registration is required for any facility that manufactures, distributes, dispenses, imports or exports any controlled substance. The registration is specific to the particular location, activity and controlled substance schedule. For example, separate registrations are needed for import and manufacturing, and each registration will specify which schedules of controlled substances are authorized. The DEA typically inspects a facility to review its security measures prior to issuing a registration. Security requirements vary by controlled substance schedule, with the most stringent requirements applying to Schedule I and Schedule II substances. Required security measures include background checks on employees and physical control of inventory through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to the DEA. Reports must also be made for thefts or losses of any controlled substance, and authorization must be obtained to destroy any controlled substance. In addition, special authorization and notification requirements apply to imports and exports.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To meet its responsibilities, the DEA conducts periodic inspections of registered establishments that handle controlled substances. Failure to maintain compliance with applicable requirements, particularly as manifested in loss or diversion, can result in enforcement action that could have a material adverse effect on our business, results of operations and financial condition. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could eventuate in criminal proceedings. Individual states also regulate controlled substances, and we and our contract manufacturers will be subject to state regulation on distribution of these products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other U.S. Healthcare Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we currently do not have any products on the market, we are and, upon approval and commercialization, will be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. In the United States, such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting, and physician sunshine laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal false claims laws, including the False Claims Act, which prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim under the False Claims Act includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. The federal civil False Claims Act can be enforced through private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, and thus non-covered, uses. In addition, a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) also created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the federal Physician Payments Sunshine Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) annually report information related to certain payments or other transfers of value made or distributed to physicians (currently defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and certain ownership and investment interests held by physicians and their immediate family members.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Numerous state, federal and foreign laws, self-regulatory schemes, regulations, and standards govern the collection of, disclosure of, use of, access to, transfer of, and confidentiality and security of personal information and health-related information, and could apply now or in the future to our operations or the operations of our partners. For example, In the United States, numerous federal and state laws and regulations, including data breach notification laws, health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by Health Information Technology for Economic and Clinical Health Act (HITECH) and regulations implemented</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">thereunder, imposes requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective &#x201c;business associates&#x201d; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, as well as their covered subcontractors. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by complaint about privacy practices or an audit by the Department of Health and Human Services (HHS), may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to criminal penalties.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For instance, California enacted the California Consumer Privacy Act (CCPA) in January 2020. The CCPA creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling certain personal information of consumers or households. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, a new privacy law, the California Privacy Rights Act (CPRA) went into effect on January 1, 2023 and modifies significantly the CCPA. Both the CCPA and CPRA could impact our business activities depending on how they are interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and protected health information. In addition to California, other states in which we have, or may have in the future, employees or operations, have passed or may pass privacy laws. For example, Virginia, Colorado, Connecticut, and Utah have passed privacy laws that go into effect in 2023, but aspects of these state privacy statutes remain unclear, resulting in further legal uncertainty and potentially requiring us to modify our data practices and policies and to incur substantial additional costs and expenses in an effort to comply.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also are or will become subject to applicable privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, if we conduct EU-based clinical trials, we will be subject to the GDPR in relation to our collection, control, processing and other use of personal data of data participants within the European Economic Area (EEA) (i.e. data relating to an identifiable living individual) including the health and medical information of clinical trial participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing activities and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data participants (in a concise, intelligible and easily accessible form) how their personal data is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EU rules with respect to cross-border transfers of personal data out of the EU and EEA. We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR, and may also be subject to the laws of other jurisdictions, such as Switzerland, which may have their own set of stringent privacy and data protection laws and regulations. For example, the Swiss Federal Act on Data Protection (DPA) applies to the collection and processing of personal data, including health-related information, in certain circumstances, for companies conducting business in Switzerland or with Swiss companies or individuals. The DPA has been revised and adopted by the Swiss Parliament, and the revised law may result in an increase of costs of compliance, risks of noncompliance and penalties for noncompliance. Fines for certain breaches of the GDPR are significant: up to the greater of &#x20ac;20 million or 4% of total global annual turnover. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, or potential civil claims including class action type litigation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the United Kingdom (UK) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#x2019;s standard contractual clauses, these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Some European regulators have prevented companies from transferring personal data out of Europe for allegedly violating the GDPR&#x2019;s cross-border data transfer limitations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, track and report gifts, compensation and other remuneration made to physicians and other healthcare providers, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#x201c;qui tam&#x201d; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmaceutical Coverage, Pricing and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we or our collaborators obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such drug products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. We or our collaborators may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Nonetheless, our product candidates may not be considered medically necessary or cost-effective. Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. As a result, one payor&#x2019;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we elect to participate in certain governmental programs, we may be required to participate in discount and rebate programs, which may result in prices for our future products that will likely be lower than the prices we might otherwise obtain. For example, drug manufacturers participating under the Medicaid Drug Rebate Program must pay rebates on prescription drugs to state Medicaid programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries may require the completion of clinical trials that compare the cost-effectiveness of a particular drug candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively ACA), was enacted, which affected existing government healthcare programs and resulted in the development of new programs. There have been judicial and Congressional challenges to certain aspects of the ACA, and it is unclear how such litigation and other efforts to challenge, repeal or replace the ACA will impact the ACA or our business. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes relating to healthcare have also been proposed and adopted in the United States since the ACA was enacted, and there has been heightened governmental scrutiny recently over the manner in which pharmaceutical companies set prices for their marketed products, which has resulted in several Congressional inquiries, presidential executive orders, and proposed federal legislation, as well as state efforts, designed to, among other things, bring more transparency to product pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the IRA also, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023. The IRA is likely to have a significant impact on the pharmaceutical industry.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that these new laws will result in additional downward pressure on coverage and the price that we receive for any approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. In addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Foreign Corrupt Practices Act of 1977 (FCPA) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Europe / Rest of World Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we or our potential collaborators obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States have a similar process that requires the submission of an application for a clinical trial authorization (CTA) much like the IND prior to the commencement of human clinical trials. In the EU, for example, a CTA must be submitted to each country&#x2019;s national health authority and an application made to an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#x2019;s requirements and a favorable ethics committee opinion has been issued, clinical trial development may proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application either under the so-called centralized or national authorization procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Centralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The centralized procedure provides for the grant of a single marketing authorization by the European Commission following a favorable opinion by the EMA that is valid in all EU member states, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, and products with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases, other immune dysfunctions and viral diseases. The centralized procedure is optional for other products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health or which contain a new active substance for indications other than those specified to be compulsory.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">National authorization procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous authorizations in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure. </span></div></div>
  <p style="margin-left:7.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.13%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4765828726400336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance with the national procedures of that country. Following this, further marketing authorizations can be sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization. </span></div></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The EMA grants orphan drug designation to promote the development of products for the treatment, prevention or diagnosis of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the EU. In addition, orphan drug designation can be granted if the drug is intended for a life threatening or chronically debilitating condition in the EU and without incentives it is unlikely that sales of the drug in the EU would be sufficient to justify the investment required to develop the drug. Orphan drug designation is only available if there is no other satisfactory method approved in the EU of diagnosing, preventing or treating the condition, or if such a method exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation provides opportunities for free or reduced-fee protocol assistance, fee reductions for marketing authorization applications and other post-authorization activities and ten years of market exclusivity following drug approval, which can be extended to 12 years if trials are conducted in accordance with an agreed-upon pediatric investigational plan. The exclusivity period may be reduced to six years if the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital and Employee Engagement</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our success largely depends upon attracting and retaining a highly skilled team with key expertise in our areas of therapeutic focus. We are committed to creating and maintaining a culture that is positive, diverse, inclusive and dynamic. Our human capital priorities include, as applicable, identifying, recruiting, retaining, incentivizing, developing and integrating our existing and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future employees. We provide our employees competitive base salaries, as well as a cash target bonus, a robust benefits package and equity compensation. In addition, we regularly conduct an employee survey to gauge employee engagement and identify areas of potential improvement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we employed 33 employees, 32 of whom are full-time, consisting of clinical, research and manufacturing, operations, finance and business personnel. Fifteen of our employees hold either an M.D. or Ph.D. degree. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into a two-year lease for certain office space in La Jolla, California in June 2021. Rent payments were approximately $29,000 per month for the first year and increased by 4.5% in July 2022. In August 2022, we extended the lease agreement (lease extension) through December 31, 2024. Rent payments under the lease extension are approximately $33,000 starting in July 2023 and increase by 4.5% in July 2024. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently not a party to any material legal proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Risk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An investment in shares of our common stock is speculative and involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report, including our audited financial statements and the related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the risks described below could harm our business, financial condition, results of operations, growth prospects and/or stock price or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Annual Report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. Any of the risks identified herein relating to Arena are also risks relating to Pfizer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Limited Operating History, Financial Position and Need For Additional Capital</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have a limited operating history, and we have incurred losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in January 2020 and we have a limited operating history upon which you can evaluate our business and prospects. Our operations to date have been primarily focused on organizing and staffing our company, research and development activities, business planning, raising capital, in-licensing intellectual property rights and establishing our intellectual property portfolio, and providing general and administrative support for these operations. LP352, our most advanced product candidate, is in early clinical development, while our other product candidates, including LP659, are in the preclinical or research stage. We have not yet demonstrated an ability to overcome many of the risks and uncertainties frequently encountered by companies in the biopharmaceutical industry, including an ability to obtain regulatory approval of a product candidate, manufacture any product candidate at commercial scale, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In addition, we have limited experience completing clinical trials as a company. Consequently, any predictions about our future performance may not be as accurate as they would be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effectiveness in the targeted indication or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses since our inception in January 2020. For the years ended December 31, 2022 and 2021, we reported net losses of $43.9 million and $27.8 million, respectively. As of December 31, 2022, we had an accumulated deficit of $86.1 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to invest in our research and development activities, including conducting preclinical studies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submit INDs and conduct clinical trials for our current and future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel and build our internal resources, including those related to audit, patent, other legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and Securities and Exchange Commission (SEC) requirements, director and officer insurance premiums and investor and public relations costs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain, expand, maintain, enforce and protect our intellectual property portfolio;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operate as a public company;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek marketing approvals for any product candidates that successfully complete the clinical trial process; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a sales, marketing and distribution infrastructure and establish manufacturing capabilities, whether alone or with third parties, to commercialize product candidates for which we may obtain regulatory approval, if any.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing clinical trials and preclinical studies of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations. Our prior net losses and expected future net losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. A decline in the value of our company could also cause you to lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. The effects of macroeconomic conditions and geopolitical events, including economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets caused by COVID-19 or another pandemic, the conflict in Ukraine or otherwise, may limit our access to capital. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we continue to develop our product candidates in preclinical studies and clinical trials and expand our organization by hiring additional personnel. Our expenses will increase substantially if our product candidates successfully complete early clinical and other studies, and also could increase beyond expectations if the U.S. Food and Drug Administration (FDA) or other regulatory authorities require us to perform clinical and other studies in addition to those that we currently anticipate. In addition, we have incurred and expect to continue to incur additional costs associated with operating as a public company. Furthermore, if we obtain marketing approval for our product candidates, we expect to incur significant expenses related to manufacturing, marketing, sales and distribution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, our cash, cash equivalents and short-term investments were $67.6 million. We believe, based on our current operating plan, that our existing cash, cash equivalents and short-term investments, along with proceeds from the follow-on public offering completed in February 2023, will be sufficient to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In any event, we will require substantial additional capital to support our business operations as we pursue additional preclinical and clinical activities and regulatory approval of our current or any future product candidates, and otherwise to support our continuing operations. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Even if we believe we have sufficient capital for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and, if approved, commercialize our current and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional funding may not be available on acceptable terms, or at all. As a result of adverse geopolitical and macroeconomic developments, such as the COVID-19 pandemic and actions taken to slow its spread, the ongoing conflict between Ukraine and Russia and related sanctions, and global supply chain challenges, the global credit and financial markets have experienced extreme volatility</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and disruptions, including severely diminished liquidity and credit availability, high inflation rates and the responses by central banking authorities to control such inflation, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty regarding economic stability. If the equity and credit markets deteriorate or are otherwise not favorable, it may make any necessary debt or equity financing more difficult, more costly or more dilutive. If we do not raise additional capital in sufficient amounts, we may be prevented from pursuing development and commercialization efforts, which would adversely affect our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital or acquiring or licensing assets by issuing equity or debt securities may cause dilution to our stockholders and raising funds through lending and licensing arrangements may restrict our operations or require us to relinquish proprietary rights.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional capital through future collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unfavorable geopolitical and macroeconomic developments could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time we may maintain a portfolio of investments in marketable debt securities, which are recorded at fair value. Although we have established investment guidelines relative to diversification and maturity with the objectives of maintaining safety of principal and liquidity, we rely on credit rating agencies to help evaluate the riskiness of investments, and such agencies may not accurately predict such risk. In addition, such agencies may reduce the credit quality of our individual holdings, which could adversely affect their value. Lower credit quality and other market events, such as changes in interest rates and deterioration in credit markets, may have an adverse effect on the fair value of our investment holdings and cash position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be adversely affected by conditions in the U.S. and global economies, the United States and global financial markets and adverse geopolitical and macroeconomic developments, including the ongoing COVID-19 pandemic and the conflict between Ukraine and Russia and related sanctions. For example, inflation rates, particularly in the United States, have increased recently to levels not seen in years, and increased inflation may result in increases in our operating costs (including our labor costs), reduced liquidity and limits on our ability to access credit or otherwise raise capital on acceptable terms, if at all. In response to rising inflation, the U.S. Federal Reserve has raised, and may again raise, interest rates, which, coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks. A weak or declining economy could also strain our suppliers and manufacturers, possibly resulting in supply disruption. Any of the foregoing could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, financial markets around the world experienced volatility following the invasion of Ukraine by Russia in February 2022, including as a result of economic sanctions and export controls against Russia and countermeasures taken by Russia. The full economic and social impact of these sanctions and countermeasures, in addition to the ongoing military conflict between Ukraine and Russia, which could conceivably expand, remains uncertain; however, both the conflict and related sanctions have resulted and could continue to result in disruptions to trade, commerce, pricing stability, credit availability, and/or supply chain continuity, in both Europe and globally, and has introduced significant uncertainty into global markets. While we do not currently operate in Russia, Ukraine or Eastern Europe, as the adverse effects of this conflict continue to develop our business and results of operations may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Development and Commercialization of Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are early in our development efforts and have only one product candidate, LP352, in early clinical development. All of our other product candidates are in the preclinical or research stage. If we are unable to advance our product candidates in clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are in the early stages of our development efforts and have one product candidate, LP352, in clinical development. We have completed the SAD and MAD portions of a Phase 1 clinical trial and are currently conducting the PACIFIC Study, a Phase 1b/2a clinical trial for this product candidate. Our other product candidates currently in development, including LP659, are in the preclinical stage. We will need to progress LP659 and any other early product candidates through IND-enabling studies and submit INDs to the FDA prior to initiating their clinical development. Moreover, none of our product candidates have advanced into a pivotal study. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our product candidates will depend on several factors, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">successful enrollment in clinical trials and completion of clinical trials and preclinical studies with favorable results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clearance of INDs by the FDA or similar regulatory filings by comparable foreign regulatory authorities for the conduct of clinical trials of our product candidates and our proposed design of future clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">demonstrating the safety and efficacy of our product candidates to the satisfaction of applicable regulatory authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effect of recent or potential health care legislation in the United States and European Union;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities, including NDAs from the FDA and maintaining such approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing capabilities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing and maintaining of patent and trade secret protection or regulatory exclusivity for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ongoing relationship with Pfizer, from whom we license our product candidates, including LP352 and LP659;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining an acceptable safety profile of our products following approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of adequate reimbursement for our products following approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our products following approval; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">building and maintaining an organization of people who can successfully develop, sell and distribute our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our business, including our ability to finance our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of our most advanced product candidate, LP352, as well as our other product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it will take several years before we can demonstrate the safety and efficacy of a treatment sufficient to warrant approval for commercialization, if we can do so at all. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks associated with the in-licensing or acquisition of product candidates could cause substantial delays in the preclinical and clinical development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to October 2020, we had no involvement with or control over the preclinical and early clinical research and development of our product candidates. We have relied on third parties, including Arena, to have conducted such research and development in accordance with the applicable protocol, legal, regulatory and scientific standards prior to the in-licensing of our product candidates. If the research and development processes or the results of the development programs prior to the in-licensing of our product candidates prove to be unreliable, this could result in increased costs and delays in the development of our product candidates, which could adversely affect any future revenue from these product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have licensed our product candidates from Arena. The fields of the licenses for these product candidates contain certain restrictions. For example, the field of license for LP659 is for developmental, degenerative and autoimmune disease, disorders or conditions of the CNS or peripheral nervous system. We also rely on Arena to help protect the intellectual property rights relating to our licensed product candidates. The scope of our license or Arena&#x2019;s failure to cooperate with us to protect our intellectual property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">could have an adverse impact on our ability to develop our product candidates and could limit our ability to successfully commercialize our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also acquire or in-license additional product candidates for preclinical or clinical development in the future as we continue to build our pipeline. The risks associated with acquiring or in-licensing current or future product candidates could result in delays in the commencement or completion of our research and development, prevent or impede our commercialization, and adversely affect or delay our ability to generate revenues from our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical and preclinical drug development involves a lengthy and expensive process with an uncertain outcome. The results of prior clinical trials and early preclinical studies and clinical trials of our product candidates are not necessarily predictive of future results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before we can initiate clinical trials for our product candidates, we must submit the results of preclinical studies to the FDA, European Medicines Agency (EMA) or comparable regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls, and our proposed clinical trial protocol, as part of an IND application or similar regulatory filing. Before obtaining marketing approval from the FDA, EMA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical and preclinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. The results from preclinical studies or early clinical trials of a product candidate may not predict the results of later clinical trials of the product candidate, and interim results of a clinical trial are not necessarily indicative of final results. Furthermore, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, while we have results from the SAD and MAD portions of a Phase 1 clinical trial of LP352, we do not know how LP352 will perform in future clinical trials, including the ongoing PACIFIC Study. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical industry have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, or after others, including regulatory authorities, disagreed with such companies&#x2019; views and interpretations of the data and results from earlier preclinical studies or clinical trials. As we investigate LP352 for DEEs and other epileptic diseases, we may encounter difficulties that we have not yet encountered. For example, LP352 is being designed and dose-optimized for DEEs. This work is ongoing and we may encounter unforeseen difficulties. Furthermore, LP659 and other of our current or future product candidates may not be able to progress from preclinical to Phase 1 clinical development.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials may not be conducted as planned or completed on schedule, if at all. A failure of a clinical trial can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory authorities on trial design or implementation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining regulatory authorization to commence a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s, EMA&#x2019;s or comparable regulatory authorities&#x2019; failure to accept our proposed manufacturing processes and suppliers and/or requirement to provide additional information regarding our manufacturing processes before providing marketing authorization;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (CROs) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining approval from one or more institutional review boards (IRBs), or IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional participants, or withdrawing their approval of the trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in recruiting suitable patients to participate in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes to the clinical trial protocol;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in manufacturing sufficient quantities of our product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">participants choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of adequate funding to continue a trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of adverse events (AEs) or serious adverse events (SAEs) associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of SAEs in trials of the same class of agents conducted by other companies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice (cGMP) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol (GCP) or other regulatory requirements;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of geopolitical and macroeconomic developments, including the COVID-19 pandemic or the ongoing conflict between Russia and Ukraine, on our ongoing and planned clinical trials; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could encounter delays if a clinical trial is suspended, terminated or modified by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political, economic and legal risks relevant to such foreign countries.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, adverse geopolitical and macroeconomic developments, including disruptions caused by the COVID-19 or another pandemic or the ongoing conflict between Russia and Ukraine may increase the likelihood that we encounter difficulties or delays in initiating, screening, enrolling, conducting, or completing our ongoing and planned preclinical studies and clinical trials. Clinical site initiation and patient screening and enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 or another pandemic, or to the extent the ongoing conflict between Russia and Ukraine escalates to involve additional countries, further economic sanctions or wider military conflict. Investigators and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or another virus, could be limited, which in turn could adversely impact our clinical trial operations. Additionally, we may experience interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or recommended by federal or state governments, employers and others in connection with the COVID-19 or another pandemic. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. For example, the initiation of the MAD portion of the Phase 1 clinical trial of LP352 was delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the SAD portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We announced topline data from the MAD portion of such trial in September 2021.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales and regulatory and commercialization milestones. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right to commercialize our product candidates, if approved, or allow our competitors to bring comparable products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have limited experience as a company in conducting clinical trials, have never conducted later-stage clinical trials or submitted an NDA or other marketing application, and may be unable to do so for any of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are early in our development efforts for our product candidates, and we will need to successfully complete Phase 1 clinical trials and later-stage and pivotal clinical trials in order to obtain FDA or comparable foreign regulatory approval to market LP352, LP659, or any future product candidates. Carrying out clinical trials and the submission of marketing applications is complicated. To date, we have only conducted a limited number of Phase 1 trials for one of our product candidates, LP352.We have not completed any later stage or pivotal clinical trials, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an NDA or other comparable foreign regulatory submission for any product candidate. We also plan to conduct a number of clinical trials for multiple product candidates in parallel over the next several years. This may be a difficult process to manage with our limited resources and may divert the attention of management. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of our product candidates will be required or how such trials will have to be designed. For example, we are currently conducting a &#x201c;basket&#x201d; Phase 1b/2a trial with LP352 in which participants with different DEEs are being enrolled and which is designed to include multiple clinically defined populations under one investigational protocol. We may seek to conduct our pivotal trials for LP352 with a basket design. A basket trial design could potentially decrease the time to study new populations by decreasing administrative burden, however, this trial may not provide opportunities for accelerated regulatory pathways and may not overcome limitations to extrapolating data from the experience in one disease to other diseases, because safety and efficacy results in each indication may be analyzed separately. Accordingly, clinical success in a basket trial, or any trial in one indication, may not predict success in another indication. The FDA and other regulatory health authorities may not view such a design or the data from such trials favorably. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in submitting marketing applications for and commercializing our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we have multiple product candidates in our pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we have limited financial and managerial resources, we focus on specific product candidates, indications and development programs. We may also conduct several clinical trials for our product candidates in parallel over the next several years, which may make our decision as to which product candidates to focus on more difficult. For example, we are currently conducting the PACIFIC Study for LP352 for the treatment of seizures associated with DEEs, which may include Dravet syndrome, LGS and TSC, among others, which we initiated in the first quarter of 2022. Further, we are investigating preclinical studies of LP659 for multiple neurological diseases, and we have other compounds in earlier research. As a result, we may forgo or delay pursuit of opportunities with other product candidates or other indications that could have had greater commercial potential or likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. In addition, if we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#x2019;s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, certain clinical trials for future product candidates may be focused on indications with relatively small patient populations, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. For example, the number of patients suffering from DEEs, such as Dravet syndrome, LGS and TSC, is small and, in some cases, has not been established with precision. If the actual number of patients with these diseases is smaller than we anticipate, we may encounter</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patient enrollment and retention in clinical trials depends on many factors, including the size and nature of the patient population, the severity of the disease under investigation, the nature of the trial protocol, the existing body of safety and efficacy data for the product candidate, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial, the ability to adequately monitor patients during a trial, clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the product candidate being studied, and the risk that patients will drop out of a trial before completing all site visits. There are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner, including due to the fact that the neurological diseases we target are rare.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials, which could be exacerbated to the extent the ongoing conflict between Russia and Ukraine escalates to involve additional countries, further economic sanctions or wider military conflict. In addition, any negative results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. For example, the impact of public health epidemics, such as the COVID-19 pandemic, may delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which could delay our clinical trials, or prevent us or our partners from completing our clinical trials at all, and harm our ability to obtain approval for such product candidate. Further, if patients drop out of our clinical trials, miss scheduled doses or follow-up visits, or otherwise fail to follow clinical trial protocols, whether as a result of the COVID-19 pandemic and related illness or actions taken to slow the spread of COVID-19 or otherwise, the integrity of data from our clinical trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent a significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preliminary, topline and interim data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, such as our announcement in December 2022 of positive topline data from our Phase 1 clinical study evaluating PK and PD of LP352 in healthy volunteers, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other AEs that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by participants. Many times, side effects are only detectable after investigational product candidates are tested in large-scale, Phase 3 trials or, in some cases, after they are made available to patients on a commercial scale after approval. Patients in our ongoing or planned clinical trials may experience similar or other side effects after treatment with one or more of our product candidates. If additional clinical experience indicates that any of our current product candidates and any future product candidates has serious or life-threatening side effects or other side effects that outweigh the potential therapeutic benefit, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352, our most advanced product candidate, is an oral, centrally acting, 5-HT2C receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes in our preclinical studies to date. 5-HT2B and 5-HT2A receptor subtypes have been known to be associated with significant adverse side effects, including valvular heart disease and pulmonary arterial hypertension in the case of the 5-HT2B receptor, and hallucinations and mild to severe anxiety in the case of the 5-HT2A receptor. LP352 has the potential to be a clinically differentiated 5-HT2C superagonist for patients with DEEs. For example, fenfluramine, marketed as FINTEPLA, a non-specific 5-HT2 agonist, was approved for the treatment of seizures associated with Dravet syndrome and LGS by the FDA in 2020 and 2022, respectively. Fenfluramine has been associated with significant side effects and FINTEPLA has a Risk Evaluation and Mitigation Strategy (REMS) program requirement and a boxed warning. Another 5-HT2C agonist, lorcaserin, is also under evaluation for its potential to reduce seizures in patients with Dravet syndrome and refractory epilepsies. Lorcaserin was discovered by Arena and approved by the FDA for chronic weight management, marketed as BELVIQ by Eisai Inc. Lorcaserin was withdrawn from the market at the request of the FDA following the FDA&#x2019;s analysis of the CAMELLIA-TIMI 61 clinical trial, for which patients in the lorcaserin group demonstrated a numerically higher but not a statistically significantly higher rate of total cancer diagnoses (7.7% vs 7.1% placebo). Based on the results of this clinical trial, the FDA concluded that the risks of lorcaserin outweigh the benefits, and requested that lorcaserin be withdrawn from the market for the approved indication of weight management. However, the FDA authorized an expanded access program for patients with Dravet syndrome to continue to receive lorcaserin. LP352 was designed and developed by Arena to be the next generation to lorcaserin, with the goal of being a safer and more effective 5-HT2C agonist. We believe LP352&#x2019;s potential for high selectivity and novel chemistry gives it the potential to reduce seizures in DEE patients and overcome the known or perceived safety limitations of available drugs in the 5-HT2 class. However, we may not be correct, and the selectivity, specificity or other attributes of LP352 may result in similar or less desirable clinical profiles than less selective and specific available drugs or other product candidates. Further, in nonclinical toxicity studies of LP352 in rats and non-human primates (NHPs) conducted by Outpost Medicine, LLC prior to returning the product to Arena, certain male rats and NHPs of varying degrees of maturity in the respective high dose groups experienced minimal to slight degeneration/atrophy of the seminiferous tubules with reduced spermatocyte maturation. Although exposure levels for these high dose groups were estimated to be far in excess of planned human exposures in our clinical trials and no similar AEs were observed in our subsequent toxicity studies in sexually mature rats and NHPs, we may see similar findings in the future.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a black box or other warning, or contraindication, in our product labeling, or adopt REMS to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidates or other products with the same or related active ingredients, several other potentially significant negative consequences could result, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require additional warnings on the label or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to change the way a product candidate is administered, conduct additional clinical trials or modify such product in some other way;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory authorities may require us to modify, suspend or terminate our clinical trials, conduct additional clinical trials or engage in costly post-marketing testing and surveillance to monitor the safety or efficacy of such product;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">undesirable side effects may limit physicians&#x2019; or patients&#x2019; willingness to initiate or continue therapy with such product;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales may decrease significantly;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may need to conduct a recall; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our brand and reputation or the reputation of any then-approved product may suffer.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could significantly harm our business, prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we estimate, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the size of the market opportunities in each of our target indications is smaller than we anticipate, we may not be able to achieve profitability and growth. We focus on developing novel medicines for neurological diseases. Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates that have been derived from a variety of sources, including scientific literature, patient foundations, or market research, and which may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and commercialization of pharmaceutical products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEEs are commonly treated with multiple combinations of anti-epileptic drugs (AEDs) though physician preference for administered therapies differs across different epilepsy types. Pharmaceutical companies, such as Lundbeck, Pfizer, and UCB have approved AEDs for the treatment of epilepsies. There are also non-pharmaceutical therapies for epilepsy patients, such as a ketogenic diet, vagus nerve stimulation, and surgery for some patients. Several companies have obtained FDA approval for the treatment seizures associated with DEEs. For example, ZTALMY (ganaxalone) was approved for the treatment of seizures associated with CDKL5 deficiency disorder in March 2022. Fenfluramine was approved for the treatment of seizures associated with Dravet syndrome in June 2020 and LGS in March 2022, and is available for patients through a REMS program. Epidiolex (cannabidiol) was approved for the treatment of seizures associated with Dravet syndrome and LGS in 2018, and the treatment of seizures associated with TSC in 2020, and DIACOMIT (stiripentol) was approved for seizures associated with Dravet syndrome in 2018. In addition, other companies are developing therapeutics for the treatment of DEEs, including alternative approaches such as gene therapy.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the S1P receptor modulator space, there are four drugs that have been approved by the FDA for the treatment of certain indications in multiple sclerosis: fingolimod, ozanimod, ponesimod and siponimod. There are multiple additional S1P receptor modulators in development for additional therapeutic indications beyond multiple sclerosis, including in other neurological diseases. There are also numerous other drugs and product candidates in development for indications for which we might develop our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of the indications that we are pursuing. More established companies may have a competitive advantage over us due to their substantially greater size, financial, technical and other resources, and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products, and marketing approved drugs. These companies also have significantly larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The key competitive factors affecting the success of our product candidates are likely to be their efficacy and safety, the scope and limitations of marketing approval, success of regulatory approval, successful protection of our intellectual property, and the availability of funding and reimbursement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted and cheaper than ours, and may also be more successful than us in manufacturing and marketing their drugs. These appreciable advantages could render our product candidates obsolete or non-competitive before we can recover the expenses of such product candidates&#x2019; development and commercialization.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#x2019;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that any product candidates we may seek to develop in the future will never obtain regulatory approval. Neither we nor any future collaborator is permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. To demonstrate the safety of our clinical products, we may also be required to conduct extensive clinical trials and nonclinical studies, some of which have not been initiated or completed, and may not be completed for several years. For example, we believe that we will need to conduct additional nonclinical studies in juvenile animals, as well as develop a liquid formulation, to support the evaluation of LP352 in pediatric populations. We also expect that we will need to conduct additional toxicology, long-term carcinogenicity and other nonclinical studies to support the safety evaluation of LP352 and any of our product candidates intended to be administered for an extended period of time. There is no assurance our development or these studies will be successful. In addition, results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional nonclinical or clinical testing or abandon a program for, including the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for any of its proposed indications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical studies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA&#x2019;s or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of the above events could prevent us from achieving market approval of our product candidates and could substantially increase the costs of commercializing our product candidates. The demand for our product candidates could also be negatively impacted by any adverse effects of a competitor&#x2019;s product or treatment.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if our current or future product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if our current or future product candidates receive marketing approval, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If they do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our current or future product candidates, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient demand;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the clinical indications for which the product candidate is approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of the product as well as competitive products;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effectiveness of our sales, marketing and distribution efforts and those of the third parties with whom we may contract;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of our relationships with patient communities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to offer such product for sale at competitive prices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments and therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential product liability claims;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies, and patient satisfaction with the overall treatment experience;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects from the use or potential misuse of any then-approved product; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any restrictions on the use of the product together with other medications.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if approved, LP352 may face challenges in gaining market acceptance by physicians, patients, third-party payors or others in the medical community as a result of it being a 5-HT2C agonist, which is part of an agonist class associated with significant risks and side effects. For example, fenfluramine, marketed as FINTEPLA, is a non-specific 5-HT2 agonist, has been associated with significant side effects and FINTEPLA has a REMS program requirement and a boxed warning. Another 5-HT2C agonist, lorcaserin, is also under evaluation for its potential to reduce seizures in patients with Dravet syndrome and refractory epilepsies. Lorcaserin was discovered by Arena and approved by the FDA for chronic weight management, marketed as BELVIQ by Eisai Inc. and withdrawn from the market at the request of the FDA based on a change in the FDA&#x2019;s risk-benefit assessment for the approved indication. However, the FDA authorized an expanded access program for patients with Dravet syndrome to continue to receive lorcaserin.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we aim to improve upon current 5-HT2C agonist product profiles with LP352, which was designed to be the next generation to lorcaserin, with the goal of being a safer and more effective 5-HT2C agonist, and which we believe has the potential to overcome the limitations of the currently available 5-HT2 class, if we are unable to do so and to educate physicians, patients, third-party payors and others in the medical community about this product candidate and successfully distinguish the safety profile of this product candidate to those of other products in the 5-HT2C agonist class, we may fail to gain market acceptance of LP352.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates, if approved, to find market acceptance would harm our business and could require us to seek additional financing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval for our current or future product candidates, they will remain subject to ongoing regulatory oversight.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain any regulatory approval for our current or any future product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, import, export, sampling, record-keeping and submission of safety and other post-market information. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCPs for any clinical trials that we may conduct post-approval. Any regulatory approvals that we receive for our current or future product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as AEs of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable regulatory requirements following approval of our current or future product candidates, a regulatory authority may:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issue an untitled letter or warning letter asserting that we are in violation of the law;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend or withdraw regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to approve a pending NDA or NDA supplement, or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic partners;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrict or suspend the marketing or manufacturing of the drug;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seize or detain the drug or otherwise require the withdrawal of the drug from the market;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to permit the import or export of product candidates; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refuse to allow us to enter into supply contracts, including government contracts.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our current or future product candidates and harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA&#x2019;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could cause changes to or delays in the drug review process, or suspend or restrict regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not as a company commercialized a product and have limited or no internal sales, marketing or distribution capabilities. If any of our product candidates ultimately receives regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in the markets that we target, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We currently plan to independently commercialize our product candidates in the United States by establishing a focused sales force and marketing infrastructure. We may opportunistically seek additional strategic collaborations to maximize the commercial opportunities for our product candidates outside of the United States. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may negatively impact the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our current and any future product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. Any side effects, manufacturing defects, failure to follow instructions, misuse or abuse associated with our product candidates could result in injury to a patient or even death. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities and could incur reputational harm. Regardless of merit or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients that may not be covered by insurance;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant time and costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants and termination of clinical trial sites or entire trial programs;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate that we may develop;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation and significant negative media attention; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decline in our share price.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large judgments have been awarded in class action and individual lawsuits based on drugs that had anticipated or unanticipated side effects. Any product liability insurance coverage that we obtain and maintain may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to obtain or maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may be regulated as controlled substances, the making, use, sale, importation, exportation, and distribution of which are subject to significant regulation by the U.S. Drug Enforcement Administration (DEA) and other regulatory agencies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates may be classified as controlled substances, which are subject to state, federal, and foreign laws and regulations regarding their manufacture, use, sale, importation, exportation, and distribution. Among other things, controlled substances are regulated under the federal Controlled Substances Act of 1970, and regulations of the DEA.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The DEA regulates controlled substances as Schedule I, II, III, IV or V substances. Schedule I substances by definition have no established medicinal use and may not be marketed or sold in the United States. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abuse and Schedule V substances the lowest relative risk of abuse among such substances. Prior to commercialization, centrally acting drugs are generally subject to review and potential scheduling by the DEA. It is possible that LP352 or our other product candidates may be regulated by the DEA as a Schedule IV controlled substance, which would subject such product candidates to additional restrictions regarding their manufacture, shipment, storage, sale and use, depending on the scheduling of the active ingredients, and may limit the commercial potential of any of our product candidates, if approved. For example, BELVIQ and FINTEPLA are Schedule IV controlled substances.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various states also independently regulate controlled substances. Though state-controlled substances laws often mirror federal law, because the states are separate jurisdictions, they may separately schedule drugs as well. While some states automatically schedule a drug when the DEA does so, in other states there must be rulemaking or a legislative action. State scheduling may delay commercial sale of any controlled substance drug product for which we obtain federal regulatory approval and adverse scheduling could impair the commercial attractiveness of such product. We or our collaborators must also obtain separate state registrations in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale, and failure to meet</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">applicable regulatory requirements could lead to enforcement and sanctions from the states in addition to those from the DEA or otherwise arising under federal law.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For any of our product candidates classified as controlled substances, we and our suppliers, manufacturers, contractors, customers and distributors are required to obtain and maintain applicable registrations from state, federal and foreign law enforcement and regulatory agencies and comply with state, federal and foreign laws and regulations regarding the manufacture, use, sale, importation, exportation and distribution of controlled substances. There is a risk that DEA regulations may limit the supply of the compounds used in clinical trials for our product candidates, and, in the future, the ability to produce and distribute our products in the volume needed to meet commercial demand. Regulations associated with controlled substances govern manufacturing, labeling, packaging, testing, dispensing, production and procurement quotas, recordkeeping, reporting, handling, shipment and disposal. These regulations increase the personnel needs and the expense associated with development and commercialization of product candidates including controlled substances. The DEA, and some states, conduct periodic inspections of registered establishments that handle controlled substances. Failure to obtain and maintain required registrations or comply with any applicable regulations could delay or preclude us from developing and commercializing our product candidates containing controlled substances and subject us to enforcement action. The DEA may seek civil penalties, refuse to renew necessary registrations or initiate proceedings to revoke those registrations. In some circumstances, violations could lead to criminal proceedings. Because of their restrictive nature, these regulations could limit commercialization of any of our product candidates that are classified as controlled substances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Compliance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers, healthcare providers, and third-party payors may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, other healthcare laws and regulations and data privacy and security laws and regulations, contractual obligations and self-regulatory schemes. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, including physicians, and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations. These laws will impact, among other things, our clinical research, as well as our proposed sales, marketing and educational programs. In addition, we may be subject to data privacy and security laws by both the federal government and the states in which we conduct or may conduct our business. The laws that will affect our operations include, but are not limited to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, in return for the purchase, recommendation, leasing or furnishing of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand, and prescribers, purchasers and formulary managers on the other. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">federal civil and criminal false claims laws, including, without limitation, the False Claims Act, and civil monetary penalty laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government payors that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing a scheme or making false or fraudulent statements to defraud any healthcare benefit program, regardless of the payor (e.g., public or private). Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the HITECH and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health information;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services (CMS), information related to: (i) payments or other &#x201c;transfers of value&#x201d; made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants and certified nurse midwives, and teaching hospitals during the previous year; and (ii) ownership and investment interests held by physicians and their immediate family members;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">state and foreign law equivalents of each of the above federal laws, state laws that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and/or information regarding drug pricing, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers, state laws and regulations that require drug manufacturers to file reports relating to drug pricing and marketing information, and state and local laws that require the registration of pharmaceutical sales representatives; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">state and foreign laws that govern the privacy and security of personal information, including health-related information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. By way of example, California enacted the California Consumer Privacy Act (CCPA), effective January 1, 2020, which gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Moreover, a new privacy law, the California Privacy Rights Act (CPRA) operative January 1, 2023, is anticipated to expand the CCPA&#x2019;s obligations on businesses. The CCPA and CPRA may increase our compliance costs and potential liability. Further, the EU General Data Protection Regulation (GDPR) imposes obligations and restrictions on the collection and use of personal data relating to individuals in the European Economic Area (EEA) (including health data). The GDPR increases obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data and requiring changes to informed consent practices and more detailed notices for clinical trial participants and investigators.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In Europe, the GDPR, as well as EU and EEA Member State implementing legislations, apply to the collection and processing of personal data, including health-related information. Importantly, the GDPR materially expands the definition of what is expressly provided to constitute &#x201c;personal data&#x201d; including by clarifying that the GDPR applies to pseudonymized (i.e. key-coded) data, which is often processed by sponsors in the context of clinical trials. EU and EEA Member States are also able to legislate separately on health and genetic data, and we must comply with these local laws where we operate. Also, notwithstanding the UK&#x2019;s withdrawal from the EU, the data protection obligations of the GDPR continue to apply to UK-related processing of personal data under the so-called &#x201c;UK GDPR&#x201d;. These GDPR regulations have &#x201c;extra-territorial&#x201d; reach in that it applies (inter-alia) to any processing of personal data that concerns the offering of goods or services to individuals in the EEA or UK (as applicable) and/or the monitoring of their behavior, regardless of the existence of an establishment in the EEA or UK (as applicable). As such, these GDPR regulations apply to any clinical trials and other operations taking in place in the EEA and UK. The GDPR provides for robust regulatory enforcement and substantial fines. While the GDPR affords some flexibility in determining how to comply with the various requirements, significant effort and expense has been, and will continue to be, invested to ensure continuing compliance. In Switzerland, the Federal Act on Data Protection (DPA), also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. The applicability of the DPA will also result in an increase of costs of compliance, risks of noncompliance and penalties for noncompliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These data privacy and security laws impose strict obligations on the ability to process personal data, including health-related information, in particular in relation to their collection, use, disclosure and transfer. This includes several requirements relating to (i) obtaining, in some situations, the consent of the individuals to whom the personal data relates, (ii) the information provided to the individuals about how their personal data is used, (iii) ensuring the security and confidentiality of the personal data, (iv) the obligation to notify regulatory authorities and affected individuals of personal data breaches, (v) extensive internal privacy governance obligations, and (vi) obligations to honor rights of individuals in relation to their personal data (for example, the right to access, correct and delete their personal data).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the GDPR regulations prohibit the transfer of personal data from the EEA and the UK to the United States, and other countries in respect of which the European Commission or other relevant regulatory body has not issued a so-called &#x201c;adequacy decision&#x201d; (known as &#x201c;third countries&#x201d;). Switzerland has adopted similar restrictions under the DPA. The implementation of the processes, including agreements with all relevant CROs, sub-processors and other third parties, is complex and time-consuming. As such, transfers of personal data from the EEA, UK and/or Switzerland to the United States and other third countries may not fully comply with the cross-border data transfer restrictions set out in the applicable data privacy and security regulations. Additionally,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of operating our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, following Brexit, the relationship between the UK and the EEA in relation to certain aspects of data protection law remains somewhat uncertain, and we may be required to implement processes and put agreements in place to enable transfers of personal data from the EEA to the UK, which could further increase the complexity and costs in our operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Actual or perceived failure to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial participants, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, may limit our ability to collect, use and disclose the information. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements. The laws and regulations discussed in these risk factors are intended to be examples, and updates to these laws and regulations, as well as other laws and regulations, could have a material effect on our operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which coverage and adequate reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One third-party payor&#x2019;s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each third-party payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a third-party payor&#x2019;s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our drugs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs by limiting coverage and the amount of reimbursement for particular medications, requiring drug companies to provide them with varying levels of discounts from list prices and/or challenging the value of list prices charged for medical products. Similarly, the containment of healthcare costs has become a priority for federal and state governments. Coverage and reimbursement may not be available for any drug that we commercialize and, if reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is available, the level of reimbursement is uncertain. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reform measures that result in decreased physician reimbursement may adversely affect our business. Further, any reduction in reimbursement from Medicare or other governmental programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which have resulted in several U.S. presidential executive orders, Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Additionally, based on a recent executive order, the Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022 (IRA), which among other things extends enhanced subsidies for individuals purchasing health insurance coverage through plan year 2025 in the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA), marketplaces. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. In response to Biden&#x2019;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. The IRA is likely to have a significant impact on the pharmaceutical industry. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot predict what healthcare reform initiatives may be adopted in the future. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our current or future product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians prescribe or use any of our current or future product candidates off-label, we may become subject to prohibitions on the sale or marketing of any of our current or future product candidates, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA, Department of Justice (DOJ), and comparable foreign authorities strictly regulate the marketing and promotional claims that are made about pharmaceutical products, including our product candidates LP352 and LP659. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or comparable foreign authorities as reflected in the product&#x2019;s approved labeling. Although physicians may prescribe products for off-label uses as the FDA and other regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clearance has not been issued. If we are found to have promoted such off-label uses, we may receive warning letters from the FDA and comparable foreign authorities and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#x2019;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA and other governmental authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve enforcement actions. If we are deemed by the FDA, DOJ, or other governmental authorities to have engaged in the promotion of any current or future product candidates for off-label use, we could be subject to certain prohibitions or other restrictions on the sale or marketing of our products and operations, or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to obtain or maintain orphan drug designations or exclusivity for our product candidates, which could limit the potential profitability of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation, however, neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation, then the drug is entitled to a period of marketing exclusivity that precludes the applicable regulatory authority from approving another marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small molecule drugs, the FDA defines &#x201c;same drug&#x201d; as a drug that contains the same active moiety and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to pursue orphan drug designation for one or more of our product candidates, as well as for potential other future product candidates. Obtaining orphan drug designations is important to our business strategy; however, obtaining an orphan drug designation can be difficult and we may not be successful in doing so. Even if we were to obtain orphan drug designation for a product candidate, we may not obtain orphan exclusivity and that exclusivity may not effectively protect the drug from the competition of different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses incurred to develop it, which would have a negative impact on our operational results and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, at times during the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By way of another example, in response to the global COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities and products through April 2020, and subsequently, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July 10, 2020, the FDA announced its intention to restart routine pre-announced surveillance inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from third parties, including Arena, and the failure by us or our licensors to protect the licensed intellectual property or the termination of our license could result in the loss of significant rights, which would harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are dependent on technology, patents, know-how, and proprietary materials, both our own and licensed from Arena. We entered into the Arena License Agreement pursuant to which we acquired an exclusive, royalty bearing, sublicensable, worldwide license to develop and commercialize LP352 for any use in humans, LP659 for the treatment of certain CNS and peripheral nervous system indications, and certain other compounds for CNS indications. Any termination of this license will result in the loss of significant rights and will restrict our ability to develop and commercialize our product candidates. If we or Arena fails to adequately protect this intellectual property, or if we seek to expand the field of our license to include additional indications we determine are advantageous or necessary for us to develop a licensed compound and Arena does not consent, our ability to commercialize these compounds could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreements under which we license intellectual property or technology to or from third parties may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Our business also would suffer if any current or future licensors fail to abide by the terms of the license, if we or the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#x2019;s rights.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the growth of our business will likely depend in part on our ability to acquire or in-license additional proprietary rights, including to advance our research or allow commercialization of our product candidates. In that event, we may be required to expend considerable time and resources to develop or license replacement technology. For example, our programs may involve additional technologies or product candidates that may require the use of additional proprietary rights held by third parties. Furthermore, other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. Our product candidates may also require specific formulations or other technology to work effectively and efficiently. These formulations or technology may be covered by intellectual property rights held by others. From time to time, in order to avoid infringing these third-party patents, we may be required to license technology from additional third parties to further develop or commercialize our product candidates. We may be unable to acquire or in-license any relevant third-party intellectual property rights, including any such intellectual property rights required to manufacture, use or sell our product candidates, that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, and as a result we may be unable to develop or commercialize the affected product candidates, and we may have to abandon development of the relevant research programs or product candidates, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license under such intellectual property rights, any such license may be non-exclusive, which may allow our competitors&#x2019; access to the same technologies licensed to us.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the license agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the priority of invention of patented technology;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amount and timing of payments owed under license agreements; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us and our partners.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty and other obligations on us and if we fail to comply with our obligations under these agreements, including due to the impact of adverse macroeconomic and geopolitical developments such as the COVID-19 pandemic or the invasion of Ukraine by Russia, or any economic slowdowns, recessions, market corrections, inflation, rising interest rates and tightening of credit markets resulting therefrom, on our business operations or our use of the intellectual property licensed to us in an unauthorized manner, or we are subject to a bankruptcy, we may be required to pay damages and the licensor may have the right to terminate the license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We depend, in part, on our licensors to file, prosecute, maintain, defend, or enforce patents and patent applications that are material to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents relating to our product candidates may be controlled by our licensor. Licensors may have rights to file, prosecute, maintain, and defend the patents we have licensed from such licensor. Our ability to settle legal claims may require consent of licensors. If our licensor or any future licensees having rights to file, prosecute, maintain, and defend our patent rights fail to conduct these activities for patents or patent applications covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, or selling competing products. We cannot be certain that such activities by our licensor has been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. If our licensor has the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and, even if we are permitted to pursue such enforcement or defense, we cannot ensure the cooperation of our licensor. We cannot be certain that our licensor will allocate sufficient resources or prioritize its or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. In addition, even when we have the right to control patent prosecution of licensed patents and patent applications, enforcement of licensed patents, or defense of claims asserting the invalidity of those patents, we may still be adversely affected or prejudiced by actions or inactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our licensor and its counsel that took place prior to or after our assuming control. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For most licensed products under the Arena License Agreement, including LP352 and LP659, we have the first right to control the prosecution and enforcement of the licensed patent applications and patents. However, we have an obligation to reasonably cooperate with Arena and will to some extent depend on Arena&#x2019;s cooperation with us to prosecute and enforce such intellectual property. A disagreement between us and Arena with respect to the prosecution or enforcement of the patent applications or patents, or unsuccessful actions to prosecute or enforce the patent applications or patents, could adversely affect our intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may enter into collaboration agreements and strategic alliances, and we may not realize the anticipated benefits of such collaborations or alliances. We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to broaden the global reach of our platform by potentially selectively collaborating with leading biopharmaceutical companies. We intend to retain significant economic and commercial rights to our programs in key geographic areas that are core to our long-term strategy. As a result, we intend to periodically explore a variety of possible additional strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development collaborations are subject to numerous risks, which may include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration, and may not commit sufficient efforts and resources, or may misapply those efforts and resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may conduct their own clinical trials which may not be compliant, may not be successful or may generate contradictory results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not pursue development and commercialization of collaboration product candidates or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may delay, provide insufficient resources to, or modify or stop clinical trials for collaboration product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, or acquire products outside of the collaboration that compete directly or indirectly with our products or product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator or series of collaborators may improperly or unknowingly sell product directly (or indirectly to a potential customer) into the &#x201c;gray market&#x201d; whereby our branded products are diverted from authorized sales channels into the hands of dealers, brokers or the open market, and may result in unauthorized sale of our product in a specific country or region;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborations may be terminated and, if terminated, may result in a need for additional capital and personnel to pursue further development or commercialization of the applicable product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a collaborator&#x2019;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The development and potential commercialization of our product candidates will require substantial additional capital to fund expenses. We may form or seek further strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop, including in territories outside the United States or for certain indications. These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#x2019;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. As a result, if we enter into acquisition or in-license agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. We may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third-party for development and commercialization of a product candidate, we can expect to relinquish some or all of the control over the future success of that product candidate to the third-party. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of our technologies, product candidates and market opportunities. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under any license agreements from entering into agreements on certain terms or at all with potential collaborators.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these risks, we may not be able to realize the benefit of our existing collaborations or any future collaborations or licensing agreements we may enter into. In addition, there have been a significant number of recent business combinations among large pharmaceutical and biomedical companies that have resulted in a reduced number of potential future collaborators and changes to the strategies of the combined company. As a result, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product candidate, reduce or delay one or more of our other development programs, delay the potential commercialization or reduce the scope of any planned sales or marketing activities for such product candidate, or increase our expenditures and undertake development, manufacturing or commercialization activities at our own expense. If we elect to increase our expenditures to fund development, manufacturing or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide companies like us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our products will require specific constituents to work effectively and efficiently, and rights to those constituents are and, in the future, may be held by others. We may be unable to in-license any rights to constituents, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. In that event, we may be required to expend significant time and resources to develop or license replacement technology. Any delays in entering into new collaborations or strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies, which could harm our business prospects, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be dependent on intellectual property licensed or sublicensed to us from, or for which development was funded or otherwise assisted by, government agencies or academic or other institutions, for development of our technology and product candidates. Failure to meet our own obligations to our licensors or upstream licensors, including such government agencies or academic or other institutions, may result in the loss of our rights to such intellectual property, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government agencies or academic or other institutions may provide funding, facilities, personnel or other assistance in connection with the development of the intellectual property rights owned by or licensed to us. Such government agencies may have retained rights in such intellectual property, including the right to grant or require us to grant mandatory licenses or sublicenses to such intellectual property to third parties under certain specified circumstances, including if it is necessary to meet health and safety needs that we are not reasonably satisfying or if it is necessary to meet requirements for public use specified by federal regulations, or to manufacture products in the United States. Any exercise of such rights, including with respect to any such required sublicense of these licenses could result in the loss of significant rights and could harm our ability to commercialize licensed products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our current or any future product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that we will file additional patent applications both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if and when any patents will issue;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the degree and scope of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether others will apply for or obtain patents claiming aspects similar to those covered by our patents and patent applications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we will need to initiate litigation or administrative proceedings to defend our patent rights, which may be costly whether we win or lose; or</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether the patent applications that we own, or in-license will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in foreign countries.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our current and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our current and future development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner, including as a result of the COVID-19 pandemic impacting our, our licensors&#x2019; or governmental patent offices' operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current or any future product candidates in the United States or in foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our current or any future product candidates, third parties may challenge their scope, validity, or enforceability, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate or companion diagnostic under patent protection could be reduced.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our current or any future product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a negative effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Composition of matter patents for pharmaceutical products often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain, however, that the claims in our pending patent applications covering the composition of matter of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label&#x201d; for those uses that are covered by our method of use patents. Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or enforce against.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to file for patent protection. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drugs, in whole or in part, or which effectively prevent others from commercializing competitive technologies and drugs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. These changes could also increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. On September 16, 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act included several significant changes to U.S. patent law that impacted how patent rights could be prosecuted, enforced and defended. In particular, the Leahy-Smith Act also included provisions that switched the United States from a &#x201c;first-to-invent&#x201d; system to a &#x201c;first-to-file&#x201d; system, allowed third party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO-administered post-grant proceedings. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The USPTO developed new regulations and procedures governing the administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became effective on March 16, 2013. It remains unclear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a negative effect on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drugs and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, or limit the duration of the patent protection of our technology and drugs. Moreover, patents have a limited lifespan. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years from the earliest filing date of a non-provisional patent application. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that read on the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Without patent protection for our current or future product candidates, including once the patent life has expired even if patents covering our product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">candidates are obtained, we may be open to competition from generic versions of such drugs. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing drugs similar or identical to ours.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we have or obtain patents covering our products or methods, we may still be barred from making, using and selling such products or methods because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering compositions, products or methods that are similar or identical to ours, which could materially affect our ability to successfully develop our technology or to successfully commercialize any approved products alone or with collaborators.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent applications in the United States and elsewhere are generally published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our methods and products could have been filed by others without our knowledge. Additionally, pending claims in patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies or related products. These patent applications may have priority over patent applications filed by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our outside counsel, patent annuity service providers, or our licensing partners to pay these fees due to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, and other similar provisions during the patent application process. We will employ one or more reputable law firms and other professionals to help us comply and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of new product candidates such as LP352, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our intellectual property rights do not necessarily protect against all potential threats to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business. These risks and uncertainties include the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we might not have been the first to file patent applications covering certain of the product candidates or inventions we own or control;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pending patent applications that we own or control may not lead to issued patents;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issued patents that we own or control may be held invalid or unenforceable as a result of legal challenges;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the patents of others may have an adverse effect on our business.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Our product candidates and other proprietary technologies we may develop may infringe existing or future patents owned by third parties. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third parties asserting their patent or other intellectual property rights against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates or force us to cease some of our business operations. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, cause development delays, and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible on a cost-effective basis or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are aware of third-party patents and/or patent applications that could adversely affect the potential commercialization of our compounds. For example, we are aware of third-party patents, as well as a third-party patent application, with broad claims to administering an S1P receptor modulator by starting with a lower dose and then increasing to a higher, standard daily dose. Further, we are aware of third-party patent applications with broad claims to administering a 5-HT receptor agonist for epileptic disorders. While we do not believe that any such claims that would cover the potential commercialization of LP352 or LP659 would be valid and enforceable, we may be incorrect in this belief.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive, time-consuming, and unpredictable. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related patent applications at risk of not issuing. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture, or methods of use or treatment that cover our product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates and other proprietary technologies we may develop, could be found to be infringed by our product candidate. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, our competitors in both the United States and abroad, many of which have made substantial investments in patent portfolios and competing technologies, may obtain patents in the future that may prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates, and may claim that use of our technologies or the manufacture, use, or sale of our product candidates infringes upon these patents. We may also receive, and expect to receive, communications from various industry participants alleging our infringement of their patents, trade secrets or other intellectual property rights and/or offering licenses to such intellectual property.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patents, or any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action, which typically last for years before they are concluded, may be too high or not in the best interest of our company or our stockholders, or it may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings and that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trials, continue our internal research programs, in-license needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim we infringe their patents or that the patent covering our product candidate is invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#x2019;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention, or decide that the other party&#x2019;s use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates and such an outcome may limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Such a loss of patent protection could have a material adverse impact on our business. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than do those in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These drugs may compete with our drugs in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biopharmaceutical products, which could make it difficult in those jurisdictions for us to stop the infringement or misappropriation of our patents or other intellectual property rights, or the marketing of competing products in violation of our proprietary rights. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, such proceedings could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims of infringement or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">misappropriation against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government agencies or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we rely on third parties to manufacture or commercialize our current or any future product candidates, or if we collaborate with additional third parties for the development of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, services agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any third-party collaborators. A competitor&#x2019;s discovery of our trade secrets could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce, and any other elements of our product candidates, technology and product discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trade secrets and confidential information, however, may be difficult to protect. We seek to protect our trade secrets, know-how and confidential information, including our proprietary processes, in part, by entering into confidentiality agreements with our employees, consultants, outside scientific advisors, contractors, and collaborators. With our consultants, contractors, and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes, or that any such agreements will be adequate. Although we seek to protect our trade secrets, our employees, consultants, outside scientific advisors, contractors, and collaborators might intentionally or inadvertently disclose our trade secret information to competitors or otherwise misappropriate our information, and in certain cases third parties who we may share confidential information have negotiated limits on their liability in their agreements with us. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and time-consuming, and the outcome is unpredictable. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third-party, we would have no right to prevent them from using that technology or information to compete with us. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, or misappropriation of our intellectual property by third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed trade secrets or other confidential information of their current or former employers or claims asserting inventorship or ownership of what we regard as our own intellectual property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other healthcare, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One aspect of the determination of patentability of our inventions depends on the scope and content of the &#x201c;prior art,&#x201d; information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Because patent applications in the United States and most other countries are confidential for typically a period of 18 months after filing, or may not be published at all, we cannot be certain that we were the first to file any patent application related to our product candidates. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For U.S. applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the U.S. patent laws, including new procedures for challenging pending patent applications and issued patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our trademarks or trade names may be challenged, opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined to be not entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Any trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages, disgorgement of profits and attorneys&#x2019; fees, if we are found to have willfully infringed a trademark. We may not be able to protect our exclusive right to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential collaborators or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties or Their Actions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical and commercial supplies of our current and any future product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have no experience in drug formulation or manufacturing and do not own or operate, and we do not expect to own or operate, facilities for drug manufacturing, storage and distribution, or testing. We will be dependent on third parties to manufacture the clinical supplies of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we also will rely on third-party manufacturers to supply us with sufficient quantities of our product candidates, to be used, if approved, for commercialization. We do not have long-term supply agreements or commitments with a manufacturer to produce raw materials, active pharmaceutical ingredients and the finished products of our product candidates or the associated packaging. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example, the extent to which adverse macroeconomic or geopolitical developments such as the COVID-19 or another pandemic, or the ongoing conflict between Russia and Ukraine, impacts our ability to procure sufficient supplies for the development of our products and product candidates will depend on the severity and duration of the spread of the virus, and the actions undertaken to contain the virus or treat its effects. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on third-party manufacturers entails various risks, some of which we would not be subject if we manufactured product candidates ourselves, including:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to meet our drug specifications and quality requirements consistently;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issues related to scale-up of manufacturing;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to comply with cGMP or similar foreign standards;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on single sources for drug components;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">misappropriation of proprietary information, including our trade secrets and know-how;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or study drug or placebo not being properly identified;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We intend to rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently have the ability to independently conduct preclinical studies or clinical trials required to develop our drug candidates. We intend to rely on CROs, clinical trial sites and other third parties to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We intend to rely upon CROs and others to monitor and manage data for our clinical programs, as well as the execution of future nonclinical studies. We expect to control only certain aspects of our CROs&#x2019; and others' activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies or clinical trials are conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs and others does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, our CROs and other third parties we might engage will be required to comply with the GLPs and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we will rely on CROs and others to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs and others does not relieve us of our regulatory responsibilities. If we, our CROs and other third parties we engage fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs or others fail to comply with these regulations or fail to recruit a sufficient number of participants, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we will have agreements governing their activities, our CROs and other third parties we engage will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs and others may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs and others, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. In addition, certain of our agreements with CROs and other third parties provide for monetary and other limitations on their liability. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed, decreased or eliminated.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our relationship with these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our current and future product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party manufacturers. Our manufacturers are subject to federal, state, and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical, radioactive and hazardous materials. Although we believe that our manufacturers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical, radioactive or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical radioactive or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development, and production efforts, which could harm our business, prospects, financial condition, or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arena was acquired by Pfizer on March 11, 2022, and Arena&#x2019;s acquisition may negatively impact our development programs and stock price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 11, 2022, Pfizer announced it completed its acquisition of Arena, and Arena became a wholly-owned subsidiary of Pfizer. We have licensed our product candidates, including LP352 and LP659, from Arena under the Arena License Agreement, and we will rely on Arena to help protect intellectual property relating to our licensed products. Arena also holds a substantial percentage of our outstanding shares of common stock. We do not know if Pfizer will cooperate with us in protecting the intellectual property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relating to our licensed products or hold or sell the shares of our common stock that it owns. We also do not know if Pfizer will view our development programs positively or negatively, or as complimentary or competitive to its development programs. We are also entitled to receive information and milestones and royalty payments under the Royalty Purchase Agreement. If a disagreement between us and Pfizer were to occur, Pfizer might challenge our rights or default on its obligations in the Arena License Agreement, the Royalty Purchase Agreement or another agreement between us, or sell its shares, any of which actions could have an adverse impact on our ability to develop our licensed products or on our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on the services of our senior management team and if we are not able to retain these members of our management team and recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our senior management team. The employment agreements we have with these officers do not prevent such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we will need to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to attract or retain qualified personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates and consultants than what we have to offer. This competition has become exacerbated by the increase in employee resignations currently taking place throughout the United States as a result of the COVID-19 pandemic, which is commonly referred to as the &#x201c;great resignation.&#x201d; We may also experience employee turnover as a result of the ongoing &#x201c;great resignation.&#x201d; In response to competition and adverse macroeconomic and geopolitical developments, including rising inflation rates and labor shortages, we may need to adjust employee cash compensation, which would affect our operating costs and our margins, or equity compensation, which would affect our outstanding share count and cause dilution to existing stockholders. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. If we are unable to continue to attract, retain and motivate high-quality personnel and consultants to accomplish our business objectives, the rate and success at which we can discover and develop product candidates and our business will be limited and we may experience constraints on our development objectives.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of our current and potential future product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance, our ability to commercialize product candidates, develop a scalable infrastructure and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, CROs, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with manufacturing standards, comply with healthcare fraud and abuse laws and regulations in the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. If we obtain regulatory approval for any of our product candidates and begin commercializing those products, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a negative impact on our business, financial condition, results of operations and prospects, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19 has impacted and could continue to adversely impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business has been and could continue to be adversely affected by the global COVID-19 pandemic. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. Specifically, the initiation of the MAD portion of the Phase 1 clinical trial of LP352 was delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the SAD portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We completed the MAD portion in September 2021. The extent to which the COVID-19 pandemic continues to impacts our business, our clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, and the emergence of new strains or variants of the virus, vaccine shortages and administration rates, the effectiveness of government policies, including travel restrictions, quarantines, social distancing and vaccine mandate requirements, and business closures in the United States and other countries, and business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the virus and its variants. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts have previously impacted and could in the future adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, to the extent the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An active, liquid and orderly trading market for our common stock may not be sustained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have a limited number of shares that trade each day compared to many other companies. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, a lesser active market may impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and you could lose all or part of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. For example, the closing price of our common stock from January 1, 2022 to February 28, 2023 has ranged from a low of $2.95 to a high of $6.00. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report, these factors include:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment or results of our ongoing and planned preclinical studies and clinical trials, or any future pre-clinical studies or clinical trials, we may conduct of our current and any future product candidates, or changes in the development status of our current and any future product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delay in our regulatory filings for our current and any future product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#x2019;s review of such filings, including without limitation the FDA&#x2019;s issuance of a &#x201c;refusal to file&#x201d; letter or a request for additional information;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse results or delays in our preclinical studies and clinical trials, including as a result of the FDA or comparable foreign regulatory authorities disagreeing with the design or implementation of our clinical trials;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval for our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in laws or regulations applicable to our current and any future product candidates, including but not limited to clinical trial requirements for approvals;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the failure to obtain coverage and adequate reimbursement of our current and any future product candidates, if approved;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes on the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to establish collaborations if needed;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to commercialize our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any termination or loss of rights under the Arena License Agreement or Royalty Purchase Agreement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">additions or departures of key scientific or management personnel;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unanticipated serious safety concerns related to the use of our current and any future product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">introduction of new products or services offered by us or our competitors, or the release or publication of clinical trial results from competing product candidates;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to effectively manage our growth;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated variations in quarterly operating results;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our cash position;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">publication of research reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the market valuations of similar companies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">overall performance of the equity markets;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issuances of debt or equity securities;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sales of our common stock by us or our stockholders in the future, including sales of our common stock by Arena, or the perception that such sales may occur;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trading volume of our common stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in accounting practices;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ineffectiveness of our internal controls;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">geopolitical and macroeconomic conditions, including the COVID-19 pandemic, the conflict in Ukraine,</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other events or factors, many of which are beyond our control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders would therefore be limited to the appreciation, if any, of their stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. Our stock market price may be negatively affected if our principal stockholders and management sell some or all of their stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers, directors, greater than 5% holders, and their affiliates beneficially own shares representing a significant percentage of our common stock. These stockholders will have the ability to influence us through their ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The dual class structure of our common stock may limit your ability to influence corporate matters. Holders of our common stock are entitled to one vote per share, while holders of our non-voting common stock are not entitled to any votes. Nonetheless, each share of our non-voting common stock may be converted at any time into one share of our common stock at the option of its holder by providing written notice to us, subject to the limitations provided for in our amended and restated certificate of incorporation. Consequently, if holders of our non-voting common stock exercise their option to make this conversion, this will have the effect of increasing the relative voting power of those prior holders of our non-voting common stock, and correspondingly decreasing the voting power of the holders of our common stock, which may limit your ability to influence corporate matters. Additionally, stockholders who hold, in the aggregate, more than 10% of our common stock and non-voting common stock, but 10% or less of our common stock, and are not otherwise an insider, may not be required to report changes in their ownership due to transactions in our non-voting common stock pursuant to Section 16(a) of the Exchange Act, and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock by our existing stockholders, including Arena (or Pfizer), in the public market, or the perception that such sales could occur, could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. As of December 31, 2022, there were a total of 13,585,950 shares of common stock outstanding, which does not include the shares of our non-voting common stock that may be converted into an aggregate of 3,629,400 shares of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as of December 31, 2022, Arena (and Pfizer) owned 3,978,540 shares, or 23.1%, of our outstanding shares of voting and non-voting common stock. The sale by Arena (or Pfizer) of a substantial number of shares, or a perception that such sales could occur, could significantly reduce the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, applicable lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, certain holders of shares of our common stock (including the shares of common stock issuable upon conversion of our non-voting common stock) are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to the Sales Agreement and our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that we will need significant additional capital in the future to continue our planned operations, including conducting clinical trials, commercialization efforts if we are able to obtain marketing approval of any of our current or future product candidates, research and development activities, and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. For example, in September 2022, we entered into the Sales Agreement with Cantor Fitzgerald, pursuant to which we may issue and sell, from time to time, shares of common stock having an aggregate offering price of up to $20.0 million through Cantor Fitzgerald acting as the sales agent. We have not sold any shares of common stock under the Sales Agreement as of December 31, 2022. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to our 2021 Equity Incentive Plan (2021 Plan), our management is authorized to grant stock options to our employees, directors and consultants. Additionally, the number of shares of our common stock reserved for issuance under our 2021 Plan will automatically increase on January 1 of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by 5% of the total number of shares of our capital stock outstanding on December 31 of the preceding calendar year (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or a lesser number of shares determined by our board of directors.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, pursuant to our ESPP, the number of shares of our common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 (through January 1, 2031), by the lesser of (i) 1% of the total number of shares of our common stock outstanding (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock) on the last day of the fiscal year before the date of the automatic increase and (ii) such number of shares of common stock that would cause the aggregate number of shares of common stock then reserved for issuance under the ESPP to equal 1,060,017 shares; provided that before the date of any such increase, our board of directors may determine that such increase will be for a lesser amount of shares. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company until December 31, 2026, although circumstances could cause us to lose that status earlier, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act or if we have total annual gross revenue of $1.235 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 or, if we issue more than $1.0 billion in non-convertible debt during any three year period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201c;smaller reporting company&#x201d; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">periodic reports and proxy statements. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and amended and restated bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that the authorized number of directors may be changed only by resolution of the board of directors;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that our board of directors or any individual director may only be removed with cause and the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then-outstanding common stock;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">divide our board of directors into three classes;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#x2019;s notice;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose);</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that special meetings of our stockholders may be called only by the chair of our board of directors, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following types of actions or proceedings under state, statutory and common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; (iii) any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; (iv) any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; (v) any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#x2019;s having personal </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">jurisdiction over the indispensable parties named as defendants; provided these provisions of our amended and restated certificate of incorporation and amended and restated bylaws do not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 66-2/3% of our then-outstanding common stock.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, as a Delaware corporation, we are subject to Section 203 of the Delaware General Corporation Law. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by our then-current board of directors, including delay or impede a merger, tender offer or proxy contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that, to the fullest extent permitted by law and subject to the court&#x2019;s having personal jurisdiction over the indispensable parties named as defendants, the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a breach of fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or bylaws;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding as to which the Delaware General Corporation Law confers jurisdiction to the Court of Chancery of the State of Delaware; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America is the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred, and expect to continue to incur, significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have incurred and expect to continue to incur significant legal, accounting, and other expenses that we did not incur as a private company. We are subject to the reporting requirements of the Exchange Act, which require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201c;say on pay&#x201d; and proxy access. Emerging growth companies and smaller reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the rules and regulations applicable to public companies to continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and results of operations. The increased costs will continue to decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 404 of Sarbanes-Oxley, our management are required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2022. When we lose our status as an &#x201c;emerging growth company&#x201d; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting once that firm begin its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biopharmaceutical companies have experienced significant stock price and volume volatility in recent years that have often been unrelated or disproportionate to the operating performance of these companies. If we face such litigation, it could result in substantial costs and a diversion of management&#x2019;s attention and resources, which could harm our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our failure to meet Nasdaq&#x2019;s continued listing requirements could result in a delisting of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the listing requirements of Nasdaq.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, or discontinues coverage, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks on our technology environment. In addition, due to the COVID-19 pandemic, we have enabled our employees to work remotely, which may make us more vulnerable to cyberattacks. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#x201c;hacktivists,&#x201d; nation states and others. In addition to the access to or extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant disruptions of our, our third-party vendors&#x2019; and/or business partners&#x2019; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of personal or health information, we may have to notify consumers, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item1b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Unresolved Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Properties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, we entered into a lease agreement for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037, where we occupy 8,681 square feet. The lease agreement will expire on December 31, 2024. We believe that the lease agreement for our corporate headquarters is adequate to meet our needs for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item3"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Legal Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. We believe there is no threatened litigation or litigation pending that could have, individually or in the aggregate, a material adverse effect on our financial position, results of operations or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item4"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Mine Safety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item5"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been traded on the Nasdaq Global Market under the symbol &#x201c;LBPH&#x201d; since March 12, 2021. Prior to that date, there was no public trading market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The last reported sale price of our common stock on February 28, 2023 as reported on the Nasdaq Global Market was $5.06. As of February 28, 2023, there were approximately three holders of record of our common stock, one of which was Cede &amp; Co., a nominee for Depository Trust Company (DTC). All of the shares of our common stock held by brokerage firms, banks and other financial institutions as nominees for beneficial owners are deposited into participant accounts at DTC and are therefore considered to be held of record by Cede &amp; Co. as one stockholder. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have never declared or paid any cash dividends on our common stock and do not expect to pay any dividends for the foreseeable future. We currently intend to retain any future earnings to fund the operation, development, and expansion of our business. Any future determination to pay dividends will be at the sole discretion of our Board of Directors and will depend upon several factors, including our results of operations, capital requirements, financial condition, future prospects, contractual arrangements, restrictions imposed by applicable law, and other factors our Board of Directors may deem relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 16, 2021, we completed our IPO and sold 5,298,360 shares of our common stock (inclusive of 298,360 shares purchased in April 2021 pursuant to the underwriters&#x2019; option to purchase additional shares) at a public offering price of $16.00 per share. The offer and sale of the shares of common stock in the IPO were registered pursuant to a Registration Statement on Form S-1, as amended (File No. 333-253329), that was declared effective on March 11, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the intended use of proceeds from our IPO as described in our final prospectus, dated March 11, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on March 12, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. Reserved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our audited financial statements and related notes included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#x201c;Risk Factors&#x201d; section of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. We were formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific GPCRs. Our small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of world-class GPCR research. We are currently focused on developing the following product candidates in our pipeline:</span></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352, an oral, centrally acting, 5-hydroxytryptamine 2C receptor subtype, or 5-HT2C, superagonist, currently in a Phase 1b/2a clinical trial (the PACIFIC Study) expected to evaluate 50 participants ages 12 to 65 years old with developmental and epileptic encephalopathies, or DEEs, which may include Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, CDKL5 deficiency disorder, SCN2A-related disorders, among others, with study enrollment expected to be completed in the first half of 2023 and topline data expected in the second half of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023; and</span></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP659, a centrally acting, sphingosine-1-phosphate, or S1P, receptor subtypes 1 and 5 modulator, for which the Company anticipates initiating a Phase 1 clinical study in healthy volunteers in the first half of 2023 and anticipates topline single ascending dose data in the second half of 2023.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a License Agreement with Arena (Arena License Agreement), pursuant to which Arena granted us an exclusive, royalty bearing, sublicensable, worldwide license to develop and commercialize LP352, LP659, LP143 and certain 5-HT2A compounds (pharmaceutical products containing any such compounds, the Licensed Products). In January 2022, we amended the Arena License Agreement to add an additional program, and in September 2022 we further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table provides an overview of our product candidates currently in development:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img8619836_9.jpg" alt="img8619836_9.jpg" style="width:720px;height:250px;" />&#160;</p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to LP352 and LP659, we plan to continue to identify and develop other clinically differentiated product candidates for neurological diseases with high unmet medical need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also eligible to receive royalties of 9.5% to 18.5% on sales of lorcaserin if approved for commercialization through the Royalty Purchase Agreement (as defined below).</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in January 2020. Since our inception, we have devoted substantially all of our resources to organizing and staffing our company, research and development activities, business planning, raising capital, in-licensing intellectual property rights and establishing our intellectual property portfolio, and providing general and administrative support for these operations. We have principally financed our operations to date through the private placement of convertible preferred stock and public issuances and sales of our common stock. To date, we have raised gross proceeds of approximately $56.0 million from the issuance of our convertible preferred stock in October 2020, $84.8 million from our IPO in March 2021 and $23.0 million from our follow-on public offering in February 2023. As of December 31, 2022, we had cash, cash equivalents and short-term investments of $67.6 million.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses since our inception. Our net losses were $43.9 million and $27.8 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $86.1 million. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and preclinical studies and our expenditures on other research and development activities. We expect that our expenses and operating losses will increase substantially as product candidates advance through preclinical studies and clinical trials, and as we expand our clinical, regulatory, quality and manufacturing capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution, if we obtain marketing approval for any of our product candidates, and incur additional costs associated with operating as a public company. We expect that our existing cash, cash equivalents and short-term investments, along with proceeds from the follow-on public offering completed in February 2023, will be sufficient to fund our operations for at least the next 12 months. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We base our estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to generate any revenues from product sales unless and until we successfully complete development and obtain regulatory approval for one or more product candidates, which will not be for many years, if ever. Accordingly, until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our research and development programs, future commercialization efforts or other operations, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, which would have a negative impact on our financial condition.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global COVID-19 pandemic continues to evolve. As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing and planned clinical trials. For example, the initiation of the multiple-ascending dose (MAD) portion of the Phase 1 clinical trial of LP352 was previously delayed, in part, as a result of the impact of the COVID-19 pandemic on the clinical site in the United Kingdom that conducted the single-ascending dose (SAD) portion of the Phase 1 clinical trial for LP352, and subsequently we modified the protocol and relocated the MAD portion of such trial to a new clinical site in the United States. We completed the MAD portion of the Phase 1 clinical trial of LP352 in September 2021. The extent of the impact of COVID-19 on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our development activities, planned clinical trial enrollment, future trial sites, contract research organizations (CROs), third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and work locations. We will continue to actively monitor the evolving impacts of the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. The extent to which the COVID-19 pandemic or a similar health epidemic may affect our business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains highly uncertain and subject to change. For a discussion of risks related to the impact of the ongoing COVID-19 pandemic on our business, see Part II, Item 1A, &#x201c;Risk Factors&#x2014;Risks Related to Our Business Operations, Employee Matters and Managing Growth&#x2014;COVID-19 has impacted and could continue to adversely impact our business.&#x201d;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the ongoing geopolitical turmoil caused by the conflict in Ukraine has contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on our business or ability to access the capital markets in the future. For a discussion of risks related to the impact of the ongoing conflict in Ukraine on our business, see Part II, Item 1A, &#x201c;Risk Factors&#x2014;Risks Related to Our Limited Operating History, Financial Position and Need For Additional Capital&#x2014;We will need substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all. A recession or other unfavorable market conditions, including economic slowdowns, recessions, inflation, rising interest rates and tightening of credit markets caused by the ongoing COVID-19 pandemic, the conflict in Ukraine or otherwise, may limit our access to capital. Failure to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts or other operations.&#x201d;</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreements with Arena</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Below is a summary of the key terms for our license and other agreements with Arena.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into the Arena License Agreement, pursuant to which we obtained an exclusive, royalty bearing, sublicensable, worldwide license of certain intellectual property for the Licensed Products. In January 2022, we amended the Arena License Agreement to add an additional program, and in September 2022 we further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products. The Arena License Agreement imposes various development, regulatory and/or commercial diligence obligations on our company, and requires the payment of royalties, including a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by our company, its affiliates or its sublicensees, subject to standard reductions, and other obligations.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Royalty Purchase Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a Royalty Purchase Agreement (Royalty Purchase Agreement) with Arena and 356 Royalty Inc., a wholly owned subsidiary of Arena (356 Royalty), pursuant to which we purchased the right to receive all milestone payments, royalties, interest and other payments relating to net sales of lorcaserin, in all countries and territories of the world owed or otherwise payable to 356 Royalty by Eisai Inc. and Eisai Co., Ltd. (Eisai), pursuant to a Transaction Agreement dated December 28, 2016, as amended (Transaction Agreement), by and among 356 Royalty and Eisai for an upfront payment of approximately $0.1 million. Under the Transaction Agreement, the royalty rates range from 9.5% on annual global net sales less than or equal to $175.0 million, 13.5% on annual global net sales greater than $175.0 million but less than or equal to $500.0 million and 18.5% on annual global net sales greater than $500.0 million. In addition, we purchased the right to receive a payment of $25.0 million, which will be payable upon the achievement of a sales milestone. Lorcaserin is currently in a Phase 3 clinical trial for Dravet syndrome.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Services Agreement</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we entered into a services agreement (Services Agreement) with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for us. The initial term of the Services Agreement was through December 31, 2021, and it then automatically renews for successive one-year terms. Neither party provided notice of non-renewal as of December 31, 2022. Each party may also terminate the Services Agreement for any reason, subject to specified notice periods. During 2022, we significantly reduced our activities under the Services Agreement, including as a result of our having hired employees or contracted with third parties with the requisite expertise, and we are no longer dependent on such services from Arena.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Our Results of Operations</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;" id="bkmk_127"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operating expenses consist of (i) research and development expenses and (ii) general and administrative expenses.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses consist primarily of direct and indirect costs incurred in connection with the preclinical and clinical development of our product candidates.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs include:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">external research and development expenses incurred under agreements with CROs, investigative sites, consultants and other third parties to conduct our preclinical studies and clinical trials; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs related to manufacturing our product candidates for preclinical studies and clinical trials, including fees paid to third-party manufacturers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indirect costs include:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation, for personnel engaged in research and development functions; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other various expenses.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We track direct costs by stage of program, clinical or preclinical. However, we do not track indirect costs on a program specific or stage of program basis because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our research and development expenses will increase substantially for the foreseeable future as we continue the development of our product candidates, particularly as product candidates in later stages of development generally have higher development costs than those in earlier stages of development. We cannot determine with certainty the timing of the initiation, duration or completion costs of future clinical trials and preclinical studies of our product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate that we will make determinations as to which product candidates and development programs to pursue and how much funding to direct to each product candidate or program on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements may occur, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development expenses may vary significantly based on a variety of factors, such as:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, rate of progress, expense and results of our preclinical development activities; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the phase of development of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per patient clinical trial costs; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of clinical trials required for approval;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of sites included in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients that participate in our ongoing and planned clinical trials;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the countries in which our clinical trials are conducted; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates, particularly in light of the ongoing COVID-19 pandemic and the conflict in Ukraine; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the duration of patient participation in our ongoing and planned clinical trials and follow-up;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety profile of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, receipt, and terms of any approvals from applicable regulatory authorities including the FDA and foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant and changing government regulation and regulatory guidance;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential additional trials requested by regulatory agencies;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of manufacturing our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we establish additional strategic collaborations or other arrangements;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the ongoing COVID-19 pandemic, the conflict in Ukraine and general disruption of global supply chains and financial markets; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, which include salaries, payroll taxes, employee benefits, and other employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to corporate matters, professional fees for accounting and consulting services and facility-related costs.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our ongoing general and administrative expenses will increase modestly for the foreseeable future to support our increased research and development activities and increased costs of operating as a public company and in building our internal resources. These increased costs will include increased expenses related to audit and legal services associated with maintaining compliance with exchange listing and SEC requirements, prosecuting and maintaining our patent portfolio, and investor and public relations activities associated with operating as a public company.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_130"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.382%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.112%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.306%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,638</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,774</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,160</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,065</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44,798</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,839</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44,798</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(27,839</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">837</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(22</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(43,945</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(27,797</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2022 and 2021:</span></p>
  <p style="margin-left:6.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.13%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.355%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.122%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.52%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct costs:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LP352</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,389</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,212</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preclinical programs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,596</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,224</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indirect costs:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,408</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,548</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,245</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">790</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,638</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,774</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses were $34.6 million for the year ended December 31, 2022. These expenses include $19.4 million in preclinical and clinical trial expenses related to LP352, $5.6 million in preclinical expenses primarily related to advancing LP659 and $8.4 million in personnel-related expenses. Research and development expenses were $19.8 million for the year ended December 31, 2021. These expenses include $8.2 million in preclinical and clinical trial expenses related to LP352, $6.2 million in preclinical expenses related to advancing LP659 and LP143 and $4.5 million in personnel-related expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses were $10.2 million for the year ended December 31, 2022. These expenses include $5.3 million of personnel-related costs, $2.0 million of professional services and consulting expenses and $1.6 million of insurance expense. General and administrative expenses were $8.1 million for the year ended December 31, 2021. These expenses include $4.0 million of personnel-related costs, $1.7 million of professional services and consulting expenses and $1.5 million of insurance expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and short-term investments of $67.6 million.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have funded our operations primarily through the private placement of convertible preferred stock and public issuances and sales of our capital stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, we completed a $56.0 million private placement of our Series A convertible preferred stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our IPO in March 2021, we issued and sold 5,298,360 shares of common stock, which included 298,360 shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $16.00 per share. We raised $76.2 million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $5.9 million and issuance costs of $2.6 million.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we entered into a Controlled Equity Offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:4.355pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sales Agreement (Sales Agreement) with Cantor Fitzgerald &amp; Co., as sales agent (Cantor Fitzgerald), pursuant to which we may issue and sell our common stock from time to time through our &#34;at the market offering&#34; (ATM) program under the Sales Agreement. We have no obligation to sell any shares of common stock under the Sales Agreement and may at any time suspend sales under the Sales Agreement. Cantor Fitzgerald will be entitled to compensation in an amount of 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. A maximum of $20.0 million of shares of common stock may be sold under the Sales Agreement. During the year ended December 31, 2022, we sold no shares of our common stock under the Sales Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we raised $23.0 million in a follow-on public offering. We issued and sold 5,750,000 shares of common stock which included 750,000 shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $4.00 per share. We raised $21.2 million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $1.4 million and issuance costs of $0.4 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Material Cash Requirements</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that our existing cash, cash equivalents and short-term investments, including proceeds from the follow-on public offering completed in February 2023, will be sufficient to fund our operations for at least the next 12 months. We believe we will meet longer-term expected future cash requirements and obligations beyond the next 12 months by utilizing our existing cash, cash equivalents and short-term investments and through a combination of equity offerings, debt financings, collaborations, licenses and other similar arrangements. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based our estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. Our ability to fund longer-term operating needs will depend on our ability to access the capital markets, our ability to enter into third-party arrangements, and ultimately our ability to commercialize our product candidates for which we may obtain regulatory approval, and other factors, including those discussed in Part II, Item 1A, &#x201c;Risk Factors&#x201d; of this Annual Report.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical trials for our current and any future product candidates and the potential indications which we are pursuing or may choose to pursue in the future;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and costs of regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of obtaining, expanding, maintaining and enforcing our patent and other intellectual property rights;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of establishing or securing sales and marketing and distribution capabilities, whether alone or with third parties, to commercialize product candidates for which we may obtain regulatory approval, if any;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third- party payors and adequate market share and revenue for any approved products;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patients&#x2019; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the timing and amount of the payments we are obligated to make under the Arena License Agreement;</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs associated with any product candidates, products or technologies that we may in-license or acquire; and</span></div></div>
  <div style="margin-left:4.139%;text-indent:0.0%;display:flex;margin-top:10.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.13%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.221967223375512%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">if we experience any delays or encounter any issues with any of the above, which may be exacerbated by macroeconomic events stemming from the ongoing COVID-19 pandemic or evolving geopolitical developments such as the conflict in Ukraine.</span></div></div>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any product candidate for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for at least several years, if ever. As a result, we will need substantial additional financing to support our continuing operations and further the development of and commercialize our product candidates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our cash needs through a combination of public or private equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic, the conflict in Ukraine or otherwise. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams or research programs or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our research and development programs, future commercialization efforts or other operations, or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves, which would have a negative impact on our financial condition.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into contracts in the normal course of business with third-party contract organizations for preclinical and clinical studies and testing, manufacture and supply of our preclinical and clinical materials and providing other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice, typically 30 to 60 days, and therefore we believe that our non-cancelable obligations under these agreements are not material.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_136"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth a summary of our cash flows for the years ended December 31, 2022 and 2021:</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.537%;"></td>
    <td style="width:1.933%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.697000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.943%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.891%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(38,063</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(24,705</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(17,064</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(40,716</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash (used in) provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(444</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,451</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(55,571</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,030</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities was $38.1 million and $24.7 million for the years ended December 31, 2022 and 2021, respectively. Net cash used in operating activities during the year ended December 31, 2022 was primarily due to our net loss of $43.9 million, adjusted for $2.7 million of stock-based compensation expense and $3.1 million from changes in operating assets and liabilities. Net cash used in operating activities during the year ended December 31, 2021 was primarily due to our net loss of $27.8 million, adjusted for $2.0 million of stock-based compensation expense and $1.0 million from changes in operating assets and liabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities was $17.1 million and $40.7 million for the years ended December 31, 2022 and 2021, respectively. Net cash used in investing activities during the year ended December 31, 2022 was related to $57.6 million of short-term investment purchases, which was offset by $40.5 million in short-term investment maturities. Net cash used in investing activities during the year ended December 31, 2021 was related to $40.7 million of short-term investment purchases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by financing activities was $0.4 million and $76.5 million for the years ended December 31, 2022 and 2021, respectively. Net cash used in financing activities during the year ended December 31, 2022 was comprised of financing related expenses. Net cash provided by financing activities during the year ended December 31, 2021 was comprised of net proceeds of $76.5 million from our IPO, which excludes $0.2 million of IPO expenses that were paid in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For detailed information regarding recently issued accounting pronouncements and the expected impact on our financial statements, refer to Note 2 &#x201c;Summary of Significant Accounting Policies,&#x201d; in the accompanying notes to our audited financial statements included elsewhere in this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.167%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on a periodic basis. Our actual results may differ from these estimates.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in more detail in the notes to our financial statements appearing in this Annual Report, we believe that the following accounting policies are critical to understanding our historical and future performance, as the policies relate to the more significant areas involving management&#x2019;s judgments and estimates used in the preparation of our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, based on a pre-determined schedule or when contractual milestones are met, but some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time. If timelines or contracts are modified based upon changes in the protocol or scope of work to be performed, we modify our estimates and accruals accordingly on a prospective basis.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We base our expenses related to external research and development services on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, a hypothetical 10.0 percent increase in our liability for accrued research and development expenses would have resulted in an increase to our net loss of approximately $0.4 million.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging Growth Company and Smaller Reporting Company Status</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; under the Jumpstart Our Business Startups Act of 2012 (JOBS Act), and as such, we can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will cease to be an emerging growth company prior to the end of December 31, 2026 if certain earlier events occur, including if we become a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Securities Exchange Act of 1934 (Exchange Act), our annual gross revenues exceed $1.235 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also a &#x201c;smaller reporting company&#x201d; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item7a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Quantitative and Qualitative Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under SEC rules and regulations, as a smaller reporting company we are not required to provide the information required by this item.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item8"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Financial Statements and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.917%;"></td>
    <td style="width:7.083%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#auditor_report"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations and Comprehensive Loss for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statement_cashflows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows for the Years ended December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#fs_notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="auditor_report"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rep</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ort of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Stockholders and Board of Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of Longboard Pharmaceuticals, Inc. (the Company) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ KPMG LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Diego, California<br />March 2, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.568%;"></td>
    <td style="width:1.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.12%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.601%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.099%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4eb6990a-a9de-42e7-918d-c22c62f3c54e" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0381df1a-2fe2-4ee4-b3ca-18a80d524332" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_511949e6-240e-4f4f-8f6f-d20af4bc26a0" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6721d1f5-0f7b-4e75-b622-18ddc68200c3" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3320168-37e9-41cf-a99a-30251ae88f8d" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0eb2b5f3-1f68-425b-bcf6-0d152501650d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,659</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e56ca81a-82a9-47df-b03c-0e0635e18b29" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_373f137d-874f-4706-9147-faf351bb7256" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5a07711-5131-4c42-9869-71ae326907fc" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">736</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7cbb2c7-ec3f-473f-bbda-895e7355ef99" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c58a9f86-5b1f-4df2-aee4-8c77067ff9e7" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca6f004d-b0a1-4c6b-aac7-ba8931713fb6" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f0e8293-b3ff-4166-8c0d-8e919f93a435" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OtherLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_872b37f8-96f9-47cb-8f26-f460f89239f0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OtherLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28cf4912-b736-459c-9bd3-a24fe117dbde" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c4bb098-0821-40de-a480-fe7c37ba75e3" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef6e1ee4-1451-427a-a93a-d92d7fa9357a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,310</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8288d3c-f020-4269-9cd6-4821151f1854" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fcc5f68-c9c2-4681-9c7c-d0049f119d97" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eabc0f48-a331-4642-a59e-7ac2dbb34c5c" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:AccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91fedb99-2a35-4f9e-ab4b-916535614af8" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_273e56ab-4600-4a2e-8449-fee09979836a" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6a45b0d-b0d5-4c12-85ed-986516a018b7" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_902075c9-4cf3-4ebe-ac94-5e249391e771" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use liabilities, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2dc95b8f-35fc-4732-a455-8779df6eb9bf" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_686daa86-7e66-4634-9f2f-d18c4b70b86c" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a8ebd7f-52e9-432e-9211-39c199bfdb9a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_865c8685-7066-4b2b-8042-5ac4966ce588" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea6127dd-54c0-499d-9876-8820d1158025" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9daf68e-0c99-4da8-a596-66b03299b7ef" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_7074996f-aa33-408c-a854-e306fcd2dcfc;"><span style="-sec-ix-hidden:F_75379c9c-6922-449b-9b8b-dd32eeaad626;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (see Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e470878-b600-43ea-8a8d-848b6ef45e84" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_858c57e5-3f58-4d30-8ac7-7f4d3aab78d8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19462267-f983-4d37-a802-c0ddc6480190" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_1917a8fc-8579-47cf-aee6-711d5e4e9a79" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e61144c-c440-4242-81eb-a8198d4dbce0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_61713ec7-ac80-48aa-a953-2dd899c533fc" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ed09cc05-6768-4979-a4f9-62accbcfcdb4" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6ecd3f3a-4726-40f4-a398-d6216567d823" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b829b30a-a717-4c7d-981c-ab68eaddc621" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f3334f-9463-4836-9ff4-3eb8e1425f5e" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_125321bd-fb5e-4a12-86bd-2bfd6d151fe7" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_93161dd0-671f-4022-b754-eea94aaacdf8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb828980-b329-4f5d-ba7c-a0c3efb9a080" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_3fbc326b-6e7a-4b0b-8ed8-e4a3c5a881d8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcecf1e6-eba8-421d-a012-5108b40198e6" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_67529525-553e-441a-b21a-3278b4e9f0a6" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,585,950</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceab748d-b6f6-4182-a3d5-83716093d723" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_7ce0a8c5-8705-4109-9230-8705369ac0e4" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively, excluding </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_134a1290-da14-4148-adef-5be7ad18fe7a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cafb0396-55cf-4e3a-bd9d-b65e273f6fdf" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">145,189</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares, respectively, subject to repurchase</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d431750-e17b-42a5-b65c-3d3ea5e914ad" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6357575-058f-4cf7-8992-d2341c75bec8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-voting common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_517f7d4f-966f-4610-a243-2505d1a30451" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_0ef23eeb-c6dd-46b9-aa0f-3fd3ae62c37b" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:numdotdecimal">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; authorized shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bab1f056-3fd6-49d7-8358-497abe46552b" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_14772714-54d0-474a-a192-073aae414172" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively; issued and outstanding shares - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_762c7d33-edf1-4f7c-8779-2ea61adf5321" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_55d5adfd-7edd-41b8-960c-eaa9d115e577" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_8d84ab0c-efa6-4749-8693-1b18e38fd9f8" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_82a753aa-61fe-4d17-b065-686059c86275" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_588e9718-d149-44cf-a6d8-1f582668adf9" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8949e49-42d4-4b8c-a896-4c354418fce3" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be129502-675e-4efe-8a18-3fef808f5dac" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148,303</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93781bfa-0c80-4b21-9951-be189401eb38" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf362a1e-8e4d-41b7-bd2d-70f752fca483" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc900ee0-adf2-4f02-bbd6-68063c916f40" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3822c3a1-75d3-4c6e-9034-9b1b1ec7d464" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d9284f5-4a2c-45a2-8b45-01a65daaa5bb" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,197</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d446cdd-8870-4685-9905-f59d8575750e" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6041fd8f-3d5b-4ac4-8b49-a06463022dec" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20930ec4-d0ba-4c6e-b1b9-f9ad022fbbdc" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e78e2cfd-205f-42b4-aa91-d8d634b6598d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108,952</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.411%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:16.351000000000003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.016%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:17.221%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c7cd8fb-2a6f-4d47-8f79-7263585b9169" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,638</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_273f5e7d-64fb-42a4-9c54-7cc2f1700c15" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceadcc29-e127-4a6a-9b16-d52e27266e6a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15508cd1-a9d4-4856-9018-848409a2ca99" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,065</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50602f1c-5a2c-4d26-b029-afa86b85bbab" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,798</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3eb4593-f78b-4869-856e-e4772be2aa60" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7c0520-ad79-41df-b41c-b01f0b0c0974" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,798</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc487818-fc28-4a91-9b39-a6ca178815e7" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1554291-2aac-4efb-a07c-106e5666afc1" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c98ab180-cf6a-4da6-888f-0f62f7e58aa8" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:InterestIncomeExpenseNonoperatingNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50d877a1-ddc9-4ad7-b3d4-99238352ac05" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_717230fe-e935-442a-8db0-d38e2b41b219" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:OtherOperatingIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10b7c86f-b4df-48eb-808c-57d7184dad2e" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0736233c-7830-4a8d-961e-4748cf420643" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a3a163e-b5b0-4682-afc2-cc52487dec8c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_8fa7640b-f36a-4db0-8dcd-e0d9554baedc" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.56</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba24b94-2253-4157-b2c6-b1928d37dc16" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_c469f77c-fe61-48db-9c92-742292bf67c3" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.93</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b2409b4-5312-4ad2-9784-545cb5faea7e" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ad5c286c-12a7-47e3-8288-8bee4b1acc2a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,150,907</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca9618c1-2720-4d07-8186-a58b19cf5879" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_42a89ac1-21b6-489d-925f-c61319a2e141" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,410,502</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f722861-4003-43fe-8906-95702296cd64" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cdaa3bc-2aca-400c-a37c-2fcfb54cc7da" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dde5d32e-be26-4992-9ea6-9d7013715843" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1701bcb-2168-4182-803c-50c3365cf260" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b5a5f44-ea52-438c-a058-6f8b007a417a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44,473</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4af3b4c-bee1-4194-a93c-bba048cc9f10" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_equity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.672%;"></td>
    <td style="width:1.069%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.793%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.069%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.91%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.069%;"></td>
    <td style="width:1.069%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.6820000000000004%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.2270000000000003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.673%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.5700000000000003%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.194999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.846%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.136%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.061%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.591%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Convertible Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Voting Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Voting Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands, except shares)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-in<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Other Comprehensive Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total Stockholders' Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7e9d33-70ab-4fb7-b64f-6cd9d873dc52" contextRef="C_dd718034-3502-4331-8733-465c9d758bcd" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,600,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f84b94e-eb01-41dc-9642-f324066b7ca6" contextRef="C_dd718034-3502-4331-8733-465c9d758bcd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03238d99-edb9-4ce4-a646-364f8cf6fc5c" contextRef="C_f7408153-655c-4c91-a796-44b1c9e2b6bc" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,840,540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3ae8bda-55fc-4280-8822-f355e3a7f6fa" contextRef="C_8814bdd7-1687-482a-bc89-42533bc5d148" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,708</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_542b333b-1f9f-4e41-8e90-32b445bfae22" contextRef="C_4f66a237-edb9-4f7a-a43e-d837a3fc0485" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9e748e3-3333-43f4-8acd-24f1ef30eba5" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of Series A convertible preferred stock to common stock in connection with initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b61095a2-8513-424c-9a87-3d283c0fcdab" contextRef="C_45ad8322-a85c-453a-9600-e04bab154cf5" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">5,600,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d3f70d5-ca89-491a-84c7-a237413f6adc" contextRef="C_45ad8322-a85c-453a-9600-e04bab154cf5" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa52347d-121e-430d-84dd-6ea0167feabb" contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">4,098,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1096144b-445c-47ad-a734-2b16ad29a6f0" contextRef="C_974c0b74-b247-493a-a244-61954bd74ea0" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_959bd8ee-a855-424d-9374-d8a25046dfce" contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5951f1f6-3743-4715-b7ac-f3ce58f325eb" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in initial public offering, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_707f48ad-c990-4f69-af49-d19250bbfd41" contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,298,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cea36d2b-37b9-4de0-afb2-84204fdb1f83" contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5974ca50-4f8c-4b78-bec3-d464bdc65ccc" contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38aebc22-37d9-45f8-9ba1-69026e766ed9" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad80289-87b9-4c45-8608-118dd9b723af" contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">203,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8aea391f-3911-4b6b-8b33-cee9c96d1926" contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5892a5a3-6be2-422c-8f3c-6de8c7bbc1eb" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ab969da-8ee6-4656-ad5c-effbd344fa07" contextRef="C_1515ae5b-ea8a-4cfb-8646-520a57119b6a" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_078ac2d3-971d-4b17-83d4-6923f0c390c8" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9987a77f-2d95-47df-abd9-376be231fb14" contextRef="C_1282f9df-89a7-4f4e-9c7a-cb95e8ead303" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40698a02-d611-48b1-aae2-8bf41cfb862f" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41bc4a52-497e-4cc1-abbb-cc5045489cca" contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3717375-de29-447d-9a12-0291415d85bf" contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7471d078-d159-4302-b5af-beff87129d7e" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8787d541-3254-4443-a77e-34e432606b8b" contextRef="C_c36fe1a1-d21f-4b74-a586-0129d93b4a19" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,683</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7af18d36-d7ed-4a22-af5f-d64bba6baf97" contextRef="C_b2da7e87-edb0-45d0-b6f2-541ed90e5347" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_296b40a8-004d-4a8b-ab0b-ea14c7255238" contextRef="C_396dcdce-0d58-40b6-bfc6-6c19ad7ef2d8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42,197</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e007c8e-abd2-4491-9720-e28a26589203" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,323</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2039093-7601-42dd-a9e0-9614a99cdfde" contextRef="C_70566aaa-8ddd-488f-8329-70945439bec9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">145,189</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b46af7b5-5090-4957-b8a1-513208c7e75e" contextRef="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c9a2355-fe39-4d93-bd70-7068d5718b8a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing related fees</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_658822a1-b91e-4000-b258-6b179e3f6f3f" contextRef="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa" name="lbph:FinancingRelatedFees" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b1a1909-17cd-4db7-9680-743a84644ff2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:FinancingRelatedFees" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized loss on short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e9ea7bf-7532-4c99-8dba-c8e2254d8096" contextRef="C_8f6a227c-60ec-49a6-8cdd-04c84137d99d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de9815ae-b606-4767-869c-0103721f2803" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34c4309e-b1b8-432d-81c1-5dadc335e02d" contextRef="C_d9891fa5-a5a6-46ca-ab8f-679aad15f810" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76835256-7e6a-4018-8585-4d881e9ec4c4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_793485b1-7f68-450b-b03b-39130d4f0243" contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,585,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4140583-ca55-462c-98db-7db8a6c19289" contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c2c31bb-e5dd-479e-b5e3-198469a10ad8" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4742d379-1ace-4dd0-bfd7-2951492ec034" contextRef="C_c34bb4d2-986f-4c99-8052-d48376f6db2f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148,303</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fab22930-0a00-41e6-8857-25333b276a7a" contextRef="C_1f4f6d27-b781-451e-928f-7197f0c3b0a9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6046986-f96d-436e-be05-5d49625a2cfd" contextRef="C_be512020-51df-4a10-b5c1-f8941f57b2b2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">86,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a0e0f36-da95-4b19-a617-88967361b708" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statement_cashflows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:68.528%;"></td>
    <td style="width:1.542%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.197999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.532%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.197999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf9bf15d-91b2-4870-872c-c9a6b5314d54" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d468e95f-0949-479c-9317-8edb947662a3" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8940ca48-3cdd-4342-8921-2d0c15d9646a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67c83f0c-3654-4537-bf6c-125a3b9dc5d9" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a39e47f2-515d-46ff-981f-4285fa7b2f4b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_839743d5-a796-4d8c-ba0f-102e4297dd97" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accretion of premiums on investments, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_771a0745-3fd3-4225-b390-1ac88ee43392" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0666e3b-1d52-401e-b966-3eeae0af2f76" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c980c0a-0e01-45d2-80db-9bd476cda523" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">183</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01e72ffc-5f10-4044-876d-9df2165c146b" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6608016b-258d-49b7-9563-06153066c15d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30874248-125e-4cd1-bf14-3ce370336d83" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d28800d-727e-483a-a718-03d8392f79fa" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf750b34-8e1f-4b28-bdf9-c49bd893cd99" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,329</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation and related expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d316b2cb-3f62-40d5-89b0-9768a43fd648" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncreaseDecreaseInAccruedSalaries" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d1553d9-d6dc-45e2-919a-641020047e31" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncreaseDecreaseInAccruedSalaries" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c5b1787-aae0-4e28-879d-0200b5c37b2d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">138</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b77486b-a922-46c4-8d7a-870d22db34c9" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating right-of-use assets and lease liabilities, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f33105cc-74e3-4c8b-b958-f2949a75aa9a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c80b7f99-c1ce-4509-a7a9-c6f47b813cc1" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79d5b86e-ab42-43ef-bb07-de5473cf8366" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">38,063</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71ace06e-0aab-4390-8d4e-200ac52b850d" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,705</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of short-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed377a46-226b-4a07-abeb-61ec870465c5" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95504acf-ddab-44b8-9d9d-62cd0421ecea" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d13fe185-fe37-4ba5-8b9d-a131938441d4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e314427a-d2b4-46c5-9dfc-8bfc2425c231" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20f19986-54ad-443b-b025-b3669a38e8b6" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6931898b-0a03-4329-91af-dc7a5f442a7d" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_206d1c75-818c-4994-b7e2-bc6c7f3c62b8" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">17,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55187ed5-365a-4e99-8756-846675cf9dcb" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,716</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Series A convertible preferred stock financing costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e598bd1-d20f-4186-a94d-32f83aa1c6d7" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6469c5f-5c67-4889-8196-e1f02bc3e7ad" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from initial public offering</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec86b563-ddd9-42f6-a335-2976519ac0a9" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e82bc1e-cfa4-48f8-b8a7-09f5e593e624" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial public offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4b1a2fc-ca11-4f5a-be90-b1bdddefadbf" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86130637-087d-4780-a8cf-f8edbcd99ff6" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,322</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing related fees</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aff51cc4-802b-423d-8bc2-8d6dbd4203e2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_822d198c-cfdd-4ee7-9bbe-1f69bc0c7caf" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash (used in) provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a164d8f-b4cc-4a9e-8de2-59319c77acee" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d96cad1-4147-4eb5-88ac-094e6f7b3565" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d306005-c3aa-44ee-bdad-a57fc3266e40" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,571</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8471fd7-2f3b-4916-8631-f9f4bd695316" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,030</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at the beginning of the period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a31a72f-08ab-4c1a-bef6-d6f124c22ccb" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3d3981d-1053-4585-a46d-f0dc0f5f6cd1" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,316</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents at the end of the period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b595766a-90f9-4769-8da8-f15e343778fd" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d69e096-edb6-4bf1-8bb5-c036fa3c71fa" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,346</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued on conversion of convertible preferred stock in connection with initial public offering</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4888de9d-58ab-4a66-b929-08488205a825" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0e9cd51-ee22-47e1-8df1-8f5d64c8af42" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,794</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fs_notes"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not</span><span id="notes"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es to Financial Statements</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fcce3195-aa16-40a8-8a65-4c5e3aa1f7f9" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 1. Organization and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. (the Company), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020 and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. (Arena), until the closing of its Series A convertible preferred stock (Series A Preferred Stock) financing in October 2020. The Company is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#x2019;s most advanced product candidate, LP352, is a serotonin receptor that is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial (the PACIFIC Study). The Company is also developing LP659, an S1P receptor modulator, which could have applicability in multiple neurological conditions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 16, 2021, the Company completed the initial public offering (IPO) of its voting common stock. In connection with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deab6a8a-3fb8-4ebf-8321-f39bbe65f65d" contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c" name="lbph:NumberOfCommonStockSharesIssuedAndSold" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,298,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock, which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62fc777f-63e8-4d66-a87b-f0da3a1d6534" contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">298,360</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcc89524-4a40-4e4e-a92c-9d420ca2d5b9" contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2065041-f2d0-4fea-9669-8e9cb3cecf25" contextRef="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">76.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b8b5a35-1b65-4bb3-839c-5de1efb9cc87" contextRef="C_c8ccaab1-2bd3-458a-8b03-8557b629abff" name="us-gaap:CommonStockDiscountOnShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d019123f-cd17-48fe-87ca-90ec9bfc5dc3" contextRef="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;common stock&#x201d; refers to the Company's voting common stock.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40a6df6f-d08e-4887-951c-0779c95e37c9" contextRef="C_fe3381e4-0776-4a65-882e-c5998ec43929" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,630,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0af19b4-c939-49c7-9a33-d569dd684986" contextRef="C_cec91faf-30a3-4e32-832f-b145d4c6a42a" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_794c6b8f-7c2c-4a15-bb49-7a4c16d7db80" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,970,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3117f83d-4689-4e1a-a21e-bda0d44ed64e" contextRef="C_e460be53-bb93-4714-a2f3-98129e137c72" name="us-gaap:ConversionOfStockSharesConverted1" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,098,600</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Forward Stock Split</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_afe7ddf2-3de9-41a4-95f3-11902967555b" contextRef="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b" name="us-gaap:StockholdersEquityNoteStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43b7e888-ca1b-4a65-b972-c40b5809ad69" contextRef="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.38</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial statements have been prepared in accordance with US generally accepted accounting principles (GAAP) and reflect all of the Company's activities. The financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2022, are not necessarily indicative of future results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to research and development (R&amp;D) activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual property portfolio, and providing general and administrative (G&amp;A) support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56b710aa-cca6-4390-937d-2ddba93950dd" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">86.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25f4ba8f-eb43-4c98-9178-2bbecc9327b0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">42.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Geopolitical and macroeconomic events, such as the COVID-19 pandemic and the conflict in Ukraine, continue to evolve and have resulted in a significant disruption of global financial markets. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from such events. If the disruption persists or deepens, the Company could experience an inability to access additional capital.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had available cash, cash equivalents and investments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_902eba0f-322d-4708-8d0c-6e4f0b588d62" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">67.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ab07614-a80c-408a-883b-a3c9b369422e" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:WorkingCapital" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">61.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to fund future operations. Management believes that its capital resources as of December 31, 2022 along with the proceeds from the follow-on public offering completed in February 2023 will be sufficient to fund the Company&#x2019;s operations for at least 12 months after the date these audited financial statements are issued.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1befd146-6464-4f1f-827e-a4945f1fa132" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8eda8b1f-df48-4dd7-a184-e555ec0d7653" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0049b4a3-8c00-41b8-ab53-13b3394a701a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_787e532e-1d42-41c5-a9f4-4411f49bffb3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_01567c0d-9e01-4494-ac79-3c26b432fb4b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. Government-sponsored enterprises. The carrying amounts reported in the audited balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13b40ecd-fc58-4a3d-88f0-49767ab994a4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:ShortTermInvestmentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying audited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16d4d2de-da80-471e-9203-2760f178a5b2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b656442-cc31-4992-92d5-6fe1bb30700f" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PropertyPlantAndEquipmentBasisOfValuation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and depreciated on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5da7131-d32b-4134-b34b-eea765fc1f75" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PropertyPlantAndEquipmentDepreciationMethods"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">straight-line basis</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> over the estimated useful life of the related assets (generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9966dab8-f3b5-4022-bcb9-d2650d18a5da;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f862b3a2-17e2-4637-8fce-fcbc92f8388f" contextRef="C_dff02006-cd88-4a9f-b084-06afef117c07" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). Property and equipment as of December 31, 2022 consists of computer equipment.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66d8e89f-10de-43dc-ac99-3996864d0c4f" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5b1b62b-3f07-4a1c-ab03-ef1372b5e22f" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_013e9cf1-5d59-47b5-9dca-948656c90ecc" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, for the years ended December 31, 2022 and 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7beb4532-ea57-47f5-960e-91ff0975af74" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company&#x2019;s board of directors and stockholders approved the 2020 Equity Incentive Plan (2020 Plan). The Company's board of directors adopted the 2021 Equity Incentive Plan (2021 Plan) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. Under both the 2021 and 2020 Plans, awards are measured at fair value and recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58aefbe6-bde4-4dac-9e98-f38abb73dc64" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b0220280-634c-4cfe-83c0-6e0af4a4bd9b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;" id="bkmk_278"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.447%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:16.405%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.34%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:16.808%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a63e7c0c-3342-480b-83eb-edd5eeec123d" contextRef="C_4a748f73-8881-44ab-8a19-7b222ef02cd3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,395,748</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69621482-b785-4429-86f0-e8dab27b9557" contextRef="C_2e064b44-0ba6-4451-b69e-017e6f114799" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,421,756</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a79de21-31c9-4358-911f-a2938e917159" contextRef="C_0b4cba7f-1def-41a7-8c96-7470a5736a61" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3ec8be5-362f-454a-b030-3d6ace97b25c" contextRef="C_a865a91f-b26b-471a-990b-888ae5f1a037" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">145,189</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8618b12-ce30-413c-976b-2d34d6931c2c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,395,748</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0301fb4-ef9b-4f1c-bb4a-bc3502f4f2ea" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,566,945</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bcb652a9-f64c-432f-a6e4-5be89be504d3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5057acd0-52ee-4f40-a6ec-5830fa8693e0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aa222aa6-836a-4d64-93ef-27636a00ba3e" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance became effective for the Company on January 1, 2023. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fd96ec7-0c08-4419-aabf-fcd03e28768c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia, have contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on the Company&#x2019;s business or ability to access the capital markets in the future.</span></p></ix:nonNumeric></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d407b7c-6ca1-4b5e-8d9e-f77de3bdae83" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 3. Fair Value Measurements</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2014; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2014; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#x2014; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_43f74d9c-93f1-49c3-93c0-86d45548e612" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.597%;"></td>
        <td style="width:2.911%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.109%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.792%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.030999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at <br />Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br />(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs <br />(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs <br />(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a08638e-bc26-4f99-9d9c-28b4c506ee3a" contextRef="C_74af52ba-c383-42f9-b16d-f0ae6869106e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd8e23c8-1939-47ff-a189-9b7e97622963" contextRef="C_2387a101-f4f7-41ac-81ac-f6f8c20ae797" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edd17cb3-9d8c-4eb8-8caf-8564f9cbf56e" contextRef="C_5baa7a2f-9417-41f3-897c-6e8e7fb9c734" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f7d2bd4-47dd-4118-ad75-435dc60518ca" contextRef="C_bac860ed-4260-4d2b-aaa0-2cf0b6ff87f9" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_766219ae-273d-44dd-83eb-96c3fe0eb836" contextRef="C_b72f156f-3735-4e2b-85b3-f2d14f32ace8" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,429</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2172ddc-624a-4dc0-9094-06d700775089" contextRef="C_605c1392-d2f6-4361-a5a7-62e125b3d648" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ea33051-7a29-433b-9a8c-8b4e1e021939" contextRef="C_53b98a5d-b6cc-435d-a362-2f3c9ec191b3" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,429</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b682ce13-c694-4305-8908-ac58610e9194" contextRef="C_46857555-d570-4cd4-ae8b-3c59794bbe00" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a491216-1911-4484-961a-99400c0efa30" contextRef="C_d0e46809-eb85-4065-bb2f-e5ee4eca223d" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,737</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5be2c55-eb95-496d-b4d4-ed067884d2bb" contextRef="C_fa63f794-52c0-4d53-92d9-a98e8d59cf61" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf570bd1-e907-4136-b283-7f4b2b2ac10b" contextRef="C_9a38ddbe-fed7-4742-ab7b-2216e168c7ab" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,737</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d70113d-eee0-417a-ae8d-9bd028076b54" contextRef="C_53dd140c-ac6e-4f56-8b33-5aa2379a8262" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c60f43d5-2b49-4cb7-b5d0-f9aca648841a" contextRef="C_cac615bb-7672-44e1-90ae-9ae47c52b057" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f98fdb4f-a3e9-4989-8e9a-f589d954185f" contextRef="C_1f18a6a6-d98f-4e05-b791-6e86ed836955" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2e71be1-c7c8-4334-ba3a-947b469c3322" contextRef="C_701bf585-2e81-4356-a0ca-8b96a608fa6e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bafaf735-c10b-4fc4-823d-c16c7bbc37f6" contextRef="C_2ffd1420-ee39-450c-bf5c-212f9be25ac4" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5321ddad-ab6c-42a0-8350-64694be7656e" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16a372c9-b4ea-4d99-bee9-ba055e97ff8e" contextRef="C_379bd6b7-5319-4b15-8167-d1c5f35d5101" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03393d5c-39f5-4246-85cc-65dec26826c9" contextRef="C_27e2ac14-7028-40bd-adb2-ee9d7609e0b2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fee677f1-4376-4f07-8d6a-9cb61e2ce07c" contextRef="C_c563b15e-dc26-4b32-8128-0eb744b0ea45" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed051866-69ed-4966-bb24-3893eb617de2" contextRef="C_6f3ce05b-630d-43cb-8922-6a4a7d3fe473" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_076baad9-c2d0-4651-ab38-5e841312b876" contextRef="C_d5c63294-9633-482f-83e8-25fa79adec30" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4a65d2c-9e0e-4a77-bbef-f19be1f964bc" contextRef="C_48d2c5e1-2f02-4441-bec9-1183eabb3c33" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_303de350-5c0c-4c99-a436-1ab8ca26680b" contextRef="C_543a9b51-1efa-42be-8dd4-628dbc709107" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52f69e1f-0721-46a6-b8c7-244201fd6b4e" contextRef="C_8be4e204-080b-4434-8ee1-a698bdb48ced" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61136139-deed-4624-8755-df12338401b7" contextRef="C_0e02f99d-7c5e-4870-8e5b-0f199407f23f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d362645-970d-4a19-917e-ebe591112c3a" contextRef="C_5c17c66e-3873-4eff-9ad7-cbee76e03837" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90b2d449-8f13-42f8-957b-7ec4bffed888" contextRef="C_3eeb2093-348a-4291-bc28-b0dd5ac681be" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9fa82b1-d53a-4856-afe2-18105d4730de" contextRef="C_78f4b339-ebd9-40c0-a799-bb28950ec2e0" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a43e72ef-7fac-4d06-a239-3e04d0ed293f" contextRef="C_b6f25d12-90a1-4bda-b22f-fb58f13cbf4f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd4b1bf7-1d80-45c1-8c43-3743f3339bb6" contextRef="C_316ea6c1-7da7-4c8b-98b3-6abc844f5486" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47fa8261-f187-472c-b44c-6affd407f325" contextRef="C_ba895260-3a97-4fca-9f2e-da37a4f7379e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b026786-0205-4322-87cd-aa52d0b83bdb" contextRef="C_31b36330-7551-4a6c-b015-e29fcadaa3ae" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bdb5c98-0a86-4573-970b-d1e945526308" contextRef="C_8c2552fb-8de3-4abb-af54-8eaa29d393c8" name="lbph:ShortTermInvestmentsAndCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0f0c3a2-c458-4306-bc2a-27134717fdfc" contextRef="C_b7cb4cfe-7014-4ddf-b9bf-2f0c02907348" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,816</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc1cc657-1fb0-4ddc-9525-26782916e4be" contextRef="C_1cb02383-4a83-4256-897d-6beb9cf7f359" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c49f5ae-d55e-4b5b-9f2f-02286eeb809d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c86d2a94-7efd-4562-af07-a4a76447c453" contextRef="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47260231-9a0f-4d82-955c-51bd725f4600" contextRef="C_2e2350c3-4151-47e7-8025-d36e129778e9" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bcc8560-e045-49d4-971d-7c9a9f0f5aaa" contextRef="C_341fea9a-781e-4a09-8de8-80cfcb42280e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5163ca19-cf4f-48fa-b852-e17d69568cbd" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76ab05af-68a3-417f-b50b-4d2d5eb73743" contextRef="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5e41188-4bd4-4d1a-b9b6-6792c3f28da0" contextRef="C_2e2350c3-4151-47e7-8025-d36e129778e9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,820</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db4700f7-1811-4554-a039-f3b4273d5428" contextRef="C_341fea9a-781e-4a09-8de8-80cfcb42280e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of the Company&#x2019;s cash equivalents and accounts payable approximate fair value due to their relatively short maturities.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a95be45-1301-4bb1-a6e8-17c26cc9b510" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_205b4411-89f3-47c4-a0f6-7f858089bc07" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes short-term investments (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.927%;"></td>
        <td style="width:3.411%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.455%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.411%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.455%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.411%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.66%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.411%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.855%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3b865f1-6860-4f97-8fc0-2fcd56d65063" contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e17673a8-0c7b-4620-afc0-5951fc94230d" contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7edf47f0-3e9b-4cb3-b5fe-1cc54d226c9e" contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d080a96-48a6-48c4-a26b-1f671502050f" contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19a56b19-bc29-4a5f-814d-f48fd55911c0" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c4b96ae-6ea6-4774-8196-2bd0a88d46c3" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a35d6ef-6058-4e6f-8669-1f9474ce696c" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05c0a772-481a-45bf-b15c-0a73a5751ac5" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,737</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e295726f-339e-4617-b0bc-5c4ca78954c4" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dee7d528-1f43-417a-b552-7c7e6bad0067" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_360b707d-660a-40f7-84f5-9c84f2420473" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_535b696b-6816-4603-a063-7ad8e03be067" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac1d8ebf-95e9-4e70-a361-559e5251668f" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d67f71d8-f4ca-4dfb-af8e-a3a6da53db73" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab446819-d3b8-4a7d-95af-d74ce0e6bef6" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23d32ab7-3bca-4c36-a1ab-abc12e0fe4af" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d3da5c7-6d3e-4932-bbe4-1f2036cda9f3" contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_029531d5-87ce-4cea-94f6-cf2eea1c6d5d" contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4975f906-f5fa-4656-859f-0fb6a77f10fe" contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_794607d0-67b3-4d1d-a1d3-df5cde8ba516" contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff9fa20e-94b2-402a-bc28-b9acc5e68663" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96a420b8-d708-472a-b1a3-13a349cb55d3" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ff0e18b-ffc2-48ca-a338-a639942c6aca" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7ade63f-6df2-478d-aeb6-90aa1ab1095c" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20eacc02-902b-4865-aa46-9f6735b5e426" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4aed97cb-2002-4a8e-9a0a-ceffad136968" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0581a0ce-bbb9-4173-8b5e-0b99b6876ef8" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47fc3fea-473b-4f37-8298-7f4884b1baa6" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9b13534-5218-4f16-80d6-bc376a5fe9fc" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19b8dcf1-0d63-44e4-ae53-10a185238b91" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a107661-b173-4bf9-8e54-5390f4ce98f8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7adb50-19b6-45c1-a81b-e90162698ee1" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_6ac94bf3-a119-4b14-a533-1b59156e79c3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.526%;"></td>
        <td style="width:3.369%;"></td>
        <td style="width:12.567%;"></td>
        <td style="width:3.379%;"></td>
        <td style="width:12.567%;"></td>
        <td style="width:3.379%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.915999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.379%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.915999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_576ad9ca-0d86-4e1c-b56c-01ed54d7e569" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,139</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6ffafb2-f858-4a5b-a64a-f5247b52cdde" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1b33219-2136-4b67-a56a-f5cbd0413dd1" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac623938-b7c7-4f5d-81b2-9270e98533e5" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_537272df-2e26-4973-bcf5-0030b0d818c8" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2bb8a59-0ac2-4944-be31-b3c07afaffcd" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1876ab94-95c9-48f2-b1ac-12decdd4d070" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the Company&#x2019;s available-for-sale investments&#x2019; gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at December 31, 2022 and 2021:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.316%;"></td>
        <td style="width:1.253%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.633%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.440999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.262%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.497%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.633%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.440999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.262%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.497%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:6.633%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.642%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_962e9c2b-6893-43c2-a52f-d0bcb1daace0" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79480c9e-114d-44de-9222-74d2cc0e353e" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fdeb8cd-090e-4a98-8e0f-180841abe3d9" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6799805b-3180-4317-982d-5d5206c65c4a" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57b335ea-899e-45d4-bba0-091c4119205c" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d3fb288-8934-42d0-a88d-75c9a8dcf584" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b80f7d9-13c6-4944-b5d6-b9439ee948fa" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_858392e2-dd3b-4ac6-a37a-6624242a44a8" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3b39957-0f72-44d2-96e6-4928509ccaff" contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24342d37-5c75-49c3-b725-4e4a083ac12e" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9c13200-f40e-4f4c-9ffb-cef972337629" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bf7c4e4-2727-4351-b311-c9dfd030b3f0" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db697ed1-b6f3-4ca9-b8ad-0ce211fed39e" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f91d94c6-6784-4e2d-9067-329917bc40c8" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,111</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f6418d2-7756-4dfc-9d27-964b84cec899" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebb23e72-062d-4b76-adae-a298434c2885" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c4b6e9d-4fe8-4a3d-87fa-6e687727c987" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,737</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77242bcc-5b59-4018-862e-b930b6793027" contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_460ab3b6-7847-46b8-bac9-3eb6a41ba659" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7795df34-554d-40a9-a8a8-0cf13827e8c5" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0885294-1b25-4148-842b-7a55bfe48716" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18f6829f-6dd8-4664-8bff-36e06ffead92" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82ab5254-7fcc-4eef-8898-7f56a5c2c64d" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,653</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5d92c8c9-4524-4b63-ae9e-0e2a3feef888" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2008a1e-9ce9-4abf-b593-0c6c92593730" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e78d2fb1-415d-4867-95f0-f4c972582d3c" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d370d8-3c95-4080-889c-639c1a9efb6e" contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">325</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3508a0a-b944-48eb-8698-1a3eb6004bac" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e420bc7a-5509-40cf-8253-9f9b901c637a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48bae4b1-6eb8-4f90-854d-7bf9d8f48695" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efd49a06-75f2-4eee-aa90-ad37e715e846" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbc1f98c-614d-4f27-8a0f-f552ffa232c0" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cae916de-badc-4592-9968-f36be4106348" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e860893d-70d0-42d9-ad04-18fd25114b76" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">33</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bbc41fa-d292-4e8b-a1d5-37d4944ab5fa" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_679b1a2e-2bb0-478d-a9e5-66b1bc3bdedf" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">693</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f3ad40a-4853-4ea2-a744-a8bf88f85eab" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0c755c1-1cb5-4635-98c9-87d39dfc9464" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0b6b9cb-aa07-4ddc-8982-09ff7449f8de" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6764844-2c87-41b0-9417-2c504c56120d" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aae3d294-cd82-426e-a669-5a552a56300f" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b9b8199-2721-4425-8b74-5b16096d8dd1" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff3f43f4-f145-46bb-95ba-b520d976fdf1" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6b98466-f59a-4f1c-be55-25fd4ebc4145" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e7a611a-f465-4e34-96a3-f1a5ae65863b" contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47f37a4a-f679-4276-b9e3-fc3984aac34c" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74305995-4b14-43ce-a34f-77055dedb9d0" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c73ffae-1193-4575-bb46-d7128ab52025" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1c5840c-254d-4681-bfdc-5575e6a032e4" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2aa38e1-e9c1-4708-be8e-ceabb3388c80" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89e83f5f-98f7-4f50-bd83-f7a14e9b4364" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85e4a373-a763-43d7-9020-eddea4304ead" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0fbe7fc-b240-4104-9fe0-842da12f8da2" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b5c9a7c-a56b-4ee1-860e-5648ed5102dd" contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12f1b1fd-def7-4418-9527-6aad13594d6e" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d83d19c6-6432-48ee-9353-0cc1fce8f380" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf8ce472-2b51-41e3-83f9-7426795e2898" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02729902-2fcf-4737-8ddf-210d45572230" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_948c8fc2-7930-454b-bb2f-80d03f6e10bb" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f9650e1-6fed-4c9b-9fce-8f13f000355e" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f17dbc6-590d-43c9-ae22-7cc9f58736f4" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb1fd3ce-7214-4bb4-909a-ed1a94458105" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a98b7e0b-e69e-439a-b73f-7d6cb774751a" contextRef="C_0f374945-0780-451f-9899-e3095382578c" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c26156b3-cf5d-4570-b7d7-e35954913321" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a498bb3-b7a2-462e-aa1e-de92249ffe95" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0302998-ce62-409d-b5df-3e6c17de83b9" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dab012c4-3833-4561-a2bd-ad4ec679fca0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a264109-e425-490c-a10f-9c087b2d4bc4" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a1940c6-8d13-4b9e-a489-c8176c5b14e0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9901af4-1015-4e32-aabb-859de409b3d9" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Securities" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d56db8a-2755-437f-93fa-d150fbb520c5" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,392</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab75d1ca-a1b2-468e-8ac0-8c96bb02bea8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#x2019;s investments were caused by changes in interest rates caused by changing economic conditions, and not from a decline in credit of their underlying issuers. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cdbb0ef6-b8b6-4f36-90d9-332fcd2de4a7" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 5. Accrued Other Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d8d00fd8-2116-461b-b8b5-c01a94b2b0b1" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other expenses consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="bkmk_281">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.251%;"></td>
        <td style="width:1.946%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.570999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.559%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.672%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_117950ac-e3e6-4b73-a230-879b0c5c3a4b" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1aba0c04-d494-408f-8ee3-c274e2cec49e" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f529fcda-488a-4b38-ba47-bc851a9480e9" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:AccruedLegalAndAccountingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b159a57-592e-42a4-bd91-2a890e9c47ed" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:AccruedLegalAndAccountingFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1dbd704-2353-4304-a0e4-802de0b134bb" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccruedPayrollTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60421e3f-5864-4dab-94f3-a399faa6f42e" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccruedPayrollTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47aac980-b67b-46e4-843b-dcac324944c5" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:AccruedComputerRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5f88fe5-eda2-47b3-bd0a-fc5aa85fabea" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:AccruedComputerRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7abfb0be-efad-4fd0-a4fd-ba0705ad9d24" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:AccruedRecruitmentFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b0cdc32-3e4f-4fa4-b4c7-5c8ca8fced52" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:AccruedRecruitmentFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55915831-39ef-421f-8b29-ff7629e4a9b4" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b05ab63-7e7d-4a03-9ddc-95c8de57f386" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bbc91db-0a14-4cc9-b2e8-3be426609c3f" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2d48631-d142-456e-9b38-7e5576427a1e" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ed92986f-250f-4363-9a7e-864b319adf91" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 6.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company entered into a Controlled Equity Offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co., as sales agent (Cantor Fitzgerald), pursuant to which it may issue and sell its common stock from time to time through an &#x201c;at the market offering&#x201d; (ATM) program under the Sales Agreement. The Company has no obligation to sell any shares of common stock under the Sales Agreement and may at any time suspend sales under the Sales Agreement. Cantor Fitzgerald will be entitled to compensation in an amount of 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. A maximum of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8674f75f-0855-4935-822f-b7bcd13d818f" contextRef="C_70566aaa-8ddd-488f-8329-70945439bec9" name="lbph:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of shares of common stock may be sold under th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Sales Agreement. The Company had not sold any shares of its common stock under the Sales Agreement as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company amended and restated the Company&#x2019;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68f90197-f1ff-41cd-b133-b53a62f5bbc9" contextRef="C_0d4f20c8-e119-4763-a167-6957a1d2975c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_347fa91a-4758-4e6d-8e5e-7aee174e4ac7" contextRef="C_355af628-daf1-4971-8c16-cbb53131df03" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95eec1ab-11e9-488a-a439-b651872e3277" contextRef="C_f36635ab-29c5-4e22-a6be-fcbab49127d7" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Common Stock and Non-Voting Common Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_972b591e-8b84-488d-8c93-58817244b58e" contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,585,950</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock outstanding and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_561706d7-7284-4390-b52c-5e62697c30ce" contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock outstanding. As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93136c36-a9cc-49bc-94ec-6ca57ceb2935" contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">13,440,761</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a012ccda-d9c9-484e-818b-d26b8a9a4df3" contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">145,189</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7aa8e67b-9369-4340-8d12-bdc8fca0d250" contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,629,400</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_266c1cd8-db99-4676-bd17-02dc454270e3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 7. Agreements with Arena Pharmaceuticals, Inc.</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into a license agreement (the License Agreement), a services agreement (the Services Agreement), and a royalty purchase agreement (the Royalty Purchase Agreement) in October 2020 with Arena, which was subsequently amended as described below. Arena was purchased by Pfizer in March 2022. The following section summarizes these related party agreements.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the License Agreement, the Company has obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 and certain 5-HT2A compounds for the treatment of any central nervous system (CNS) indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). In January 2022, the Company and Arena amended the Arena License Agreement to add additional 5-HT2A compounds, and in September 2022 the Company and Arena further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products. As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#x2019;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Services Agreement</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the License Agreement, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a8882813-0e1b-4cef-ac1f-6dbb72c41d24" contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36" name="lbph:RenewOfSuccessiveAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> terms. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has significantly reduced its activities under the Services Agreement, including as a result of its having</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hired </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a44cabc-f7f8-4ad0-a5e6-0d06df86b111" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the services expensed under the Services Agreement (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.002%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.555%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.49%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.953999999999997%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_791f9ede-27f1-46c8-b55d-23275bd7f5ae" contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2574dcc4-4aa7-48d0-bbcf-42af23275c32" contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">930</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_361f76ec-bd7a-42f2-8732-798ee45e0d10" contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eed6ccba-2a57-4e8b-960b-5bd2bec36e07" contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8dae182-e616-43e8-883a-1d86d3fff94f" contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1126dde2-e2ee-44c6-af14-dec6efa79101" contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,024</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97ff00c7-bb3e-4250-8ba0-4dfdc3d2abaa" contextRef="C_d29e8ef9-ee88-456f-b2dd-f017a70b32f1" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fda7c4bd-7750-4abd-a594-7b59c5ebe4c9" contextRef="C_288ded8c-213e-400a-8676-efb385f835af" name="us-gaap:AccountsPayableRelatedPartiesNoncurrent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">188,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of related party amounts related to the Services Agreement in accounts payable as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f9c969b7-8b14-4d81-9bed-d07ec6eb044c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 8. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company&#x2019;s board of directors and stockholder approved the 2020 Plan, which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#x2019;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's board of directors adopted the 2021 Plan in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ffb6235-d8ae-4fb6-9c8c-15682d4cc453" contextRef="C_41221969-e7b7-45c7-916d-09ca02aa8b4a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of December 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2b6875d-b1ca-4ea0-a6e1-6fc29dceaf5b" contextRef="C_997cf810-2610-4985-8384-a99e8aea8da6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,694,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#x2019;s board of directors prior to the applicable January 1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recipients of stock options are eligible to purchase shares of the Company&#x2019;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, Equity Plans) is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8e67fc5-c577-45b6-a53f-5478f792ecdc" contextRef="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and, in general, the options issued under the Equity Plans vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c1171003-0a4e-4fc3-897f-9cf0a00e25b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2d38108-6c04-436a-aac8-cd13b35db353" contextRef="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period from the vesting commencement date. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55f80d8f-bdb6-4dc8-a72f-95e29b1e22ed" contextRef="C_f5f0dc44-7d37-4e54-8447-edb5ba753a90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,299,251</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for grant under the 2021 Plan as of December 31, 2022.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Award Grants under the Equity Plans</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ced83f2e-e66e-4ce8-8975-5219c03fd8ea" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.322%;"></td>
        <td style="width:0.131%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.947000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.071%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.282%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.131%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.235%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.689%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.192%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value<br />(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0984f106-18be-4ef4-8726-67d16be0a24c" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">873,264</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_315ef729-fb8e-4703-aa46-1c8ee22f5a79" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.42</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fa0f01d2-e2d9-4a48-b320-a894683d7463" contextRef="C_76c0819f-9885-4686-b0fe-6c11ff7e48b6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ee216e3-90a2-4f4f-9985-9aebf63763c7" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b65ae777-8fe3-483d-bc38-01554bb5c69e" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">548,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6b49516-369a-427b-be89-10128e59b592" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d002da67-a6a6-4fe4-9dfb-847485083178" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20643da0-9b9f-46b4-ad78-80d9041f9d8c" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45e23751-d147-4d02-926a-971fc924f676" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbc00b32-7362-491d-a43e-79744afb597a" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11382e16-7673-4e13-b3e8-d924ff123c29" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,421,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_407f5d5d-d5b7-4dba-ad71-a0ac58bce60d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd960da3-2466-4a55-b433-8f1b31b8b807" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1c08c81-4dc4-488a-b6cc-2eb8ec5e6d9c" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd1a3ca6-10a6-4d57-b7fa-9ca75de9ed83" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,244,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a328bda7-1e8d-4daf-9641-734e8e1e73a0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9518bd7-a7fe-4f43-8e0c-24cd76a38902" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ddd4bae-0e2e-49c2-8699-ad97eac66c5a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b48f97a1-f2b8-4ac9-bb46-b846b385b17d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">270,810</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_470b6504-c895-4d34-b411-cea5c53ac977" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46033084-b768-43d4-985e-989b78750ef5" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,395,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45a76293-c456-4337-8ab7-5d64d4b25c04" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d2e1838-b5a5-4536-8f8d-ac818a0994f9" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_014ecd3f-7794-4b59-8f8d-2a731343238d" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4838cdf6-fedd-4a84-a84f-4291eb958c35" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,395,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df6c19d0-75b3-443d-9053-76cb4d02ee82" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.50</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e14bdb5d-a5ad-4578-aad2-8b96781f88d3" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15c52bbe-38ce-486c-863b-ed1f93926fea" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a135c804-c316-40c7-9087-5ca09932d159" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,055,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eebf85e0-631f-48b1-a8ad-7e14cf7a97ef" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">5.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e56633a9-34de-4444-ac9c-26c03ebac5b9" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfefd9ef-f9d3-41ab-9426-b56973781006" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022 included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_980e5964-6698-49d6-bacc-0b50e634f80e" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">736,434</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vested stock options and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_385d1da9-d77d-424a-b558-ccb4632c1f0a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">319,413</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options that are subject to an early exercise provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0df87d8f-a115-4108-8bb7-17c709362933" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the years ended December 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.328%;"></td>
        <td style="width:2.173%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.212%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.164%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.123%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91c7077d-c0ad-40dd-ad13-5e47270b94cf" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:WeightedAverageStockPrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.61</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08c9646e-ae5a-4d3f-9d5d-7d9e827f4ab9" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="lbph:WeightedAverageStockPrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">10.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1732d59c-6b4d-448d-a219-d20cac024dae" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">2.15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cf70e06-f879-45ae-8dda-7de82ca39a10" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_997acf53-92a5-40d3-b769-cb74472ff656" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4988c02a-0b47-4732-9fa7-dfcb41915473" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7f69852-eaa4-4458-96a0-552be0416f34" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">75.28</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e9c99d7-f9e9-4067-b960-3774a0aad412" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">74.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8f10d4c4-cd9e-4164-8ad8-68984d525952" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5e4b543b-0fdb-4cf4-8178-7d4e1c0af8af" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e407f7e-bc9f-4656-bfc8-e9397acd07b0" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd8a9172-96b1-425b-a3f4-76ca390e0f1c" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">7.04</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these third-party valuations of our equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to considering the results of these third-party valuations, the Company&#x2019;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#x2019;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#x2019;s common stock including liquidation preferences of the Company&#x2019;s preferred stock; the progress of the Company&#x2019;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#x2019;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#x2019;s business conditions and projections; the Company&#x2019;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">life</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b94f79f-8446-44a4-b25b-23d9305338ea" contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">348,450</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock awards were granted to an employee under the 2020 Plan, which vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a9a9c5e3-ef4f-4802-80c2-87d806b359ed" contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and had an estimated fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68614df7-df72-4816-a57f-0330dba72da0" contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.12</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share at the time of grant. During 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44d9735e-3bbd-44a3-b1c3-2ef10fb6f04f" contextRef="C_15377397-0660-4b11-971f-4f76f43bcec3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">145,189</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21891a3d-b8bf-4f0d-acf7-d0e1b0e9411d" contextRef="C_a6fbcb62-1dd5-47e8-a5f0-a9811e2e702b" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">203,261</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock awards vested, respectively; the total fair value of the vested awards was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9173cf75-2a4f-4a3a-868a-af91458d2e3b" contextRef="C_15377397-0660-4b11-971f-4f76f43bcec3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, all restricted stock awards were vested. For the years ended December 31, 2022 and 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bfb3ca5-7574-4d23-8f42-fa6c4ac4284c" contextRef="C_097b4d4d-1926-4a4a-8cc2-59de0584c1ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3da1fdd8-b2f0-479f-b23b-04f49f2740c6" contextRef="C_8fb4ce3e-c646-46e9-a87a-ec14ffdb12ec" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of stock-based compensation related to the restricted stock awards was recorded in general and administrative expense, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2fb8cca4-765e-4f7f-8bfe-c63a94e82264" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.852%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.692%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.503%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.953%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94a7af3b-4b64-4594-b128-c5f445a8f449" contextRef="C_35559507-1949-4257-b3c7-aa78f7685bfb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,016</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0a87771-513e-425e-9578-d1a5fd643103" contextRef="C_1111d63f-8f4d-4079-a133-a11d3aa8b573" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_188399a6-49fe-4881-9b59-76484375f60a" contextRef="C_aa114e73-9d3e-4367-b67d-0376849d85a2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,641</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a9d4400-9f07-49b7-a5c7-2d40ddf0a6e9" contextRef="C_351fd3fe-1bac-41ec-aaee-86835367c6a7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3692e3f-d716-47a2-b575-c1d346c84aac" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00ca5002-a5c4-4d07-a4bc-371e98708d6b" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,967</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, unrecognized stock-based compensation expense</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1c7667d-49b1-48c8-b2cb-1da370b2ceba" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> millio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ac1153fc-5d71-469f-9f27-36dd276b78d2" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (ESPP) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. The ESPP initially authorizes the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0285ad1-fa85-4f00-8a3a-eba2dc3b8056" contextRef="C_092f0ada-7a1d-48a7-a337-44d3d7397cba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">353,339</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock under purchase rights granted to the Company's employees. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 through January 1, 2031, by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35f04fe2-d673-4383-9032-ea47024ea155" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:PercentageOfSharesOfCommonStockOutstanding" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">aggregate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number of shares of common stock then reserved for issuance under the ESPP to equal </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da1466ec-9c03-4764-903d-c020f4281014" contextRef="C_092f0ada-7a1d-48a7-a337-44d3d7397cba" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,060,017</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be for a lesser amount of shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc305bab-7b18-4d79-84c3-f17a1a22e6de" contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701" name="lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e732b4f-3733-47bf-83f6-b542e5bdd542" contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701" name="lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the Company&#x2019;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2359d4e9-9afe-473f-b57e-878421f10347" contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701" name="lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da16ad97-2fab-43a8-a51f-da630ab8f450" contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701" name="lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of December 31, 2022, the ESPP had not yet been implemented.</span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a5dc78a-b377-4cad-9289-f123d05dec81" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 9. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company entered into the lease agreement (original lease) for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e398e0c6-c9bf-4556-90c9-710690a9a5eb" contextRef="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1" name="lbph:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">8,681</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. The original lease became effective </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_806151b3-5c5a-4c10-ae37-79c7c6ce3790" contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf" name="lbph:EffectiveLeaseDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and continues through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c4884558-e294-40be-b499-e283ab585052" contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5dc0a5ab-e2f1-4c5f-b6d2-cac698ff837c" contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf" name="us-gaap:PaymentsForRent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">29,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month for the first year and increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_183b1fe7-22e7-4db7-8f26-5ffbb9856619" contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf" name="lbph:PercentageOfIncreaseInRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in July 2022. A security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05db194e-c353-4adb-bf94-afab5e442a0b" contextRef="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1" name="us-gaap:SecurityDeposit" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">33,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was paid in June 2021 and is included in other long-term assets on the balance sheet as of December 31, 2022. In August 2022, the Company and the landlord extended the lease agreement (lease extension) through December 31, 2024. Rent payments under the lease extension are approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9e29378-1fc0-438a-b721-59e2fb7fa14b" contextRef="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3" name="us-gaap:PaymentsForRent" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">33,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> starting in July 2023 and increase by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42ebc7ac-36d1-4a44-ba76-46a2850f4697" contextRef="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3" name="lbph:PercentageOfIncreaseInRent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in July 2024.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54b0bbc2-c59e-4d09-8a83-2aa0aff7ff64" contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf" name="lbph:PaymentsForRentHistorical" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense totaled approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d647d827-dc16-4387-90ca-92a332d0e941" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">394,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e70a5cde-a4b3-4a76-ba94-568c0ddb987d" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">198,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96b73105-4033-4801-a6ad-f89c3300333a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.55%;"></td>
        <td style="width:59.162%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.48%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.707%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.1%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b98f572a-a2f7-40cc-80b7-a8e1f4a4d53d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">370</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30c8bfb6-830f-4121-a1a3-f63a5b355f30" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e5c0956-dca8-4aa2-bc20-b9e21ed72c62" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb2f9af9-03c2-4a72-be32-7d1ca70749c6" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96225eae-e616-4f54-b0f3-4eae9de352eb" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.51%;"></td>
        <td style="width:58.656%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.957%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.676%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.202%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f35b6184-5aec-4c0f-94d1-41758bf09e5c" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">736</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b90954c8-2190-4c66-809f-321d4959e120" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b82f0d33-b231-4dbd-9e36-607ac7573f05" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">358</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ccd01ea-d40b-42d2-ac09-a4454d17d0ff" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">339</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a04ae07-8fc2-4942-8b1a-c0fd4c2ec144" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d69dedf-bcf3-49a1-89eb-9e1554bbe7f8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da8cb555-cf2b-4677-add9-67552f9fe6d3" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd581439-a149-45d0-b5cf-31f4f22eb21b" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_35b4a6ca-678a-4825-bc22-928d3f1531a5" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5c211ce-ec8c-48cb-b0c0-bdc9222e5611" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c6f730d-666f-471c-afd4-46696b74401a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_365ffbae-4b4c-4213-b299-6481e1202ade" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:nonNumeric id="F_bf628488-ddad-440c-9803-5e2960747efa" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease commitments are as follows as of December 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:2.791%;"></td>
        <td style="width:73.534%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:21.676%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5087d7b0-1241-4541-a147-7e9f2bd089f7" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f262606a-e725-49ff-a56a-2e40de919f17" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49ceb6e2-b5d6-4e2f-bbdc-efd69e2627da" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a232378-2f76-4112-b7c8-4f4f5606acae" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56522d14-af8c-41ce-957a-a86c576f57b2" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2022 and 2021, the Company is not a party to any litigation.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3f9c41df-d6c9-4e4c-a166-9dc03e69e8fe" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_09051c03-2e82-4be0-87eb-1aa05ecf48aa" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the net loss attributable to stockholders before benefit for income taxes by region for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.475000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.103%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3848440-17b9-4c67-8bd5-7b38a8061497" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_252e9f2a-5f4b-4bb0-8fc1-2779c6e2d73b" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fd3e412-382a-4b93-b6bc-ac9bfed0593d" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeLossFromContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ea4347e-b732-49c9-a65f-f7981647110a" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeLossFromContinuingOperations" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">27,797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d3131e3-8c3f-4441-a78e-8e3dbd6c2040" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The benefit for income taxes are as follows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.475000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.103%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit for income taxes at statutory federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6396088-6f91-4a47-ad19-54e11061a999" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,229</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54904210-fdb5-4c8d-9ea0-4a040f8efd3a" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,855</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcfe9468-42b2-49f2-95d9-500a8b2e9161" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:PermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a48f0a5a-9692-428f-ace4-a17adff06d89" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="lbph:PermanentItems" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40ee81f7-3e38-4ace-9a21-514fab419b51" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a8cf084-3b5d-430b-aa0b-c0660e7c9f74" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c625db-99d9-4bcc-83bf-48b1c2e563da" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54c853f4-25f5-42a7-8832-f39ff89908ff" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,437</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bca2741e-f55e-44dd-b63f-14104000d766" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a97e289f-457c-4ece-84dd-0f0b1ed2d098" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3041303a-57f9-4bfb-ab27-128793c10ae4" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company's net deferred taxes were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.475000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.103%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_971ae643-6dc2-4ffc-ad89-c839321b5eab" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,512</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71f45fb4-b411-49e3-b33a-e287ac8f32f8" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California research and development carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df4e8626-dfe4-4345-a40e-fab827ef62f2" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,528</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ec18208-6c0c-45d3-bae6-4862e72af406" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">840</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cc22a17-bc2c-4804-8990-0af4a4221f59" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">404</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deab6bdf-e692-4682-8e72-8f50efb108b7" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0d5fdea-0f5e-46b7-b8d4-190ead31cbbf" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:DeferredTaxAssetsCarryforwardsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afb36e4c-c83e-416c-84d3-8863b3299f72" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:DeferredTaxAssetsCarryforwardsLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 capitalized R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0250b5d-f012-44f9-b7de-6da9340ec8ac" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5697be6-9f2e-4322-93a0-a95f521b404d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3863bbbd-d4e6-40f3-9187-b267794454f0" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">491</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_999e8249-03ac-4b97-82c6-0c9904ae8893" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66fd2420-3240-4233-bd52-04018854790a" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf56dd2c-b791-45c3-97e2-144ac2872497" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,970</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f62f7437-1ee8-419b-8131-475982172b01" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b68a7b89-2663-46fa-874a-4b79b81b0a4c" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed asset basis difference</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3b3a59f-9096-4e03-acba-326cbec6dd17" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:FixedAssetBasisDifference" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ae65d6e-869c-40bb-a226-b819753e31a0" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:FixedAssetBasisDifference" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b892086-45b5-4769-80c4-9f5d6ef1eaad" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bab4f13-ef32-4fd2-84e2-0a300e1eb565" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0dab0ca2-6008-4fa7-9561-f58c7bebbe0d" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3cb63a0-b2ce-49c6-b878-1ca520bb799d" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527a9334-2d7d-46e6-ab9b-785a0b412813" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dba83398-654d-493a-ac49-2cdfe655e3de" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff16f34-3e12-4de4-875d-6d7dbaafd840" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="lbph:TaxDeferredAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3be09535-f6a9-4faf-aaac-6ceb0f81d620" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="lbph:TaxDeferredAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements &#x2014; Continued</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The deferred income tax assets have been fully offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_467b5286-99da-40cc-9484-6e536caba34b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. We will continue to assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that may exist.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96f54c0e-3243-48cb-bcb0-ffb76b62ceda" contextRef="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that will not expire and California net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a812b6f-6d43-40e7-b12a-9410585369d3" contextRef="C_db5b19d0-862e-49e9-b69a-8b019f65a709" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that will begin to expire in 2040. As of December 31, 2022, we also had federal and California research and development tax credit carryforwards, net of reserves, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30d07590-d41d-4afc-85e6-8d34bd95b650" contextRef="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36d5f79d-397a-4a69-aeb6-5a8f261d4f9b" contextRef="C_db5b19d0-862e-49e9-b69a-8b019f65a709" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively. Federal credit carryforwards will begin to expire after 2040 unless previously utilized. The California research and development credit carries forward indefinitely.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation's ownership. We have not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c2e3a6b-c0a3-4b7b-8d97-e08e181fda2a" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="lbph:PercentageOfUncertainTaxPositionsNotRecognized" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% likelihood of being sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_39db5a45-b0e4-4f8c-8d6d-21f97d0c295c" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.475000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.103%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96dc5034-e439-4c46-89e2-b06af8b99eac" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c5d4995-5363-4aff-9820-80b2599f50d0" contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ce57072-18ac-47f0-aad9-effc60a3fed6" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">359</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d5d966e-3920-4d3a-868e-0590ac7d2949" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_394b9ec8-8792-4898-9293-7af977187447" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6c9a546-7472-487b-a673-0c4dabcee4a7" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions from tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c55829b-96b0-4a00-b94f-cc707cffe91b" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a1f4102-a010-4105-964c-01b01645be73" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax settlements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1e2815a-530f-4504-8884-85503b89cd8c" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">703</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b04fe307-5b18-421c-9573-900c7a681705" contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e201100-e4f3-4e60-968f-7e33313d356b" contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits will have no impact on our effective tax rate. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our balance sheet as of December 31, 2022 and did not recognize any interest and/or penalties in our statements of operations and comprehensive loss for the year ended December 31, 2022.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized net operating losses and tax credits. To our knowledge, we are not currently under examination by any taxing authorities.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b01c8c80-5a48-4c8e-a45b-7c0b2e440d68" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PostemploymentBenefitsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 11. Employment Benefits</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc3efedc-b21f-4ca5-ba9d-338e7c99dfd5" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the years ended December 31, 2022 and 2021, the Company incurred approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc444a1b-ae32-41fd-885c-e1124deca3ce" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">265,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fedab0d-3a2e-4be5-90c3-11458aef7b34" contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, in expenses related to the safe harbor contribution.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_afb8465f-7a43-4029-b8e3-d0e8d3dcaa22" contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 12. Subsequent Events</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5827af8f-81a8-4d78-97ae-2a19f1325ed0" contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in a follow-on public offering. We issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4eceeb5c-0bf3-4000-91e4-98d51e3ca3da" contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12" name="lbph:NumberOfCommonStockSharesIssuedAndSold" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_613fbebb-65b7-4789-a540-2d8cf2b94bf0" contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21b270e1-11fc-4dec-b747-a2c5a141eae4" contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d3f4506-64f3-49db-aa45-dbb327fa585c" contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1b41d26-d412-473e-a8ea-19ca8b046c72" contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12" name="us-gaap:CommonStockDiscountOnShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aee2b5b-8584-49d0-8d18-5b8da360d2c3" contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9a"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Controls and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain &#x201c;disclosure controls and procedures,&#x201d; as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2022, the end of the period covered by this Annual Report. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting due to an exemption established by the JOBS Act for &#x201c;emerging growth companies&#x201d; and because we qualify as a &#x201c;non-accelerated filer&#x201d; (i.e., we do not qualify as either an &#x201c;accelerated filer&#x201d; or a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Report on Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). We maintain internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the supervision of and with the participation of our principal executive officer and principal financial officer, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &#x201c;Internal Control-Integrated Framework&#x201d; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fourth fiscal quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item9b"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Other Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="disclosures_regarding_foreign_juris"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PA</span><span id="part_ii"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RT III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Directors, Executive Officers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Information Regarding Committees of the Board of Directors &#x2013; Audit Committee,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Information Regarding Committees of the Board of Directors &#x2013; Nominating and Corporate Governance Committee,&#x201d; &#x201c;Election of Directors,&#x201d; &#x201c;Executive Officers,&#x201d; &#x201c;Code of Ethics,&#x201d; and &#x201c;Delinquent Section 16(a) Reports&#x201d; in our definitive proxy statement for our 2022 Annual Meeting of Stockholders to be filed with the SEC by May 2, 2023, or the Proxy Statement.</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain a Code of Business Conduct and Ethics that applies to all our employees, officers and directors. This includes our principal executive officer, principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Business Conduct and Ethics is posted on our website at </span><span><span style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">www.longboardpharma.com</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on the &#x201c;Governance&#x201d; page of the section titled &#x201c;Investors.&#x201d; If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director that are required to be disclosed pursuant to SEC rules, we will promptly disclose the nature of the amendment or waiver on our website or in a current report on Form 8-K. Information contained in, or that can be accessed through, our website is not incorporated by reference herein, and you should not consider information on our website to be part of this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Executive Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Executive Compensation,&#x201d; &#x201c;Director Compensation&#x201d; and &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Information Regarding Committees of the Board of Directors &#x2013; Compensation Committee&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item12"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and &#x201c;Equity Incentive Plans &#x2013; Equity Compensation Plan Information&#x201d; in our Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance &#x2013; Independence of the Board of Directors&#x201d; and &#x201c;Transactions with Related Persons and Indemnification&#x201d; in our Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item14"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Principal Accountant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Principal Accountant Fees and Services&#x201d; in our Proxy Statement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item15"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Exhibits and Financial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	The following documents are filed as part of this Annual Report:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The financial statements filed as part of this Annual Report are included in Part II, Item 8 of this Annual Report.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Financial statement schedules have been omitted in this Annual Report because they are not applicable, not required under the instructions, or the information requested is set forth in the financial statements or notes thereto. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The exhibits listed in the accompanying Exhibit Index are filed as part of, or incorporated by reference into, this Annual Report.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:90.917%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,1);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000095017021000164/lbph-20210331-ex3_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192), filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000095017021000164/lbph-20210331-ex3_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192), filed with the SEC on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000095017022002818/lbph-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Capital Stock (incorporated by reference to Exhibit 4.3 to the Registrant&#x2019;s Form 10-K (File No. 001-40192), filed with the SEC on March 3, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of grant notice, stock option agreement and notice of exercise under the Longboard Pharmaceuticals, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521072157/d16883dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of restricted stock award grant notice and restricted stock award terms and conditions under the Longboard Pharmaceuticals, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex105.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of grant notice, stock option agreement and notice of exercise under the Longboard Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. Performance Bonus Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement by and between the registrant and each director and executive officer (incorporated by reference to Exhibit 10.8 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Agreement by and between the Registrant and Kevin R. Lind, dated March 1, 2021 (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312521072157/d16883dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Offer Letter by and between the Registrant and Brandi L. Roberts, dated March 1, 2021 (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and between the Registrant and Arena Pharmaceuticals, Inc., dated October 27, 2020 (incorporated by reference to Exhibit 10.13 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000095017022002818/lbph-ex10_14.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment, dated January 28, 2022, to Arena License Agreement (incorporated by reference to Exhibit 10.14 to the Registrant&#x2019;s Form 10-K (File No. 001-40192), filed with the SEC on March 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000095017022021597/lbph-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment, dated September 13, 2022, to Arena License Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192), filed with the SEC on November 3, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001832168/000119312521049139/d16883dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Royalty Purchase Agreement by and among the registrant, Arena Pharmaceuticals, Inc. and 356 Royalty Inc., dated October 27, 2020 (incorporated by reference to Exhibit 10.14 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended (File No. 333-253329), filed with the SEC on March 8, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000119312522255508/d380143dex12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controlled Equity Offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sales Agreement, dated as of September 30, 2022, by and between the Registrant and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 to the Registrant's Registration Statement on Form S-3 (File No. 267674), filed with the SEC on September 30, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1832168/000095017022007877/lbph-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement by and between the Registrant and Randall E. Kaye, M.D., dated March 17, 2022 (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Form 10-Q (File No. 001-40192), filed with the SEC on May 5, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on the signature page to this report).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.083%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:90.917%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="lbph-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended and 18 U.S.C. Section 1350.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.082%;"></td>
    <td style="width:95.918%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information in Exhibit 32.1 shall not be deemed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">filed</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report), unless the Registrant specifically incorporates the foregoing information into those documents by reference<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item16_form10ksummary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form 10-K Summary</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.472%;"></td>
    <td style="width:5.046%;"></td>
    <td style="width:3.019%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 2, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin R. Lind</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 2, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brandi L. Roberts</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin R. Lind and Brandi L. Roberts and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.009%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:43.296%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:21.62%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin R. Lind</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brandi L. Roberts</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Vincent E. Aurentz</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vincent E. Aurentz</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Corinne Le Goff</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corinne Le Goff, Pharm.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Casey C. Lynch</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Casey C. Lynch</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Phillip M. Schneider</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phillip M. Schneider</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Paul J. Sekhri</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paul J. Sekhri</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Jane Tiller</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jane Tiller, MBChB, FRCPsych</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>lbph-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in the registration statement on Form S-8 (No. 333-254244) and (No. 333-263272) and on Form S-3 (No. 333-267674) of our report dated March 2,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023, with respect to the financial statements of Longboard Pharmaceuticals, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ KPMG LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">San Diego, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>lbph-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Kevin R. Lind, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Longboard Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.855%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>4
<FILENAME>lbph-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Brandi L. Roberts, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Longboard Pharmaceuticals, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:5.519%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5276933986727492%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.855%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>lbph-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Longboard Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.3262834815583%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.13%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.3262834815583%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.855%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Kevin R. Lind</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.855%;"></td>
    <td style="width:4.017%;"></td>
    <td style="width:3.248%;"></td>
    <td style="width:46.88%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brandi L. Roberts</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Longboard Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img8619836_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &\!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **BD=_,54VX()Y^HI,S?],_UH FHJ'=
M+_L?K1NF_P!C]: )J*AS-_L?K1NF_P"F?ZT 345#NF_Z9_K1NE_V/UH FHJ'
M=+ZQ_K1NE_Z9_K2N!-14.Z7/\'ZT;IO^F?ZTP)J*BS-_TS_6C,W_ $S_ %H
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M?ZT9F_Z9_K0!+1469O\ IG^M,DDF12?W?4>OK0!8HJ'=-_TS_6C=+G_EG^M
M$U%0;Y>^P?G2[I?5/R- $U%0[I?^F?ZT;IO^F?ZT 345%F;_ *9_K1F;_IG^
MM $M%19F_P"F?ZT9F_Z9_K0!+1469O\ IG^M&9O^F?ZT 2T5%F;_ *9_K1F;
M_IG^M $M%5UDF?=CR^#CO3LS?],_UH FHJ#=+_L?K1YDW7Y/UH GHJ#=+ZI^
MM+NF_P!C]: )J*AW3?['ZT;I>GR?K0!-1469O^F?ZT9F_P"F?ZT 2T5%F;_I
MG^M&9O\ IG^M $M%19F_Z9_K1F;_ *9_K0!+14#/,K*/W?)]_0T[,W_3/]:
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M;IO]C]: )J*BS-_TS_6C,W_3/]: ):*BS-_TS_6B-G\PJVW  /'U- $M%%%
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M2K8W]O=F(X<6\RN5/O@\5Y;X=GT[0_A2=;TVPL[_ %6WM?)FV@.<%EW+)CG
M7!P>@&.!2Z5J%H/BGITKZC'=)>:3M\WY425B_"@#KT/!R1TS3E@XWG9Z1O\
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M&6R6#?#=&)C('3Y ZL#N]@<\5WX.,9>TYU>RT_ \3,YU(>R5.35Y:^EG_P
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M >HS1M%%V/E3*T:LG"1 #TR*?OD _P!7_P"/5,%Q1M%&O4:22LAGF2_\\O\
MQX4>9+_SR_\ 'A4E% R/S)?^>7_CPH\R7_GE_P"/"I** (_,E_YY?^/"CS)?
M^>7_ (\*DHH C\R7_GE_X\*1I)-I_=?^/5+2,!M- $,4DGE(/+_A'>AO,9<&
M+_QX5)#_ *F/_='\J?B@35U9E959>D./HU((R,_N!S_M"K6VC;3N^Y/)'L5=
MAV[?(&/]X4NUMNWR<CTW"K&T>E&VE=]Q\L>Q6VMMV^2,>FX4,KX^6$9'3D"K
M.T4;11=BY([6.%\"^&]7\/:AK,M]!8F/4+E[L&WN&8HS8^3!C&1U^;/X5V1W
M?Q19^K5/Y8I=@K6I5E5ESRW,,/AX8>G[*&WF5_F/'E#'IN%&UMP;R>?]X58V
M"@*!65V='*NJ*Y5F.?)&3WW"C:VW'DC'^\*L[:-HIW8N2-[V*_S]/*X]-PI%
M5E4J(?E]-U6=HHVBI5Q\J[%7RS_SQ'/^T*5%9>%AP/0,*L[12;1VXIW?<2A%
M.Z17VGM"!_P(4;3_ ,\!^8JQMHV47>X^5=B(-)_SR_\ 'J=YDO\ SR_\>%24
M4%%>9Y#&,QX^9>_^T*D\R7_GE_X\*+C_ %8_WU_]"%24 5=AW;O)&?\ >IS;
MG7!AR/=A4WEBG;:=V1R1M:Q6PP4+Y7'^\* K*<B(#_@0JSM%)M%+4?*NQ7VM
MR1"!_P "I/+[^0/S%6=HI=M.[%R1[%4QEB/W XZ?,*7RSN)\@9/7D59VT;:+
ML.2'8JA2N<0X'<;A1M/3R1CTW"K6T4;11=CY8[6*VTCD0 '_ 'A0NY1A80H_
MWA5G:*3;2U[B48K9#/,E_P">7_CPI@>3SF/E\[1W]S4]1C_CX;_='\S061L7
M;@Q?FU(@9?NPC'^\*L;11L'THUV%9-WL5V4MSY SZ[J5=R\B$9_WA5C%&T4:
MBY5>]BJ(SNW>2,^NX5)OD_YY_P#CU2[:-HYHU[@DELK#/,E_YY?^/"CS)?\
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MG!&GIOA?6(H?%]S9O;Z!JVH3B#3KB: 7*VUM#&L<),8D4$9\V15W#'F<\Y%
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MFMQ<1C!Y#Q[E+*1P<,I]"*Y1/AQJ.M7G]H>*M;M]3U&&SN+*T.EZ=]C@MUF
M$D@1Y)F:0A0,ERH X7DT 8/PT^-$FKZ=X)TOQ!HVN6/B/7-/%RLUQ:1F"<);
MB1YA)"[1J"<@1Y$@R,QJ"#6]I/QJT+7=";4K"VU*=WU*;2+73Y+7R+J[NH@Q
M>-(Y"NTX1SF38%",6P!6,OPB\10:3X#$/BNP36?"1:*&[;1F:WN;=H/)*20_
M:-P?: =ZR 9S\N.*KVOP2UNSDN+BW\6P)J$.OS:]IMPVE$B)IED26&X3S\3(
M4DP-GE$%<@T <]X;^*FH>"=.^*/B3Q%9>*M7L]+UF('3YQ:-<Z?;M:PR, JR
M)%Y:,YRR,V5PQ+<L/5;/Q])>>*K/0AX>U2-Y]/74);QFMFM[56) CE*3,V\D
M8&U64X)#$*Q'.V/A./P)>>--7\6^)],NM!\1RQ-<07EJ+58Y3#';F/S&F*LC
MA%54*[N0"S'DZ_PC\$R>!_!UG97%U<WUSL"+-> ><ENN5MX6_P"N<6U3ZMN;
MJQH [BBBB@ HHHH **** "BBB@ J)?\ CX;_ '1_,U+42_\ 'PW^Z/YF@"6B
MBB@ HHHH **** "BBB@ HHHH **** (F_P"/A?\ </\ ,5+4+?\ 'PO^X?YB
MI-U #J*9N]N*&<CVH ?13-U('STYI 245'YAYXHWG&<B@"2BF!LT;SGD<4P'
MT444 %%%% "-]TU';_ZF/_='\JD;[IJ.W_U,?^Z/Y4 2T5QWB/Q-XGA\1'2O
M#FAZ3JGE6T=S/-JFKRV6W>[JJJ$MIMQ_=MG..HZ\UTD<U\VEK(]O;KJ/DY:W
M6=FB$NW[OF; =N>-VS..=O:@"[17F_PS^)'B/Q]I/B.YN?#FEZ5<Z9?7.F6\
M,>L23I/<0,R/O;[,IC3<% 8*YP2=HP >?\(_&+Q[XUT.+5-/\!:*L#2WL1:;
MQ),%4VTWDL"PL3R[!]@[A221TH ]HHKR'P/\7/&GC3PSH^N1^!=/CL]8L1=6
M0@UR24HYDC4)<$VBB,;79BRESB,X4UH1_&R+0['Q2?&.FKH.H>'?(>Y@L+@W
MT=PDY(@,#>6CNSL"FPHI#8['- 'IU%>>_P#":>.(X8M0E\"6XTMBA>WCU@R:
MG&K$#YK<0>5N4')59STX)KT*@ HHHH **** "BBB@ I&^Z?I2TC?=/TH 9#_
M *F/_='\JDJ.'_4Q_P"Z/Y5YWXB^(7BRS^(T?A71?#.C:B)M/;4HKR_UR:UR
MB.D;*R):2X;=(,88Y R<'B@#TBBO-=%^*NJWGB'5?"FJ^';?1O&-O8_VA96L
MFHF2QU"'.W<ER(@R[7^5PT65!4@,#6;\,?BMXU^)?AG1/$D'@S1;31-2<;O^
M*AE>ZAC$IC=_+-DJ,1AFV^8,@>IH ]<HKR33?BIXWU[QSXO\-Z9X/T!Y/#DT
M$<MQ=^(YXA,LT?F1,H6Q?!VXW G@Y +#FO3]+NKJXTRTFOK5;*]DB1I[5)?-
M$,A4%D#X&[!.,X&?2@"Y13/,]*-_\Z 'T4SS,\CUYKDK[X@2V7Q.TGPA_8UP
M8[_3[B_&J--&(@(FC4H$!+$YD7)(4#(P3S@ ["BF;CNQCBLCQ1XLLO"5K9W%
MZ)"MW>V]A$L2AB99I!&G4@8RV3ST!^E &U17'>%?B!-XE\:>*] ET:?2SH30
M*)KB:-C="4.0ZJA;:F$R-Q#$'E5(KKM] #Z*9N.>E/H **** "BBB@ HHHH
MBN/]6/\ ?7_T(5+4$[?NP/\ ;7_T(4_>?I0!)13-Y].*=F@!:*3=1F@!:*3-
M&: %HI,T9H 6BDS1F@!:*3-&: %J)?\ CX;_ '1_,U)FHP?](;_='\S0!+12
M9HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +4-Q_JC]1_.I<U%<?
MZL_4?SH FHI,T9H 6BF[J3?0 ^BF;C2[J0#J***8!1110 4444 %%%% $,/6
M3_?-35##UD_WS4U !1110 4444 %%%% !1110 4444 %%%% $4G^LC^I_D:E
MJ*3_ %D?U/\ (U+0 4444 >5:Q\4/%<?Q6N_!.D>%M%O7CTQ-8BO;W7IK</
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M)FMSX':Y_:.N>/%?3-;T_P"V:Y+?V[ZIHUW9)+ 88(PRM-$HSN1OD^]QG&*
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M7_B&*SC2^N%(.^4+SDC@D="W<@GO71K_ ,?#?[H_F: ):*** "BBB@ HHHH
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M<?N0?VAB_P#G]+_P)_YG6?\ "W/'/_0Y^(?_  :S_P#Q='_"W/'/_0Y^(?\
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MXI?]"L__ ('6O_QVC^V,O_Y_Q^]!_8.:?] \ON/)Z*]8_P"&5?BE_P!"L_\
MX'6O_P =H_X95^*7_0K/_P"!UK_\=H_MC+_^?\?O0?V#FG_0/+[CR>BO6/\
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M_P# ZU_^.T?VQE__ #_C]Z#^P<T_Z!Y?<>445ZQ_PRK\4O\ H5G_ / ZU_\
MCM'_  RK\4O^A6?_ ,#K7_X[1_;&7_\ /^/WH/[!S3_H'E]QY0M!.*]9'[*O
MQ2SSX68>_P!OMO\ XY71^%_V1?''VR*34]*C09XC-S$4'NQ#$X^@KDQ&?9?0
MINI[12?9:F]'AW-*LN7V$E\CE_ >ES6^BVT01FGNG+K&H.26("@>Y &/RK]
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M)C&%C9"NS&=ORD<CM==^#/A7Q#>:7=7%MJ%I+I<1ALO[+U>\L%MU.=Q58)4
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M/A?]P_S%2U$W_'PO^Z?YBI* %HI** %HI** %HI** %HI** %HI** %HI**
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MR$]_^^C1Y">__?1J2B@"/R$]_P#OHT>0GO\ ]]&I** (_(3W_P"^C1Y">_\
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M]&CR$]_^^C4E% $?D)[_ /?1H\A/?_OHU)10!'Y">_\ WT:/(3W_ .^C4E%
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M_K&4$A?O$#.,4 >I^(M?'AW3&NS9W.H2EUBBL[,*99I&("JN]E7OU8@  DD
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M*** "HE_X^&_W1_,U+42_P#'PW^Z/YF@"6BBB@ HHHH **** "BBB@ HHHH
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M^/K1^%?>K@JC;6L_N1^6R\2,1?3#Q^]GZB_\+E\ ?]#MX?\ _!I!_P#%4?\
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M_P CIC@ZLE*$^=1NG&SU7NV?RN>;ZAJ6L?%#X8Q7D=LLVIZ=?!I(X5YEVKU
M]</T]CC'2G^)M9OO%7B;P,3I-WILHN=QCNEV.=K1ER!G.W /)QGFO2]%\,CP
M;X?6QTB*.XF4[S]ID,8D<_>9F"MC\NPI-+\,R-KS:YJ4B3ZAY7E01Q ^5;H>
M2%SU)[L?H !Q5_7:4)2<(^ZN;E^:L9RRO$5(Q4YOF?)S=O==[W[G3+]T?2EH
MHKP#[$**** $;[IJ.W_U,?\ NC^52-]TU';_ .IC_P!T?RH P/$7P]\+>,+N
MWNM>\,Z/K5W;@"&;4K"*XDB .0%9U)&"3T/<U+XB\"^&_&%E;6>N>']+UNTM
MFWPP:A9QSQPMC&45U(4XXX KROXZ7.L^"O%VA>,]%O\ 4VMM)MKB\UG1X[R9
M[:\LD>".4B MY8DC29Y P4$[.<\8B^._B2\\06_AJUT#6;NSTC^U-)EU"[TF
MZ>![B&ZNXXHX5EC96"M&\LAVD'B/G#4 >CWWPD\"ZI96-G>>"O#MW9V"-%:0
M3Z5 Z6ZEMQ6-2F$!/) QSS75JJ1KY:@(%'"CH!VKSS7OC%I7A%M5ACT?7-8T
MWP\!'J^J6:I-%I^(UD/F&25992L;J[>4LA ///%<[\=/B7+-\-O%B^$WUJ6Z
ML;!YI=:T$6Y6P?R1,@<RMN.]&7/E*S*K9RF0: /1M%^&_A+PWJ%W?:1X7T72
MKV[5DN+BRT^*&296;+!V506!(R<GGO5.X^$O@:XL;.TF\%^'IK2Q9FM+=]*@
M:.W8G+&-=F$)/4@<U1T[XG:99ZLWAN6#5Y]2L-&759Y1832+)&-@_=D+F=R6
MZ1!N00<-Q7*0^/&\;>.OA3X@T35]4A\.:[%?9TN94BBE\N%RLCJ%W[L]F8J,
M*0H.20#TW5O ?AK7M4L]3U/P]I6HZE9X-M>7=E%+-!@Y&QV4E<'G@U5F\"Z#
M!K4WB2S\,Z+)XIV-Y>HR6L<=P[;2 &G",X!Z$\X!/!Z5EQ?%B$^+(- N?#VM
M:?=7MO-<:;+=Q0I'J B4,Z1XE+(^&!VS+&>M<A\/?CAJ-[X-MK[Q'X<UA-5U
M#4KFRTVUC6T+:@XFN"(80LY"^5'"=S3%%.TG<V<T :GP,^%TO@#2+F37-!\.
MVGB22ZN7;4]')FEGBEF>55DE>&)\KYFW'(.T'C.T=Y_PA?A_^T-3O_[#T[[=
MJD8BO[G[)'YEV@  65MN7   PV> *X>3]H#0+.W/V_2]=T_4H]4AT:XTN2P,
MDUK<2E!'YCQ,T01A(A5PY#;L#)R*[[P_K4FNZ5'>2:;>Z3(SR(;/4$59DV.R
M9(5F7!V[@02""#WH RQ\+?!@\/G01X2T+^PC+YYTS^S8?LQD_O\ E;=N[WQF
MMS2='L-!TV#3],LK?3K"!=D-K:Q+%%&OHJJ  /8"KE% !1110 4C?=/TI:1O
MNGZ4 ,A_U,?^Z/Y5B77@?PW?>(H/$-SX?TNXUZW7$6J2V<3748 ( 64KN Y/
M?O6W#_J8_P#='\JXSQWXQ-HM]HFE6VL7^M?9?.E.A);F>QB?<J3GSV"'E&PN
M'8[3A#B@#4\0?#_PMXJM8+?7/#6CZQ!;N\D,.H6,4Z1LYRY4.I )/)(ZTM]\
M.?"FJ7D=Y>>&='N[N.U-DEQ/81/(MN593"&*Y"%68;>F&(QR:\O^%OQ(1/#/
MPJL=7U?7IM8U31FOI9&M?,M[O$!=S/.\>=R[20D;!@2NX;2*ZJS^.&G77A\:
MY+HFLVFEW"V[:;<21PR#5//;;"L'ERMAF)7Y9?+*[@6"C. #:TCX0^!?#^I0
MZCI?@OP]INH0KMBNK/2H(I4!4J0KJ@(!4E>O0D=ZJ'X0^"K#[/=Z;X$\,#4;
M#]Y8,=-AA\J0,73;(L9,?S\[E!(/.":-,^*0U2SU/9X:UR/6=.G6WGT)XX/M
M09H_,0[Q,8-K+R',H7/!(/%9UO\ '#2;[1[.ZM=(U:?5+O49M(30BL$=X+N)
M7>6(F258OE1&;/F8(^Z23B@"G\#?A;+X!T>Y?7=!\.VGB.2ZN7?4M')FEN(I
M9WE59)'AB?*^9MQR#@'C.T=1:_"#P)8V%]8VW@OP];V5]M^UVT6E0+'<;<[?
M,4)AL;CC.<9..M8NK?&BSTH2 >'->O9[2Q34M3M;>"(2Z9;ONPTP:50S?NW^
M2(R-A2<<C.AI/Q7LO$/B)]-T?2=2U6SBF2WGUBV$/V6"5HEE574RB;E'0[A&
M5^8?-G( !U.BZ#IOAO3(=-TFPMM+TZ $16EG$L,48)R0JJ !R2?Q-9^K^ /#
M/B#6[/6=4\.Z5J.L66W[+J%W912W$&UBZ[)&4LN&)88/!.:WZ* .;N?AKX1O
M?[5^T^%]&N/[6=9-1\W3X6^V,N=K397]X1DX+9QDXI+CX:>$;S0[31;CPMHL
M^C6<GFVVG2:?"UM _/S)&5VJ?F;D#/)KI:* ..OO@WX!U26XEO/!'AR[DN9C
M<SO/I-NYEE.<R,2GS,<GD\\FM+6?A_X8\10V,6K>'=)U2*PQ]D2\L8I5M\
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M_A@2;_H=U_\ !7_]NK[!HH_UCS3_ )_/[E_D'^IV2_\ /C\6?'W_  P)./\
MF=U_\%7_ -NJYI_[!EO;R*]UXM-UM_A_L_:I^O[T_P Z^M:-M1/B#,ZBY95G
M^!4>#\EB[JA^+/(O!?[./ASPK/!<7;/JTT.#&DBA(4(/&$'\B2/:O654*,#(
MQTIY7/>C;7@2DY-M]3Z;#82CA(\E"/*AU1+_ ,?#?[H_F:EJ)?\ CX;_ '1_
M,U)V$M%%% !1110 4444 %%%% !1110 4444 %0W'^J/U'\ZFJ&X_P!4?J/Y
MT 34444 %%%% !1110 4444 %%%% !1110 4444 0P]9/]\U-4,/63_?-34
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MM([>:\F9F,K*,$Y8YQV&>< 5TNVEV_A0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5$O_ !\-_NC^9J6HE_X^&_W1_,T
M2T444 %%%% !1110 4444 %%%% !1110!$W_ !\+_NG^8J2F20B1PVYE(&.*
M3R/^FDG_ 'U0!)14?D?]-)/^^J/(_P"FDG_?5 $E%1^1_P!-)/\ OJCR/^FD
MG_?5 $E%1^1_TTD_[ZH\C_II)_WU0!)14?D?]-)/^^J/(_Z:2?\ ?5 $E%1^
M1_TTD_[ZH\C_ *:2?]]4 245'Y'_ $TD_P"^J/(_Z:2?]]4 /;H:9;_ZB/\
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M5'D?]-)/^^J )**C\C_II)_WU1Y'_323_OJ@"2BH_(_Z:2?]]4>1_P!-)/\
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M?ID_R-25$UL&(/F2<?[5+Y'_ $TD_P"^J )**C\C_II)_P!]4>1_TTD_[ZH
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117D/@+]H!O&_QL\9?#
MT^%[[3O^$>02#59'W1S#*C#)M'EEMVY/F;<H)XQB@#UZF[ORIU>2_$!8M)^,
M'@C5[O6-3L=+-IJ N+>+4KB.S=H8UF222)7$;;4$^=RG.1G.T8 /5]QH+?\
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M0F\(4W?+NSQ0!VM,\P\<5R6O?$B#1?%5OX>32-4U'4KFSGO(%M8XPD@B,89
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M6: S7;&-I J;BJCY%9B7*J "210!NEL4>9^=>.^(?C9?:C8>'4\-^&]8DO\
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M;?V<&N1,84C*F8R;3'^[4[?+#<8WXK,TWX0ZAIW@WP7H/_"2JY\/W<5S).+
M 7"QQ/&J*AD.P[F$FYC)\ZYQC"CT&]NYK>2W6*QFN_.D,;21LBK"-K'>^Y@=
MN0!\H8Y8<8R1S?P_\9:IXV\'W.JRZ39V%^ES=VL5M'?O+;RF"9X@PF,*L%9D
M//EY P<'I0!B6_PKU73?#NM:99ZWILR:EJ4MX8M6T<W=NT;N[&.5/.5I7PR
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M=AW,)-S&3YUSC&%'9^,M:N?#GA;5M6M;:WNY[&V>Y\FZN6MXV5 6;=(J.5&
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M92VT(2R$*M,ZHGG ;F*D(L@P2Q/G/D\@#T#@CD<]?ZTCL55CMW$ X&1D]^]
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ML9\P8C !&P99N<]R<#KCKW-9$_B6T@\30:"BR2:C-:27@"K\B1HZI\[=LL^
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M:+X.\/SQWFI.=3M/M%\@8K&D!$[RR?P@L8 @)Y!EXZD5Z9M%&T4 ?/\ XO\
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MKX\M;WPS\,_$">$+#R-3CM)Y+2&QA7?YS!F:1$_C?)9\8)9O4FNTV]:3:.:
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M\V0&G(VB2$1 !58LOGDJ,%C7K^T'%&T4 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***3- "T4W=1NH =14;2?X5SGC#XC^'_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY=/N/N34?V]?@+I?^M^(MC)_P!>]M<3#\TC(KD[_P#X*:_ >S_U6O:E>_\
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MBDS10 M%%% !1124@%HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]*LQS KLD&Y/Y5+2[!=QV.TT#X_?$[PJP;2/B%XGT\CH(-7G4?EOQ7I/A_\
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MW%^*LG=83#6_Q/\ R/KW6OVH_"6EY6V6\U"3L(HM@_'>01^5<+KG[7%^T?\
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M* 0W*_\ H:G]*_)A=DV ?D?U'2E*O"W/ ^G!^GK6+P=&6Z+^O5H]3]N/#?\
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ML#4?^>-K_P!\-_\ %4>WB:?5*G='> %>F:3"MVVFN$_X6!J/_/&U_P"^6_\
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M4/9:I97BG^*WG5Q^A-:*NK?Q#\*_FBA^/7B.WD$D4-C&XZ,J2 _GOKH]+_;
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M /\ !=??_)E'_#ZOXW_]"M\/_P#P77W_ ,F4 ?M317XK?\/J_C?_ -"M\/\
M_P %U]_\F4?\/J_C?_T*WP__ /!=??\ R90!^U-%?BM_P^K^-_\ T*WP_P#_
M  77W_R91_P^K^-__0K?#_\ \%U]_P#)E '[4T5^*W_#ZOXW_P#0K?#_ /\
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MW_D?<H7G.>:D51_G@5\+_P##<OCO_H$^'?\ P&G_ /C]._X;H\>#_F$^'?\
MP&N/_C]/^TJ75/[E_F0^&<9_-'[W_D?=2G:,#(%.5J^%/^&Z?'O_ $"/#G_@
M-<?_ !^C_ANGQ[_T"?#G_@-<?_'Z?]I4>S_#_,G_ %7QF_/'[W_\B?=F*>K=
MJ^$?^&Z_'O\ T"?#G_@-<?\ Q^C_ (;L\>_] CPY_P" UQ_\?I_VG2[/\/\
M,A\,8S^>/WO_ .1/NZI-QKX/_P"&[O'W_0(\-_\ @-<?_'Z7_AO#Q]_T"/#?
M_@-<?_'ZI9I1[/\ #_,S?"^,_GC][_\ D3[QJ5?K7P5_PWCX_P#^@1X;_P#
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M#^&O_ 6X_P#C]-_X;P\?_P#0(\-_^ UQ_P#'Z/[6H=G^'^9JN%<;_/'[W_\
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>^'__  'G_P#CU']JT.S_  _S'_JUC/YH_>_\C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img8619836_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )B!+$# 2(  A$! Q$!_\0
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M_P"XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_P"B/_\ ES__ ''1_P /G#_T1_\
M\N?_ .XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_Z(__ .7/_P#<='_#YP_]$?\
M_+G_ /N.CZG7_E_$/KE'^8_3'-&:_,[_ (?.'_HC_P#Y<_\ ]QT?\/G#_P!$
M?_\ +G_^XZ/J=?\ E_$/KE'^8_3'-&:_,[_A\X?^B/\ _ES_ /W'1_P^</\
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M<_\ ]QT?\/G#_P!$?_\ +G_^XZ/J=?\ E_$/KE'^8_3'-&:_,[_A\X?^B/\
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M /N.CZG7_E_$/KE'^8_3'-&:_,[_ (?.'_HC_P#Y<_\ ]QT?\/G#_P!$?_\
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M='_#YP_]$?\ _+G_ /N.CZG7_E_$/KE'^8_3'-&:_,[_ (?.'_HC_P#Y<_\
M]QT?\/G#_P!$?_\ +G_^XZ/J=?\ E_$/KE'^8_3'-&:_,[_A\X?^B/\ _ES_
M /W'1_P^</\ T1__ ,N?_P"XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_P"B/_\
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M/KE'^8_3'-&:_,[_ (?.'_HC_P#Y<_\ ]QT?\/G#_P!$?_\ +G_^XZ/J=?\
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M_P"XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_P"B/_\ ES__ ''1_P /G#_T1_\
M\N?_ .XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_Z(__ .7/_P#<='_#YP_]$?\
M_+G_ /N.CZG7_E_$/KE'^8_3'-&:_,[_ (?.'_HC_P#Y<_\ ]QT?\/G#_P!$
M?_\ +G_^XZ/J=?\ E_$/KE'^8_3'-&:_,[_A\X?^B/\ _ES_ /W'1_P^</\
MT1__ ,N?_P"XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_P"B/_\ ES__ ''1_P /
MG#_T1_\ \N?_ .XZ/J=?^7\0^N4?YC],<T9K\SO^'SA_Z(__ .7/_P#<='_#
MYP_]$?\ _+G_ /N.CZG7_E_$/KE'^8_3'-&X5^9W_#YP_P#1'_\ RY__ +CK
MZ\_9!_:9'[5?PUU'Q8OAP^&#9ZK)I9L_MWVK<4AAEWA_+CZ^<!C;_#UK.IAZ
ME-7FK%PQ%.H[1=SW:BBBL#I"BBB@ HHHH **** "DI:2D!\R_P#!27_DRSXA
M_73O_3E:U^'5?N+_ ,%)?^3+/B']=._].5K7X=5]!E_\-^I\_C_XB] HHKIO
M!GPO\9?$=;L^$O">N>*!9[/M/]BZ=->>1OW;-_EJVW=M;&>NTXZ&O2;45=GG
M).3LCF:*]+_X9C^,7_1)O''_ (3=Y_\ &Z/^&8_C%_T2;QQ_X3=Y_P#&ZCVM
M/^9%^RG_ "L\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$
MF\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]
M$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF
M/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-*
M*]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG
M\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0
M>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]
MK3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$
MF\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]
M$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF
M/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-*
M*]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG
M\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0
M>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]
MK3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$
MF\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]
M$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF
M/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-*
M*]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG
M\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0
M>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]
MK3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$
MF\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]
M$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF
M/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-*
M*]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG
M\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0
M>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]
MK3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$
MF\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]
M$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF
M/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-*
M*]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG
M\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_T2;QQ_X3=Y_\;H]K3_F0
M>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C^,7_ $2;QQ_X3=Y_\;H]
MK3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;H_X9C^,7_1)O''_A-WG_
M ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3=Y_\;H_X9C^,7_1)O''_
M (3=Y_\ &Z/:T_YD'LJG\K/-**]+_P"&8_C%_P!$F\<?^$W>?_&Z/^&8_C%_
MT2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?^$W>?\ QNC_ (9C
M^,7_ $2;QQ_X3=Y_\;H]K3_F0>RJ?RL\THKTO_AF/XQ?]$F\<?\ A-WG_P ;
MH_X9C^,7_1)O''_A-WG_ ,;H]K3_ )D'LJG\K/-**]+_ .&8_C%_T2;QQ_X3
M=Y_\;H_X9C^,7_1)O''_ (3=Y_\ &Z/:T_YD'LJG\K/-**]"U/\ 9V^*VB:=
M=ZAJ/PR\8Z?I]I$UQ<7=UH%W%##&H+,[NT8"JH!)).  2:\]JHRC+X7<B491
MW05^O/\ P2!_Y-M\3?\ 8VW/_I%95^0U?KS_ ,$@?^3;?$W_ &-MS_Z165<.
M._A'?@?XI]S4M)2U\Z?1!1110 4444 %%%% !24M)2 ^9?\ @I+_ ,F6?$/Z
MZ=_Z<K6OPZK]Q?\ @I+_ ,F6?$/ZZ=_Z<K6OPZKZ#+_X;]3Y_'_Q%Z!7Z7?\
M$9<[OC ?^P/_ .WU?FC7Z7_\$9.OQ@_[@_\ .^K;&_P)?UU,<'_'B?I=M[8I
M=M**.?2OF=3Z6R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*-
M>X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7G
MTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$
MVT;:7GTHY]*->X60FVC;2\^E)NHU[A9!MHVT;O:C=BC7N%D&VC;1N]J-WM1K
MW"R#;1MHW#..]&ZC7N%D&VC;2YHY]*->X60FVC;2\^E'/I1KW"R$VT;:-W&>
MU&ZC7N%D&VC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E)N[=Z->X60;
M:-M+N]J3=WHU[A9!MHVT;O:@-NZ<T:]PL@VT;:7GTHY]*->X60FVC;2\^E'/
MI1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;
M2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X
M60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTH
MY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT
M;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1K
MW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^
ME'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60F
MVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*
M->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7
MGTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R
M$VT;:7GTHY]*->X60FVC;2\^E'/I1KW"R$VT;:7GTHY]*->X60FVC;2\^E'/
MI1KW"R$VT;?:EY]**861Y?\ M01D_LU_%C/_ $*6K?\ I'+7\^%?T)?M/_\
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M/M+B75WM6CG+*O[Q!;N GSI\P8GK\O'/LU?+7[8AW?$SX"8Y_P"*IC_]'6]
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MH **** "BJLFI01NRL9-RG!Q$Y_I2+JMF[;?M$:O_=8[3^1H MT4F1U'(I:
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M.J^@R_\ AOU/G\?_ !%Z!7Z7_P#!&/K\8/\ N#_SOJ_-"OTO_P"",?7XP?\
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M^0?#^/\ ,U=JEI/_ "#X?Q_F:NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%(#S']I__ )-K^*__ &*6K?\
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:6, X)9%8D 'CD4WQ)\1?"?@^ZAMM?\ $^C:)<3#,4.I7\-N\G/50[#//H*
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MM+2+2U\T?2K8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7FGQ^C^(W_  KFY_X5<85\5?:(BOF>3N,.[]X$\[]WNZ?>
MXQNQSBO2Z* ,CPJ-8_X1G2?[?^S_ -N_9(OM_P!E_P!5Y^P>9L_V=V<5!XW\
M-'QEX.US0?MDFG?VG936?VJ$9>+S$*[@.,XST[^U;U4=4TNVUC3;FPO$\^TN
M(S%)&S%=RD8(R.1]1R.U 'E'_"0>*/A['X9T?6/"&ASV<DO]FZ;J&@W;'R+C
MR'\LFUDA7RD95<$I(Y )!XR:=^RTNFWWP<TK5(V2\UG4PTNN74OS7$U]N(F6
M<GDLK K@G@   # KM] ^&FA>'=22_MX[Z\O8@RQ3ZMJEUJ+P!AAA&UQ(YCR,
M9VXR*IZE\'O"^H:U<ZNEK>Z9J5TP>YFT75;O3OM##H\JV\L8D;_:8$_A0!Q_
MQ!^$>F:]JFAZ3H;1>'=6T?3[B]T&]@49L;A9X6W!>\;;MCI]TJY'IB3P;\1(
M/&VO:;-K%J-%\1Z%9:A;:WIKL=]E,#;$L#_%$Z_.CC(92,<@UW%E\-= T_Q)
M::];07<.HVL#6T>S4;D0^6YW/NA\SRW+-\S,REBP#$DC-32?#_P])XV7Q<VE
MPCQ$MFVGF^RP9K=F#%&7.UAD#D@GK@XH \)^'MOK'@^X^%MOKEG8ZAX0DNG3
MPYJ5B3%?QR36TK1"]BP5;="9-S1L<O@L*N?%;QAJ</B"U\>6/AK6+G2_">H%
M?[8AEM6M)-/ ,5^=GG^<#NW'(B(/V:,CCD>KZ9\&O">BR%[.RNX L4D-NG]J
M73)9*ZE7^RJ9<6Q()&Z'80#@&I;7X3>'+/P+-X/ABU%= F!5X#J]X9-IQN03
M&7S%0XY56"G)XP3D ZAKAI['[19^5<,\?F0[I-L;Y&5RP#8!XYP<>AKPG_A>
M7B^Q\!VWB?4;#1T2ZU*;0DL;&&ZNY([M;]K=904&Z:,(DC%%C5V*J!C=\OLO
MAWPCIOA;PS;^'M-6Y@TRWA,$,<E]/+)'&<X42NYD '1?F^4  8P ,#2_@GX1
MT?PI>^&H=-N)M%O)?M$MK>:E=7($F_S-\;22,T;>8=^Y"IW?-UYH \EU[7K[
MQK-X6NO$&D1M?:/XQTZ'3]:ET&ZTMIXI1N<1PW8,L9#*%;#LK;5/L.MUSXQ:
MGIGQ$T+3[.XTW6-&U'5O['F@L].NBULW[SYS?9\@NI3YH=H888!B175ZE\$_
M#6K:=865XVO74%C<?:[<R>)=2,B2\8?S/M&XE<?+D_*2<8R:CF^!/@N>3>=-
MND(U ZI%Y6J7<8M[DLS-)"%E'D[B[%@FT-GD' H \LM/'7BGX:IX\UB^OM/U
MA+SQ8NEV]M#I-TTRSR);(LGR2R.T:1Y/DJFYBO#KG ZK0?BYXFU"2/1KBRC7
M5K_4QI^FZQ>:)>Z9;2K]EDN&E-I<,)3L\ID*K)AB5.Y03CM[SX1^%;YM>^T:
M:\D6N2)/?6YNY_(DE7;B58M^R.7Y%/F1A6RH.213KGX3^';[P^FCWD6HW]I'
M<K=PRWNKW=Q=03#[LD5P\IEC8#/W''4^IR <=\"-$DT'Q-\3[:Y33%N_[?CE
MF;2+;[- [M96[,XC)8HS%B2"S$L2<G.:VOC!\3+CP#)X=T^PASJ&N74EO'<?
MV;<ZB+=(XFD=_LUN/,E/ 4*I7[Q8L I!Z#PS\.]!\):SJFJ:5;SV]YJFPWA>
M]GE29E4*'9'<KYF%&7QN/<GK5KQ9X)TCQO90VFL6K3QV\RW%O)#/);S02@$!
MXY8V5XVPS#<K X)H \KTOXM>.M3O_"6G-HFG6#:Q?7MA)J&HVUY:.WDQR2)/
M'92JKJC*JG#29R2N?XZJZE\0/%"ZQ9Z+XBT#PUK3:?XMLM,DU18Y$B'G1QRP
MRP6[^85F59""3+\A (W!L#0^)GP[N]1\2?#K3K+P]X@UG0=)O)KB[U&'7BD\
M DADC5O/DNEN&9696X)^7.,D!3V^O?!_PSXDL["TO;6^6&QN#=P_8]6N[5S.
M2#YSO%*K229&=[DL,G!Y.0#QG0_&\?PGAUG0/#^GPV#ZIXTU"UMA;:3/>0V<
M<=M'(S+9VH#R=  BE1\Q8L O/4Z7\6O'6IW_ (2TYM$TZP;6+Z]L)-0U&VO+
M1V\F.21)X[*55=4954X:3.25S_'76VOP#\&6MG=6RV>I2+<78OVEFUR^DFCN
M "OGQRM,7BD*L071E+="3@8YCXF?#N[U'Q)\.M.LO#WB#6=!TF\FN+O48=>*
M3P"2&2-6\^2Z6X9E9E;@GY<XR0%( VX^)?CRQ36-,N-/LI[[2M76QN-<TO2+
MF]MUMWM1.DOV&.7SRV62-E61MI<-R.*/#'Q.;4/&O]H7VG:!=V\?A.34DU[3
M$D^TSK',JRQ8D17A02!_W1+G(R2#E:]"U'X8:#J>GVMF\5];1VTK3I+8:I=6
MDS2,,.[RPRK([-W+L2>IS5?3/A!X8T?Q-:Z]96=W;7]K:BRA6/4[H6ZP!=OE
M>1YOE%>-V"G+?,?FYH X3X7_ !E\2^.-4TIYM':;2]6T][T)'H.H6(L)-JO'
M&UW.ODW(<$C>@3E00&#9&]\*?B%K/BG5+RQ\0O;6.IBUCN_[';2+JQN+3+$.
MI>5V2Y13A?.BPI/89%=%X;^%_A[PBL\>DPWUI:S1M!]@_M2Z>TC0]5A@:4QQ
M#T\M5QTXJUX4^'NB^"I)I-+ANVFE18C-?ZA<7LHC4G;&KSR.RH"2=JD#))Q0
M!TU%%% !1110 4444 %%%% !1110!2TG_D'P_C_,U=JEI/\ R#X?Q_F:NT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%%(#S']I_\ Y-K^*_\ V*6K?^D<M?SVU_0E^T__ ,FU_%?_ +%+5O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%)N% "T4F11D4 +129%&10 M%)
MD49% "T4F11D4 +129%)N'K0 ZBDW4M !1110 4444 %<S\0/B3X;^%OAQ]>
M\4ZHFE:4DBPF=HWD)=C@*%168GZ#L3T!KIJYGQ]\.?#WQ2\.2Z#XITQ-6TJ1
MTD,#2/&0RG*LKH0RD>H(X)'0XH V]*U:SUS2[34=/N8[NQNXEG@N(CE)(V *
ML#W!!!JOX@^WC1;LZ9/;6FH"-C#-=V[3Q*PZ;HU="PZ\!A4VE:3::'IMKIUA
M;1VEA:0I!!;Q#"1QJH55 [   ?A4/B*>YM=#O9;73[C5+A8CLL[5HUEE)&,*
M9'1,\_Q,!Q0!Y/\ #GXC>-?'_P .-"NH)="D\4ZS'%>M+%I\PL=+M6(R9E,Y
M:60@,%4.A8D<!49JW5\<>(_%7BS6?#?AG^S;:301%%JFN:G;230_:719!%#;
M)*C$!&!+-* N0!OY(\R^$/PQ\;?"GP?H^K:%X?N[+5HXH[7Q#X3OKZW,6J,J
M*OVRUD29XXI@,+\Q42!"&"G:Y[JST'Q7\/?'?B#Q#I&@R^(= \3217EWI$5Q
M!#?V%VL:QLR>9(L,B,J+N_> @@8W#- $_C#7/BGX<\.7$ME%X:U/5X+RWCMM
MUO-#%J22,JL@4SDVSJ2<,S2J>.G-6)OB7J'C'X7V/B3P5/9V5]+>0VMQ:ZU9
M23M;2-,L,T$D:RQ%98W;GG'R=,,&%CQ7KGBC5-'TV:U\!ZJ9!J5I*]FU[8B>
M.-)5>5G'VCR\;5PNV1B2>0H'.#X]^&_B'2/&D/B#P79Q7EGKE]9CQ'I$DR1*
M?*FC=;V(MP)%5"CK_&NW@LN2 ;[>,/$7BSQ)K6B>%I=+LDT-H[:_UK4K66YC
M>[:-9&ABMTEC.%1T+,9>"P&&P2,^U^(GBW1_&4_@O7;#3+S6KO3Y;_1-3L-]
MO:WIC*K)')$[.T+H65N)'#*<C!XK-U1M<^"OC#Q3K]GHUSXJ\+>(KA+Y[+2F
M0ZE:W@B6-Q'#(RB=76)6PK;U*M\K"L_0_&MO\1O&B>+;6U+:SH.DSQ:9X)FN
MH8-79YVC,LEQ%(RB'B-%'S$8+$MG"T =KX9\4^)++XB3>$O$<VDZD\VFMJEM
M?Z3:RV@55E6)XY(GEEYRP(</S@Y QSV^J:]IFAQI)J6HVNGQN&*M=3+$#M4L
MV-Q'106/H 37 _#.36O[6N[G7/!VN:?K.I*K7NKWTNG_ &<!,^7!&D-W*ZQK
MN<*-IY9F8Y8FL_XL>%[[4OB9\.]9L?!4FOKI-Y-+>:G ;-7BA>WFB$8,TJ.1
MYDB.0O&%[MQ0!WQ^('A==0TRP/B32!?:I&LUA:F^B\V[1AE6B7=EP1R"N0:Y
M?P'\3)]1T7Q/J/B]M(\.KHVKSZ?*\=X3;QI&J$,TT@3)^8\E5^E>=7'P:UN/
MQGXDTV[B\02^%=9U:WU"%]!.D+:11QK$(TF6X3[0GEF)0/*+#:H*A3D5/IEC
M\0K&WUHVO@G4+#[=XIFU)I))=-ENX[66$J)+8-<-$)5=%W>9QMD.W<<X /0?
M&WQL\*>"_#>BZX^M:5<Z?JU]!:6MTNH0I ZO(%DE$F<%(U+,2,],'&<CHU^(
MGA5K[2[(>)M'-YJL:S:?;B_B\R\C895XEW9D4CD%<BO$?#_P]\8:!X+O;.7P
MU>:A>V?C6/754WED&O[<W"R,\6UHXPX R5=81G.*DNOA-XCU#QMXEBU6/Q-+
MX?\ $&K6^JB32'T@0Q;%BV+<>>IN \31 9A=P5 *X.10!WGQ>^+8\"+I]CI-
MWH=UK]Q?6<,VFWU_LN([>:=(C,L"@L^"_<JHZY.,'T[-?/FO^$/&4?@K5M 7
MP<VMWUOXFCUN#4HKNU"7L/\ :*W/R>;(&2=8_P!V0X5<)PY&%KWVW9YK>-WA
M:!V4,8Y"NY#C.#M)&0?0D4 9D?C3P_+XB?0$UW37UY%WMI:W<9NE7&<F+.X#
M'/3I4'_"Q/"O]K6FE?\ "3:/_:=X6%M9?;XO.FVL5;8F[+896!P."I':O$?!
M/P9UF'6(-&\61:_J>EVFL7>J17$?]D/I-P97E;=("@O,NLI5D.X$D_,5Z5/A
M7X/D\9?".V\*P^%/['TRW\037D>KK);I!MAU)WS"L;^:LNV,1C*J #]X@8(!
MZ7XN^)&NZ'?:,MG9Z'=6EUXCBT6YFBU.2:2"-V7:3&(E E(+90OA?DY?=QVT
M?C+0)?$3^'TUS37UZ-/-?2UNXS=*F,[C%G<!@@YQWKYUL?"/BO1K$V&F_"O5
MK&QC\;)XBAM[6YTJ**.U4I\BH+L /\I^7&WGKZ:?@?X,:S#JUMH_BN+Q!J&F
M6FL7>J13Q_V0VDW#2O*VZ0%!>9=)2CH=PY(W%<8 /</^%A>%?[6M-*_X271_
M[4O"RVUE]OB\Z8JQ5@B;MS896!P."I':I[/QIX?U#7[G0K77=-N=;M5WSZ;#
M=QO<Q+QRT0.Y1R.H[U\__"OP?)XR^$EMX5A\*_V-IEOX@EO(]75[=(-L.I.^
M85C?S5EVQB,950 ?O$#!ZGPYX0UVTUZ^B/AO5$\)JFI27.AZT^F7<-TT[L^R
MS96,@\QF<L+AU3#!<#^$ ]$7Q]I6E^&8-9\2:QH.B6TDK1_:1JR/:;@S*%6=
MUC#'"\C'!R.<9.CKGCCPYX9L;6]UC7]+TFSNR%M[B^O(X8YB1D!&9@&)!SQ7
MS;X9^%_CS1;+P=?0Z'K^B#1K._TN33=(ET9KJ,37 F66+[0983&5PC#=&X*#
M *GGL]<^&VI^'O#_ (8L?"VC>)3?V.D3V$-_'<Z6?)65D8V]W%-^Z:/<BY,*
M,0%(7KR >\+(LBAE8,I&00<TZJ.D6]U;Z390WC0O=QPHLS6Z;(RX4;BB]EST
M'I5Z@ HHHH **** "BBB@ HHHH I:3_R#X?Q_F:NU2TG_D'P_C_,U=H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****0'F/[3__ ";7\5_^Q2U;_P!(Y:_GMK^A+]I__DVOXK_]BEJW_I'+7\]M
M>WEWPR/#S#XHA7Z\_P#!('_DVWQ-_P!C;<_^D5E7Y#5^O/\ P2!_Y-M\3?\
M8VW/_I%95T8[^$8X'^*?<U+24M?.GT04444 %%%% !1110 4E+24@/F7_@I+
M_P F6?$/ZZ=_Z<K6OPZK]Q?^"DO_ "99\0_KIW_IRM:_#JOH,O\ X;]3Y_'_
M ,1>@5^E_P#P1CZ_&#_N#_SOJ_-"OTO_ .",?7XP?]P?^=]6V-_@2_KJ8X/^
M/$_3!:6D6EKYH^E6P4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M444 %%%% !7SM^T#_P CI:_]>*?^C)*^B:^=OV@?^1TM?^O%/_1DE?)\3?\
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MW0[>12VWQ@T&\U^?2[:+4[EX=(&M_:(M.F,<MN0A7R?EW3,0XXC#8(*G#<4
M;_AKP=H7@NVEM/#^AZ;H-I(VYH=-M([=&;'WBJ 9/O4.O> ?#/BJ_M;[6O#>
MDZQ>VF/LUQ?V,4\D.#D;&925YYX[TO@7QE8_$#PGIOB+2UF73]0C,L'VA-DA
M7<0"5[9QG\:\)\)^(H]$^.'CGPK;^(=3_MV[OEMM'BUK5[NYM+:#[+!+.T<<
MLA1Y TF50?-C@;4W&@#W;4? ?AG6M;MM9U#P]I-]K%KM,&H75E%)<0[3E=DC
M+N7!Y&",5FP_!SP#:V<]K#X'\.16MQ*DTT,>DVZI(Z;MCLH3!*[VP3TW''4U
MQ6H:7/\ #SXA_#FQ@\4:]<Z)+'?B]AU34&N5F:.V+^?)(_SDY_AW>6,#:B]:
MV%^.5I>V+S6OA_68A=:;/J6CS744*1ZK'$@8^7^]W(<,K!9A&2#D X. #JI/
MASX2FMM3MI?"^BO;ZI(LU_$VGPE+MU.5:4;?G(/(+9(IUU\//"M]JUCJESX9
MT>YU2R"K:WLUA$T\&WE1&Y7<N.V#Q7A=E\0->O?#?@%9?#'BR>7QB[3:D(=7
MA2:Y"V1ES:-]M'V:-F(8*AB($;94$C=WB_M!Z);Z+<ZE%H'B:31-.O\ ^S+_
M %":R$?V-@8U#R1S2+,RYD&2J,PVL6 ^7(!VVI_#?PEK5Q?W&H>%]%OY]058
M[R6ZT^&1[E5(95D)7+@$ @-G! K=MK:&U@CA@BCAAC41I'&H554#A0!P ,=!
M7&>+_BQ8>%=1OK*/2-5UR;3+5;[4CI<43BQMVW;9'\R1"V1&YV1[WPOW>1F"
MS^,VE:OXEN=&TK2]<U.XM39M/-#8F.)(KEF6.8-*5+QC8<L@;CD9 ; !O7'@
M/08-:F\26GAG17\4"-A'J,EK'%.S%2 K3A&<*>A//'8]*X[X&_"N;P%HUQ)K
MF@>';3Q))=7,CZGHY,TL\4LSRA9)7@C<E3)MQR/E!R,X'JU?/<VK0:!JVNZA
M\2+_ ,9:-J$6HSO:ZAI\E_\ V/;V8DQ;L/LP-N $*;S<J3NW;LC% 'H__"A?
MAD6+'X=^$\]<_P!AVN?_ $76M+X%T"UUB7Q%9^&=%;Q1Y;"+4&M8XIW;:0%:
M<(7"GH3@\=CTKGX?C-9W&N>*M-30=6SX?L5U*2Z:2S6&[@<,8W@<W'S!E1R&
M;:HV$,0>*@M?CA;7VI)I5OX0\4OKS::NJ'2I+**&41%U4+YDDJPEL,"0LA P
M5)#_ "4 0? WX6S^ =&N&UO0O#MIXDDNKF1]2T=C-+/#+,\H$DKPQOE2^W'(
M.T'(S@=?8_#GPGIK:H]GX7T6T;5$:*_:#3XD^V(V=R2X7]X#DY#9!R:Q+/XP
M:;KOAK1]0T6QU35+S6+>2>TTFVCBCO L;!)2PF=(T\MF )9\$X"[LC/$?#/X
MI_\ "(_#FVO?%%QXBUB[OO$MYI,4MQ:&:X5S?-!$LOEJ(XL?*,?*,Y" ]* /
M1A\(? BZ(='7P5X=&D^>;G^SQI4 M_-("F39LV[\ #=UXQ5W4OASX3UIM..H
M>%]&OCI@"6)N;"*3[(!C BW*=@&!PN!Q7.3?&)$D:UM_"/B2_P!8A@-U>Z3;
MPVXN+.'S)(TDD+S*C;S"Y18W=F SC!!JO:_'W0=9U+3[#0-.UOQ%>7^DMK-H
MME9B))H \:E5DG:-"^9!D;OEVD$AL @'IO IV:\ST/XZ:1KK>&)8]'UJWTOQ
M#)]FM-4N+:-(%N0')MY%\SS$<&-USLV%APQJW8_&32[_ %FTMH]+U3^R;R_D
MTNVUYHH_L4UTA=6B'S^:/FC=0[1A"5P&.1D ]"HHHH **** "BBB@ HHHH I
M:3_R#X?Q_F:NU2TG_D'P_C_,U=H *XWQ1\)?"/C37!K'B'P]INO74=J+6-=3
MLXKE$0,6^4.IP<D\@UV59VO:Q!H6DW-]<1W4T4*9,=E:RW,S9('RQ1*SMR1]
MT&@#YE_91^"O@OQA^S]X5U*_\/6,>L"[N)QK%I L%^&CO)=N+E )%.%"Y5@0
M.A'&-7X#ZU+X#A^*=CIV@^(/%2V?C*]416LJ33)"(8MN9;J9/,(VE=H=GZ<'
M.:W/V/YKCPW\!K'2=8TC6M)U'27NI+FUO])NH9"KW$TB^6&C'FDJ0<1[CR!C
M) I?V;-4E_MWXE07.C:[I;:GXFN]6LGU31;NTCGMF2)%</)&JAB5/R$AN.E
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M>'?$&F>'+Z:."+Q#-;PFS5I,!#(JRF:-22%#/&HR1SS5+]K#'_#.OCH]?]!
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M=V.W-.W"@#Q[PM\$->\(IH<UEXMM?[1TA[V"&2326,$UC<S),\,L?VC)D61
M5E1TP!@H><U;OX%^*'\--HMOXTT_R%\2?\)#'-=Z$\LF1=?:A$^VZ0-^\QE@
M%^7@ 5[7N&<9YI-PH \YU7X:ZVOC*;Q3X?\ $MOI&IZA8PV.JQW&F&YM[@1%
MBDL:^<C1.OF.!EF7!&5)&3DZ-\$-3\(>)-"O?#GB&QM=+T719]'MK._TM[F5
MS*R2/-+*MPFYC+$C$!5&"ZC&[<.K^'/CV3Q]:ZS-+HMQH<NF:G+IC6MU-')+
MF-4)9O++*,[^@9NG7GCLMP]: /'-*^"6OZ7X$\/:$WBO3Y;[0M:_M:UOCHSB
M)P6D8Q21?:<DYE?#B0<8RI(R7>!?V==,\!^*SJ%K:>&+JQ6ZFNX9;GPZC:M"
MTC,^U;X2@E59B 6C+;1@L>H[#PKX^D\2>,/%>@RZ-<:6VA/ AGN98V-RLJNR
MNJHS;5PO&2&YY5<5V.X4 +12;ATJ&\O(;"TGN9WV00HTDC8)VJ!DG ]A0!-N
M%+7G=O\ %R/4/$7@:QM-$NWT[Q59O>P:E/+$B0J(3+Y90,SE\;<C 4!N')!6
MO0]PXYH 6BDW"EH **** *6D_P#(/A_'^9J[5+2?^0?#^/\ ,U=H *CY..X^
MM25RGB#QE<Z'XR\+:''I37<.M-=+)>";;]F\F+S%^7:=VX_+U&/>@#I\'/7B
MC&[Z&O---^-MJ/AKH'BC6=)N=.U#6I/LUGH-HPN;F><NP6*,X0,2JEMQV@ $
MD@#-3ZIXS^(.DV<NHR> ;&]L(U\QK6PUXR:ALQDXA:W6(N/[HFY[$T >B<9.
M.M+NQUP/K^E<-X=^-?@[Q-\-V\=6VL11>&X49KB><%&MF4@-'(F,JX) V\YR
M,9R*H?$[XOS?#G4_"UN/#%]J=CKFIVFF#5%FBCMH'G<J P+&4L "W^KVG@;P
M>* &?M">"?$_Q'^&NJ^%O#,6E+-JT7D3W>J7LD @4,K JJ0R;R<$8)7&<Y-=
MOX9_M@Z';?VY:V=IJ:C;+'873W,7!X(=HXB<CG&T8SCFM;</6C<#R.10 W;M
MZ#BC\LXX_P ^E.W#US5>X:9;>0P(DD^TF-)'**S8X!(#8&>^#CT- $P&/;/-
M-QZX)ZUXUX!^+_CWXAKXA_L[P-H%N=#U:?1K@7GB>==\T)4,R;;!LI\W!.#Q
MTKH/ OQD3Q)XOOO!WB#1IO"OC*S@%V=-GG6XAN8"<>;;S* )%S@'*JPSRO!P
M >C=&[#OS2Y [^]>->&OB]XW\7>,O&'AW3?!F@K<>&;J*VN9KOQ+,BR^8GF(
MR!;%OX>N<8/3-:OB;XH^*/"?PIU_Q9J/A"TAU'1FG>;2_P"UW\N6WB/,L<WV
M?)R.0"@]R* /4*-I^M>5Z?\ $'XB:AX9TO7HO NA3V5]';SB&U\23/<)%+M^
M;:;!5)57R1NZ \UZKN'K0 W YR!Z_P#UZ7FN \9?$R[\*Z]JVG0>'VU".P\-
MW&O).+GRQ-)$^T6P&PX+==V>/[M=;X;U*76_#^F:E-:_8YKVVBN7MB^[RF=
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M#^NG?^G*UK\.J^@R_P#AOU/G\?\ Q%Z!7Z7_ /!&/K\8/^X/_.^K\T*_2_\
MX(Q]?C!_W!_YWU;8W^!+^NIC@_X\3],%I:1:6OFCZ5;!1110,**** "BBB@
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M,[<#. J@DGV R:FW"J.KZQ8:#IMQJ.J7MMIUA;KOFN[R58HHE_O,S$ #W)H
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M6RRO+ ;>ZBC8(HBVIY.58LI&P[AN]KOM1M-+M9;J]N8;2UC&YYKB0(BCU)/
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M$>H-<U\-OA[%\-?#[:/!K.IZS;FXEN4DU0PL\;2N9'53%%&-I=F;!!QNP,
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MC\MWD1[=XR2N>%10"QP!QBO)\$[.S\5:GX@\/^(=<\)WNJN)=1ATJ2![:[E
M \UH;B&5%D(499 I/?/.0#R+Q1>?%/P_\-_AI=>(?$^H:+XFN?$=AH]]9PBT
M>&>-[E]LDIC0L7,80,J3;#@\<G/O/P^\&W7@?1[NPO/$6I^)Y)KN2Z%YK$HD
MG57Q^[R %"@@X"JJ@'H._/\ Q ^!\'Q#M]$M[KQ7XCTZWTB\CU"!+.:V<M=1
MNSI,[302,2"QPF=@&/EX&/0=/LY;.RMX);J6^EC15>ZN @DE8#!=@BJNX]3M
M51SP!TH \=_9BF26/XH['5P/'6J=&SCYDK)\=6!US]L3X:G36W3Z+HVH7>J-
M'_!;R+Y<(<YZ&0G _&NF\(_L]MX%&K+H?Q!\66,>JW\NIWB;=-?S;B3&]\M9
MDC(4< C&.,5VW@WX>Z1X'%[)8133:A?R++?:G>S-/=7;J,*9)&Y( X"C"J"0
MH H \4^'.F^*[OXW_&N?PYK>C:9 =4L8Y5U/2I;UF9;1?NE+F$(!GT.?;OT?
MQ2:]M?V3?%5IK%P)-=M?##PZCNN!*ZW/V8%@S \DD@YSDY![UL:3\!7\.^(_
M$FM:/X]\4Z7=>(+O[9>I"NG21F0 A=HDLV*@*=O7D 9R>:NZO\$;;Q!X$\2>
M%]3\3:[>IX@F\V_U-VM5NF&V--BA(%C52L2CA,\GG)S0!S_@71_'6E^'OAW=
M7^OZ-<>';*VBDO8K*PDLI(X!8R!6DF>Z=9$5S'E?+&2 W 7%8WQ2U/6])\;:
MQ=>)-#\;:EX.\J!=(OO ]_)']D!3]^]Q#!-'(Y5_FRRR*%  'WL]BWP3OYO#
MO]@R_$CQ;)I!M19-;&/2QNA"A=A<60?E>"=V>3SWK:UCX9W6K:C?S)XS\1:?
MI]]M$^E6CVOD;1&L95&>W:6,$+SL=3DD@@F@#4\'W6C>*/">D:II]RFM6%Y8
M1B'4)D_>7,+*.7W 'YNI! Y/(S70K&(T54&U5& !T ]*I:)HMGX>TBRTS3;6
M.QL+.)8(+>(86-%& !^ K0H \2\'S'XY:QX[?6-5U2VT[1-=GT.TTS2=2FL/
M+$*J&ED>!T>1I"Q.UR4 "C;G)-22XU&[^+FA_"F[U[4AHVG^&/[3N+N&[DM[
MW4Y!,(4#W",)0%"EF*,&9CR<9![*Z^"=C#XRU/Q-H.NZUX3U'50O]I1Z1) 8
M+QEZ.\<\,BJ^.-R;2<DYR2:L>)O@[I?B670KT:AJNE>(-$C\JRUZPN1]M$?
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M3SS74)J4_P 2?BWXQ\)W5_>V&@^'+2QS;:==RV<UU/<*\AD::(K(JJJJH5'
M)+[L\ 5M2_9KAUC0_#6D7?CWQ5)8>'+BWNM,C"Z:##) ,0L6^QY;:.,,2#W!
MKHM2^#=O>>);'Q):^(M<TCQ+#9+I]SJMB]L'OX5.0)XGA:%CDD[EC4C. 0,
M '$?L[Z/_8/Q(^,FG_;KS4O(UBT47&H3>;,R_8XR SX&XC.W)&2 ,DDDU[U7
MF_@?X'Z9\.?%^MZYH>LZQ!#K,PN+W29I89K:64)M\PLT1FW9RQ/F9+$YSTKT
MBD!YC^T__P FU_%?_L4M6_\ 2.6OY[:_H2_:?_Y-K^*__8I:M_Z1RU_/;7MY
M=\,CP\P^*(5^O/\ P2!_Y-M\3?\ 8VW/_I%95^0U?KS_ ,$@?^3;?$W_ &-M
MS_Z165=&._A&.!_BGW-2TE+7SI]$%%%% !1110 4444 %)2TE(#YE_X*2_\
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M$U\[?M _\CI:_P#7BG_HR2OD^)O^1?+U1Y^._@,\RHHHK\;/EPHHHH ****
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M/6C<*X/Q9XZLIVU?0['2M:\375LBIJ,/AV58);177</WS318?;@[8W,@#*<
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MW%_X*2_\F6?$/ZZ=_P"G*UK\.J^@R_\ AOU/G\?_ !%Z!7Z7_P#!&/K\8/\
MN#_SOJ_-"OTO_P"",?7XP?\ <'_G?5MC?X$OZZF.#_CQ/TP6EI%I:^:/I5L%
M%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;[I^E?(7C+_D
M;]<_Z_I__1C5]>M]T_2OD+QE_P C?KG_ %_3_P#HQJ^!XN_W>GZGD9E_#1CT
M445^6GSH4444#"BBB@ HHHH *]I_9O\ O^(/I;_^U*\6KVG]F_[_ (@^EO\
M^U*^EX=_Y&5/Y_DSNP7^\1^?Y'MAI:0TM?M1]4%%%%, HHHH **** "BBB@
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MGZG'2G9% "T444@/,?VG_P#DVOXK_P#8I:M_Z1RU_/;7]"7[3_\ R;7\5_\
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M_HR2OHFOG;]H'_D=+7_KQ3_T9)7R?$W_ "+Y>J//QW\!GF5%%%?C9\N%%%%
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M]_Q!]+?_ -J5]+P[_P C*G\_R9W8+_>(_/\ (]L-+2&EK]J/J@HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5\[?M _P#(Z6O_ %XI_P"C
M)*^B:^=OV@?^1TM?^O%/_1DE?)\3?\B^7JCS\=_ 9YE1117XV?+A1110 444
M4 %%%% !7:_!S_DI&C?67_T2]<57:_!S_DI&C?67_P!$O7IY9_OM'_$OS-\/
M_%CZK\SZ@;I2TC=*6OWP^Q"BBBF 4444 %1E3VJ2LW7O$FD^%=,DU+6M4L](
MTZ,J'N[Z=(84+$!078@#)( YYS0!?VGT_6JFJ0WTVFW":;<V]I?,A$,]U;M/
M$C>K1JZ%A[!E^M6H9X[B%)8G62)U#+(ARK C((/<8JKJC7L&FW4FGV\%U?+&
MQAAN9S#&[ <!I CE1GN%;'H: .2^#OP_U/X8^![/PYJ.LV^NBT=_)NX+!K1M
MKL7(=3+("VYFY&WC QU)S5^$^J^%O$&JZGX(\1PZ%#JT[7=]I.IZ>;^R-PV-
M\T2K+"\;-C+8<J3@[>*S_A?\4O&OQ+\,Z'XE@\&Z+::)J3Y;_BHI7NHH_-*.
M_EFS5&(P6QY@R.AS1IOQ2\;Z]XX\7^&]+\(:"\GAV>&*6XNO$<\8F6:/S8RJ
MK8M@[3\P)X/ +#F@#1\4?#WQ7KFJ>&-6@\5Z9!JFBSS7)^TZ(\MO(TD)AVHB
MW*,B!69OF=SN;[V!MJ]IGP\U:;7HO$7B+7+?6M>LX)8--6"P-M8V1D&&D6$R
MN[2, %+-*?E!"[-S9[#2IKJZTRUFO[9;*]DB5I[9)?-6)R 60/@;@"2-V!G%
M7=P'4XH \W^&/P[\1> -)\26UUXDTS5;G5+ZXU.">/1Y+=;>XG9G?>AN7WQA
MBN%#(V 06.01G>$OA/XK\)_#?5?"L/BW29YKJ:XE@OFT*0"!;B6224&/[7\Y
MW2MM.X;>X:N[\5>)#X=72UBMOM=WJ.H06,$/F;,[FW2-G!^Y$LLF,<[,<9S5
M7QWX\L? &EVUS<PW%]=7ES'8V.GV2AI[NX?.V- 2%' ))8A0 22 * ,70? O
MBK0?AKIGABW\664&H6,45HFKVVCX;[.B! %B>=U$N!]\EE_V*Z3P7X,L/ NA
MIIFG"9TWO--<7,ADGN9G8M)-*Q^\[L22>G/  P*Q;/Q+XTAU2R35O"%C'IMS
M,(3/IFL-=SVX8'#RQ/;QJ%S@$J[8SWKN-P]: %I-PHW"N8M?&T&J)KYTNPO-
M5N-%O?[/FM[<1H\LH2-V$?FNJX591DL5S@XSQD Z>EIOUX-+F@!:*:'#=#FE
MW =30 M%)N%&X4 &X=:-P]:XGQIX\O=!\0Z/X=T328M9\0:I%/<Q0W-Y]DMX
MH(=@>220([#F1% 6-B2>P!K?\/WFJW>GEM:TV#3+]7*-#;79N86& =R2%$8C
MJ/F13D'C&"0#7W"C</6J.KWD^GZ?+<6^GW&J3)C;:6C1K+)D@<&1T3CKRPZ5
MSGAWQ])KGC[Q+X8ET>XTU]'@M;A;J>6-A=I,TRJR*C':H,)^\0W/*B@#LJ3(
MHS61XFOM1TKP]?W>DV,.IZA!$TD5G/<&W28CJID"/M)'3Y3S@'C)H U]PHR*
M\@B_: M-/^%?A#QGK>F)9#Q%<6L,=G:737 MXYF'SR2&),"-,LV5P"-H8Y!/
M8GQ-K3?$C_A'X]'L9-(6R^V3:G_:+B>++%%0P>3C+,K8/F=$8]@" =?12;AZ
MTFX>M #J*;O7.,\TZ@ HHHH **** *6D_P#(/A_'^9J[5+2?^0?#^/\ ,U=H
M *Q_$WB[2?"%G%<ZK=_9UFD$$$:1O+-<2$$B.*) 7D<@$A4!) /%;%>0?'+Q
MXW@_7O UJ\FDZ-8ZA>W G\3ZU )(=+*6[[=A9E5))-S(&8XP6&#G% '4:+\:
M_!.N:;K5_%K\-E;:+*L.I?VM')I[V;M]T2I<*C)G. 2,$\"L\_M$> &T!=<@
MUR6]T4M(KZA8Z==7,$&QRC&9XXF6(9!PTA4$#()'->4?#/QMX:\)_'KXFSZ]
MXUAD-UIVER6^I:]);V1ND59BS1@)$CH,IA@#E2#N((--_9U\4:)KG[)NM65I
MJEG=W-E:ZNUW:K.K20+)-<NGF)G*!EY&X<B@#Z,OO%&D:;H\6JW.I6L6FS",
MQ7)E!27?CRPA'WRV0%"Y+$@#.:\*M_B$^O?M0>&+#3/$^O3Z=/I]_-=>']2L
MWL$MG5(Q&PA>&*1E(9B&DWC.=I&#7(:'XRTZ'X?_ +/?BD7T5_X2\.HMGKLE
MJXG73KIM/$4<DX0D(L99@Q8#9YBGC-=%XR^*GA>7]IKX;:@=:LXM#_LC4XHM
M;EG1;"XD<Q?NXIR=LA&W!(XW$+DL"  >V^+O <7C*]TV2ZU35K*UL_-+VVEZ
MG<V/V@N% +O!(C';M. <_>->%?!?P/-X_MOB=!>>*?%L=UI?BR_TK3;H>)]1
M;[)!&(_+79]HVOC<>7R3GDFOI>[OK:PM9KFYGCMK:%&DEFF8*B*HRS,QX  Z
MD]*^>?V1_&6@ZQJOQ7M;#6;"]NKCQEJ&HPPV]PCO);-Y0690#DQDC&X<4 0Z
M'XWT/QS\0_'>F>//&EUX:U#2-6;3],T&'7I=&46JJIBN%\J6-YFDW%B69@/E
M  '+=%\0_'6L_ ?X3Q+#>-XL\0:GJO\ 9FA/J,OF[S/(WD><X52P1.I/)V@%
MB3FI_$'C/X/>.KJ\LO',?A:/6K&ZGLOL/B181=825T1HEF4.P=0'78"/GQR<
MUY$_[/FO7GPKU\>#[6XL8=+\7KXC\):+J3E"T,( ,>V3F(2-YC*KXZ+G&XF@
M#W[3_@ZMQ9QR^(/%/B?5]9909[RWURZL(@_4^7;V\D<2J#T!4G &2W.>H\#Z
M%JGAWP^EAJVKS:W=13S[+RXV^8T)E8PJ^U5!98R@)QR0:X[PS^T9X(UBSC76
M=:M?!VN+M2YT3Q'.MC=P2'^#;+MWCT9<@^M>B:/K5IKUBMY9/));,6"N\3Q[
ML$C(# $J<<,.".02.: ,WQ-X\T3PC+#!J%S,UY,I>*QL;6:\NI%! +K!"CR%
M02,L%P.YJA:_%;PS<^%(?$3:@]KILT[6L8O+:6&X:<.R&$0.HD,FY6 0+N..
M :\LA\767PQ_:2\:W'C2>/1M+U^QL#HFMZ@PCM-L,;"6V\YL*C^8S/M)YS[@
M&/XL:K9V/C;X6_$6SB^U^!=+O-0_M*\M;=FC@>>,QI>, N2FY6S* 1ALYPV2
M >I^'_C%X1\2:AJ-A;ZJUGJ.G6_VN[LM7M)].N(H.\QCN$C;RQW?&T9&363#
M^T9\/;S2[_4;#7GUBQL)FANKC2-/NKY("J!RSF&)]L>T@^8?D/.#P<<-XJNM
M'^)/QL^'7B?PSJEG?Z5X7AU"[U?7[.X5[.&W>'8L+3@^669LDJ#E54L< C.9
M^SS\4/!D=U\8)9O%6BQP?\)5>ZANEOXE4VI2!!."6YC+?+OY4D@#KR >MZM\
M;_!6BZ;8ZG=:R?[(O%C9-5@M)YK% Y4)YMPB&*+)9?\ 6,O45P?QRUZ^\(^/
M?AIK!\8WVF>';W61:WMB)8H[1U%O*ZDD)O8LRJ-I=@25PN:\X^%_B+1M6_8*
MU^SM-2L[FYT_0M32[MHYD:2V+-<%!(O5,CE<@9&".*T_$WC[PW-X+_9_UR35
M[6]TG3M2MFOKR%OM"6KQZ>ZOYI3.PH[)NW?=SDXQ0![EHWQJ\&ZUJ=[IRZL^
MFZA9VQO9[36K*XTR5;<9W3;;F.,E!@Y89 QR16!X1^,/A>U\-:_X@U7XDZ7K
M&B)K$T$&I21)96]O\JNMI&^<3E5R=ZY+9/I65K<FE?$#XI>"O&>DWUG)X<\)
M6^H7-]X@651:,)81&L23_==1\[L5.U=@R<D5YAX.^+7@B'X=?':$^*=%MI;K
M6=:EM86OX%>Z1X%5'B4-F178X!&=QX&30![RWQ^\"1VFE7K:U(NF:FL)MM4.
MGW(LLRX\M7N?+\J-CD?*[*PR,@5T_B7QII'A%8!J5RZSW&[R+.UMY+FYGV@%
M_+@B5I'V@@G:IP#SBOFWQ!XBTC7OV 9#8:E9Z@MEX;LK2Y%O.LGV>X18<QO@
M_+("1\IYR12>,-?MU^.V@>.3XUN-"\"ZOX:&EVOBC1_LES:P7*W!9H99989H
MXE8G[YVY9,9X( !]&>%?B%X?\:V=[<:3J(E%C(8;R&XB>WGM7 R5EBE57C..
M<,HXYKPO]H[XM6C>'=-?PUXQUK3+E]0LXX5L;5X;+4XY+B(/Y=VT.)<1EB/(
MF'&200#B#QI\.[+5OAA\4]<\$^)]2\>>(M?TZW6ZO0T#QW<4).(H6M88XV<Q
M"1,+D\@'J,U?VAOC%X1\4? JPDT*^2\MUU/2VNH[=1_Q*U2YB?%T.L!&W:$;
M#$YV@A690#ZGHJCHVN:=XBTRWU+2K^VU/3KA=T-W9RK+%(,XRKJ2#R#T-7J0
M'F/[3_\ R;7\5_\ L4M6_P#2.6OY[:_H2_:?_P"3:_BO_P!BEJW_ *1RU_/;
M7MY=\,CP\P^*(5^O/_!('_DVWQ-_V-MS_P"D5E7Y#5^O/_!('_DVWQ-_V-MS
M_P"D5E71COX1C@?XI]S4M)2U\Z?1!1110 4444 %%%% !24M)2 ^9?\ @I+_
M ,F6?$/ZZ=_Z<K6OPZK]Q?\ @I+_ ,F6?$/ZZ=_Z<K6OPZKZ#+_X;]3Y_'_Q
M%Z!7Z7_\$8^OQ@_[@_\ .^K\T*_2_P#X(Q]?C!_W!_YWU;8W^!+^NIC@_P"/
M$_3!:6D6EKYH^E6P4444#"BBDW"@!:*3<*,B@!:*3(HR* %HI,BC(H 6BDR*
M,B@!:*3(HW"@!:*2EH **** $;[I^E?(7C+_ )&_7/\ K^G_ /1C5]>M]T_2
MOD+QE_R-^N?]?T__ *,:O@>+O]WI^IY&9?PT8]%%%?EI\Z%%%% PHHHH ***
M* "O:?V;_O\ B#Z6_P#[4KQ:O:?V;_O^(/I;_P#M2OI>'?\ D94_G^3.[!?[
MQ'Y_D>V&EI#2U^U'U04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *^=OV@?^1TM?\ KQ3_ -&25]$U\[?M _\ (Z6O_7BG_HR2OD^)O^1?
M+U1Y^._@,\RHHHK\;/EPHHHH **** "BBB@ KM?@Y_R4C1OK+_Z)>N*KM?@Y
M_P E(T;ZR_\ HEZ]/+/]]H_XE^9OA_XL?5?F?4#=*6D;I2U^^'V(4444P"BB
MB@ KA?C%\']#^.'@V3PUXA>[BLFF2=9K&14EC=2<$%E9>A8$%3PWXUW5)N%
M&9X;\/6?A/P[IFB:=&T=AIUM':6Z.Y=ECC4*H)/4X J[=W"6]K/*P=EC1F81
MHSMP,X"J"2?8#)J;<*S]9UO3O#VFW&HZK?VNF6%N TMW>S+%%$,X!9F( &3C
M.: /FWX"V^B^$_!_@T:AIOQ#M_$]DNV33YK#6VLA+)YD>TQR)]E10),[AM /
M<#(-J^TC1IOBQ\3YO$=EX\M(+^XM8K.YT*SUM8)D6S2-V_T5#')AP1EPP..Z
MU[_I?BS0]>TF#5=.UK3M0TRX<0PWMK=1RPR.7V!5=25)+87 [\=::WC/P\GB
M5?#K:]IB^(&3>NDM>1_:BN-V?*SO(QSTZ4 ,\JQ\>>$7BN[&8:;J=LT;VNH6
MYCE\M@1AXW&5..<,,C/(%>.:%X>\6:7X=\'7/V"[^U6$,OA.[M-GRR0%?*6^
M,6,8,T4;DD?ZIF(X//OW<C(SFC.>U 'GNCZ#8P_$#3=(T^&.VTCPGI*B&VB0
M!5GN"44\#ADBA<<<XN#ZU6^-?A/6]67PIK_A^T35=3\,:LNI?V7)(L9NXC$\
M4B(S':L@60E2V!E>HS7H#0V.E_;+PI;V8?\ ?7-QA8]P5 N]V[X50,GLH]*S
M_#/CSPSXU\__ (1[Q%I6O?9R!-_9E['<>7GINV,<?C0!@V/Q.B\36SVFEZ/X
MBM-6DCPD>IZ%=6D<+GC<\LD:Q$*>3M=B0#M#5XCX;\)//I?@V1/"^O:'XUTQ
M\^,=:%G=0W%Y;B!TN?\ 2HAF\:1]AC$3R.#M(V[<5]4=S@Y['VI,>O6@#Y0\
M+^&;72_AIX!\11>%=>B\2Z)XD2*\NVT:].J)9M<2M(.4\Z2 QR D %3N.1NR
M*A\:> =$TKP[\38K/P/JUGXFFUP2V%QHNA78:YMW$+!1-;1E9(24D9HV8KO
M+J&VU]6:AJ5II5O]HO;N&SM]ZIYMQ(J+N8@*,DXR20!ZYQ5CIGG'M0!\R_\
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M.!Z1X9\#V5AI^N2&Q;2[KQ!<27E^EK,8I59U"X$D;95PH&61OO[F!YS69;?
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M?A?_ ']>C+R_^/\ (]3/6G4T]:=7[&?2A1110 C?=/TKY"\9?\C?KG_7]/\
M^C&KZ];[I^E?(7C+_D;]<_Z_I_\ T8U? \7?[O3]3R,R_AHQZ***_+3YT***
M*!A1110 4444 %>T_LW_ '_$'TM__:E>+5[3^S?]_P 0?2W_ /:E?2\._P#(
MRI_/\F=V"_WB/S_(]L-+2&EK]J/J@HHHI@%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5\[?M _\CI:_P#7BG_HR2OHFOG;]H'_ )'2U_Z\4_\
M1DE?)\3?\B^7JCS\=_ 9YE1117XV?+A1110 4444 %%%% !7:_!S_DI&C?67
M_P!$O7%5VOP<_P"2D:-]9?\ T2]>GEG^^T?\2_,WP_\ %CZK\SZ@;I2TC=*6
MOWP^Q"BBBF 4444 %<S\0/B3X;^%OAQ]>\4ZHFE:4DBPF=HWD)=C@*%168GZ
M#L3T!KIJYGQ]\.?#WQ2\.2Z#XITQ-6TJ1TD,#2/&0RG*LKH0RD>H(X)'0XH
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M>(1%K.HQ;OFBND8(\>WH5N D9(/!\N;C+5Z[M.?7\: 'T444 %%%% !1110
M4444 4M)_P"0?#^/\S5VJ6D_\@^'\?YFKM !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1112 \Q_:?\ ^3:_BO\
M]BEJW_I'+7\]M?T)?M/_ /)M?Q7_ .Q2U;_TCEK^>VO;R[X9'AYA\40K]>?^
M"0/_ ";;XF_[&VY_](K*OR&K]>?^"0/_ ";;XF_[&VY_](K*NC'?PC' _P 4
M^YJ6DI:^=/H@HHHH **** "BBB@ I*6DI ?,O_!27_DRSXA_73O_ $Y6M?AU
M7[B_\%)?^3+/B']=._\ 3E:U^'5?09?_  WZGS^/_B+T"OTO_P"",?7XP?\
M<'_G?5^:%?I?_P $8^OQ@_[@_P#.^K;&_P "7]=3'!_QXGZ8+2TBTM?-'TJV
M"BBB@8C?=/TKY"\9?\C?KG_7]/\ ^C&KZ];[I^E?(7C+_D;]<_Z_I_\ T8U?
M \7?[O3]3R,R_AHQZ***_+3YT****!A_G%%%% !1110 5] _L\_\BC??]?S_
M /H$=?/U?0/[//\ R*-]_P!?S_\ H$=?6\,?[^O1GIY?_&^1ZF>M.IIZTZOV
M,^E"BBB@!&^Z?I7R%XR_Y&_7/^OZ?_T8U?7K?=/TKY"\9?\ (WZY_P!?T_\
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M+/\ ?:/^)?F;X?\ BQ]5^9]0-TI:1NE+7[X?8A1113 **** "DR*6O-/V@/
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M_D'P_C_,U=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDFTS3X;9W4G.UBB@D9YQZ\TFD_#/PAX?UJ36-,\*Z'INKR;M^H6>G0Q3MO\
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M@ HHHI >8_M/_P#)M?Q7_P"Q2U;_ -(Y:_GMK^A+]I__ )-K^*__ &*6K?\
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MV"_WB/S_ "/;#2TAI:_:CZH****8!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?.W[0/\ R.EK_P!>*?\ HR2OHFOG;]H'_D=+7_KQ3_T9)7R?
M$W_(OEZH\_'?P&>94445^-GRX4444 %%%% !1110 5VOP<_Y*1HWUE_]$O7%
M5VOP<_Y*1HWUE_\ 1+UZ>6?[[1_Q+\S?#_Q8^J_,^H&Z4M(W2EK]\/L0HHHI
M@%%%% !494]JDK-U[Q)I/A73)-2UK5+/2-.C*A[N^G2&%"Q 4%V( R2 .><T
M 7]I]/UJCKUG?7VD75OIMS;V=[)&5BGNK=IXD)[M&KH6'7C</K5V&>.XA26)
MUDB=0RR(<JP(R"#W&*K:SK%EX>TB]U34KE+33[.%[BXN)/NQQJ"68_0 T >0
M:/\ L_:EI'A'P99P^*K:#Q+X1D":=KEMI)17M" LEK/"9VWJX'.'7!"D8*\U
M9/@7XU?>#XYT%2_B%?$A(\,SY^T+MP@_T_\ U?R].3[UU<?CSQQJFDQZUI7@
M2UGTJ:+[1#;7VM_9]2E0C*@0"!XE9EP0K3#KAMI!J[X8^,GA[Q9IOA>[L?M2
MOX@N)K2&UEB"2V\T,<CS1SC.$9/*92,GG&,CF@#A?C/X+ET73_'FO7E[#>:+
MXBMK&RGLVTQG;3Y$<1K>&4.WR1AC(1Y>044AE(S67\-;C5O[:N]$\(^+/#OB
M>"_T^::Y\5V%K=WIL;A618%EFGOY_/R&EQ")%*;<]#AO6OAQX\E\?6FLRS:/
M<:%)IFIRZ:UK=31R2YC5"68QED&=_168<=><5UW7D<<T >8:3\)M=D\+:EX6
M\0:WHNH>'=1M9[:[33]&GM;R9Y5(>9IY+R;+DDL24))[UM>%? &J:?KEIK'B
M+7HM?U#3[)]/L9+>Q^R!(7:,R-*/,?S)6\J/+#:OR_*BY-=ON'K2[A0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9O\ O^(/I;_^U*^EX=_Y&5/Y_DSNP7^\1^?Y'MAI:0TM?M1]4%%%%, HHHH
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M"0/_ ";;XF_[&VY_](K*NC'?PC' _P 4^YJ6DI:^=/H@HHHH **** "BBB@
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M?<];^T(=C^A+</6EW#UK^?E_VE?BZNBQ3#XI^-1,UPZ&3_A(;S<0$4@$^9G
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MUXE_\&]Q_P#%U\1_J#B7_P OE]QY/*?JU17Y2_\ "YOB!_T/7B7_ ,&]Q_\
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MU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX/\ CQ/TP6D;O2K2-WKYH^EZ'\]G[3?_ "<G\6/^QMU;_P!+):\TKTO]IO\
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MA+%=;O,C +!MNPX8'!&01Q?6<PIWBJ:LG9;MV[]MK?J!XG1117TRV$%%%%,
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M&K=BR@'(QU%=9X^^('A;7OA;X(\/:7<:S)JGALSY>]L8D@G\UU<X99V9=FT
M?*<_[/2MGXE?'BS\96^I7>E7=YH=WJT,,>H:9'H5CMD*[=W^G*PG9<J&4,O4
M#D #'R]"IF$%&\;MMIMWV6VBZR5W<#S'Q%\/-=\)V?VG5+>WMP)%ADA2^@EG
M@<@D++"CF2(D*W#J.AKG*]E^*?QFTKQWX1;398YM?UE[E)DUO4M*MK*ZMXE4
M@Q%X78S;N/F.SI]T\8\:KW<%4KU:;EB(VE?I_5Q!1117H %%%% $EO\ \?$7
M^\/YU8UK_D,W_P#U\2?^A&J]O_Q\1?[P_G5C6O\ D,W_ /U\2?\ H1K/[2-/
MLE.BBBK("BBBF(*EMFA6XB-PDDL =3(D;A&9<\@$@@$CC)! ]#45%2]AGO/B
M+X->&O%&C^&?%_@F6YM/!\P,&O+<2>=-I4D0WRNYZ?,N=HX!8J !O5:X3_A7
M>K?$+4KO4?"GAI=.TBYFD&GV+WJJ\JH,E(?.DWW#A1EO+S@G& "!6QX#\>^%
M=!^$7C+POJ=QK(U'Q ;=@UK8Q200&&3>N29T9MQX/ VC^]6MX7^.-AIO@'PY
MI#37.A:WX?><VFHVVA66I>8LCF0$-.RO X8D90D=\<5\K&6/P[E&G[W+*R;O
M\.]_/73\0/.;?X;^(+C0_P"UOLD,%F8Y)D%U>P032I'GS&CB=Q)(%VMDHI^Z
M?0US->V>'/CAIFG^ WT;7!<>)E^S7,<>DZAI-JT$,TK.PEBNMWF1@%@VW8<,
M#@C((\3KV,'5Q-1S6(C:STMU$%%%%>H 4444 :'AW_D8-+_Z^HO_ $,5GUH>
M'?\ D8-+_P"OJ+_T,5GU'VF:R^%!1115F04444 %%%% !2C/:DH_&@9W_P )
M[7PSJ%UJ<'B>T#VGD*R7BR.KVSLZQAN&"X^?)RIZ<=P9]6\%+X$O/$=CJ^F6
M^I^5:B>RNI&E52K2*BR)L< C#9P0>5QV.>:\-WNE6NDZW%?7-U#<W%NL-NMO
M LBY#JYW$NI4?(!QG[Q/;!Z2#XI+??#2[\-:M"]U=PJJ:;>8!:)-Z,T;$G.W
M" #KC '0#'I4Y4G3M4T:3M_DU^1X=>&(C7=2DVXMI-7V6GO+]5U^1AV/PS\1
MZE9PW-MIX=9XS-#"T\:S2QCG<D18.XXZJ#7/6MA/?74=M#'NF<D!<@=.I.>@
M !Y/I7JME\5M%_M'PWK]Q%>IJ^B68M%LHD4P7!52$;S"V4^]R AZ=>]<+X4U
M;28_%D=[X@M7N].+2-)#%UR5.T@9&<,0<$@'&.]95*5%.*C+=Z_<;4L1BK3=
M6&RTMO?73?72VNFX^Y^&_B.UU"RLQICW,]Y&9;?[&ZW"RH.K*T992!WYX[TN
MH?#?Q#IMG<7<M@IAMY1#.(IXY'A<G 5T5BRY/ R!GM7I&B^,M+\6>*/A[;VL
MDZWFF7@BDS9Q00NK2[@RA&PIQCC;ZG)/7F_&7B:RT/4/%6E:0]U<?VM<[;E[
MJ,1^4$E+E5PS!^<?,<<=AFMY8?#Q@Y\VG_ O^>ART\7C)5%3<4I=='MS6[Z>
M[KZF(OPC\5F01-I+17+1&9;6:5(YW09R5C9@S=#T!J#0_ACXH\1VT,^GZ+<3
MV\[F..8@(C, 2<,Q P-IYZ"O2_'?B#3O"&M^%M:BDN9=7M-'MBEJT:B YB.'
M,@;<,9Y7;S_>KB6\7:3)\+GT,W-\FJ/?M?LJVZ^0Q*A0A;S >G.=OM@]:<Z%
M&G-P;V\UY6_4*.*QM:FIQ2U:UL]-7?2_334R['X7^)=2MX9K?3M_G1M-#"T\
M:S2H,Y=(BP=UX/*@CBF?\*XUQ=)L=2:&U6SO91#!(U[ -SDXP07RN#UR!COB
MNVM/BIHO]H>&]?N([Q=7T6S%H+&*-3!<%58*QD+@I][D!#TZUB^&?B9;:;X=
MU?3M3M'NWDN%OM/*XV07 R,D'^'!Z=\8/7(GV6%VYGK<OZQC]6J:MIZ[M/KT
MT=S$@^&NOW.I7-DEK#YUO*()&:[A6/S#TC$A?:S?[()/!XX-5].\%ZO<:C-;
M-:&!K:3RIS<3);I&W/R%W(4,<' )R<<5U?@_XE6FG^%9]&OVDMIOMGVV&^6P
M@O3N*A6!CF(&> 0P.<U$?'NGZYX?U?2M:N+QI;C4/[1BU*WMTWR-MV%7CWJ
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M =_[G[MFPWL>>#Z5TWB[QAX;UW6/"\Y;4-0L--MH;2ZM;B)83+&AY*LLC8+
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MJI (7@GIG/8<]2G04&X-W7I^AZ%"MBW44:D5RM;J^F_?RL<;1117">J%%%%
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M>WZ4;?I1_:%3L']GP[G\]G_#,?QB_P"B3>./_"<O/_C='_#,?QB_Z)-XX_\
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ME']H5.P?V?#N?SV?\,Q_&+_HDWCC_P )R\_^-T?\,Q_&+_HDWCC_ ,)R\_\
MC=?T)[?I1M^E']H5.P?V?#N?SV?\,Q_&+_HDWCC_ ,)R\_\ C='_  S'\8O^
MB3>./_"<O/\ XW7]">WZ4;?I1_:%3L']GP[G\]G_  S'\8O^B3>./_"<O/\
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MP4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+")7 :0(I"AB!G'W5& .ZH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"WM;8W^!+^NIC@_P"/$_3%:6F].M+FOFSZ46BDS1FD,6BDS1F@!:*3-&:
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MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
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M.]_^.UYG11[*G_*@]I4[L],_X:<^,7_16?''_A1WO_QVC_AISXQ?]%9\<?\
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M.]_^.UYG11[*G_*@]I4[L],_X:<^,7_16?''_A1WO_QVC_AISXQ?]%9\<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img8619836_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *3!G(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\
MU#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H
M_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^
MH;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\
M3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!
ML45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0
MW_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG
M_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_
M .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$_
M_P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45
MC_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R
M)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\
MU#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H
M_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^
MH;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\
M3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!
ML45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0
MW_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG
M_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_
M .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$_
M_P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45
MC_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R
M)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\
MU#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H
M_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^
MH;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\
M3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!
ML45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0
MW_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG
M_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_
M .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$_
M_P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45
MC_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R
M)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\
MU#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H
M_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^
MH;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\
M3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!
ML45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_ .1*/^)__P!0
MW_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$__P"H;_Y$H_XG
M_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45C_\ $_\ ^H;_
M .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R)0!L45C_ /$_
M_P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\ U#?_ ")0!L45
MC_\ $_\ ^H;_ .1*/^)__P!0W_R)0!L45C_\3_\ ZAO_ )$H_P")_P#]0W_R
M)0!L45C_ /$__P"H;_Y$H_XG_P#U#?\ R)0!L45C_P#$_P#^H;_Y$H_XG_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGU4T =Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !69/\ \C!:_P#7!_YK6G69/_R,%K_UP?\ FM &G1110 4444 %9EU_R']/
M_P"N4O\ [+6G69=?\A_3_P#KE+_[+0!IT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'R7X*_Y2.>/O\ L6XO_1=E5+XVQK9_
MMW?".72TVZI/9$7?EC!>$FX4LV!S\GF\GLHKL_B1^R+<^-OBQJ_CS2/B)K?@
M_4M1BB@<:0#&PC2.--OF*ZL03&K8/H*Z#X1?LN:-\,/%ESXNU+7=7\:>,)XO
M(_MC7)O->),!<(#D@E0%W,Q.T8& 3D \9^'OQ"UHWG[39U;XAWGANRTG6OL]
MEJVH>;?)I<1NKI-L$!<<E5555#UV<' %>?Z-XVUCP?\ %+X1R^'/%OQ-U/3]
M<U:WL[Z^\8;TT[58Y9(59[6-R24*R,?FR5W)AL\U]'O^R#HMYIWQ5LKS7+V>
M#Q]?IJ,OEPK&UE(EQ).@4DG< T@Z@9"^]9?_  Q_J>HS>#KS7OB=J^O:GX3O
M+>?2Y)K&)+>*.)E94,8.6=BD>Z1G).T9I@<U-#X@_:$_:<\=>&I_&WB7PEX<
M\)6\45M:>'KTVDTLK!<RN<$,-P?JO0I@CG/'?#WQIXTM_!?[3UOJ?C+5M8U'
MP[FWL]0DNI%,3HUTADB ;$6XHIPF.@'85=_:"?P=X:_:(O\ 5M8UOQI\*]1N
MK2.*7Q)HP9[75H1'&"@*@NCC:$X!7]RK8!YJ7]E'X/MXP\"_&>*&+4]'\)>,
M;G[)H]]J,9-R]LIG(E*L?G.V5/FS@L&YX-(#DO&-GX[\-_LQ^$/BXGQ2\6R>
M)2UKNM&OC]B\DLRHICQ\SX"%FD+;_FR.:]0^+7C#Q1\6/V@O!GPLTWQ+J'@S
M0KG25UC4;K1Y3#=3L4=_+63K@!  !Q\S$AMH ],\5?LTVGBKX Z7\+7UR>WM
M+!8%74EMPSMY3$C*;L<_6E^*W[,]E\1M0\.Z_IGB'4?"?C/0;9;2RUVP 8F,
M C;)'D;E^9^ PSO8'(XH \M\!Z]XW^%/QZ\3_">#Q1J'C*TO-"DU/0[G7)3<
M3VMR(\H)),_ZLD,",8^X1C+9\/T_QWKWA&[T^/XA^-OBK\/O&XU%I)=3O5:^
MT>2,.3A;8LA*X('R>8O!.,$!?KWX6_LNZ9X)O/$VL^(-?U/QEXJ\1VKV.HZU
M>,87,# !DC56R@(5.0QQL4+@"N/_ .&+[YO#I\&3?%'7)?AL9_./AYK*#SB?
M-\T@W.,X,GS8V8SS0!%XL\::PW[<'PXTNPU^[D\/ZAX9>[:R@NI!97+%+TK*
M8PVUL[4()!X5?05\]ZEXR\6>&;J_3XJ>*/BEX%\7R:C_ */KEC(9]%"A@3BW
M#(&0*#Q$S Y!QU4_9=]^SOI=U\:/"WC^"^DLX_#^D'1K?2(X08FBV3H#OW;A
MA9CQC^$>M<#=?L::@NDW_A73_BCKMG\/+Z=II_#\UK%/+\SAV5+ECN52PSC;
MR22=V3E^H'T%X-U6'7/"6C:A!J2:S#=6<,R:C''Y2W09 ?-"?P[LYV]LXKY>
M\4:CXE^//[5^O_#@>,-9\&^%O#.FBZ,?A^Z^S7-W(5ARS.#TW3CJ" (QP"VZ
MOJ7PKX;L?!OAO3-"TR-H=/TVVCM+=&;)"(H49/<X&23W->2?%#]F=?&'CX>.
M?"?BW4O 7C%X!:W.H6$8FBNHQ@ 2Q%EW'"J.6Q\J\9 I >(:;J'BF33OCO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S)_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^*7P \6:EX$^#VC:1HFE2W&@:S'?:K!HK+:V=NK/OD,:S2;F4,S=#D\G S@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BF[J7=0 M%)NHW4 +12;J-U "T4FZC=0 M%)NH
MW4 +12;J-U "T4FZC=0 M%)NHW4 +12;J-U "T4FZC=0 M%)NHW4 +12;J-U
M "T4FZC=0 M%)NHW4 +12;J3=0 ZBDW4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLM_Y](?^L^;_ //^1]!?\-O_ ! _Y\]!_P# :?\ ^.T?\-O_ ! _Y\]!_P#
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M_$#_ )\]!_\  :?_ ..T?\-P?$#_ )\M#_\  :;_ ..U\^\>M''K1_J]EO\
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M\S.JX$84;2_)^7- %GPW\9O'/CKXBZ[HF@^%=/&B>'==.FZGJ=[>.IDARF#
MH7F55+NRL<8V?WJ\=M?&2S?!CX :YX3\&QVI?Q/<"R\-VETQC\S-Y'M\UP2
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MP&) PO0#KS7':U\(?'UO^S?XN^&=OH=QJ+:/KL9\/2>?"/MNG?:EE3YC)]]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !69/_P C!:_]<'_FM:=9D_\ R,%K_P!<'_FM &G1110
M4444 %9EU_R']/\ ^N4O_LM:=9EU_P A_3_^N4O_ ++0!IT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW7__  63?_$U^I&P?W12;5]!^5'^N&,_DB+_ (AY@O\ G[+\#\N/^%1^.O\
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MT4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4
M+129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10
M M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49%
M "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D
M4 +129%&10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 +129%&
M10 M%)D49% "T4F11D4 +129%&10 M%)D49% "T4F11D4 075S%:6\L\TBQ0
MQ(7>1SA54#))/H *_/\ \,?&?QI9_%K2_C'J6J7Z?#;Q%XDN-!&GS2,EO!;;
M52&4KRHQ@DLHR3;R<_,:^K_VG+7Q9JWP;US1_!6ES:KKFK(+ +%-%%Y4+Y\U
MV,C*,; R\'.7'O7B/B']@>+_ (5'+H]IXU\5:CJ-G9M/::/-?(--:]"EL+"5
MP@9V;G=D;R23S0![-\6_V@!\._%FB>$=$\-WWC'Q?JT1N8=+M)D@5(%)S(\C
M\#[K8X_A.2.,^4_ OXQ2W7Q4^.GB'Q!-JVEZ+H\-K.^EZI(6:PV)+YJ+&&*@
M[D/W/O<5G1>%_C#X9\1?#GXE?\(:?$'B"R\/MX<US0CJ$,<_R2/Y=P)=Q4E\
MHY"@XP1WR)_"GP+\>>-+[XZOXNT6W\.3^-+*W.GE+Q)X8Y0KLD3.@R?+8HKD
M+@_-MR* ./\ VE/VF/$7C3X'VVI:?X5\1^"M.U+48FTK7ENU47<05\A_+8-&
M6'('(8*2#Q7W2)EAM5=V"JJY9F/ &.237PEX\\#_ !N^(GP#T?X;R?#..P;P
MV;9/[1_MB!OMRPHT2+''T!PP8L7Q\I]<5]QZKI<6M:'>:;<%TBNK=[>0H<,%
M92IP?7DTP/G2Z_;422&^U_1_A]KVM?#O3YVM[OQ1 Z)A@<%HX&&73I\Q9<9Y
M /%=?X\_:?TGP?JW@2UL-&U#Q+%XQMFN--DT\ 2-\@,0V.!]XLHR2-N22<"O
M$=(\&_&KP)\(=3^"UEX LM8LKH7-I:>*DU2..VCMYI"SL\1^;(#OU(/3"G'S
M>AV/P)UWPK\1_@(MG;'4=%\(:;>6NIZDLBJJRM;%0P0MN(9SP #BD!VWP:^/
M\GQ-\5>(_"VL^&+SP?XJT/8]QIMU.DX:)_N.KJ!U&#Z89<%NU/X8_P#)T'QL
M_P"O70O_ $GFK'\.>$]3\&?M2_$SQ[KL,.D>$-0TZRAMM6N[F)(G=8H$8'Y]
MRX92.0!53X<_$;PG:?M(?&&]F\3Z-%9WEMHHM[A]0B$<Q2"4/L;=AMI(S@\9
M% 'TE156SO(=0MXKFVE2>WF421RQL&5U(R"I'!!'I5G(H 6BDR*,B@!:*3(H
MR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,B
MC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR
M*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@!:*3
M(HR* %HI,BC(H 6BDR*,B@!:*3(I-U #J*2EH **** "BBB@ HHHH **** "
MLR?_ )&"U_ZX/_-:TZS)_P#D8+7_ *X/_-: -.BBB@ HHHH *S+K_D/Z?_UR
ME_\ 9:TZS+K_ )#^G_\ 7*7_ -EH TZ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (V7<,
M$<5\]>(OV<S>?$2![';;^&[IC/<;!@P$8W1J/1L_+Z<^G/T/]*,=ZI.QPXK!
MT<6DJJV=RII]C!I=G!:VT:PV\*+''&@P%4#  'L*N-11U[U)VQBHJRV%HHHH
M&%%%% !1110 5G7VAV6I3"6Y@$KA=H)8CC.?7U)K1HH R/\ A$]*_P"?-?\
MOIO\:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_ (1/2O\
MGS7_ +Z;_&M>B@#(_P"$3TK_ )\U_P"^F_QH_P"$3TK_ )\U_P"^F_QK7HH
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M7HH R/\ A$]*_P"?-?\ OIO\:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\
MGS7_ +Z;_&C_ (1/2O\ GS7_ +Z;_&M>B@#(_P"$3TK_ )\U_P"^F_QH_P"$
M3TK_ )\U_P"^F_QK7HH R/\ A$]*_P"?-?\ OIO\:/\ A$]*_P"?-?\ OIO\
M:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_ (1/2O\ GS7_ +Z;_&M>B@#(_P"$3TK_
M )\U_P"^F_QH_P"$3TK_ )\U_P"^F_QK7HH R/\ A$]*_P"?-?\ OIO\:/\
MA$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_ (1/2O\ GS7_ +Z;
M_&M>B@#(_P"$3TK_ )\U_P"^F_QH_P"$3TK_ )\U_P"^F_QK7HH R/\ A$]*
M_P"?-?\ OIO\:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_
M (1/2O\ GS7_ +Z;_&M>B@#(_P"$3TK_ )\U_P"^F_QH_P"$3TK_ )\U_P"^
MF_QK7HH R/\ A$]*_P"?-?\ OIO\:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/
M2O\ GS7_ +Z;_&C_ (1/2O\ GS7_ +Z;_&M>B@#(_P"$3TK_ )\U_P"^F_QH
M_P"$3TK_ )\U_P"^F_QK7HH R/\ A$]*_P"?-?\ OIO\:/\ A$]*_P"?-?\
MOIO\:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_ (1/2O\ GS7_ +Z;_&M>B@#(_P"$
M3TK_ )\U_P"^F_QH_P"$3TK_ )\U_P"^F_QK7HH R/\ A$]*_P"?-?\ OIO\
M:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\ GS7_ +Z;_&C_ (1/2O\ GS7_
M +Z;_&M>B@#(_P"$3TK_ )\U_P"^F_QH_P"$3TK_ )\U_P"^F_QK7HH R/\
MA$]*_P"?-?\ OIO\:/\ A$]*_P"?-?\ OIO\:UZ* ,C_ (1/2O\ GS7_ +Z;
M_&C_ (1/2O\ GS7_ +Z;_&M>B@#A?$&K>!O"5PEOK6IZ7I$\B[TCO;U869<X
MR S#CK65_P +"^%8_P"9I\/_ /@UC_\ BZ^;/VZF)^(.A?\ 8-_]JM7S5VS7
MZ!EO#$<?A8XAU+7\C\CSGC6MEF-GA8TD^7K<_2C_ (6'\*_^AHT#_P &L?\
M\71_PL/X5_\ 0T:!_P"#6/\ ^+K\UJ*]/_4N'_/[\#Q/^(B8C_GROO/TI_X6
M'\*_^AHT#_P:Q_\ Q='_  L/X5_]#1H'_@UC_P#BZ_-:BJ_U+I_\_OP#_B(F
M(_Y\K[S]*?\ A8?PK_Z&C0/_  :Q_P#Q='_"Q/A7_P!#1X?_ /!K'_\ '*_-
M?\*/PH_U+I_\_OP%_P 1%Q'_ #Y7WGZ4?\+$^%?_ $-'A_\ \&L?_P <I/\
MA87PK_Z&?P__ .#2/_XY7YL<^E'X4?ZET_\ G]^ _P#B(N(_Y\K[S])_^%A?
M"O\ Z&C0/_!I'_\ %TO_  L/X5_]#1H'_@UC_P#BZ_-:C\*/]2X?\_OP#_B(
MF(_Y\K[S]*/^%A?"K_H9_#__ (-8_P#XY1_PL3X5_P#0T:!_X-8__BZ_-?-+
M^%+_ %+I_P#/[\ _XB)B/^?*^\_1C7O$_P 'O$VCWNE:EX@\.W6GWD30S0R:
MI'AE(Z</P1ZC!'%?%_P[_9M\%:;\=KY/$'C/0;OP#I;K>6<CZG 6U$%LQPN
MW&TJ?,SUP,##@CS849H7!=/_ )_?@'_$1,1_SY7WGZ3K\0OA4HQ_PE'A_'_8
M4C_^.4O_  L3X5_]#1H'_@TC_P#BZ_-C=[4;O:C_ %+A_P _OP%_Q$7$?\^5
M]Y^E'_"P_A7_ -#1H'_@UC_^+H_X6'\*_P#H:- _\&L?_P 77YK?A11_J7#_
M )_?@/\ XB)B/^?*^\_2G_A8?PK_ .AHT#_P:Q__ !='_"P_A7_T-&@?^#6/
M_P"+K\UJ/PI_ZET_^?WX!_Q$3$?\^5]Y^E/_  L/X5_]#1H'_@UC_P#BZ/\
MA8?PK_Z&C0/_  :Q_P#Q=?FMGVHH_P!2X?\ /[\ _P"(B8C_ )\K[S]*?^%A
M_"O_ *&C0/\ P:Q__%T?\+#^%?\ T-&@?^#6/_XNOS6HH_U+I_\ /[\ _P"(
MB8C_ )\K[S]*?^%A_"O_ *&C0/\ P:Q__%T?\+#^%?\ T-&@?^#6/_XNOS6H
MH_U+I_\ /[\ _P"(B8C_ )\K[S]*?^%A_"O_ *&C0/\ P:Q__%T?\+"^%?\
MT-&@?^#6/_XY7YK4OX4O]2X?\_OP#_B(N(_Y\K[S]1O#O_")^++5[G1;FQU>
MVC?RVFL;H2JKX!VDJQYP0<'UK8'A72O^?13_ ,";_&OG[]A-B?AQK@_ZBSC_
M ,@PU]+[J_.,=AOJN(G0O?E9^PY5C7F&#IXF2LY*YE_\(GI7_/FO_?3?XT?\
M(GI7_/FO_?3?XUKT5Q'K&1_PB>E?\^:_]]-_C1_PB>E?\^:_]]-_C6O10!D?
M\(GI7_/FO_?3?XT?\(GI7_/FO_?3?XUKT4 9'_")Z5_SYK_WTW^-'_")Z5_S
MYK_WTW^-:]% &1_PB>E?\^:_]]-_C1_PB>E?\^:_]]-_C6O10!D?\(GI7_/F
MO_?3?XT?\(GI7_/FO_?3?XUKT4 9'_")Z5_SYK_WTW^-'_")Z5_SYK_WTW^-
M:]% &1_PB>E?\^:_]]-_C1_PB>E?\^:_]]-_C6O10!D?\(GI7_/FO_?3?XT?
M\(GI7_/FO_?3?XUKT4 9'_")Z5_SYK_WTW^-'_")Z5_SYK_WTW^-:]% &1_P
MB>E?\^:_]]-_C1_PB>E?\^:_]]-_C6O10!D?\(GI7_/FO_?3?XT?\(GI7_/F
MO_?3?XUKT4 9'_")Z5_SYK_WTW^-'_")Z5_SYK_WTW^-:]% &1_PB>E?\^:_
M]]-_C1_PB>E?\^:_]]-_C6O10!D?\(GI7_/FO_?3?XT?\(GI7_/FO_?3?XUK
MT4 9'_")Z5_SYK_WTW^-'_")Z5_SYK_WTW^-:]% &1_PB>E?\^:_]]-_C1_P
MB>E?\^:_]]-_C6O10!D?\(GI7_/FO_?3?XT?\(GI7_/FO_?3?XUKT4 9'_")
MZ5_SYK_WTW^-'_"*:5_SZ+_WTW^-:]% "*-HQ2T44 %%%% !1110 4444 %%
M%% !69/_ ,C!:_\ 7!_YK6G69/\ \C!:_P#7!_YK0!IT444 %%%% !69=?\
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M )&"U_ZX/_-:TZS)_P#D8+7_ *X/_-: -.BBB@ HHHH *S+K_D/Z?_URE_\
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M  AD\-?!/XV>&?#FAZ_I>K:7XL\/0V-Y)87:3?\ $ULHP!*P!^198V( R-S
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MN+9KQ=-A#);*<>;*[K'&A.. 7=03@X!)QQ7EOBKQQ\4O@[X;LO'/B^_T/6M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /AW]NK_ )*%H./^@=_[5:OFKMC(K]"/C?\  WPS
M\4->LK_6_$$VD3P6_DI%')&H9=Q.?G!YY_2O-O\ AC_X?_\ 0[77_?\ M_\
MXFOU?)<]PF#P4*-2]UY,_ ^(>&\=CLRJ5Z7+9^:/C_'O1CWK[ _X8_\  '_0
M[7?_ '_M_P#XFC_AC_P!_P!#M=_]_P"W_P#B:]K_ %FP/G]S/F_]4,R_N_\
M@2/C_'O1CWK[ _X8_P# '_0[7?\ W_M__B:/^&/_  !_T.UW_P!_[?\ ^)H_
MUFP/G]S#_5#,O[O_ ($CX_Q[T8]Z^P/^&/\ P!_T.UW_ -_[?_XFC_AC_P
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M]O(^/\>]'XBOL'_AC_P!_P!#M=?^!%O_ /$T?\,?^ /^AVNO_ BW_P#B:?\
MK/@?/[F+_4_,NT?_  )'Q]CWHQ[U]@?\,?\ @#_H=KO_ +_V_P#\31_PQ_X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2$\#M&X$0(# X(R%J#PWX-T/4?#>HZWJ-_=6UI:W1@7RD!)7"[21CJ=U<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F3_ /(P6O\
MUP?^:UIUF3_\C!:_]<'_ )K0!IT444 %%%% !69=?\A_3_\ KE+_ .RUIUF7
M7_(?T_\ ZY2_^RT :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %-9=U.HH Y;Q=\.?#?CNW$.
MNZ-9ZDJ@JC3Q@NF>NU^JGW!%>?M^R'\+\\>'F ]/M]S_ /'*]HI.]==/&8BB
MN6G4:7DSRZV5X+$RYZU)-^AQ7@OX.^#_ (?L&T+0;2RG V_:-IDFQZ&1R6(]
MLUV87:..*7%+Q6%2I.J^:;NSLHX>EAX\M**2\AU%%%9G0%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\%4'_P 10!0_X7Y\,?\ HHWA/_P>6W_QRC_A?GPQ_P"BC>$__!Y;?_'*O_\
M"HO O_0E^'O_  50?_$4?\*B\"_]"7X>_P#!5!_\10!0_P"%^?#'_HHWA/\
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MO+7KWZ4GEBLK_A&_^HGJ7_@1_P#6H_X1O_J)ZE_X$?\ UJ -BC-8_P#PC?\
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M_@1_]:@#C_B-\*#X]U6VN_[2%B(HO+*>1YF>2<YW#U]*Y3_AFMN^OC_P#_\
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M_P!:C_A&_P#J)ZE_X$?_ %J7]M8__G[^0?ZMY9_SZ_,\E_X9K;_H/K_X"?\
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M(_\ K4 ;&:,UC_\ "-_]1/4O_ C_ .M1_P (W_U$]2_\"/\ ZU &QFC-8_\
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M_P#D8+7_ *X/_-: -.BBB@ HHHH *S+K_D/Z?_URE_\ 9:TZS+K_ )#^G_\
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MK[@_XB-1_P"?#^__ (!^L?VB/_GHOYBC[1'_ ,]%_,5^3G_"0:G_ -!.\_\
M A_\:/\ A(-3_P"@G>?^!#_XT?ZF5?\ GZON#_B(U'_GP_O_ . ?K']HC_YZ
M+^8H^T1_\]!^8K\G/^$@U/\ Z"=Y_P!_W_QH_P"$@U/_ *"=Y_X$/_C2_P!3
M*O\ S]7W!_Q$:C_SX?W_ / /UC^T1_WU_.OB[_@H))\1]%\.27FE:]+>?#S4
MUCMM3TO[';M]DD5E*-YGE^9L<JO);AAC.&"U\V_\)!J?_03O/^_[_P"-1W&K
M7UY \-Q?7$\3<-'),S*><\C/J*:X,J_\_5]P?\1&I?\ /A_?_P  ^[/V2;[X
MF^(O!/\ PE/Q(\2/??VFJMINF-9V]OY,&.)7,<:L2_92<!0#_%Q[Y]HC_OK^
M=?DV->U,<#4KP#I_KW_QH_X2#4_^@G>?]_W_ ,:/]2ZO_/Y?<+_B(U+_ )\/
M[_\ @'ZQ_:(_^>B_F*/M$?\ ST7\Q7Y.?\)!J?\ T$[S_O\ O_C1_P )!J?_
M $$[S_P(?_&C_4RK_P _5]P_^(C4?^?#^_\ X!^L?VB/_GHOYBC[1'_ST7\Q
M7Y.?\)!J?_03O/\ P(?_ !H_X2#4_P#H)WG_ ($/_C1_J95_Y^K[@_XB-1_Y
M\/[_ /@'ZQ_:(_\ GHOYBC[1'_ST7\Q7Y.?\)!J?_03O/_ A_P#&C_A(-3_Z
M"=Y_X$/_ (T?ZF5?^?J^X/\ B(U'_GP_O_X!^L?VB/\ YZ+^8H^T1_\ /1?S
M%?DY_P )!J?_ $$[S_P(?_&C_A(-3_Z"=Y_X$/\ XT?ZF5?^?J^X/^(C4?\
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M\ _UWI?\^G]Y]H^;'_>'YTGG1_WA^=?%_P#:5Y_S]S_]_&_QI#J5Y_S]S_\
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M!J?_ $$[S_P(?_&C_A(-3_Z"=Y_X$/\ XT?ZF5?^?J^X/^(C4?\ GP_O_P"
M?>W[4_P'M_CIX!DBLY!!XFTU7GTR<.%WM@;H&YQM? &<\$ ],Y\8_89_9CN_
M"3'QWXPM9K+5!OATO2[I2C6PR5:9U/(9N0HQPN3SN&WYP_X2#4_^@G>?]_W_
M ,:/^$@U3_H)7G_?]_\ &E_J95_Y^K[A?\1&I?\ /A_?_P  _6/[1'_ST7\Q
M1]HC_P">B_F*_)S_ (2#4_\ H)WG_@0_^-'_  D&I_\ 03O/_ A_\:/]3*O_
M #]7W#_XB-1_Y\/[_P#@'ZQ_:(_^>B_F*/M$?_/1?S%?DY_PD&I_]!*\_P#
MA_\ &C_A(-3_ .@G>?\ @0_^-/\ U,J_\_5]P?\ $1J/_/A_?_P#]8_M$?\
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M@_\ -: -.BBB@ HHHH *S+K_ )#^G_\ 7*7_ -EK3K,NO^0_I_\ URE_]EH
MTZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCPK_ +]Q_P"D\M?I GW17YO_ ++/_)>/"G^_<?\ I/+7Z0+]T5^,<7_[^O\
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MS5H?BCX9T)-0FBTEKBXF:T1MJ._V=^6QRW0<'.,=*]9X[%5,J^M0LIVN>+'
M82GF_P!4J7<+V/+?$FBOX;\1ZGI3RB=[&ZDMFE5<!RC%<XS[>M9G7 KJ?BE_
MR4SQ7_V%;G_T:U<M_%7OX2I*KAX3GNT?,XN$:>(G".R;$HHHKL.(**** "BB
MB@ HHHH /2C^&CTH[5A6_AR]&=-#^+#U1^M>E?\ (-M?^N2_RJYZ53TK_D&V
MO_7)?Y5<]*_FB?Q,_LRC_"CZ(6BBBI-@HHHH **** "BBB@ K,G_ .1@M?\
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M(2K,=QQMZ54\+_M":K?>#_BU9CQ%HGBC6_!^D2:C8>(-'5/LU\AMY'1FB#L
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M0TE[R32[-]1CA@U!H4-S';2-)$LFT;PC%5+*#G!*@D8X'2K] !1110 4444
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M"OWTZ^"-&9456#(<9!5@01D#J.PKL_\ A1&H=/\ A)M"_P#)S_Y'H_X4/?\
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M*=U7_H(:=_WW+_\ &Z/[6PG\WX,/[#QW\GXHX.BN\_X4[JO_ $$-._[[E_\
MC='_  IW5?\ H(:=_P!]R_\ QNC^UL)_-^##^P\=_)^*.#HKO/\ A3NJ_P#0
M0T[_ +[E_P#C='_"G=5_Z"&G?]]R_P#QNC^UL)MS?@P_L/'?R?BCDM7U[4-=
M:%K^?SA"@CC 55"*">,  5:T_P 9:SI=K:VMK>M'!;2&:%#&K"-R#D@D?[1Z
MGN:Z/_A3NJ?]!#3O^^Y?_C=)_P *;U7_ )_]._[[E_\ C=<;QF6RCR-:>AU1
MR[-8SYU>_J4?^%L>+&SG5CS_ -.\7_Q%4=*\?:_HBW"V.H& 7$K3R@0QMN<]
M3ROM6]_PIO5?^@AIW_?<O_QND_X4YJO_ $$-._[[E_\ C=9*ME232BON_P"
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M[^YA_JUF?_/K\4>%\T<U[I_PQ[XQ_P"@SX?_ ._]Q_\ &:/^&/?&/_09\/\
M_?\ N/\ XS1_;V _G?W,/]6LS_Y]?BCPOFCFO=/^&/?&/_09\/\ _?\ N/\
MXS2?\,?>,?\ H,>'_P#O_<?_ !FC^WL!_._N8?ZM9G_SZ_%'AOWN*VO"7C+6
M/ FK'4M#O38WQB:'S1&C_*2"1AP1V'/M7K'_  Q[XQZ_VQX?_P"_]Q_\9H_X
M8_\ &/\ T&/#_P#W^N/_ (S6-3.<NJQ<)RNGY/\ R-J?#^;4I*<*=FO-'BUC
MJ-SI>I6^HVLIAO+>99XYA@E9%.X-S[UWEE^T-\0M.N[ZZM_$31W%\ZRW+_8[
M<^8RHJ _<QPJ*.!VKK/^&/O&'_08T#_O]<?_ !FC_ACWQA_T&/#_ /W^N/\
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MII9, ;G8Y)P !U]*JCTKW/\ X8^\8]?[8\/_ /?^X_\ C-!_8]\8]3K'A_\
M[_W'_P 9JHYWE\$HQE9+R?\ D92X=S2<FW3NWYH\,YHYKW3_ (8]\8_]!GP_
M_P!_[C_XS1_PQ[XQ_P"@SX?_ ._]Q_\ &:T_M[ ?SO[F1_JUF?\ SZ_%'A?-
M'->Z?\,>^,?^@SX?_P"_]Q_\9H_X8]\8_P#09\/_ /?^X_\ C-']O8#^=_<P
M_P!6LS_Y]?BCPOFCFO=/^&/?&/\ T&?#_P#W_N/_ (S1_P ,>^,?^@SX?_[_
M -Q_\9H_M[ ?SO[F'^K69_\ /K\4>%\T<U[I_P ,>^,?^@SX?_[_ -Q_\9H_
MX8]\8_\ 09\/_P#?^X_^,T?V]@/YW]S#_5K,_P#GU^*/"_6DKW3_ (8_\8_]
M!CP__P!_KC_XS1_PQ_XO[ZQX?^OGW'_QFL*N>8&4&E-[=F;T>',RC4C)T]FN
MJ/OC2O\ D&VI_P"F:_RJT*@L8S#9PQGDJ@4_@*G'6OPB6LF?U-13C3BGV'44
M45)J%%%% !1110 4444 %9D__(P6O_7!_P":UIUF3_\ (P6O_7!_YK0!IT44
M4 %%%% !69=?\A_3_P#KE+_[+6G69=?\A_3_ /KE+_[+0!IT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2;AZTC'"U\G_%'XP?'3PO#XR\7V^C>
M'O#W@[PW>&WAL-:21KG4HBRJ)E96P<EU8;67J5^8@T ?65)7@VM?M$:XUM\)
MX_#GA"'4]4\?V$U[#:WFH&V6T\N"*9@S^6VY=LC<@#.P8'S5YO\ M!?'[QCK
M_P */B9-X9TL:+IGAO4H=%N?$%MJ\D-XEY'<0"<0QK'R@9Q'N+J2'!QU% 'V
M#GO15>-C]B5L\[,Y[]*\/_8]^-'B#XZ?#74]>\1I9QWUOJ\MBBV,+1IY:PPN
M"06/.9&[]A^(![Q2UY9\8O%VM>&=>\!V^DZ_H>B1:EK,5K>0ZN6\V\B9T!BM
M\*W[T@G&2!R.:T_$GQV^'_@VYU:WUKQ9IVG7.D;!>P32$21LZ[T4+C+,R@L%
M4$D \4 >@45S7AKXB^&/&'AUM?T;7;'4-&C#&2]BE'EQ;5#,)"<;"H()#8('
M6L#P=^T!\.OB!X@GT/P_XOTW4]6B=D%K'(5:4J"6,6X#S0 "<IN&.: /1**2
MEH **** (^HKP_\ :+_9ZA^+=C%J6FR1V?B.T0K'(Z_)<)R?+<]L$Y#<XR?4
MU[E[YIO6NG#8JIA*JK4G9H\_'8&CF%"6'Q$;Q9^4'B3POJW@_5I=.UK3Y]-O
MHS@PSK@G!QE3T92?X@2/>LKC.37ZN>(O".C>*K/[+K&EVFIVV<B*[A60 ^H!
M'6O/)OV5/AA<71N6\,1K(6W;8[J=8_\ O@/MQ[8K]*P_&4%&U>F[^1^-XOP]
MK*HWAJJY?,_._3=/N]6O(K2PM9KVZE.V."VC+NY] HY/X5]G_LT_LQ2^#+J+
MQ1XJ13K*K_HFG\,MKG@NQ'5\<<<#GJ>GO/ACX=^&_!D+)H>B6.F!AAVMH%1G
MQTW$#)_&NDVA17@YKQ-6QT'1HKEB]^[/I\BX+HY;46(Q,N>2V[(%7::?117Q
M1^FA1110 4444 %%%% !1110 4444 -9=RD'I7 :;\!?AWH_B%=<LO!>AVVJ
M1N)8KB.QC'E.""'1<;5?(^\H!]Z]!HH 11M&*6BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .1^*
M?_(@ZS_UP-?)]?6'Q3_Y$'6?^N!KY/K]'X8_@S]?T1^.<:_[U3]/U"BBBOMC
M\X"BBB@ HHHH **** "BBB@ H!S5K2=-EUG5K6QA_P!9<2+&.,@9/)/L!G\J
M[SXG>!]&T73+:_T$AH(9VM+L+(S[9!ZYSC!!'XBO+K8ZEAZ\:$MY'J8?+ZV(
MP\Z\-HGG.:3</6O4H=!\-Z1X+T34+S0KK4[F\1M[032 @CN0&[Y[5G:3I_AW
MQ%XVT;3[?1+C3K67S#/#/*^7PA*D9.1RIZ$5Q+-H/F:@[1OVZ?,[Y9+5CR)S
M5Y6[]?D>?\>M%>HC2_!&L^(;CP[%IUWIEX)G@CNUF9UWJ3V9CP<>E>;ZMITN
MCZG=V4N&EMY6C8@'!(.,CIUKJPN.AB7R\K3M?7L<>+RZIA(J?,FKVT[E:BO0
MO#FE>#M0DTS2&BO-2U.]3]Y=0.RBW?:3@+QD#&<D'^E<3K&GC2=7OK(/Y@MI
MGAWXQNVL1G%5A\=#$57246FNY&)P%3#4HUG)-/L4Z***]4\L**** "BBB@ H
MHHH **** .Q^$/\ R4;1O]Z3_P!%/7U7_#7RI\(?^2CZ-]9/_1;U]5_PU^7<
M2?[XO3_,_:N"_P#<I_XOT0ZBBBODS] "BBB@ HHHH **** .1\8?\?D7^Y_6
ML*M[Q=_Q_0_[G]36#7OX7^$CY7&?QF%%%%=APA1110 4444 %%%% !1110 9
MHSG^=>.?'[XAZYX;;2=%\*3&/7KOS;IRD:2,(8T+,-KJ1SR?^ >]7+_XE7FJ
M_ 2;Q9IMPL&I"T5C($5A%,KA7PK CJ&ZBNA86I*,9K:3L>3+,Z,:DZ3W@KGJ
M])GWKY[\-M\3?$6@Z?J8^).EVJWD"3"&:S@W)N&<-\G^<5H^/_$/CEOBEH/A
M+0O$46FO<:6L\TSVL4B/*&DW-RI(!"#@5?U62GR<ROKWZ&"S:')[3D?1+;K\
MSW2BO&_!_CKQ7X9^(EMX+\:3VFIRW]N9K+4[6/RRQ&X[7  7HK= ,<=<\>A^
M.KW7K#PS=S>&M/CU+6N!!!*ZJF20"S$LO 'OZ5A*C*$E%O?J=U'&PK4W-)Z;
MKJ=#17C?P[\:>)[?XD7'A#7]4LO$96S-V]Y9Q*AMG# &)]N!QGN,\CUX]DI5
M*;HOED7A<3#%0<X::]0HHHJ#L"BBB@ HHHH **** "BBB@#JO"'_ !Y3?]=3
M_(5T'<U@>#_^/&7_ *Z?T%;_ '-?-5OXC/KL+_"B+1116)U!1110 4444 (>
ME(_W32MTI&^Z:!/8\W;[QI*5OO'ZTE?3T_A1\7+XF%%%%:$!1110 4444 %%
M%% !112,<+0#?*KL7=[^U%?.N@_'/6;[XL1F6<'P3?WTNF68\M2!*H3#AMF[
MYBR]3C]Y_LUM_%SQAXJMOB=X?\-Z!K\6AP7]HTK2SP1.BL#(<DLI/1 .*Z_J
M=3G4'U5SP_[7H>SE4C=V=CV[(I:\P\!6/C2WUF677?&UAX@L%@8?9;:WB1@^
M1M;*J#QSW[UY_P"!=4^+?CCPV^OZ=XJLY(TE=5L+JSB7S"IQM++'GGV(^HJ8
MX5N[YE9?J.6:15KP>OIT^9]'T5PGP=^(C?$SPBFHS1);W\,K6]U%%G:)1@Y&
M3G!!!QVSWK&^)^I>.8=6D_L>\L?#7A^TM3</JU[Y;^=(/^66"3M!X&=N>.O:
MLU0E[1TWHSKECH*@J\4VCU2BN-^$?C"\\=> M-UF_@2WNY]ZN(P0C;7*[E!/
M0XKLJRE%TY.#Z'71JJM!5([,****#4**** "BBB@ HHHH *3^*EI!WJ);,N/
MQ(])A_U:TY>E-A_U:TY>E?+GVD=D+1110,**** "BBB@ HHHH *S)_\ D8+7
M_K@_\UK3K,G_ .1@M?\ K@_\UH TZ*** "BBB@ K,NO^0_I__7*7_P!EK3K,
MNO\ D/Z?_P!<I?\ V6@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** &NVU<]:^,?VAOB!\)/CQX#\4RZSJ5UX>\6>"?MMO8:;J<T<%P]X%0@+ &
M<3(TD2QGC(^?.W(-?9]<)XB^"'@#Q?KRZUK7@_1M3U52";JYM$9GP !OR/GP
M /O9QB@#@/@?X=O/BQX+^$?Q%\7&ZM?%.A6=X8(H8T@AG6X!A\R2/9T:)(W7
M85'S9Z8%6?&_[)?A;QM<>)/,UGQ%H^F>(9UN]1TC2KV.*SFN05/GE#$W[PLJ
ML><$@$C(!KVZ.-85"JH55' 48%24 0&/R[9D!R%7 SUZ5\2_L!?%CP7X#^#N
MLZ?XB\5:3H=[)KTTZ6]_>)"[1FWMU#@,1P2K#_@)K[?8;E(KSO\ X9S^%O\
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M$_[-_M6^BL?[2O8M.M/-)'G7$A.R)>/O-@]?2MJO"OVJ_N?"'_LHFC?^A24
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M5^#?PP^']GIUO;^.?%%[=K;0:E\\&EV^][B5W"L"[)&P/E[@=S'^[@@'U:6
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M'4;Y_&FE2:3#- \,<7RS^7%*P=BXWCE@%X;&.* /O$,#]:7</6O!]-\7>/\
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MKK_P)_\ K5TGF+V/ZTO\.:/;5O\ GX_O94<-A);4X_<CFO\ A6GAG_GRNO\
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M'U>E_*C%_P"$5LO^FG_?7_UJ/^$5LO\ II_WU_\ 6K:HH]M4[A]7I?RHQ?\
MA%;+_II_WU_]:C_A%;+_ *:?]]?_ %JVJ*/;5.X?5Z7\J,7_ (16R_Z:?]]?
M_6H_X16R_P"FG_?7_P!:MJBCVU3N'U>E_*C%_P"$5LO^FG_?7_UJ/^$5LO\
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M*V?_ $T_[ZK;^M%:^VJ=SG^KTWKRF+_PBME_TT_[Z_\ K4?\(K9?]-/^^O\
MZU;5%'MJG</J]+^5&+_PBME_TT_[Z_\ K4?\(K9?]-/^^O\ ZU;5%'MJG</J
M]+^5&+_PBME_TT_[Z_\ K4?\(K9?]-/^^O\ ZU;5%'MJG</J]+^5&+_PBME_
MTT_[Z_\ K4?\(K9?]-/^^O\ ZU;5%'MJG</J]+^5&+_PBME_TT_[Z_\ K4?\
M(K9?]-/^^O\ ZU;5%'MJG</J]+^5&+_PBME_TT_[Z_\ K4?\(K9?]-/^^O\
MZU;5%'MJG</J]+^5'F7QK\-VD/P;\>R+O#+H%^P^;O\ 9Y#57X >&[2?X&_#
MZ5]^]] L6;#8'^H2N@^.7_)%?B!_V+VH?^DTE5?V>?\ D@WP[_[%^Q_]$)1[
M:IW#ZO2M;E.G_P"$5LO^FG_?7_UJ/^$5LO\ II_WU_\ 6K;HH]M4[A]7I?RH
MQ/\ A%;+_II_WU_]:C_A%;+_ *:?]]?_ %JVZ*/;5.X?5Z7\J,3_ (16R_Z:
M?]]?_6H_X16R_P"FG_?7_P!:MJBCVU3N'U>E_*C$_P"$5L_^FG_?5'_"*V?_
M $T_[ZK;XHR*/;5.XOJU+^4Q?^$5LO\ II_WU_\ 6H_X16R_Z:?]]?\ UJVJ
M*/;5.X_J]+^5&+_PBME_TT_[Z_\ K4?\(K9?]-/^^O\ ZU;5%'MJG</J]+^5
M&+_PBMG_ --/^^J4>%;+T?\ [ZK9S1D4>VJ=P^KTOY1$&U0!VXIU%%9'0%%%
M% !1110 4444 %%%% !69/\ \C!:_P#7!_YK6G69/_R,%K_UP?\ FM &G111
M0 4444 %9EU_R']/_P"N4O\ [+6G69=?\A_3_P#KE+_[+0!IT444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!2U*SCU"RGMID$D4R,CHW1E(((/X5^6GCSP?=^ ?&&K>'[T'S["=H
MPYP-Z$ H^,_Q(5;KQFOU59=W2O#?VCOV>8OBW8IJ6EM%:^)+1"D<D@^6XCY_
M=N>HP22#VR?7CZSAW-(Y=B'&K\$OP/S_ (OR2>;853HKWX;>:/E;X:_'2/P&
MGAYIM*OK^;1!<+#'#JA@MYEE+D^9%Y;!BID;!!'1>N!79^!?VN1X?\7>*=6U
M/P]YL&M2PS)!:RC,)1!& 21\^5"\\<@\<\>"^(O#.J^$]4ET[6;"?3KV)L-#
M<(5/!QE3W4X.&!P?I6;U^M?ISR?+L6I5+7YNMWZ_F?BM/.\SP#C2O;DZ-?(^
MC?C-^U=8_$OP%?>'+#P_-8F\:(R3SS*0JK(K\ #DDJ!U'6OGFQLKC5+VWL[6
M)KB[N)%BBB099W8X50/4DBBQL;G5+R.TL[::[NI2%C@@0N[MTPJ@9)Y["OLW
M]FC]F&7P?=0^*O%<:_VPJ_Z)I_#"VSU=SW?&< <*">I(V\6(K8+AW"RA1>KV
M76YZ&%PV8\58V,ZRT6[M9)'NGPM\'KX"^'^A:"-I>SM4CE:,?*TN,R,,_P!Y
MBQ_&NL[C- &T8IWXU^*U)NI-S>[/Z3H4HT*<:4=HJPM%%%0;A1110 5YC\;O
MASJOQ$7P)_9<ELG]A^+-/URZ^TNRY@@+[PF%.7.X8!P.O->G44 >:>!?A[JG
MAGXN_$WQ1=O;/I_B5]-:R6)V,J_9[;RG\P;<#+=,$\=:XBR^!/B.W\#G1VFL
M/M7_  G:^)=PF;;]E%Z)]N=G^LV@\=,]Z^@J* /*-)\$^*?#?QX\0^);2'3;
MSPQXDM+..]>6X=+JTDMHYE78FPJX8R+U88Y].?)M/_9G\6Z'X'^$=M-9:#XI
MG\&-?M?>'M0N66RO6G9C&Z.86&^/<"-Z$9)QCO\ 6%% 'A7@;X6^,K?X[+X_
MURUT'2M/;P[)H<.CZ/,\GV0"X25"7,:"0L?,R0JX^48.,USEC^SSXNO/@_>>
M [^XTFPFT35O[7\,:U;RO,6F^U2W"FXB9 %QY@7@L/F/!QS],44 >*:3X?\
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M!8QG)X8#>#ZX7I7HGQD^'^K_ !*U+PWI:!(_#D-S]IU"0R!7;'"A1US@N/\
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M:E !1110 4444 %%%% !1165KOB32/"]FMWK.JV6D6K2"-9[^Y2%"Y!(4,Q
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MQ ') Y]: +U%0PS)<1K)&ZR1L,JRD$$>H/<5-0 4444 %%%% !1110 4444
M%9D__(P6O_7!_P":UIUF3_\ (P6O_7!_YK0!IT444 %%%% !69=?\A_3_P#K
ME+_[+6G69=?\A_3_ /KE+_[+0!IT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <'\5O"NJ
M>)/#;MHFHWFGZK;YDA^S7+0B7U1L$#D#@GH?QKY1E\<>*;>5XY=?UB.1#M9&
MO9@5(.,$;NH(/6ON<KNKS'7O@?I.N?$"U\02+&+8 O=617*SR@C:Q[8]>QVC
MU-6F?+YMEM;$RC4P\K/J5/@3X;UVWTDZWK^J7]W->H/(MKJZD=8H^#N*D_>;
MCW QZFO6O<4Q(PB@"G_SI-W/>PM#ZO25-,=1114G4%%%% !1110 5FW^O6.F
MS"*YF\J0KN V,>,]<@>QK2I,<YH Q_\ A+])_P"?K_R&_P#\31_PE^D_\_7_
M )#?_P")K9HH QO^$OTG_GZ_\AO_ /$T?\)?I/\ S]?^0W_^)K9HH QO^$OT
MG_GZ_P#(;_\ Q-'_  E^D_\ /U_Y#?\ ^)K9HH QO^$OTG_GZ_\ (;__ !-'
M_"7Z3_S]?^0W_P#B:V:* ,;_ (2_2?\ GZ_\AO\ _$T?\)?I/_/U_P"0W_\
MB:V:* ,;_A+])_Y^O_(;_P#Q-'_"7Z3_ ,_7_D-__B:V:* ,;_A+])_Y^O\
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M_P#">N__ (W7ME% 'B?_  UUX$_Y]_$G_A/7?_QNC_AKKP)_S[^)/_">N_\
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M HHHH **** "BBB@ HHHH **** "BBB@"&ZN([6!YI6V1H,LV":SO^$LTO\
MY^O_ "&W^%2^(O\ D"W?^X:\VH ]$_X2S2O^?K_R&_\ A1_PEFE?\_7_ )#?
M_"O.Z* /1/\ A+-*_P"?K_R&_P#A1_PEFE?\_7_D-_\ "O.Z* /1/^$LTO\
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MX2S2_P#GZ_\ (;?X5YY2-0!ZM;7"74*2Q,6C<9!P14U4-#_Y ]E_UR7^57Z
M*E]J$&FQ"2Y?RT)V@[2>>N.!5/\ X2S2O^?K_P AO_A5/QQ_R"H_^NR_R:N'
MH ]$_P"$LTK_ )^O_(;_ .%'_"6:5_S]?^0W_P *\[HH ]$_X2S2O^?K_P A
MO_A1_P )9I7_ #]?^0W_ ,*\[HH ]#/BK2FZW/YQO_A7S-\4?V7/#_CCXY:%
MX\TC6_\ A'[?SQ<:W'9F6"XED7!1X6095G(PY!7'W@2Q->K44 >A1^*=*10O
MVHG'JCG^E._X2S2O^?K_ ,AO_A7G=% 'HG_"6:5_S]?^0W_PH_X2S2O^?K_R
M&_\ A7G=% 'HG_"6:5_S]?\ D-_\*/\ A+-*_P"?K_R&_P#A7G=% 'I]AJ5O
MJ4;26S^8BG:3M(YXXY%7*YOP+_R"YO\ KLW\EKI* "BBB@ HHHH **** "DI
M:* ,C_A*]+'6Z_\ (;?X4?\ "6:5_P _7_D-_P#"O/9/OGZTV@#T3_A+-*_Y
M^O\ R&_^%'_"6:5_S]?^0W_PKSNB@#T3_A+-*_Y^O_(;_P"%'_"6:5_S]?\
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M#5Y*(T,K'_0I&/#*>R$GYAT&<COFY\=/V6K3X3^"_P"WK'7+B_6*=(9(;F(
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M#E0KLH)^;Z#H(;>?Q-^T9<W<D;-IWA;0EM[<R0G:;N\EW2,C'NL5O$..TIH
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ME<7X%_X^[G_<'\Z[2@!K?=KS#5O^0M>?]=7_ /0J]/;[M>8:M_R%KS_KJ_\
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MWJ6J11MO2.]NY)E5L$;@&8X.">@[UL?"GX;W_P 5/&EEH=D&6)F\RZN%'$$
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MS$8&$WL,\D=/45IZ;JUEK4,DEC=V]Y%%,]O(]O*L@25&*NA(/#*P((Z@@YH
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M<W_?!_PH_L6__P"?.;_O@_X5V_\ PEFE?\_7_D-_\*/^$LTK_GZ_\AO_ (4
M<1_8M_\ \^<W_?!_PH_L6_\ ^?.;_O@_X5V__"6:5_S]?^0W_P */^$LTK_G
MZ_\ (;_X4 <SX;TJ\M=;MY9;:6.,;LLRD#E2!^M=[65:^(+"^N$@@G\R5LX7
M8PS@$]Q6I0 M%%% !1110 4444 %%%% '(>,-/N;R\A:""24",@E%)[YQ6!_
M8M__ ,^<W_?!_P *[^^UJSTV0)<R^6[#<!M)XSCL*K_\)9I7_/U_Y#?_  H
MXC^Q;_\ Y\YO^^#_ (4?V+?_ //G-_WP?\*[?_A+-*_Y^O\ R&_^%'_"6:5_
MS]?^0W_PH XC^Q;_ /Y\YO\ O@_X4?V+?_\ /G-_WP?\*[?_ (2S2O\ GZ_\
MAO\ X4?\)9I7_/U_Y#?_  H XC^Q;_\ Y\YO^^#_ (4?V+?_ //G-_WP?\*[
M?_A+-*_Y^O\ R&_^%'_"6:5_S]?^0W_PH XC^Q;_ /Y\YO\ O@_X4?V+?_\
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M ,^<W_?!_P *[?\ X2S2O^?K_P AO_A1_P )9I7_ #]?^0W_ ,* .(_L6_\
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MO_(;_P"% '$?V+?_ //G-_WP?\*/[%O_ /GSF_[X/^%=O_PEFE?\_7_D-_\
M"C_A+-*_Y^O_ "&_^% '$?V+?_\ /G-_WP?\*1M#U C'V.;_ +X-=Q_PEFE?
M\_7_ )#?_"D;Q9I8&?M7_D-_\* -:/[@^E.IJG<H(Z4Z@ HHHH **** "BBB
M@ HHHH *S)_^1@M?^N#_ ,UK3K,G_P"1@M?^N#_S6@#3HHHH **** "LRZ_Y
M#^G_ /7*7_V6M.LRZ_Y#^G_]<I?_ &6@#3HHHH **** "BBB@ HHHH ****
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M)7B7P'HO@K6_$_B71TCD6VL-FR96C61G9R?W:*'1=QZLR@ YH ]]HKPSP/\
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M 4444 9OB+_D"W?^X:\VKTGQ%_R!;O\ W#7FU !1110 4444 %%%% !1110
M4444 %%%% '3^!?^/NY_W!_.NTKB_ O_ !]W/^X/YUVE #6^[7F&K?\ (6O/
M^NK_ /H5>GM]VO,-6_Y"UY_UU?\ ]"H JT444 %%%% !1110 4444 %%%% !
M1110!J^%?^1@MO\ @7_H!KT:O.?"O_(P6W_ O_0#7HU !1110 4444 %%%%
M!1110!Q'CK_C^@_ZY'_T*N;KI/'7_']!_P!<C_Z%7-T %%%% !1110 4444
M%%%% !1110 4C4M(U 'INA_\@>R_ZY+_ "J_5#0_^0/9?]<E_E5^@#G/''_(
M*C_Z[+_)JX>NX\<?\@J/_KLO\FKAZ "BBB@ HHHH **** "BBB@ HHHH ***
M* .W\"_\@N;_ *[-_):Z2N;\"_\ (+F_Z[-_):Z2@ HHHH **** "BBB@ HH
MHH \FD^^?K3:=)]\_6FT %%%% !1110 4444 %%%% !1110 5J^%O^1@M/JW
M_H)K*K5\+?\ (P6GU;_T$T >C4444 >=>+/^1@N?HO\ Z"*R:UO%G_(P7/T7
M_P!!%9- !1110 4444 %%%% !1110 4444 %(WW32TC?=- 'K4?W13J;']T4
MZ@ HHHH **** "BBB@ HHHH *S)_^1@M?^N#_P UK3K,G_Y&"U_ZX/\ S6@#
M3HHHH **** "LRZ_Y#^G_P#7*7_V6M.LRZ_Y#^G_ /7*7_V6@#3HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OC/XH?LG^,_#^C_%+Q+H?Q&O+P
M^(4N;R\T.#0UEEOEPY2V$GFLV KE!M7OP*^S** /GS]EOX5W</[/^CZ/X^C3
MQ#;W 6>'1=;TM%&G(.! 4<'<0P9MS 'Y_:O8YO ?AJXL=0L)?#NE26.H2+->
M6SV41BN74C:TB[<.PVK@G)^4>E;]+0!%(NV%PH[8 %?"/[(_Q/U?X!_#G4?#
M^O?"_P"(%[=W.JR7ZR:;H+N@1H88P"7*G=F-NWIWK[RI: /D_P"-&I:K\7+S
MX%>(M,\)^(K""'Q=#-=6>HZ<Z7-I&D\:F295SL0A2V6/3%7?A=X5U:U_;A^*
M6N76D7T.DW6DQ16VH2VSK;RMMM,JDA&UCE#P#_":^HMH]*-H]* /A:;X.^*_
M&'@']I+2+/1;RWO]1\5-?:;'=0O M[''=M+F(L,.&0'!!P25K#\)^$5\?:EX
M"T*3P9\6-0O;6:WDU%_$FJR6FG:3)&$#21>9&X8* ^%^1B H'+<?H+M'I2;!
MZ#\J %7I2TE+0 4444 ,^HI"PR>*&KQ#]HS]H2+X1Z?%I^F)%=^)+Q2T<,A)
M6"/G]XX'7D8"\9YYXKIPN&JXNJJ-)7;.#'8ZAE]"5>N[)'J_B#Q=HWA6U^T:
MSJEII<!.T27<RQ@G'0$D9->?R?M3?#**Y\H^*(F.<96WF9?^^@F/UK\^/$WB
MK6/&6J/J6N:C<:E>OQYMP^[:N2=JCHJ@L<*!CDUE>PK])P_!T'!/$5'=]C\:
MQ?B%6]HUAJ2Y5W/U1\+_ !%\-^-$+:'KEEJ>T;G6VF5G4$\;ESE?Q%=(I'8U
M^2>FZE=Z1>0WEC=36EY"VZ.>WD9'0XQ\K Y!QGH>]?:'[,_[3DWC>ZC\,>*I
M$76=O^B7XPJW>!RK+P ^.>.#SP,<^#FO#-7 P=6B^:*W[H^GR+C2CF518?$Q
MY)/;LSZ?HIJMNIU?%GZ:%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 9OB+_D"W?^X:\VKTS68)+K2[B&)=\CIA5R!7$?\ ")ZK_P ^
MG_D1/\: ,JBM?_A$]4_Y]?\ R(O^-'_")ZI_SZ_^1%_QH R**U_^$3U3_GU_
M\B+_ (T?\(GJG_/K_P"1%_QH R**U_\ A$]4_P"?7_R(O^-'_")ZI_SZ_P#D
M1?\ &@#(HK7_ .$3U3_GU_\ (B_XT?\ ")ZI_P ^O_D1?\: ,BBM?_A$]4_Y
M]?\ R(O^-'_")ZI_SZ_^1%_QH R**U_^$3U3_GU_\B+_ (T?\(GJG_/K_P"1
M%_QH T/ O_'W<_[@_G7:5RWA32;O2[B=KF+RPZ@+\RGO[&NIH :WW:\PU;_D
M+7G_ %U?_P!"KU!NE<%?^&M2N-0N9H[?,;R,RG>HX)X[^E &%16O_P (GJG_
M #Z_^1%_QH_X1/5/^?7_ ,B+_C0!D45K_P#")ZI_SZ_^1%_QH_X1/5/^?7_R
M(O\ C0!D45K_ /")ZI_SZ_\ D1?\:/\ A$]4_P"?7_R(O^- &116O_PB>J?\
M^O\ Y$7_ !H_X1/5/^?7_P B+_C0!D45K_\ ")ZI_P ^O_D1?\:/^$3U3_GU
M_P#(B_XT 9%%:_\ PB>J?\^O_D1?\:/^$3U3_GU_\B+_ (T -\*_\C!;?\"_
M] ->C5Q.@>']0L=8@GG@V1+NW-O4]5..,^M=M0 4444 %%%% !1110 4444
M<1XZ_P"/Z#_KD?\ T*N;KL?%6CWFI7<3VT/F*L>"=RCG.>YK%_X1/5/^?7_R
M(O\ C0!D45K_ /")ZI_SZ_\ D1?\:/\ A$]4_P"?7_R(O^- &116O_PB>J?\
M^O\ Y$7_ !H_X1/5/^?7_P B+_C0!D45K_\ ")ZI_P ^O_D1?\:/^$3U3_GU
M_P#(B_XT 9%%:_\ PB>J?\^O_D1?\:/^$3U3_GU_\B+_ (T 9%%:_P#PB>J?
M\^O_ )$7_&C_ (1/5/\ GU_\B+_C0!D4C5L?\(GJG_/K_P"1%_QIK>$]5/\
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M444 %%%)0!Y/)]\_6FUKMX5U4L<6O_D1/\:/^$3U3_GU_P#(B_XT 9%%:_\
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M .1%_P :/^$3U3_GU_\ (B_XT 9%%:__  B>J?\ /K_Y$7_&C_A$]4_Y]?\
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M5(!!&,UY)KFHZSXE^+&F_##PMX@N/"_A;2?#L>HWFHZ=LGO9U9S%# DLP?:
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MKP)XEU'^WKCPO9VDEKK3Q)%+<V]R"Z)(B +OCV%=P W<<=20#ZYCD61 P/!
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MX3JP_P">5Q_WRO\ \56CXB_Y MW_ +AKS:@#N/\ A.;'_GC<?]\K_P#%4?\
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MI(7BGWQL5.%7&0>WS5OM]VO,-6_Y"UY_UU?_ -"H Z[_ (3FQ_YXW'_?*_\
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M'HJY(Y8XYK[>_9Q_9K@^&*C7M<,5YXFE3:BH 4LU(Y53W<CJWU XR6\[%XS
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M !1110 4444 %(U+2-0!Z;H?_('LO^N2_P JOU0T/_D#V7_7)?Y5?H ****
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M .%_X0>__P">MO\ ]]-_A1_P@]__ ,];?_OIO\*[JB@#A?\ A![_ /YZV_\
MWTW^%'_"#W__ #UM_P#OIO\ "NZHH X7_A![_P#YZV__ 'TW^%'_  @]_P#\
M];?_ +Z;_"NZHH X7_A![_\ YZV__?3?X4?\(/?_ //6W_[Z;_"NZHH YWPW
MH%SH\\KS-&X=0!Y;$]#GTKHJ** $;I7&7G@^]N[Z>99(%61V8!F;/)/7Y:[2
MB@#A?^$'O_\ GK;_ /?3?X4?\(/?_P#/6W_[Z;_"NZHH X7_ (0>_P#^>MO_
M -]-_A1_P@]__P ];?\ [Z;_  KNJ* .%_X0>_\ ^>MO_P!]-_A1_P (/?\
M_/6W_P"^F_PKNJ* .%_X0>__ .>MO_WTW^%'_"#W_P#SUM_^^F_PKNJ* .%_
MX0>__P">MO\ ]]-_A1_P@]__ ,];?_OIO\*[JB@#A?\ A![_ /YZV_\ WTW^
M%'_"#W__ #UM_P#OIO\ "NZHH Y'1?"MWINJ0W,CPNBYR$+9Y4CT]:ZZBB@
MHHHH **** "BBB@ HHHH YOQ)X?N=8NHWA:-$5-IWL03SGT-9/\ P@]__P ]
M;?\ [Z;_  KNJ* .%_X0>_\ ^>MO_P!]-_A1_P (/?\ _/6W_P"^F_PKNJ*
M.%_X0>__ .>MO_WTW^%'_"#W_P#SUM_^^F_PKNJ* .%_X0>__P">MO\ ]]-_
MA1_P@]__ ,];?_OIO\*[JB@#A?\ A![_ /YZV_\ WTW^%'_"#W__ #UM_P#O
MIO\ "NZHH X7_A![_P#YZV__ 'TW^%'_  @]_P#\];?_ +Z;_"NZHH X7_A!
M[_\ YZV__?3?X4'P/?\ 3S;?_OIO_B:[JB@"GI<#V=A! Y!>- I*YQQZ5<HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M I*6B@#ACX(OV)/FV_\ WTW^%)_P@]__ ,];?_OIO\*[JB@#A?\ A![_ /YZ
MV_\ WTW^%'_"#W__ #UM_P#OIO\ "NZHH X7_A![_P#YZV__ 'TW^%'_  @]
M_P#\];?_ +Z;_"NZHH X7_A![_\ YZV__?3?X4?\(/?_ //6W_[Z;_"NZHH
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M;Z_\^%__ . S4 :M%97]OK_SX7__ (#-1_;Z_P#/A?\ _@,U &K165_;Z_\
M/A?_ /@,U']OK_SX7_\ X#-0!JT5E?V^O_/A?_\ @,U']OK_ ,^%_P#^ S4
M:M%97]OK_P ^%_\ ^ S4?V^O_/A?_P#@,U &K165_;Z_\^%__P" S4?V^O\
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M_P#^ S4 :M%97]OK_P ^%_\ ^ S4?V^O_/A?_P#@,U &K165_;Z_\^%__P"
MS4?V^O\ SX7_ /X#-0!JT5E?V^O_ #X7_P#X#-1_;Z_\^%__ . S4 :M%97]
MOK_SX7__ (#-1_;Z_P#/A?\ _@,U &K165_;Z_\ /A?_ /@,U']OK_SX7_\
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M7_\ X#-0!JT5E?V^O_/A?_\ @,U']OK_ ,^%_P#^ S4 :M%97]OK_P ^%_\
M^ S4?V^O_/A?_P#@,U &K165_;Z_\^%__P" S4?V^O\ SX7_ /X#-0!JT5E?
MV^O_ #X7_P#X#-1_;Z_\^%__ . S4 :M%97]OK_SX7__ (#-1_;Z_P#/A?\
M_@,U &K165_;Z_\ /A?_ /@,U']OK_SX7_\ X#-0!JT5E?V^O_/A?_\ @,U'
M]OK_ ,^%_P#^ S4 :M%97]OK_P ^%_\ ^ S4?V^O_/A?_P#@,U &K165_;Z_
M\^%__P" S4?V^O\ SX7_ /X#-0!JT5E?V^O_ #X7_P#X#-2-X@1>387_ /X#
M-0!K44BMN&:6@ HHHH **** "BBB@ HHHH *S)_^1@M?^N#_ ,UK3K,G_P"1
M@M?^N#_S6@#3HHHH **** "LRZ_Y#^G_ /7*7_V6M.LRZ_Y#^G_]<I?_ &6@
M#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
M+U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO
M^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M
M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y
M_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__
M #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT?VUI_P#S_P!M_P!_E_QH O45
M1_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\: +U%4?[:T_P#Y_P"V_P"_R_XT
M?VUI_P#S_P!M_P!_E_QH O451_MK3_\ G_MO^_R_XT?VUI__ #_VW_?Y?\:
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M5JB@"K_9=G_SZP_]^U_PH_LNS_Y]8?\ OVO^%6J* *O]EV?_ #ZP_P#?M?\
M"C^R[/\ Y]8?^_:_X5:HH J_V79_\^L/_?M?\*/[+L_^?6'_ +]K_A5JB@"K
M_9=G_P ^L/\ W[7_  H_LNS_ .?6'_OVO^%6J* *O]EV?_/K#_W[7_"C^R[/
M_GUA_P"_:_X5:HH J_V79_\ /K#_ -^U_P */[+L_P#GUA_[]K_A5JB@"K_9
M=G_SZP_]^U_PH_LNS_Y]8?\ OVO^%6J* *O]EV?_ #ZP_P#?M?\ "C^R[/\
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M  H_LNS_ .?6'_OVO^%6J* *O]EV?_/K#_W[7_"C^R[/_GUA_P"_:_X5:HH
MJ_V79_\ /K#_ -^U_P */[+L_P#GUA_[]K_A5JB@"K_9=G_SZP_]^U_PH_LN
MS_Y]8?\ OVO^%6J* *O]EV?_ #ZP_P#?M?\ "C^R[/\ Y]8?^_:_X5:HH J_
MV79_\^L/_?M?\*/[+L_^?6'_ +]K_A5JB@"K_9=G_P ^L/\ W[7_  H_LNS_
M .?6'_OVO^%6J* *O]EV?_/K#_W[7_"C^R[/_GUA_P"_:_X5:HH J_V79_\
M/K#_ -^U_P */[+L_P#GUA_[]K_A5JB@"K_9=G_SZP_]^U_PH_LNS_Y]8?\
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M^_:_X5:HH J_V79_\^L/_?M?\*/[+L_^?6'_ +]K_A5JB@"K_9=G_P ^L/\
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MJ* *JZ?;1L&2WB5AT*H ?Y59I:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img8619836_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +( S4# 2(  A$! Q$!_\0
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MFO?LV^'M7;0;BQU?7/#NKZ/IJZ1%JNCWGDW$UJ!@1RG;AN.^*?KW[-WA76_
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M;58NM_ZZ+_=_K5T]R);&=11174<X4444 %%%% !1110 4444 %%%% !1113
M;)\N&[ TVXD$R;4&YNOI2NRK(A;IG%-NI ,;.O<J,UD]RD0_OD).) /< TOG
M$C_6JWLXQ31=/W9<>I4BG^8S+DK$_/8U0QOG*WRF)&_W2*FML_,8X]J^C&H_
M.1N&@/X 5);L0#Y28C]&XYJ9 /&6D<MPWI3J8F269OO=Z?5K83"BBBF2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.>&=-CU34/,\II9F(3>.JC'7'.2:N?#KXMIXNU&;2=2LQINK1[L*A)23:?F
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MUE>/Y$2IZ\T39NID;3)Y4=7C,#.KJV01M."#W%>9_LTVC0_#4W#<&ZO)''T
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MC2&Y>HHHKG-PK%UO_71?[O\ 6MJL76_]=%_N_P!:NGN1+8SJ***ZCG"BBB@
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M3?XYHKQ;P3\0];\-Z?%87]D^MV<0VPS1R!9XU[*<\,!V/6M^\^*.KWRF+2=
M-I(W N-0D#!?<(O4_4XK@EA*L9VML;JI&R9Y_P#M"V<$WC8/&@:7^S4,V!G#
M!FV$_A7NOA.-8?">B1KC:MC#CT_U:FO)X?!<U\UQ=ZC.UW?71WS32=6.,8QV
M ' ':K]C)XL\.V8LM/U-'M%79$MU )6B7T5N.G;.:[:T/:484XOX3&#M)R[E
MWXX_$)_#NEC0=+=FUK45VMY9^:&(\9'HS=!^)J3X;_!/3/"UK;W>KPQZCK.T
M-MD&Z*V./NHIZD?WCSGI7G>IZ'-HNKVFN7TDE]/%>175S-*=S/M<$D_AT'05
M](+(LRK)&P>-P'1AW!Y!'UK&N_84HTX/?<N"YY7D+V [#H/2@<=.**<%/H:\
MPZ \QNI.?K2%B>IH*GT-)2V#0**** "BBB@ HHHH **** "LSQ1;K>>&-8@D
M&Y)+.92#_N&M.N$^,GBY_#/A-K2T0S:QJ[?8;*!!EF9N&('L#^HK6E%RJ14=
MQ2:29YKX&^.LV@^"]&T1-#N=6U>&,6T.V0!90/N8'+$X]JZV7P7X\^(T _X2
M;6X_#>G2?\PG2DW.1Z2.3^F<>U;?PJ^%=M\/]-2>Y5+C79H\33]1"./W:>@'
M<]S6;\9/B3+H$*>'M$W7'B'41L"P#<\"-QG _C;G [=>U>C*4)5K89?-G/M&
M]1GG/A_QMI?PU\>2:;H%C--I33"SFFD=7EN&7(9N!TSDC'%?1]E>0ZA:17-O
M()8)5W(Z]Q7GOPS^#UAX4T%O[3@6ZU>]AV7+M@^2I_Y9H>W/5AU/M46EZE<_
M#76)--O]T^DS'?%*H)P/[P'?W'XU\QF&)C@<5SZNE+=MWM+OY)GNX:C]<H.-
MK5%LEU7;U/3:*YR\^(6@VD(=;S[4S#B.W4LWX^GYUBS?%F!9/W>ES&/U>55;
M\JSJYM@J+M.JOEK^0J>6XNK\--G>XW @X*G@@]*\Q\9: _A#4[76])'DQF3Y
MHA]U']/]UNGUKK]#\;Z5KS+%%,;>Y/2WN!M8_0]_PK3UC2XM9TRXLION3(5S
MZ'L?P-88NE1S3#\U"5Y+5-=&:X6=7+Z_+5347HT^H:/JD.MZ;;WUN?W<R[L=
MU;NI^AXKSWQ)$?!/CBVU2%<6=P3(ZCH,\2#^34GP_P!6FT#7KC1+WY%ED*;3
MP%F _DPKH/B=IOVSPZMR%W-:RASQ_ ?E;^>?PKR:U9YAEWMTOWM)W?DUN>E2
MIK!8[V+?[NIHO.^QL^)=)3Q#H,]LA#.Z"2!^VX<J?\^M<1\.M>32]/UPW&52
M!1<F,]<X*D?F!72_#?6#J/AY(';=/9-Y)SU*]5/Y<?A7G?BR%;3Q%K,=G+B%
MY-K*O1B<,5_!JY\PQ"2H9I2W::?S1O@L.Y>VRZKLM?Q-/0=#O/B!JTM_J,K+
M:JV)&4_B(D]!ZUZ<\EGH>F;F\NULK=/HJ@?UK/LVL?!?AFV6YD$,42 ,<<NY
MY.!W)-<!J.J:I\1M4%M:0%+6,[EB8X2,?WY#Z^@K>%2GE-&UN?$3^;O_ )&,
MXSS.JW?EHP*VO:W=^--8B2"%BN2EK;=^>KM[^OH*]-\,^'XO#>EI;I\UPWS3
MR]W?U^@Z"H?"_A.T\,P$H?M%Y(,2W##D^P]!6U)*EO$\DCK'&@W,S'  ]2:]
M#+<OG1G+%XMWJ2_!'%C\="K%8;#:4U^(ZN6\5>/;70-]O;A;J^QRF?DC]W/]
M!7.^*OB)+?%K32&>*V/R&Z4?O)3Z1CL/?J:M>#_ASM\N]U>+YL[X[,\X/7=)
MZGOC\ZYZV95<74^K9>M>LNB]#:C@*>%@J^.Z[1ZLS]!\)W_C*\_M769)!;-R
M-WRO*/11_"G\Z[76/$6E^#[&.$[495Q#9P##'\.P]S7/^,OB&+-GL=)D4RKQ
M)=C!6/\ V4[%OY5E>&OA_=:W+]OU9I(;:3YMKD^=-[L>R_K7!2J+#R>&R]>T
MJOXIO;[SMJ4_;Q6(QKY*:VC_ , JV]KJGQ(UDSR_N;6,[3(/N0)_=7^\QKU6
MSM8K"TAM8%V0PH$51V I;6UALK=(+>)888QA8T& *EKZ/+\O6$YJE1\U26[_
M ,CPL9C?K5H07+".R"BBBO7/+"BBB@ HHHH **** "BBB@ K=TG_ (\$_'^=
M80ZUNZ3_ ,>"?C_.LJFQI#<O4445SFX5BZW_ *Z+_=_K6U6+K?\ KHO]W^M7
M3W(EL9U%%%=1SA1110 4444 %%%% !1110 4444 9&I>+M&T?7M)T6^U"*UU
M35M_V&VDSNGV#+8/3(';O6OBO,OVAO ,WC;X>3W.F9A\2:$XU72;A/OK-'\Q
M4'T8#!_"NF^&7C>#XD?#_0O$D"A1J%JLDD8XV2#AU_!@:WE37LU4CZ,Y(UG[
M=TI=KKS[_<=%#9)>*9)"0S<#''>J;:E):LT>V-@AVC+X/Y5;CMY)T=XY3 K'
MA5YSVR:J^=#$Q5[5F=3@LL>X'\:XEN]3T'M<2/49IFP@MQ[-+S2MJ4T.0ZV[
M?[LO-*TD<V -.D<?]<P*:TT-LQ,EDT6.^U:OT(OW&C5)9G5!Y(WMM&&)-<9\
M:OA&/'?ANWN=*NVTWQ5H\HO='U$'_53#^$_[#="/I73W7B;2[=?WTMK #P'E
MF10/KS5.]^('AFQ6/S_$]A.5/,23!S_X[GI6D'.G)3CN8U52JP<)O1F5\&OB
MG_PLO0+A-1MO[*\5:3+]DUG2WX:"8?Q =T;J#[UZ!7S_ /$34M,\.?%[P%\0
M_#5]!<QZU?+X>UA+9P5N4=<Q,P'\2L._.*^@67:Q'H<5T5H*-IQ5D_P[G)A*
MLI)TYN[CI?NNC$HHHKF.\**** "@J9%9=^PL" P_A)'7\***8'QSX/OO&OPR
MN/%/CG4?!EUXFO-&N[BUU;7]5U&1)Y;429_T2+&W8J;23TSTKU;Q/X+\8?'/
M2-?@U.^T>#P'JFGE]%M+>)FN9)&4/!/(Y^XRMP5Z5U?Q!^"EG\2-8^UZAXCU
M^TL)K=;6\T>SO-EK=Q YVLN.,]\=:[^SLH-/LX+6VC6&V@C6**-> B*,*/P%
M>E4Q*=IQ7O+\#PJ.!E[U*HWR>JU_X'KU/+['X33>.OA#X2T+QS$-.UO27@N?
M-TF10T4T1^5D8# W #/'>O49+.WGGAFD@CDGA!\N61 SIG@[6/()'6DNKVVL
M?*^TW$5OYK!(Q*X4NQZ 9ZFHM4>_CM?^)=#;RW18 ?:G9$0=V.!DX]!CZUPS
MJ2J/7S_'<]2G1ITE[OE^&QSOB?X<VWBKQ9H^NW.JZE:OID3QQ6ME*(XWWL"Q
M8X)YV@<=1D5);:;X/^'=Q<3VMIIFA7%\=T@@C"23\YX4<D9[ 8R>E:NDV&IV
M\SSZCJOVUV7 MX8%BAC^@Y8GW)K1\F/SA-Y:F51M$FT;@/0'M0Y.R3>@1I1N
MYQC9LJZ7JT.L6[3P1SI$&V@W$+1%O<!N<>Y%4[X>(9KJ1+,Z9:V@/R33^9+(
MP]=HP!^?:MDT5%]3?ENK-D-G'/':Q)=3+<7"C$DJ1^6&/J%SQ68_AMY6)DUO
M5R"<[4G10.>@PG2MFBBX<JM8CEA$ELT)=U#)LWJV''&,@^M>0:'\ ;S2_C1J
MOCM_%VI)#<;$CTV"3_7(JA<3L?O#(X 'XU['15QJ2@FEU,:E"%5Q<OLZKU#^
M=%5M2U*UT?3[B]OKF.TLX%\R6:0X5 .YKR#6OVF-,AF:+1-+FU+!P)YY/*0^
MX4 L1^552HU*W\-7-I24=SVBEW''4XKP_3_VC+^-UDU7PI,EA_%/9^9\@]<.
M,'\Q7JWA7QAI'C331?:/>)=PYPZCY7C/HRGD552A4HZSB*,XRT1L]>M8_BSP
MO:^,-$GTZZ0$L-T$N/FAE'W7![8/YBMBE7[P^M81DXNZW+>JLSQ;P*WVBR*7
M*@7$;&.5?1U.&_45U4S0V<$LTFV**-2S-Z =ZYW2HA9^,O$ENOW5OG8#TW -
M_6K?CAF7PS=;<\E V/3<,YKV)+GJ13ZV.5;,Q+CXBS><WV>QC\C/'G.0Y'X<
M"M_0?%%MKNZ,*UO=*-QA8@Y ZE3W%>9UI^%HY9/$5@(OO*Y=O90#G^GYBNVI
MAZ?(VNAC&;;/1]0T^._MVCD7(((Y[UY]JGB37_ ]F8-/UR2WL8ON0S(LJH/0
M9Y ]!7H6I7:V5F\C8& >M9OP[\'KX@ND\3ZM%YL.XG3[609& ?\ 7,/4X^4=
MNM<,)J$.:IJC:2<G:.YREE:?%WQ9:B:.]N;.U<95[B2.U+CL0H4MCZXJ.;X2
M_$J8[I-9\UO?5I1_2OH/);K16'UZ2?NQBOD7[%/=GS]#\+OBA;,#!J[1$?\
M47<_H15_[/\ &C0L,DL>J(O.W?%-D?B%->Y44GC92^*$7\A^R71L\1C^/'B3
MPVP3Q1X0FA7H9X5:+^8*_D:Z_P /_'3P?KY5#J#:;.W2.^3RQG_?Y7]:[YAY
MB%7 =3U5N0?K7'>(OA#X3\3J[7&E1VMPW_+Q8_N7'O@<'\14\^'J?'!KT#EJ
M1V=SKX9H[B%)89%EB?E9(V#*?H13Z^>M2T'Q+\ =275-+GDU;PS(W[^)OE4
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M?^/!/Q_G6%WK=TG_ (\$_'^=95-C2&Y>HHHKG-PK%UO_ %T7^[_6MJL76_\
M71?[O]:NGN1+8SJ***ZCG"BBB@ HHHH **** "BBB@ HHHH 4;>=_P!S!W>F
M,<_I7B?[([?\6RU58?FTY/$.HBQ/8Q><<8]J[#X[3ZQ;_!WQ>^@+(VK#3Y!%
MY0S)@C#[?]K;NQ7(_#?XH?#_ ,+_  5TV'PSKNFR_P!G:8/+L'N%6<W&S)5D
M/.XN>17=3BY4)<JO=K\#RZU2*Q<7+3E3^=^QZ-XH\9VG@O3+FZGN(0P'[BS=
MP)KB3H%1>O)(YKA[?1O%/B3_ $[4=?FTWSCN^QZ>H5$]LD$L?>N:U?PE%:^#
MX]>U!S>:NUY;W-Q>2\MS(-P]E&> .!BO6+-EDM8BA!4J,8K+DC15UJ1*M*O*
MVR.53X>!FW7&N:O<'OF\=1_X[BGK\,=$;/G1S76>OVB9Y/YFNLI<5/M)=!<D
M>IST'P^\/6^-FDVV1W,8)K0C\/:9"NU+&%1[(*T..Y _&F-<11Y+2*OU(HYI
MOJ#C&VR/,?''@/2+3Q9X5\0FR0M9ZK"YC&55B3L!('4C<",^E=_XX^-G@?X>
M:W!I7B+Q':Z=J$XW"%@S%5)P&?:#L!]6Q7*>.-6AUN\L-%LG$]QYZ7,VS_EC
M#&0[NWH %/XFL?\ 9S\(Z;XU\#Z]XQ\0V$&J7_C*^N);A[J,.?LH<QQQ#/10
M >E=?*I4^>KLNB\S"%2<:KIT$KRUUVT/=+>XBN[>.>"5)H)5#QR1L&5U(R""
M.H(J2O$_V>9[CP9K7C#X77L\DX\-W"W.E22G+-83?,BY_P!@Y%>V5QU:?LYN
M-[H];#UG6IJ35GU]4%%%%8G2%%5]0U"UTJTDNKVXCM;>,9:64X4?_7]JJ:/K
M$NL-)*MA/:V. 89KG"/-ZD1]0/0G!.>E.SW%S).P_6->L-"C5KVX6-Y#B.%0
M7DD/HJ#))_"K-K,U[8I,8IK1I4SY<P"R1Y]1S@TD>G6L>H27RVT0O9%"-<[?
MG*CH,]A["K%/07O==C(TWPKIVFW'VKRVO+\_>O;UO.F/T)^Z/9<5KT44AI*.
MP4444B@HHHH$%%%% !1110!#>6=OJ%K);W4$=U;R##PS('1AZ$'@U!8:)INE
M_P#'EI]I:?\ 7&!%/Z"KM*,9&>157:T3%9/5H0L9%*GY@1@J>1^7>O#/B-H,
M_P )/%%IXS\,Q"+3[AQ#?V*\1')[CH%;G']UL>IKIKSPK\4&U"9[;QK8?9F=
MC&DEEC:I.0,>P]ZCU?P'\0?$.B76FZAXOTFXM[A-DD?]EX##C^+/'3J.E=U%
M1IR3<U9[K7_(QE>2TBSOO#?B*R\5:+:ZK82>9:W"Y&[[R,/O*WH0>#6F.H_.
MOF#2=8\4_!'7)HY[*0VK-^_MW#-;W '21' X;W_,5Z+_ ,-':)=:>[6>GWSZ
MB5^6WD50@;ME\\C/M55<%/FO3UB]@C55O>T9#I<BWGC3Q+<+]UKYUS_N@+_2
MNDNK6*\MY()D$D,BE64CJ*\S\+>)K;18"UW<)YTC-)(S'!9F)+'\S76VWCS2
M;A@HNHP3QC<!734IS35NAFFFO4Y[4O ^H6<S"T47MN3\IWA7'LV?YUT?A/PV
MVBQR7%R5:[E&#M.0B_W0>^>];,.H6]PNY)%/XUB:YK5S)>6VF:8@FO[J3RHE
M)P/4DGL ,DU3JU)KDD)147=$7CR;=HMQ%&?G*$<'VKTKPCJMCK7ANPN=,D26
MU$*Q@)_RS*@ J1V((Z&N&E^#=U?V_P#IWB67SFZB"W7RP?;.2:YN3X'>+?#=
MU)=^&O$T:3.<LOS0%_J/F4_E6$E1JP4.>S1<>:+YK'N>1ZT5X!9?&+QCX&UP
M:=XMM/MB#EU,82;9_?C=?ED'^>*]TTG5;/7--M]1T^9;FSN$#Q2+W'I_];M7
M'6H3HV<MGU1M&HI%NBBBN4T"BE"YK#U7QQX=T.0QWVN6%K(/X'G7/Y"K4>;2
M*^X6AL2PI-&\<B+)$ZE720 JRGJ".XKRW5OV?]/74'OO#6LWWAB=SN,=LQ,8
M/L,@@>W-=_HGB[1/$K.-*U6TU!D&66"4,P'J1UQ6M6L:E2BVD[$N*EJ>02^&
M?BUX=&=/\2V>OPKR([M0&/M\P_K2Q>/?BE:KLN_ L%VXZR1,0#^3D5Z]16OU
MCF7OP3_#\B?9];GD+>/_ (HWC".V\!PV[?WIG.!_WTP%/D\ ^./B"J1>,M;A
MTO2"<OI>D@!I?9V]/SKUO]:/7/-+ZQ;X(I"]GW9F^'_#NF^%=+BT_2;..RM4
MYV(.6/<L>K$^IK2HHKD;;=V]37;1"KUZ9]O6O'/A#;IX?^(OCWPRR@6GFBXC
MC(XV$X/'IM<#\*]B_6O&_&&I+\,_C-!XFO8I/[#U:R%I/<1H6\N1<#D#Z*?<
M9KKP_O*5-;M:>J,I[IG)?#_0?"?_  E6O>#O%&EP23_;'6RNIF*G@X\K.>"5
MP5]<UW__  S9X-6X\S9J*J#_ *D7)P/;IG%6/%7PW\+?%R$ZQIU^B7[*H^WV
M+AU;'3S$[D>O!'X5SMK!\7_!*_8X([7Q+:+\L4TK!R!VY+*WYY^M=TJDZCO"
M?*^J9DER[JZ/5O#OA+1_"5MY.D:=#8J>&9%R[_[S'D_G6M7B?V[XSZQ<QP_9
M;?1D9AOF5(0J+GDYW,?PKVM054 G) P3C&:\ZM3G!KGDFWV=S>$DUH<+\7OB
M[IOPCT.VNKFTN-5U2]D,.GZ39+NFN7 R<<<*!U/O7BF@_MFZ]#J0?Q?\-M0T
M30=P\W4(4E/V53@;GWJ 1ZUE?MW:7KVE:QX*\:Z6\T=MI>Z'[1#G_1I]X=&/
MH#C'X8KC/VC/VJI/C1\._"OA?0XY1=ZA&DVL00J27G!VK"H'WE+?-_WS[U\O
MB<5.%647*UMEW/U[)<@PV*P>'G[%5%5YN>3;7L[>FFW?=GW19W<&H6D%W:RK
M/;3QK+%*A^5U89!'L1BJ6L^&=-UZ,B\ME>3'$R#;(/HPK$^$/AZ^\)_"WPKH
M^I9%_9Z?'%.I.2K8SM_#./PKKJ]ATX8BFE5C=-;'YC6?U7$3C1G\+:375)GE
M6J>%]8\#71U'2[B22V7K-&/F ])$Z,/>L;[9]OO);E;=;=)OG98SE _\17T!
MZU[=7F'B_3;73?$GEV:")9H1+)&OW0VXC(';.*^"SC*_JM+GHR]QOX?/R/J\
MLS+ZQ/EJQ]^V_EYF_P"'_$%IX=\#V$]V^&8,(X4.7D.X\ ?UKDA_:OQ&UO<N
M(HHN W)CMD_]F8U3M]'DU34[>QM<M-)D!F.1$G\1]AWKUW2-)MM#T^*SM4VQ
MIU)ZLW=C[FML)"MG$8TZGNT8)+_$S+%2I97*4Z>M66OHC/TCP7I.D1*!;+=3
MX^:>X4.Q/MG@?A6U'%'"NV-%C7T10!^E.HK[:GAZ5%*,()6/DZE:K5;<Y-AT
MHHHKH, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W=)_P"/!/Q_G6%6
M[I/_ !X)^/\ .LJFQI#<O4445SFX5BZW_KHO]W^M;58NM_ZZ+_=_K5T]R);&
M=11174<X4444 %%%% !1110 4444 %%%% !7@/[0_AOP=HUMIT.G>!-)U;QU
MXBNOLFF;8%C<28R\Q(Q]P<Y]37OU?.OQR\?:%X#_ &B/ASJNM7H^R6-A>I+!
M;J9IHI'&$/EKEN<@"NW!J3JVC?J].IY>8RA&AS3MNEKTN=OX3U+3_$WA,Z=>
MX8B,VMU;2G#*P&'4^A!']:S[72?$WAM3;:?JVGZC8+Q$]Z[1RJO8-@$-CUXK
MBO$OQ,T'XC:G$-%\%>(]-U*_;R(O$%U;O8P],Y89R[  X!'I63\7-/B^%VD>
M'$@CCUC5-7O/LGF:UJ$D<$8"%B[,&&!G'MS75"C*4N5Z-]#R*E>$(N<7=1ZH
M]+FOO$B*6NO$.AV0_P!E7?'YD5FW6M+PMY\0K:(]UM;9/ZL:A^$7@ZT\0>&F
MOM<TWP[?W$D[>2^B3M<P>6 ."Q)^8'/Z5S/B7QMH_P ,_C__ &1K\NFZ1X1E
MT47,:SVJ*%N-V/O ;LG!XJHT^:<HK5K70F57EIQG+9]S>;7- DDVMXNUF^;^
M[;* #_WRE8.OQQZP\4.FV?B8VTC@7&H22.#''_$45B-S=ABLSP/KMM\9_B1\
M1M!T[Q1?CPVT5K<Z;<Z6_DM" PWK&<9 )R#6=\*_A7IVK?&+QSI&M:IKFI_\
M(U=6TVGM/J4O*GY@9 " W..U="IQI\SF]8I/[SE]M.HX\BTDVK^A[]X<_P"$
M3C\!^((O#,/V>2*PF2Z6Y0K=Y\IL-*6^8_7IZ51_99_Y-]\&?]>K_C^^?FN=
M^+FDZTMU:_\ "*-:VNMZN'THR765B\N92&+ ==N"1[UZI\.?!L/P]\"Z%X;A
ME\]-,M4@,V,>8PY9L>Y)/XUY=2WL79[NY[V'YI8A:645;YL\Z\0J-#_:W\(W
M48VKKWAZZLYL=&:)PRY^@S7M%>,_$P[_ -I#X/HG#B+46;_=\O'\Z]FJ:VL:
M;\OU9TX32=9?WOT05AWWB<-J#:;I5N=4U",@3;&VPVP/>1^Q_P!D9)J[H^JR
MZHLTIL9K.W5]L#7 VO,!U;9U49Z9Y/6KD<,<"E8HUB5F+$(H7)/4G'?WKFT6
MYVN\EH+)#'+M$D:2!6#+O4'!'0\]_>G'+=3FBBI+MK<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** $P,8I?UHHH /O#:<$'^]TKYK\27%Q\7/B>UEH,42
M6EN#!'<*@"K$#^\F;'7+# !ZX'K7<_&WXE'2[9O"^BLT^MWP\F4P<M"K<!!_
MTT;ICL#FNG^%/P]B^'WAM8'"MJESB2\E7UQQ&#_=4?F<FO4H_P"RP]L_B>R_
M4YY?O)<JV+OA?X;Z!X3M42VL8[JYQ^\O+I!)+(W<Y/0>PK7O?#NE:E&8[K2[
M.=",8>W3IZ9QFM"BO/<YR=V]3?E5K'CWC;P+=^#(9-5T$RW&DH,W%BQ+O .[
M(>I7U7M4'P5D'B#Q5JNIN?,6SMECB/7#2')(_ "O:-HD^5AE6^4^X->$_ &\
MBT?QCXGT1FVM(S&$>OE2,I4?12#]!7I4ZDJN'J)[K_,P<5&:/=J.G3BBBO).
MDP/&W@G3O'>BO87Z;9%^:WND'[R!_P"\/;U'>O$?!?B[4O@MXFO/#^NPR2Z8
M[^8PA!.PGI/$.ZMW7KFOHVN)^*GP_3QUH)^SHJZS: R6<G3=ZQD^C?SQ7?AZ
MT5^ZJ_"_P\S"I'[4=S2M/B1X4OH%FA\0Z>489^>8*1[$'FL?7_C=X3T2%_)U
M#^UK@#(@L%+G\6^ZOXFO(_A[\*['XC:'+<)K$UAJUI*T-Y:7-LD@1@3@CD$
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MPGX^LM6T;6&M]'CD+RVK[O-9<$>62.'7GJW/%>N\9R***UJ5956G/=$QBH;
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M7*S;Y5H=*O;4****@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O(OB(_F>)]0_P!F%%_\=KUWL:\;\;2?:/$NLX/&\1_DH%?)<2R_V6,>\E^I
M]+D"_P!HE+R?Z'K&BJ4T>P4]1;I_Z"*N5%:+Y=G;I_=C4?\ CHJ6OJ**M2BO
M)'S]5WJ2?FPHHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK*C*Z^:[D3BI*QB>"_%=KXV\-VFKV?RK.N)(LY,<@X9#]#^>:W*Y#P'\/(O
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MY_G4WD20JRG4E12,?=4536QNI% ,<@]?,G//Y5/#ITT9.+:TR1@L26/ZU7R
M'ALL S7AF_WI/Z"I+/RC-MTYMC]7+ [<?C35TF1CN>5(SZ0Q@?J:E6+[%('C
MN'ED^[L<@Y]J4KVV!;E@+)#<D3$2/(/E8=..U357\R62X5KE/*;&$7J/SJQ5
M0V)EN%%%%62%%%% !1110 5A:AH]_:WTFI:-<@SR$&XT^Z<F"XQQD'K$^.XX
M/<5NT4Q./,(FYU7*[6(R5SG'M[TOOT-5M2TZ/5K.2UE>6)'Q^\@D,;H0<A@P
MZ$&J>CPZO9R26]_<0ZA:JH,-[CRYCS]V1<8)_P!H8^E.UQ<W*TCRKXL6VM>)
M/%R6ESHDFE:/I,+7]MXC@:2::3RP))8X@C!87(7:#(#G)Q71_#CQ-XQ\1S:7
MJ.IOHUWH^JV9NV@L#MFTW< 8D8Y/FA@<%L#!![5Z./F##.1_$/KZC_&L?P_X
M-T'PK+>2Z+H]GI<EVV^X>UC"F0C.,_F>!QR:W=1.'*T<?U>2J^T4K]S8HHHK
MG.\****0@HHHH *51N( [TE.CXD7ZB@#F=-U+1?BEX7O$-N;K2Y99;.6*X7:
M248J2/3D9!KP;4-'OOA#\2O#\^L3SZCH5E)ML;B0;MMN<Y7_ 'DW9QZ#(]*]
M1^ R?8]$\1V)^_::W<QD>@.#_C7=^(/#VG^*=)FTW4[=;FTEZJW!4]F4]01Z
MBO2C56&J2A]E_P!71@X\Z4NI;L[R#4+6*ZM9DN;:9=\<T;!E<>H([5-7SWJ>
M@>,/@5=27NBW;:KX9+;GCE4LB#_IH@Y4_P"VO![BO6OA[\1-.^(>EM<6@-O=
MPX%Q9R-EHR>A!_B4]FK&IAW&/M(.\?ZW*C.^CW)_'G@>Q\?:+]AO&:&6-_-M
M[J,?/"^,9]P1P1W%>(6\OBOX ZSNN8/MFA7$F)/))-O-[K_SSDQZ]>E?2507
MUC;:G9S6EY#'<VLR[)(95RK*>N1_G%%'$.FG3EK'L$J?,^9:,S++Q)8>(O"D
MFL:?/YUG+;2.&Q@J0IRI'9AW%<7^SE8?8_A=:3$;3=7$LQSW&0H/Z5YU<ZE-
M\&-9\9>&SYTVDZA9/)9#EBKNI$;'\RI/^R#7M7PKTX:5\-_#EMC!6R1C]6^;
M^M;UJ?L:3L])-,F,N:6NZ-K5_#^E^((UCU/3K:_1?NBXB#E?H3T_"L"ZTOPA
M\,K&;6QI=EIODKM$L,0\UR?^6:$\Y/I74W5U#8VLUS<RK!;0H9))&. J@9)]
MJ^7_ !9XNU'XJ>*A]DM+BZ@C)6PT^%<E4_YZ-V!;KD]!Q486C.N[-VBM]=!U
M)*&J6IUOPKTJ\^)7Q&U'QGJL6(+1\6\/51)C")]$7GZM7O+*5!9AA>NYN*\!
MT+X#>);F,R7>M_\ "/(YW_9[25W?=ZMM8*#^=6]3^ /B2:$QQ^,&OXCQY-Z\
MP!^OS$8_"NBO&C5J:5$DM$K=#.FY16QI?%;XRBQC?1/"\PN]3F/DRWEO\XA)
M.-D>/O2'I[?6KGP]^%ND_#?2?[?\2/ VJ;?-EN+M@T=KGG"D]7]6ZD]*X6'X
M,^.="O[6ZTZWL/M%HXDAEBN5PI'3Y67'>M=/@SXR\:7T<_C'7MENASY:2^:_
MT10 BGWYK64:,(<M.HDNO=DWDY7E$H>)/$VN?'?Q ="T!9+;P_"P,LLH(5AG
M_62_^RQ]^IKVSP?X1L/!.A0Z7IZGRT^:29_ORR'[SM[^W85/X<\-:;X3TJ/3
MM+M5M;9.<#EG;NS-U+'U-:=>=6KJ:5."M%?CYLZ(PL^9[A1117&:!1110 44
M44 %%%% !1110 4444P"BBBD!G>(?$6E^$](N-5UF_ATW3H!F2XN&VJ/\3Z
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M^H!YK>IR5*<:5_A)C=2<K;F5\:/&TOBJ^M_"&A2B6&2X2*ZN$.5DD+ +$#W
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M8XK<E7<]R<$<#N3TKU'Q#J(TW3)IF/"J3^E:?PQ\(C2=/&LWB!M8U! [,?\
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MO)?!MWJ4L/EZ+I=WJ83Y6D@3*;N^6.!FNP_M/Q+IZ%[[PYJ$<2C)DC02 ?\
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MM.YL$]Q701_#7XER?-<>/_);TC+M_05D?$K1AX+\06GQ \)RQ20M-B]AA8%
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ME]HF3/\ O"K<5]#-RLBL?7->+' T>>_/HNAZ<L354=8Z]R?K69>-)I=];:C
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M<^&?!&EZ?>#;=HA>1,YV%CG;^&:Z:OL,-.=2C"=16DTKG9%MQ384449"@DG
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M?'BK^K/:'ECB&7D1!_M, *R[SQ9HMB3YVIVZD?PJ^X_I7EB^$-8N#QH]P?\
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MI ,_1ATKVUB<XIVG*E&4?)GD^PRN?N1J2B_,M_$_0D:S35XH\30D)/Q]^,\
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M27S?L]WJ;G_EI(#M_ G 'X5Z'X=\ V.DJL]V%O[[KO<?(G^Z/ZFNI_A Z =
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M98A_WV>]FNBH+^X@HHHKZ0\)$%]8P:E:2VMS&)8)1M9#W_\ KUYEI4TOP_\
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M"NTG_3.[!RH0JJ6(5XGEEK;WNOZ@R0"2_OY>9)7/3W8]%'M7JGA?PO!X;M"
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M8KHZ]!0H9EA8^T5XR1Q2E5P&(DJ;M),\9M[K6/!.IM$/]%ESE[=_FAF'J/\
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M_P#'@GX_SK"K=TG_ (\$_'^=95-C2&Y>HHHKG-PK%UO_ %T7^[_6MJL76_\
M71?[O]:NGN1+8SJ***ZCG"BBB@ HMH9]0F:.WPJJ</*PR%/H/4U'<2-'"Y3[
MW1?J>E=-8V26-K'"@P%'/N>YK*<K:&D8WU913PW#M'FSSRMZ[]H_(4[_ (1N
MT_O3?]_36K16%V;61E?\(W:?WIO^_IH_X1NT_O3?]_36K11=A9&5_P (W:?W
MIO\ OZ:/^$;M/[TW_?TUJT47861E?\(W:?WIO^_IH_X1NT_O3?\ ?TUJT478
M61E?\(W:?WIO^_IH_P"$;M/[TW_?TUJT47861E?\(W:?WIO^_IH_X1NT_O3?
M]_36K11=A8RO^$;M.N9O^_IH_P"$;M/[TW_?TUJT4786,C_A&++KF8G_ *ZF
ME7PS9KT,W_?PUK4478&2/#5H/XIO^_II?^$;M.?FF_[^FM6BB["R,K_A&[3^
M]-_W]-'_  C=I_>F_P"_IK5HHNPLC*_X1NT_O3?]_31_PC=I_>F_[^FM6BB[
M"R,K_A&[3^]-_P!_31_PC=I_>F_[^FM6BB["R,K_ (1NT_O3?]_31_PC=I_>
MF_[^FM6BB["R,K_A&[3^]-_W]-'_  C=I_>F_P"_IK5HHNPLC*_X1NT_O3?]
M_31_PC=I_>F_[^FM6BB["R,K_A&[3^]-_P!_31_PC=I_>F_[^FM6BB["R,K_
M (1NT_O3?]_31_PC=I_>F_[^FM6BB["R,K_A&[3^]-_W]-'_  C=I_>F_P"_
MIK5HHNPLC*_X1NT_O3?]_31_PC=I_>F_[^FM6BB["R,K_A&[3^]-_P!_31_P
MC=I_>F_[^FM6BB["R,K_ (1NT_O3?]_31_PC=I_>F_[^FM6BB["R,K_A&[3^
M]-_W]-'_  C=I_>F_P"_IK5HHNPLC*_X1NT_O3?]_31_PC=I_>F_[^FM6BB[
M"R,K_A&[3^]/_P!_34%QX?:-<VMPV[_GG-RI_'J*W*0C-/F861R2N=SHZ&.5
M#AT/;_$4^M#Q%;B-K>Z'W@WE/[J?_KUGUT1ES(PDK,****L@****!A1113$(
MZK)&T;*KQL,%& (/U'>O,/%7[/GAW7IGGL7ET6=R69(%#PDGOL;I^!%>H45K
M3K5*3O!V)<5+='@J?L[^(M+<G2_%,,([;3-"?QVMBKL7PC^(FW:?')B3VN)F
MKVVBNGZ[6>]ON1'LHGC5O^SM)J,Z2>)/%5]JR Y,,9;!]MSDX_ 5ZGX?\.:9
MX5T];'2;*.QMAU6,<L?5B>6/N:TJ*PJ5ZE723*C!1V"BBBN<L*\O^/7A[4+S
M1=,UW2=_V_1;CSP8ERXC/5@.^T@$CTS7J%%:TZCI24["E'F5CS[P)\6-!^(=
MC#'?/:VVKJ );2Z*X9O[T9;AE/7'45W]O"ENF($2-.PC4*/TKA_%7P5\*^+I
MGGFL6LKM^3/8MY98GN5QM/Y9KF[7]G:Q5FC3Q9K)MUX,$,H&/8X/]*Z9?5YO
M237EN1&-2VU_,]*UKQ1H_AV(RZIJ=I8CK^^E 8_1<Y/Y5YQJW[1NB+.UKH6F
MWVO7?W5\M"BD_3!8C\*UM+^ /@O3I!)+83:E+UWWUPSY_ 8%=QI>AZ=H<(BT
MZPMK! /NV\*I_(5,70ALG+\ ]]J[LCQ_PSJ_B+5/B-8W_B/38](GF=!#;)G(
MC*E06R>M>VUYKXZD^R_$+19N@Q"<_20C^M>EL,,?K7R^7SOB<4K6]_;Y'O8]
M?N,/+^[^HE%%%>X>*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %;ND_\ '@GX_P ZPJW=)_X\$_'^=95-C2&Y>HHHKG-PK%UO_71?[O\
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MJ***ZCG"BBB@"*Z_U:?[Z_\ H0KL*X^Z_P!6G^^O_H0KL*YZFYO#8****R-
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MZUM5BZW_ *Z+_=_K5T]R);&=11174<X4444 177^K3_?7_T(5V%<?=?ZM/\
M?7_T(5V%<]3<WAL%%%%9&@4444 %%%% !12;J-U "T4F:-U "T4FX44 +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &5XD_P"0;_VT3_T(5DUK>)/^0;_V
MT3_T(5DUT4MF8U HHHK4R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****8&3XNA\[PKJR=S;N1^ S7/?":0_V/?1GG9<9_-%-=3KR[M!U$?\
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M0['*G(4AEZ@\FOI?P;:W]CX3T>WU2&WM]1BM(DN(;//DHX4 JF?X0>E;%+0
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MM+7GR:V2/9@I;MW'4445)H%%%% !124BNK9PP/T-(!U%%%, HHI,T +1124
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M?P751_TT\0P#^0H ]THKPO\ X6E\:O\ HC=M_P"%%#_\31_PM+XU?]$;MO\
MPHH?_B: /=*2O"S\6?C);?O+CX+K+"O+I:^((&D(_P!D$ 9IJ_$KXU^*IGDT
M#X7Z?X?LXP%;_A*]4"S2-WVI"&X]R: /=J*\-_X2W]H&WYD^'_A&Z]H-<D4_
M^/1TT_$CXY0_ZWX1:7-_UP\1Q_U2@#W6BO-?AQXV^(?B+6YK;Q7\/XO"VG+"
M72\CU:.Y+29&$V*,],\^U>E4 %%%% &5XD_Y!O\ VT3_ -"%9-:WB3_D&_\
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MZLKH [D=3UQCMUS1S(5CVVBN9^'/C2;Q]X6AUFXT#4O#4DDCQ_V?JJA9U"G
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M0 F**6B@!,"BEHH 2BEHH 3&:,4M% "44M% ";:,"EHH 3%%+10 FT"EHHH
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M^>T?_?0H^U0_\]H_^^A0!+147VJ'_GM'_P!]"C[5#_SVC_[Z% $M%1?:H?\
MGM'_ -]"C[5#_P ]H_\ OH4 2T5%]JA_Y[1_]]"C[5#_ ,]H_P#OH4 2T5%]
MJA_Y[1_]]"C[5#_SVC_[Z% $M%1?:H?^>T?_ 'T*/M4/_/:/_OH4 2T5%]JA
M_P">T?\ WT*/M4/_ #VC_P"^A0!+147VJ'_GM'_WT*/M4/\ SVC_ .^A0!+1
M47VJ'_GM'_WT*/M4/_/:/_OH4 2T5%]JA_Y[1_\ ?0H^U0_\]H_^^A0!+147
MVJ'_ )[1_P#?0H^U0_\ /:/_ +Z% $M%1?:H?^>T?_?0H^U0_P#/:/\ [Z%
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M'_/&/_OD5(D:QC"*J?[HQ3J*+!=A1110(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****8!1110 4444@"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** #O6[I/_ !X1_C_.L*MW2?\ CP3\?YUE4V-(
M;EZBBBN<W"L76_\ 71?[O]:VJQ=;_P!=%_N_UJZ>Y$MC.HHHKJ.<**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOR%'M(AR,R**U_[#7_GJWY"C^PU_YZM^0H]I$.1F116O_8:_\]6_(4?V&O\
MSU;\A1[2(<C,BBM?^PU_YZM^0H_L-?\ GJWY"CVD0Y&9%%:_]AK_ ,]6_(4?
MV&O_ #U;\A1[2(<C,BBM?^PU_P">K?D*/[#7_GJWY"CVD0Y&9%%:_P#8:_\
M/5OR%']AK_SU;\A1[2(<C,BBM?\ L-?^>K?D*/[#7_GJWY"CVD0Y&9%%:_\
M8:_\]6_(4?V&O_/5OR%'M(AR,R**U_[#7_GJWY"C^PU_YZM^0H]I$.1F116O
M_8:_\]6_(4?V&O\ SU;\A1[2(<C,BBM?^PU_YZM^0H_L-?\ GJWY"CVD0Y&9
M%%:_]AK_ ,]6_(4?V&O_ #U;\A1[2(<C,BBM?^PU_P">K?D*/[#7_GJWY"CV
MD0Y&9%%:_P#8:_\ /5OR%']AK_SU;\A1[2(<C,BBM?\ L-?^>K?D*/[#7_GJ
MWY"CVD0Y&9%%:_\ 8:_\]6_(4?V&O_/5OR%'M(AR,R**U_[#7_GJWY"C^PU_
MYZM^0H]I$.1F116O_8:_\]6_(4?V&O\ SU;\A1[2(<C,BBM?^PU_YZM^0H_L
M-?\ GJWY"CVD0Y&9%%:_]AK_ ,]6_(4?V&O_ #U;\A1[2(<C,BBM?^PU_P">
MK?D*/[#7_GJWY"CVD0Y&9%%:_P#8:_\ /5OR%']AK_SU;\A1[2(<C,BBM?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img8619836_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BF[J-U #J*;OHWB@!U%-WBC>* '44W>*-
MXH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH
M =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =
M13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13
M=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=X
MHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHW
MB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@
M!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U
M%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-
MWBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WB
MC>* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>
M* '44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>*
M'44W>*-XH =13=XHWB@!U%-WBC>* '44W>*-XH =13=XHWB@!U%-WBC>* '4
M4W>*-U #J*;NI=U %=I*:9O>J$UUM[U6:^'K0!K^?[TGG#UK%^WCUH_M >M
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M6+_: ]:/[0'K0!M></6CSAZUB_V@/6C^T!ZT ;7G#UH\X>M8O]H#UH_M >M
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M6+_: ]:/[0'K0!M></6CSAZUB_V@/6C^T!ZT ;7G#UH\X>M8O]H#UH_M >M
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M6+_: ]:/[0'K0!M></6CSAZUB_V@/6C^T!ZT ;7G#UH\X>M8O]H#UH_M >M
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M6+_: ]:/[0'K0!M></6CSAZUB_V@/6C^T!ZT ;7G#UH\X>M8O]H#UH_M >M
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MG_/]_P"0O_LJZ2B@#F_^$1D_Y_O_ "%_]E1_PB,G_/\ ?^0O_LJZ2B@#F_\
MA$9/^?[_ ,A?_94?\(C)_P _W_D+_P"RKI** .;_ .$1D_Y_O_(7_P!E1_PB
M,G_/]_Y"_P#LJZ2B@#F_^$1D_P"?[_R%_P#94?\ "(R?\_W_ )"_^RKI** .
M;_X1&3_G^_\ (7_V5'_"(R?\_P!_Y"_^RKI** .;_P"$1D_Y_O\ R%_]E1_P
MB,G_ #_?^0O_ +*NDHH YO\ X1&3_G^_\A?_ &5'_"(R?\_W_D+_ .RKI**
M.;_X1&3_ )_O_(7_ -E1_P (C)_S_?\ D+_[*NDHH YO_A$9/^?[_P A?_94
M?\(C)_S_ '_D+_[*NDHH YO_ (1&3_G^_P#(7_V5'_"(R?\ /]_Y"_\ LJZ2
MB@#F_P#A$9/^?[_R%_\ 94?\(C)_S_?^0O\ [*NDHH YO_A$9/\ G^_\A?\
MV5'_  B,G_/]_P"0O_LJZ2B@#F_^$1D_Y_O_ "%_]E1_PB,G_/\ ?^0O_LJZ
M2B@#F_\ A$9/^?[_ ,A?_94?\(C)_P _W_D+_P"RKI** .;_ .$1D_Y_O_(7
M_P!E1_PB,G_/]_Y"_P#LJZ2B@#F_^$1D_P"?[_R%_P#94?\ "(R?\_W_ )"_
M^RKI** .;_X1&3_G^_\ (7_V5'_"(R?\_P!_Y"_^RKI** .;_P"$1D_Y_O\
MR%_]E1_PB,G_ #_?^0O_ +*NDHH YO\ X1&3_G^_\A?_ &5'_"(R?\_W_D+_
M .RKI** .;_X1&3_ )_O_(7_ -E1_P (C)_S_?\ D+_[*NDHH YO_A$9/^?[
M_P A?_94?\(C)_S_ '_D+_[*NDHH YO_ (1&3_G^_P#(7_V5'_"(R?\ /]_Y
M"_\ LJZ2B@#F_P#A$9/^?[_R%_\ 94?\(C)_S_?^0O\ [*NDHH YO_A$9/\
MG^_\A?\ V5'_  B,G_/]_P"0O_LJZ2B@#F_^$1D_Y_O_ "%_]E1_PB,G_/\
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M7_V5'_"(R?\ /]_Y"_\ LJZ2B@#F_P#A$9/^?[_R%_\ 94?\(C)_S_?^0O\
M[*NDHH YO_A$9/\ G^_\A?\ V5'_  B,G_/]_P"0O_LJZ2B@#F_^$1D_Y_O_
M "%_]E1_PB,G_/\ ?^0O_LJZ2B@#F_\ A$9/^?[_ ,A?_94?\(C)_P _W_D+
M_P"RKI** .;_ .$1D_Y_O_(7_P!E2CPDX_Y??_(7_P!E71T4 8">%W7_ )?,
M_P#;+_Z]6(]!:/\ Y><_\ _^O6O10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@!BO>32?CCX7\'>"X=7\0^.CXIL;S5;BTM=:T_1IFA9O,.RW'V='4E00@?\
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MGSX>_#-['X^>,FL;NWG\"I=6_B**SA4%8]6FA9'^8'! 3,NW'62(\8&?H2D
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M\,6"KD!L*IQ]XJ$!FZY\='\#_#/3]<LO$4/Q#_M#Q*NF)JEKIC^2D4D^"B)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KY*^(7@UYM:\1ZK\-D^('@OXA7&IR V5C8W:Z-
MJ<RS;?M,SRQ"WVL@W;MX')X<_>^M:* /DWQ3\/\ Q5K_ ,:-97Q#<W%@QO\
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M P:;\6/B'IVB^%KFT\/>)/!T9BBATN6.QN;W,V?,)01K-M*Y#X;)]2:^E:*
M/CSPOHI\,^'_ (!II_A;Q+ITUA=JWB&UM-"OXHED%OL::XB6(([^;L_>D%B
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7?C[X.TW6?VGOA>/\
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M: +E%4_[9T__ )_K;_O\O^-']LZ?_P _UM_W^7_&@"Y15/\ MG3_ /G^MO\
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M^7_&@"Y15/\ MG3_ /G^MO\ O\O^-']LZ?\ \_UM_P!_E_QH N453_MG3_\
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M_P"- %RBJ?\ ;.G_ //];?\ ?Y?\:/[9T_\ Y_K;_O\ +_C0!<HJG_;.G_\
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M?\:/[9T__G^MO^_R_P"- %RBJ?\ ;.G_ //];?\ ?Y?\:/[9T_\ Y_K;_O\
M+_C0!<HJG_;.G_\ /];?]_E_QI\.IV=Q((XKN"61NBI(I)_#- %FH+BQMKM@
M9[>*8C@&1 V/SJ>L/7+B6&[0)*Z#8#A6([FJ2N[$2ERJYH?V-I__ #XVW_?E
M?\*/[&T__GQMO^_*_P"%<]]NN/\ GO+_ -]FC[=<?\]Y?^^S5\C,?;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
MOLT<C#VZ['0_V-I__/C;?]^5_P */[&T_P#Y\;;_ +\K_A7/?;KC_GO+_P!]
MFC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\ "C^QM/\ ^?&V_P"_*_X5
MSWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8VG_\^-M_WY7_  H_L;3_
M /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\ OLT<C#VZ['0_V-I__/C;
M?]^5_P */[&T_P#Y\;;_ +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]
MNNQT/]C:?_SXVW_?E?\ "C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_
M #WE_P"^S1R,/;KL=#_8VG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^
M>\O_ 'V:/MUQ_P ]Y?\ OLT<C#VZ['0_V-I__/C;?]^5_P */[&T_P#Y\;;_
M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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M +\K_A7/?;KC_GO+_P!]FC[=<?\ />7_ +[-'(P]NNQT/]C:?_SXVW_?E?\
M"C^QM/\ ^?&V_P"_*_X5SWVZX_Y[R_\ ?9H^W7'_ #WE_P"^S1R,/;KL=#_8
MVG_\^-M_WY7_  H_L;3_ /GQMO\ ORO^%<]]NN/^>\O_ 'V:/MUQ_P ]Y?\
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MK)NUCHJY_P 0?\?B?]<Q_,UT%<_X@_X_$_ZYC^9I0W'6^ S****Z#A"BBB@
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M=-M+AUV/-$DA4C&"5!QBK--CC6&-41=J* JJ.P':G59@%%%% !1110 4444
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MREN[!1113$%%%% !1110 4444 %%%% !7(>-/'.H>#+VV<^%=4UK173,]_I
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M_P!I2?ZBF;9_^>D?_?L__%5-12'<AVS_ //2/_OV?_BJ-L__ #TC_P"_9_\
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MMG_YZ1_]^S_\51MG_P">D?\ W[/_ ,54U%!-R';/_P ](_\ OV?_ (JC;/\
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M\9?&[PCX2\/ZYJ"Z]I.H76DQDRZ?#J,/F^8>%C8;B5)/'(SUX/2@-3M]L_\
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M_P#Q5344!<AVS_\ /2/_ +]G_P"*HVS_ //2/_OV?_BJFHH"Y#MG_P">D?\
MW[/_ ,51MG_YZ1_]^S_\54U% 7(=L_\ STC_ ._9_P#BJ-L__/2/_OV?_BJF
MHH"Y#MG_ .>D?_?L_P#Q5&V?_GI'_P!^S_\ %5-10%R';/\ \](_^_9_^*HV
MS_\ /2/_ +]G_P"*J:B@+D.V?_GI'_W[/_Q5&V?_ )Z1_P#?L_\ Q5344!<A
MVS_\](_^_9_^*HVS_P#/2/\ []G_ .*J:B@+D.V?_GI'_P!^S_\ %4;9_P#G
MI'_W[/\ \54U% 7(=L__ #TC_P"_9_\ BJ-L_P#STC_[]G_XJIJ* N0[9_\
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MN)TF((+;K9G\@!AD86, 9XQ5+X_7WBG3OA[)-X4MK^ZNQ=P"\325#7GV3?\
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M 'P:/M2_W)/^^#0&NUCPM_AKX@\-ZCX6T_3-'N9;6&XU6ZGOM/EMQ;:<;WS
MB1K)*DC+$7!.U.0,@9.T7O@W\.=8T*\\/CQ!!K\5UX>L'LK=YWTMM.(8*KB$
MP(MP5.U6 E Z<Y/)]F^U+_<D_P"^#1]J7^Y)_P!\&C0+R[$U%0_:E_N2?]\&
MC[4O]R3_ +X-,BS)J*A^U+_<D_[X-'VI?[DG_?!H"S.6OO[2N/B1:1-X?N9]
M#.FS03:DTEN8=[LC!"AD\PC",#\A&67MDCCO"GP]\2>#/&#Z'9 2>!HK"[_L
MF_:8&;37F:,_92I.YT4J61NR_*3P*]:^U+_<D_[X-'VI?[DG_?!H*U['B7A/
MX?\ B.;2OAUH-_X>31)O!UU'--K2SPR17:)$\9$ 1O,S*6!?S$0 9^\<5WGP
MATW5-"\*OI.JZ3+IEQ:7ET5D,L4D5RLD\DBR1E&)P0X^^JMGM78_:E_N2?\
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MY)_WP: LR:BH?M2_W)/^^#1]J7^Y)_WP: LR:BH?M2_W)/\ O@T?:E_N2?\
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M_P :/^$1TG_GT_\ (C_XT>T#V'F8E%;?_"(Z3_SZ?^1'_P :/^$1TG_GT_\
M(C_XT>T#V'F8E%;?_"(Z3_SZ?^1'_P :/^$1TG_GT_\ (C_XT>T#V'F8E%;?
M_"(Z3_SZ?^1'_P :/^$1TG_GT_\ (C_XT>T#V'F8E%;?_"(Z3_SZ?^1'_P :
M/^$1TG_GT_\ (C_XT>T#V'F8E%;?_"(Z3_SZ?^1'_P :/^$1TG_GT_\ (C_X
MT>T#V'F8E%;?_"(Z3_SZ?^1'_P :/^$1TG_GT_\ (C_XT>T#V'F8E%;?_"(Z
M3_SZ?^1'_P :/^$1TG_GT_\ (C_XT>T#V'F<;XF\)Z9XNLX;;4XIG6&43PRV
MUS+;312 $!DEB974X)'!'!(IV@^&-.\-0NEC#)YD@42W%S/)<7$NW.WS)I&9
MWQD@;F.!TKL/^$1TG_GT_P#(C_XT?\(CI/\ SZ?^1'_QI<_D/V'F<!XZ^'FA
M_$C2_P"S?$$%U=Z?SOMH;^XMHY<X.)!%(H<9 (#9QVIR^ =*C\+?\(\LFJ#3
M/^PO=^>!G.T3^;YH7MMWXQQC'%=[_P (CI/_ #Z?^1'_ ,:/^$1TG_GT_P#(
MC_XT<_D'L7_,>=^#?AGH'P_T6;2=!AO;+39%*BW;4[J98@=V?*\R1O*R6)RF
MWGGJ!57PI\(?#/@G6KK5M(BU*"^NG,ER\VLWMPMPY&W?(DDS*[8Z,P)':O3O
M^$1TG_GT_P#(C_XT?\(CI/\ SZ?^1'_QHYUV#V+_ )CQ3QA^S+\-_'VOW.M^
M(- EU/4[@CS)Y=3NQP.@"B4!0.P  %:</P-\&VNFZ!I]M87MI9Z"SOIL5KJU
MY"+=F+%FRDH+,=[#+9.&(Z'%>L?\(CI/_/I_Y$?_ !H_X1'2?^?3_P B/_C1
MSKL/V+_F."\<_#_1/B1HYTGQ!;W%WIS-N>WAO9[99/0/Y3KO&<'#9&0#UK7T
MG2X-#TVVL+4S&WMT$<?VBXDGDP/621F9OJ2373?\(CI/_/I_Y$?_ !H_X1'2
M?^?3_P B/_C1S^0O8=+F)16W_P (CI/_ #Z?^1'_ ,:/^$1TG_GT_P#(C_XT
M_:"]AYF)16W_ ,(CI/\ SZ?^1'_QH_X1'2?^?3_R(_\ C1[0/8>9B5E:IX3T
M/6]2L=1U'1M/O]0L6W6EW=6L<DMN<@YC=@2IR >".E=A_P (CI/_ #Z?^1'_
M ,:/^$1TG_GT_P#(C_XT>T\A^P\SF+S1[#4+RSNKJQMKFZLG:2UGFB5W@8C:
M61B,J2#@D=JJ#P?H*^(/[>&B:<-<V[/[3^R1_:=N,8\W&[&..M=E_P (CI/_
M #Z?^1'_ ,:/^$1TG_GT_P#(C_XT>T\@]AYG)VOAW2;'5[S5;;2[.WU2\"K<
MWT5NBSSA1A0[@;F  &,GC%)J?AK2-:O+.ZU'2K*_NK)B]K-=6Z2/ QZE&8$J
M?<5UO_"(Z3_SZ?\ D1_\:/\ A$=)_P"?3_R(_P#C1S^0>P\S@)/AGX/FT6/1
MW\*:(^DQR&9+!M.A,"R'JXCV[0Q]<9J])X1T*:;2YGT73WFTL;;"1K6,M:#
M&(CC]WP /EQT%=C_ ,(CI/\ SZ?^1'_QH_X1'2?^?3_R(_\ C2Y_(/8ON<3I
MG@CPYHNIW6I:=H&EV&HW0(N+NULHXY9@3DAW506R?4U'8_#_ ,+Z7!J,-EX:
MTBTAU)2M['!81(MT#G(E 7YP<G[V>IKNO^$1TG_GT_\ (C_XT?\ "(Z3_P ^
MG_D1_P#&CG\@]B^YPG_"O/"NZT/_  C.CYM+=K2W/V"+]S"P(:)/E^5"&;*C
M@Y/K3)OAMX1N+.RM)?"VBRVEC@VL#Z="4M\$D>6I7"\LQXQU/K7??\(CI/\
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M^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\
M/I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H
M'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A
M$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_
M^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\
M/I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H
M'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A
M$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_
M^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\
M/I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H
M'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A
M$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_
M^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\
M/I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H
M'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A
M$=)_Y]/_ "(_^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_
M^-'_  B.D_\ /I_Y$?\ QH]H'L/,Q**V_P#A$=)_Y]/_ "(_^-'_  B.D_\
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MF8E%;?\ PB.D_P#/I_Y$?_&C_A$=)_Y]/_(C_P"-'M ]AYF)16W_ ,(CI/\
MSZ?^1'_QH_X1'2?^?3_R(_\ C1[0/8>9B5=T?_D)0_C_ .@FKW_"(Z3_ ,^G
M_D1_\:FL_#NG6%PD\%OLE7.&WL<9&.Y]Z3GH5&C9IW-*BBHY)XX<!Y%0GIN8
M"LCI)**A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?
M_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW
M_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1
M]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_
M +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\
M\]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9
M;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":
MBH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8
MH FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'
M_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_
M .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4
M?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\
M[[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV* )J*A^V6_
M_/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?_?8H FHJ'[9;
M_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\ WV*
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M^^Q1]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\
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M'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW_P">\?\
MWV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1]LM_^>\?
M_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_ +[%'VRW
M_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\ \]X_^^Q1
M]LM_^>\?_?8H FHJ'[9;_P#/>/\ [[%'VRW_ .>\?_?8H FHJ'[9;_\ />/_
M +[%'VRW_P">\?\ WV* )J*A^V6__/>/_OL4?;+?_GO'_P!]B@":BH?MEO\
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M86\B..-E(D1@=@(Y!SQ7H?B#7(O#^ERWDB-,^5CA@C^_-*Q"I&ONS$#T&<G
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MF?\ /G'^5'_"-Z9_SYQ_E6E10!F_\(WIG_/G'^5'_"-Z9_SYQ_E6E10!F_\
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M9R/1O@_XU\0^,;'61XATJ2REL;YH+6].F7.G)?P;05E6"XS)'U*D$GD9!P:
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M+0M(&A)7)V2'/*X^D-)U.+6M,M;Z&*XABN(Q(L=W;O;RJ#V>-P&4^Q -7**
M"BBB@ HHHH **** "BBB@ HHHH **** "O"?C%XB\GXS?#2:/1?$5]:Z#>WD
MVHW5AX?OKF&%9;-DC(>.%EDRS@'86QSG&*]VHH \;_:LO);SX)>(-%L-+UC5
MM4UBT,5I;:7I5S=DL'0G>8XV$?!_C*YP<9P:[.X^(D%CX-LM<MM!\1:G%--%
M;?8;?2)H[Q"SA"[02A'5%/)8C&T9&178T4 <'?\ C/3;/Q!JNEZCX4U9KZ<+
M )K719KNWU"':=@-PD9C4?,RE9F4*2>QR?+;GX<7EK\*?#OPFET2ZGGUB[GN
M7O8()/LGAZW-P]PI6=?E$L0*I&H;E@#]W@_1U% 'EG[/^IZA9^%6\(:SH5YI
M&K^&W:QENC8RQ6>HJK';=02L-K^9]YAG<&+9Z@GU.BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#J58!E(P0>AI:* /+_#
M_P *-?\ AVLMAX*\56NG^&VE:6+1];TM[];,LQ9DMY$N(66/))"MOQDXXXK=
MM?"7B*+QQI^M7'B2UN].M[*6TEL6TPK+(TCJY<2K,%4*40*#&QVY!9B=U=G1
M0!YUI/P=C\/_ !2U#Q9I.KS6&GZC;S?:M#2%3";R0Q[KM&)^1F$:[A@AB QY
MZONOA_XD\30)IWBKQ-I^J:&LL4SVNGZ.;2>Y,;AU665IY%*EE4GRTC)QP0#B
MO0J* .?\%QZ]_9]U<>(9E^UW5U)-#9H$Q9P$XCA+*/G8* 6;)^9F ) !KDE^
M$NJ^&=>UF_\ !?B.VT>RUJX:[OM&U?3#J%F;AP \L2K-"\9?&6&]E)R=HKTV
MB@#P>X_9A>Q\'WNB>'=:TG06U/6(-:U!X]!'D&2%HFBB@ACGC\J(&$94LY^=
ML$9KW&R6XCLX%NY8I[I442RPQF-'?'S%4+,5!.< L<>IZU/10 4444 %%%%
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M?[+60GED'GX'?\SZG/I-<K\4/'B_#+P/JGB632[K5X=/B,LEO:/&K!1U8EV
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M^-']D6G_ #R_\>/^-7** *?]D6G_ #R_\>/^-']D6G_/+_QX_P"-7** *?\
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MD6G_ #R_\>/^-']D6G_/+_QX_P"-7** *?\ 9%I_SR_\>/\ C1_9%I_SR_\
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M &1:?\\O_'C_ (T?V1:?\\O_ !X_XU<HH I_V1:?\\O_ !X_XT?V1:?\\O\
MQX_XU<HH I_V1:?\\O\ QX_XT?V1:?\ /+_QX_XUE_$#QA;_  ^\#Z[XENXF
MGM]*LY;MH4(#2;%)"@]B3@?C7):5X;\>>(O#]KJ]YXWN-%UFYMQ.NEZ;8VK:
M?"S#<L;^;"\S@9 9A(F[!("]* /0?[(M/^>7_CQ_QH_LBT_YY?\ CQ_QKF=6
M^*&A^$9K&P\0WYMK^0PP3W$-E<-9QSN% 5YPACAW%AM$C@D,*=-\7/",?B&Y
MT)-:BN=6M;B"TN;:TBDG-O+,Q6-9#&I"988RQ !(SC(R =)_9%I_SR_\>/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;MW&0"*EUG]I'0M+C\52V^@^)-4M_"[JNK36]@L(M@5+;ML[QLP &3M!."&
M*G-8MM^SSX@M-#^'&FQ^,--*>"IQ/;R-H4A-R0I10X^U\?*3G'4X/'2KEQ\
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MEFT24RG4)+.-B#,MPLAB#LH$@CV' .TL6KV6WF%Q;QRA602*&"N,$9&<'WH
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M^W^-7** *?\ 9:?\][G_ +_M_C1_9:?\][G_ +_M_C5RB@"G_9:?\][G_O\
MM_C1_9:?\][G_O\ M_C5RB@"G_9:?\][G_O^W^-']EI_SWN?^_[?XU<HH I_
MV6G_ #WN?^_[?XT?V6G_ #WN?^_[?XU<HH I_P!EI_SWN?\ O^W^-']EI_SW
MN?\ O^W^-7** *?]EI_SWN?^_P"W^-']EI_SWN?^_P"W^-7** *?]EI_SWN?
M^_[?XT?V6G_/>Y_[_M_C5RB@"G_9:?\ />Y_[_M_C1_9:?\ />Y_[_M_C5RB
M@"G_ &6G_/>Y_P"_[?XT?V6G_/>Y_P"_[?XU<HH I_V6G_/>Y_[_ +?XT?V6
MG_/>Y_[_ +?XU<HH I_V6G_/>Y_[_M_C1_9:?\][G_O^W^-7** *?]EI_P ]
M[G_O^W^-']EI_P ][G_O^W^-7** *?\ 9:?\][G_ +_M_C1_9:?\][G_ +_M
M_C5RB@"G_9:?\][G_O\ M_C1_9:?\][G_O\ M_C5RB@"G_9:?\][G_O^W^-'
M]EI_SWN?^_[?XU9FC:2%T61H692!(F-RG'49!&1[@BOEB3QYXJTSPSXSFN/B
MMJ#>*].UJ^T[0=#>RTR1M5\AD\J/R$M5ED9MZJQC9=N[/ % 'T]_9:?\][G_
M +_M_C1_9:?\][G_ +_M_C7*6?Q6TJ&:VTW4Q=1ZXL*B\@L=.NKJ""X\D2O!
MYT<;1^8!R(]V\@K@<C,%E\<O"&I>%['Q#:W6I7&D7MZ-/MYX]$OB9)RVT*$\
MG=@M\NXC;N^7.>* .R_LM/\ GO<_]_V_QH_LM/\ GO<_]_V_QKG=8^(VE0W[
M:-:7LJZK,YM(;I=*N;NR@N3PJ32QJ(U(8C*-(A.<9&:XWX2_&JTU#PMX8M_%
M6KL_B/5I[BW2Y&G2Q6DTRSS*L2RJGDJ^V/B,OO( ZDY+ ]4_LM/^>]S_ -_V
M_P :/[+3_GO<_P#?]O\ &N2T'XI:'J&AZGK$?B"TU_38=0DM()=#L9I3D*&\
ME50R-<2 9):(8/91@UA^,/C]HVD^$=%UW1/M&KVVHZQ!I;&+3;N5X,S*DRO$
MD>])5&X"-PK%L !NA0'I/]EI_P ][G_O^W^-']EI_P ][G_O^W^-<9)\>/ D
M,MS%)X@CBEM/(%Y');S*UEYV=GVD%/W'((;S=NPX#;<BK&B?$_1Y/!NG:U<:
MW!KD=Z9?L\^BZ;<,;L([ F&V4RRN% Y*[@<;N 10!U?]EI_SWN?^_P"W^-']
MEI_SWN?^_P"W^-1Z#KMGXFTFWU*P:5K6<$IY\$D$@PQ4AHY%5U((((8 C%:%
M %/^RT_Y[W/_ '_;_&C^RT_Y[W/_ '_;_&KE% %/^RT_Y[W/_?\ ;_&C^RT_
MY[W/_?\ ;_&KE% %/^RT_P">]S_W_;_&C^RT_P">]S_W_;_&KE% %/\ LM/^
M>]S_ -_V_P :/[+3_GO<_P#?]O\ &KE% %/^RT_Y[W/_ '_;_&C^RT_Y[W/_
M '_;_&KE% %/^RT_Y[W/_?\ ;_&C^RT_Y[W/_?\ ;_&KE% %/^RT_P">]S_W
M_;_&G1:>D,@<2SL1V:9B/RS5JB@ K.U#_7+_ +O]36C6=J'^N7_=_J: *M%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!HZ?_ *EO][^@JU573_\ 4M_O?T%6J "BBB@# \7+XE2&TN/#
M(T^XN8I?W]CJDKPPW$9&"!*D;M&P."#M8'D$<@C M_AZ_BCQ WB#QE8Z;/<G
M3)-*31X&:[M(X975I@[R(GG%RD?6-0 N,'.:[ZB@#QGXN?!-M0^%^N^$?AQX
M9\*Z =>C\J\G/_$O1-I!5MD%N_FG[PY*XSU/2NXA_P"$OC\ K"=)T0^)%B$
MM1JLWV,C[N[S_LV\''.WRNO&>]==10!Y;\ /!?BSX9?"VR\+:[;:-+<Z5$R6
MEQI^H32)<EG=_P!X'MT,6"RC(WYY.!T-3X4>#_'GA?QUXQU37]/\.IIWB2_6
M_8Z;JL\TMJ4@2)4"O:H),^6N6W+C)X/2O7:* /#OB)X<^->K^/X]3\.)X!;0
MK#_D'6NO3WTCK(1@SLL2*OF8) Y;:,X.6)-_Q9X4^)/C;PKX7TO6]/\ !^H@
M7:W/B.UCO;F&UNT1V:."-6MY24)\MFW]=A7&&R/8J* /"OB[^SGI^I>'[/\
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M@",@C@@&KM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO*98T;N%<JI8>Y4?058HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M )_+[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\
MO^: -BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^
M:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL
M?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O
M^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\
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M[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^:
M-BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\
MA&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&
M8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O^?R^
M_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\ G\OO
M^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O^?R^_P"_YH V
M**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\ G\OO^_YH_P"$
M9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B
M_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_
M +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[
M_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8H
MK'_X1F+_ )_+[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F
M+_G\OO\ O^: -BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_
M )_+[_O^:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\
MO^: -BBL?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^
M:/\ A&8O^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL
M?_A&8O\ G\OO^_YH_P"$9B_Y_+[_ +_F@#8HK'_X1F+_ )_+[_O^:/\ A&8O
M^?R^_P"_YH V**Q_^$9B_P"?R^_[_FC_ (1F+_G\OO\ O^: -BBL?_A&8O\
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M]*'L(I$:)(G6?Y<\?O5.XJ2,D-5[1? -O=?M!>*/#LVO^+I-#M-"L;VWL_\
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MHHH **** "BBB@ HHHH *K:E<O9Z?=7$<9EDBB:18Q_$0"0/QJS10!X;\%?
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MJ?Q]UJZT+4-;7X;IX<NQ%<7*Z>-0%V(' 8A-Y*;\'N<9H ]C\W4/^?:V_P#
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MS:'K<FDI#93/.I"11.6,C*NXDR'^!<8QSUH [7S=0_Y]K;_P(;_XW1YNH?\
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M* *?FZA_S[6W_@0W_P ;H\W4/^?:V_\  AO_ (W5RB@"GYNH?\^UM_X$-_\
M&Z/-U#_GVMO_  (;_P"-U<HH I^;J'_/M;?^!#?_ !NCS=0_Y]K;_P "&_\
MC=7** *?FZA_S[6W_@0W_P ;H\W4/^?:V_\  AO_ (W5RB@"GYNH?\^UM_X$
M-_\ &Z/-U#_GVMO_  (;_P"-U<HH I^;J'_/M;?^!#?_ !NCS=0_Y]K;_P "
M&_\ C=7** *?FZA_S[6W_@0W_P ;H\W4/^?:V_\  AO_ (W5RB@"GYNH?\^U
MM_X$-_\ &Z/-U#_GVMO_  (;_P"-U<HH I^;J'_/M;?^!#?_ !NCS=0_Y]K;
M_P "&_\ C=7** *?FZA_S[6W_@0W_P ;H\W4/^?:V_\  AO_ (W5RB@"GYNH
M?\^UM_X$-_\ &Z/-U#_GVMO_  (;_P"-U<HH I^;J'_/M;?^!#?_ !NCS=0_
MY]K;_P "&_\ C=7** *?FZA_S[6W_@0W_P ;H\W4/^?:V_\  AO_ (W5RB@"
MGYNH?\^UM_X$-_\ &Z/-U#_GVMO_  (;_P"-UQVK?'3P/H\VLQ2:W]KDT5PF
MI#3;2>]^Q$AB3+Y*/L"[&W$X"' ;!(S>\4^)III/"EGH5XADUJ]C=;J$+(OV
M.-3/*XR""KHJQ[AT,RD<X- '1^;J'_/M;?\ @0W_ ,;H\W4/^?:V_P# AO\
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ME_S]1_\ ?5']L67_ #]1_P#?5 $UG;BTM(( <B)%0$]\#%353_MBR_Y^H_\
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MNEZ[HVM74&KQM*LL<MW(_GO+$X S$WG J" 0, YQDH#UZBBB@ HHHH ****
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M_P!!#4/^_P /\*/^$5C_ .@AJ'_?X?X4 +12?\(K'_T$-0_[_#_"C_A%8_\
MH(:A_P!_A_A0 M%)_P (K'_T$-0_[_#_  H_X16/_H(:A_W^'^% "T4G_"*Q
M_P#00U#_ +_#_"C_ (16/_H(:A_W^'^% "T4G_"*Q_\ 00U#_O\ #_"C_A%8
M_P#H(:A_W^'^% "T4G_"*Q_]!#4/^_P_PH_X16/_ *"&H?\ ?X?X4 +12?\
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M "F_\(W_ -134O\ P(_^M1_PC?\ U%-2_P# C_ZU &Q16/\ \(W_ -134O\
MP(_^M1_PC?\ U%-2_P# C_ZU &Q16/\ \(W_ -134O\ P(_^M1_PC?\ U%-2
M_P# C_ZU &Q16/\ \(W_ -134O\ P(_^M1_PC?\ U%-2_P# C_ZU &Q16/\
M\(W_ -134O\ P(_^M1_PC?\ U%-2_P# C_ZU &Q16/\ \(W_ -134O\ P(_^
MM1_PC?\ U%-2_P# C_ZU &Q16/\ \(W_ -134O\ P(_^M1_PC?\ U%-2_P#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ4?V</2@#:_X2+3_ /GN?^_;?X4?\)%I_P#SW/\ W[;_  K%_LX>E']G#TH
MVO\ A(M/_P">Y_[]M_A1_P )%I__ #W/_?MO\*Q?[.'I1_9P]* -K_A(M/\
M^>Y_[]M_A1_PD6G_ //<_P#?MO\ "L7^SAZ4?V</2@#:_P"$BT__ )[G_OVW
M^%'_  D6G_\ /<_]^V_PK%_LX>E']G#TH VO^$BT_P#Y[G_OVW^%'_"1:?\
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M^$BT_P#Y[G_OVW^%'_"1:?\ \]S_ -^V_P *Q?[.'I1_9P]* -K_ (2+3_\
MGN?^_;?X4?\ "1:?_P ]S_W[;_"L7^SAZ4?V</2@#:_X2+3_ /GN?^_;?X4?
M\)%I_P#SW/\ W[;_  K%_LX>E']G#TH VO\ A(M/_P">Y_[]M_A1_P )%I__
M #W/_?MO\*Q?[.'I1_9P]* -K_A(M/\ ^>Y_[]M_A1_PD6G_ //<_P#?MO\
M"L7^SAZ4?V</2@#:_P"$BT__ )[G_OVW^%'_  D6G_\ /<_]^V_PK%_LX>E'
M]G#TH VO^$BT_P#Y[G_OVW^%'_"1:?\ \]S_ -^V_P *Q?[.'I1_9P]* -K_
M (2+3_\ GN?^_;?X4?\ "1:?_P ]S_W[;_"L7^SAZ4?V</2@#:_X2+3_ /GN
M?^_;?X4?\)%I_P#SW/\ W[;_  K%_LX>E']G#TH VO\ A(M/_P">Y_[]M_A1
M_P )%I__ #W/_?MO\*Q?[.'I1_9P]* -K_A(M/\ ^>Y_[]M_A1_PD6G_ //<
M_P#?MO\ "L7^SAZ4?V</2@#:_P"$BT__ )[G_OVW^%'_  D6G_\ /<_]^V_P
MK%_LX>E']G#TH VO^$BT_P#Y[G_OVW^%'_"1:?\ \]S_ -^V_P *Q?[.'I1_
M9P]* -K_ (2+3_\ GN?^_;?X4?\ "1:?_P ]S_W[;_"L7^SAZ4?V</2@#:_X
M2+3_ /GN?^_;?X4?\)%I_P#SW/\ W[;_  K%_LX>E']G#TH VO\ A(M/_P">
MY_[]M_A1_P )%I__ #W/_?MO\*Q?[.'I1_9P]* -K_A(M/\ ^>Y_[]M_A1_P
MD6G_ //<_P#?MO\ "L7^SAZ4?V</2@#:_P"$BT__ )[G_OVW^%'_  D6G_\
M/<_]^V_PK%_LX>E']G#TH VO^$BT_P#Y[G_OVW^%'_"1:?\ \]S_ -^V_P *
MQ?[.'I1_9P]* -K_ (2+3_\ GN?^_;?X4?\ "1:?_P ]S_W[;_"L7^SAZ4?V
M</2@#:_X2+3_ /GN?^_;?X4?\)%I_P#SW/\ W[;_  K%_LX>E']G#TH VO\
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MVW^%'_"1:?\ \]S_ -^V_P *Q?[.'I1_9P]* -K_ (2+3_\ GN?^_;?X4?\
M"1:?_P ]S_W[;_"L7^SAZ4?V</2@#:_X2+3_ /GN?^_;?X4?\)%I_P#SW/\
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M0=V<<UPNK> [MOB=-+90K%HGBRP4Z];2,NY'MR@!P,AC+')Y+X/101G%=/\
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MNCRZ *?V<>E'V<>E7/+H\N@"G]G'I1]G'I5SRZ/+H I_9QZ4?9QZ5<\NCRZ
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M6P Q=B"%VH#URBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLL<N,BN8\"^-/''Q(U;P_:WWB&'PY!K'A1=6$>DV$?VB*831H9%:X$BE7!R
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M%(R[JH9OF7;M )I@?2U97BCQ3I'@O0[K6==U&WTK2[5=TUU<N%1<G 'N22
M.22 *\%^(GQ9\7>&? R7,E[>6'C#1-/M;O5=/M+6R:T5Y)&4?:7E<Y$@0X2V
M?>ISRP*U>^+OB34/&'@CXP6Z>(CH$7ANTFM#IT44+?:T>Q63=.9%+A7,K*GE
MLGW>K'( ![Y:W45]:PW,#;X9D61&P1E2,@X/M4M<5H^N:B+'1=(@\/:P;6?3
MX0=>MI++[/;DQ=2LDWF$@X_Y9,,D=1FO(O FK:UX;\%>$;)O&FHE?%/B"]L)
M=5OX[1WLF62[?;"?)"^;*\:C]Z)!DD*HR!2 ^DJQ-%\::'XDUC6-*TO4X+^_
MT=TBOXH#N^SNV[",W3=\IRN<C'.*\]\'>._%.FWGBS2+K3M2^(0T755L[?4M
M-%E;SO&\"2E9A))!$7C+[28^N1E00:Y[5H];D\;_ !>U'1]>NO#5W8Z=I]XO
MDVUO,SR):S,(Y/,5U*9'(3#'LX[L#WZBOG#4OBIX]\7:PNG>'K758+V/PY8:
MO;QZ,FF%)Y[A'8^?]ME5C &4+B$!OO9<?**U/%_Q7UNQ\6^'SI^H7@ UZQT/
M5=/6WM?[/BDF5#+$7<BXDE7S-P>(E ,!APQI >P^*?&>A^";.VN==U.WTR&Y
MN$M(#,V#-,YPL: <LQ] .Q/:MJOFOXF>(M0\<?#B[UR3Q&;*"W\50:6_A^.*
M$Q?N=5CC42,R^<)L().'"X/W".:]<^)WBZY\-S>%[""Z73(]<U0:;+JC!3]D
M!AED4J'RN]FC5%W C+]#TH [BBO(]4NO$.F^,O#_ (%G\<7UO_:5K>W\>N/:
M6:WT[1-"%MDS%Y!(61V8B'<548QAF/*Z+X^\=ZS-X$LI?$-K#;WOB#5-"N]0
ML]/3S-0CMX;DQW,9?*)S",@(07&0=OR$ ^AJ*^>;KQ9XTTCPIXNU:7QG-._A
M#718J)-.M@NHVY-NS?:0L8.X+,RAH?*Z D,:Z.YU;Q1KWQ$\?>'Y/'$?ARRT
MJRL[ZRFT^PMQ+ L@FW&4W'FJZ#8-Q"KGC!3G(!['17S1XT^-/BBP^&MEJ\=_
M>6?BG3=)L=1U.PL[&V6S#3,0/M)N2'VR!3B. B13G.<@5W=O>>-->^+/BO1H
M_%T.GV6FVNFZA96T&E1LFV5KD/'/O):0'RERR/&>!C;SN /4=+U:RURQBO=.
MO+?4+*7/EW%K*LD;X)!PRD@X((^H-6Z^<U^(7CC4/A;H.O2ZK=A8[34+G5;S
M0(K!;I6BN"D;_9[OY# $5]P1O,R% )).;6O?$;Q#K&A_$#7=*\7C0I_"*QR6
MVDR64!CNXS:Q7"O=*ZM+B8NZ+Y31XQCYF!I@?05%>#77B3QUKDWQ#1O%0\/S
M:-IEIJEC;:?I\#/ 9+>60P3^<)-XW( Q 0G *E.0?5O!GBZ#Q%H.@RW%S:QZ
MOJ&EP:D]BD@\P*Z*68)G=L#-C/2D!H>(O%&C>$=..H:[JUCHM@&"&ZU&Y2"+
M<>B[G(&3Z5CZ#\6O _BG44T_1?&7A_5[]P2EK8:I!/*P'7"JY)K#_:,_Y(?X
MR_Z\&_F*ROVEH],NOA1?6LT,=SXBF54\/PQ@&[_M'(,#08^8.& 8D=%5B> :
M /3?[?TSSM0B_M&T\W3E5[V/SUW6RE2RF09^0%02-V.!FJ*^--+:VLIO].!O
M)C## VG7 G8APA<Q&/>L88C,C*$ 96+;2"?"OBEK7B?4O!/QHT/5]:0II>GV
M+VK:?:I"465&:1&W[]Y;;@MQQ]T+6UK.CZQH_P :-$F3Q3KFI3:=X2O+HHT5
MD&O2ES"QB<+;@ /E5)0(?D7!!W$@'O%%?/'PY\:?$SQEHEIKT+WD-AJ>CRW<
MEYJUOILNGVMQM5H_LL=K<>>R_P"L4K.Q/0D@@J:K?$+QM8^!?AM?-K>I:S<>
M-8K3SI-/M=/BFM'^QM*ZVQG\N+=*P!Q+NQM?:.5 8'TC17A-CKOQ(&M>"='U
MG5CH,>K7&I6D@N+2T?4Y(XXGD@F9HGDMU<+MRJ(5W+D@AM@-+^)6OV-C!HFI
MZUYDTGB^Y\--XDG@ACE2)87FB8H%$7FL0D0.S:20=I)Q0![M17SGX@\2_$BP
M\<:[X/TC5/$&NW>EV$-_8W5K;:,DETTIDP+L3M$&A5D"YMT1OO9;.W/3-XN\
M56/Q&TL:Y=7UAI=]?QV-O;:6+&YT]G-L':*<G%TDPD$AW)F/:JYZDT@/9J*\
M)^(WCOQQ=_$G6_#'A>WU=)M,TNWO;1=)33"+F64R#-Q]LE5C""BK^Y ;[V7'
MRBE\2>./%?A_QU9Z)<Z^+72==^SQ7.HFWA=O#EVX)6W1Q'Y<GG8*H90Q1MI;
M>'12 >U6^K6-Y?7=E!>6\]Y9[/M-O'*K20;QE-Z@Y7<.1GJ*MUXM?^*O&[^(
M/B%HMGJ5O=3Z?/I:Z<(8H;:9(9MQE5#*6C>X* [2^$+ ?*HR*YN&[U;QMKWP
MZ'_"9^)]/FBUC4[.=;BWTV.<30P3<.(XI(78#*;D^4@D@!N0 >YW7C30[+Q5
M8^&IM3MUU^]A>Y@T\-F9HESND*C[J\$9. 2"!DBMJO*OBA;O=?%#X<P6^K?V
M->3+J4272+&\P!A0GRUD!3?P,%E8<?=-<1KGQ(\<>';B+PZ+R^UN"Z\1R:5:
M>(;&*PCOIX5LQ/L43&.U\T2[X]Q7!$;@)N% 'T917SU<6/C76_$'PUB\0Z_K
MOAN].IZC&B*-.\Z:-+>5H99E2.6'S2A*D(=N,D*I/%W7OB1XL\*77C+3DO#J
MM_H.H1ZP_P!IACW'0]D4DBH(T7YR?/C4D$GRFYR,T >\45X9XZ^(GB'3;3PX
M^CWVHZA9^+=8ECM;C3X[ 3VUJL+-$ENUR8X2TICWAI=YVL0 3BL2\\?_ !)A
MU;P_X4O[+Q!97UY;WUVMSIPT;^U+F.*9%A#B:7[*"$?,@CW$_*0$&X!@?1U0
MW=W!I]K-=74T=M;0HTDLTS!410,EF)X  &237BVAZI\1-<\8:9X<U[Q!'X:G
MNO#7VZ:'3;*W:[@N4GCC9B[F:([LG@*5 9E&2 ];'AGQIXDUS]GA_$(O[6/Q
M+#I]TQOIK3?&\D#R(9#$K*,L(\X!P"W0@8I >I6MU!?VL-S;31W%M,BR131,
M&1U(R&4C@@@@@BI:\0\/^(?&/B_Q+H&E2^+5TNSU3PA!JX?3["#[9'<;H0[E
MI1(A#%SQY8 !(QD!AT'@?5/$WQ&^!=K<Q:X=*\57%M-"FL06T1 GBE>-9#$Z
MLF&,8++CHS;<<$ 'I-W=P:?:S75U-';6T*-)+-,P5$4#)9B>  !DDTMK=07]
MK#<VTT=Q;3(LD4T3!D=2,AE(X(((((KPC1_%7BSQ/\/X]=TGQ?>6U_HFB7)U
M:#4;"UF1]27<&BE5(XR&C*2<(R#F$D,"P9=!CU[Q7\2?!6IMXOU&SNKGP8NH
M&U2&V:V>5GM_,#1F+=M=B"VUU;@!604 >]T5\\:;X^\8:9\,1XKU;Q=%/)+J
M\FAW$C:?#%9V0_M5K;[6!@,"D8*X=V7.TG.&+=WX%U77]-^)WB'PGJ.N2>*=
M-M=.M=1AU"ZAACN;9Y'D0P2^1''&P(CWKA0P&<YX- 'IE%>"7OB;Q5)K6LZ;
MJFO:SI<NH66IRZ<^FIITUAY<+9C>"4*9TD5-H<3*5+,VTC IOP_U+Q%X7'P:
MTL>*9-4T37-,=I8K^UA,^Y+(2(BRQJ@,:G&!MWD@[I&!P #WVL7P_P",]#\5
M7FJVVCZG;ZE-I5Q]DO1;MN$,V,F,GIN'< \=#7DNA?$[7YM+TW3M2UZU>^U3
MQ9>Z ^M6]HD,4"1I*\8A1BZ[V\I57>7Y<_>X%<Y#I_C"VM_C0?"WBR\NO$FF
MZK:3I?):VC37JQV,)>!E,1B#E<J"J+\ZKQC((!]+UB^*?&>A^";.VN==U.WT
MR&YN$M(#,V#-,YPL: <LQ] .Q/:N:^'>J7?C#4)?$UGXEO=1\*W%G!%96<T-
ML(Y)-@:2?>D0?.2%V[L!A+QC:%\J^)GB+4/''PXN]<D\1FR@M_%4&EOX?CBA
M,7[G58XU$C,OG";""3APN#]PCF@#Z4J&[NX-/M9KJZFCMK:%&DEFF8*B*!DL
MQ/   R2:\'NO'_Q \1?$+Q)::!9:JR:#K$%BME;C3!826Y6)W>Z,THN@S*[E
M6B   7AR&%&J>./&FEZMK<<^L75E?3V.IW6EJUK97NCM';ME&C,3)<JXCP&$
MQ*[V.,A=I8'O-K=07]K#<VTT=Q;3(LD4T3!D=2,AE(X(((((J6OG7Q1\0?&F
MJZ3HUAIFK:OIFM:AX4M]4TVXT72(;W[;?LI$B7 >)U@B#-#ACY:_.?W@QBNE
MMT\;?\+"MO!]WX[E6"7P\;[[9;V%J+]9UGC5F+&,Q,/F*C$(&WC&[YZ0'LM%
M?.TGQ%\::E\+?#VNG4KR*.#3[V;5KW04L/MAD@E\M9F@N_D,)"2,ZQD/N*A:
M]9\5^+[?2? MKJ3:A<6C7YMH+:>"T$D[RS,JHJ1M\H=BV!O^52<MD B@#L**
M^;]%^)WC>\T. ?VY';M:>.$\/SR:M96TEY/;N8L*QMY/($@+L"47D ?<(.=N
M[^(WB#P#/XVTO4-=.LQZ;J.D06VKZK;PQM:Q7KI&[2^2D:,L9W,#M7J QP,T
MP/6['QGH>I>)M0\.VFIV]SK6GQ)->6<3;GMU?[F_'"D]0#SCG&*VJ\:\$V%U
MIG[17B:WN_$$_B*1?#=B1-=1P)+$#<W)\MO)1%(&<CY0<,,D]:CU[5O&6H>/
M/B)I,'BYM(L](TBRU/3AI^G0%HV?[5N24S+)Y@)A&2-O;;MP2R ]IHKPS1?'
MGBJSE\"ZU>:PVK1>*=#GO9=$6SB2&&XCM4G46S*OF 'Y@1*\F<\$5A>"O%WQ
M$\=>$QK4ESKEEI&JZ%/=3Z@PTE8+.XV*\?V'R7DEVYWJ1<*S 8.588H ]UOO
M&FAZ;XHTWPY<ZG!'KNI(\MKI^<RR(BDL^!T4!3\QP"1@<\5MU\W:%H6H+#\"
M;:/Q/J$\]U8W,D>H3Q6SS6R-IR?)%MB"';SM,BN>?FW5JV/Q&\1K#9>'+[Q$
M8)Y_%]WX;;Q+);0+/Y:0/-%A=ODB=R%C!,94X/R9(H ]\K%\/^,]#\57FJVV
MCZG;ZE-I5Q]DO1;MN$,V,F,GIN'< \=#7C]A\2/$FF^(+CP?J&NQW<;>)5T2
MW\5201)*$>R:Y\ME5!";A6 C!"[3N'R9&#B6/BC4?AW=?%2X_M];^X_X272=
M/FU^^AB_T:.6"UB>:58PD>Z-6(SA5W $KC(I@>]^+O&>A^ ](.J>(-3M]*L?
M,6(2SMC<['"HH'+,>P )X-;5?-/Q6U77]-T+XD>$]1UR3Q3IMKI-AJ,.H74,
M,=S;/)<[#!+Y$<<; B/>N%# 9SG@UO\ C7QUXCN(/B9J>F^+$\/77@J0"#1V
MM8)(;I!;1SJUSO1I2)2SHAB:/I_$P- 'N]5+?5K&\OKNR@O+>>\L]GVFWCE5
MI(-XRF]0<KN'(SU%>#>*/&'CSQ5XDO-%T;4];\+:W%+IKV]EI^E075HUK,L;
M7$EQ<2P.L4B?Z0 &9#^[&$D)Q3/&'Q2\9>!KCQK8/J/]L_8+W1;&TNH[2WAE
MMXKHE9)6WND32]/F8I'N(^15RM 'T/17A2ZI\3X]%EMIH]<AC.H@PSW$NC)K
MDMI]G+.(U4M9L5F Y8*?+)XR-Q]&^&WC*S\3>$] E;53>ZA>V(N0+Q(X+J90
M=K2-"A('S8!*Y7)&#@BD!U]%>&?$#XIZEIGCS24T/5KZ:SC\16F@W]J;6U6P
M4RA"Z,SD7#S 2!@T1*#@,.&-9>K>,_'-EX-\:>(9?%\;7?A?Q ULMG8:= EK
M=0!K?,4H<22#Y9& *2*P)));@  ]R\4>*=(\%Z'=:SKNHV^E:7:KNFNKEPJ+
MDX ]R20 !R20!6A:W45]:PW,#;X9D61&P1E2,@X/M7@GQ@\1:AXN\%_&*V3Q
M&= A\-6D]H=/BBA;[6CV*R;IS(I8*YE94\LI]WJQR!Z5K7B6Y\&_!FYUZSM/
MM]UINAF[BMN<2,D&X X[<=J .VHKRZ\U:Z\.^&_^$@N/'U]JMCK"VT%FL%A:
MRA9YI%5/LFR-?O;B!YS2*I*LQPK \#H/Q4\92Z98F?6-L=KX[C\/73:E:6S7
MD]LWED*[V[^0K@LRDHO(QC8P- 'T?53^UK'^U/[,^V6_]I>3]H^Q^:OG>5NV
M^9LSG;NXW8QGBO ?B5KGB#6?!OQFTV[\4-"ND2PK;2:3;1P>7;R1*QA8N)"2
M=S*S9!.W@("16IXN\=>+/A?K7B*U.L_\)+8Z9X/N-9M1>V4:S-.DP7?.T(17
M4 GB-8_E&.6^:F![K17@VM^)O&/AO6(;32/&]OXEMM8\.WFK17>I64#K8/"(
MV29/LZQ!H)!)M <L00IW, P.AX3\4^)X_$7PQN;[Q))JUEXMTN22ZL)+6WCA
M@E2UCF$D+(@<9.X,'=@=Q(V@ 4@/::Q/"OC30_'%I=W6@ZG!JMK:W+V<L]L=
MT8E0 LH;HV-PY7(]^#7GGQ0\5>(O#?BN&Z6_U"R\,6YLT>31DL;C$LDY5UNX
MI\3;&!C"& [N7)!P*XF;4M?\*>&_B7XHT?7IK :5XNGD.FK;0R07BEK=765G
M0N,J2 8V3!.3NI@?2E%>$>-?'7B.X@^)FIZ;XL3P]=>"I (-':U@DAND%M'.
MK7.]&E(E+.B&)H^G\3 TEU\1/&GV+XJL^KZ?IE]H^EV>H:?#-I^Y;,2022O&
MZF0&1\J$WD@9 (3JI /7H/&>AW7BRX\,0ZG;S:_;VPNY["-MTD41( 9\<+DL
M, \D'(&*)O&>AV_BNV\,OJ=N-?N+=KN/3PV93"IP9"!]U<\9.,D''2O&?$?C
M:Y\->+)O%B)_:-W9_#B340'7 E83(^6"@8!/)P!QG%7HX;I?CY\/[F?Q6WB2
M*\T34[F)&BMU2$-]E^:(Q*I,3=MY<_*?G-(#UBU\::'?>*KSPU;:G;W&NV4"
MW-U8Q-N>"-B-I?'"DY! /)!!QCFMJO(O$EA-J?QZ-K9^(9?#MS)X8#/<6:0/
M<E5NF(V"970#DY)1N#U'6N(_X6AX_OKOPYX;<ZG+<7<6I3+JWAV+3DNM02WN
MA%#(JWKK"%:,B1@BDG<I7:N<,#Z4HK!\"7&N77@_2)/$ULMIK[6Z_;85*8$@
MX)^1F4$]<*Q S@$]:WJ0!1110 4444 %%%% !1110!D:IX/T'7-6L-4U'1-.
MO]3T\[K.]NK2.2:V.<YC=@60Y /!'2K<VCV%QJEOJ<MC;2:C;QO%#>/"IFB1
MR"ZJ^,@-M7(!P<#TKS_XI_&S3_AQK>FZ(9=%BU2^MY+Q7\0:RFEVBQ(RJ09F
M1R78M\JA#G:Q)&.<M?VA-MKX9U"7PY*=)\46ZKH]Q;7:RO-?D9%I(NT+'NPV
MV4.R$*22O&0#T;2_!7A[0]8O-6TW0=,T_5;W_CZOK6SCBGGYS\[JH9N>>34$
MGP[\*36.I63^&-&>RU*8W-];MI\1CNI2<F25=N';/\39->;>//VD+?P%JD^D
M7T'A^#6=/L(K_4K6_P#$:6@.\,?)LS)%NN9,(>&6(?,G(+8&[IOQ<U37?&&H
MZ3I_A.1-.T^*QO)M0U"_2$O:W'FYFCC57SM$6=CLC$9X7 # ';:;X/T'1X=.
MAL-$TZQBT[?]BCMK2.-;7>,/Y0 &S<"<[<9S4?B?P1X=\;0P0^(M TO7X8&+
MQ1ZI9QW*QL1@E0ZG!(]*XB[^)NM:IX-G\2VWA)K_ ,(W6EO?6\UCK AU%XS'
MN4F,JBQ!EY#+.77CY<\"@OQP6QN/"NF6UAI\"ZCIUA=#^W==-M-(L_ 2V:2-
MOM<B!27!=6Y7J6H ]!NOA[X6OM0TR^N?#6CW%[I:)'87,MA$TEHJ'*+$Q7*!
M3T"XQ277P[\*7J:JEQX8T>=-6=9=0673XF%XZ_=:;*_O",G!;.,UYIHG[4&B
M:YXNM-.@;1VTZZOYM.C\O6XWU-'C\P&62Q"96$F,X;>6PRDH 3C+\8>)-2\9
M>*OA#KZ:2]EX?OM:C>QNAJLGF2QR6D[@3V@41C(565MSLN"/DR00#VRQ\+Z-
MIF@_V)9Z18VFB^6T/]FP6R);[&SN7RP-N#DY&,')K/M_AKX1L\_9_"NB09ME
MLSY>G0K^X5@RQ<+]P, 0O0$9Q5?Q9XXE\)^)?#-C-90MIFL3S6SZA)<E/LTB
M0O, 4\L@AEB?DLN"/>LCPW\2#\1+&TAM-(FM4NKF]LM0AN+M[:ZLHXLKY@V+
MDE@T)&&4@2J0>* .N\/^%=$\)Z:=.T/1]/T;3RQ<VNGVJ01;CU.Q !D_2H_#
MO@OP_P"$/M7]@Z%INB?:G\RX_LZSCM_.;^\^P#<>3R?6O%/@SXZU/P;\/? M
MI<:(L_A[4=2FTH:FVI,]TD\ES/L9H2AW(2 "YEWY))7')U=*_:ATK6_%%OIU
MA!I=_;75]/IUO;6NN0OJ[31^8 S61 "1.T9 <RY 9&95!)# ]EM]+L[..X2"
MT@@2XD:698XE42NWWF; Y)[D]:SO#?@?PYX-^T_\(_X?TO0_M3!I_P"S;*.W
M\TC."VQ1N/)Z^M>>Z+\<=5U.Q\)ZO<^$1IV@Z]J']E-)+J0:[M;@R2QKNA6/
M:R%HP"PDR"Q^4@9/:>*/&4^EZU8Z!I%C#J?B&^MIKR&WNKHVT"PQ-&KO)*$D
M8?-*@ 5&))[ $T@-&^\&Z!JFJ2:E>:'IMWJ,ELUD]Y/:1O,UNV=T)<C)0Y.5
MS@Y/%4[?X:^$;//V?PKHD&;9;,^7IT*_N%8,L7"_<# $+T!&<5S-U\2O%$UU
M<:5I7A"TO?$.FV,=[JEG/K/E0Q>89!'%#*(7,KMY3$;DC7#+D@D@9NE_':]\
M7:IH5CX:\*2W)UK0I=:M;C5KY;.+,<D2/ VQ975E,N"VS&0,;@2R@'=VOP[\
M*V7AR?P_;^&='@T&<[IM+BL(EM9"2"2T07:3D \CL*K7'PI\$WEAI]C<>#M
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MPJ2O$94E=@XP2,8KHJ* *FDZ18:#IMOI^F65OIUA;KLAM;2)8HHU]%10 ![
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M6=2^,>G:3J=S:OINIWMEI]U%8:GK5I%']CLKB39A'W2"0C]XF3&CA=WS$8.
M"GK?P&TK6-2U&\CUO6M,:]U2VUGRK-X-D5W"$"R+OA8L"(T!1RRC'RJIJ:Q^
M#*V-EXQMQXN\03?\)3(9KR21;+=$YC6)FBQ; #,:(F&## R &):JDO[06C+8
M7FI1:%XAFT>PU(Z7J&H-9+ EE)NC7?)'*Z2E,R#E$8@ D@#!.:O[0LFD:;XW
MU;Q%X/US3M&\.WLENMQ:QPW1D"1QL598IF96)9FW,%C5=N7!S3 W/"OP73PI
MXCT;5X_%_B'4&TO3/[(AL[S['Y#VPP0KB.V5B050[@P/R#)(R#YSX^^%%AH,
M/A?PWJ!\1:EX0M)KS4(=0MM%@UB>UNG8;8&@6TE7RR))6#O"[!@!O7C/J^I?
M$R;3=#N]2;P?XCF%K)+OMHX;?S##&JL9U+3!"A##"[O,.& 3*D#GO#OB:?7O
MC99W-GK5]>>'=5\)KJ=K8R[4@C+3QA75 H;<5/.\L1D@8'%(#5\$^']3\5?#
M&]T;QP)=1@U W5L%O(8[:YDL79EB$RPA520QD9V!<<<!@:BA^"L/]JZ'J-YX
ML\1ZG=:3#<6D37<UN?-MIE0/#)M@&1^[7]X,2'G+GC":U\<=.TN[\3VUIX>\
M1:Q-X;"/J2VEDL?EQLCN9$\]X_,4!#]S<6R-H89(FUKXU:3IH=K#3-5\110:
M?%JMY+I44;+9VDBLR2OYDB%LJCG9&'?"_=Y&0"GX;^ >E>&;O2IH=<UJYCT_
M2I=$2VG>W\J2S?&(V"0K@KM7#*58X&XM1#\!=.CM-#AD\1:]/)I.G3:1'</)
M;"66SD" PL5@&-OEIATVO\O+-5C_ (7=87GB#4M'T7P]X@\076GI:RRM96D<
M4;1W'F>6Z-/)'O3,9&]<KR#G 8JGA_XU0>)- \/ZO;>%M>BMM9O9+-$G^QK)
M;",,7EF'VCY$7RY,@9<%""N2H(!;F^$&GW/PUTKP;-JVJ2VVEFV:TU%C!]JC
M:W=7A)'E>4VW8HPT9! Y!/-9W_"A=*\O4]NO:\ES=ZJNMP7BSPB:QO!'Y;2P
MMY71T^5DD#I@D!0.*DM?COH\MYI N='URPTK6E8Z1K$]HK6^H$1F0+&B.TRL
MR!BBR1H7QA03@&QI?QNT'5M-\)WMO9ZOY7B:ZDM++?8LH1D9U)F;[L7^K8A6
M.X@<+D$!@2:S\*9=>U'PK?W?C'7VN_#TS7$$BI8C[1(R/&S2C[-CF.1TP@48
M.0 P#5'KGP7TO6M6UJZ&K:QI]AKVW^V='M)XQ::AB,1DN&C9XRR*JL87C+!1
MG-:7AGXD0>+-:GM+'1M4.G1R7$*:VP@:SEDAD\N1!ME,BL'# ;T7.TXR*KW7
MQ2C_ .$@U'2M-\.:UKO]GR&VN;O3A;-%%<>2)A"P>97#%63#%=F7 +CG" 9>
M?"B#4M;AO;OQ#K4]E:S_ &JRT@M;K:V<PC,:O$5A$GR@G:K.R@G.*N>$?AU%
MX7U:XU:ZUO5?$FK36R68OM6,'F1P(Q81J(8HUQN8DLP+$]36'X?^.%KXE\/>
M&]9L_"^O?8]<N9;=!(+0/:K'NWRSK]H^5!L?.-S K@J"5!S/$/QZN8/ASJ_B
MC1?!NL74,-G'=V$]RUJMM>129"3*RSGY1P2C;9,,/EYX .KNOAI'J/BJWUC4
M-?UC4;6UN_M]KH]PT'V2WG"%5=2L0EX!;"M(5R2<5E2?!&P;PN=#37];BMX=
M5&L:?,CV_FZ=,)FE"Q$PD,FYFXE$APV,],+J7QHATE9DG\*^()+VQM!?:K9V
MZ6LDFF0$N%>4B?8Y(C=@D+2/@?=Z"H[_ ..VEQ:CKMEINA:_KTNBVEO?736-
MHB(;>82%9(VFDC$J@1G[F<Y^7<0V !;OX%Z7J4VO27VN:W>-K(M9)RTL*-'<
MV^PPW43)$K)*"BG .S_8QQ3;SX()?:AJ%_-XS\2-J&H:3_8UY<DV1,\(=V#;
M3;;48>8R_(J@@Y(+?-6CX>^+NF^(]<TFPBTO5K6UUFT:]TK5+J!%MKZ-55FV
M@.9(R%<'$J(2,XS722^(/*\46^B_V;J#^=:27?\ :*P9M$V.B^4TF>)&WY"X
MY"L>U '&:7\$H= ;3YM)\7>(M-OK:QATZ:\A-FS7L$);R5F1[=H\H&*AT16P
M>2:UKCX9QZAXHM]7U'Q!K&IVUK=_;K72+EH/LEO.$**ZE8A+P"V%:0KEB<5A
MVNLZ]\3/%GBG3],UV?PKHOAZ\736GL+>"6\NKGRDE=MTZ21I&HE10/++,03N
M X./\4HO&WA'P+%);>.[R.[76[&UAOX["S,TUM//!"RSJT)C+J7D*M&J#[N0
M><@'L]%<]KGBJS\$V-BNI#6-19U\L36.CW-_([*!EI%M86"$]?NJ"<X'&*-)
M\<Z;K>CW^IV\&J06UDK-*-2TJZL)"%7<=J7$:,PQW ([9H Z&BO*?!<?BSXI
M>$]+\62^,;[PQ'JT"WMGI6CVEF\4,#@-$LSSPRO(^TC<4,8Y( &,G<\3?$2;
MX;^'K2Z\0Z9?ZH+>")M5U32+=!:VQ)"M(5DD#E=V3MC$C*,$@ @D [JBN+/Q
M.BN/$UYH^G:!J^L+93?9;J_LA;F""X\D3")PTRR E63YMFS+@%ASCC_#O[0[
M2>$[#6?$7A'6]).H:M_9=FMO#%<QR,]TT$>7CE81[2%#&78"Q.P-Q0![)17G
MEY\8EMXV2'PAXDOM4@MOME]I5O#;_:+&'?(JM(6G",6,3E4B=V( (&"*S(?C
MQX7O-0FU&TO]<OM.C\/#6O)MM+9[=X"ZCS$/E>:\HW;656*IAMP4@T >K45Y
M]H_QELM8U72+)= UNV76K!K_ $JZN8X%BO@L:R-$G[TLD@5^DBH#M)#$<G$\
M(?'BYUCPS:7^J^$-6LM2U&^GL],TVW>UE>^*239$9$^U2B1$NTIC7(.TD$4
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M8&QC&:T_C=XVUZW;2M*\)ZM_9$AOM/.I:G#!%.\<%S=I;I'&)%9-[[I'W$'
MBZ?.#3 ]AHKGM<\56?@FQL5U(:QJ+.OEB:QT>YOY'90,M(MK"P0GK]U03G X
MQ5CPSXLLO%EK-<6,&IP1Q/L8:GI5U8.3C/RK<1HS#W (I ;-%>>7?QLTS2K[
M5;75=$U[2Y+'3FU:/S;(3-=VJN$:2)(6=P067*R*C ')  )#M'^,MEK&JZ19
M+H&MVRZU8-?Z5=7,<"Q7P6-9&B3]Z620*_214!VDAB.2 >@T5XOX=^.4_B#1
MO#UWK>BZ_P"%9=3UW[!:-:PVUQ!<XGDC$<D@:41KA0'+>6Q8'RR1FO3?&'BR
MS\%:(VI7B2S*9HK:*WA*"2::618XXU+LJ@LS*,LP SR0* -NBN!N/BVL*V-J
MOA3Q#+X@NDFE&@+';"[CBB<(\K,TXAV99<$2G=N&W/.*&D?&+2/$&O2'2CX@
MU!QH']K)I<>GJD4J[P,1LZJS3Y/EE0^Q2"&PPS0!Z;17D-Q^TCINEG7_ .U?
M"/BC3%T/R4O)#;VUU&DLN-D1>VGE57P0QWE0H*[B-R[NLU#XJZ1INOZ]I$MG
MJ[W&BV*:A<M#ILSJ\;$A1" NZ8Y!_P!6& P02""* .RHKS/3OCMI^J:/I5_;
M^'-?9M9C@DT>U,, EU(2PM-^Z/G;%V(K;S*R 8')W+GHM+^(VGZGX/OO$!L]
M1MH[!IH[S3VM3+=P2Q,5DC,<6_<P(XV%@0002#F@#JJ*\OTWX^:?JB^'GA\,
M>(O*\167VO1I&@@VWS>4)3"/WW[MPF3F78AVG#D8)O0?&K2[K1;6YBTG6'U:
MZU";2HM \F-;TW409I(\F01 *JEMYDV8QACD"@#T*BN"MOB]I^IZ=#]ATO5;
MG7)FN8O[ C2%;Z-X&"3!B\@A7:63YC)M;>NTMN&?/OAI\2IK/PGIBZ]J_B:6
M]OO&-WI<$TUG'),P6Y=$ANF\ORH5P #LV'Y3L[T >_45R,'Q%BU#5X[;3=#U
M;5=--T]E+K5HD)M()D8HZL&D$I"N"I9(V4$')X.,J\^,4=K>:Q8?\(QKB:I9
MZ8^K6MK<)!'_ &A;JP4M&QEPF"5RLNQP#]WM0!Z'17DOA'XPMXAF\")K=AK?
MAK5-:LI+L69@@>QN%%N)&D:=3)M4<E%#K)W=,$5HVOQWT>6\T@7.CZY8:5K2
ML=(UB>T5K?4"(S(%C1':969 Q19(T+XPH)P" >DT5YGHWQZTC7$\.74.B:[#
MHVO7)L;75KFVCC@2XW2*L4B&3S5+&,X;R]N64%@<@>F4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'Q!X.\2Z!J-WXGTW4;32M"30/LT.C2022Q(0ROYANG"ME5S\I!&1@9R/5Z*
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M_P!GEY-*\6I=:KI=KJFO6"V+7&A:&+"W!5BPGEA\Y_-E+'EMR_*, #K7L]%
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M=3IOPHUFQA^'#2>([*>\\(J\$DHTIU2]A:(0X">>3&^P#YMS#=SMQ\M>G44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ%K\?/B5:J%B^('BB#T\O5[@#\M];=K^U=\:=.C5(/BGXM2,=,:O.1^K5/\
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M^9\)C/$G'UKQPE&--=V^9_HOP9[=XN_;*\5ZINCT6RM-$B.0'QY\H_%OE_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !137D6-2SL%4=2QP*Y[5OB-X7T-BM[K]A"
MXZQB=6?_ +Y7)_2M(4YU7:G%M^6IS5\30PT>>O-17=M+\SHZ*\DUC]I[P5IB
MN+>6[U-U[6\&T9^KE:X?6/VP#N*Z7X?4+VENIBW_ (ZH'\Z]BCDN85OAI->N
MGYGR6+XTR#!WY\5&3_NWE_Z2FCZ3I&8*"2<#U-?&>O?M*^-]2!$%]!I\;?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img8619836_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_5.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1D!*,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI* %HI*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDHH 6BDI: "B
MBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!.]%!IK?*,T"'=Z.]>0>*_V
MG_"'@O5;BPU6+5+:2&0Q&1K)_+9AUVMT-9,/[9'P_NB1;G5+@CJ(K%V(_*N^
M.7XN<>>--M=SQYYSE].;I3K)2[=3W6CFO Y?VTO =OM^T6VMVJ-P'GTYT'ZU
MUW@O]HSP)XZO8[/3M;C2\?[MO<#RV;V&>]$\!BJ<>>5-V] IYQE]2:A&LKOS
M/3A2U&LF:=OK@/8'44W?1NH&.HINZC=0 ZBF[J-PH =13=XI=U "T4W=1NH
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M7EY?'#Y;56*Q,TW':*UN_/HCW,VK8O.:#P6#I2BI;RDK67YLT/V/?AI<>"O
M<VJ:A"8+[6'$_EL,%8@/D!^H)/XBK_[7'P__ .$T^%ES>0)OO]';[9#@<E0,
M.O\ WSG\0*]KAC\M54* HX '2H=0LH]0LI[690T,R-&ZGG((P:\W^T:DL?\
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MVK>(/B?J\3)=:U*8K&-^3%;KQQ]3_(U1_:A^ &H?$CQ!X>U70;4273R+:7S
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M8_8SV_\ "DK,YX^USX]_F%<A^WA=6\?@WP[ VW[0U\S(.X4(<FN0^'L?QL^
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ML9'$87B&&,5*4H2C;1=?,]A_;*8?\*5O,][B(?K7+?L)MN\#:Z/XOMW)_P"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% $?E#M1Y?(YJ2B@!C1^])Y>.E244 1^6?6G;>,4ZB@!*6BB@ HHHH ****
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M3SD?C7/_ +!NLW U#Q)I1D8VGEQW"QG[J-G!(^M>S4RS#5<OEC<,Y7B[-/\
M0^=HYYC:.:PR[&1C:>SC<^B[CXW^!+6\N;6?Q3I\5Q;N8I8WDP48'D&KWAOX
MK>$_%FK/INC:[::C?(GF&"%\MM]:\(_;0^%ME<>$(/%&G:?#%=6$_P#I30Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4*>-IRJUN91:;>OW(^BKQG6RVK3HX;DE--):7UZL\]_8-D_XDOB=,]+B,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD-
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M_P#%4 ?JM17Y4_\ "W/^"C'_ $)C?^"FP_\ BJ/^%N?\%&/^A,;_ ,%-A_\
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M_P#%4 ?JM17Y4_\ "W/^"C'_ $)C?^"FP_\ BJ/^%N?\%&/^A,;_ ,%-A_\
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M_P"*H _5:BORI_X6Y_P48_Z$QO\ P4V'_P 51_PMS_@HQ_T)C?\ @IL/_BJ
M/U6HK\J?^%N?\%&/^A,;_P %-A_\51_PMS_@HQ_T)C?^"FP_^*H _5:BORI_
MX6Y_P48_Z$QO_!38?_%4?\+<_P""C'_0F-_X*;#_ .*H _5:BORI_P"%N?\
M!1C_ *$QO_!38?\ Q5'_  MS_@HQ_P!"8W_@IL/_ (J@#]5J*_*G_A;G_!1C
M_H3&_P#!38?_ !5'_"W/^"C'_0F-_P""FP_^*H _5:BORI_X6Y_P48_Z$QO_
M  4V'_Q5'_"W/^"C'_0F-_X*;#_XJ@#]5J*_*G_A;G_!1C_H3&_\%-A_\51_
MPMS_ (*,?]"8W_@IL/\ XJ@#]5J*_*G_ (6Y_P %&/\ H3&_\%-A_P#%4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#(!^,'_7SI?_H-U7ZBU^77_!#?_D _&#_KYTO_ -!NJ_46@ HHHH ****
M"BBB@ HHHH **** "BD8XI ^: '44W<*6@!:*3=2;J '44@.:6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3-61H;^97O'@?K$)#E5/OC!_&@#VJBBB@ HHHH **** "BBB@ HHHH ****
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ML!K\]OV/O^4E'[3GT'_HY*_0DU^>W['W_*2C]ISZ#_T<E S]"J*** "BBB@
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MM%&!2T5SG2)2T44 )1BEHH *2EHH *3 I:* "BBB@ HHHH 2C%+10 E+110
MAK\]OV/O^4E'[3GT'_HY*_0DU^>W['W_ "DH_:<^@_\ 1R4 ?H51110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO#8N-+75K6>>ZBBN)-C2"1?F SP3N-?I4W2OSX_X*=_\C=X$_P"O&Y_]&1T
M?5G[-OPXT/P/\,=$O-*M#'>ZI8P3WMS)(SO,Y3.26)]37K73%<?\&?\ DD_A
M#_L%V_\ Z+%=/J>H0Z;I]U=S'$-O$TK_ .ZHR?Y4 27%Y#:1&6>:."(<%Y6"
MK^9IMIJ-KJ$9>UN8;E!U:&0.!^5?GM\%[Z__ &TOC]K=WXOO[W_A%-,MVNK?
M1H)VBB"%PL:$*1V.XGOS57]ISPS<_LA_%'PWXA^'VI7VEZ;?(TK:>UR\D6Y"
M Z88G*LIZ'IF@#]&MWO47VV ><?/BQ#_ *WYQ\G^]Z?C7@/QVLKGXE?L]_\
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M:K9I.M05"4I6^6OJ>+1RU4JSK<J_'0Z>/[OMVI]-C&!3J\ ^@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7Y[?L??\I*/VG/H/
M_1R5^A)K\]OV/O\ E)1^TY]!_P"CDH _0JBBB@ HHHH **** "BBB@ HHHH
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M)!(1" 1C&XUZC^U2OA1OV>/'K>-4M9/#R:3<--]LQMW;#Y>W/\>[;MQSG&*
M.X\ >/-$^)W@W2?%/AR^34=$U2!;BUN$_B4]B.Q!R".Q%;C2;?8=SZ5\4?\
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M;)0H8CWX85L\X]Z .=^('C_P]\+O".I>)O$^J6^CZ'I\?F7%W<-A1V 'JQ.
M .2:_-CQ%JWC_P#X*J_$>'1]"BO/"'[/FBW:FZU"92)-19#DD#HSG&%7D)P3
MDUY;^V7^TUI'QP_:H;PQXW/B&+X->$;Y[=]-T6W)FU"XB)61SD@ %P5!YPHX
MY.:^D_"'_!53X'> ?#=AX?\ #_@3Q7I6CV$0AMK2VTV-410/3?U]^] 'U/\
M$KQKX3_8[_9VN]7BL&M_#GA>Q2WL["W'S2-D)&GU9R,GW)KX?_8F^.OP@T;6
MO$GQJ^+/Q)TC_A:OBR9R+60N1I-F.%A3Y3@D#GT 4>M?7WPQ^)GPZ_;[^#^L
M^?X;OI_"POQ976GZW#Y1DDC"2A@%8Y ++WZ@U4_X=W_L\]_AGI?U)?\ ^*H
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MD)Q3?,'KQ0 ^BF[CZ4;NU #J*** "BBB@ HHHH **0MBDW"@!U%%% !1110
M444AH 6BJ\=Y#.TBQ31R/&=KJK E#Z'T-3J<T +1110 4444 %%%% !1110
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M6AX,^(7C'QI(C6,OAZ6-6'G1+,XE5>_RD4[ >S44BYVC/6EI %%%% !1110
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M_H_PHT ['_A:7A/_ *#UG_WW69XC^+OANQT6]FL]9M)[Q(F,,8;.Y\<5@_\
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M\+Z,H>_276+GJ6G;"?@H_K0!SNJ?M-/=2&'0-!FNY.BM-DG_ +Y6N2\9>/\
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M2U\V?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "&OSV_8^_Y24?M.?0?^CDK]"37Y[?L??\
M*2C]ISZ#_P!')0!^A5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML?\ =1G8J/I@T >Q4444 %%%% !1110 4444 %%%% !69XH_Y%K5O^O2;_T
MUIUF>*/^1:U;_KTF_P#0#0!^9O\ P0W_ .0#\8/^OG2__0;JOU%K\NO^"&__
M " ?C!_U\Z7_ .@W5?J+0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "5Y;^T!XN?POX2ACMT0W
M=Y+Y4<CJ&\L 98C/?%>A:YKEEX>TV:_U"Y2UM8AEG8_H/4U\M_$3QU??%K4
MMO''8Z-9,QA>X;:&;'\3?WB.@JD!YKG>Q9N23DDUZS^SC'I=UXON+:]L8[B[
M\KSK69QGRRO7CIGWKR5OE9@3STZU[O\ LU:#81W]SJ<U[$^IM$4ALU<%DCS\
MS'Z]*I[ ?0RJ&4$BGTB]*6LP"BBB@ I#2TC=* &%NV:^</VJ/%]SJ5WI/@?2
MV+7%Y(LEPJ=3DX1#_/\ "OH#7=6M]!TB[U&Z8);VT;2N3Z 9KYH^ ^D7'Q2^
M*6L>.]44M!:RDVZ'IO/"@?[J_K7M9=!4W/&5-H+3UZ'C9C-U.7"T]Y[^G4^@
MOAYX-M? O@_3M'MU_P!1&/,;N\AY9C^-=.!Q3%Y45)7D3FZDG.6[/6IP5.*A
M'9!1114%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "&OSV_8^_P"4E'[3GT'_ *.2OT)-?GM^
MQ]_RDH_:<^@_]')0!^A5%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)) G)X'4GL*^;?'
MW[;7P<\*^)I]-O/M6NWMJQC>XT_3UG1&!Y4.S#.#Z5]":Y:RWVCZA;0-MGFM
MY(T/HQ4@?K7PA^R9^R;X/\86?BEOB%;37GB72]4DL9-+>Y:+RE"J1*0I!;>2
MV#TXH ]%US_@H-\(;VSFD_L?6;V[CB;R%NM+C(W8X!)<X&<5]#_!KQ)<^,?A
M?X9UR\BAANKZQCFDCMTVQJ2.BCL*\MU+]B;X)06%Q+<>'#!!&ADDE&H3*54#
M).0_'%>N_"]= C\ :$OA5F?PVMJ@L&8L28L<<M\WY\T =31110 4444 %%%%
M !1110 4444 %9GBC_D6M6_Z])O_ $ UIUF>*/\ D6M6_P"O2;_T T ?F;_P
M0W_Y /Q@_P"OG2__ $&ZK]1:_+K_ ((;_P#(!^,'_7SI?_H-U7ZBT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !5+5M6M=#T^>]O9EM[6%=SR,> *FN[R*QMY)YY%BAC4N[L<!0.YKY
MR\2:YJGQ\\7IHND;K?0+5MSRGH0#S(W]!3 CNKK6/VAO%RVT&ZQ\-6;9+=@O
MJ?5SV':O>M(\%:/HVBP:7#I\#6D/19$#9;^\<]2:E\*^%;#P?HT&FZ=$(X8Q
MRV/F=N[,>Y-;&W% &7_PBVC_ /0+L_\ OPO^%36FAV&GRF2ULK>WDQC=%&%.
M/3(J_12 0<#%+110 4444 (::^=O6G$U#=74=K;RSS,$BC4N['H .2:+7$VE
MJSP']JSQQ):Z38^$=.+/?ZHX:54Z^6#@+_P(X_"O3_A'X&3X?^!-.TO&;G9Y
MMPV.LC<M^73\*\%^&L+_ !F^/6H^)9U+Z3IK&2+=R.#B,?\ LU?5B?=KW,=_
ML]&&#CZR]7_D>)@4\16GBI==%Z#EX%.I!2UX9[@4444 %%%% !1110 4444
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M.LSQ1_R+6K?]>DW_ * : /S-_P""&_\ R ?C!_U\Z7_Z#=5^HM?EU_P0W_Y
M/Q@_Z^=+_P#0;JOU%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9(Q7G.!2MTKR#XY?$J30K5/#VD-YFLWN
M$<Q\M$C=A_M&F!S7Q6\<7WQ$\1Q>"O#3F: R;;B:/HY'7)_NKWKV#P!X%L/
M>@0V%H@:7&Z><CYI7[GZ>@KG/@W\,5\!Z)]HO$5]9NP&F<<^6.R _P Z](7@
M4 +1112 **** "BBB@ HHHH :U>-?M.^.O\ A%/ 3V$,F+[528$ /S!.K'\N
M/QKV-N&Z^]?*%\K?&_\ :*6W8F;1M(;! Y79&>?S;^5>KEM%2JNM4^&&K_0\
MG,JKC2]E#XIZ(]@_9X\"_P#"%_#JR$\>R]O\74W'(W#Y0?H/YUZBJX7%11J%
M4 #  QBIEK@K5I5ZDJLNIWT*2H4XTX]!:***Q-PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 0U^>W['W_*2C]ISZ#_T<E?H2:_/;]C[_ )24?M.?0?\ HY* /T*HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KR?X]:AH>D:3;7.HP2W>H$LEI!'.
M\8R>K-M/05ZQ7SU^U#HMV\NE:JJ,]E&K0NPZ(Q/&?K30'BHUJ[6X\TRR% V3
M'YC;<>F<YKT/X.^%4^(7CMK^YAV:;I^)3;F0N-W\*98YQGDUY8:^@OV7=%NH
M;?5]3D1EM)]L4;-QO(Y./85; ][7[M.I%X%+68!1110 4444 %%%% !1110
ME,;V-/;I7'_%+QC'X%\#:KJSMB2.(I".[2-PH'XU=.$JDU".[9G4J*G!SELC
MP#QW,WQH_:$L-"MB9-*TM@DS=L(=TC?G@?@:^J8(EMX4C0;40;54=@.E?/\
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MI7XD''X5]%_L2_LAZC^US\2+C2?ML^B^&].@\_4]4ABWE,\+&F>-S'UZ $T
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MK6WV/$_]X<]:]BHH 15VC'6EHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $-?GM^Q]_RDH_:<^@_]')7Z$FOSV_8^_P"4E'[3
MGT'_ *.2@#]"J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (:_/;]C[_E)1^TY]!_Z.2OT)-?GM^Q]_P I*/VG
M/H/_ $<E 'Z%4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "LSQ1_R+6K?]>DW_H!K3K,\4?\BUJW_7I-_P"@&@#\S?\
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MF[N_:C>.YH =69XH_P"1:U;_ *])O_0#6E6;XH_Y%K5O^O2;_P! - 'YF_\
M!#?_ ) /Q@_Z^=+_ /0;JOU%K\NO^"&__(!^,'_7SI?_ *#=5^HM !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5YU\:?'O_  A/A.58'QJ-[F&#
MU7CYFQ[#]:]!GF2WC>21@D:+N9CT '4U\WZ;#)\</BY)=S[GT/3B"J?P[%/
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MZ 5ZJ.!3 -H]*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#7Y[?L
M??\ *2C]ISZ#_P!')7Z$FOSV_8^_Y24?M.?0?^CDH _0JBBB@ HHHH ****
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M ) /Q@_Z^=+_ /0;JOU%K\NO^"&__(!^,'_7SI?_ *!=5^HM !1110 4444
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M!_Z.2OT)-?GM^Q]_RDH_:<^@_P#1R4 ?H51110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AK\]OV/O^4E'[3GT'
M_HY*_0DU^>W['W_*2C]ISZ#_ -')0!^A5%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5F>*/^1:U;_KTF_\ 0#6G69XH
M_P"1:U;_ *])O_0#0!^9O_!#?_D _&#_ *^=+_\ 0;JOU%K\NO\ @AO_ ,@'
MXP?]?.E_^@W5?J+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 444A- #9&VC).!7RC\=_B%_
MPEOB3[!93[]*L?E&W[LDG\3>_M7?_&CXI2W4W_")>&R]QJ-PWDW$L')7/\"X
M[GOZ5D:C^S;,/!EHUG,I\0Q_O)T9OD<$?<![$>M4@/"3R/6OJ?\ 9SUZZUGP
M2\%TYD^Q3&*-F.3MQD#\*\4TWX(^,+Z^2W?27M59N9IF 0#/7@U]-?#OP7;^
M _#D&F0OYT@)>:;&-[GJ:;8'44M%%0 4444 %%%% "9YII>E/6O-OC1\6K?X
M6:&DJQK=:G=$K;6[' XZLWL*UHTIUZBI4U=LQK5H4(.I4=DCTC?^%+NYKX67
M]H[QXNI?:SJP89S]G\H>5],>E?4WP<^*UK\4?#IN5B%KJ-N=EU; \*W9E_V3
M7K8W)\3@8*I46GD>9A,UP^,FZ=/<]"+?-7!_%SXI6/PQ\-R7DS++?S K:6N>
M9&]2/[H[FM7Q_P"/=-^'OA^XU74Y $08CA'WY'[*!7S%H-F/B5J6J?$OXBWL
M6E>#-+5IGDNGV0[%YV G^$=_4\5C@\+&<7B*^E./X^2+QF*E%K#T=9O\/,VO
MA/X;@ABU3XN?$:^BM-/MU>[6:\.V- .3*<]AT45\3?%_XJ>._P#@J%\<(?AU
M\.A=:7\+=*E$ES=NI6-D!P;F?U)_@2F_&+XQ>/O^"EGQ<A^%GPJAFT?X7Z:Z
MF>X*%(FC4X^T3X_A_N1_UZ?IA^SG^SAX1_9H^'=KX5\*V^  'O=0E4>?>S8Y
MDD(_' Z 5S8K%2Q53F>BZ+LCJPN%CAH<N[ZONS0^!/P(\*_L\_#O3_"'A&R6
MWLK=09[A^9KJ7'S2R-W)/X#H*]'48&*15VC'6G5QG8%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AK\]OV/O^4E'[3G
MT'_HY*_0DU^>W['W_*2C]ISZ#_T<E 'Z%4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !69XH_P"1:U;_ *])O_0#6G69
MXH_Y%K5O^O2;_P! - 'YF_\ !#?_ ) /Q@_Z^=+_ /0;JOU%K\NO^"&__(!^
M,'_7SI?_ *#=5^HM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?V<OV=/"/[,_P]MO"OA2UPO$EYJ$JCS[V;&#(Y_D.@%>JJH7H*%4>E.KSCT
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!#7Y[?L??\I*/VG/H/_1R5^A)K\]OV/O^4E'[3GT'_HY* /T*HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1]DE!^5E=>=X]!]#Z5A^._C=XB^)5M>M9W4/A+P?;*6N]2O)A#&J#J9)2?\
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M_#G>?7^U"/\ V2OT7_X==_LT?]$Y_P#*S?\ _P ?H_X==_LT?]$Y_P#*S?\
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M)_9K_P"B@2?^">]_^,U)_P .N_V:/^B<_P#E9O\ _P"/T?\ #KO]FC_HG/\
MY6;_ /\ C] $?_#TG]FO_HH$G_@GO?\ XS1_P])_9K_Z*!)_X)[W_P",U)_P
MZ[_9H_Z)S_Y6;_\ ^/T?\.N_V:/^B<_^5F__ /C] $?_  ])_9K_ .B@2?\
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M_1_PZ[_9H_Z)S_Y6;_\ ^/T 1_\ #TG]FO\ Z*!)_P"">]_^,T?\/2?V:_\
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M^'7?[-'_ $3G_P K-_\ _'Z (_\ AZ3^S7_T4"3_ ,$][_\ &:/^'I/[-?\
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M_10)/_!/>_\ QFI/^'7?[-'_ $3G_P K-_\ _'Z/^'7?[-'_ $3G_P K-_\
M_'Z (_\ AZ3^S7_T4"3_ ,$][_\ &:/^'I/[-?\ T4"3_P $][_\9J3_ (==
M_LT?]$Y_\K-__P#'Z/\ AUW^S1_T3G_RLW__ ,?H C_X>D_LU_\ 10)/_!/>
M_P#QFC_AZ3^S7_T4"3_P3WO_ ,9J3_AUW^S1_P!$Y_\ *S?_ /Q^C_AUW^S1
M_P!$Y_\ *S?_ /Q^@"/_ (>D_LU_]% D_P#!/>__ !FC_AZ3^S7_ -% D_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:V13J0X[T
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M:Z='*,J;F0[4)'< \D>U?(G_  2*_P"1^_:&_P"PW#_Z-NJZ;_@LE=2)\#?
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MH **** "BBB@!IKXJ^+'[&?QR\<?$CQ!K_A_]H_6/"VBZA=&:UT>".8I:(0
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M'\:?AI\3]&\1^*OVA-6\:Z%9LYN-$N8Y1'< J0 =TK#@D'IVKPSX(3Z7:_\
M!6KXG?\ ":,JZQ)!*OAYKPC&XK'@)GC)CWX[^E?INRY%?,'[67[!OA3]I[4M
M/\1QZG=^#_'.GJ$M]>TT?,R@Y42 $$[3T(((]: /7_CY)X>C^"WC4^+6MD\/
M'2K@71NR!'C8<#GOG&/?%?(W_!&XZDW[.>OB?S?[)_MZ7^S_ #,[=NQ=^W\<
M9K#;_@E_\1/'K6NF?$_]H7Q!XK\*V[JW]E[IF,@!SSYDK+GW()%?=?PS^&>@
M?"'P/I/A+PM8)INB:9%Y4$*G)/<LQ/)9B223W- '5BEI*6@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /ES]IS]F3XK_&3
MQW::QX(^-NI_#C2H;-8'TRS25DDD#$F0[9%&2"!^%9O[.O[*?Q@^$OQ-MO$/
MC/X\ZIX^T..WFA?1;J.41NS+A7.Z1A\IYZ5]:48XH _+O]A>+2O@1_P4"^-?
M@37Y4L=5UAY?[)DG&P3J9S/L0GCE'!'KLQ7W=^U%XJT3P7^S[X\U+Q#/#!IW
M]D7$)6=@!([H55 .Y)(P*\U_:S_8-\*_M07UAXA35+OPAXXT]0EOKVGC+,H.
M5#KD9P>C @CUKPZW_P""7/C/Q]JVF1_&#XZ:YXZ\-Z=(&BTHM+\^/]J21MN1
MP2!GWH [C_@D7X?U+0_V1K6>_BDMX-1U>ZN[-) 1F+Y5WCV)4_E7VRO2LOPO
MX9TWP;X=T[0M'M([#2M/@2VMK:(86.-1@"M6@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &25\G?M%_LJ_&#XM_$B?7_!O
MQXU3X?Z*]O'$NC6L<I174?,_RR*.?I7UI28% 'QCX!_9B^._P@T'QUJ%S\:=
M3^).KWFA3VFD:==!XQ#=M]R4%Y" 1SSQ7S-^S[\+_P!L_P#9L\/ZEIOA3X=Z
M(\FJ7;7M]?W]Q!+<W$A[N_F<XY_.OUGP/2@]* /P_P#C=XE_:2O/VQ/AC?>+
MO#FEVGQ2A$7]@V$#1F";YFV[B'*]=W4BOUS_ &<=3^).L?"O3[GXL:=:Z5XU
M:647-K9%3&J!SY9&UB.5QWKROXQ?L?ZC\3OVL/AQ\7X/$=O8VGA01B33)+=F
M>?:S-PX.!G=Z=J^GT[T /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:*
M $P*,4M% "8HQ2T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4E+10 F**6B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2C%+10 E+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TUOSH 6EKP/X[?M,:
MG\!9VN-2\#7=]H+3+!!JD-XBK(Q7.-F,CN/PJ_\  7]H34_CM"FI6W@FZTGP
M\S/'_:DUVC@R+_"$ R>O6@#VVBFK]VEH 6BF[A2T +12;A1N'K0 M%%?/O[9
M'Q\\1_L_^#] U;P[:Z==37VH-:3+J,3R*%\IG! 5UYRM 'T#2UXM^S_XJ^)_
MQ T#2?$_BM_#4.B:E:>?#9Z9;SI<J2?EW,[E<<=!7M / H 6BDH) ZT +12;
MA2;A0 ZBDW#UHH 6BDW"EH *2D;I[U\Y?M,?M->)O@#")8/ Z:AIUP_DVVK3
MWP$9DQG!C"[OU'2@#Z.S17DOPW\:>,?BA\"M'\2:>VD6/BG48/.7[5!(UFGS
M$8*AMW0>M>$P_M4?%70_VBM-^&7B&R\+R>;=Q0SW.GV\XS&XSE2TG!QZB@#[
M1HI!2T %)7,_$#Q'K'A?0FOM%\/R>)+E6^:SAG6%@N,ELMUQZ5\T^#?^"A^@
M>)/'&F^'M0\+W>AB[NQ9R7DURK) Y.W+ #IGB@#Z]HIH8>M<Q\3O']A\+_ N
ML>)]2!>TTZ$RF-3AI#V4$]R: .HS2U\I?"O]N"Y^,?B(Z+X:^'5]=W4:"6<M
M?1JL4>X N21[]*^JT^[0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I,4M% 'RI_P %'%!^!-ID=-5@_DU;
MO[ 2!?V;M)_VKNX)_P"^A6'_ ,%'/^2#VW_85@_DU;W[ 9!_9OTC!SB[N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG?E%.#SSGT')K,^-UQJ?[:&K:!X6\&Z+J%IX6T^Z^TW_ (DU2T:WBQC&V,.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !364G&*=10!6EL8;C'FP
M1R[>GF(&Q^=2JNW  P/05)10 4E+10 E+110 4444 %%%% ",N:JKIMLF0MM
M"!U.(UZ_E5NB@"&WM8K96$421!CD[% R?6IJ** "BBB@!*,4M% "8'I12T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !12$XY)P*9YT?\ ?7\Z )**C\Z/
M^^OYT>='_?7\Z )**C\Z/^^OYT>='_?7\Z )**C\Z/\ OK^='G1_WU_.@"2B
MH_.C_OK^='G1_P!]?SH DHJ/SH_[Z_G1YT?]]?SH DHJ/SH_[Z_G1YT?]]?S
MH DHJ/SH_P"^OYT>='_?7\Z )**C\Z/^^OYT>='_ 'U_.@"2BH_.C_OK^='G
M1_WU_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_ +Z_G1YT?]]?SH DHJ/SH_[Z
M_G1YT?\ ?7\Z )**C\Z/^^OYT>='_?7\Z )**C\Z/^^OYT>='_?7\Z )**C\
MZ/\ OK^='G1_WU_.@"2BH_.C_OK^='G1_P!]?SH DHJ/SH_[Z_G1YT?]]?SH
M DHJ/SH_[Z_G1YT?]]?SH DHJ/SH_P"^OYT>='_?7\Z )**C\Z/^^OYT>='_
M 'U_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_ +Z_
MG1YT?]]?SH DHJ/SH_[Z_G1YT?\ ?7\Z )**C\Z/^^OYT>='_?7\Z )**C\Z
M/^^OYT>='_?7\Z )**C\Z/\ OK^='G1_WU_.@"2BH_.C_OK^='G1_P!]?SH
MDHJ/SH_[Z_G1YT?]]?SH DHJ/SH_[Z_G1YT?]]?SH DHJ/SH_P"^OYT>='_?
M7\Z )**C\Z/^^OYT>='_ 'U_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_OK^='
MG1_WU_.@"2BH_.C_ +Z_G1YT?]]?SH DHJ/SH_[Z_G1YT?\ ?7\Z )**C\Z/
M^^OYT>='_?7\Z )**C\Z/^^OYT>='_?7\Z )**C\Z/\ OK^='G1_WU_.@"2B
MH_.C_OK^='G1_P!]?SH DHJ/SH_[Z_G1YT?]]?SH DHJ/SH_[Z_G1YT?]]?S
MH DHJ/SH_P"^OYT>='_?7\Z )**C\Z/^^OYT>='_ 'U_.@"2BH_.C_OK^='G
M1_WU_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_ +Z_G1YT?]]?SH DHJ/SH_[Z
M_G1YT?\ ?7\Z )**C\Z/^^OYT>='_?7\Z )**C\Z/^^OYT>='_?7\Z )**C\
MZ/\ OK^='G1_WU_.@"2BH_.C_OK^='G1_P!]?SH DHJ/SH_[Z_G1YT?]]?SH
M DHJ/SH_[Z_G1YT?]]?SH DHJ/SH_P"^OYT>='_?7\Z )**C\Z/^^OYT>='_
M 'U_.@"2BH_.C_OK^='G1_WU_.@"2BH_.C_OK^='G1_WU_.@"2BFJZL,J<CV
MIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $5U_J)/\ =K)7CI6M=?\ 'O)_NFLF@ S1FBB@
M S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1F
MBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@
MS1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FB
MB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S
M1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB
M@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1
MFBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@#0T__ %;?6K55=._U3?6K
M0H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (KK_CWD_W3636M=?\>\G^Z:R: "BBB@ HHHH
MXGXF_%_P]\)+6TN?$+7L<%R6"26EG).%V]2Q0':.>]><6?[<7PHU"X6"UU/4
MKF=C\L<.ESLQ^@"U[%XVA2X\':]&X#*UC,"I&0?D-?G;^P-:QR?M#%F0,8;"
MY9,CH>G\C0!^D6EZE%J^G6U[ )!#<1K*@E0HP4C(R#R#@]*YKXD?%/0_A3I=
MOJ&O&\6UF<QJUG:27!4@9)8(#@<=377XZ57U*-9--O$9=RM!("I&01M- 'A-
MO^W-\);J58X-5U":1NB1Z9,Q/X;:L6_[;?PEEU"*SGUN[L))#@->:=-&J_4E
M>![U\=?L6V<#?M+V<31J\<8N=JLH(& <<5[]_P %#O!NB+\-])\0+9P6VL0W
MZVZS1H%:6-E.Y#CJ!@'\*8'UEI6K66MZ?!?Z==PW]C.GF17$#AXW7^\".U<O
MXA^-'@/PG>?9-8\8:+I]TK8,$]XBN/J,\5\]?LA76O1?LG^(&MH+F^N@UTFF
M0QY+ME0 %_X$:I>%_P#@G?X=O_!\4_B36]6_X2RZ@\Z>2&51#!*PSM*E26 )
MP3N_*D!]:>'_ !'I7BBP6^T?4K75K-ONW%G*LB'\16=XI^(OA?P1<6T'B'Q%
MIFASW0)@CO[E8C+@X.T$\]17Q)^P7;ZYX;^.'B[P[%/)<Z)9P30W;*3Y/FI)
MM1QVW'!Q[9KU7]J[X5V_QC^,7PQ\,7%X^GQ7L-[ON8D#LJHGF< GOMH ]R_X
M7A\/ ,GQQX?Q[ZA'_C72Z!XCTOQ7I<.IZ+J%OJNG39\NZLY!)&^#@[6'!P>M
M?)G_  [7\,8./&&J'_MV3_&O>-!\(6_P%^!EYI.GW4U]#HNGW$L<[H ['#-T
M'?)H WO$GQ>\$>#[S[)K?BW1]*NLX\FYO$5_RS6QX>\6:-XNL_M>AZO9:O;=
MYK*=95_-37QK\,OV"=.\=>!;#Q!XK\1ZHFO:M MW^ZVXCWC*[]P)8\^HKR;X
M&MKOP+_:MM_"D-Z\J+J1TV[CC)$=Q&>C%?7!!]C3 _3H444$X%( HKSOQ!^T
M)\-_"^L-I6J>,])M;]"%DA:X!\LGLY'"_C7;Z/K%CK^G0W^FWL%_93C=%<6\
M@='7U!'!H NUPGQ6^,>A_!W2X;_7(-0GAFW;?L%JTVW;U+$<*/J17;S3)!&T
MLKK%$@)9Y" J@=<DUXM\2OCU\-=;\%^+="@\9:+<ZA)IMQ$+=;E3O;:1M4]"
M<]A3 D^ _P"T]I/Q]\1:UI^CZ1>6%MIL*S?:+QEW2;F QM!./7K7M-?!_P#P
M33C_ .)UXXE*G/V>!?IEB<?I7W>3[X'?GI2 YKXA?$#3?AKX=DUG58KR:U5@
MFRQMFGD)/^RHX'N>*\G^%G[87A[XP_$J'PGH6C:A&KPR3&\O-J8V#.-@)//O
M7=:Q\?OAOH^JS:+?>--%@U!0T;PO=+\C8QM8] ?8U\4_L7K#-^U5J[P;7@\J
M]:-EY4J7."/;% 'Z-44A[G.!W-<!K'Q\^'/A_5_[+U'QMHMK?YVO%)=K^[/H
MQSA?QH ] HJOI^H6NK64-W97,5W:S*'CFA<.CJ1U!'!J+5]:L/#^GS:AJ=[;
MZ?90KNDN+F41H@]230!YI\8?VE/"_P $[H6^MVFK7$K('4V=H6BYZ R'"Y)]
MZM_ 3XX6GQX\-W^MV.F3:7;6UT;94N'#,^!G<<=.M>/_ +5_QF\ ?$']G_Q/
MIFA>*M*U?4(Y;9TMH)P9#B922HZD#U%3_P#!.V/;\%=1?&"VJRC/T5:8'U-3
M6;:"QX4<DGH*<,5\B_\ !1'Q=K7AGPCX9@TG5KK34O;B5+B.VE,?FJ$) ./_
M -5(#ZUAN([B,20R++&V<.A!!_&I:\I_9EFMH?@7X+@^U1O</8"0H907R222
M1UKM_%WCOP]X!T[[=XCUJST:UZ*UW,J%CZ 'DGZ4 ;]%>6:#^U!\+?$6HI86
M7C.P^U2$*BW&Z .?12X )KU%&#J&4@JPR"#D$>M #J**AO+N"QM9;BYGCMK>
M-=SS2N%1 .Y)Z"@":BO-;']I'X8:EJG]GV_CG1FNM_EA6N0%9LXPK$X)S7HQ
ME58]Y90@&XL3@8]2?2@"2LOQ1XBM?"/A^]UB]2XDM;2,R2+:PM+(0/[JKDDU
MR-U^T)\-;/6CI4WCC1([T-M*-=J%#9QMW=,Y[9KOK>XCN(XY89%FB<!EDC((
M8>N: /G+1OVXO"OBKXB:-X2T31-4FN=0NUM&FNU6$1$G&=I.>/?%>K?%?XR:
M%\&],AOM=@U&>&;=M^P6C38V]2Q'"_B:^'&M4M_^"AZPJH"#Q-&< >L:D_SK
M[V^*$"W'PU\51,H*OILX((_V#3 \]^!?[4&D?'OQ!K-AHVD7=C;:?"LOVF[9
M07W' &T$X_.O:J^"O^"9ZAM>\9L>OV.#'_?5?<7B#Q)I7A32Y=2UK4;72K&,
M9>XNY0B+^)I :=%>8:9^TS\+]8U)+"U\;:6;IV"()9/+5V/0!C@'/UKTU?S]
MZ '445R/CCXM>#OAP8E\2^([#1Y)O]7%/*!(WN%ZX]\4 ==17.^#?B)X9^(5
MF]UX;UVQUJ&,XD-G,KE">S#J#]:NZYXJT7PW TVK:O9:7$HW,]U.L84>IR>E
M &K17'6_Q@\$W/A5_$R^)].7P^LS6_\ :,DZI"9%ZJ&/4\CIUJSX,^)WA/XB
M),WAKQ#I^M&'F6.TG5GC';<N<C\: .HJ"_O(].L;BZEW>5#&TC[%+-@#)P!R
M3[5,?_U5R'C3XN^"_AU-%%XD\3:;I%Q(,I!<3@2$>NW.<4 >*>)/V]/"&E:[
M!H]AH.M7>H23I"5NH?LRKN( .&^;OGI7TQ#)YL*/C&Y0V/J*_-C]J3Q!HGC#
M]J#0=3T'4+35["X2Q NK*02(Y#G(R.]?I/"-L,8]% _2@!YX%1-<1I,L+2(L
MS E8RPW$#J0.]%TVVUN&#;2L3$'TX/-?GW^R-XLU3Q7^U!JUYX@UN>^-K!>"
M.2]N"54!R !DX''I0!]??&#X_>'/@G';MKUOJ<YGC,J_8;0R( "!\S_=4Y/0
MFJ7P!_:"T[]H"QU^]TS2[C3;72[B. ?:7#-+N4MNP.F,=*A_:J,-[^SKXR,;
M))&;3<K(0PX8="*\._X)XZKI_A[X6^-M4U.^@TZQCU&)I;FYD$<<8$9Y+'I0
M!]GT5QWA#XP^"/'U])9>'O%6EZO>H"6M[>X4R8'4A<Y(]Q789XH 6BN1\:?%
MKP;\/)(X_$GB;3M(F?E(+B=1*P]=O7'X5J>%_&6@^-M/^W^']9LM:L]VTS6,
MPD4'T..A]J -JBCJ*R]8\3:1X>@:75-4L]-B499[J=8P/<Y- &I17$+\:O S
M>%+OQ,OBC3VT"UG-M)J"R?NC(.JJ?XC],UTGAWQ%I_BS0;+6=)NDO=,O(_-M
M[E#A73D9Y^AH TZ*X+7OCU\._"^K?V7JGC/1[*_!VM#)=+F,^C'HOXUV>G:G
M::Q8PWMA=0WMI,H>*>W<.CKZ@C@B@"U17(^-OBSX.^'+1IXD\16.DRR#*033
M#S6'LHY-0^"/C)X)^)%Q+;^&O$MAJMU&-[VT<F)@OJ4/./?% ':45S?B7XC>
M%?!ML]QKGB+3=+B3);[3<JAX[ $YS[5>TSQ3I.K:#9ZU;:A"VE7D8E@NY'"(
MZ'H03B@#5/:O'OC%^U'X4^"NHM8:U9ZM<7?EJZ_9;0F([AD#S#A2>.F<BNWT
M?XI>$?$7B9_#NE^(;#4]8CB:9[6TF$K(HZ[B.!7BW_!06%9/V>99",M'JMIC
MCU8CB@#T_P"!/QCM_CEX'?Q-::=+IEM]LEM4AF<,QV$?,2/7/2O0+BXCM8S)
M/(D,0ZO(P4?F:^<_^"?B!?V=+5@.?[6O<G_@2UX!^VCXLUJ;]I6R\.C6;I=#
M7^SG%BLQ6%6=_F) X_.@#]#U^8@>O2O#/"/[7W@WQE\69O =G#>)=B62WAOI
M% AEE0X8#G/4'J*]I74+&&-A'>6[1P *S><NU<<<G/%>!>&?AG\$/"GQQCUK
M2]6MIO&>H2NUOI<=ZLR1RG)9UC494GGDDCTH ^AUZ4M4=2UK3]%A,NHW]M81
M*,E[F58QCN><5S^C_%KP9K]CJM]I_B?3;K3]*8+>WJ7 \B$GD R'B@#KJ*XW
MPC\8_!'CW4)++P_XJTO5KU,YMK:X5I"!U8#/(]Q78G_//% "T5Y_XP^/GP^\
M WSV.N>*K&UOH^7M48RRH/\ :502!6IX/^*W@_Q]9O=>'O$FG:I%&<.L5PNY
M#_M \C\: .LKAOBK\8-$^#NCP:CKD&H3P3,RJ-/M6F(VC)+$<*/<XKMXY$FC
M#Q.LB'HRD$'\JY?XK1";X8^*XVY5M,G&#T^X: . ^!/[4&C_ !^\1ZYINC:1
M>6-OIENEQ]INRN9-S[<;0>/SKV@'(S7P1_P3=N+?3]6\?WES-';6\-C!YDTK
M!551(3DD]J^P/#OQN\ >+-8_LG1_&&CZCJ).$MX;M"TGKLY^;\* .XHI.WH:
MXCQO\;O WPXG%OXB\36.G79&?LI??-CUV+DXH [BN*^*OQ;T7X/Z+#JFMP7\
M]O,[(HL+5IRI"Y.[ PHQW.!4/@?XX^ _B1<FV\.>*+'4;P#/V42;)B/78P!_
M2MKXA0BX^'_B>)QE6TRYX(R.(FH \Q^!W[5&C?'OQ?K&CZ'I%Y9VVGVBW7VJ
M\907R^T#:"<5UGQM^-VA? GPK%K6MI/<"XG^SVUK;@%YGQD]>@ Y)-?('_!,
MY1_PF_C9R.1H]O\ ^CC7UM\<O!?@#XB>$6TCQY?VMC8PR">*X:[6"6W<#[R,
M>G'7@\=J -GX1_%71_C)X)M?$NBB5+69VB>&==LD<BG#*>WXBNSKSSX#Z;X'
MT;X>VMA\/;B.]\.VTLD0ND??YTH/SL6_B.>XX]*W?&GQ,\+?#N%)?$NOV.CB
M7B-+F4*[_P"ZO4_E0!TU-9MJEF("CDD^E<-X+^.'@/XB:@;#P]XHL-2O\;A:
M*^V9@.I"'DU\[_\ !17Q;K/AKPWX3MM*U:[TZ&^FG2YBM9BGG*$& V.<9H ^
MOH;B.XB62*194;HT9# _0BO$OB9^UWX/^%OQ(M?!VIP7LUW(8Q<7," QV^\X
M7.3D^^.E=%^SC-:V_P #_!4 NH7F.FI(RF52W.221G-</\8_AO\  _6O'FG^
M+O&6LVEIK,+QK]GCOE5;Q@PV!X^2Q!QTQ[T ?0T<BRQHZG<K ,".X/(IU,B*
M>4FP8CVC8/1<<?I7/^,OB%X;^'EBMYXFUVRT6W8[5-U,JESZ*.IH Z.BN1\$
M_%KP;\1I'B\->)-/U>:-=[P6\H,J+ZE>N*ZZ@ HHHH **** -#3O]4WUJT*J
MZ=_JF^M6A0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 177_'O)_NFLFM:Z_X]Y/]TUDT %%%
M% !1110!D>,/^11UK_KRF_\ 0#7YX?L!?\G"7'_8.N/YBOT,\;3);^#==DD8
M*BV,Q+$X ^0U^</[#?B32_#OQXDN]4U"VTZT>PN$$]U*(TW9! R: /TXJ"]_
MX\;K_KB__H)KDM4^,W@72].N;J3Q?HNV*-GQ]NCR2!D#KUK+^%/Q"G\;?!VT
M\5:S-:VSWD%S*67$<?EAG"=3UV@9H ^!OV18;VY_:(EBTVY2SU!X+Q;>XD3>
ML4F&VL5[@'M7U'XL_95\9?&;7M.G^)WCN"^T>Q;<FF:+:F%6SP>6Z$^O/M7R
M[^QEJUK!^TM83RSQQ17'VE8VD<!22&(Y-?I]&ZR*&4JRGH5((- &7X8\,:9X
M-T&RT71K1+#3+./RX;>/^$#]2?>O"OVA$^/&H:MJ-I\/8K2'PY]E5/,R@NG<
MYW[">AZ"O3/CA\0KSX5?#VZ\46MM'=I8SPFXBE!(\DN!(5Q_$%R1[UN>%_B#
MX=\8>&X->TK6+.XTN2,2F;SE'E\9(;)X([YH ^(/V._V@)O /C:/X<^(="M[
M)M0O#;&]2(I=K=EB-LY).[+<=L5[G^T]\.?B)XT\=>"[WX?L+"ZL8;I)=5:1
M46W$BA2/7)!/2O$_"_@T?'W]M'5O%OA],^$=+U&.YFU%5Q%*T2*H5?4LRG\.
M:^IK#X[:=#\8O$'@#7_LVAWMN(I]+FEFPM[$ZY)R< ,&R,=\4 ?%OQ6\$_'7
MX QV_B74/%=[=VC2@&\M;UI51^H#J>Q^F*^R?V7_ (N7'QL^$UIK6HQI_:D,
MSV-Z% VR2* =V.VX,./7-<K^V]XRTG3_ ('ZEH;3PW6KZQ+#%96<3B21R'!+
M!1SQC^56?V8?!<?[/W[/_P!H\5SII;R/)J=\9SCR P4!#[X4<>I(H ]A\9>,
M=*^'_A6_U_5[B.VTVQB,CL3U]% ]2> *^3OV6?A'J?Q'^*6J?&SQ/:M9V]Y<
MR7&DV4@Y<L<+(<]E48'J>:XGQ?\ M1^#?B]\3!/XTFOT\ :1('T_1+:$M_:$
MH/\ K9_;T7_Z]>QP_P#!03X8V[0V=I9:L(EVQ1K';*JJ.  !G@#B@#ZAZ5SW
MC_PW<>,O!>L:)::E)I$]_;M M]$/FASP2.1SC-;UO.MU;Q3(,)(H<9ZX(S7S
M;^WIXXUSP7\(;./1+J:Q_M*^%K<W,!*N(]C-M##IDC^E '%?'[X,_ OPI\,M
M4TN*_P!+TOQC:6C36CI=[[J:95S\ZY.0YZY]:J?\$VM=OKC1_&.D2SR26-O+
M#/#"QRL;,&#8';.!^58?PG\5?"+PW^S3=A$M;_Q]>Z?<I<Q-;&>],Q+8(R#M
M4+M.1@8!-7/^":=Q'')XWB,BB<_9R$+?,?O9('XU0"?M*?$_6?B=^T-H_P )
M+._FT_PN;RWM;]+<[7N&<@N6;NH!  ^M>T_&/]F'X;3?"K7%M/#-KIMQIUC)
M/:W=H-LJLBY&6_BSWSUKY,_:@MM3^#_[5O\ PE MR\;7<&K6C-D+,%P"N?7(
M((^E?4'CK]K/P%XM^%6L0:#>S:IK>I:;*D>DV\#&:-BAW%^, +SD^U2!Y/\
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M'S.K2,%12!T)Z_2OJ*ST%?AO^SF=%O)8X9-.\/2PREV"C?Y3;A^9Q3 ^4O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\G:.,GVKJOAG\ _ WPB>27PUHD=I>2#:]Y(3),5]-QZ#Z5Z%10 =L5Y]XZ^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]Y/]TUDUK77_ ![R?[IK)H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\L_:+^'.E>.OAUJUS?O>17.EV4\]K):7
M3P[7"YY"G##CN*]3KDOBY)Y/PM\6.>@TR?OC^ T ?(/_  351I-4\<W#_,YC
MMP6)R3R2:M?\%"/A[INAZ7IWB>TFO4U#4[PQW:-=NT+@)QA"<+T'2JG_  32
MF'V_QQ#QN\JW;KCC)Z"NN_X*12;?AYX8C_B.H,>>OW#0!A?!S]E&'XU? WP_
M?>+/%>K!!;N-)T^R=4M[--S8+*0=[$Y)/';FO-_V-]0UCX>_M+3>$!>.UI(]
MS9W,.3Y<ACSA\>O'ZU]B?LDR+-^SQX**'<OV5AD8[2-D5\@_ >6.;]N&\DR.
M=1OMN?7YN* /9_\ @H-X3N;CX:Q^(&UV^^R6UU#"FC#:+8LS<R'C);ZGBL7]
MC?X :;K_ (#\->-I_$&NPW5O>R2#3H+K;:$HV!E,<Y[UWO[?X/\ PSY.=N57
M4;;/M\^*I_L._$#PY;_ _2M'GUNRM]5AO)8VLYIE64EF&W"GDY]J /.?VF?B
MU?>-OVB=+^%TFM-H/A&WNH8-4>.;R1(6 9C(_90I'?O6-^U_X!^%_A/P9HNN
M?#R]TVPUNTNU@9=*O-\CQX.'(#$[@0/FKBOVJM)7P)^UA=ZSK&G?;-&OKJWU
M Q3+E)XMJJZ^_P!T\5]H^#?AO\%?%6@V^O:%X?\ #<^G3QB03*J';ZALG@CO
MF@#CO /QTU:Z_8UN_'$G^D:]I=A/;F1@2'GC^57;\&4FO,/V%?!&B?%:W\9^
M)O&-K#XIUK[7%!OU(><8U968D ^I'X8KZR^R^#+KX<:A%;1Z;+X-DMIA.MF%
M^SM& 1)]W@]"/PKX2^!-YI.E^,/%]_X#^*UI\-M":9(H+;Q$(WENE.3NVL0,
M+V/7D9H P-?^'\.C_M<7'@;0+S4-(T2^U2.%TTN<QM'&P!.TCL,GKTKZN^.G
MP'T31_@#?HVJ:U>7?AVQFDL[Z:_?S&+$,?,P0'Z=QTK+^"_A'X/^"_&D_B6Y
M^)VD^,_'5](Q;4+B^B7#-U\N,$X/;KT]*]8_:,E7_A1'C23<K*=-DPP.0<CC
M![B@#X9_94^#WB#XW>$_%VA6_B4^'?#9GADO_)BWRW4@5MBGD?(.2>>N*^OO
MAW\#?$7P]_9[O_ 6G:[':ZY)).8=5@!'EAV&&'<-M%>/_P#!--P?#OC= ?F6
MZMF_\<>O0/VYOBIKWPS^%^FQ^';EK"ZU>]^S2WD?WXXPA8A3V)QCZ9H \\_:
M _9)^''A?X6ZIJMMK,MKXLL8#<_:-0U 2/?2 99&5N[<X(Z9[UI_\$Z?%^IZ
MWX-\3:)>7<MQ:Z?-&]IYAW& .IR%)Z#(!Q7)>$;'X3V/[,-WXGUO4K+6_'6H
MZ?.LDNH7!N+M;DE@L:(22N!M[=\UK_\ !-/C2?&W/(EM_P#T$T >+?M:>#9M
M!_:0BTN]UR_UJ2^2TG>]NRHE422,-JX& % XXK[C\)_"[1_V;?#_ (NU]-;U
MK78EM6N9SJUUYQ41*2 O QGO7Q]^W-<+8_M3:;<3$K#'8Z?(S8XVB1R3^ K[
M=\;:KHGQ>^&_BS1O#FLV6L7%]I4H1+.=7(WJ=A(!XS[T ?(W[/>NZ'^T1XZ\
M5>*OB[K5G<0VA2/3M%U"[$5M'O).53(R% Q]3FN/\4:UI7P#_:JM)OAYJD;>
M'+B>!I+:SN#+ 5<[7C."<@=1GI63^R'=>"-.^(VI>&_B3I%@Z7B?9[>35$&+
M:Z5L&,D],\CZXK[X7X<?"GP8;:Z_L7PWII>18X))%C^9R?E5<YR?04 >;?MG
M_M#:E\&_".GZ?X<*Q:[K0?;=.,FWA Y91TW$D 9Z=:@^'7[(/@7Q9\,]+O/%
MMG<ZYXGUBT6[N]8N+F3SUDD7<-O./ER,9!KR_P#X*3^&[O[1X1UU%8V/ER63
M2C[J2'#*/;(!_*O9?@)^U#X$U/X1:)-K/B.QT74M+M([:[L[R<)+NC 4%0?O
M;L#&.YQ0!\I_LZ^%T\$_MH6F@Q3O<Q:=>75NDT@^9PJ'!/O7Z85^:WP/\16O
MB#]N*+5K=9$M+[4KIX1*NQBK*=N0>F>/SK]*338'C'[5GQNN?@?\,6U+35C;
M6KZ;[)9&1=RHQ!+.1WP 3BO*/@S^ROX=^,GP[LO&?Q%O=2\0^(M>C:X-VUT5
M^SID@; ..WT]JN_\%%O#-WK'PKT35+:.22#2]0+7!49"*Z%0Q_'O6_\ L2_%
M[1?%GPETOPV]]!!KNBH89+.60*[1;LK(N>HYY]*0$'PE\*W7[*7P3^(-Y?P.
MPLKRXNK-IF!\^(#$3<=,\9KR?]F>3PK\;KCQ-XN^,&MV6KZF9Q#:66K7@CC@
M0@DE(\C [9KZF_: T1O'/P7\::-ISK>7KV+XB@<,P8?-C /4XKXB_8JO/ASJ
M&O:IX9\?:5ID]]>,KZ=/J2#&\<-$&/0]_P * #P?XIM_@/\ M>-I7@W55O/!
M]WJ,=JT$,WFPO!*!QD'!*$G![8KWO_@HPNWX0Z*.F-54?^.&O9[?P'\+O!>I
M:>8=(\.Z9>W,RQ665C#R2_PJG4EOI7BG_!1J4#X2Z%&>K:J#U_V#0!Z9^QVH
M3]F_P6!P/L[G_P BM7R;^VT@;]JK1 >08-._]&FOJ[]C.7SOV:_!A#!B(9%/
MU\QN*^2?VX+C;^U+IC!@#%#I^?;$M 'WS\4/ 6E_$3PW?:7JQN5MUWS*UI</
M"ZNJD@[E/Z5\$?L%VKM^T=J$DDCRR6MA=)YDS98_-MY)ZU^C&I9FM[P)R7BD
MV^^5./SK\S?V1/&^D?#G]HR^E\0WL>DVEPMW9M<7#;(XY-YP&)Z<C'- '9?\
M%"/ .G>$-2T/5--FODEUIIY+R&6Z>2)F&""JDD+WX%?9'P"MQ9_!/P1".BZ5
M"?S&?ZU\9_\ !0?XE>'?'-YX9L/#^IPZPVG),UQ<6C>9"C-C"[AQG'Y5]H_
MF1;CX,^"73E6TJ#'_?.#^M 'Q#J"!_\ @HQ#GMXFA/X^4M?>OQ"TC6/$'@G6
M=-T#45TC6;JV:*UOC_RP<_Q?A7P!JEX!_P %$+>8NJH/%$*L<\?<4=:^H/VV
M/B9KOPR^$(FT&X>PO[^[6T:Z3[\2$9.T]B?6@#S/XW?LB?#W0/A7J>IR:U-'
MXQM;;[2=0U#4 [7DP&64JW8G.,<TW_@F_P",M2U+0?%6@7=U)<6=B\,]JDI)
M\G<"&5<] 3CBN>^&=C\+%_9PU#Q9XGU*SUKQM=VEPCRZE<F>Y28@A$CC))'8
M\"K/_!,__F>1QNVVW&>>A_2@#@_V]OA[IG@/QMI!TN2]\K58);JXAN;IYD\S
M?U4,>,YZ=*]:TK]D?Q5XUOO!'CW7/%\-WJUNME/_ &;Y)6""V1%VQQMD\A0,
MY'4FN)_X*32K_P )MX0 .=MA(QXZ?.,5]P^!9%D\#^&V'*MI=J0<@_\ +%*
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M^Z:R: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPKP5\)OCK\%M._L'POX@\.>)_#<+'[''JZ21S1*3G'' ^@)H \/_ &J?V/\
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MZ<MVD1)AG3Y9HB>NUNH'MT]J[>B@#YZM/V+?#<.DIHMUXK\5WWAR-@R:/-J
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MOK5H55T[_5-]:M"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH BNO^/>3_=K(!K:90ZE2,@]:
MB^Q0]T_4T 9=)FM7[#!_SS'YFC[#!_SS'YF@#*S1FM7[#!_SS'YFC[#!_P \
MQ^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H RLT9K5^PP?\ /,?F:/L,'_/,?F:
M,K-&:U?L,'_/,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_ #S'YF@#*S1F
MM7[#!_SS'YFC[#!_SS'YF@#*S1FM7[#!_P \Q^9H^PP?\\Q^9H RLT9K5^PP
M?\\Q^9H^PP?\\Q^9H RLT9K5^PP?\\Q^9H^PP?\ /,?F: ,K-&:U?L,'_/,?
MF:/L,'_/,?F: ,K-&:U?L,'_ #S'YFC[#!_SS'YF@#*S1FM7[#!_SS'YFC[#
M!_SS'YF@#*S1FM7[#!_SS'YFC[#!_P \Q^9H RLT9K5^PP?\\Q^9H^PP?\\Q
M^9H RLT9K5^PP?\ /,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_/,?F: ,
MO=29K5^PP?\ /,?F:/L,'_/,?F: ,K=1FM7[#!_SS'YFC[#!_P \Q^9H RLT
M9K5^PP?\\Q^9H^PP?\\Q^9H RLT9K5^PP?\ /,?F:/L,'_/,?F: ,K-&:U?L
M,'_/,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_ #S'YF@#*S1FM7[#!_SS
M'YFC[#!_SS'YF@#*S1FM7[#!_P \Q^9H^PP?\\Q^9H RLT9K5^PP?\\Q^9H^
MPP?\\Q^9H RLT9K5^PP?\\Q^9H^PP?\ /,?F: ,K-&:U?L,'_/,?F:/L,'_/
M,?F: ,K-&:U?L,'_ #S'YFC[#!_SS'YF@#*S1FM7[#!_SS'YFC[#!_SS'YF@
M#*S1FM7[#!_SS'YFC[#!_P \Q^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H RLT9
MK5^PP?\ /,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_/,?F: ,K-&:U?L,
M'_/,?F:/L,'_ #S'YF@#*S1FM7[#!_SS'YFC[#!_SS'YF@#*S1FM7[#!_P \
MQ^9H^PP?\\Q^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H RLT;JU?L,'_/,?F:/L
M,'_/,?F: ,K-&:U?L,'_ #S'YFC[#!_SS'YF@#*S1FM7[#!_SS'YFC[#!_SS
M'YF@#*S1FM7[#!_SS'YFC[#!_P \Q^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H
MRLT9K5^PP?\ /,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_/,?F: ,K-&:
MU?L,'_/,?F:/L,'_ #S'YF@#*S1FM7[#!_SS'YFC[#!_SS'YF@#*S1FM7[#!
M_P \Q^9H^PP?\\Q^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H RLT9K5^PP?\\Q^
M9H^PP?\ /,?F: ,K-&:U?L,'_/,?F:/L,'_/,?F: ,K-&:U?L,'_ #S'YFC[
M#!_SS'YF@#*S1FM7[#!_SS'YFC[#!_SS'YF@#*S1FM7[#!_SS'YFC[#!_P \
MQ^9H RLT9K5^PP?\\Q^9H^PP?\\Q^9H RLT9K5^PP?\ /,?F:/L,'_/,?F:
M,K-&:U?L,'_/,?F:/L,'_/,?F: ,K-&:U?L,'_/,?F:/L,'_ #S'YF@"+3_]
M4W^]5RF1PI"N$7:.M/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img8619836_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\^3_ )Z-_P!]&CSY/^>C?]]&F44 /\^3_GHW_?1H\^3_ )Z-_P!]&F44 /\
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M/<FOH\KPRDG7DMMO\SP\SS#ZG#E@KR9YIHO[(]Y-"KZOXBAMY",F*S@,F/\
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MCK*Q;^SI&/\ KD]$S]Y?3)'(Y_6"*5)XTDC=9(W 974Y# ]"#W%?S^5^NG[
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MU!!J,3=4**C\-OQOJ$=V2T445YAH%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5SWQ#U8Z%X$\07Z,4D@L9FC8=GV';^N*Z&O//V@9_L_P?\1-G&8XT
M_P"^I4']:Z,/'GK0B^K7YG#CJCHX2K472,G]R9\.T445^JG\T!1110 4444
M%%%% 'IWP9:UTZ+5=6?Q$VD7=I);F.S@NX;.:Y4L=Q$T@/RJ.6102W QTKT]
MM>TC3OB1XT>WN-*;3-6N+:1-2TGQ%;V-U$FT[W1PX##<"63(8G!(.:^8J*\Z
MK@U5G*;EO_P/3L>]ALV>&I0I1A\+OO\ XEU3W4OP3W/I7PCXD\/VMUK5F-;\
MO29M8GN?^$AMM8ALKTKM7F6W8#STSNP%5@>?D]:?@[Q9H7A_P=HLWAZ:&\N;
M.YNEU'3Y]:M]+%ZK,WEM.DR'ST,9& &&TG&,]/GVUT^ZOA,;:VFN!#&993%&
M6V(.K-CH!ZFH*S> A*Z<NWY-:_?TL=$<[JQY6H)6O9]KM/2Z:Z=;O5W9]">&
M_$VB7GPY:PU"[C\-6BVEVRR:3K41,K.SXBGLS\SM@@!@IXP05[0>(O$&CZI\
M)9K2[U!-'N+?3;>*VM-+UF*YM;V0;3AK49:)\C+,54Y!^8C@^!45?U&/-S7Z
MW_K^O1&7]L3=/V;@OAY?PMT2V\K/NVCTO]GGQ%;^&_B1!-=ZBFF6TUK<1---
M-Y498QML#,2 /F QGC.*Z'P_JVJ:3\+_ !M+-XEL5\37%];S1R'6H)+N019W
MNC^823@\%3D\@9KQ.BM:F%52;G?>W3L[G+A\RG0I*E;;FMK;XTE^'0^EKC6_
M#=S\3(]3O]5TN2ZOO#216^I07T*E-05%W,T@#B"3' D=>,<=*\M^+'B1O$&M
M:()[.W2YL[9()+M]7AU)[H!OE:::$ %@.#GG%>=T5%+!QI24KWLK&N)S6>)I
MRI\ME)W?GUUTOOUNM-'<^CO'>K:!XLLM.2ZU^/P_=-JUNL=G#JL.J:<D8RIF
M1!GR44'[K; <\J>T7CR\MM1\$Z+:V'B.VO\ 6-)UYA'>7NNVCW(@(P)$<,NV
M,DJ=H)V@<GY>/GVTL+G4&E6UMIKDQ1M+((4+[$499CCH .I[4NGZ==ZM>16E
MC:S7MW*=L<%O&9)'/7 4#)K*."C"WO?#K_77[V=4LXG5YKT]9JVCWUOVM>_9
M(^E=:\5:1??&S7)M2\0VMWI\VFNN@W2:K$T-K<%(P2DF9%MG)5L.R]>?2L[P
MS\1H5^+6A2:C/;Z1Y.DS64NHR:[!>F[.QO+:>XB"IN! ^]ST]J^=IH9+::2&
M:-HI8V*/&X(96!P00>A!IE)9?#EY;]+?A;^O,'GE;VG.HV]_F]=;V>E]-E9K
M334]W^&?B+4?%.D^,O OB'Q/-!-<0&^AU)[_ .T(C1'=*OF*Y#JR\D D?*QK
M@_&IU7QU9ZAXUNKU3ID5TNFVD5Y<,\[!5!5%!SG"D,Q)&22>2:Y^S\4R6&A3
M:=;6%G#-,&CDU)5?[2T3$;H\[MNTXQPN<9&<$BF2-K>I>&8"8+F70M-D95E2
M ^1#)(03N<#&YL+]XYP .@%;0P_LZCJ*RN_^'MZV1S5<;[>A&A*\K)]^]U?_
M  WEK;71;'HUIXG>;]G^UTN#6UCFMM7D:]T_^T%@E>T,8^4(S R*6/W5!Y[5
MWNL>,M(75O$EQ)KNFW/P\NM!$.G:-#=1L4FV($1;7.^-PVX[MHQD$GT^9**F
M6!C)MWZM_?9_?IHRZ><5*<4N7916_P#*FON=]5U9]%6M_P"&[.\^$QUR_P!)
MNK'3[*:VNUCO(+D6\[ F,NB,V #@[B"H/6JMYXJ6^\8>"["_&EW45CJ#O)K&
MK^(++5/-MBP,BN^U0B@9*!@&!^[ST^?ZM6&DWVJ>?]BL[B\^SQ---]GB9_+C
M'5VP.%'<GBI^HQ7O2EW_ !OY^9:SBI+W(0ZK;K915GI_=3TM9W/<K[Q'<>(O
MB+KD%[XKL=+TW2UN[O2/[*N+.'SO,D!V1W(^5)'P"68EASZFNDE\5:%:_&C3
M/$)UK2X[6Z\/>1+>?;(9S]JV;<3;.=WS("64 @'C ('SQI7@OQ#KMBUYIN@Z
MGJ%FI*FXM;.26,$<D;E4C(JMHOAW5O$D\D.DZ7>:I-&N]X[*W>9E7.,D*#@9
MJ)8.D[KFLDK/;K_5]3>&;8B+3]FVW)25VW>VWW+32VECUV/XB:G)H^C^%-:U
M2QUS4UUQ;QKJ]NH+JU@MPN-IE<F,YW.0,D*,#@X Z74I-.?Q%\6Y8-9T,6NK
M6"PZ<5U:U"S' PJCS..AZXKP76/!?B#P_#'+JFA:EIL4C;$>\LY(E9O[H+*,
MGVINH>$==TBXM+>^T74+*>[.VWBN+62-IB2  @(RW)'3UJOJM-ZPDE?_ #3[
M^1"S+$13C5IMV[WNERN*OI_>?J['N$NO6.DZS\(+\ZKH]M]B(BU/^S;NV A9
MW!.](6X!4<G&/4TO@WQMJ-S\6O$WAG4O$<L^F>)!<6UI=V^I"X2!F+&!D='(
M7CY=H.>0"!7B.K^"?$7A^".;5-!U/389'$:27EG)$K,>0H+*,G@\>U:D<FN?
M#RU9+WPV=.O;K+6NH:C:317$/&UC"257H>I5L$@C!P:S>%IRBU&2;::6W>]_
MDS6.95H5%*<'%1:;WVY5&ST^TEY:O[G?$#Q!+K.KV6D-JDE[I>C1KI]M.\C2
M(0N \J@GHS D?[(4=A7L/BF73/\ A6OB/0;;Q/8:]=VUS:7.GRWVIV9C<#!<
MV\.0(E RIC))// SS\WT5UU,*I*"3MR_YI_UZGF4<RE2=5RC=S5MWHK-6Z[7
M5NUD?4G_  ET$?Q$TRTD\0Z(OARX\-M;W5K#?VRV;7 B(9'5&V [V&,X&,A3
MC(KBO!UY%H_A?PH=!\0Z;H&IVFJ2KX@8W\4$DJ>:NPYW?OX@@/"[ADG@]:\0
MJ>;3[JVMH+B:VFBM[C=Y,KQD))C&=I/!QD9QZUBL#&*MS=NF]K_Y_@CKEG$Z
MDG/DVOU=U=QV?36/W-KJ=O\ ':>"\^*FNWMI=VM]:74JS0SV=S'.C+M ZH2
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M'"CR35I1;NCC6\ 6^ME9HMD-QU.Y<H_U]*ZGP[X+U?3]J)8AD_Z=RI%=[:^
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M;'X>^#KSPWX7UUAKB6^K:FVEO:"YA+JV0!*)/*P!C^#:<Y^\,<U(?A/:V_Q
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M P8GE<C'2N^^#.FZKI?Q0^(<&LZV_B&^^RZ0[7TEM';LV8IN"L8"X!SC Z$
MYQDV?^&=M/F\.:7HMSJ]S-:6>DZOI+LL2JTJ7[HS/G^%DV<>N>:W/AK\/[[P
M?KWB#4M7\4#Q)J^J16D<I6S2U$20(Z+A%9OO;B22>N<<<!SJ4W"7+OZ>>GX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH _2B?\ UTG^\?YTRGS_ .ND_P!X_P Z97Y$?U*%%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M13779L[.BN,_X7%X1_Z"I_\  :7_ .(I/^%Q>$?^@J?_  &E_P#B*OZCBO\
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M^!Q_S/1:*\Z_X:$\ ?\ 0=/_ (!W'_QND_X:&^'_ /T'C_X!W'_QNE]3Q/\
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M ,%EY_\ &:/J];^1_<P^N8;_ )^Q^]'MU%>(']M;X-#KXP/_ (*[S_XS3?\
MAMCX,#_F<3_X*[S_ .,T?5ZW\C^YC^N8;_GY'[T>XT5X;_PVU\%_^AQ/_@KO
M?_C-)_PVY\%O^AR/_@KO?_C-'U>M_(_N8_K>'_Y^1^]'N=%>%_\ #;_P5'_,
MYG_P57O_ ,9I#^W#\%!_S.9_\%5[_P#&:7U>M_(_N8?6J'_/Q?>CW6BO"/\
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M!>O?FV.R29H1&-_< !FR/?CG/%8-=,9QJ14X[,\RM1GAZLJ-16E%V>SU7FM
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M^.8]2"TA!!YX8$<\8XQ#+X#>'4K>SGUW18I)41BZW9E6-V8J(V\M6.X$<X!
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M9F8J."6/S54^&7Q:\#_#^#2'72KU+Z&.ZAU"YCT^"66YWAA&Z2/+NCP",HN
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ML@L3D]*Y2BA8>G'96UO\QRQN(G\<K^[RZI?#V6FGKN>HZ3\8=+L_A5)X'O\
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M+N=5BEMDDE#?-Y?V8$A2V0-W8<TO@'XD:9X-\+^(=(N=$N]0;6XA;W$\6H+
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M^RVC6.XWLAAE\R==K@JW3(.."3Q5[4/CUI>F37L-QH>L1SPZL=%MD8VJ+?7
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M;1C+,QR2<]*Z36M0\,>#+SX;_9O FB72ZY8027,=Q$TP42,N0@<DELGAG+G
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MGI%*_N]5%IM/G6][O9IZWT5]7XV>&G\+?$*]M6CL8TDBAF0::H2%E,:C<J@
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MVQ/%NL6%Q8W^@>&;VRN$,<UM<6<TD<B$8*LIFP0?0T:;^V)XLT6P@L=/\/\
MABQLK=!'#;6UE-''&HZ*JK, !["C_5/,^R^\/]?,E_FE_P" GT#\#_A'JWPU
MO;Z2ZEAT_39+2&WBT6PU2YO;42J6,EP@F5?)+Y \M00 /O'M._@?Q7>?&V]\
M375EHO\ PCEUH_\ 8;+%JDXN_*\UI/-VBW #'=C:'&.H<UX!_P -K>./^@5X
M?_\  >?_ ./4?\-K>./^@5X?_P# >?\ ^/4?ZIYGV7WA_KYDO\TO_ 3W>_\
M@-I?@KX8^*/#/PUT+3].G\0026UP=0U"X"#?$T?F;RLS$J&X3@')Y'>U:^&?
M&]OX+T;0Y-$\)W3PZ4=*N9+C4)W$8"J@=/\ 1OWBL%#-$=G*@;SU'S]_PVMX
MX_Z!7A__ ,!Y_P#X]1_PVMXX_P"@5X?_ / >?_X]1_JGF?9?>'^OF2_S2_\
M 3ZR\&>#%\%_#_2?"]K?SD:?8)9)?!5\W*IM\P!@R@YY ((' Y%0_P#"'ZM_
MT/.O_P#?C3__ )%KY3_X;6\<?] KP_\ ^ \__P >H_X;6\<?] KP_P#^ \__
M ,>H_P!4\S[+[P_U\R7^:7_@)]6?\(?JW_0\Z_\ ]^-/_P#D6C_A#]6_Z'G7
M_P#OQI__ ,BU\I_\-K>./^@5X?\ _ >?_P"/4?\ #:WCC_H%>'__  'G_P#C
MU'^J>9]E]X?Z^9+_ #2_\!/JS_A#]6_Z'G7_ /OQI_\ \BT?\(?JW_0\Z_\
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M[U__ ,*+4/\ X_1_PK?2?^?O7_\ PHM0_P#C]?*?_#:WCC_H%>'_ /P'G_\
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MO_ 3[5KS?QU\+]9\2?$?PUXPT?Q!8Z5<Z';7%O%;7VEO=I)YP =F*W$1X &
M.^>3TKYR_P"&UO''_0*\/_\ @//_ /'J/^&UO''_ $"O#_\ X#S_ /QZC_5/
M,^R^\/\ 7S)?YI?^ GT+)\%KC4O^$FU74_$MQ+XPUK3FTN/6K&#[,NG0<E4M
MH][%1N.XDNS$_P 0XQC>&?ACH_P3/B75_$&NZ);^'=:M+6SOX6T[['#YJJ8O
M,+M,XQ)O;<&!)9L[O7Q/_AM;QQ_T"O#_ /X#S_\ QZC_ (;6\<?] KP__P"
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MC1N 1@[74AE/H001U!KXO_X;6\<?] KP_P#^ \__ ,>H_P"&UO''_0*\/_\
M@//_ /'J/]4\S[+[P_U\R7^:7_@)]6?\*WTG_G[U_P#\*+4/_C]'_"M])_Y^
M]?\ _"BU#_X_7RG_ ,-K>./^@5X?_P# >?\ ^/4?\-K>./\ H%>'_P#P'G_^
M/4?ZIYGV7WA_KYDO\TO_  $^K/\ A6^D_P#/WK__ (46H?\ Q^C_ (5OI/\
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M\)7=AX:7Q5X?TO1[K1)=#,L*D*ZQ^5(!,RHP!CPV6W#Y2 2*X+_ANC_J2?\
MRK?_ &BC_ANC_J2?_*M_]HH_U9S;_GS_ .31_P#D@_UTR'_H(_\ )9__ ")Z
M'X-^ ^M:7I'A>[U'QWXFCUO2--CMCIUGJA&EO*BL%+Q;,R $C)8_-M&1CBN
MC_9\U_5M.U>WLM&D\*7VH>';G3]<NKK4([B+7+\[3#. C,0-XD8R.L;XDQM/
M.(_^&Z/^I)_\JW_VBC_ANC_J2?\ RK?_ &BC_5G-O^?/_DT?\P_UTR'_ *"/
M_)9__(G9VO@/Q3XK\3?VSJ6AS:##?66FZ->6<]S!*X@@DDGN'S'(P*.=L*@'
M<1(254"M'QS\((_&WCH"UT";2;&74+/4-8U>:^/DZB(-KI'%;)*1YA941I9$
M0A0V-V17G?\ PW1_U)/_ )5O_M%'_#='_4D_^5;_ .T4?ZLYM_SY_P#)H_\
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MEQ;:;;+;I+-C<V.YQT^G;I4OC6SM-0\&Z]:ZA=?8;">PN(KBZQ_J8VC8,_X
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MW-%<-_PN[P5_T&O_ "5G_P#B*/\ A=W@K_H-?^2L_P#\119A_:."_P"?T?\
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M_I*/Y SS_D:XO_KY/_TIA1117J'AA1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@ KZ<_:*_Y([KW_;O_P"E$=?,=?3G[17_ "1W7O\
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M+?PP_P"A9_\ )^Z_^.UZK7#>'?'FJ:OX_P!8T&]TF+38;&QANU_?^=,_F,P
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ML5FT;_O:C5[7O.W;K_PXZ>!R&=E["BG:]N6G=:7Z7Z/T\SCO^&6_AA_T+/\
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M^7&7;:2 NWC<3EN,1>*O!OB/4/B-'X@TZ#2Y+2'1Y].C%U>21R^9(0P? A8
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M^J[ZGC7AOX9>(O#C_#VXO3HY@\,V5U:7OEW4N'210/,0F+D@ DJ<<]^]</\
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MY<:*=T87.[Y@=V#M ( )QZY<>.?#=G#+-/X@TN&&)8VDDDO8E5!("8R26X#
M$CUQQ7/^.OB)X;TF7P]IFJ'3K[3?$+LGF74\7V81!-_F-NR&4G:!V)(YK6AC
M,7*K%>ST\DUMRR[]H+^F<^*R_ 0HS?MK/:[::3ESQ5U;:]22_P"&.9^#VK:I
M#XTUW2]>\,W6EZ[=6T>H76H76IV]X\Z@^5&K""-$CP =H &<,?>O8:XWP>=.
M\'^&;R6^_P"$9T.UANI1(^C[;>T1=V$WDX DV[=V>_2NAMO$6DWFD_VI;ZG9
MSZ9C/VV.X1H>N/O@XZ^]>;CI>VK.I"%EHM+VNETNW;R5W9'LY9'ZMAXTJE2\
MM9:VO9N^MDKZ[RLKO?4T:\,^+4<2_%".029F;2K=6C]%$UQ@_B2WY5[#I'B;
M2/$$ERFEZK8ZD]LVR=;.X24Q-SPVTG:>#U]#7CWQ:\C_ (6A'MW?:?[*M]_I
MM\ZXV_KN_2O.E&4'RR5F>O"<:BYH.Z\C>\-_ZF.N]TW_ %(K@O#?^ICKO=-_
MU(J2S5CI],CI] !1110 4444 %%%% !1110 4444 %%%% 'COQVCB;Q!X5D,
MF)EAO%6/U4M;Y/X$+^=.\+_ZE:;\=O(_X2#PKNW?:?)O-GIMW6^[]=OZT[PO
M_J5H ]#TK_5ULQ=JQM*_U=;,7:@"2BBB@ HHHH *R/&&GOJWA+6[&*[6PDNK
M&>%;IFVB$M&P#D]@,Y_"M>L7QK9VFH>#=>M=0NOL-A/87$5Q=8_U,;1L&?\
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M117IGSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO3<E.FTX[Z/3U['/45T.E_#_ %[6K'3KNTL5>WU&Y:TM'DN(H_-D498 ,P.
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M#)XJ)3C#XG;_ ()I3HU*ND(WW_!7?W(YBBBBK,@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _22\_P!<_P#O'^=05/>?ZY_]X_SJ"OR(_J4**** "BBB
M@ HHHH **** /G[Q@\[?%+Q$)5Q&LT B..J_9H3G_OHM^5=MH'^K3Z5Q/C!)
MU^*7B(RMF-IH#$,]%^S0C'_?0;\Z[;0/]6GTH [BQ_U:UHITK.L?]6M:*=*
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M].M&4?*%<DLH[?*V0/;;7->+/&Q\776G32Z+IMA]BA2V6.R\\(\2 !48-*W
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MCFN%0H/LT(P03[$_C73Z)\0O"T,:!_$NCIQ_%?Q#_P!FKYS_ &GO^2Y>)?\
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MOS@HH _1_P#X6MX)_P"APT#_ ,&<'_Q5'_"UO!/_ $.&@?\ @S@_^*K\X**
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M\.N1VZ7EG$D,X0(K#,B ,3EC\Q.<'&<<54_:,=K[_A!=3NHQ_:=]H$$MW<8
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M)G_0M?\ D_;?_': /+:*]2_X9A^)G_0M?^3]M_\ ':/^&8?B9_T+7_D_;?\
MQV@#RVBO4O\ AF'XF?\ 0M?^3]M_\=H_X9A^)G_0M?\ D_;?_': /+:*]2_X
M9A^)G_0M?^3]M_\ ':/^&8?B9_T+7_D_;?\ QV@#RVBO4O\ AF'XF?\ 0M?^
M3]M_\=H_X9A^)G_0M?\ D_;?_': /+:*]2_X9A^)G_0M?^3]M_\ ':/^&8?B
M9_T+7_D_;?\ QV@#RVBO4O\ AF'XF?\ 0M?^3]M_\=H_X9A^)G_0M?\ D_;?
M_': /+:*]2_X9A^)G_0M?^3]M_\ ':/^&8?B9_T+7_D_;?\ QV@#RVBO4O\
MAF'XF?\ 0M?^3]M_\=H_X9A^)G_0M?\ D_;?_': /+:*]2_X9A^)G_0M?^3]
MM_\ ':/^&8?B9_T+7_D_;?\ QV@#RVBO4O\ AF'XF?\ 0M?^3]M_\=H_X9A^
M)G_0M?\ D_;?_': /+:*]2_X9A^)G_0M?^3]M_\ ':/^&8?B9_T+7_D_;?\
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M#/\ AF/_ *F7_P D/_ME4F?'\08#$X[V7U>/-R\U]4M[=VNQX;17N7_#,?\
MU,O_ )(?_;*/^&8_^IE_\D/_ +9571\?_8&9?\^OQC_F>&T5[E_PS'_U,O\
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M5^1']2A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KS;]HK_DCNO?]N__ *41UZ37FW[17_)'=>_[=_\
MTHCKLP?^\TO\2_,\K-O^1?B/\$O_ $EGQ71117ZB?S>%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z27G^N?_>/\Z@J>\_US
M_P"\?YU!7Y$?U*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7FW[17_)'=>_[=__ $HCKTFL#QYX4MO&_A6^T6[>:.WN0FYK<@.-
MKJXP2".JCM71AYJG6A.6R:?XG#CZ,L1A*U&&\HR2]6FCX!HKV+6?V?+NUO72
MS^T20@_*TA!/Z 51_P"%"ZM_<D_3_"ON/[:PG=_<?C?^J.:=H_>>5T5ZI_PH
M75O[DGZ?X4#X"ZL2!LD_3_"C^VL)W?W!_JCFG:/WGE=%>L?\*!U7^Y+^G^%'
M_"@=5_N2_I_A1_;6$[O[@_U1S3M'[SR>BO6/^% ZK_<E_3_"C_A0.J_W)?T_
MPH_MK"=W]P?ZHYIVC]YY/17K'_"@=5_N2_I_A1_PH'5?[DOZ?X4?VUA.[^X/
M]4<T[1^\\GHKUC_A0.J_W)?T_P */^% ZK_<E_3_  H_MK"=W]P?ZHYIVC]Y
MY/17K'_"@=5_N2_I_A1_PH'5?[DOZ?X4?VUA.[^X/]4<T[1^\\GHKUC_ (4#
MJO\ <E_3_"C_ (4#JO\ <E_3_"C^VL)W?W!_JCFG:/WGD]%>L?\ "@=5_N2_
MI_A1_P *!U7^Y+^G^%']M83N_N#_ %1S3M'[SR>BO6/^% ZK_<E_3_"C_A0.
MJ_W)?T_PH_MK"=W]P?ZHYIVC]YY/17K'_"@=5_N2_I_A1_PH'5?[DOZ?X4?V
MUA.[^X/]4<T[1^\\GHKUC_A0.J_W)?T_PH_X4#JO]R7]/\*/[:PG=_<'^J.:
M=H_>>3T5ZQ_PH'5?[DOZ?X4?\*!U7^Y+^G^%']M83N_N#_5'-.T?O/)Z*]8_
MX4#JO]R7]/\ "C_A0.J_W)?T_P */[:PG=_<'^J.:=H_>>3T5ZQ_PH'5?[DO
MZ?X4?\*!U7^Y+^G^%']M83N_N#_5'-.T?O/)Z*]8_P"% ZK_ ')?T_PH_P"%
M ZK_ ')?T_PH_MK"=W]P?ZHYIVC]YY/17K'_  H'5?[DOZ?X4?\ "@=5_N2_
MI_A1_;6$[O[@_P!4<T[1^\\GHKUC_A0.J_W)?T_PH_X4#JO]R7]/\*/[:PG=
M_<'^J.:=H_>>3T5ZQ_PH'5?[DOZ?X4?\*!U7^Y+^G^%']M83N_N#_5'-.T?O
M/)Z*]8_X4#JO]R7]/\*/^% ZK_<E_3_"C^VL)W?W!_JCFG:/WGD]%>L?\*!U
M7^Y+^G^%'_"@=5_N2_I_A1_;6$[O[@_U1S3M'[SR>BO6/^% ZK_<E_3_  H_
MX4#JO]R7]/\ "C^VL)W?W!_JCFG:/WGD]%>L?\*!U7^Y+^G^%'_"@=5_N2_I
M_A1_;6$[O[@_U1S3M'[S[-O 3,^!GYC_ #J#:?0U:G_UTG^\?YTROS\_<B#:
M?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/
MH:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@
M"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#
M1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ
M>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-
MI]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T
M^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ*
M (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT
M-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&
MIZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @
MVGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;
M3Z&IZ* (-I]#1M/H:GHH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H:GH
MH @VGT-&T^AJ>B@"#:?0T;3Z&IZ* (-I]#1M/H?RJ>B@"J;=3UCS^%'V9/\
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M1<=_\_R_(<)J:;7335-;>OY[/H%%%%06%%%% !1110 444@8-R#GM0 M%%%
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METVX\/"VB\F.-I738A">:)%50V2[=>F*V_LFK*UFEMNWNW+3;3X7OIYZG/\
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MY53S96^ZBY/+'!P!R<4 6J*** "BBB@ JM'_ ,A&?_KE'_-ZLU6C_P"0C/\
M]<H_YO0!9HHHH Q-4\#^'-;U)-0U'0-+O[]-H6ZNK*.25=IRN'921@].>*L-
MX9T=];766TFQ;6%78-0-LAN N,8$F-V,$CK6G5*QUS3M2N[RUL[^UN[JS8)<
MPP3*[P,>@=0<J>#P?2MU4JM:-V2\]O\ (YG2H1EK%7;OLM6NOJC+C\'Z9X=6
M]O?#?A_1K+6)4.)%MUMQ*2<XDD1"V">^#ZX-'@_PQ_8*ZE>3PVT6JZM<F\O?
MLN3&'VJH56(!8!5'S$#)+' S@87Q?\2^)/"^G:)/X=N-+@EO-5M=.F&J64EP
MN)Y5C#KLFCP5R3@YW<#*]:T]>OO$%GXF\.V]KJ&EQ:;<;Q?)<6$CROL4L3&X
MG41@@8^97QUYZ4W7J2BXMWOOW]/04<+2C.,HJUMEI9-[OUZ&QKGAC1_%$,4.
MLZ38ZM%$V^..^MDF5&QC(# X.*I:?\/?"VDY%EX:T>S!D28_9[")/G0Y1N%Z
MJ22#U&>*S;?XO>%;FSO+L7UQ%;6HB)EN-/N85F$K%8C!OC'G[V&%\K=N.,9R
M*W_#OB33_%6EKJ&FS/+;EVC(EA>&2-U8JR/&X5T8$$%6 (]*E5JL8\BD[=KE
M2P]&4_:2@G+O97^\&\+Z-)J%W?-I%BU]>1>3<W)MD,D\> -CMC++@#@\<"LS
M_A6/@XV8M#X3T/[*)/-$']FP[ ^,;MNW&<#&:K6?Q8\,:AK$>F0WTYN9ED:V
M9K&X2&\V+N<6\S1B.<@ G$3,< GM53X6_$*3XA>&KCQ"\<L%C(VZWM'TNYMY
M8D R06D_X^">NZ-0O.WYB,TXUJL=I-?-BEAJ$_B@G\EUW^\Z*Z\':!?36<US
MH>FW$UF@BMI);2-F@0# 5"1\H]A55_AQX3DLX+1O"^BM:6[L\,#:?"8XV/5E
M7;@$X&2/2N)\(_'S1]4T%=:U>YFLK>]W36FGKHEZMQ! @'F2.=K>;&-RDS*B
MQKNVDDC-;]]\;O!=C<:E"-9^W2::5%[_ &9:3WHMMP)!D,*.%4!3ECPO&2,B
MA5ZL=IO[V$L-0E=NFG?R7]=%]QT$W@OP_<:M!JDNA:9+J<&WRKU[.,S1[?N[
M7V[ACM@\4ZW\'Z#::U)K$&B:=#JTA)>_CM(UG8G@DR ;CGZUP'C;XL7JZ\="
M\+S0QW@TG^V$U"[T>ZO[.>,ARB!X7C2,$)GS&?'( !)XZ/P[\3]&OK&"#4=6
ML8-:@T>+5]3@C8B.TC9%9G<G(1><@,<[1GD FE[:I:W,^V_3MZ%?5Z-[\BO>
M^RW[^OF:L/@'PQ;M?&+PYI,1OE*792QB'VA2<D287YP3S@YYK5TW3+/1K&*R
MT^T@L;.$8CM[:-8XT&<X"J !R3TKE;CXQ^#K>TT:X_MN.8:U#)<:=#;Q2337
M<:*79HXD4NPPIZ+SP!DD5/)\5/#,.H:79O?RHVIF);6=K.<6\CR('CC,^SRU
M=E((1F#'(XI2J5)JTI-CA1I4W>$4O1%_5/ ?AK7+X7FI>'=)U"\&#]HNK&*6
M3CI\S*3V%/U#P3X=U:^M[V^T#2[R\MU58;BXLXY)(@IRH5BN0 >1CI7/P_&_
MP3<RHMOK8NHGN9+);JWMII;9KA!DPB94,?F$?=3=N?HH-/F^*F@WMKHEQ9:_
M:V/]H:F-.2#4;*9;B:16*O (6,<D<@..74A1R5((-5[:JK6D]/-DO#4'>\%K
MOHM3H(/!^@VNM/K$.B:;#J\A)?4([2-;AB1@YD W'(]Z;;^"_#UKIUWI\&@Z
M9#87C;KFUCLXUBG/JZA<,?K7.+\<_ \@9X=<%U:QW1LI;ZUM9YK2&4%1B2=$
M,<8RP 9F"GG!X.-AOB)X?7Q,- ^WEM2,OD$+;RM"LVSS!"TP7RUE*?,(RP8C
MD"E[:K_,_O[;?<'U>BMH+KT77?[^O<D;X>>%6TM=,/AG1SIJR^>+,V$7DB3&
M-^S;C=CC.,TZZ^'_ (7ODLTN?#>D7"62".U66QB80*#D*F5^49["LWXH^.#X
M#\.P7B-''/=WD-A#--"TR1R2MM5C$K*TG/\ "I!)(Y'6M_PY-J5QX?TR768(
M;;5WMHVO(;<YCCF*@NJ\G@-D#D_4T_;UM^=_>R?JN'M;V:^Y%&[^'_A:_EFD
MN?#6D7,DTWVB5YK")B\G/SL2O+<GD\\UJV.EV6F-<&SL[>T-Q(9IC!$J>9(>
MKM@<L?4\UR6G^,[S3_$GC*'Q!=:?%H^E&UDM)H(7CD"2JWR29=M[[@H78!N)
MQMR12-\;/!=OH^JZE>:S_95OI907L>JVL]E/#OSY>89D63Y\';A?FP<9P:F5
M6I)<LI-KU-(T*4'S1@D_0[BBN4E^*'AV.PFNOM-W*(9I(&MX-.N9;DLFTN5@
M6,R,H#H=X4KAU.<$&FM\5?#,>H:7:/?31OJ9B6UF>RG6W=Y%#QQF8IY:R,I!
M",P8Y'%9&QUM%<G_ ,+4\,K>ZA;R7\D"V$4TT]W<6<\5H$B(64K<,@B?83A@
MKD@\'FJS?&;P=#9Q7%QK'V'S;U-.CM[ZVFMKA[AP"B"&1%D.X,"#MP0<YQS0
M!VM%>?Q?&;PM)J%U,_BG3[;3[333>W-K=6TD%S; 2^69)6<CRQN^3RFC#ENA
M[5IZ#\5/#/B75+33["_F>YO8/M-H9K*>"*ZCVAB89)$5)" 02$)(YR!@T =;
M1110 4444 %%%% !1110 4444 /G_P!=)_O'^=,I\_\ KI/]X_SIE !1110!
MYQ\>/%VO>"_!MM?:'#=;7U"&'4+ZRL_M<]A9L3YMPD6"&*X'4,!G)!QBN"@^
M+4$WPN\=>(?#OQ*O?&-K96D<T-W#8V+W^E\-OD>W*6RLN!N ?D[6 R1@^P^-
M-%U_6(M-;P]KT.@W=I=^?(US9-=Q7,?ENAB=%EC.,N&SNX*"N#UOX#W>O:'X
MY\_7[1/$GBZTCL+W48=+*VT4"*R@1VXFW;B';YGE8Y([#;3 G?XO:I9_%/PO
MX4&CS7NFZCH)U2XU']S')&0R*78&4 (H;+!0QR1M! -30_M&>%C"]W<P:E8:
M5)ID^KV.I7$">3J%K#CS'A"N7!&Y3MD5&(.0,5./A'?-XO\ "_B&37+5[K3-
M'DT6^A_L]A'=PN4):/\ ?9A;*=29!STKG/!?[--MX)T'4]'LKC0/*FLIK*TU
M1?#<<>J(KG@3W"R 3J!\I&Q=X R>N0#M=(^*@UC3-/OD\+>((X[W48[! L,%
MP%5X]XN6>&9T$ ^Z7W$AN"*W/$?CC1O",T":M=/9I*I<W!MY6@A4=7FE52D*
M_P"U(5'O7#>!O@G>?#^.=M%URQT>:^U>+4-1@TG1D@LIH4B\LV\4#2/Y.["L
M7#$Y!P #BO5J0'D?Q8\=2Z9X9M?%.B>+;VSL'C62T:QTG[9I\J[QNENYA#(R
M0[3G>KQ_*"07XJ+Q!XR\0B'7O%-CK'D:5HNJPV,>DK##);WUOF$2R,^WS Y\
MU]A5PHVKE6R:[3Q9X3UGQ0UUI_\ ;EO;>&[^!K>\L_L!:Z*,I5A%.)0$!!_B
MC<C)P1QC'D^$CQ:C=V]EJT=IX6OKR"_N](^Q[I/-B6,*L4V\!(V\F,LI1B?F
MPRYX8&YXN\?1>%;ZTL(=(U'7M2N89;E;+2Q#YHAC*AY,2R1@@%U&U26.>%.#
M7)^*?BX?#VG>/;[3;/6=6O="2W#:?=6T4$$+NAP8V;RVD3HSG<W;8:V/BA\-
M;GXD10VC7.BC3?+>.6'5-%%](C-C][!(94\J0#HQ# '!QQ61>_!S5=07QA;3
M>)H'TW7+""RMXCISF:U,*[8W>0SXESDEOE4MQ@KB@#5OOC%8Z7<&"\T75H)+
M:."7525@9=)69BL9G99B#G!)$1D*CDX'-:OAOX@1>*=8N+6RT;4_[/C>:--8
M<0FTEDBD\N1!ME,BD-D#>BYVDC(YKD]3^!D>L>.;?Q5?_P#"-ZIJ$L%O'J"Z
MIX>%TI>$G$EJS3;K8D'&"T@^53C().EX=^%,^F^/7\4ZC>:3/>JDT:2:7HXL
M9YUD(.+J7S7\_: -O"8.3R>B ]$HHHH **** "BBB@ HHHH **** "JVG_ZA
MO^NLG_H;59JMI_\ J&_ZZR?^AM0!9HHHH **** .5^)&H^+M,T&.7P9I5GJ^
MJFX17@OI=B"(YW,/F7)Z=^_0]*ZB(NT:&1563 W*IR >X![TZBM95$X*'*M+
MZ]7?OZ=#"-)QJRJ<S=[::65K[:7UOKJ]D9'C!A'X2UMF(55L9R23@ >6U>0>
M/K73;_\ 9<TFUNDBDU:?1;./15X\\Z@84%OY!ZB3?MP5Y R>F:]NU#3[75K&
M>RO;:&\L[A&BFM[B,/'(A&"K*>"".H-8?A_X9^#_  E?&]T/PIHFBWA4H;C3
M].A@DVGJ-R*#BLC<\K\/^,?B!XD\;W]A!'J'V?2M572KQK<:>+..#R$+3L9&
M^TF;<_F+A/+(VC:>6JQX=\0>+)=/DMI_$VI7^O>%[F_?6H3;686]1%W6T9"0
M902J8W79AMID!)(!'K,W@_0;CQ!%KTNB:=+KD*[(]3>TC-RBX(P)2-P&">,]
MZT(=/M;>ZN+F*VABN;C;YTR1@/+M&%W$<G X&>E 'SE#XL\5>*OA/K&K>(X+
MN7P]J&CVUZ+K4!8"(7#2H2ELMM([&$@Y'G9<%0,DD@=AXR\6:]/:^/=3T[Q1
M_P (_<^$V;R=):"W>"Y40)*C7&]#)ME+,BF-X^!W(-=W)\*O!,T%[!)X/T!X
M;Z43W4;:9 5N) 20\@V_,P)/)R>35R;P'X:N+S3+N7P[I,EUI:+'83O8Q%[1
M5^ZL3;<Q@=@N*8'DU_XD\677_">21^,+C1KG1[2UU.TT^6UM)#&\EN7-M)F+
M<\6_"#&),_QGI2:UXN\;VZ^-+^X\20Z6=#;3[FWL8=/B\C;*@,D$YDW.XYQN
M1HSD9&!Q78Z!\/[I?BMXB\3ZSH>@R)/Y0TS4(Y3/>P!$V$8:!?+W#D[7..G/
M6M'Q%\._AU#'J&JZ[X8\+HEPXDO;[4=/M@)6+<-([KR2Q'+'J: ///&7Q"\4
M^!6\1:4FI7.MR1ZGI4$%\\%JEQ;Q7;,KJF1'"2#'A#+P#(-Q;'-O3]4^(LVM
M>%])U76)?#UO?SW\&+JTLY-4GC2,O%*S1,]NK@'HB8R@)&&*CTYOA_X7D,I;
MPWI#&6T73Y,V$1WVRXVP'Y>8Q@83H,#BJ\/PN\&6TVG30^$="BFTW_CQD338
M0UK\Q;]T0OR?,2?EQR<T@/*-?NO$6N>&XM+NO%5^EQIWC:VTK^TK:WM4FN(M
M\3HTBF)H]REQ]U%4[1E2,@Z7C'XAZII7C#2TT;6M3OK6WURST34(I;2S6RW2
M>6'5F;;.TV) ^Z'*#(!7@D>G7G@'PQJ":HEUX<TFY75'22_6:QB<7;)]QI<K
M^\*]BV<=J;??#SPKJES<7%[X9T>[N+D1B>6>PB=Y1'CRPQ*Y;;@;<],#%,#'
M^%[0--XS$&S*^(KD2;!CY]D1.?4]*XE?B+K.H?$O0X-%UF]NM%UFXU"R5M0L
M;46*201RD-"JLERQ1XBK%\HXSM9<K7JV@>#= \*27<FB:'INCR7CA[EM/M(X
M#.PSAG* ;CR>3ZFL2U\*_#SQ-?:HEMH_AG5;RWO3)J"Q6UO-)'=%2"TN 2)2
MI(RWS8)I <!H/B3QA'X9\&>)+WQ;_:4E]J\>FWEA%8VZ6<J/<O$67"^:KKQ@
M^9CY1E2<DP:EKU]XP;P=KTNMM' _B[["=#$40BB,,T\8.[;YOFX0%LN5Y.$'
M!KU:'X:^$;;0GT2'PKHL6C/,+AM.33H1;M*,8<QA=I;@<XSP*AUKP/X*9KN_
MU;P_H):\EA-S=7ME!F:0,%BWLR_,P8@+GG) %,#B/BUXT\5VGCC3O#/AJ+41
M+<:5/J$;:6MB999DD1%1OMCJGE#=EQ'E_F7!7J<B^U_QDP\>>;XQDT?4-%M+
M748+ 6UI*L<LEN7:V8^5N>$R#8,8D/\ ST.<5[#XA\(Z%XNAAAUW1=/UJ&%_
M,BCU"UCG6-_[RAP<'W%<=X=^'EQ%\5/$'B75]!T!HIA"NEWT4IGO+<1IY>,-
M OEAAR=KG&,<]: .0\7>(]6U'P[\2K/Q'=V<EM9VNG3Q6,5ML%H)1N9'))+M
MN'7CH,*,U-9>,_'/BKXC:W9:;%J4.FZ;K)TJ?[.-/%I!;&%29V\QC<F<%]ZX
M0QD;05;EJ]&U#X4>"=6O+R[OO!V@7MU>G==3W&EP2/.<@Y=BF6.0#SZ58D\"
MZ!9WD.JV/AG13K=C;>18W#6L<3Q*JD)$LH0M&F./E!P#P#TH \N\&>(_%FI:
M3X&U1O%\NK2ZK=S:??6!M;55\M1-F=2D6Y94V(6R?+/38N:J>"K[Q)X<\"^$
MKQ/%<UW'J7BA[:]74K2!Y'C>\F4I$T:)M+,,L6#GD[2@&*[WX+_#U_ /A<0Z
MAHVBZ?KLCO\ :KO2&\PW2[BRM)(T4;,1N(P0<8Z\X&U>?"WP9J"NMUX1T&Y6
M2Y:]<3:9"X:X;&Z4Y7ES@9;J<=: ,7P'J6J>-KG^W_\ A(IK>WMKZ\L;KP_'
M! T*>5+)&H9MGFK*-J,?GVG/"@$&L#XM>-/%=IXXT[PSX:BU$2W&E3ZA&VEK
M8F669)$14;[8ZIY0W9<1Y?YEP5ZGTF'P?H-OX@DUZ+1-.CUR1/+?4TM(Q<LF
M -IEQN(X'&>U5O$.C>%O%UY#H^NV.CZU=P)]LBL-0ABGDC7.WS5C<$@9XW =
M>,T@/-DO_'>LW7C..\\6)H=SI-G:WD%GI-C;OY#O [M%*THE\Q=PP2NTG:"I
M7D5?T3Q5K?Q&N;;38?$#>%=070].UA396\$C733K)YA*3*^85957"[6R?O\
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MM:&:\LXY7,+<M%N92=A[KT-07WP[\*:H<WGAC1[L_9%L,SV$3_Z,I!6'E?\
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M#$X'7/05DW/@/P9I^FVQN/#NA6VGZ3#-Y'F6,*16<3@^=MRN(U89W8P",YH
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MZA6=20/85##\-?"-MH3Z)#X5T6+1GF%PVG)IT(MVE&,.8PNTMP.<9X% $'Q
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M@)$CC2,@< 80<*,Y.2<M_A%X$DTN+3'\%>'6TV*5IX[-M*@,*2, &<)LP&(
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M)(P<%UCSN*@]P,5H5X9HFI:AXD\8?#'Q!)XB6_;6M-O+R.S,$7D6CM;H<1;
MKE 3@AW8Y'#+THT7QEXKM?A^GB35/%,5RTVI2Z/<.+"&*VLL:BUO]J'.Y=J
M@J[,N=A/1MP![G17@OC+Q3XW\&S>*-(T[Q4NK+8V=CJ$>J:E8027$!EN&B>W
M981%'\P4.K%,@;@0V01:\4^(/%7AL>-9(?&-Q=KX;>TOHH9K.UWS)*,O;S%8
MQ^[PIVE CC=R[8I@>X4R:>.W4-+(L:EE0%R "Q( 'U)( ]S7B=CX\\<:[\1]
M:BT^TNVTO1]9.G7$+&Q33TM1"K&65FD^U>;EMX*KL*X&#RU7O!=]JWB)=?\
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MR\19<+YJNO&#YF/E&5)R2 >SZMJUCH.G3ZAJ=[;Z=86Z[YKJ[E6**-?5F8@
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MH_YO0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** 'S_ .ND
M_P!X_P Z93Y_]=)_O'^=,H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9#"(4*@D@LS<^Y)_K3Z* "BBB@ HHHH
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M0(XW<NV*D\2:UXFBU3XDQ6GCB>Q.@Q07]A;O:6C\O"S^2^8MS1,P"C&),_\
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M_*"V%'09]Z\YFOK*U_:2>+Q&T<;3:+"/#+76!&9!))]L6(GCSC^XR!\Q4<<
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M-M";Q=8^(&%Q!KHTJ3PF\%OY#+]L\CRBVSSA.4(D!W[<X^3::)?&GBS1]/\
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M6]M-?LQ!:,N<-*2<9&3GBJ^FZ-\--2U1-#T^Q\*76HZ$DB)IMM#;/-IZN?G
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MPA9GER=S*JD=N"3_ %I]% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 /G_ -=)_O'^=,I\_P#KI/\ >/\ .F4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5 !DUHT4 8EEX'\.:;=:E<VGA_2[6YU,%;Z:&RC1[L'.1*0N7SD_>SU-5/\
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M_&/GC"[6X '(-4]4^$/@37+QKO4O!7AW4+ME5#/=:5!*Y55"J-S(3@* !Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M?/\ ZZ3_ 'C_ #IE/G_UTG^\?YTR@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"OVF/$4L:Z5HD;
M%8I UU,/[V#M0?\ H7Z5[K7BWQZ\+6-YJVE:MJ6IKIUIY7V8_N9'+D,6 !53
MMR">3Z=#36YX.>*I+ 35/K:_32YXAX=\.R^(+IE\^&QM(\&>\NFVQ1+[GN3V
M4<FO;?"WA/X5Z?X=O=3F>ZU\6,;/+=7$4T4;D<;8QA5))(PI)/(/O7.6^H>
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M'S74/[4'Q1U*71-;BTW5K2T@LKRXT>ZBMYW@AVR 2-$% RI )(#<;2V15_\
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M?X=\.Z;X3T6UTG2+1+'3[9=L4$>2!DDDDGDDDDDDDDDDUHT4 %%%% !1110
M4444 %%%% 'F/QP^$.I_%ZU\/VMIXAM=#M])U*+5<3::UTTTT>?+&1-'M3YF
MR,$G(Y&.?1[!+J.QMTO9H;B\6-1-+;Q&*-WQ\Q5"S%03T!9L>IZU/10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7$?$#X>WWBS7/#FMZ5KIT?4]#EEDACN;7[79S>8FQO-AWH2P&
M=K*ZD;CZUV]% '#Z/\.;A_&-KXL\2ZE;:SKUE:R6=F;*Q^R6]M&Y!=E1I)'+
MM@ EI" ,X R<]Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &W1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 453TG6+#7K);S3+ZVU&T9F07%I*LL996*L-RDC(8$$=B"
M*N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 457L]0M=0,XM;F&Y-O*89O)D#^7( "4;!X8 C@\\B
MK% !115>'4+6YNKBUAN89;FVV^?"D@+Q;AE=P'*Y'(SUH L4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !4=Q&9H)$5MC,I4-SQD=>"#^1%244 <
M)\,_A_J?@BZUV34=<FU@7UQ'*C2!,L%AC3<Y*>86&S:-TLGRJN3NW$^86EO9
M? WXJ:KXDM5M](\$:[J@TK6((U$5O9W7E1M;76 -J!V=XW/ R\;'N:^BJXR'
MX0>%H['7;*:SN]2LM<8/J%MJFIW5[%,PQ@A9I'"'A>5 X51_",,#S'3M%L_%
MWQ\\->+]<M(K@W&C:C=Z7'>H"ME;PSV@MY55AA)&#R2%L;AYNW/RBI9OC1K.
MJ7_B32HK;0O%%BWAR?6;0FSNK2TD1657A,TBNEW&5?(DB50V,%5W CTW5?A/
MX;UKQ=;^)KR"^EU>WB,$;+JMVD*Q';NC\A91$4;:NY2F&P-P-9'_  S[X'$4
M*)8:A#Y-E)IR/#K=]&_V5R"8"RS!C&,#"$X7HH% &!X=\<>,=;U'0M"T>Q\.
MZ%:7GA:WU>UNGBFN$C?,2M']F5HMJ#>54"0\8.>"AR+?QUXW\=#X4W^FZMI>
M@-JDMXFH6K:?+<PRS013*QXGC)C)0E5/(.TDMC%>A>'O@KX4\+Z]IVL:=!JB
M:AI]I]AMGGUN^G1+?_GELDF963H0I! (4]0")+7X,^%+&QTVTM[.]@ATV^?4
M;/R]5NP]O,X(?8_F[@C!FS&#L.XY7FD!Y[X9^.GB?Q;KUJ^EZ,;K3;J_N;!;
M!]"U&'R5C,J+<2:D4-N5+QKN0)E0Y 9F7!M:'\5_&EQH_@KQ!J=OH4&G:SJ_
M]C7NF6T4SSQ.TTT2RQSF0*0&1,H8^1N(89"CT"U^%7AW3]6O=1LHM0TZ:]:6
M2>&QU:[M[9WD!#R>0DHB#G).\*&S\V<\U1L_@?X0T_PK!X=@L[]-)M[X:E!'
M_;%Z9(;@'<'CE,WF)\Q+85@,DG&226!S,WQ@U;_A:&EZ%ITFDZUINJ27MK"L
M-K=1+;SP1NP#7V&AD),95T1 T9S]_:<T]#^*_C2XT?P5X@U.WT*#3M9U?^QK
MW3+:*9YXG:::)98YS(%(#(F4,?(W$,,A1V,GP,\&M=07*:?>6\]O=S7MO):Z
MM>0FWEE!$OE;)1Y:ON8E$PI)SC-+9_ _PAI_A6#P[!9WZ:3;WPU*"/\ MB],
MD-P#N#QRF;S$^8EL*P&23C))(!GZ;XZ\0^(K.\\2Z<^EV_AO3KR\MKG3KBTE
MDO9DMI9(G=95D"HQ,9(0QMD8^89XQ/A+\8O$7C[6M(:ZTQSI&K6#7N8_#^H6
M:Z<V$9(VNIP(KH,&8;HPG*Y (.1Z!I_PU\/Z3XEO-=LK:YL[Z\9I+F."_N$M
M9W9=K2/;"3R6<@<N4W'KG-)X3^&N@^!IY'T2*]LH64HME_:5S)9Q*3G$5N\A
MBB&?[BKCI2 \VTSX6^"_$WQX^(;:QX1T'56^QZ9-NO=,AF/F.+C>_P RGYFV
MKD]3M&>E8]CXA7X0>-O&>@>%H4ET!)-'MK.QGF<VFG:A>3-$R*>2D83RI3$,
M<L -N_->I:O\&_#6M>(;_7)CK5OJ=^L:7,NG^(=0LUE5 0BE(9U7 !. !_$3
MU)K0;X9^%V\(W/A=M$M7T*Z):>T<%O.<L&,CL3N:0L WF$[MP!SGFF!P&H?$
MCQSX=U?Q!X<O+#3]=UBTM+/4+34='T^7R_L\TYAE:2S,[R,T6QW"I)F0# VD
M5B3?M :Q-)I6C65U:W.JSQ7D]SJEMX3U6Z2,0S+&(FT]#Y\4A+_,7?"8'WMP
MKTZ/X0^&8]*N;%8=1Q<2QRRWIUB\-\[1DF/-V9?.PN3A=^!DX')J.X^#/A&X
ML-.M1I]S;MI[2/;WEIJ5U;WJM(<RDW,<BS,7(!;<YW$#.<"@#/O?B9JEC\+=
M"UZYT;[!KVJS6=B+&^$D*07%Q,L.YPRAP@+;MI 8C"G:3D>>?%KQMXSL?"'Q
M(\*:I=:6=3M="BU.UUG2[26&.2WED:*2-X&G=HWRC ,)""#G VD'W'6/!^D>
M(O#,GA[5;,:GI$D2PR07DCS%PN"I9V)8L" =Q.[(!SGFN>NO@GX2OO#NH:+<
MVE_<6>H%#>2S:O>/=7(3.Q)+@R^<R#)PA?:,GB@#E_V@-#DOOV:?%\/B0:;K
M-];:3/.)H;$Q0K*J,4DCC=Y"C*,8.\G.2,=*[B;PSX=B\!Q^&VT[3?[%ELS!
M%IC0Q^1(H0MM$>-IZ%L =LU8UGP#HWB'P7-X4U*.[O-$G@%M-'+J%P9I8P1\
MK3^9YK9Q@DODC(.036/;?!?PU:A@LWB&3,+0+Y_B?4Y?+5@ ?+WW!V' QN7!
MQD9P32 \;^!_P5AOO"_PMUS3-#T+PU#86=M?SZYIC,NJ:D6@(>"4+$H",S9+
M-)(2%&%4G(ZFX\/1?#[XY>%;RW\(:;I&FZJ]UIB:GHEV3=7LK0^:K7T1A7<
M(9"&WR$-R2,G/JGA'P#HG@;PPGAW2+::/1D5D2UNKR:Z"(1@HK2NS!<?P@X'
M.!S5?0?AGX?\.S/+;V]U=R-&T2MJFH7-_P"5&PPR1^?(_EJ1@%4P" ,CBF!Y
M9I/P[7X6^+O"4LWAOP;<G5;EM-&HZ3H@MM6LYFMI7,YN2S>?D1R!CLC.&SR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYXP?"/Q0\77_ (=\)V$^A:5J'C#5M*&J;1JSQ6GV95A#32R?9MR.SR@"-(W
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M8=-K_+RS4@([/XS:AXAUG2-+T'PI+//JV@KKUI=:G?QVUL4)C_=L4$LBD>:
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MNT$@\C\;+2XU;X@?#2VM9?$.GF"_N)I=4T/3)+@6H>WDB0O(8)8E!=@")!@
MY. ,T 0:M^T@OAA9]-\0Z5IN@>)H]4_LP0W^M+%IA_<"X68WCQ@B,QD#_5;M
MY"[>]2Z7^T)=^(8?#*:+X7CU2?6;R\T[[7!J\3Z='<6\<KX2X56>1'$0(<1
M -S\PV5UVK?"/2]4M;9DO]2L-9M[W^T4UVUDC%Y]H,?E,[;D:-@8_D*%"FT
M!1@8AU?X4RZYJ'A:^O/&7B"2[\/3M<P2+'8KY\C*Z,TH%KCF.1TP@48.?O?-
M0!SUK\7CIFJ>*A?^&=2L-:MI]+LQ8RZHL\=S<W0V1K$-YCBC#=6 5F +%,@
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M^<5P&K_M!17_ (:\:)<:(NI2>'Y;1;AO"WB(20F.9CM?[2ODR(5*8=%4MR
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV!X#FSN8I\>O#;*_,=%JTDV0!*OF+VSU'XUB\#0?V2XYMC:?V[KS2/UUT/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img8619836_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_7.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1D!3$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?\
M\?#?[G]:TZS-/_X^&_W/ZUIT %%%% !4<W^J?Z'^525'-_JG^A_E0!D4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!8T_\ X^&_W/ZUIUF:?_Q\-_N?UK3H **** "HYO\ 5/\ 0_RJ2HYO
M]4_T/\J ,BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ I":6D;K36X"%B.U)O/I7RS^TM
MXC\<?">\TZ\TOQA>26NJ2S%8)(DQ#MP=H..G-=G^S9<>*O&GAVU\5:YXINKZ
M.1Y8AI[1H(R <!B0,YXKVIY;*&$6+<ERL^6I9Y&KCW@%3?,CW44M-!Q2[J\0
M^I%HI"U&Z@!:*3=1NH 6BF[J7- "T4A:C=0 I--W<4FX>E?-7[6UKX@\.:*-
M=L/%6IV]I<W"V[:=#)Y<:@@]Q@GIWS7=@\/];K1HWM<\G,\=_9V&EB.7FL?2
MB2"3E6##U4YJ2O'OV4Y)9O@SILDTCR2--*2SL2Q^;UKV $5&)H?5ZTJ5[V-\
M#BOKF'A7M;F5Q:*3-&ZN0[Q:*3=1NH 6BBDW4 +2&C=2%J %)I-QKC_BE\3]
M.^%7ALZSJ4%Q<Q-((DBMP"Q8].IX%5?@Y\1G^*G@U?$#60L5EN)(HX=VX[5.
M 2?4UU?5JKI>WM[M['!]>H?6/JJE[]KV.[W4M-W<T[(KE.\1C2;L4-535+.7
M4-/N;>"YDLYI4*)<1@%HS_>&>]4DFTF*3:5UT+F[UI-QKXE^,7Q*^(GPQ\=S
MZ!;^,;J\B5(W262&,,=W;I7K>M_#GXGQ^%?[3TOXBW5Q??9Q<?9I8$4-\N2H
M('6O?J92Z4*<YU$E/;<^-I\1JM4J4Z=%MT]]CW_<:4&OD[]G']HKQ+XB\;P>
M%O$\ZZ@MT'6*X*!9(Y%'W3C@C@\U]8_=Z]:\_'8*I@:OLJG:Y[65YG1S6C[:
MCI9V8M%)NHR*\X]D4\<TT,?2AONUQWQ0T'4M=\*W*Z7KEWH5S;H\PFM,9DPN
M0IST'TK:E!5)*+=KG/B*SH4I5$KV.O\ .&[:&7=_=SR*?NKXV_8_UK5=<^*F
MMS:IJ-UJ$PL2&>XE9SD/CO7V.&Q7;C\$\#6]BW=VN>7E&9+-,/[=1MK8?12;
MA1NKS#W!:*3=1N%  2:0-5'7M8@T#1[S4KD,;>TB:>01C+;5&>/>O+/@[^T'
M;_&3Q9JUA8:9)9Z?96JSK-.P\QRS8Y X _&NFGA:M2$JL5[JW."MCJ%&M"A.
M5I2V1[#NI=WY5Y3^TEIOBK5/AM+!X3^T&\\]3/':-ME>+N%/7\NM2?LX:=XH
MTOX:VL/BPSB^\UO*2Z;=*L78,?\ &M_JR^K>WYE>]K=3G^O2^N_5/9NUK\W0
M]3HI-Q[T;A7GGKBT4FZC=0 M%)NHW4 '-(S4;LUPWQB^)UI\*/!ESK$Z^=<M
M^[M;?O)(>GX#J:VI4IUIJ$%=LYL1B(86DZU5V2.W64,Q4?>'49YIVX^E>1?!
MSPIJ]]X%O=<U?5KJ/Q)XE3SY+I6S]E7_ )9B-3P,"OGWXJ_%+XA_#GXB7?AJ
M'Q?=7,431B.:2&,$A_7 KU\-E<L56E1IS5X_H?.XW/HX'#PQ%2F[2/M[<?2C
M>?RKYU\;>"_BEH'@V37M*\?7>HW%O +F6S>W12RXR0N!C@5!^S!^T#K?Q"UB
MY\/>(C'=W4=N9X+R- C,!U# <?C4O*YNA+$4I*2CN$,_IK$PPM:#BY[-]3Z2
MW49->+?'K]HBU^%'EZ7IT"ZAX@F7<(3]R%3T+8Y)/85A^$_A[\3_ (AZ3#K/
MB7QS>: +I1+%8::@C,:GD9Q[=N:QC@)>Q5:J^5/;S.BIG,/;O#8>+G);VZ?,
M^ALGTI-QKYA^(FD_%3X*V']OZ5XNG\2Z1 1]H@OXP[H/4Y[?0@UZ/\"/CM9_
M&#2Y4EC6QUNU :XM5)*LIZ.OM_*JJ9=.-'ZQ3?-%;M=!8?.Z=3$?5*\7";VO
MU]#UFBBBO(/I HHI-U  QINZE9J^8OVC_#WQ*U3XF://X8^W/I:Q1^1]CD*K
M%*&^<OSQVZ]J[<)AUB:G(Y*.F[/*S#&2P-)5(P<M;61]/*<TM4]*6XCTVU6[
M96NEB43,O0O@9_7-6]U<LH\LFCT82YHJ7<6BDW4;J@T%HI-U)F@ R:1I55@I
M90Q[$\UB^,-!O/$6AS6=CJUQHEPQ!%W:@;QCMR.AKX]^ &K:SJ7[0R6^JZO>
M:G):M=1%[F9FSL)7."?:O8PF ^M4:E52MR*]CYO,,W^H8BE0<+\[M<^W5)IU
M,5L4[<*\<^C%HHHH&%(306KG/'F@WWB/P_+;:?K-UH5PN9!<VF-YP#\O/05I
M"*E))Z&-:HZ5.4TKV.A,RJX3(W'HN>33@U?%7[,6M:SK'QZE75=6O-3DAM[A
M"]U,TAXR.]?:@->AF&">!JJDY7NK_>>1D^:+-:+K*-K-K[AU%(6 HW5Y9[HM
M%)NHW4 +12;A1N% !N/--60-R.1ZBAP&4@]",&OGBR\;7/P1^,1\(ZE<23^%
MM:?[1I\T[%C;.YY7)_AW>O3(KKP^'EB.90W6OJ>;C,;'!\LJB]UNU^Q]$AJ6
MFITIU<AZ*?,KH****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %C3_\ CX;_ '/ZUIUF:?\
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M3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** +&G_P#'PW^Y_6M.LS3_ /CX;_<_K6G0 4444 %1
MS?ZI_H?Y5)4<W^J?Z'^5 &11110 4444 %%%% !1110 4444 %%%% !1110
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MU>W]I"MO'<6MPGE2!1@$\\=J]ZVTM<U+$1IPY)1NCMQ> EB*BJPJ.+M8^?\
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MN"S$@=*^GJXA^WC3E1C**LKVZ=S\^HX.+PT\1#$2C-W?+Y]B?X._';Q!\3/
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M7E-N3NSZ"$5"*C%62"BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 6-/\ ^/AO]S^M:=9F
MG_\ 'PW^Y_6M.@ HHHH *CF_U3_0_P JDJ.;_5/]#_*@#(HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@""XMXKJ%H9XDFA?ADD7<K#T/M4&FZ/8:2K+8V<%
MFC=5@C" _E5ZBK4I)63T,Y4X2DIR5VA%^E+114&@4444 %-;-.HH R'\,:1)
M,\KZ59O(QRSM N3[DXJ:QT/3],F:2TL;>UD<89X8@I(]"16C16CJ3:Y6]#!4
M*49<ZBKA11169N%%%% !1110 4444 )^%4M1T>RU:,1WUG#>1J<A9XPR@^O-
M9=]X^T:P\12:"UPTVJQV;7TMO;QM(T<*_P 38'!/8'D]JX2;]JSX;V^I+ID^
MKW4&JN<+I\FG7 G)/0!-F:J,G%W3L1*$9JTE='JMK9PV4*PV\4<$*\*D2A5'
MT J>J&A:W;>(=+MM0M5F6WN%WH+B%HGQ[JP!!^M:%)MR=V.,5%*,59!1112*
M"BBB@ HHHH **** "BLCQ1XEM/".CSZI?)<R6\.-RVENTTASTPB@DUQOPE^.
M_AOXT76LP^'5N]NE.L<[W47E_,>P!YX]Z /2:*** "BBB@ HHHH **** "BD
MW"@-F@!:*** "BBB@ HHI'D6-69VVJ!DLW0#W- "T5@^$?&VD>.+.ZN]%N?M
MUG;7#6QN%4B-W7AMA_B /<<5O4 %%%% !15#7-:M_#VDW>I70E:WM4,CK!$T
MKD>@502WT%>=_#7]HCPO\5/&.H^'=#BOQ>:?#YMPUY;F$+SC;AN<_44 >IT5
MX_\ $#]J#PA\.O$%OHFI0ZHVHSW*6D2K9NL;NS ?*[8# 9ZBO8-I5F4]0<4
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M /'PW^Y_6M.@ HHHH *CF_U3_0_RJ2HYO]4_T/\ *@#(HHHH **** "BBB@
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M%?)_Q Q_P\*\"_\ 7@O_ *+:@#Z]Z<BN9\:?$SPS\.X[:3Q)J\.D1W)VQ27
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M/XW_ !H\+Z?NBT:QNT>WMMQVQ_.1Q^'% 'T#?_&WP-I_B2QT!_$MA-K5Y/\
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MW#"2-5 5LCN0* *WC;P5;>.M*33KN]OK*U$@DD_L^X,+2 ?P%ASM/L:^4/\
MA#M)\(?M[>'=.T6PCL+./3!((X_[Q1LL2>23W-?:-?)7B+_E(5HG_8(7_P!
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M;6[U72[C1]9A)MK^SN%(*3)PQ4D?,I/((]:ZTQAL;E#$=-P!Q0!XC\6/#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% %C3_ /CX;_<_K6G69I__ !\-_N?UK3H
M**** "HYO]4_T/\ *I*CF_U3_0_RH R**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?\ \?#?[G]:TZS-
M/_X^&_W/ZUIT %%%% !4<W^J?Z'^525'-_JG^A_E0!D4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8T_\
MX^&_W/ZUIUF:?_Q\-_N?UK3H **** "HYO\ 5/\ 0_RJ2HYO]4_T/\J ,BBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** +&G_P#'PW^Y_6M.LS3_ /CX;_<_K6G0 4444 %1S?ZI_H?Y5)4<
MW^J?Z'^5 &11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 5'-_JG^A_E4E1S?ZI_H?Y4 9%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\T_:,U.[T?X/Z_=V%S):74:+MFA
M8JR_,.AKTNO*_P!IX_\ %D_$7^XG_H0KOP$5+$TT]FU^9X^;R<,!5E'HF?#0
M^)WB_C_BIM3_ / EJ=_PL[Q=_P!#+J?_ ($-7-=NE-/L*_H!8'#<OP+[C^4G
MF.+YOXK^\^[_ -D77-0\0?#":YU.]GO[@7\J^;<.6;;A<#)KV^O OV+?^23S
M_P#81E_DM>^BOPC-HJ&.JQBK),_J+AZ<JF6493=VT,F61D80E1*1A3("0&[$
MXKROX.?$KQ%\0->\7VNK6VEVMMX?U Z<&LEEWS,!G?\ ,Q 'MBO5UXD7ZBO"
MOV:.?$WQ>Q_T,S_^@"O'/HSI?V@/B5KGPC\!OXDTBUT^_6&XA@EM[X298R2!
M 5*L,8SWK+\8?%/Q=\,Y/#-]KVGZ1J.BZO>0V,KZ6)8Y[=Y,;6P[,''TQ6)^
MU_JUKJ?P'UY;>3S#9ZS96LW'"R":-BOY,/SKTJ'X=V&L7VCZKJMU=ZH]B%GL
M[6X8&""3:,.$'4CL3TH ;J7CZ>\\77?A;PW:1ZAJMBJ27]S<$BVL@V=@8CEF
M(!.T8.*J>//%7C#1=6T;3/#&AZ=KEU=6TD]R;JY:!8]A4?+UX);H:\>\ ^";
MOQ+X#^(>K2>*M4T;6(=<U&7=8S>6(G0 H9.[C '#<8Z5W/@71+/XW>!?"NI^
M)KNZ;7(=*5;NWM;AH"XE((=PN#SLR.W6@#:F^)'B3POX72[\6Z#9VFLWVH1:
M?IVGV-UO69Y#A=SD<<YSQT%78_B!J>A_$#2/"WB.SM%EUBWDGL;VP9O++1XW
MQ.&R<X.01P<=*\G\-_"S5/&^C^-?"8U_4(;?P_K\,_AO6+IC/)!*BABA)Y=5
M; _&KNCZ#XJ\8?M >&[G6-9M=<3PG:SF^N--MC!:Q3R@".(9)+.0"6YX]J /
M7_&WC9_#NH:)H]E%'=:YK4S16D4Q(C557<\CXYVJ.PYYK/\ !?Q#O=2\;:YX
M.URTM[;7--@CO$ELRWDW$#G =0V64@\$$GJ*YCXFK+9_M!_"F]=<63QW]H)#
MP/-9 RJ/<A3^5.TV G]J7Q+J9*I96?A>"VN)6.U5=I]XR3P/E4F@#M_&NN^(
MK.2RL/"^DV^I:E=*[F6_D:.VMT7'+D#)))& .:R?A/\ $/5O&4VOZ9X@TF'2
M-=T.Z%K=+:RF2"7<NY70GG&#T-=->:E8Z]NTFSUAK>\GMA=1S63J7,6<;T/0
MC.!D>M>9?"'^T_#WQ4\>>%?M#:MHEH(+U=2N%'V@7$H.Z*1P/F.!D9Y Q0![
M.TFWDD#TW'%,^T1^6L@=?+;HVX8ZXKP?XC>&['6_VF/ ]K>><]K=Z5?-/;K,
MP27:HP&4'!%8_@WX5^'=0\:?%?PK<PW%QX?TV6*6QTY[AS':-)#N9H^>#G\J
M /I,-GV'>FPS),NZ-UD3.,H01FOE72?$.O7'[,OPUUE[R2]L+35 FMP-/MFO
M;5;B2-8E8_>/"#'4XKT[P?\ "^.U^*6I^)+73;CP_P"'OLD*16#2&)9+A26:
M;RP2  N!SUH U_'OB_Q#9^(KC3?#C6:/8Z1-J5RU[$TB%LXC4A2",X;H>U;/
MPE\47WC3X9^&]>U,(M]J%DES,(5VH&;G@=A7(>$_,USP[\1/%\TA9=7:XBM,
MC[MI C1I^!82-^(KRSX,^(HM1L? ^A^/[?['H,VG6Y\-MYV+.]D"_,)3Q^^!
M^ZIX].: /JZ6XCMU#R.D2YZN0!4@;I^E>$^(-/DOOC3X@TG7]+;Q'H]SH\;Z
M59P,'^R[<ARR9&QF.,/[>U=G\#_ %W\/_ UA9:I+--JS*QG::=I-J[V*("3_
M  J57/M0!Z)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 6-/_P"/AO\ <_K6G69I_P#Q\-_N?UK3H **** "HYO]4_T/\JDJ
M.;_5/]#_ "H R**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?BAIWCS5+:.#P==
MZ;:I(C).U^A8\\?+BO'_ (+_  +^*'P>O;U;?6-%O++4+K[1=[HVWG)RVVOI
MW'-+0!Y;\5OAWXE\07NEZUX2U2'2M<L_E8SJ3'(AZJPJO8>!O&_BZQ>Q\=:G
M8_821NBTI2OFC^Z^>U>M44 5=.T^#2[&"TM8EAMX$"1QJ. HX%6J** "BBB@
M#YJ_;X_Y([:?]A"/^1KW;X?_ /(BZ!_UXP_^@"O"?V^/^2.VG_80C_D:]V^'
M_P#R(N@?]>,/_H H WZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K@_CEX4U'QM\,=9T;2466_N441*[;0<-D\U
MWE<'\</B)<?"GX::QXGM;2.^GLD4K!,2%;+ <XKJPKG&M!T]TU8SJ8/^T(O"
M_P VGWGR#_PR7\1O^@;;_P#@2*0_LD_$;_H'6W_@0M+_ ,/&O$A_YE/3?^_S
M_P"-+_P\:\2=/^$3TW_O\_\ C7Z8L;GMOA1XW_$&[Z\K^\^G_P!FGX?ZS\-O
MA_)I>N1)#>M>22A8WW#:0,<_A7K(KR?]FOXR7GQO\ R>(+[3X=-F6[DMO)@8
MLN% YY[\UZS7YQCI598B<JWQ-ZGL4LM_LB"P5O@T$9=S>WUKB;?X,^%+2>]F
MMK"2UFO93/<O;W#H9I#U9L'DUVDLHAC=RK,%&2J]3CL!7)^#?BGH/CV^U&ST
M>6>>?3I##=>9 R"*0?P$GO[5P&I7N?@OX0O= _L2XTKSM*:X:Z:UDE8J\I()
M=N?F.5!Y]*ZO3=,ATFQAM+<,((5VH'<N0/3)ZUA>/OB1HGPUTM=1U^>:TL&<
M1_:$A:159B H)'3)XK/C^,WAG^U--T^ZN;C3+G4F"6?V^W>%)V/158C!)]#0
M!H7_ ,,O#NHWVHW4MAMDU';]M6*1D2YVC \Q1PWX]:EU3X>:)JVI6^H26TEO
M>00_9TELY6A/E#HAVD94>_2KNN>*M-\-B 7]R$FN&*P6Z@O+,1U"H.3CN>U8
MGC3XN>&/AXFGGQ%J0TTWZ,\"R1L2V,9X ..HH W(_"^G6VB?V3;PFTL<;=EN
MY1N>2=PYR?6IM#T#3_#>GQV6F6D=G:H21'&.I/4D]R?4USV@_%SPKXF\.WVN
MZ?J\<FD63^7/=.C(JMZ8(!)Y[5?T?QWH^MZHVFP7+1:B(_.%I<Q-%(T><;E#
M 9'OVH N>)/"NF>+;..UU2V6XCAE6>(Y*M'(O1U8<@CU%00^"=&ATO4M/^R>
M;;:D&6\\UB[3@C!#,>3QQ[59U[Q/I7A>R^UZOJ%OIUMG DN'"Y.,X ZDX["D
M\+^)M.\8Z%::UI%RMWIMXI>"X4<.H)7/TR#0!BS?"?PQ-#HD::>;;^Q8C!8/
M:RM$\$9QE P/(.!6[H_A^P\/V[PV%NL"R.9)&ZO(YZLQZD^YIGB#Q-I_AFUB
MGU"X\E99/*A3!9Y7[*BCDGV%5_#/C+2O%T=R=-N1+):OY5Q ZE987QD!U.",
MC\Z (;_X?:)JGB:V\07-JSZQ:J4@NO,8-&IX*KZ ]_6DTGX>Z'HFL:EJMG:O
M'J&I#%Y,TK,9^,#=GK@<#T%=)FDW#CF@#PCXJ?#/3M+T7PQX<LM#D?P$^I^=
MK%O:*TLD(&61D ^95,G+;>>:SQ\++2?QMH5S\/)=3T6UCBN$U*ZNFF^SR1,A
M58_+D(+-N(.<<8KZ&P.2*.J]<T <_IW@FPM?!=KX:D#2V$-NMN^UBGF #D\>
MIR3]:H3?"/PG<>$8O#$VCQ3Z'"ZR0VDA++"P.1L/5<>U3^+/B+I?@V[CMKY+
MF:9K:6[*VL7FLL4>-S$#MR*T?"/BJQ\:^&M.UW36=K"_A$\#2+M.T],B@#Q'
M4O FB:I\6O$5QXYT>[$%O#;VFA7-G',4>U"Y8,\?)8.3][\*Z_X#^#;[PG+X
MM;?>Q>'+S4!)H]CJ$C/+!$$ <_-R S9(!["O5E;;T/X4=_6@!U%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBW=V0A=H^\?E89Z<5>L/A?KGABW\2Z5H&K64&BZW<272K=PLTUF\HQ-L((#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *HZQ=V-C82S:D\262C]XTX!3\<U>KA_C9_R3/6<\_(O_
M *$*I;Z'/B*LJ%*56/1"?\)9X!_Y^M'_ ._2?X4O_"6> A_R\Z/_ -^D_P *
M^1PJ^E+M5NU;<T^Y\'_K;BEI;\3[:\/ZAI6IV/G:/);26FXKNM5"J&[].]:M
M>4_LX\> 7'_3Y)_(5ZM6$G=ZGW&#Q$L50C5ENQ,^U&:1X_,^0D@-P2IP1[CT
M-?.?POU;^U/$'Q0MO$GCC5K>+2=7:VLA-K+1>3%Y>>!D;L$TCL/HT'-+7EJZ
MK:Z+JG@+2KOQKJ#:A-N:&-D9AJX*DCS&([#GKGBM2Y^.7@^VU#5-/_M":XU#
M3=OVNTM[2626/(R/E"Y(P"<T =]28KEK'XH>&-2\+V_B*VU:*72+F40Q3*#E
MY,X\L+C=NSQC&:K:7\7O#&J^)'\/QWDL&MJ5S8W%NZ28/1L$?=/K0!V=)GTY
MKCM5^+7AG1XKJ>XO7^Q6KF.XO8X'>"%AP0S@8X]>W>N$\>7AN/CO\*;JRU2X
MET[4(+R0PQW!-O*!&"CA<X[]?>@#VS<*.M>?^'O&&D_\))XSE7Q+=ZBMBT37
M.GRQ-LTX;6X0;<G=@GOTJK#^T9X FL;*^CUMFTR[?RH[_P"SR"W#9P TF,*<
M^M 'I=%<7I7Q@\*:QXHC\/VVHD:K,C2012PO&MP@ZF)B,.![&K.K?$[0-%FO
M8Y9YI_L'_'XUK TJV_&?G*CCCGUH ZLTTGVXKGV\?>'VT.PU>/5()["_(%I)
M"V\W!(Z(!R3[#TKRCPMXFMO$G[4UVME>ZD8(?#+/+8WHD18I/M$8RJ-P,CN*
M /7?$W@_2?&%O;PZM9K<K;RK/;R E)()1T=''*GW%)I/@W3-'U!K^&.6XU!H
M_*^UWDS32A,YV!FZ#/I6EJ$-S/9RQV<ZVURPVI,R[@A]<=Z\I^!^N:YJ'C?X
MFZ;K&M7&L1:3JD-O:-< +Y:&$,0% P,EOT% 'KXZT,>U<'\</'5Q\/?A[>:G
M9+NU"6>"QMLC[LLTBQA\=]N[/X5R_BO4M6^%WC[X?C^VM0U/2=<NCI%_!>S&
M4&=ES'*F?N_,.@XQ0!Z!??#W1M0UR;6?)FL]4GC6*:ZL;AH'F4?=#[3\V/>M
M;0]!L?#EBMGIMM':VRL7VQ_Q,>2Q/4DGDDUE^-OB%H/PYTU+_P 0WPT^S>18
MUF,;,-Q. ,@'&36)'\=?!LFJSZ:VI207Z1><EO-;2(\Z9QNB!'S\^E '?T5R
MWA7XG>'/&FGZA>Z7J*O%IS%+U9T,+VQ SB16 *\>M9=Y\</".GW%DEU?S6\5
M]_QZ7,EM((KDXSA&QR<<XQS0!W>X#K2[L8S7G7Q/N(_$:^%?#]O<2(NMZA')
M)Y>58V\7[U\]P#@#\:Y?X1:Q!X9U+XJWFLZM.UE9^(#$D]],TICC$*$*">3R
MW % 'MU%<_/XZT>TTNQOIKEH8;Y_+MHY(F665B,A0A&<XYZ5G>'?BUX:\4:O
M/I-C=RC5;=_+FLYK=TEB;&0&!'&1R.: .QHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** +&G_ /'PW^Y_6M.LS3_^/AO]S^M:= !1110 5'-_JG^A
M_E4E1S?ZI_H?Y4 9%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?-7[?'_)';3_ +"$?\C7NWP__P"1%T#_ *\8?_0!7A/[?'_)';3_
M +"$?\C7NWP__P"1%T#_ *\8?_0!0!OT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 ?-7[?'_)';3_L(1_R->[?#_\
MY$70/^O&'_T 5X3^WQ_R1VT_["$?\C7NWP__ .1%T#_KQA_] % &_1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +&G_
M /'PW^Y_6M.LS3_^/AO]S^M:= !1110 5'-_JG^A_E4E1S?ZI_H?Y4 9%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '-^-O'-CX#TT7^H0W4\);;MLX3(^?H*\ZNOVLO!MC)#'<V^L6\EPVR)
M9+!U,C>@]37M#(K?>4-_O#->*_'R-%\9_"W$:8_MD_PC^X: .T\!_%K2OB%<
M7$.GVFH6[0KN/VVV:('V&>M=O3?+0,<(H/\ L@"G4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% %C3_^/AO]S^M:=9FG_P#'
MPW^Y_6M.@ HHHH *CF_U3_0_RJ2HYO\ 5/\ 0_RH R**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!C1JW55;Z@&CR4_YYK^0I]% ";>]-\M>H50?4 "GT4 %%%%
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MH'_7C#_Z * -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\7^/W_(Z?"S_ +#)_P#0#7M%>+_'[_D=/A9_V&3_
M .@&@#VCU^M%'K]:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_D=/A9_V&3_Z :]GW5XO\?#GQI\+?^PR?_0#568KH]I]?K12;N32U(PHHHH
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MABJV*RR-2O+FE<****^7/N HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^Z?Y5Y)^S%_R(.I?]AF[_P#0Z /7:*** "BBB@ HHHH **** "BBB@ HHHH
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M3E"*3T/L>BBBOR<_# HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444F: %HHHH **** "BBB@ HHJ&Z:5+>1H5#RA245C@$]@?QH FHKQ
M;7/'WQ;T.SO[YO!6E26=JCS,WVT[BBC/3UQ4?@'XG?$WQM8Z5JH\'Z;;:1>@
M/YGVPEU0GKCUH ]MHI%R5!(P:6@ HHHH **** "BBB@ HHHH **** "BBB@!
MLG^JD_W3_*O)/V8O^1!U+_L,W?\ Z'7K<G^JD_W3_*O)/V8O^1!U+_L,W?\
MZ'0!Z[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>+_ !^_Y'3X6_\ 89/_ * :]HKQ?X_?\CI\+/\ L,G_ - - 'M'K]:*
M/7ZT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% %C3_^/AO]S^M:=9FG_P#'PW^Y_6M.@ HHHH *CF_U3_0_RJ2HYO\ 5/\
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MK-08MHSD>M>H^#? /CO0]=BNM:\=-K=@N=UJ;8)N_&L3XV?\E1^%7_81E_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@!O\7M7Y^?M0?\E@UG!QRG_H(K]
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MK.T'Q%IOBC38]0TJ[COK*0_)-$<@^M:- !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!XUXTG\3>*OC(GA31_$DGAVSBTS[8TD,0=
MG;=C'-4/$'[.?B3Q-?:5=7_Q+O99=+G^T6Q^S*-CXQG\JV;7_DZ*7_L '_T.
MO6,_+@T >$:];^,_A?XN\%BZ\:S^(+/6-0^R36TT"H -N<@BO>J\>^/G_(T?
M"W_L.?\ LAKV&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH L:?_ ,?#?[G]:TZS-/\ ^/AO]S^M:= !1110 5'-_JG^A_E4
ME1S?ZI_H?Y4 9%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <;JWQ$M?#OC
M*UT756CLXKQ"UK<2-@.PZJ2>E5?BUX@TZU\ :Q \L=S+=V[0PV\;!C*S#  Q
M6AX_^%_A[XFV,5KKUG]I2)MT;*Q1E/L15'P;\&?#'@:0R:=;32-G(^V2M+M/
MJ-W2@#'_ &</AW+\,_A?I^F7#-Y\A:X9#_!N.0OX5ZE2#I2T %%%5Y-0MH6V
M2W,,;?W6D"G]: /G+]OC_DCMI_V$(_Y&O=OA_P#\B+H'_7C#_P"@"O ?V\KR
MWG^#MH([B*1O[0C.$<$]#SP:]T\ ZG9Q^"=!5KRW!%C$"#*O]P>] '4T55_M
M6R_Y_;?_ +^K_C2?VI9_\_MM_P!_5_QH MT55_M:QQC[;;_]_5_QH_M2SX)O
M+?U'[Y>?UH M456.J67_ #^6_P#W]7_&N2USXS>"_#FHR6&H>(;6"Z3EHP2Q
M'UQ0!QNH?\G6:3_V Y/_ $(5[17S'>_&3P;)^TAIFKKKD1TY-'DB:XV-M#%N
M%SBO;_#GQ6\)^+KA[;2==M;J:-=[1[MIQZ\T =;150:K9'_E]MQ_VU7_ !IW
M]J67_/[;_P#?U?\ &@"S15;^U++_ )_;?_OZO^-']J67_/[;_P#?U?\ &@"S
M154ZI9#_ )?;?_OZO^->8>-/B-XJD^($/A7P79:9J-S]B^VRRWD^% SC Q0!
M4^.W_(Z_#'C_ )C!_P#0:]DW<GZU\Z^,O"/QH\8:MX<OYM,\/0MH]W]J15N"
M=YQC!KH&^(OQ#\)>)O#]KXPTG1[?3M8NOLJS6<Y+1MC.3F@#VJBJQU.R4X^V
MV_\ W]7_ !H_M2R_Y_;?_OZO^- %FBJW]J67_/[;_P#?U?\ &C^U++_G]M_^
M_J_XT 6:*K?VK9?\_EO_ -_5_P :3^U+,YQ>6[?]M5X_6@#Q[XV?\E2^%7_8
M1E_] KVH=Z\-^-E]:M\3_A65NX&5=1ERPE!Q\GUKVD:I99(%Y;GO_KE_QH M
M456_M2R_Y_;?_OZO^-']J67_ #^V_P#W]7_&@"S15;^U++_G]M_^_J_XT?VI
M9?\ /[;_ /?U?\: +->=_'?P7JOC[X?SZ7HODG45N8;B);@X1BC!L$^^*[O^
MU++_ )_;?_OZO^-)_:=C_P _MO\ ]_5_QH \<U3QU\9M#T>ZOIO"'A\P6<!D
M?%X2Q51_@*RM+\>?%_XE>!?M-KX3T&&QU>T95=KMMRJP(SCUKUCXA:E9-X$\
M0JMY;LWV"8 "53_ ?>N>^ .H6<?P>\+J]U KBT7(:49ZGWH Z#X6^&KKP?\
M#_1-'O65KNS@$<OE_=W>U=754:G8C_E]MQ_VU7_&E_M2R_Y_;?\ [^K_ (T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP:AYLUI$[8O9 ,E03CFOE_\ :8T<ZA\5/'5^J[TAE@4,HR#\M??/P]96\#Z
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ME/<(X8_I7AW@7XA>&_ _Q(^)<.OZO#I4MQJ$;Q+,#\Z[>H]: /8O^$2T#_H
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M@"QI_P#Q\-_N?UK3K,T__CX;_<_K6G0 4444 %1S?ZI_H?Y5)4<W^J?Z'^5
M&11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4C4QCE!W/S+B>K"MCW*FTU;H.HHHKYP^1"BBB@ HHHH **** "BBB@ HHHH
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M6ZN8T0^@Q7>Z#X%T+PW"D=AIEO"4Z.4#/^9YK?VTM92KSEI?0QGBJM32]D-
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MH **** "BBB@ HHHH **** "BBB@"QI__'PW^Y_6M.LS3_\ CX;_ '/ZUIT
M%%%% !4<W^J?Z'^525'-_JG^A_E0!D4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*** "BBB@ HHHH **** "BBB@ HHHH ***S/$>K3:'H]Q>P6,VI20KD6MO\
M??V% 'D_QL_Y*E\*O^PC+_Z!7M7K7R]\0/&WBKQ=XP\&:M;?#?7$AT2[>>=7
M"Y92N,"O6?"/Q8U7Q/KD5C=>!]8T6)\G[5= ;%^M 'I-%(O049H 6BC-)N%
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M444 %1S?ZI_H?Y5)4<W^J?Z'^5 &11110 4444 %%%% !1110 4444 %%%%
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M92IZ)W?D>A7VH6^GPM+=3QP1@9)D8"N#O/BPNIS/:^%]/FUFX!VF<+B*)O\
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MC"3]G'YL_'*E>G1DXT8_><7X5^$_ASPJ?,M[%;BZ;E[BX^=F/KS79*@50%X
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MZE86]V@*I,@< ]1FK=(]B,E)*2ZA11104%%%% !1110 4444 %%%% !1110
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M/@K:6]Q(93:W$D*,QY"AC@5[[7A/['&FW5C\(4ENH_*-U=S2J#_=+'!KW:@
MHHHH ^:?V^&'_"GK3_L(Q_R->Z>!X3)X#T%"" UA$I_%!7,?'SX/Q?&CP)-H
M;7+6=PC^=;RKT$@'&[VYKQ&S_9[^.FGVL-M;_$N.."%0B(I/RJ.G:FGRM-%)
MN+31LZM^P/X-U;5+J^DU/45DN)6E8#&,DY_K55O^">_@L\'5-2_,57_X4/\
M'C_HIJ_K_A2-\!OCRP_Y*<OYG_"O76:XR*LJCT/=CGN81BHJJSE?$'P]L?A;
M>/X>TZ66:UM6PDDWWCD9K*/UKO?^&<_BO<*/M_B+2M2GZM<3JQ=OK3?^&;/B
M3C_D*:&/^ M7G2J.<G*6K9^+X_)<=B\54KNSYG>YU/P7\5:EX;L+WR=$N-1L
MI)%WS6^/W?U%?%_[5&MV^L_&S7[F'<J.Z_*XP1QT(KZ@U+X#_&O2-/FDT3Q;
M:6)52?LMED"4X[Y%>7S?#FZN/WGCC3%N?$I8BZFDQECV/%?1Y7C:. E[64;^
MA^D\/9D^#J4<3BO?35K+='RH9$_O?K7WY_P3M_Y$?Q&1R/M:C_QT5Y1_PK+P
MY_T!8J]$^''PK\9R6=P/A]K5KX;LMP-Q;MG,CXX(_"O4S#.*./H.BE:Y[^8^
M(6&SR@\)AJ+YGJ?9BJ1VILDR0\R.$_WCBOF?_A4?QUW?\CW:?K_A6+K'[//Q
MHUO=]H\>V_)[,PKY+V%%:N?X'Q;KXO94;?,^IYM<T^V5O-OH%QS_ *P9KFM2
M^+'A_3Y/*6XDN9CT2&,MFOE&X_8J^)US<><_CB$OG.=[UOZ7^S+\:-%C\NT^
M(5JB_P"[D_J*+8:/=A_MM3>T3W>;XE>(=2E\G2O"5YL;[MU<<)^5?%G[<:^(
M6\<:,_B 6R2/9YB2WSPN>ASWS7MW_"B?CP!@?$U /Q_PKYJ_:>\!^.O"?B;3
M8?%VMOXENY+?=%-&"P1<].E>_D=:'UM6BDK;GVG"--X?,HU:]3H_)'B5?5O_
M  3U4_\ "QM8.,C[#_[-7RO]AN_^?2?_ +]FO7OV;_"OBW6O$U^OAWQ&OA&=
M+?,EU=$H'7/W>:^RS:I"6#G&+OH?L&>8JA6P%2$)INVR9^I^..%H*GTKXIU/
MPK\3='C9[GXU6>U>?W3%S^@KE+H_&F\S_P ([XZNM>]/+1DW?F*_)EAZLNA^
M&1PE66RL?H#M;KBFM\O+<#\A7Q'X1^''[1_B+!OO$]QHRG_GM("?T%=7=? '
MXYW=N\,GQ*1D88.6(_I6GU=1^.1M]54=:DTCZ7U;QEHNAPM+>:E!&%Z@."WY
M"O#_ (P?%#3/%]C90Z,UQ(D,C%IS&R*>.@SUKR9/V(OB7'JG]I#QO"UWG)D9
MW;]#6SK7PM^(/@2WAD\6>)X-<L9/E@MX4VE& Y/2E+V,5:&K/ SQT(8"HJ=V
MS%_M"?\ YZ-_WV?\:ZCX<Z7;>+/%%GINIQM=V<K_ #Q%C@X'UKD1"W]T_E6A
MHOA_7O$-TEAX=U'^R-7E;$-X3@(<5A?EU1^0Y?4JK%4W=[GV7I/AW3M"ACAL
M+&&UB0879& WYUH[,'.#7R<OP&^/ Z_$U"?J?\*=_P *'^//_13E_,_X5$I.
M6Y^V\TI?$[GU?M_SBEQ[''TKY/\ ^%#_ !X_Z*<OYG_"C_A0_P >?^BG+^9_
MPHT)/J]E/I7,_$3Q%=>$O"MSJ=LBM-$5&''&"<5\[?\ "A_CS_T4Y?U_PK.U
MOX2_%OPU8R:CXF\=KK&C18\ZS!/SY/':DCAQTY4\/.4=&D=D?VC=;W$?9[7'
M^Z:LZ3^T%K>H:A!;F"WQ(ZKPI!Y.*\7_ (C]:GL;>YO)Q!:3?9[J3"Q2_P!U
MB< _@:TLC\LI9MC'5BG4=C[ECW-&I(() -.P?0_E7R;'\!_CQM!_X6:N.W)_
MPI__  H?X\_]%.7\S_A6?4_7H.\4V?5^#Z'\J,'T/Y5\G_\ "A_CS_T4Y?S/
M^%'_  H?X\_]%.7\S_A3T+/K#!]#^5&#Z'\J^3_^%#_'G_HIR_F?\*/^%#_'
MG_HIR_F?\*- /K#!]#^5&#Z'\J^3_P#A0_QY_P"BG+^9_P */^%#_'G_ **<
MOYG_  HT ^L,'T/Y48/H?RKY/_X4/\>?^BG+^9_PH_X4/\>?^BG+^9_PHT ^
ML,'T/Y48/H?RKY/_ .%#_'G_ **<OYG_  H_X4/\>?\ HIR_F?\ "C0#ZPY]
M_P JQ?&2$^%=6^4_\>S_ ,J^:O\ A0_QX_Z*:OYG_"HY/@3\<D^>Z^(BWUJO
M,MKDYE7NO2EH<V)3E1DDNAPTW,S_ %IUJ,7$8'K79M\'_$Y<G^S)O?@4L?P@
M\3K(/^)9.OY5K=6/QOZCB?:7Y'N?4'A-2/#6E\'_ (]T_E6M@^A_*ODR/X$_
M'-AN@^(JVEN>8[?)_=KV7IVI_P#PH?X\_P#13E_,_P"%9Z'[-ATXTHI]D?6&
M#Z'\J,'T/Y5\G_\ "A_CS_T4Y?S/^%'_  H?X\_]%.7\S_A1H;GUA@^A_*C!
M]#^5?)__  H?X\_]%.7\S_A1_P *'^//_13E_,_X4: ?6&#Z'\J,'T/Y5\G_
M /"A_CS_ -%.7\S_ (4?\*'^//\ T4Y?S/\ A1H!]88/H?RHP?0_E7R?_P *
M'^//_13E_,_X4?\ "A_CS_T4Y?S/^%&@'UA@^A_*C!]#^5?)_P#PH?X\_P#1
M3E_,_P"%'_"A_CS_ -%.7\S_ (4: ?6&#Z'\J,'T/Y5\G_\ "A_CS_T4Y?S/
M^%'_  H?X\_]%.7\S_A1H!]88/H?RHP?0_E7R?\ \*'^//\ T4Y?S/\ A1_P
MH?X\_P#13E_,_P"%&@'UA@^A_*C!]#^5?)__  H?X\_]%.7\S_A1_P *'^//
M_13E_,_X4: ?6&#Z'\J,'T/Y5\G_ /"A_CS_ -%.7\S_ (4?\*'^//\ T4Y?
MS/\ A1H!]88/H?RHP?0_E7R?_P *'^//_13E_,_X4'X#_'G_ **<GYG_  J0
M.E_:27_BH+3(Q_HX_G7C6WK7>-\%?B3:JZ>(]5;Q3<''EW$?(1<_=.:B_P"%
M/>*/^@7/^0K6+T/R/-L)7J8N<HP=KG7?LUIN\17N!TMS_,5]%*#GH?RKY+'P
M5^)5TJIX;U9O"UP.9;F3^-?[O%2?\*'^/ _YJ:GYG_"LV?=9#3G2PBC-69]8
MX/H?RHP?0_E7R?\ \*'^//\ T4Y?S/\ A1_PH?X\_P#13E_,_P"%&A]$?6&#
MZ'\J,'T/Y5\G_P#"A_CS_P!%.7\S_A1_PH?X\_\ 13E_,_X4] /K#!]#^5(3
MMZU\H?\ "A_CS_T4Y?S/^%>D?!/X<?$?P;K5Y<>,O%H\0V<D06*$9^1L]:6@
M'M%%(.!2T@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +&G_\ 'PW^Y_6M
M.LS3_P#CX;_<_K6G0 4444 %1S?ZI_H?Y5)4<W^J?Z'^5 &11110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'G/QG^#>G_%[08;:>5K+4+203V=]%PT;CISZ5
MR*_#/XD>)=/@T#Q3X@L&\/JHCF>R1A<3*.S'W[U[I10!0T71[;0=*M=/LHQ%
M;6\8CC11V%7Z.E% !1110 4444 %%%% !28I:* &5@ZEX!T#6+N2ZO-.CN+A
M_O.W4UT-%!E4I0JKEFK^IR3?"WPNRD?V1#Z9YKF-2^ =A),\NEZSJ.B.W_/I
M)BO4\4;:VA4<'=!AZ5/#3YZ44GZ'D"_"/Q5I*C[!XYOKDCI]LYI6T#XMV?\
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M_0(A_6K6G^ = TFZ2YM-.B@F0Y5U[&NBQ10<T<'0BU*,$)@4M)BEH.P****
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MHUM=?9IM6LX[D'!B>90V?3&:TE<,H*G<#Z'@T .HHHH **** "BBB@ HHHH
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M;(Q_H:<&@#T2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?BQ\3M/\
MA7X7EU6]/F3N?)M;4?>FD/"J/QKMJ^2OVJI-0U[XW?#?0+)T \[[1MF&8]P/
M!([T >I^#OAIJ7C)(O$'CJXDN[BXQ-%I:L5AMU/*C [XJ;]H3X@2_"GX;$Z6
MGE7EVZV5IM_Y9LW&?PKDOBS\)_%VBZ#>^)_#WC74X]5LD^TM8,_^CN%Y**.U
M>5?%;XE7GQ/^#WPXUJ_007K:O''<HO"[E;!- 'M-G^S?X<UKP"&U-)KCQ)=6
MWGR:L9")EE(W CGL:ROV0?B%K'B+1=<\-ZY,UW>Z!=-;I<2??D3/!->]:;AM
M%ML?=-NOY;:^</V4TB3XF?$[R#F(7WWO>@#Z?HI!2T %%%% !1110 4444 %
M%%% !1110 4444 %>)_M5_$+4/ 7@&#^SY6M7O[E+9[Q!_J48\M[5[97F7Q]
MU+P]'X,?2M>L_P"T1JC"VM[5?O/(>A'TH Y#5O@3X#U#X9S:C$%^VBS\\:U%
M,?,\T+G=G.,YJCX#^)FM^#?V9[CQ%KS27-Y:1LEO)-]^09PC']*\KU7]G7XI
M?#3P_P#;?#VOMK>C0?Z0_A^X8[2G4J?7 K2^(OQ>A^*O[*^H7$%G_9EY97$=
MM=6J#"HP89Q[4 >F?#'X+:+\0O =MKWB^*35];U>,S-<3.080WW0@!XQFN?_
M &9?%6K>&_B9XO\ AIJ5U+?V6ER>=8S7!RX0_P .?2O</A+@_#;PY@@@V<?W
M?H*\/^'\<*_MA>+?).__ $)2_'0YH ^H**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH L:?_ ,?#?[G]:TZS-/\ ^/AO]S^M:= !1110 5'-_JG^A_E4E1S?
MZI_H?Y4 9%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<1
MB:&2-AD.I4_B,5)10!\G> [V]_9C^(?B73M?L;B3PIJ\YNK74;:)I-KGDJ0*
MZZ*Q;X_?$S1/$,=G/#X5T/YX9KA"C3S9R, ]!7OTUM%<<2QI(/1U!_G2Q0)"
MNU$5%_NJ !0 \=NU+110 4444 %%%% !1110 4444 %%%% !1110 4444 4-
M;UF#0=+N;^YWF"W0NXC4LV!Z#O7R!J7[7:7GBN:[OO ^L:A96S%;.,1E4QG[
MQ!'6OLN2-9%*L R]P1D5"+"U'2VB_P"_:_X4 ?.W@7]L(>,O%.GZ,/!&K6(N
MI @GD3Y$]SQ61J%CJG[/OQYU7Q5)83WOA#Q N;FXMT+M;R>ZBOJ);.W4AD@B
M5AT(0 _RI\D"3+MD19%]& (H ^=_%VH1_M+:QH>F:+;7/_"-:?<K<WUY<1&,
M,1T50?>OH>WA6WACB082-0BCV Q1#;QVX(BC2('J$4 ?I4M !1110 4444 %
M%%% !1110 4444 %%%% !1110!%<VT5Y!)#,@DBD!5E/<'M7C_CGX=_";P%I
MYU+6/"UNL+O\QMX7<EC[ U[+44MO'.,2(L@]'4'^= 'P-\#[WP!:?%GQ7<ZW
MX8NH-+N[A?[(,EI)M3!ZCT_&O7OBOX=U;X=?&31/BAHFGR:EHDD MM0@A!+0
MQXX8#O7TO_9UKP?LT.1T_=K_ (5,T:LNPJ&3^Z1D4 ?.WQ \>0?M :/%X2\)
MVMW-%<RH]]=7$#1+#$#R/FZFO=_#>AP>&=!T_2K88@M(5B3\!BK\-I#;DF*&
M.(]]B!?Y5-0 4444 %%%% !1110 4444 %%%% !1110 4444 !KYX_:8\ :S
M)XD\+^/] M6U"[T&;,]G']YXNY%?0]-*@@@\@]: / /$_P"T!:>//"=QHOA7
M3-0N_$FH0>0+>6W:,0,PP2S$8XK#\4_LUZB?V<[#PW:3+-X@TV0:B,?\M)0=
MQ2OI:.QMXGWI!&C?WE0 U.: /GKPI^TM9P^#;;2M4TK4;?Q?%%]E.G"W8AI
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M10 4444 %%%% !1110 4444 %%%% %C3_P#CX;_<_K6G69I__'PW^Y_6M.@
MHHHH *CF_P!4_P!#_*I*CF_U3_0_RH R**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH L:?_ ,?#?[G]:TZS
M-/\ ^/AO]S^M:= !1110 5'-_JG^A_E4E1S?ZI_H?Y4 9%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO3/V/_+U'X(W7@J_M;VPU,"43+<0,@ ?I@GK7D'A'_A8/[)OCS5+8^&YM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB_YZ+^8H DHJ/[1%_P ]%_,4?:(O^>B_F* )**C^T1?\]%_,4?:(O^>B_F*
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M6F71O+<.PVNIVN/<<&NF89XKDM#^[>?]?#_TH U**** "BBB@ HHHH L:?\
M\?#?[G]:TZS-/_X^&_W/ZUIT %%%% !4<W^J?Z'^525'-_JG^A_E0!D4444
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MIJ%O?6RW%O<Q7$##*R1.&4CV(JO_ &YIWF31_P!H6V^%/,E7SES&N?O-SP*
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M%% %C3_^/AO]S^M:=9FG_P#'PW^Y_6M.@ HHHH *CF_U3_0_RJ2HYO\ 5/\
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M(('2H/@SK'Q0^!_AR'P-XA\ W_B>RTPF+3=8T>6-DEAR2JN"1M(]Z '?LX^
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MICPO\+%N)+3P^MFVI:G'%(4:\(!*Q$CG8."0#SWIW[1?@GQ7K?Q@^%7B70-
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M=6.EZQ/86S-,PD2+^Z&SD?A7KWP#&L:9\,M!T37-#N=%U#2;*&TE6=D82%5
M+(5)R*\R_9*\(>+OAK?>,--\0^&;JPAU;5IK^WOO,C:+8> & ;<"?I0!PG[-
M?P@\+^)_B;\8(M3M+JY33=?,5M_I]PA503C<5<%S_O9K[.CC6&%43[BKM'X5
M\P?#7PYX_P#A'\;/B$D7@Z36]"\4:I]OMM6BND2.%2>?,!.>!V'-?4"DM%\V
M-V.<4 ?.OC?Q5<>/OVH=(^&4T\D'AO3],;5-0MXY"AOI"!L1B,$H 0<9Y(YK
MG/VS_@OX+L?@3KVN:?H5KIFJ:>(VAN+%1$6!=5*L!PPP>_I6O\>OA3XSTOXO
M:%\6OAU:0ZMK-G;_ &+4-(F<)]JAZ94YZXX_X"#6=\=;'XG_ !^^"NKZ79^#
M9O#$Q,9;3KN='GO6# [5(.%0<G)Y.!B@ _:%^)FJ_#7]E+PS)HER]GJ.IV]G
M8K=1??B1D!8K_M8X_&K/B;1_#/B+X.76@6?P[\1OJDNF_P"C7K:'*)OM6S*2
M>=C.2^/FS5[QG\']6^.'[.-IX1U#2[CPSXBTF&#[,UZZLC3QH!D%"?E/(SZU
MH?#?XG?$W0_#]AH'B7X8:I=ZU91K;-?64\7V6<+P'WE@!D=: /._$WQ$\?\
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MQ6)\._!/CW]ECQEXBL='\,7/C?P#K5TUY VGR*+NSD)SM9#U'./PKW?0]?\
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MX6V<HTT84YC+#D!N^,&D_:P^!WA[X6>#;3XB^ [3_A%_$.A7<+'["[*+F,N
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M<WLX4A%" G:@R<D]: /._P!I7P/9W'[2OP@CT^2;2I]6N93<W%NYWG!7D9.
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M!21']ZMW<2,1U"@H36LOA;Q+\&?CGXF\5:7H-QXB\(^+(XY+VWTP!KFSND&
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MHVBEI: &[!1M%.HH ;L]Z3RQ3Z2@!-@HV =*=10 WRQ0(P*=10 W90% IU%
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M_P"/AO\ <_K6G69I_P#Q\-_N?UK3H **** "HYO]4_T/\JDJ.;_5/]#_ "H
MR**** "BBB@ HHHH *IP_P#(R67_ %S>KE4X?^1DLO\ KF] '3T444 %%%%
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MAI>P7I@$<UWW@?0[WP7KGB#6%\67'B+P2^GK<VRW5RL[6TB;C)M<<E2H!YH
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M%? 7AXW4*^+?$,L-C-J,V&BM@%'G3'H">N.V: /H+S!TY_*G YKY9^.VI?\
M"K_A]<>,?"/Q O+_ %[2)(YI+2YU!+B*^3<-Z-'C@GL5QBOH7P'XI3QMX+T7
M7XXVA34K2.Y\IARA902/P.: .<^-TOQ C\';OANEE)X@^U1AEOON^3GY\9XS
M7;Z6US_9MI]M*_;?*3S_ "_N^9M&['MG->"?MGZ]XK\$_"^7Q'X;\276D20W
M5O;26T*(5D1Y &.XC(('I6G\>[[Q+I?[/=_XFT/Q+=Z/J&G:,ET6AB1_/;8N
M2Q8$CJ>E 'N:O]32AP:^;/"OP]\??%KX4Z!J^H^/]2\.ZE-IL;VEOI94KN*Y
M#SN1EV8XSC '3FM']D_XJZ]XP^'GB!/&-RMUJOAG4)K&YOE4#S40$[B!WP#0
M!] ,V[@$@U\VWFK^*-%_;)\,^')O$^H:CX=O='NK[[#/L5$<< ?*HW 'IG]:
MT?AGX@UC]IO1]4\0OK%_X:\+1W\MEIEGI+B*><1G:999"#U/0#%<%H/@W6_!
M?[;GA>QU7Q+=>)K5]!O)+&:^4>?#%QF-V'WN>AH ^O\ S M'F CUKYC^.GB+
MQ=X2^/WPFTZT\4W@T3Q!J_E7.G;$5 JC.T,!D@^AKIOVP=:\2^#_ (/ZMXD\
M.>(+G1+BP5<Q01H1,&8#))&01VQ0![LL@:EW=N]>)ZM\8'^%W[-.F^-=2635
MKY=-@98W;#7%Q( %W'W)YJO'\)?$WC_PG::SK'CS7=,\1WEHMP(]'F6&UMW9
M=RHL>T[@,@9)YH [?XS?%S2O@MX)G\2:O%<7%NDB0I#;+EGD8X5?;GO70MJ5
M[JGA,7^FQQQW]S9">VBN#\HD:/<BMCMDC-?(?[66B^-K/]F[PM#X@UR.65+R
MUAOH9+4--/.9<+(9-V  ,';C\:]XTKP7XZT?P'J/VWXAR7D_V!7LY+;2HK<V
MQ2/./O-N!P!SB@#=^"4GC^3P2C_$A;./Q'Y[Y6RP$\O/R]">>M>A;^F.?PKY
MS_9+^)VJ:Q^SW?>+?&&I2ZE=6MQ=2W$\F,[$YVCVXXJU\&+K5OVB/",OC;7=
M4U'2['4)Y$TS2],N# MO;J<*S,!EG/7)X]J /H,,/I36D KYC\ _$CQ+\/\
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M:=9FG_\ 'PW^Y_6M.@ HHHH *CF_U3_0_P JDJ.;_5/]#_*@#(HHHH ****
M"BBB@ JG#_R,EE_US>KE4X?^1DLO^N;T =/1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;SR316\44LAS))'& S_4@<T]=/MT8E(8UXVG:@&1Z4 ?'WQ0\"_ #Q_X'O\
M7-%DT^W\2W4)ELUT24K=-=%<JBPK_%NXQ@5S?Q:^$_CFV^#/PA\6ZO82>(=:
M\)$/J^FR#SI6MV.<$8.XJ!@YK[:M_"^DV=V;JWTRRM[ICDS16Z*Y_P"! 9K2
M$8H ^>_#?QF^!7B#3;2^L;/1OM]PHV::FDK]LW_\\P@3.[/I7OFF^6UC T<)
MMXS&I6$KMV C.,=L>E0V_A_3;.Z>YM["U@N7.6FC@57/U(&:OJFT8H ^7O\
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M['^-'_"8P_\ /C>?]^Q_C0!T%%<__P )C#_SXWG_ '['^-'_  F,/_/C>?\
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M>?\ ?L?XT?\ "8P_\^-Y_P!^Q_C0!T%%<_\ \)C#_P ^-Y_W['^-'_"8P_\
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M>?\ ?L?XT =!17/_ /"8P_\ /C>?]^Q_C1_PF,/_ #XWG_?L?XT =!17/_\
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MF,/_ #XWG_?L?XT?\)C#_P ^-Y_W['^- '045S__  F,/_/C>?\ ?L?XT?\
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MC0!T%%<__P )C#_SXWG_ '['^-'_  F,/_/C>?\ ?L?XT =!17/_ /"8P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB*Q\.VZS7LA17;:B1H7=C[*N2: -.BN>U3QUHNDZ??7MU>J(+%@MT8T9S"2
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MT@52>H R>YH ?17.V?C[0K[1Y-5BU!%T^.Z-DTTP*?O@P4I@]\D"N@R5^]0
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MW<* %HI-PHW"@!:*3</6C=0 M%)N%&X4 +1110 4444 %%%% !1110!8T_\
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MW<RW&S D( )& ,# '%5]9\ KK7BO3M>;5[VWN; ,MO#$(_+ 8#>""I)SCUH
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M7<<^T#>XPQ7: 1QVJAI?PDM]+O-"NCK>IW-QHY86IF="%C88\LC;R,#KU]Z
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ME@O+759K>"YMXXMIB\Y059#GG!/?K46F:QXOUX>*8K;4["U?2;R2"&1[4L)
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M.LWQN=5@6VF^6/:JJ"%*C;P1D]?6JJ_"FS_L'0-+_M*^,>BW*W5I-E/,!7(
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M,%9 IY&<XQ[5TU9VCZ;)I=BL,M]/J4V26N;G&]S]%  'L!6C0 4444 %%%%
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M&3&P2.%W#CG%=8[+&VQF4<X&>]>/_%*QT+2=#M+K2Y856XUO3MZ02ADXE&&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"QI__ !\-_N?UK3K,T_\ X^&_W/ZUIT %
M%%% !4<W^J?Z'^525'-_JG^A_E0!D4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!8T__CX;_<_K6G69I_\
MQ\-_N?UK3H **** "HYN8V [BI*2@#*^R2_W?UI?L<OI6IM'I10!E_8Y?2C[
M'+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V
M.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E
M% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L
M<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8
MY?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J4
M4 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^Q
MR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]C
ME]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I1
M0!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['
M+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.
M7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E%
M &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<
MOI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y
M?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44
M 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR
M^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE
M]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10
M!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+
MZ5J44 9?V.7TH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7
MTH^QR^E:E% &7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E%
M&7]CE]*/L<OI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% &7]CE]*/L<O
MI6I10!E_8Y?2C['+Z5J44 9?V.7TH^QR^E:E% %&S@>.<EEP-N*OTF*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img8619836_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ," X,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH <GWU^M7JHI]]?K5ZID5$****D
MH*@N?NK]:GJ"Y^ZOUIK<3V*U%%%60%%%% !6+>^+-&TV\%K>W$EO*QPHD@<
M]L@XP1[UM5PWC70?^$BUVRLED\N46DKQMV+ K@'VK6C&,I6GL8XB<X0O3U9W
M ((!!!!&0166OB+3GU'[ #=?:AR8_LLG SC/3I[]*Y'P+XEFMK@^&M9W1W,+
M%(&D/I_!_A721_\ )0)SW_LU/_0S5RI<DFI$0Q'M(QE#O9F_163<ZXBZO_9%
ME$+B_$?F.K-M2-?]IN?R -5-,\4"[UJZT:\M/LVH0#(19-ZR#&>#@=O6L_9R
MM>QJZT$[7\OF=#17-6/BT7WB=]$.G302QJ6D,KKD8&0!C(/7UH_X2[_BJ8=!
M;39HII,EGE=< 8)!&W.>E/V4]K>?R)^L4[7OUM\SI:*YGQ)XP7PY-%'-ITSB
M4XCE+J$;IGH21C/<4ZS\6K=:C=1S:?<6MA#;F=;N=2OF*".0I'3FCV,^7FMH
M#Q%-2Y+ZG245S%OXIO=0TN?5=.TD2V,1.TRS[)) .I50"/S-7--\36^KZ&VI
MV%O--L.'@!4.I'7J0*3I36Z'&O3EHGYFW17'Z;XWN=:M;J72]"GN'@8 *954
M$8ZDGO[#-7_"WBJ+Q+%<#[,]K<V[8DB8YQ]#^%.5&<4VUL*&(IS:47OL=#11
M161L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 53N]4M+$XN7= >C>6Q!_'%7*Q_$$ NH+6!C@23A<^G!H,ZLI1@W'<
MT[:YBNX%G@??&W0XQ2SSQVT#S3-MC098^E<WX9N7M+NXTJ?A@Q*9]1U']:L^
M(':[S8QL0L<9FF([ =!1<R6(O1Y^O;S-2SU.UOSBV=W ZMY; ?F1BF6FK6U[
M>36L6_?%U)'!^E9WA0E=&D8*6/F$[1U-6=.U*&[U*Y@CL_)D09D8XW$^^* A
M5<HP;>YK451NM26*X^RV\1N+K&?+4X 'N>U1VFHW,\L\4U@T4L*AM@<'=GT/
M H-O:QORFE16%'XE65ITBLIGDC^[&O))[YQT%6'UM(X+3,#&YN0"D(/3ZFBY
M"Q%-ZIFK167+J[6=Y%;WT C$OW)(WW+GWX%37VI1V<L, 0R3S'"(#C\2?2@K
MVL+-WV+U4+W6+6QE6*42[V.% 0X/T/2JMQKCV5Z+6ZLG+L,IY#;]WYXJCXF?
MS)-,<JR[GSM;J.1UHN95:]H-P>J-O4=2@TRW6:<.0QP HR:M1NLL:R+]UAD5
MFZQJ$5C;J;BS,\9Q@G!7/X_X5;:[6*Q2X9&^8#")R<GH!0:*?OM-[%FBL637
MI;6\C@OK!H%D.%<.&K:H*A4C.]N@4444%A1110 4444 %%%% !1110 4444
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M%%%<IW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVTMH6B@A\M6^\58@G\>M!I2ISIW6C6YA^&/^0CJ1[[OZFDU4&'Q98S2'$;8
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ML+VZ^TS1.)]H4R13/&Q [$J1FI[6PM;*%XK>((K\N0268^I;J3[F@#$TX_\
M%?ZVO?[+ ?PYJOJR%_B1HBAF0M97 #+U'N,UJV_AG2K6]^VPPS+<G&9#=2DM
MCH#EN1[&G7'AO2[K41J$T,K7:_=D%Q("OL,-@#V% "P:3;6%P^I7$]Q=7*QE
M?/G(9D3N%   _ 5SNO>$=*CT.?4[1YUOXD,MO=^>Q;<3D <XQST KM2 P((R
M",$5GVFA:=9,#! P .51Y7=5/J%8D#\!0!:LC.;"V-R,7!B7S1_M8&?UJ>BB
M@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]8N(99]0O8Q#()8HXF0*CCORI/YFG:MH,>LZ6-/N[Z\\DC$A1D#2_P"]\O\
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M0!<HK.LM11=)@N=0OK$NP^:6%\1,<X^7/Y5-%JEA->-:17L#W*_>B5QN'X4
M6Z*K7FHV6GJK7EW#;ANAD<#-312QSQ++#(LD;#*LIR"*!#Z*YBP-U#\0+ZUD
MO;FXM_L*2HLK A27YP  /ZUM3ZSIEK<BWN-0MHIB<;'D - R[14-U=VUE"9K
MJ>.&(<;Y&P*9;:A9WENT]M=0RPK]Z1'! ^IH LT53M-6TZ_E,5I?6\\BC)6-
MP2*N4""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BC(/0@T4 %%<O/J.N#Q@NC17EDL,ENUPLC6I+* <;?O\ /UJQ
M8ZKJ,7BB31-1^SS;K?[1%<0(4XSC#*2<?G0,Z"BD9T4@,ZJ3T!(&:4D $DX
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MUZI_*D_X131/WX6S:-9SF58YY$5S[@,!5[3M,M-)MOLUE&T<(/"&1F ^FXG
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MW)7S68?@"3C\*GM+"UL/.^RP+%YTAEDV_P 3GJ:+!<Y'5UM=8L]<>WTZ.Y6
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,GUHHHH
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M+-*"40GEL4Y*UD9TI<S<B6BBBH-@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 1F"*68@*!DD]JKVZF:3[5(",C$2G^%?7ZFD?_2Y_*'^HC/SG^\W]WZ#
MO5J@GXGY!11104%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .3[Z_6KU44
M^^OUJ]4R*B%%%%24%07/W5^M3U!<_=7ZTUN)[%:BBBK("BBB@ HHHH ****
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M7ZU/4%S]U?K36XGL5J***L@**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *5Y:R&5;NTP+
MI!@@\"5?[K?T/:IK6ZCO(?,CR"#M=&X9&[@U/5&ZMI8I_MMFN9@,2Q=!,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=_QK8[ #@#H!T%%%0VV=48J*L@HHHI#"HYH(;E=L\22CT=0:DHI@( %
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MFAWP+T0NWZ\\_C26.E6.FY^Q6XA#=0K''Y$T[ <EX1>TOM%-C+J5S!)'N62
M2JBE3Z CWK>@L=/L/#M]#IC;H-DA8A]WS8P>:L7/A[1[R?SKC3H))"<EB,9/
MX59ETVSFM!:/;I]G'2-<J/TQ22 Y[X??\B_*1_SW;^0KJZHV6C:=IKE[.U6
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M5!<_=7ZU/4%S]U?K36XGL5J***L@**** "BBB@ HHHH **** "BBB@ HHHH
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MHHHK<X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN88-1TV:!"K12*5!7IGV_&N4\/RRW:1Z-(K;89C)+Z;1_#_WU2C&,HMVV?X
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MM&CIU_\ :T,<H"W,8^=?[P_O#VJ[6'-;[V62-S'*O*NO45,FJSP_+=V^\?\
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MTB[D(IVFR?NGA/6,\?0THJ"(^3J*'M("IIHS9IT4450@HHHH **** "BBB@
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M?$34%6\MV#V42J1*N"VX\#GD\TP.MKG?$6JR6FIZ5IPNOL4%Z["2ZX&W:,A
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MRK:1_13CZUDY\JTYZXI.36PTKE[2HDBLL1J%0N2 *NU%;1^5:Q(>H7GZU+3
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M\QN(E^X#_.K%C;Y/VF08)^X#V'K20V_GN'8?NEZ#^\?\*OTD@"BBBF(****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?49KLJ8T,+R"1H8VD'1R@)'XT >;ND.F:+X3M]2>&.Y2_5F25EWI$=VW=GD
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MX<MM.O+KQ/;1PQ261N5.Q0=OW/\ $4#-:[UFZL/"DVJ7,=L;J-3\D$F^/=G
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MN+@3B2ZMY @CS;3M$"HZ# ^M6K2S@L8!#;1A$R2>Y8GJ2>Y]Z8'/Z4D'B/\
MM.74T\TV]Y)!'&6($*KC!'H3US69HFCP:UX%O+(,6;[3<>1+O)*MN.#D=?\
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MK4>GZHUU=SV<\:I<0DYVGY6'M5<ZO8S]E.S?8TZ***HR"BBB@ HHHH ****
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M&!/Y4YY$B7=(ZHOJQP*YOQ!8P60MKJTC$,GF;?DXS4VJM>0ZA:7HMFGA6/E
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M&S"V3-(Z-=G+%EQ@'9V]:FNK#4U\60ZO;6]O+"+/[.Z/.48-NSD?*<BN@HH
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M1114E!4%S]U?K4]07/W5^M-;B>Q6HHHJR HHHH **** "BBB@ HHHH ****
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M7/W5^M-;B>Q6HHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 445EZIK]EI$UO#<B<O<2+&FR(E<L<#+=!^>:!FI2,H=&1AE6&"/:F&>$7
MMS-'YY7<(]PW8]<=<5)0(YZU\/W]EI[:7!JJC3_F5/W/[Y$/\(;./QQ6W:6L
M-C:0VMNFR&) B+Z 5-37=(T9Y&5$499F. ![T#'44V.1)HUDB=7C895E.01Z
M@TZ@04444 %%%% !1110 4444 .3[Z_6KU44^^OUJ]4R*B%%%%24%07/W5^M
M3U!<_=7ZTUN)[%:BBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
E44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img8619836_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img8619836_9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &\!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **BD=_,54VX()Y^HI,S?],_UH FHJ'=
M+_L?K1NF_P!C]: )J*AS-_L?K1NF_P"F?ZT 345#NF_Z9_K1NE_V/UH FHJ'
M=+ZQ_K1NE_Z9_K2N!-14.Z7/\'ZT;IO^F?ZTP)J*BS-_TS_6C,W_ $S_ %H
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M?ZT9F_Z9_K0!+1469O\ IG^M,DDF12?W?4>OK0!8HJ'=-_TS_6C=+G_EG^M
M$U%0;Y>^P?G2[I?5/R- $U%0[I?^F?ZT;IO^F?ZT 345%F;_ *9_K1F;_IG^
MM $M%19F_P"F?ZT9F_Z9_K0!+1469O\ IG^M&9O^F?ZT 2T5%F;_ *9_K1F;
M_IG^M $M%5UDF?=CR^#CO3LS?],_UH FHJ#=+_L?K1YDW7Y/UH GHJ#=+ZI^
MM+NF_P!C]: )J*AW3?['ZT;I>GR?K0!-1469O^F?ZT9F_P"F?ZT 2T5%F;_I
MG^M&9O\ IG^M $M%19F_Z9_K1F;_ *9_K0!+14#/,K*/W?)]_0T[,W_3/]:
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M;IO]C]: )J*BS-_TS_6C,W_3/]: ):*BS-_TS_6B-G\PJVW  /'U- $M%%%
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M2K8W]O=F(X<6\RN5/O@\5Y;X=GT[0_A2=;TVPL[_ %6WM?)FV@.<%EW+)CG
M7!P>@&.!2Z5J%H/BGITKZC'=)>:3M\WY425B_"@#KT/!R1TS3E@XWG9Z1O\
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M&6R6#?#=&)C('3Y ZL#N]@<\5WX.,9>TYU>RT_ \3,YU(>R5.35Y:^EG_P
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M >HS1M%%V/E3*T:LG"1 #TR*?OD _P!7_P"/5,%Q1M%&O4:22LAGF2_\\O\
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MBY5>]BJ(SNW>2,^NX5)OD_YY_P#CU2[:-HYHU[@DELK#/,E_YY?^/"CS)?\
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MG!&GIOA?6(H?%]S9O;Z!JVH3B#3KB: 7*VUM#&L<),8D4$9\V15W#'F<\Y%
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MFMQ<1C!Y#Q[E+*1P<,I]"*Y1/AQJ.M7G]H>*M;M]3U&&SN+*T.EZ=]C@MUF
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M*)KB:-C="4.0ZJA;:F$R-Q#$'E5(KKM] #Z*9N.>E/H **** "BBB@ HHHH
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MJ*3_ %D?U/\ (U+0 4444 >5:Q\4/%<?Q6N_!.D>%M%O7CTQ-8BO;W7IK</
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M)FMSX':Y_:.N>/%?3-;T_P"V:Y+?V[ZIHUW9)+ 88(PRM-$HSN1OD^]QG&*
M.I\;>,/$WA]KN;1O"UOK-A86XN+J6YU,V<CCDE8%,3J[!5S\[1KD@9ZXRI_B
MY?ZXULG@SP\FOR-I,&M3"^O38JEO.&,*(1%)OF<1OA3M4;>7'%5/BMXR2:_/
MA*:S\06^F74).I:EIFA7]V&A88,$,D$+J'8<,^?D7./F/RY>GZHG@OQ[J>MV
MOAW69O#NNZ-8PZ<MCHUQOAGMVF0V\D/EA[<%9(L&150;6RPQ0!N2_%C6M7\+
MVOB7PMX6CUC1'TZ/497OM1^Q3E64L8X5\ITDD51SN=%R0-W7%WQ!\1]8C\'6
M_BCPUX=@UK2&TU=5D-[J/V.5H60R;8E$4FZ0*.0YC7)4;NNWSY;J7PEX%\/_
M  XU.PUZTB&F(-;U'2-#O[U/G!,EM;R00NNYB7!?/R+T^9@5Z/QW<^&/%'AF
MST.XT+QC'8RVH_L^WT:PU*R5QM*+&_E!!%MP!LN0BC .,<T >GZ%K$?B#0]/
MU2".2&"]MX[E(YP%=5=0P# $@$9P>35M?^/AO]T?S-<Y\-[#7=-\!Z#:^)[P
M7_B&*SC2^N%(.^4+SDC@D="W<@GO71K_ ,?#?[H_F: ):*** "BBB@ HHHH
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M<?N0?VAB_P#G]+_P)_YG6?\ "W/'/_0Y^(?_  :S_P#Q='_"W/'/_0Y^(?\
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MXI?]"L__ ('6O_QVC^V,O_Y_Q^]!_8.:?] \ON/)Z*]8_P"&5?BE_P!"L_\
MX'6O_P =H_X95^*7_0K/_P"!UK_\=H_MC+_^?\?O0?V#FG_0/+[CR>BO6/\
MAE7XI?\ 0K/_ .!UK_\ ':3_ (97^*6<?\(JW_@=:_\ QVC^V,O_ .?\?O0?
MV#FG_0/+[CRBBO6/^&5?BE_T*S_^!UK_ /':/^&5?BE_T*S_ /@=:_\ QVC^
MV,O_ .?\?O0?V#FG_0/+[CR>BO6/^&5?BE_T*S_^!UK_ /':/^&5?BE_T*S_
M /@=:_\ QVC^V,O_ .?\?O0?V#FG_0/+[CR>BO6/^&5?BE_T*S_^!UK_ /':
M/^&5?BE_T*S_ /@=:_\ QVC^V,O_ .?\?O0?V#FG_0/+[CR>BO6/^&5?BE_T
M*S_^!UK_ /':/^&5?BE_T*S_ /@=:_\ QVC^V,O_ .?\?O0?V#FG_0/+[CR>
MBO6/^&5?BE_T*S_^!UK_ /':/^&5?BE_T*S_ /@=:_\ QVC^V,O_ .?\?O0?
MV#FG_0/+[CR>BO6/^&5?BE_T*S_^!UK_ /':/^&5?BE_T*S_ /@=:_\ QVC^
MV,O_ .?\?O0?V#FG_0/+[CR>BO6/^&5?BE_T*S_^!UK_ /':3_AE?XI#D^%6
M_P# ZU_^.T?VQE__ #_C]Z#^P<T_Z!Y?<>445ZQ_PRK\4O\ H5G_ / ZU_\
MCM'_  RK\4O^A6?_ ,#K7_X[1_;&7_\ /^/WH/[!S3_H'E]QY0M!.*]9'[*O
MQ2SSX68>_P!OMO\ XY71^%_V1?''VR*34]*C09XC-S$4'NQ#$X^@KDQ&?9?0
MINI[12?9:F]'AW-*LN7V$E\CE_ >ES6^BVT01FGNG+K&H.26("@>Y &/RK]
M/ >@MX9\&Z/ID@_?6]NBR8Z;R,M^I->??"OX"6W@ZZCU75YTO]4CYB2-3Y4)
M]1GEF]\ >U>P[1V-?AV,Q$L57G6EO)W/Z!X;R>>6T>:IHVDA]%%%<1]J%%%%
M !1110 4444 0P]9/]\U-4,/63_?-34 %%%% !1110 4444 %%%% !1110 4
M444 12?ZR/ZG^1J6HI/]9']3_(U(WW30 S.>E/6N'^'?_"8FZUK_ (2O[.T'
MVC_03'L^YDY^[_#]W&[YNN:[C-,QI5/:Q4K6..UCXR> _#VISZ=JOC;PYIFH
M6[;)K6\U6"*6,XSAE9P0>G!]:Z+3]>TW5M)BU2RU"UO-,DC\U+RWF62%TY^<
M.#M*\'G..*\DULZE:?M)7-QH>GV>H:HW@Y$6#4+Q[6)U%\2<R)%*1@,>B'/3
MBJ47@^;X?>"E\%_V5=>++SQ%?7FI:MI^AM#;I#;RN6F6$32QJL6YXX\%PQ#L
MP'4!&Q[HLFY0PP5/0CD5SB?%#P?)K_\ 8:>*]#?6M_E_V:NHPFYW?W?*W;L^
MV*^?-6\:ZNO[,>HZ3JCWVE:GX;U.UT+7I)' NH;#[1$#*S1LP!:U=261B,EL
M,<5]$1^$_#FH>$[718=.L9/#ZQQ_9[2!%\@1KAHR@7@ 8&"/3(H S/\ A=GP
M\*W+#Q[X8*VO^O;^V+?$7S;?G^?Y>2!SW-)9_&SX>Z@MR]KX[\,W*6T9GG:+
M6+=O*C!"EVP_RKEE&3QD@=Q7D^K*$T7]IW:N/DDSV_Y@\1KO/AS)XFU#POI8
MU[0=&L]/BT-!:W%C?O>2LQC088/!%Y>5YVKOSZC'S '::/XZ\/>(M)GU72=>
MTO4]*@+++?6=Y'+"A4 D,ZDJ, @\FHO#/Q%\+>-)I8O#_B31]=EA&Z6/3+^*
MX:,>K!&.*^;OAR;6\M/V=]'UTI_PC=QHMQ/!;3_\>]QJ4:Q&!7!^5F5&E9 <
M_,,@9&:^H+C0=/N]4LM2GM8I+^RWBVN"/GB#C#*".Q& 1["@"?5-9L="T^>_
MU.\M].L;<;IKJ[E6**,>K,Q  Z=3WJIX;\8:'XRL6O/#^LZ?KEHK^6UQIUU'
M<1AA_#N0D9]JYSXH^![[QE;Z#<:=-:&]T34UU.*TU*,O:W3+'(@23&64CS-R
ML VUE4[37EWQ<\7>)]0\'>//#U]HNF^&/$B:-%=-J%C</J%O=V;2-&8Q)MMY
M$<-O&&4@ DC.30!]%Y_*D+$ \9KRW3?&'C>Q\>W'A/4(/#^HS1Z#)J5K>6OG
MV@NI1*J*LB,9?(4$E3AI2<;N/N5G>%?BKK_Q \.^$K.V@TO2_$.O:9<ZG-)=
M0O<VMO'#-'&4$2R(TA)E49WJ!@GGA: /6;'5K35(WDLKJ"\CCD:%W@D#A74X
M921T8'@@]*N5\Q>%]7\1?"OX*2:AX?3P_9V&F^*-1BU=3I\DL$%I_:$B/- D
M<L>U8Q\VTY&T<$8Y]N\,ZMK^K>*->DFNM+F\+P.MOI_D6KI</*%4REI/.9'1
M22O"J2P8$#9EP!==^+O@?POJDVFZSXS\/:3J,.WS;2^U2"&6/< 5W(S@C(((
MSZCUK5\-^,="\963WF@:UIVN6B2>4UQIMU'<1J^ 2I9"0#@CCKR*\X_:-TNT
MM?AS<3QP(LUUKVD32OC)=Q>VR!OP5%'X5=U3Q)K=]\0O$?AGP<=&TR]L+2VU
M2_NM7MY;D7,DP>-(U1)(_+PENN9,M]X87(- 'J=4Y]4M;6XM[>:YAAN;DL((
M9) KRD D[03DX SQVKQCP;\9_%WQ)U+0;72].T30K;5] DU5+N[>:]>*6.6.
M)U,2^4"N]F Q)\PPV1]TXEOK&I>*/B!\/=;O]#TM/&%I=:[H\ES"3%!=FWBD
M1<2[7D2%GW':=Y0LW#$<@'T6&/I3Z^?O!/Q(\3W&G_#W3='T#POX?M/$ U)6
M,"RM':30M,2$MU"!ERJN6W@N2PPF=U/NOCYX@TRPM]*O;:S/B23Q!>:(U]IV
MEWE[ $MX_-,ZV<+-,Q(*+L$G!)8O@8H ]^KF?$GQ*\)^#+N&U\0^*-%T*YF3
MS(X=2U"*V=UR1N578$C((^HJI\+?%>K^+O"[7FLZ>]C?17,UN&DL;BR6Y16P
MDRP3@21JZX.ULX.1ENM8GQ$8-\4?A6.PU&^Z_P#7A-0!V'AOQQX>\9PRR^']
M>TO78H2!))IMY'<*F>F2C'&?>MRO%_B5IL%E\=/AEJ6CQ)!KT\MY%J4D.U6E
MTM8&9S-W*++Y.TGHS>IINA_&/6]5^).F:##<Z7J>EZU9W4UI>66EWD<5J\:*
MRD7+MY5XA#?\LMAZ< &@#V?<?;VI]?/OPOU[Q'X5^$Z7>J^)="-QJ&I7J64D
MNE7+R^9]IN7D_=+<,]TY*DB-/+(4-EFVUZ%\%OB!J/Q#\*W=YJMM';WUEJ5S
MITCPVTUJD_E-@2"&;]Y%D$91\D$'DCF@#T"BN*U#XN:+IE_<6<MAXF>6"1HW
M:W\*ZI-&2IP2KI;E7'H5)![5U6GZ@FI6-O=PI*L4\:RJMQ"\,@##(#(X#*>>
M0P!'<4 6Z*** "HE_P"/AO\ ='\S4M1+_P ?#?[H_F: ):*** "BBB@ HHHH
M **** "BBB@ HHHH B;_ (^%_P!P_P Q4M1-_P ?"_[A_F*EH **** "BBB@
M HHHH **** "BBB@ HHHH 1ONFH[?_4Q_P"Z/Y5(WW34=O\ ZF/_ '1_*@"6
MBBB@!NT4!0.E.HH **** &[:7;2T4 %%%% !1110 4444 %(WW3]*6D;[I^E
M #(?]3'_ +H_E4E1P_ZF/_='\JDH **** "BBB@ HHHH ;M]Z6EHH *;L'IB
MG44 %%%% #=@],4ZBB@ HHHH **** "BBB@""?\ U:_[Z_\ H0I^T=<Y^IIM
MQ_JQ_OK_ .A"I2N:0#=HYSSGUI:7;1MH 3\:/QI=M&VBP"?C1^-+MHVT6 3\
M:/QI=M&VBP"?C1^-+MHVT6 3\:/QI=M&VBP"?C48_P!<W/\ "/YFI=M1J/W[
M?[H_F:+ /_&C\:7;1MHL GXT?C2[:-M%@$_&C\:7;1MHL GXT?C2[:-M%@$_
M&C\:7;1MHL GXT?C2[:-M%@$_&HY_P#5'ZC^=2[:BN!^[/U'\Z+ 2?C1^-+M
MHVT6 ;BEI<4;:/(!I4'KS[4M+1BF M%%% !1110 4444 %%%% $,/63_ 'S4
MU0P]9/\ ?-34 %%%% !1110 4444 %%%% !1110 4444 12?ZR/ZG^1J6HI/
M]9']3_(U+0!'M[\_B:=QS2X]Z,4P.1C^%/AV/QX_C)8M0_X2%X_):X.K79C,
M8R1'Y/F^5L!);;MV[N<9YJVGP^T:/QK)XL"WW]MR0BV:0ZE<F$Q '">09/*Q
MR3C9]XENIS7*6?B[Q<_QWO/"LUYHK>'8=*CU9?+TV9;LK)+)$L1D-P4R&0,7
M\OD9&T=:IV/C+QW=?%+QEX?CFT&[L-'L;>\M(5T^:*>5KCSA$CRFX90$,0W,
M$^8$X5>*0'6:1\*?#6B>)=:UZVMKR34M:3R]0:[U.ZN8KA>P,,DC1X ^5<*-
MJDJ, D54TOX)^$=%<"QM+^UL@6QI<>KW@T_!ZK]D\WR-G^QLV^U5?#'BOQ-9
M_$27PEXDETG4WETTZI;7^DVLMKL595C:.2)Y9>27!5P_.&&T8R;7C[4O&NG0
MZAJ&@2Z':Z?I]K]H:/5K:64WC*&9U$D<J^0H50-Y23EB=O&" 4O^&?/!7DZ]
M%]GU@QZ[QJ:GQ%J)^U<!?G_TCGY0%_W1M^[Q716?P[T;3_!@\*V_]H1Z,L?D
MJ@U2Z,ZIG[JSF3S0!T #\#CIQ7%6_P 2O$WCR:&#P?#I>ERQZ)9ZS<MK<$EP
M&>Y5VBM@(Y(RA C.Z0[L9&$-)'X_\9>+/ 5GXQ\.KH>DZ>=+34)+/6()9WFD
M"LTL7FQRIY(7;MWE')))*C&" =+8?!?P=I_@A?""Z2USX=C8-%97UW/=>20!
MM,3RNSQ[<#;L(VGD8-7O#OPWT7PO<)/:'4[J2/F(ZIJ]WJ'E'!7,8N)7V'!(
MRN."1W-<UX@\:^*+WX=VOB_P^^CZ7;'24U5K/6+>6=YBT7F>1O22,1'[JA\2
M9+?<&/F[S0=2N-4T/3[VZLVT^[N+>.6:S<[F@=D#-&3@<J3C.!TZ"@"MXF\'
MZ;XNM(K?45NAY,GFQS65[-9SQM@C*RPNCKD$@@-@UF#X4^%SX=U71)=-:ZL=
M53R[][NYFGN+D 84R3NYE8J/NL6RO8BNMHH XZX^$OAJ\U#1M0FM[Z34-)A:
MVMKMM4NO.:)F#-',_F[IT)4';*7'7U-4K'X%^#=-TO2["UL+V"'2YGGL)%U:
M\\^U+@!TCF\WS%C; S&&V'NIKOJ* . _X072_!6C:CI7ASP]<W-OK]S*;N%K
MLRVMNTP8R2O'-,-L9)Y2$9.?N]2.K\-^';'PGX?T_1M.B\BQL8$MX4ZG:J@#
M)[GCD]S6EM]Z6@#E_'GPTT#XE6-O9^((;RYM;>59TBMM1N;0>8I#*S>3(FXJ
MRAAG.",CGFJVM_"/PQXANK"[O;6\-]96PLH[V#4[J"Y>#.?*EE217F0GDK(6
M!))/)-=E10!XGX@^'\VK?&WPY*GA/5;7PKI.C2Z?#J>DZG'816\ADB=%5(;A
M)C&%C9"NS&=ORD<CM==^#/A7Q#>:7=7%MJ%I+I<1ALO[+U>\L%MU.=Q58)4
M8AB"V,D'&<5VI4&G4 >;:/\ L\^"-!O=(NK*VUB.329FGL5?Q%J,D=N[$ERJ
M-<%?FRVX8PP8@Y!-7[OX)^#[Z;4YI=/NO-U"_75)9(]2NHVCNPI7SX2L@\AR
MI*EHMA88!R *[JB@"AHNBV^@Z;#8VTEU)#",*UY=RW4IY)^:65F=CR>23Z=A
M6+XP^&NA>.KK3+K5EU#[3IK2-:36&JW5B\1==KD&"5"25XY[$CH3GJ:* .:\
M,_#GP_X3DNY;"SEDNKQ!'<7FH74U[<S(,X1IIW>0J-QPI; R>*QM'^!?@W0;
MK1;FPT^\@GT5F.GR?VK=L;=6 #1#,I_<G:/W1S'U^7DUWU% '"?\*1\("Q2T
MCLKVW@BOVU.W6WU6[B-K<-OW- 5E!A4^8^4C*J=QR.:V?"7P_P!"\"_VB-#M
M)+&/4+DW<\/VF62+S2<LR1NQ6/)Y(0*">37144 -V#I1L&<TZB@ HHHH *B7
M_CX;_='\S4M1+_Q\-_NC^9H EHHHH **** "BBB@ HHHH **** "BBB@")O^
M/A?]P_S%2U$W_'PO^Z?YBI* %HI** %HI** %HI** %HI** %HI** %HI**
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MR$]_^^C1Y">__?1J2B@"/R$]_P#OHT>0GO\ ]]&I** (_(3W_P"^C1Y">_\
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M]&CR$]_^^C4E% $?D)[_ /?1H\A/?_OHU)10!'Y">_\ WT:/(3W_ .^C4E%
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M_K&4$A?O$#.,4 >I^(M?'AW3&NS9W.H2EUBBL[,*99I&("JN]E7OU8@  DD
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M*** "HE_X^&_W1_,U+42_P#'PW^Z/YF@"6BBB@ HHHH **** "BBB@ HHHH
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M^/K1^%?>K@JC;6L_N1^6R\2,1?3#Q^]GZB_\+E\ ?]#MX?\ _!I!_P#%4?\
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M_P CIC@ZLE*$^=1NG&SU7NV?RN>;ZAJ6L?%#X8Q7D=LLVIZ=?!I(X5YEVKU
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M<SO/I-NYEE.<R,2GS,<GD\\FM+6?A_X8\10V,6K>'=)U2*PQ]D2\L8I5M\
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M_A@2;_H=U_\ !7_]NK[!HH_UCS3_ )_/[E_D'^IV2_\ /C\6?'W_  P)./\
MF=U_\%7_ -NJYI_[!EO;R*]UXM-UM_A_L_:I^O[T_P Z^M:-M1/B#,ZBY95G
M^!4>#\EB[JA^+/(O!?[./ASPK/!<7;/JTT.#&DBA(4(/&$'\B2/:O654*,#(
MQTIY7/>C;7@2DY-M]3Z;#82CA(\E"/*AU1+_ ,?#?[H_F:EJ)?\ CX;_ '1_
M,U)V$M%%% !1110 4444 %%%% !1110 4444 %0W'^J/U'\ZFJ&X_P!4?J/Y
MT 34444 %%%% !1110 4444 %%%% !1110 4444 0P]9/]\U-4,/63_?-34
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MM([>:\F9F,K*,$Y8YQV&>< 5TNVEV_A0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5$O_ !\-_NC^9J6HE_X^&_W1_,T
M2T444 %%%% !1110 4444 %%%% !1110!$W_ !\+_NG^8J2F20B1PVYE(&.*
M3R/^FDG_ 'U0!)14?D?]-)/^^J/(_P"FDG_?5 $E%1^1_P!-)/\ OJCR/^FD
MG_?5 $E%1^1_TTD_[ZH\C_II)_WU0!)14?D?]-)/^^J/(_Z:2?\ ?5 $E%1^
M1_TTD_[ZH\C_ *:2?]]4 245'Y'_ $TD_P"^J/(_Z:2?]]4 /;H:9;_ZB/\
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M5'D?]-)/^^J )**C\C_II)_WU1Y'_323_OJ@"2BH_(_Z:2?]]4>1_P!-)/\
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M?ID_R-25$UL&(/F2<?[5+Y'_ $TD_P"^J )**C\C_II)_P!]4>1_TTD_[ZH
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M 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !117D/@+]H!O&_QL\9?#
MT^%[[3O^$>02#59'W1S#*C#)M'EEMVY/F;<H)XQB@#UZF[ORIU>2_$!8M)^,
M'@C5[O6-3L=+-IJ N+>+4KB.S=H8UF222)7$;;4$^=RG.1G.T8 /5]QH+?\
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M0F\(4W?+NSQ0!VM,\P\<5R6O?$B#1?%5OX>32-4U'4KFSGO(%M8XPD@B,89
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M6: S7;&-I J;BJCY%9B7*J "210!NEL4>9^=>.^(?C9?:C8>'4\-^&]8DO\
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M;?V<&N1,84C*F8R;3'^[4[?+#<8WXK,TWX0ZAIW@WP7H/_"2JY\/W<5S).+
M 7"QQ/&J*AD.P[F$FYC)\ZYQC"CT&]NYK>2W6*QFN_.D,;21LBK"-K'>^Y@=
MN0!\H8Y8<8R1S?P_\9:IXV\'W.JRZ39V%^ES=VL5M'?O+;RF"9X@PF,*L%9D
M//EY P<'I0!B6_PKU73?#NM:99ZWILR:EJ4MX8M6T<W=NT;N[&.5/.5I7PR
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M=AW,)-S&3YUSC&%'9^,M:N?#GA;5M6M;:WNY[&V>Y\FZN6MXV5 6;=(J.5&
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M92VT(2R$*M,ZHGG ;F*D(L@P2Q/G/D\@#T#@CD<]?ZTCL55CMW$ X&1D]^]
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ML9\P8C !&P99N<]R<#KCKW-9$_B6T@\30:"BR2:C-:27@"K\B1HZI\[=LL^
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M:+X.\/SQWFI.=3M/M%\@8K&D!$[RR?P@L8 @)Y!EXZD5Z9M%&T4 ?/\ XO\
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MKX\M;WPS\,_$">$+#R-3CM)Y+2&QA7?YS!F:1$_C?)9\8)9O4FNTV]:3:.:
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M\V0&G(VB2$1 !58LOGDJ,%C7K^T'%&T4 .HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***3- "T4W=1NH =14;2?X5SGC#XC^'_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY=/N/N34?V]?@+I?^M^(MC)_P!>]M<3#\TC(KD[_P#X*:_ >S_U6O:E>_\
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MBDS10 M%%% !1124@%HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]*LQS KLD&Y/Y5+2[!=QV.TT#X_?$[PJP;2/B%XGT\CH(-7G4?EOQ7I/A_\
MX*"?M >'F4Q?$?4+M5_@OX8;D'ZET)_6OG^:U*?,IW(>A%1*O7-0Z<)=$6JL
MNC/MCP__ ,%7_C=I^TW \.:RR_>CO-.*$_0Q.E>BZ#_P68\20,JZY\-M+NL'
MYFL-0D@/_?+J_P#.OSD4E3D$C\:MJZ7GRR'RYN@DZ!O8^E8/#4?Y2EB*D7N?
MJ[X?_P""R7@"Z91K7@3Q%IN>]E-!=8_[Z:.O3] _X*D? /6M@N-<U316;_H(
M:7* /J8PXK\2Y(7A?8PVM_GFF#@FL98*B]C=8NH?T#^'?VSO@?XJ*+8?$[P\
MK-T6\NQ:L?PE"FO2]$\=>'/$NW^R=>TS5-W3[%>1S9_[Y8U_-<K;3D<&IK>X
MDAD5X)7@E'3RV(_(UD\O721HL8^J/Z90WO2YK^<WPW\=OB3X.9/[%\>^)-+"
M?=CM]4F5!_P'=C]*]3\-_P#!0[]H#PR5\GX@W5\@_@U&U@N<_B\9/ZUA++Y]
M&;1QD>J/WAR:6OQQ\-_\%=/C'I+*-5TKPSK:8Y+V<L#GZE) /TKU?PO_ ,%F
M'953Q!\,U9^\FFZJ0/\ OEXO_9JQE@ZL>AK]:I=S]-Z*^&_#G_!7;X0ZG\FJ
MZ-XFT.3.#YEI%,H]\I)G]*]5\,?\%#_V?_%"KY7Q!M;"1OX-2M9[;'_ G0+^
MM8NA5CO$U5:F]F?1]%<'X=^/'PY\7*IT;QWX=U(M]U+?4X6<_P# =V:[>.X2
M9 \<BNIZ,IR*Q<6MT:*47LR6BF;CZTN[\Z10ZBD^M% "T4W<:7- "T4E+2 *
M*3FBF M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-W4N: %HIN[W
MI: %HI-U&:0"T4F:-W% "T4TL N35&^U[3M,0O=WUO:H.K32!!^M7&+EI%7,
MJE6G25ZDDO5V-"BN#U;XW^#-'5C+K<$Q':W!E_\ 0 :XW5OVJO#MGN6TLKV\
M?L=JHOZG/Z5Z%++<76^"F_N/GL5Q-D^#_C8F*^=_R/:STIOUS^-?+^J?M;:O
M,&73M'M;8]FN':7^6VN)UC]H'QMJS-_Q,_LB'_EG;QJ@_/&[]:]>EPWCJFLK
M17FSX_%>).24-*3E-^2T^]GVK)/'"N7=4'N:YK5OB=X6T/(NM<L4<=8UE#O_
M -\KDU\-ZIXGUC7-W]H:E=WN[M<2LX_(FLQE9CDEB?7/->W1X47_ "^J_<CX
MW%^*LG=83#6_Q/\ R/KW6OVH_"6EY6V6\U"3L(HM@_'>01^5<+KG[7%^T?\
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M* 0W*_\ H:G]*_)A=DV ?D?U'2E*O"W/ ^G!^GK6+P=&6Z+^O5H]3]N/#?\
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ML#4?^>-K_P!\-_\ %4>WB:?5*G='> %>F:3"MVVFN$_X6!J/_/&U_P"^6_\
MBJ0^/M0/_+&U_P"^&_\ BJKZQ$KZK4[H[IHR.>HIFT5Q \?ZB.D-M_WRW_Q5
M(WCR_;_EA:CZ*W_Q5'UB)2PM3NCM2II.1R.#7%?\)U?_ //&V_[Y;_XJC_A.
MK_\ YXVW_?+?_%4?6(E_5JG=';%5?_8/Z4QHRO!X/;WKBO\ A.+[_GC;_P#?
M+?\ Q5.7QW?KD>3;$'J"K?\ Q5'UB)7U:HNJ.OVCTI-OX5QQ\;7S?\L;?_OE
MO_BJ3_A-+W_GC;_]\M_\51]8B7]6GW1V@;Y=KC(]>]-:'C*_,OK7&_\ ":7W
M_/*W_P"^6_\ BJ5?&]^AR(K?_OEO_BJ/K$0^KS[HZWRSZ4FW\JY)O&MZ3D0V
MX^BM_P#%4G_"97O_ #QM_P#OEO\ &CZQ$KZO/NCLE?*[7^9?Y4C0[1N!W+ZB
MN-_X3*]!SY5O_P!\M_C3E\:WR'(CM_\ OEO\:/K$0^KS[HZHK2?A7*-XRO&)
M/DVX^BM_C2?\)?>?\\H/^^6_QJOK$>P_J\^YV <-A7Y Z'N*:T!7W7L17(GQ
M=>'_ )90?]\M_C3U\:7R\>5;D'J"K<_K4_6(C^KS6S.GVT<URG_"77G_ #R@
M_P"^6_QH_P"$MO/^><'_ 'RW^-'UB)7U>?<[# FX;Y6[-5>2(HV#P>U<N/%U
MX/\ EG!_WRW^-./C*\9-IBMR/=6X_6CZQ$/833.DV^M.5VC/!R.]<K_PE5W_
M ,\X?^^3_C1_PE5W_P \X?\ OD_XT/$1+]A(ZYHA*N^/KW6J[+CM7-+XLO(V
M!6.$$?[)_P :63Q==RMN,5N&[D*W/ZT?6(B5&:>YT8&*GBF&W9(-T?IZ5R7_
M  E%W_SSA_[Y/^-'_"477_/.'_OD_P"-1[>)3H29UDUJ8P'0[XFZ,/Y57VX[
MU@0^,+V$G;' 5/!4J<']:B;Q1=,Q/E0#/8*?\:?UB(*C,Z9?EQ5Q94NP%G.V
M3H)?7ZUQG_"3W7_/.'_OD_XT?\)1=?\ /.'\C_C3=>#!X>3ZG53V[P/M=<'^
M=1USX\8WOD^68K=U[;E;C]:A_P"$GNO^></_ 'R?\:4<1$(T9G50S-#(&4X-
M66B2[4M&-L@^]'_45QG_  DUU_SSA_[Y/^-.7Q7>1L&5(00<@X/^-)UXH'AY
M;IG3,A4\BD45STWC"\N#EH;?/<A6Y]^M1?\ "47?_/.'_OD_XU2KQ!49M'3\
MCIQ4F1(,-U_O5RG_  E%W_SSA_[Y/^-'_"4W?_/.'_OD_P"-/ZQ$/82.L92O
MT]:-M<LOBV\7_EG 1Z%6_P :3_A++O\ YY0?]\M_C1]8B1["9U@]JE$@;AQG
MW[UQ_P#PEMY_SR@_[Y/^-'_"77G_ #R@_P"^6_QH^L1$\/+N=GY)"Y'(]:3&
M*Y!?&5ZO(C@'_ 6_QH/C.])SY-N/^ M_\51]8B9_5Y]SL,&K$<A48/S)_=-<
M/_PFE[_SRM_^^6_^*I1XUOA_RRM_^^6_^*H^L1)>&F^J.[6$2<Q')[H>H_QI
MZ/MX<$_SK@_^$XOQSY5O_P!\M_\ %5(WC_4&7#0VI/\ >V-G_P!"JEB(HR>%
MGW1Z#&H893YA4B[E8,IP:\Y7Q[J"-D16X/KM;_XJIF^(VI-UM[3/][8V?_0J
MKZQ#L82P=3HT>E*T<V X\MO[Z\@TYK=HP"1E>S Y%>9#XC:D/^6%K_WPW_Q5
M31_%#583\L%ICN"C8_\ 0J/K$%T,)8.IT:/1ESC&<_YZ5*J__6KS3_A9VI[L
MBULE^B/_ /%4?\+0U3_GWL_^^'_^*JOK,.QF\'4[K^OD>JPR.@QP5_NM5A%1
MV!B;RG'(&>/P->2#XI:J/^7>S_[X?_XJG#XJZL,?Z-9<?[#_ /Q=5]8AV,G@
M*JU37XGONB_$;QCX6*KI?BC6M+"]%M;^6(?D&Q7H>B?MC?&G0=OV;XAZM*J]
M!=NMS_Z,5J^15^,&LJNW[-8LO]UHW/\ [/3/^%M:QS_HUC_W[?\ ^+J?:T7\
M4?P'&ABX_#4_%GZ :'_P4C^-&E[1=7VDZN%ZF[TY$)_[]E*]#T7_ (*I^,8=
MO]J^"M&O1T)M9Y8"?S+U^7J_%W6%Z6UC_P!^W_\ BZ=_PM_6./\ 1;#_ +]O
M_P#%UG*.%E]@Z5/,8;5?Z^X_8/0?^"J.@W*J-5\#7UI)_%]DOTF'_CRI7=Z3
M_P %*OA1?;5O;?7M*D[^=9(ZCZ%')/Y5^(0^,6L@Y^RV'_?M_P#XNID^-NNH
M,?9M/9?[K1R$#_Q^N>6'PCZ,WCC,SA]N+_KT/WNT;]N/X+:T/W?C2&W/]VZM
M)XC_ ./)7;:/^T-\,]='^@^/?#LK<?(VI1(W/3Y68&OYVC\:M;/_ "YZ=CT\
MN3_XNGK\;]=7I:Z?_P!^Y/\ XNL7@\.]FU]QU1S/&KXHQ?S?^1_2CI_B;2=6
M4/9:I97BG^*WG5Q^A-:*NK?Q#\*_FBA^/7B.WD$D4-C&XZ,J2 _GOKH]+_;
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M /\ !=??_)E'_#ZOXW_]"M\/_P#P77W_ ,F4 ?M317XK?\/J_C?_ -"M\/\
M_P %U]_\F4?\/J_C?_T*WP__ /!=??\ R90!^U-%?BM_P^K^-_\ T*WP_P#_
M  77W_R91_P^K^-__0K?#_\ \%U]_P#)E '[4T5^*W_#ZOXW_P#0K?#_ /\
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MW_D?<H7G.>:D51_G@5\+_P##<OCO_H$^'?\ P&G_ /C]._X;H\>#_F$^'?\
MP&N/_C]/^TJ75/[E_F0^&<9_-'[W_D?=2G:,#(%.5J^%/^&Z?'O_ $"/#G_@
M-<?_ !^C_ANGQ[_T"?#G_@-<?_'Z?]I4>S_#_,G_ %7QF_/'[W_\B?=F*>K=
MJ^$?^&Z_'O\ T"?#G_@-<?\ Q^C_ (;L\>_] CPY_P" UQ_\?I_VG2[/\/\
M,A\,8S^>/WO_ .1/NZI-QKX/_P"&[O'W_0(\-_\ @-<?_'Z7_AO#Q]_T"/#?
M_@-<?_'ZI9I1[/\ #_,S?"^,_GC][_\ D3[QJ5?K7P5_PWCX_P#^@1X;_P#
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M#^&O_ 6X_P#C]-_X;P\?_P#0(\-_^ UQ_P#'Z/[6H=G^'^9JN%<;_/'[W_\
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>^'__  'G_P#CU']JT.S_  _S'_JUC/YH_>_\C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>lbph-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-02T14:53:22.8479+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PermanentItems" xlink:label="lbph_PermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfSecurities" xlink:label="lbph_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TaxDeferredAssetsNet" xlink:label="lbph_TaxDeferredAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedFinancingCosts" xlink:label="lbph_AccruedFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredFinancingCostsPolicyTextBlock" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NonVotingMember" xlink:label="lbph_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AreaOfOfficeSpace" xlink:label="lbph_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FixedAssetBasisDifference" xlink:label="lbph_FixedAssetBasisDifference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_VotingMember" xlink:label="lbph_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfUncertainTaxPositionsNotRecognized" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:label="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IssuanceOfSeriesAConvertiblePreferredStock" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageStockPrice" xlink:label="lbph_WeightedAverageStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DefinedContributionPlanArenaMatchingContributions" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EffectiveLeaseDate" xlink:label="lbph_EffectiveLeaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FinancingRelatedFees" xlink:label="lbph_FinancingRelatedFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfIncreaseInRent" xlink:label="lbph_PercentageOfIncreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PaymentsForRentHistorical" xlink:label="lbph_PaymentsForRentHistorical"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShortTermInvestmentsPolicyTextBlock" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageDiscountRateAbstract" xlink:label="lbph_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Benefit for Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short Term Investments And Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, vested fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party amounts related to accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Rent payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future rent payment per month for first year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares authorized for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and California net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, shares purchase price as a percentage of market fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Shares Purchase Price As Percentage Of Market Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, shares purchase price as a percentage of market fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from contributed capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Contributed Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remining Contractual Term, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share based payment award, options forfeitures in period, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due in one year or less, amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, eligible earnings contribution, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Eligible Earnings Contribution Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, eligible earnings contribution, percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TaxDeferredAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax deferred assets net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TaxDeferredAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Deferred Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TaxDeferredAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TaxDeferredAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arena Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and shareholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued financing costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases, Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renew of successive agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Renew Of Successive Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RenewOfSuccessiveAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Renew of successive agreement term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Other Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury and Government [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Financing Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Financing Costs Policy Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Loss Attributable to Stockholders Before Benefit for Income Taxes by Region</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at the beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at the end of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets carryforwards right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Carryforwards Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NonVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Voting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NonVotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Voting Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Series A convertible preferred stock financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Related Party Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets carryforwards lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Carryforwards Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated grant date fair value per share of award granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, maximum shares purchased, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Shares Purchased Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, maximum shares purchased, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during conversion of convertible securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of shares of common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, subject to early exercise provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Office Space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Income (Expense), Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards, Issued But Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards Issued But Unvested [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards, issued but unvested [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due after one year through two years, amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due after one year through two years, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investment securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FixedAssetBasisDifference_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed asset basis difference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FixedAssetBasisDifference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed asset basis difference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FixedAssetBasisDifference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed asset basis difference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock available for conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Pension and Other Postretirement Benefits Cost (Reversal of Cost), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses Related To Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock by Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Basis of Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, basis of valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Basis of Valuation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Split [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PostSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase of common stock by Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in initial public offering, net, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable includes related parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of convertible preferred stock to common stock in association with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvotingCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvoting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued consulting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate fair value of unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Description of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options Vested and Expected to Vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholder&#8217;s equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated By Reference Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 174 capitalized R&amp;D expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_VotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_VotingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Voting Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, vested stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued recruiting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Recruitment Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedRecruitmentFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of uncertain tax positions not recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Uncertain Tax Positions Not Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of uncertain tax positions not recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of uncertain tax positions not recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets and lease liabilities, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Right-Of-Use Assets and Lease Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, Grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remained to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity And Stockholders Equity Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity and stockholders equity disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProFormaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProFormaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pro Forma [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company's Financial Assets Recognized at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Discount on Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDiscountOnShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount and commissions paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, subject to repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Government and agency securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Depreciation Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, depreciation method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Depreciation Methods</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets carryforwards research and development state and local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Carryforwards Research and Development State and Local</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and California research and development carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued on conversion of convertible preferred stock in connection with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued On Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued on conversion of convertible preferred stock in connection with initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Voting Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award expiration term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed maturity securities, available for sale, due in one year or less, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employment Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Postemployment Benefits Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Stock Issued During Period, Shares, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares exchanged during period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financing related fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing related fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost not yet recognized, period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arena 2017 LTIP [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arena Two Thousand Seventeen Long Term Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Arena two thousand seventeen long term incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal and accounting fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Legal and Accounting Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of series A convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental balance sheet information related to leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fixed maturity securities, available for sale, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Stock Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions from tax positions taken in the current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (see Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Salaries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Split [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PreSplitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (in Years) [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions from tax positions taken in prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and Uncertainties Policy Text Block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Matching contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Arena Matching Contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined Contribution Plan Arena Matching Contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 Equity Incentive Plan member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccruedComputerRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued computer related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per share, Options outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per share, Options outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Services Expensed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting rights percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options exercised in period, weighted average remaining contractual term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements with Arena Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Temporary equity, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, Balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, Ending Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering (IPO)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted stock award, Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Series A convertible preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, liquidation preference, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Liquidation Preference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective lease date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Lease Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EffectiveLeaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective lease date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forward stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FinancingRelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financing, accounting fees and other fees such as printers, transfer agent, etc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FinancingRelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing related fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_FinancingRelatedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing related fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Options outstanding, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Options outstanding, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in rent by second year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Increase in Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PercentageOfIncreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining contractual term, options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Contractual Term, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual term for option awards granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Historical rent paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Rent Historical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_PaymentsForRentHistorical_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments For Rent Historical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-Term Investments [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-sale Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions from tax positions taken in prior year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_WeightedAverageDiscountRateAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts payable related to stock based compensation expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Related to Stock Based Compensation Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable related to stock based compensation expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Provides Safe Harbor Contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Costs, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Costs, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, conversion basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockConversionBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Conversion Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturity of the Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Common Stock Shares Issued and Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock Shares issued and sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payroll Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock On As Converted To Common Stock Basis [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Preferred Stock (on an as-converted to common stock basis) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock (On As-Converted To Common Stock Basis)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_SeriesAConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and Equipment Estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend rate, per-dollar-amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Dividend Rate, Per-Dollar-Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee stock purchase plan, maximum offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Maximum Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan, maximum offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit for income taxes at statutory federal rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock award, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per share, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShortTermInvestmentsAndCashEquivalents" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PermanentItems" xlink:to="lbph_PermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:to="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedResearchAndDevelopmentExpenses" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_NumberOfSecurities" xlink:to="lbph_NumberOfSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:to="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TaxDeferredAssetsNet" xlink:to="lbph_TaxDeferredAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ArenaPharmaceuticalsIncMember" xlink:to="lbph_ArenaPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedFinancingCosts" xlink:to="lbph_AccruedFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RenewOfSuccessiveAgreementTerm" xlink:to="lbph_RenewOfSuccessiveAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DeferredFinancingCostsPolicyTextBlock" xlink:to="lbph_DeferredFinancingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" xlink:to="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_NonVotingMember" xlink:to="lbph_NonVotingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" xlink:to="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:to="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AreaOfOfficeSpace" xlink:to="lbph_AreaOfOfficeSpace_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_FixedAssetBasisDifference" xlink:to="lbph_FixedAssetBasisDifference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PostSplitMember" xlink:to="lbph_PostSplitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvotingCommonStockMember" xlink:to="us-gaap_NonvotingCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_VotingMember" xlink:to="lbph_VotingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedRecruitmentFeesCurrent" xlink:to="lbph_AccruedRecruitmentFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PercentageOfUncertainTaxPositionsNotRecognized" xlink:to="lbph_PercentageOfUncertainTaxPositionsNotRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lbph_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:to="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProFormaMember" xlink:to="srt_ProFormaMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDiscountOnShares" xlink:to="us-gaap_CommonStockDiscountOnShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" xlink:to="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:to="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedLegalAndAccountingFeesCurrent" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_IssuanceOfSeriesAConvertiblePreferredStock" xlink:to="lbph_IssuanceOfSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WeightedAverageStockPrice" xlink:to="lbph_WeightedAverageStockPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PreSplitMember" xlink:to="lbph_PreSplitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lbph_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_DefinedContributionPlanArenaMatchingContributions" xlink:to="lbph_DefinedContributionPlanArenaMatchingContributions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WorkingCapital" xlink:to="lbph_WorkingCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccruedComputerRelatedExpenses" xlink:to="lbph_AccruedComputerRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestments" xlink:to="us-gaap_OtherLongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_OptionsToPurchaseCommonStockMember" xlink:to="lbph_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EffectiveLeaseDate" xlink:to="lbph_EffectiveLeaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_FinancingRelatedFees" xlink:to="lbph_FinancingRelatedFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PercentageOfIncreaseInRent" xlink:to="lbph_PercentageOfIncreaseInRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_PaymentsForRentHistorical" xlink:to="lbph_PaymentsForRentHistorical_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_ShortTermInvestmentsPolicyTextBlock" xlink:to="lbph_ShortTermInvestmentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_WeightedAverageDiscountRateAbstract" xlink:to="lbph_WeightedAverageDiscountRateAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" xlink:to="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionBasis" xlink:to="us-gaap_CommonStockConversionBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_SeriesAConvertiblePreferredStockMember" xlink:to="lbph_SeriesAConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:to="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>lbph-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-02T14:53:21.0080+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="lbph-20221231.xsd#StatementCondensedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="lbph-20221231.xsd#StatementCondensedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="lbph-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:href="lbph-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:href="lbph-20221231.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherLongTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IssuanceOfSeriesAConvertiblePreferredStock" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FinancingRelatedFees" xlink:label="lbph_FinancingRelatedFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_IssuanceOfSeriesAConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_FinancingRelatedFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_VotingMember" xlink:label="lbph_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NonVotingMember" xlink:label="lbph_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PostSplitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PreSplitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_VotingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_NonVotingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_WorkingCapital" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockConversionBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_RenewOfSuccessiveAgreementTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageStockPrice" xlink:label="lbph_WeightedAverageStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_WeightedAverageStockPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfUncertainTaxPositionsNotRecognized" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lbph_PercentageOfUncertainTaxPositionsNotRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>lbph-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-02T14:53:21.2445+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.longboardpharma.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:lbph="http://www.longboardpharma.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lbph-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2">
        <link:definition>100030 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" id="Role_DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>100080 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100090 - Disclosure -  Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments" id="DisclosureShorttermInvestments">
        <link:definition>100110 - Disclosure - Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses" id="Role_DisclosureAccruedOtherExpenses">
        <link:definition>100120 - Disclosure - Accrued Other Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100130 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" id="Role_DisclosureAgreementsWithArenaPharmaceuticalsInc">
        <link:definition>100140 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100150 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>100170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits" id="Role_DisclosureEmploymentBenefits">
        <link:definition>100180 - Disclosure - Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>100220 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" id="DisclosureShorttermInvestmentsTables">
        <link:definition>100230 - Disclosure - Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" id="Role_DisclosureAccruedOtherExpensesTables">
        <link:definition>100240 - Disclosure - Accrued Other Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables">
        <link:definition>100250 - Disclosure - Convertible Preferred Stock and Stockholder's Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" id="DisclosureAgreementsWithArenaPharmaceuticalsIncTables">
        <link:definition>100260 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100270 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100280 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>100290 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>100320 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" id="DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Fair Value Measurements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" id="DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails">
        <link:definition>100340 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" id="DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
        <link:definition>100350 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" id="DisclosureShorttermInvestmentsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Short-Term Investments (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" id="DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails">
        <link:definition>100370 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" id="DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails">
        <link:definition>100380 - Disclosure - Short-Term Investments - schedule of short term investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" id="Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails">
        <link:definition>100390 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" id="DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" id="Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" id="DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails">
        <link:definition>100420 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" id="DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" id="DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper">
        <link:definition>100460 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails">
        <link:definition>100480 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails" id="DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails">
        <link:definition>100510 - Disclosure - Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" id="DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails">
        <link:definition>100520 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" id="DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails">
        <link:definition>100530 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100540 - Disclosure - Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" id="Role_DisclosureEmploymentBenefitsAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Employment Benefits - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" name="RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" name="AccountsPayableRelatedToStockBasedCompensationExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_AccruedComputerRelatedExpenses" name="AccruedComputerRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedFinancingCosts" name="AccruedFinancingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedLegalAndAccountingFeesCurrent" name="AccruedLegalAndAccountingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedRecruitmentFeesCurrent" name="AccruedRecruitmentFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" name="CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" name="DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" name="DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" name="DeferredTaxAssetsCarryforwardsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" name="DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" name="DeferredTaxAssetsCarryforwardsRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_DefinedContributionPlanArenaMatchingContributions" name="DefinedContributionPlanArenaMatchingContributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_EffectiveLeaseDate" name="EffectiveLeaseDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" name="EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" name="EmployeeStockPurchasePlanMaximumOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" name="EmployeeStockPurchasePlanMaximumSharesPurchasedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" name="EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_FinancingRelatedFees" name="FinancingRelatedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_FixedAssetBasisDifference" name="FixedAssetBasisDifference" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" name="IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_IssuanceOfSeriesAConvertiblePreferredStock" name="IssuanceOfSeriesAConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_NumberOfCommonStockSharesIssuedAndSold" name="NumberOfCommonStockSharesIssuedAndSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_NumberOfSecurities" name="NumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PaymentsForRentHistorical" name="PaymentsForRentHistorical" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_PercentageOfIncreaseInRent" name="PercentageOfIncreaseInRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PercentageOfSharesOfCommonStockOutstanding" name="PercentageOfSharesOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PercentageOfUncertainTaxPositionsNotRecognized" name="PercentageOfUncertainTaxPositionsNotRecognized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_PermanentItems" name="PermanentItems" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_RenewOfSuccessiveAgreementTerm" name="RenewOfSuccessiveAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShortTermInvestmentsAndCashEquivalents" name="ShortTermInvestmentsAndCashEquivalents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_TaxDeferredAssetsNet" name="TaxDeferredAssetsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lbph_WeightedAverageStockPrice" name="WeightedAverageStockPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ArenaPharmaceuticalsIncMember" name="ArenaPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" name="ArenaTwoThousandSeventeenLongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_NonVotingMember" name="NonVotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_PostSplitMember" name="PostSplitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_PreSplitMember" name="PreSplitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_RestrictedStockAwardsIssuedButUnvestedMember" name="RestrictedStockAwardsIssuedButUnvestedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" name="SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_VotingMember" name="VotingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_DeferredFinancingCostsPolicyTextBlock" name="DeferredFinancingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_ShortTermInvestmentsPolicyTextBlock" name="ShortTermInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" name="TemporaryEquityAndStockholdersEquityDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>lbph-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-02T14:53:21.0092+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lbph-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="lbph-20221231.xsd#StatementCondensedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="lbph-20221231.xsd#StatementCondensedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:href="lbph-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="lbph-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses" xlink:href="lbph-20221231.xsd#Role_DisclosureAccruedOtherExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="lbph-20221231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:href="lbph-20221231.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="lbph-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="lbph-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits" xlink:href="lbph-20221231.xsd#Role_DisclosureEmploymentBenefits" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="lbph-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lbph-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="lbph-20221231.xsd#DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" xlink:href="lbph-20221231.xsd#Role_DisclosureAccruedOtherExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:href="lbph-20221231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:href="lbph-20221231.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="lbph-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:href="lbph-20221231.xsd#DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:href="lbph-20221231.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:href="lbph-20221231.xsd#DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="lbph-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherLongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProFormaMember" xlink:label="srt_ProFormaMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAConvertiblePreferredStockMember" xlink:label="lbph_SeriesAConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ProFormaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_SeriesAConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IssuanceOfSeriesAConvertiblePreferredStock" xlink:label="lbph_IssuanceOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FinancingRelatedFees" xlink:label="lbph_FinancingRelatedFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_IssuanceOfSeriesAConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_FinancingRelatedFees" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" xlink:label="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" xlink:label="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsDisclosureTextBlock" xlink:label="us-gaap_PostemploymentBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PostemploymentBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredFinancingCostsPolicyTextBlock" xlink:label="lbph_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShortTermInvestmentsPolicyTextBlock" xlink:label="lbph_ShortTermInvestmentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RisksAndUncertaintiesPolicyTextBlock" xlink:label="lbph_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_DeferredFinancingCostsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_ShortTermInvestmentsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lbph_RisksAndUncertaintiesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:label="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PostSplitMember" xlink:label="lbph_PostSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PreSplitMember" xlink:label="lbph_PreSplitMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_VotingMember" xlink:label="lbph_VotingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NonVotingMember" xlink:label="lbph_NonVotingMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WorkingCapital" xlink:label="lbph_WorkingCapital"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PostSplitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_PreSplitMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_VotingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lbph_NonVotingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromContributedCapital" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lbph_WorkingCapital" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentBasisOfValuation" xlink:label="us-gaap_PropertyPlantAndEquipmentBasisOfValuation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDepreciationMethods" xlink:label="us-gaap_PropertyPlantAndEquipmentDepreciationMethods"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredCostsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentBasisOfValuation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentDepreciationMethods" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_OptionsToPurchaseCommonStockMember" xlink:label="lbph_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RestrictedStockAwardsIssuedButUnvestedMember" xlink:label="lbph_RestrictedStockAwardsIssuedButUnvestedMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" xlink:label="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_RestrictedStockAwardsIssuedButUnvestedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="us-gaap_USTreasuryAndGovernmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShortTermInvestmentsAndCashEquivalents" xlink:label="lbph_ShortTermInvestmentsAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lbph_ShortTermInvestmentsAndCashEquivalents" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfSecurities" xlink:label="lbph_NumberOfSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lbph_NumberOfSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedFinancingCosts" xlink:label="lbph_AccruedFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedComputerRelatedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedRecruitmentFeesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lbph_AccruedFinancingCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvotingCommonStockMember" xlink:label="us-gaap_NonvotingCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_GrossProceedsFromIssuanceOfCommonStock" xlink:label="lbph_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockConversionBasis" xlink:label="us-gaap_CommonStockConversionBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_NonvotingCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember_1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lbph_GrossProceedsFromIssuanceOfCommonStock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockConversionBasis" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RenewOfSuccessiveAgreementTerm" xlink:label="lbph_RenewOfSuccessiveAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" xlink:label="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_RenewOfSuccessiveAgreementTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lbph_AccountsPayableRelatedToStockBasedCompensationExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableRelatedPartiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaPharmaceuticalsIncMember" xlink:label="lbph_ArenaPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lbph_ArenaPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfSharesOfCommonStockOutstanding" xlink:label="lbph_PercentageOfSharesOfCommonStockOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" xlink:label="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" xlink:label="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" xlink:label="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" xlink:label="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_PercentageOfSharesOfCommonStockOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" xlink:label="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lbph_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageStockPrice" xlink:label="lbph_WeightedAverageStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" xlink:label="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lbph_WeightedAverageStockPrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfIncreaseInRent" xlink:label="lbph_PercentageOfIncreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_EffectiveLeaseDate" xlink:label="lbph_EffectiveLeaseDate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AreaOfOfficeSpace" xlink:label="lbph_AreaOfOfficeSpace"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PaymentsForRentHistorical" xlink:label="lbph_PaymentsForRentHistorical"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_PercentageOfIncreaseInRent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PaymentsForRent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_EffectiveLeaseDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_AreaOfOfficeSpace" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_PaymentsForRentHistorical" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PaymentsForRent_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:label="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:label="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:label="lbph_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_WeightedAverageDiscountRateAbstract" xlink:label="lbph_WeightedAverageDiscountRateAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lbph_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_WeightedAverageRemainingLeaseTermAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lbph_WeightedAverageDiscountRateAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PermanentItems" xlink:label="lbph_PermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lbph_PermanentItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FixedAssetBasisDifference" xlink:label="lbph_FixedAssetBasisDifference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TaxDeferredAssetsNet" xlink:label="lbph_TaxDeferredAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lbph_FixedAssetBasisDifference" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lbph_TaxDeferredAssetsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PercentageOfUncertainTaxPositionsNotRecognized" xlink:label="lbph_PercentageOfUncertainTaxPositionsNotRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lbph_PercentageOfUncertainTaxPositionsNotRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DefinedContributionPlanArenaMatchingContributions" xlink:label="lbph_DefinedContributionPlanArenaMatchingContributions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="lbph_DefinedContributionPlanArenaMatchingContributions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PostemploymentBenefitsAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_NumberOfCommonStockSharesIssuedAndSold" xlink:label="lbph_NumberOfCommonStockSharesIssuedAndSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDiscountOnShares" xlink:label="us-gaap_CommonStockDiscountOnShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="lbph_NumberOfCommonStockSharesIssuedAndSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockDiscountOnShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>lbph-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-02T14:53:21.3566+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="lbph-20221231.xsd#StatementCondensedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="lbph-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:href="lbph-20221231.xsd#Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:href="lbph-20221231.xsd#DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:href="lbph-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" xlink:href="lbph-20221231.xsd#DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="lbph_AccruedResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherLongTermInvestments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedResearchAndDevelopmentExpenses" xlink:label="lbph_AccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments" xlink:label="us-gaap_OtherLongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbph_TaxDeferredAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbph_TaxDeferredAssetsNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbph_TaxDeferredAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="lbph_FixedAssetBasisDifference" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lbph_TaxDeferredAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_TaxDeferredAssetsNet" xlink:label="lbph_TaxDeferredAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset" xlink:label="lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal" xlink:label="lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_FixedAssetBasisDifference" xlink:label="lbph_FixedAssetBasisDifference"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DeferredTaxAssetsCarryforwardsLeaseLiability" xlink:label="lbph_DeferredTaxAssetsCarryforwardsLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedSalaries" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="9" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet" xlink:label="lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree" xlink:label="lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedRecruitmentFeesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedComputerRelatedExpenses" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedLegalAndAccountingFeesCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lbph_AccruedFinancingCosts" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedRecruitmentFeesCurrent" xlink:label="lbph_AccruedRecruitmentFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedComputerRelatedExpenses" xlink:label="lbph_AccruedComputerRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedLegalAndAccountingFeesCurrent" xlink:label="lbph_AccruedLegalAndAccountingFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_AccruedFinancingCosts" xlink:label="lbph_AccruedFinancingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="lbph_PermanentItems" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="lbph-20221231.xsd#lbph_PermanentItems" xlink:label="lbph_PermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307835968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Longboard Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001832168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-5009619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4275 Executive Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">592-9775 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LBPH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,965,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated By Reference Text Block</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the registrant's Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in May 2023, which will be filed with the Securities and Exchange Commission on or before May 2, 2023.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313144432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,775<span></span>
</td>
<td class="nump">$ 66,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">56,814<span></span>
</td>
<td class="nump">40,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">69,838<span></span>
</td>
<td class="nump">108,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Other long-term assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">70,616<span></span>
</td>
<td class="nump">108,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">2,438<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use liabilities, current portion</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,764<span></span>
</td>
<td class="nump">5,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use liabilities, net of current portion</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">148,303<span></span>
</td>
<td class="nump">145,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(86,142)<span></span>
</td>
<td class="num">(42,197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder&#8217;s equity (deficit)</a></td>
<td class="nump">61,470<span></span>
</td>
<td class="nump">103,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and shareholders&#8217; equity (deficit)</a></td>
<td class="nump">70,616<span></span>
</td>
<td class="nump">108,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313314272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Non-Voting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307510096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 34,638<span></span>
</td>
<td class="nump">$ 19,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">8,065<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,798<span></span>
</td>
<td class="nump">27,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(44,798)<span></span>
</td>
<td class="num">(27,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,945)<span></span>
</td>
<td class="num">$ (27,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (2.56)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, Diluted</a></td>
<td class="num">$ (2.56)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">17,150,907<span></span>
</td>
<td class="nump">14,410,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">17,150,907<span></span>
</td>
<td class="nump">14,410,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,945)<span></span>
</td>
<td class="num">$ (27,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">(528)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (44,473)<span></span>
</td>
<td class="num">$ (27,961)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313389312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-Voting Common Stock [Member]</div></th>
<th class="th"><div>Voting Common Stock [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Preferred Stock [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance, Value at Dec. 31, 2020</a></td>
<td class="num">$ (2,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,795<span></span>
</td>
<td class="nump">$ 11,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,840,540<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Series A convertible preferred stock financing costs</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">4,098,600<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock to common stock in association with initial public offering</a></td>
<td class="nump">55,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,795)<span></span>
</td>
<td class="nump">55,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in initial public offering, net, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,298,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in initial public offering, net, Value</a></td>
<td class="nump">76,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(27,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value at Dec. 31, 2021</a></td>
<td class="nump">103,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,683<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(42,197)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Series A convertible preferred stock financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_FinancingRelatedFees', window );">Financing related fees</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on short-term investments</a></td>
<td class="num">(528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,945)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,945)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance, Value at Dec. 31, 2022</a></td>
<td class="nump">$ 61,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,303<span></span>
</td>
<td class="num">$ (692)<span></span>
</td>
<td class="num">$ (86,142)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">13,585,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_FinancingRelatedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing, accounting fees and other fees such as printers, transfer agent, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_FinancingRelatedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313500896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (43,945)<span></span>
</td>
<td class="num">$ (27,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of premiums on investments, net</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">282<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">1,923<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued compensation and related expenses</a></td>
<td class="nump">959<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued other expenses</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet', window );">Operating right-of-use assets and lease liabilities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(38,063)<span></span>
</td>
<td class="num">(24,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(57,614)<span></span>
</td>
<td class="num">(40,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">40,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(17,064)<span></span>
</td>
<td class="num">(40,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Series A convertible preferred stock financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">84,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Initial public offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing related fees</a></td>
<td class="num">(444)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(444)<span></span>
</td>
<td class="nump">76,451<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(55,571)<span></span>
</td>
<td class="nump">11,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">66,346<span></span>
</td>
<td class="nump">55,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">10,775<span></span>
</td>
<td class="nump">66,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering', window );">Common stock issued on conversion of convertible preferred stock in connection with initial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 55,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued on conversion of convertible preferred stock in connection with initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311489648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 1. Organization and Basis of Presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of Business</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longboard Pharmaceuticals, Inc. (the Company), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020 and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. (Arena), until the closing of its Series A convertible preferred stock (Series A Preferred Stock) financing in October 2020. The Company is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#8217;s most advanced product candidate, LP352, is a serotonin receptor that is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial (the PACIFIC Study). The Company is also developing LP659, an S1P receptor modulator, which could have applicability in multiple neurological conditions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 16, 2021, the Company completed the initial public offering (IPO) of its voting common stock. In connection with the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,298,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock, which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,360</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Company raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the IPO after deducting underwriters&#8217; discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8220;common stock&#8221; refers to the Company's voting common stock.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the closing of the IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,630,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series A Preferred Stock were exchanged for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,970,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,098,600</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Forward Stock Split</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 5, 2021, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company&#8217;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial statements have been prepared in accordance with US generally accepted accounting principles (GAAP) and reflect all of the Company's activities. The financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2022, are not necessarily indicative of future results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its resources to research and development (R&amp;D) activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual property portfolio, and providing general and administrative (G&amp;A) support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Geopolitical and macroeconomic events, such as the COVID-19 pandemic and the conflict in Ukraine, continue to evolve and have resulted in a significant disruption of global financial markets. The Company&#8217;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from such events. If the disruption persists or deepens, the Company could experience an inability to access additional capital.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had available cash, cash equivalents and investments of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and working capital of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to fund future operations. Management believes that its capital resources as of December 31, 2022 along with the proceeds from the follow-on public offering completed in February 2023 will be sufficient to fund the Company&#8217;s operations for at least 12 months after the date these audited financial statements are issued.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311486080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. Government-sponsored enterprises. The carrying amounts reported in the audited balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying audited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and depreciated on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">straight-line basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> over the estimated useful life of the related assets (generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9966dab8-f3b5-4022-bcb9-d2650d18a5da;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). Property and equipment as of December 31, 2022 consists of computer equipment.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#8217;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, for the years ended December 31, 2022 and 2021.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company&#8217;s board of directors and stockholders approved the 2020 Equity Incentive Plan (2020 Plan). The Company's board of directors adopted the 2021 Equity Incentive Plan (2021 Plan) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. Under both the 2021 and 2020 Plans, awards are measured at fair value and recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.447%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.405%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.34%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.808%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,421,756</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,189</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,566,945</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance became effective for the Company on January 1, 2023. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential impacts to the Company&#8217;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#8217;s ability to raise capital and conduct business development activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia, have contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on the Company&#8217;s business or ability to access the capital markets in the future.</span></p></div><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313312192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 3. Fair Value Measurements</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8212; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8212; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#8212; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.597%;"/>
        <td style="width:2.911%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.030999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at <br/>Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs <br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs <br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,816</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of the Company&#8217;s cash equivalents and accounts payable approximate fair value due to their relatively short maturities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309204176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 4. Short-Term Investments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes short-term investments (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.927%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.855%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,090</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,506</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.526%;"/>
        <td style="width:3.369%;"/>
        <td style="width:12.567%;"/>
        <td style="width:3.379%;"/>
        <td style="width:12.567%;"/>
        <td style="width:3.379%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.915999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.379%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.915999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,980</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the Company&#8217;s available-for-sale investments&#8217; gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at December 31, 2022 and 2021:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.316%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.440999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.497%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.440999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.497%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.642%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,111</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,071</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,764</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#8217;s investments were caused by changes in interest rates caused by changing economic conditions, and not from a decline in credit of their underlying issuers. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309158672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Other Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Other Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 5. Accrued Other Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other expenses consisted of the following (in thousands):</span></p><p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.251%;"/>
        <td style="width:1.946%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.570999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.559%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.672%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309168864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock', window );">Convertible Preferred Stock and Stockholders' Equity (Deficit)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 6.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company entered into a Controlled Equity Offering</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp; Co., as sales agent (Cantor Fitzgerald), pursuant to which it may issue and sell its common stock from time to time through an &#8220;at the market offering&#8221; (ATM) program under the Sales Agreement. The Company has no obligation to sell any shares of common stock under the Sales Agreement and may at any time suspend sales under the Sales Agreement. Cantor Fitzgerald will be entitled to compensation in an amount of 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. A maximum of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of shares of common stock may be sold under th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Sales Agreement. The Company had not sold any shares of its common stock under the Sales Agreement as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2021, the Company amended and restated the Company&#8217;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Voting Common Stock and Non-Voting Common Stock</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,585,950</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock outstanding and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock outstanding. As of December 31, 2021, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,440,761</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of voting common stock outstanding, excluding </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,189</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares subject to repurchase, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,629,400</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of non-voting common stock outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity and stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311517824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Agreements with Arena Pharmaceuticals, Inc.</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 7. Agreements with Arena Pharmaceuticals, Inc.</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company entered into a license agreement (the License Agreement), a services agreement (the Services Agreement), and a royalty purchase agreement (the Royalty Purchase Agreement) in October 2020 with Arena, which was subsequently amended as described below. Arena was purchased by Pfizer in March 2022. The following section summarizes these related party agreements.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreement</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the License Agreement, the Company has obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 and certain 5-HT2A compounds for the treatment of any central nervous system (CNS) indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). In January 2022, the Company and Arena amended the Arena License Agreement to add additional 5-HT2A compounds, and in September 2022 the Company and Arena further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products. As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#8217;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Services Agreement</span></p><p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the License Agreement, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> terms. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has significantly reduced its activities under the Services Agreement, including as a result of its having</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hired </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the services expensed under the Services Agreement (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.555%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.49%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.953999999999997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of related party amounts related to the Services Agreement in accounts payable as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313495072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 8. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Incentive Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company&#8217;s board of directors and stockholder approved the 2020 Plan, which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#8217;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's board of directors adopted the 2021 Plan in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of December 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,694,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#8217;s board of directors prior to the applicable January 1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recipients of stock options are eligible to purchase shares of the Company&#8217;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, Equity Plans) is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and, in general, the options issued under the Equity Plans vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_c1171003-0a4e-4fc3-897f-9cf0a00e25b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period from the vesting commencement date. There are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,299,251</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for grant under the 2021 Plan as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Award Grants under the Equity Plans</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.322%;"/>
        <td style="width:0.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.947000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.071%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.235%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.689%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.192%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">873,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">548,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,421,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,244,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.61</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">270,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,055,847</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022 included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">736,434</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> vested stock options and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">319,413</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> stock options that are subject to an early exercise provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the years ended December 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.328%;"/>
        <td style="width:2.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.212%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.164%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#8217;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these third-party valuations of our equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to considering the results of these third-party valuations, the Company&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#8217;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#8217;s common stock including liquidation preferences of the Company&#8217;s preferred stock; the progress of the Company&#8217;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#8217;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#8217;s business conditions and projections; the Company&#8217;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#8217;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-free interest rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected dividend yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">life</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Awards</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">348,450</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock awards were granted to an employee under the 2020 Plan, which vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two years </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and had an estimated fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.12</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share at the time of grant. During 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,189</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">203,261</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> restricted stock awards vested, respectively; the total fair value of the vested awards was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. As of December 31, 2022, all restricted stock awards were vested. For the years ended December 31, 2022 and 2021, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of stock-based compensation related to the restricted stock awards was recorded in general and administrative expense, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.852%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.692%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.503%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.953%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,016</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,406</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, unrecognized stock-based compensation expense</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> millio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">n, which is expected to be recognized over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (ESPP) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. The ESPP initially authorizes the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353,339</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock under purchase rights granted to the Company's employees. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 through January 1, 2031, by the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">aggregate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">number of shares of common stock then reserved for issuance under the ESPP to equal </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,060,017</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares; provided that before the date of any such increase, the Company&#8217;s board of directors may determine that such increase will be for a lesser amount of shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal will be </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair market value of the Company&#8217;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of December 31, 2022, the ESPP had not yet been implemented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309152496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 9. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company entered into the lease agreement (original lease) for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,681</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> square feet. The original lease became effective </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and continues through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month for the first year and increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in July 2022. A security deposit of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> was paid in June 2021 and is included in other long-term assets on the balance sheet as of December 31, 2022. In August 2022, the Company and the landlord extended the lease agreement (lease extension) through December 31, 2024. Rent payments under the lease extension are approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> starting in July 2023 and increase by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% in July 2024.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per month.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense totaled approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">394,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">198,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for the years ended December 31, 2022 and 2021, respectively.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.55%;"/>
        <td style="width:59.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.707%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.1%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">370</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.51%;"/>
        <td style="width:58.656%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.957%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.676%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.202%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">339</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">382</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease commitments are as follows as of December 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:2.791%;"/>
        <td style="width:73.534%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.676%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2022 and 2021, the Company is not a party to any litigation.</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311517824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 10. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the net loss attributable to stockholders before benefit for income taxes by region for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,945</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The benefit for income taxes are as follows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit for income taxes at statutory federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company's net deferred taxes were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,512</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California research and development carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,528</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">840</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 capitalized R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">491</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,970</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed asset basis difference</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,251</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The deferred income tax assets have been fully offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. We will continue to assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that may exist.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had federal net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that will not expire and California net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million that will begin to expire in 2040. As of December 31, 2022, we also had federal and California research and development tax credit carryforwards, net of reserves, of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively. Federal credit carryforwards will begin to expire after 2040 unless previously utilized. The California research and development credit carries forward indefinitely.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation's ownership. We have not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% likelihood of being sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">359</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions from tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax settlements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">703</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits will have no impact on our effective tax rate. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our balance sheet as of December 31, 2022 and did not recognize any interest and/or penalties in our statements of operations and comprehensive loss for the year ended December 31, 2022.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized net operating losses and tax credits. To our knowledge, we are not currently under examination by any taxing authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634310002080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock', window );">Employment Benefits</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 11. Employment Benefits</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the years ended December 31, 2022 and 2021, the Company incurred approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">265,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, in expenses related to the safe harbor contribution.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 12. Subsequent Events</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in a follow-on public offering. We issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6410195&amp;loc=d3e80090-111668<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313312192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Note 12. Subsequent Events</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, we raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in a follow-on public offering. We issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock which included </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We raised $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and issuance costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307739440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. Government-sponsored enterprises. The carrying amounts reported in the audited balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ShortTermInvestmentsPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Short-Term Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying audited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and depreciated on a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">straight-line basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> over the estimated useful life of the related assets (generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_9966dab8-f3b5-4022-bcb9-d2650d18a5da;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">). Property and equipment as of December 31, 2022 consists of computer equipment.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">R&amp;D Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">R&amp;D Expenses</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#8217;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;D expenses amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, for the years ended December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2020, the Company&#8217;s board of directors and stockholders approved the 2020 Equity Incentive Plan (2020 Plan). The Company's board of directors adopted the 2021 Equity Incentive Plan (2021 Plan) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. Under both the 2021 and 2020 Plans, awards are measured at fair value and recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.447%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.405%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.34%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.808%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,421,756</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,189</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,566,945</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recent Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments - Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance became effective for the Company on January 1, 2023. The Company does not expect the adoption of this standard to have a material impact on its financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential impacts to the Company&#8217;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#8217; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#8217;s ability to raise capital and conduct business development activities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia, have contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on the Company&#8217;s business or ability to access the capital markets in the future.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShortTermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShortTermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309158672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:</span></p><p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:61.447%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.405%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.34%;"/>
          <td style="width:1.0%;"/>
          <td style="width:16.808%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,421,756</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock awards, issued but unvested</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145,189</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,566,945</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634314571552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Company's Financial Assets Recognized at Fair Value</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.597%;"/>
        <td style="width:2.911%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.109%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.792%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.030999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements at <br/>Reporting Date Using</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quoted Prices in Active Markets for Identical Assets <br/>(Level 1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Other Observable Inputs <br/>(Level 2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant Unobservable Inputs <br/>(Level 3)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,429</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,589</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,014</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Government and agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,816</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,820</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634312017488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Short-Term Investments</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes short-term investments (in thousands):</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.927%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.66%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.411%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.855%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,090</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,639</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,506</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,814</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,379</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Maturity of the Short-Term Investments</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the maturities of the Company's short-term investments at December 31, 2022:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:35.526%;"/>
        <td style="width:3.369%;"/>
        <td style="width:12.567%;"/>
        <td style="width:3.379%;"/>
        <td style="width:12.567%;"/>
        <td style="width:3.379%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.915999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.379%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.915999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one year or less</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,139</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due after one year through two years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,980</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Total short-term investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,814</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Summary of Available-for-sale Investments</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the Company&#8217;s available-for-sale investments&#8217; gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at December 31, 2022 and 2021:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:22.316%;"/>
        <td style="width:1.253%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.440999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.497%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.440999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.262%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.497%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:6.633%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.642%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,111</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,737</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,653</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">288</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,164</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">325</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,071</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,764</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">693</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More than 12 months</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Count</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,017</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government and agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,392</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634309208656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Other Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Other Expenses</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other expenses consisted of the following (in thousands):</span></p><p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.251%;"/>
        <td style="width:1.946%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.570999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.559%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.672%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued consulting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">254</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued legal and accounting fees</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued computer related expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued recruiting fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">352</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313495072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Schedule of Services Expensed</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the services expensed under the Services Agreement (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:52.002%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.555%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.49%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.953999999999997%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">930</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634312017488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A summary of the Company&#8217;s Equity Plans stock option activity is as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.322%;"/>
        <td style="width:0.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.947000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.071%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.131%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.235%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.689%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.192%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Exercise Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-Average Remaining Contractual Term (in Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">873,264</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">548,492</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.90</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,421,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,244,802</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.61</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited/cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">270,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,395,748</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.50</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,055,847</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the weighted-average assumptions used for the stock option grants for the years ended December 31, 2022 and 2021, along with the related grant date fair value:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:54.328%;"/>
        <td style="width:2.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.212%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.164%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.123%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.61</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.92</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.28</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.35</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected life (years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimated grant date fair value per share of award granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.04</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.852%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.692%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.503%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.953%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,016</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">561</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,641</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,406</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634314511984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The below table provides supplemental cash flow information related to leases as follows (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.55%;"/>
        <td style="width:59.162%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.48%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.707%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.1%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of lease liabilities:</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating cash flows from operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">370</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets obtained in exchange for lease obligations:</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:3.51%;"/>
        <td style="width:58.656%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.957%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.676%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.202%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">736</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">521</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">339</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">382</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average discount rate</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Commitments</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum lease commitments are as follows as of December 31, 2022 (in thousands):</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:2.791%;"/>
        <td style="width:73.534%;"/>
        <td style="width:1.0%;"/>
        <td style="width:21.676%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">740</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313273632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Net Loss Attributable to Stockholders Before Benefit for Income Taxes by Region</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the net loss attributable to stockholders before benefit for income taxes by region for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,945</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,797</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Benefit for Income Taxes</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The benefit for income taxes are as follows:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Benefit for income taxes at statutory federal rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,855</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent differences and other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">524</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">679</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,437</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of the Company's net deferred taxes were as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,512</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and California research and development carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,528</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">840</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">343</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 174 capitalized R&amp;D expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">491</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,408</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,970</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed asset basis difference</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,251</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,858</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,251</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the periods presented:</span></p><p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.508%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.475000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.103%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at the beginning of the year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in the current year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">359</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions from tax positions taken in prior year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions from tax positions taken in prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax settlements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#160;Gross unrecognized tax benefits at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">703</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634305691728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split, description</a></td>
<td class="text">On March 5, 2021, the Company filed an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#8217;s common stock on a 1.38-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company&#8217;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Forward stock split</a></td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering (IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 84,774,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Number of shares exchanged during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,970,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (86,142,000)<span></span>
</td>
<td class="num">$ (42,197,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investment securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_WorkingCapital', window );">Working capital | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_NumberOfCommonStockSharesIssuedAndSold', window );">Number of Common Stock Shares Issued and Sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,298,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public Offering Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering (IPO) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Discount and commissions paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease', window );">Number of shares exchanged during period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,630,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lbph_VotingMember', window );">Voting [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,098,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember', window );">Non Voting [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_NumberOfCommonStockSharesIssuedAndSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock Shares issued and sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_NumberOfCommonStockSharesIssuedAndSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the number of shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lbph_VotingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lbph_VotingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lbph_NonVotingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307525264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation', window );">Property and equipment, basis of valuation</a></td>
<td class="text">Property and equipment are stated at cost<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods', window );">Property and equipment, depreciation method</a></td>
<td class="text">straight-line basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 34,638<span></span>
</td>
<td class="nump">$ 19,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease Liability</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentBasisOfValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentBasisOfValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDepreciationMethods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the methodology for computing depreciation for classes of depreciable assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDepreciationMethods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307802768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">2,395,748<span></span>
</td>
<td class="nump">1,566,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">2,395,748<span></span>
</td>
<td class="nump">1,421,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember', window );">Restricted Stock Awards, Issued But Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lbph_RestrictedStockAwardsIssuedButUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307835312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">$ 66,589<span></span>
</td>
<td class="nump">$ 76,393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307415936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">$ 56,814<span></span>
</td>
<td class="nump">$ 40,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">66,589<span></span>
</td>
<td class="nump">76,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ShortTermInvestmentsAndCashEquivalents', window );">Short Term Investments And Cash Equivalents</a></td>
<td class="nump">18,639<span></span>
</td>
<td class="nump">12,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">8,784<span></span>
</td>
<td class="nump">36,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">19,429<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">19,737<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">23,543<span></span>
</td>
<td class="nump">45,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ShortTermInvestmentsAndCashEquivalents', window );">Short Term Investments And Cash Equivalents</a></td>
<td class="nump">14,759<span></span>
</td>
<td class="nump">9,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">8,784<span></span>
</td>
<td class="nump">36,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">43,046<span></span>
</td>
<td class="nump">30,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="nump">2,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">19,429<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">19,737<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Government and agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShortTermInvestmentsAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Investments And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShortTermInvestmentsAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307546064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 57,506<span></span>
</td>
<td class="nump">$ 40,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(693)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">56,814<span></span>
</td>
<td class="nump">40,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">20,090<span></span>
</td>
<td class="nump">14,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">19,737<span></span>
</td>
<td class="nump">14,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,963<span></span>
</td>
<td class="nump">12,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(325)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,639<span></span>
</td>
<td class="nump">12,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,453<span></span>
</td>
<td class="nump">13,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 18,438<span></span>
</td>
<td class="nump">$ 13,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311976624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of unrealized loss position</a></td>
<td class="nump">$ 42,835<span></span>
</td>
<td class="nump">$ 26,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307777936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Fixed maturity securities, available for sale, due in one year or less, amortized cost</a></td>
<td class="nump">$ 49,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fixed maturity securities, available for sale, due after one year through two years, amortized cost</a></td>
<td class="nump">8,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">57,506<span></span>
</td>
<td class="nump">$ 40,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Fixed maturity securities, available for sale, due in one year or less, fair value</a></td>
<td class="nump">48,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree', window );">Fixed maturity securities, available for sale, due after one year through two years, fair value</a></td>
<td class="nump">7,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fixed maturity securities, available for sale, fair value</a></td>
<td class="nump">$ 56,814<span></span>
</td>
<td class="nump">$ 40,379<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634305894128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-Term Investments - schedule of short term investment (Details)<br> Securities in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Securities</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Securities</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | Securities</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</a></td>
<td class="nump">$ 20,071<span></span>
</td>
<td class="nump">$ 26,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="num">$ (95)<span></span>
</td>
<td class="num">$ (164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | Securities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</a></td>
<td class="nump">$ 22,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="num">$ (598)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions | Securities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</a></td>
<td class="nump">$ 42,835<span></span>
</td>
<td class="nump">$ 26,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">$ (693)<span></span>
</td>
<td class="num">$ (164)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | Securities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</a></td>
<td class="nump">$ 7,626<span></span>
</td>
<td class="nump">$ 14,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="num">$ (43)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | Securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</a></td>
<td class="nump">$ 12,111<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="num">$ (310)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions | Securities</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</a></td>
<td class="nump">$ 19,737<span></span>
</td>
<td class="nump">$ 14,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">$ (353)<span></span>
</td>
<td class="num">$ (100)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | Securities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</a></td>
<td class="nump">$ 4,511<span></span>
</td>
<td class="nump">$ 12,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="num">$ (37)<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | Securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</a></td>
<td class="nump">$ 10,653<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="num">$ (288)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions | Securities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</a></td>
<td class="nump">$ 15,164<span></span>
</td>
<td class="nump">$ 12,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">$ (325)<span></span>
</td>
<td class="num">$ (64)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions | Securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</a></td>
<td class="nump">$ 7,934<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions | Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions | Securities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</a></td>
<td class="nump">$ 7,934<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634305859872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Other Expenses - Summary of Accrued Other Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued consulting fees</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_AccruedLegalAndAccountingFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued taxes</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_AccruedComputerRelatedExpenses', window );">Accrued computer related expenses</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_AccruedRecruitmentFeesCurrent', window );">Accrued recruiting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedComputerRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued computer related expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedComputerRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedLegalAndAccountingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedLegalAndAccountingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AccruedRecruitmentFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AccruedRecruitmentFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313395712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember', window );">Nonvoting Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,629,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,629,400<span></span>
</td>
<td class="nump">3,629,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,098,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock by Arena Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,298,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634313178560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details) - Arena Pharmaceuticals Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_RenewOfSuccessiveAgreementTerm', window );">Renew of successive agreement term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent', window );">Related party amounts related to accounts payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 188,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_RenewOfSuccessiveAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Renew of successive agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_RenewOfSuccessiveAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634306222016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 34,638<span></span>
</td>
<td class="nump">$ 19,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,160<span></span>
</td>
<td class="nump">8,065<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,798<span></span>
</td>
<td class="nump">27,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember', window );">Arena Pharmaceuticals Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lbph_ArenaPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307036080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable, vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber', window );">Options exercisable, subject to early exercise provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_PercentageOfSharesOfCommonStockOutstanding', window );">Percentage of shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,657<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,802<span></span>
</td>
<td class="nump">548,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage', window );">Employee stock purchase plan, eligible earnings contribution, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue', window );">Employee stock purchase plan, shares purchase price as a percentage of market fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue', window );">Employee stock purchase plan, maximum shares purchased, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod', window );">Employee stock purchase plan, maximum offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member] | General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,299,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,694,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock award, granted</a></td>
<td class="nump">348,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Restricted stock award, vested fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Shares remained to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,189<span></span>
</td>
<td class="nump">203,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock award, Grant date fair value</a></td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, eligible earnings contribution, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, maximum offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, maximum shares purchased, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan, shares purchase price as a percentage of market fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PercentageOfSharesOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of common stock outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PercentageOfSharesOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lbph_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307563136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options outstanding, beginning balance</a></td>
<td class="nump">1,421,756<span></span>
</td>
<td class="nump">873,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Options granted</a></td>
<td class="nump">1,244,802<span></span>
</td>
<td class="nump">548,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Options cancelled</a></td>
<td class="nump">270,810<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options outstanding, ending balance</a></td>
<td class="nump">2,395,748<span></span>
</td>
<td class="nump">1,421,756<span></span>
</td>
<td class="nump">873,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares, Options Vested and Expected to Vest</a></td>
<td class="nump">2,395,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Options exercisable</a></td>
<td class="nump">1,055,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options outstanding, beginning balance</a></td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options granted</a></td>
<td class="nump">4.61<span></span>
</td>
<td class="nump">10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options cancelled</a></td>
<td class="nump">5.65<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options outstanding, ending balance</a></td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">$ 6.31<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options vested</a></td>
<td class="nump">5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per share, Options exercisable</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (in Years) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">9 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options vested and expected to vest</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options exercisable</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Intrinsic value</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Intrinsic value</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634306312848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_WeightedAverageStockPrice', window );">Stock price</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.28%<span></span>
</td>
<td class="nump">74.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Estimated grant date fair value per share of award granted</a></td>
<td class="nump">$ 3.07<span></span>
</td>
<td class="nump">$ 7.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WeightedAverageStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average stock price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WeightedAverageStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634305693248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,657<span></span>
</td>
<td class="nump">$ 1,967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634314606560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_PercentageOfIncreaseInRent', window );">Percentage of increase in rent by second year</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent payments</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_EffectiveLeaseDate', window );">Effective lease date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_PaymentsForRentHistorical', window );">Historical rent paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Future rent payment per month for first year</a></td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Total rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_EffectiveLeaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective lease date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_EffectiveLeaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PaymentsForRentHistorical">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Rent Historical</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PaymentsForRentHistorical</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PercentageOfIncreaseInRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PercentageOfIncreaseInRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307771056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307361840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">$ 736<span></span>
</td>
<td class="nump">$ 521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use lease liabilities, current</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use lease liabilities, noncurrent</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634314552496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(44)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307567392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (43,945)<span></span>
</td>
<td class="num">$ (27,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Total</a></td>
<td class="num">$ (43,945)<span></span>
</td>
<td class="num">$ (27,797)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634314552624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit for income taxes at statutory federal rate</a></td>
<td class="num">$ (9,229)<span></span>
</td>
<td class="num">$ (5,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_PermanentItems', window );">Permanent items</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="num">(1,688)<span></span>
</td>
<td class="num">(679)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">10,393<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634307678272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and California net operating loss carryforwards</a></td>
<td class="nump">$ 8,512<span></span>
</td>
<td class="nump">$ 6,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal', window );">Federal and California research and development carryforwards</a></td>
<td class="nump">2,528<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_DeferredTaxAssetsCarryforwardsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Section 174 capitalized R&amp;D expenses</a></td>
<td class="nump">6,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">18,408<span></span>
</td>
<td class="nump">7,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_FixedAssetBasisDifference', window );">Fixed asset basis difference</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">18,251<span></span>
</td>
<td class="nump">7,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(18,251)<span></span>
</td>
<td class="num">(7,858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_TaxDeferredAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DeferredTaxAssetsCarryforwardsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets carryforwards lease liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DeferredTaxAssetsCarryforwardsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets carryforwards research and development state and local</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets carryforwards right of use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_FixedAssetBasisDifference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset basis difference</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_FixedAssetBasisDifference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_TaxDeferredAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax deferred assets net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_TaxDeferredAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634306218368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Beginning Balance</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions from tax positions taken in the current year</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions from tax positions taken in prior year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions from tax positions taken in prior years</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits, Ending Balance</a></td>
<td class="nump">$ 703<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634308486848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_PercentageOfUncertainTaxPositionsNotRecognized', window );">Percentage of uncertain tax positions not recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 703<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation allowance</a></td>
<td class="nump">10,393<span></span>
</td>
<td class="nump">$ 6,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards research</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carryforwards research</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_PercentageOfUncertainTaxPositionsNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of uncertain tax positions not recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_PercentageOfUncertainTaxPositionsNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634311647280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Company Provides Safe Harbor Contribution</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Expenses Related To Contribution Plan</a></td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140634305677968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 84,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,585,950<span></span>
</td>
<td class="nump">13,440,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lbph_NumberOfCommonStockSharesIssuedAndSold', window );">Number of Common Stock Shares Issued and Sold</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDiscountOnShares', window );">Common Stock, Discount on Shares</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lbph_NumberOfCommonStockSharesIssuedAndSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock Shares issued and sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lbph_NumberOfCommonStockSharesIssuedAndSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lbph_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>lbph-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lbph="http://www.longboardpharma.com/20221231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lbph-20221231.xsd" xlink:type="simple"/>
    <context id="C_a6fbcb62-1dd5-47e8-a5f0-a9811e2e702b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_396dcdce-0d58-40b6-bfc6-6c19ad7ef2d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_542f2c4a-2e6b-42f0-8322-3069af427f7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_db5b19d0-862e-49e9-b69a-8b019f65a709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41221969-e7b7-45c7-916d-09ca02aa8b4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_288ded8c-213e-400a-8676-efb385f835af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b4cba7f-1def-41a7-8c96-7470a5736a61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6490df2c-634d-4037-be30-74e94250a14c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b8a21ac0-4ab6-4676-b445-ba6f8022ca4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_1515ae5b-ea8a-4cfb-8646-520a57119b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8fb4ce3e-c646-46e9-a87a-ec14ffdb12ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d29e8ef9-ee88-456f-b2dd-f017a70b32f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_56ed215b-7913-48c7-bad3-4df734060549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_408b138b-5567-4c0d-8740-e0f77b39b6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9519f058-65b9-4a77-993f-c530aca0ec5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b846d527-268f-4a88-a431-c7de28a3105b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_31b36330-7551-4a6c-b015-e29fcadaa3ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c17c66e-3873-4eff-9ad7-cbee76e03837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_708a2984-e296-43ff-8866-08ed7b02f589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f6a227c-60ec-49a6-8cdd-04c84137d99d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba895260-3a97-4fca-9f2e-da37a4f7379e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_341fea9a-781e-4a09-8de8-80cfcb42280e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_974c0b74-b247-493a-a244-61954bd74ea0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_35559507-1949-4257-b3c7-aa78f7685bfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8c2552fb-8de3-4abb-af54-8eaa29d393c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_74af52ba-c383-42f9-b16d-f0ae6869106e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c36fe1a1-d21f-4b74-a586-0129d93b4a19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c8ccaab1-2bd3-458a-8b03-8557b629abff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d0e46809-eb85-4065-bb2f-e5ee4eca223d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1cb02383-4a83-4256-897d-6beb9cf7f359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="C_dff02006-cd88-4a9f-b084-06afef117c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b72f156f-3735-4e2b-85b3-f2d14f32ace8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f7408153-655c-4c91-a796-44b1c9e2b6bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_351fd3fe-1bac-41ec-aaee-86835367c6a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2387a101-f4f7-41ac-81ac-f6f8c20ae797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f3f38f3c-0e13-4518-80d3-a72bb118157d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e8180cb1-d339-43ce-8382-ffb65f743b36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lbph:ArenaPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_543a9b51-1efa-42be-8dd4-628dbc709107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_53dd140c-ac6e-4f56-8b33-5aa2379a8262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1f4f6d27-b781-451e-928f-7197f0c3b0a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a865a91f-b26b-471a-990b-888ae5f1a037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:RestrictedStockAwardsIssuedButUnvestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="C_d9891fa5-a5a6-46ca-ab8f-679aad15f810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0e02f99d-7c5e-4870-8e5b-0f199407f23f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_40404be9-80f7-4dc1-b501-800029d9ebce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8be4e204-080b-4434-8ee1-a698bdb48ced">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1f18a6a6-d98f-4e05-b791-6e86ed836955">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe3381e4-0776-4a65-882e-c5998ec43929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e2350c3-4151-47e7-8025-d36e129778e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7cb4cfe-7014-4ddf-b9bf-2f0c02907348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3eeb2093-348a-4291-bc28-b0dd5ac681be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d5c63294-9633-482f-83e8-25fa79adec30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bac860ed-4260-4d2b-aaa0-2cf0b6ff87f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_605c1392-d2f6-4361-a5a7-62e125b3d648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_701bf585-2e81-4356-a0ca-8b96a608fa6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c563b15e-dc26-4b32-8128-0eb744b0ea45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_27e2ac14-7028-40bd-adb2-ee9d7609e0b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e460be53-bb93-4714-a2f3-98129e137c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:VotingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f5f0dc44-7d37-4e54-8447-edb5ba753a90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7302ab2c-5265-4951-b1f5-570da21cd701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_316ea6c1-7da7-4c8b-98b3-6abc844f5486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cac615bb-7672-44e1-90ae-9ae47c52b057">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70566aaa-8ddd-488f-8329-70945439bec9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e064b44-0ba6-4451-b69e-017e6f114799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_092f0ada-7a1d-48a7-a337-44d3d7397cba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b6f25d12-90a1-4bda-b22f-fb58f13cbf4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9a38ddbe-fed7-4742-ab7b-2216e168c7ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f36635ab-29c5-4e22-a6be-fcbab49127d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_53b98a5d-b6cc-435d-a362-2f3c9ec191b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fa63f794-52c0-4d53-92d9-a98e8d59cf61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c8378fee-8af8-4c6c-9f01-c15be4f76329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_aa114e73-9d3e-4367-b67d-0376849d85a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_48d2c5e1-2f02-4441-bec9-1183eabb3c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2ffd1420-ee39-450c-bf5c-212f9be25ac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4f66a237-edb9-4f7a-a43e-d837a3fc0485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_097b4d4d-1926-4a4a-8cc2-59de0584c1ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cec91faf-30a3-4e32-832f-b145d4c6a42a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lbph:NonVotingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_be512020-51df-4a10-b5c1-f8941f57b2b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c34bb4d2-986f-4c99-8052-d48376f6db2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_77aa498b-d2ae-4aea-ba96-b80a84ca1ab4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_0b7a9061-a201-4231-855f-78dd8445bc9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4a748f73-8881-44ab-8a19-7b222ef02cd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">lbph:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1282f9df-89a7-4f4e-9c7a-cb95e8ead303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d4f20c8-e119-4763-a167-6957a1d2975c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_0f374945-0780-451f-9899-e3095382578c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8814bdd7-1687-482a-bc89-42533bc5d148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_45ad8322-a85c-453a-9600-e04bab154cf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_76c0819f-9885-4686-b0fe-6c11ff7e48b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_15377397-0660-4b11-971f-4f76f43bcec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_78f4b339-ebd9-40c0-a799-bb28950ec2e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_b2da7e87-edb0-45d0-b6f2-541ed90e5347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd718034-3502-4331-8733-465c9d758bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_115b4147-e78e-43dc-81da-9e776c6fefa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="C_1111d63f-8f4d-4079-a133-a11d3aa8b573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_355af628-daf1-4971-8c16-cbb53131df03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_46857555-d570-4cd4-ae8b-3c59794bbe00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_997cf810-2610-4985-8384-a99e8aea8da6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lbph:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1e8da0f5-7411-4acd-b359-d2226605885a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5baa7a2f-9417-41f3-897c-6e8e7fb9c734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6f3ce05b-630d-43cb-8922-6a4a7d3fe473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_379bd6b7-5319-4b15-8167-d1c5f35d5101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001832168</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Securities">
        <measure>lbph:Securities</measure>
    </unit>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_56ed215b-7913-48c7-bad3-4df734060549"
      id="F_9966dab8-f3b5-4022-bcb9-d2650d18a5da">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:AmendmentFlag
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_4dfc8584-5325-43eb-b80f-dcd0108315f4">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_2c59c8cc-00ea-404f-95e9-edc59dc884a5">0001832168</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      id="F_7074996f-aa33-408c-a854-e306fcd2dcfc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_3a5bd633-6fb2-4428-91ac-efb4e0c66392">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_6490df2c-634d-4037-be30-74e94250a14c"
      id="F_c1171003-0a4e-4fc3-897f-9cf0a00e25b7">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_65bc4d84-441c-43ae-adc4-890075daa0a2">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      id="F_75379c9c-6922-449b-9b8b-dd32eeaad626"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_e990f497-5e08-4c9a-9233-67ed6280fe2d">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6afaab35-7c35-4451-a2c4-f3e27d3cd6ea">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1013e482-47bb-4c7f-bea5-2790b4302567">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_7068c631-35dd-4ff9-a6a3-b4de2e74db78">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_4657c7e6-cf56-47ff-b150-1fc89e2b2c35">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_e641f589-f7e4-403c-95f4-be4f6d795390">001-40192</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1ab7fe3d-3df5-4265-ae21-8347140c70a4">Longboard Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1cca0e1d-4102-4958-a7b9-5db20d3f0290">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_351c3cfa-f374-49b1-adcf-d07143e07fdc">84-5009619</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_2f3c80a4-c4b6-4c44-8d5f-9de8c96022a8">4275 Executive Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_7e370db2-a75d-4d04-ba60-32515068821b">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_3edd3577-5ab3-49b6-a1fe-f95ff912ba43">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1a201417-67c4-430d-99ff-6a533f29e3b2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_5555366c-e091-453f-bbf8-8164062a9c29">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_2d795a85-8b2f-4434-a988-637221dd2381">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_4e5ff524-ce44-4ceb-91a9-da8681de1c26">592-9775 </dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_232357ba-2726-4952-9cf1-cc95594fbee2">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_9d71c57c-43da-4e8c-8ec9-5a17e9f69db0">LBPH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_e472eb73-4046-41ab-9b95-e03a04db05e0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_aa902150-edba-46e5-a4f5-a56bdfc466b0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_5bfa1f27-4241-4536-b9cf-1d3946709dac">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_17b986a8-5c40-4d40-8745-1efc6107201f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_073754b8-fe1e-4444-86c9-1e76a087feed">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_d7398aec-8a24-41eb-9944-caa869285dc1">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_0283d1b1-ee23-4928-9ba1-a2988a399d6c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_df8cf9e3-bba0-4f41-9c17-e4bda8cb4dc4">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_f805dd30-dc70-4c5e-8708-c6c0b10bf008">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_16551218-d242-4cdc-820d-6ba646c9c303">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_b8a21ac0-4ab6-4676-b445-ba6f8022ca4b"
      decimals="0"
      id="F_10e95754-e313-4b05-b6af-04671528fa60"
      unitRef="U_USD">52100000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_77aa498b-d2ae-4aea-ba96-b80a84ca1ab4"
      decimals="0"
      id="F_4f831739-33b5-4969-af92-f6dae53984ef"
      unitRef="U_shares">22965350</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_a2479afd-9781-490b-82a3-61d295677b3f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Certain information required by Part III of this Annual Report on Form 10-K is incorporated by reference from the registrant's Definitive Proxy Statement for the Annual Meeting of Stockholders to be held in May 2023, which will be filed with the Securities and Exchange Commission on or before May 2, 2023.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_a000d2e8-9790-4635-b0f7-58cb8cb3f1b3">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_b01ecaf7-cb8c-4824-b6f1-d90e8475c31b">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_c09360da-5f72-497f-97a9-d350e8215d2b">San Diego, CA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_4eb6990a-a9de-42e7-918d-c22c62f3c54e"
      unitRef="U_USD">10775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_0381df1a-2fe2-4ee4-b3ca-18a80d524332"
      unitRef="U_USD">66346000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_511949e6-240e-4f4f-8f6f-d20af4bc26a0"
      unitRef="U_USD">56814000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_6721d1f5-0f7b-4e75-b622-18ddc68200c3"
      unitRef="U_USD">40379000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_d3320168-37e9-41cf-a99a-30251ae88f8d"
      unitRef="U_USD">2249000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_0eb2b5f3-1f68-425b-bcf6-0d152501650d"
      unitRef="U_USD">1659000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_e56ca81a-82a9-47df-b03c-0e0635e18b29"
      unitRef="U_USD">69838000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_373f137d-874f-4706-9147-faf351bb7256"
      unitRef="U_USD">108384000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_c5a07711-5131-4c42-9869-71ae326907fc"
      unitRef="U_USD">736000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_c7cbb2c7-ec3f-473f-bbda-895e7355ef99"
      unitRef="U_USD">521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_c58a9f86-5b1f-4df2-aee4-8c77067ff9e7"
      unitRef="U_USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_ca6f004d-b0a1-4c6b-aac7-ba8931713fb6"
      unitRef="U_USD">14000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherLongTermInvestments
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_4f0e8293-b3ff-4166-8c0d-8e919f93a435"
      unitRef="U_USD">33000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_872b37f8-96f9-47cb-8f26-f460f89239f0"
      unitRef="U_USD">33000</us-gaap:OtherLongTermInvestments>
    <us-gaap:Assets
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_28cf4912-b736-459c-9bd3-a24fe117dbde"
      unitRef="U_USD">70616000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_5c4bb098-0821-40de-a480-fe7c37ba75e3"
      unitRef="U_USD">108952000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_ef6e1ee4-1451-427a-a93a-d92d7fa9357a"
      unitRef="U_USD">1310000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_b8288d3c-f020-4269-9cd6-4821151f1854"
      unitRef="U_USD">1028000</us-gaap:AccountsPayableCurrent>
    <lbph:AccruedResearchAndDevelopmentExpenses
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_6fcc5f68-c9c2-4681-9c7c-d0049f119d97"
      unitRef="U_USD">4168000</lbph:AccruedResearchAndDevelopmentExpenses>
    <lbph:AccruedResearchAndDevelopmentExpenses
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_eabc0f48-a331-4642-a59e-7ac2dbb34c5c"
      unitRef="U_USD">2245000</lbph:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_91fedb99-2a35-4f9e-ab4b-916535614af8"
      unitRef="U_USD">2438000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_273e56ab-4600-4a2e-8449-fee09979836a"
      unitRef="U_USD">1480000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f6a45b0d-b0d5-4c12-85ed-986516a018b7"
      unitRef="U_USD">490000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_902075c9-4cf3-4ebe-ac94-5e249391e771"
      unitRef="U_USD">352000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_2dc95b8f-35fc-4732-a455-8779df6eb9bf"
      unitRef="U_USD">358000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_686daa86-7e66-4634-9f2f-d18c4b70b86c"
      unitRef="U_USD">339000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_3a8ebd7f-52e9-432e-9211-39c199bfdb9a"
      unitRef="U_USD">8764000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_865c8685-7066-4b2b-8042-5ac4966ce588"
      unitRef="U_USD">5444000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_ea6127dd-54c0-499d-9876-8820d1158025"
      unitRef="U_USD">382000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_f9daf68e-0c99-4da8-a596-66b03299b7ef"
      unitRef="U_USD">185000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="4"
      id="F_2e470878-b600-43ea-8a8d-848b6ef45e84"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="4"
      id="F_858c57e5-3f58-4d30-8ac7-7f4d3aab78d8"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_19462267-f983-4d37-a802-c0ddc6480190"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_1917a8fc-8579-47cf-aee6-711d5e4e9a79"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_3e61144c-c440-4242-81eb-a8198d4dbce0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="0"
      id="F_61713ec7-ac80-48aa-a953-2dd899c533fc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_ed09cc05-6768-4979-a4f9-62accbcfcdb4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="0"
      id="F_6ecd3f3a-4726-40f4-a398-d6216567d823"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b829b30a-a717-4c7d-981c-ab68eaddc621"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_c2f3334f-9463-4836-9ff4-3eb8e1425f5e"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="4"
      id="F_125321bd-fb5e-4a12-86bd-2bfd6d151fe7"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="4"
      id="F_93161dd0-671f-4022-b754-eea94aaacdf8"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_cb828980-b329-4f5d-ba7c-a0c3efb9a080"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_3fbc326b-6e7a-4b0b-8ed8-e4a3c5a881d8"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_bcecf1e6-eba8-421d-a012-5108b40198e6"
      unitRef="U_shares">13585950</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_67529525-553e-441a-b21a-3278b4e9f0a6"
      unitRef="U_shares">13585950</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_ceab748d-b6f6-4182-a3d5-83716093d723"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_7ce0a8c5-8705-4109-9230-8705369ac0e4"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_134a1290-da14-4148-adef-5be7ad18fe7a"
      unitRef="U_shares">0</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="0"
      id="F_cafb0396-55cf-4e3a-bd9d-b65e273f6fdf"
      unitRef="U_shares">145189</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_6d431750-e17b-42a5-b65c-3d3ea5e914ad"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_e6357575-058f-4cf7-8992-d2341c75bec8"
      unitRef="U_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="4"
      id="F_517f7d4f-966f-4610-a243-2505d1a30451"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="4"
      id="F_0ef23eeb-c6dd-46b9-aa0f-3fd3ae62c37b"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="0"
      id="F_bab1f056-3fd6-49d7-8358-497abe46552b"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="0"
      id="F_14772714-54d0-474a-a192-073aae414172"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="0"
      id="F_762c7d33-edf1-4f7c-8779-2ea61adf5321"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="0"
      id="F_55d5adfd-7edd-41b8-960c-eaa9d115e577"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="0"
      id="F_8d84ab0c-efa6-4749-8693-1b18e38fd9f8"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="0"
      id="F_82a753aa-61fe-4d17-b065-686059c86275"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="-3"
      id="F_588e9718-d149-44cf-a6d8-1f582668adf9"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="-3"
      id="F_a8949e49-42d4-4b8c-a896-4c354418fce3"
      unitRef="U_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_be129502-675e-4efe-8a18-3fef808f5dac"
      unitRef="U_USD">148303000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_93781bfa-0c80-4b21-9951-be189401eb38"
      unitRef="U_USD">145683000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_bf362a1e-8e4d-41b7-bd2d-70f752fca483"
      unitRef="U_USD">-692000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_cc900ee0-adf2-4f02-bbd6-68063c916f40"
      unitRef="U_USD">-164000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_3822c3a1-75d3-4c6e-9034-9b1b1ec7d464"
      unitRef="U_USD">-86142000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_3d9284f5-4a2c-45a2-8b45-01a65daaa5bb"
      unitRef="U_USD">-42197000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_5d446cdd-8870-4685-9905-f59d8575750e"
      unitRef="U_USD">61470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_6041fd8f-3d5b-4ac4-8b49-a06463022dec"
      unitRef="U_USD">103323000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_20930ec4-d0ba-4c6e-b1b9-f9ad022fbbdc"
      unitRef="U_USD">70616000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_e78e2cfd-205f-42b4-aa91-d8d634b6598d"
      unitRef="U_USD">108952000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_7c7cd8fb-2a6f-4d47-8f79-7263585b9169"
      unitRef="U_USD">34638000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_273f5e7d-64fb-42a4-9c54-7cc2f1700c15"
      unitRef="U_USD">19774000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_ceadcc29-e127-4a6a-9b16-d52e27266e6a"
      unitRef="U_USD">10160000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_15508cd1-a9d4-4856-9018-848409a2ca99"
      unitRef="U_USD">8065000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_50602f1c-5a2c-4d26-b029-afa86b85bbab"
      unitRef="U_USD">44798000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_c3eb4593-f78b-4869-856e-e4772be2aa60"
      unitRef="U_USD">27839000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_eb7c0520-ad79-41df-b41c-b01f0b0c0974"
      unitRef="U_USD">-44798000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_cc487818-fc28-4a91-9b39-a6ca178815e7"
      unitRef="U_USD">-27839000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_d1554291-2aac-4efb-a07c-106e5666afc1"
      unitRef="U_USD">837000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_c98ab180-cf6a-4da6-888f-0f62f7e58aa8"
      unitRef="U_USD">64000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_50d877a1-ddc9-4ad7-b3d4-99238352ac05"
      unitRef="U_USD">16000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_717230fe-e935-442a-8db0-d38e2b41b219"
      unitRef="U_USD">-22000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_10b7c86f-b4df-48eb-808c-57d7184dad2e"
      unitRef="U_USD">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_0736233c-7830-4a8d-961e-4748cf420643"
      unitRef="U_USD">-27797000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_1a3a163e-b5b0-4682-afc2-cc52487dec8c"
      unitRef="U_USDollarShare">-2.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_8fa7640b-f36a-4db0-8dcd-e0d9554baedc"
      unitRef="U_USDollarShare">-2.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="2"
      id="F_9ba24b94-2253-4157-b2c6-b1928d37dc16"
      unitRef="U_USDollarShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="2"
      id="F_c469f77c-fe61-48db-9c92-742292bf67c3"
      unitRef="U_USDollarShare">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="INF"
      id="F_1b2409b4-5312-4ad2-9784-545cb5faea7e"
      unitRef="U_shares">17150907</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="INF"
      id="F_ad5c286c-12a7-47e3-8288-8bee4b1acc2a"
      unitRef="U_shares">17150907</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="INF"
      id="F_ca9618c1-2720-4d07-8186-a58b19cf5879"
      unitRef="U_shares">14410502</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="INF"
      id="F_42a89ac1-21b6-489d-925f-c61319a2e141"
      unitRef="U_shares">14410502</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_4f722861-4003-43fe-8906-95702296cd64"
      unitRef="U_USD">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_5cdaa3bc-2aca-400c-a37c-2fcfb54cc7da"
      unitRef="U_USD">-27797000</us-gaap:NetIncomeLoss>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_dde5d32e-be26-4992-9ea6-9d7013715843"
      unitRef="U_USD">-528000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_f1701bcb-2168-4182-803c-50c3365cf260"
      unitRef="U_USD">-164000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_1b5a5f44-ea52-438c-a058-6f8b007a417a"
      unitRef="U_USD">-44473000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_f4af3b4c-bee1-4194-a93c-bba048cc9f10"
      unitRef="U_USD">-27961000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_dd718034-3502-4331-8733-465c9d758bcd"
      decimals="INF"
      id="F_ef7e9d33-70ab-4fb7-b64f-6cd9d873dc52"
      unitRef="U_shares">5600000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_dd718034-3502-4331-8733-465c9d758bcd"
      decimals="-3"
      id="F_4f84b94e-eb01-41dc-9642-f324066b7ca6"
      unitRef="U_USD">55795000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_f7408153-655c-4c91-a796-44b1c9e2b6bc"
      decimals="INF"
      id="F_03238d99-edb9-4ce4-a646-364f8cf6fc5c"
      unitRef="U_shares">3840540</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_8814bdd7-1687-482a-bc89-42533bc5d148"
      decimals="-3"
      id="F_e3ae8bda-55fc-4280-8822-f355e3a7f6fa"
      unitRef="U_USD">11708000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4f66a237-edb9-4f7a-a43e-d837a3fc0485"
      decimals="-3"
      id="F_542b333b-1f9f-4e41-8e90-32b445bfae22"
      unitRef="U_USD">-14400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="-3"
      id="F_d9e748e3-3333-43f4-8acd-24f1ef30eba5"
      unitRef="U_USD">-2692000</us-gaap:StockholdersEquity>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_45ad8322-a85c-453a-9600-e04bab154cf5"
      decimals="INF"
      id="F_b61095a2-8513-424c-9a87-3d283c0fcdab"
      unitRef="U_shares">-5600000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_45ad8322-a85c-453a-9600-e04bab154cf5"
      decimals="-3"
      id="F_1d3f70d5-ca89-491a-84c7-a237413f6adc"
      unitRef="U_USD">-55795000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a"
      decimals="INF"
      id="F_fa52347d-121e-430d-84dd-6ea0167feabb"
      unitRef="U_shares">-4098600</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_974c0b74-b247-493a-a244-61954bd74ea0"
      decimals="INF"
      id="F_1096144b-445c-47ad-a734-2b16ad29a6f0"
      unitRef="U_shares">-3629400</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7"
      decimals="-3"
      id="F_959bd8ee-a855-424d-9374-d8a25046dfce"
      unitRef="U_USD">55794000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_5951f1f6-3743-4715-b7ac-f3ce58f325eb"
      unitRef="U_USD">55794000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a"
      decimals="INF"
      id="F_707f48ad-c990-4f69-af49-d19250bbfd41"
      unitRef="U_shares">5298360</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a"
      decimals="-3"
      id="F_cea36d2b-37b9-4de0-afb2-84204fdb1f83"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7"
      decimals="-3"
      id="F_5974ca50-4f8c-4b78-bec3-d464bdc65ccc"
      unitRef="U_USD">76214000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_38aebc22-37d9-45f8-9ba1-69026e766ed9"
      unitRef="U_USD">76215000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0b7a9061-a201-4231-855f-78dd8445bc9a"
      decimals="INF"
      id="F_8ad80289-87b9-4c45-8608-118dd9b723af"
      unitRef="U_shares">203261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b838ac5a-9277-449b-b4cf-99bfb3e27cd7"
      decimals="-3"
      id="F_8aea391f-3911-4b6b-8b33-cee9c96d1926"
      unitRef="U_USD">1967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_5892a5a3-6be2-422c-8f3c-6de8c7bbc1eb"
      unitRef="U_USD">1967000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_1515ae5b-ea8a-4cfb-8646-520a57119b6a"
      decimals="-3"
      id="F_2ab969da-8ee6-4656-ad5c-effbd344fa07"
      unitRef="U_USD">-164000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_078ac2d3-971d-4b17-83d4-6923f0c390c8"
      unitRef="U_USD">-164000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_1282f9df-89a7-4f4e-9c7a-cb95e8ead303"
      decimals="-3"
      id="F_9987a77f-2d95-47df-abd9-376be231fb14"
      unitRef="U_USD">-27797000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_40698a02-d611-48b1-aae2-8bf41cfb862f"
      unitRef="U_USD">-27797000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287"
      decimals="INF"
      id="F_41bc4a52-497e-4cc1-abbb-cc5045489cca"
      unitRef="U_shares">13440761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287"
      decimals="-3"
      id="F_d3717375-de29-447d-9a12-0291415d85bf"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="INF"
      id="F_7471d078-d159-4302-b5af-beff87129d7e"
      unitRef="U_shares">3629400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c36fe1a1-d21f-4b74-a586-0129d93b4a19"
      decimals="-3"
      id="F_8787d541-3254-4443-a77e-34e432606b8b"
      unitRef="U_USD">145683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b2da7e87-edb0-45d0-b6f2-541ed90e5347"
      decimals="-3"
      id="F_7af18d36-d7ed-4a22-af5f-d64bba6baf97"
      unitRef="U_USD">-164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_396dcdce-0d58-40b6-bfc6-6c19ad7ef2d8"
      decimals="-3"
      id="F_296b40a8-004d-4a8b-ab0b-ea14c7255238"
      unitRef="U_USD">-42197000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_7e007c8e-abd2-4491-9720-e28a26589203"
      unitRef="U_USD">103323000</us-gaap:StockholdersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_70566aaa-8ddd-488f-8329-70945439bec9"
      decimals="INF"
      id="F_e2039093-7601-42dd-a9e0-9614a99cdfde"
      unitRef="U_shares">145189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa"
      decimals="-3"
      id="F_b46af7b5-5090-4957-b8a1-513208c7e75e"
      unitRef="U_USD">2657000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_2c9a2355-fe39-4d93-bd70-7068d5718b8a"
      unitRef="U_USD">2657000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <lbph:FinancingRelatedFees
      contextRef="C_b6b6affe-e6fc-4685-b68d-4e01ed48acaa"
      decimals="-3"
      id="F_658822a1-b91e-4000-b258-6b179e3f6f3f"
      unitRef="U_USD">-37000</lbph:FinancingRelatedFees>
    <lbph:FinancingRelatedFees
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_9b1a1909-17cd-4db7-9680-743a84644ff2"
      unitRef="U_USD">-37000</lbph:FinancingRelatedFees>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_8f6a227c-60ec-49a6-8cdd-04c84137d99d"
      decimals="-3"
      id="F_7e9ea7bf-7532-4c99-8dba-c8e2254d8096"
      unitRef="U_USD">-528000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_de9815ae-b606-4767-869c-0103721f2803"
      unitRef="U_USD">-528000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="C_d9891fa5-a5a6-46ca-ab8f-679aad15f810"
      decimals="-3"
      id="F_34c4309e-b1b8-432d-81c1-5dadc335e02d"
      unitRef="U_USD">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_76835256-7e6a-4018-8585-4d881e9ec4c4"
      unitRef="U_USD">-43945000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d"
      decimals="INF"
      id="F_793485b1-7f68-450b-b03b-39130d4f0243"
      unitRef="U_shares">13585950</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d"
      decimals="-3"
      id="F_b4140583-ca55-462c-98db-7db8a6c19289"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="INF"
      id="F_1c2c31bb-e5dd-479e-b5e3-198469a10ad8"
      unitRef="U_shares">3629400</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c34bb4d2-986f-4c99-8052-d48376f6db2f"
      decimals="-3"
      id="F_4742d379-1ace-4dd0-bfd7-2951492ec034"
      unitRef="U_USD">148303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1f4f6d27-b781-451e-928f-7197f0c3b0a9"
      decimals="-3"
      id="F_fab22930-0a00-41e6-8857-25333b276a7a"
      unitRef="U_USD">-692000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_be512020-51df-4a10-b5c1-f8941f57b2b2"
      decimals="-3"
      id="F_d6046986-f96d-436e-be05-5d49625a2cfd"
      unitRef="U_USD">-86142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_9a0e0f36-da95-4b19-a617-88967361b708"
      unitRef="U_USD">61470000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_cf9bf15d-91b2-4870-872c-c9a6b5314d54"
      unitRef="U_USD">-43945000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_d468e95f-0949-479c-9317-8edb947662a3"
      unitRef="U_USD">-27797000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_8940ca48-3cdd-4342-8921-2d0c15d9646a"
      unitRef="U_USD">2657000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_67c83f0c-3654-4537-bf6c-125a3b9dc5d9"
      unitRef="U_USD">1967000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_a39e47f2-515d-46ff-981f-4285fa7b2f4b"
      unitRef="U_USD">5000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_839743d5-a796-4d8c-ba0f-102e4297dd97"
      unitRef="U_USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_771a0745-3fd3-4225-b390-1ac88ee43392"
      unitRef="U_USD">-101000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_d0666e3b-1d52-401e-b966-3eeae0af2f76"
      unitRef="U_USD">-157000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_1c980c0a-0e01-45d2-80db-9bd476cda523"
      unitRef="U_USD">183000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_01e72ffc-5f10-4044-876d-9df2165c146b"
      unitRef="U_USD">1645000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_6608016b-258d-49b7-9563-06153066c15d"
      unitRef="U_USD">282000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_30874248-125e-4cd1-bf14-3ce370336d83"
      unitRef="U_USD">-185000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_9d28800d-727e-483a-a718-03d8392f79fa"
      unitRef="U_USD">-1923000</lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_cf750b34-8e1f-4b28-bdf9-c49bd893cd99"
      unitRef="U_USD">-1329000</lbph:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_d316b2cb-3f62-40d5-89b0-9768a43fd648"
      unitRef="U_USD">959000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_3d1553d9-d6dc-45e2-919a-641020047e31"
      unitRef="U_USD">1318000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_1c5b1787-aae0-4e28-879d-0200b5c37b2d"
      unitRef="U_USD">138000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_8b77486b-a922-46c4-8d7a-870d22db34c9"
      unitRef="U_USD">146000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_f33105cc-74e3-4c8b-b958-f2949a75aa9a"
      unitRef="U_USD">0</lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet>
    <lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_c80b7f99-c1ce-4509-a7a9-c6f47b813cc1"
      unitRef="U_USD">4000</lbph:IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_79d5b86e-ab42-43ef-bb07-de5473cf8366"
      unitRef="U_USD">-38063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_71ace06e-0aab-4390-8d4e-200ac52b850d"
      unitRef="U_USD">-24705000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_ed377a46-226b-4a07-abeb-61ec870465c5"
      unitRef="U_USD">57614000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_95504acf-ddab-44b8-9d9d-62cd0421ecea"
      unitRef="U_USD">40700000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_d13fe185-fe37-4ba5-8b9d-a131938441d4"
      unitRef="U_USD">40550000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_e314427a-d2b4-46c5-9dfc-8bfc2425c231"
      unitRef="U_USD">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_20f19986-54ad-443b-b025-b3669a38e8b6"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_6931898b-0a03-4329-91af-dc7a5f442a7d"
      unitRef="U_USD">16000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_206d1c75-818c-4994-b7e2-bc6c7f3c62b8"
      unitRef="U_USD">-17064000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_55187ed5-365a-4e99-8756-846675cf9dcb"
      unitRef="U_USD">-40716000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_7e598bd1-d20f-4186-a94d-32f83aa1c6d7"
      unitRef="U_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_f6469c5f-5c67-4889-8196-e1f02bc3e7ad"
      unitRef="U_USD">1000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_ec86b563-ddd9-42f6-a335-2976519ac0a9"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_4e82bc1e-cfa4-48f8-b8a7-09f5e593e624"
      unitRef="U_USD">84774000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_d4b1a2fc-ca11-4f5a-be90-b1bdddefadbf"
      unitRef="U_USD">0</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_86130637-087d-4780-a8cf-f8edbcd99ff6"
      unitRef="U_USD">8322000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_aff51cc4-802b-423d-8bc2-8d6dbd4203e2"
      unitRef="U_USD">444000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_822d198c-cfdd-4ee7-9bbe-1f69bc0c7caf"
      unitRef="U_USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_8a164d8f-b4cc-4a9e-8de2-59319c77acee"
      unitRef="U_USD">-444000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_1d96cad1-4147-4eb5-88ac-094e6f7b3565"
      unitRef="U_USD">76451000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_5d306005-c3aa-44ee-bdad-a57fc3266e40"
      unitRef="U_USD">-55571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_b8471fd7-2f3b-4916-8631-f9f4bd695316"
      unitRef="U_USD">11030000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_9a31a72f-08ab-4c1a-bef6-d6f124c22ccb"
      unitRef="U_USD">66346000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="-3"
      id="F_c3d3981d-1053-4585-a46d-f0dc0f5f6cd1"
      unitRef="U_USD">55316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b595766a-90f9-4769-8da8-f15e343778fd"
      unitRef="U_USD">10775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_6d69e096-edb6-4bf1-8bb5-c036fa3c71fa"
      unitRef="U_USD">66346000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_4888de9d-58ab-4a66-b929-08488205a825"
      unitRef="U_USD">0</lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering>
    <lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_e0e9cd51-ee22-47e1-8df1-8f5d64c8af42"
      unitRef="U_USD">55794000</lbph:CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_fcce3195-aa16-40a8-8a65-4c5e3aa1f7f9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 1. Organization and Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Longboard Pharmaceuticals, Inc. (the Company), formerly Arena Neuroscience, Inc., was incorporated in the state of Delaware on January 3, 2020 and is based in San Diego, California. The Company was organized and initially wholly-owned by Arena Pharmaceuticals, Inc. (Arena), until the closing of its Series A convertible preferred stock (Series A Preferred Stock) financing in October 2020. The Company is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The Company&#x2019;s most advanced product candidate, LP352, is a serotonin receptor that is being developed for the treatment of seizures associated with developmental and epileptic encephalopathies and is currently in a Phase 1b/2a clinical trial (the PACIFIC Study). The Company is also developing LP659, an S1P receptor modulator, which could have applicability in multiple neurological conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 16, 2021, the Company completed the initial public offering (IPO) of its voting common stock. In connection with the IPO, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,298,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of voting common stock, which included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,360&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its voting common stock issued pursuant to the option granted to the underwriters to purchase additional shares in April 2021, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The Company raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds from the IPO after deducting underwriters&#x2019; discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. Unless otherwise noted, all references in the financial statements and related footnotes to the Company's &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x201c;common stock&#x201d; refers to the Company's voting common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Immediately prior to the closing of the IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,630,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series A Preferred Stock were exchanged for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of non-voting common stock and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,970,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,098,600&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of voting common stock. Following the IPO, there were no shares of Series A Preferred Stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Forward Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.38&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with US generally accepted accounting principles (GAAP) and reflect all of the Company's activities. The financial statements include all known adjustments necessary for a fair presentation of the results as required by GAAP. These adjustments consist primarily of normal recurring accruals and estimates that impact the carrying value of assets and liabilities. Operating results for the year ended December 31, 2022, are not necessarily indicative of future results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since its inception, the Company has devoted substantially all of its resources to research and development (R&amp;amp;D) activities, organizing and staffing, business planning, raising capital, in-licensing intellectual property rights and establishing its intellectual property portfolio, and providing general and administrative (G&amp;amp;A) support for these operations and has funded its operations primarily with the net proceeds from the issuance of Series A Preferred Stock and common stock. The Company has incurred losses and negative cash flows from operations since commencement of its operations. The Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management expects the Company will incur substantial operating losses for the foreseeable future in order to complete preclinical studies and clinical trials, seek regulatory approval, and launch and commercialize any product candidates for which it receives regulatory approval. The Company will need to raise additional capital through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Geopolitical and macroeconomic events, such as the COVID-19 pandemic and the conflict in Ukraine, continue to evolve and have resulted in a significant disruption of global financial markets. The Company&#x2019;s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from such events. If the disruption persists or deepens, the Company could experience an inability to access additional capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had available cash, cash equivalents and investments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;67.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and working capital of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to fund future operations. Management believes that its capital resources as of December 31, 2022 along with the proceeds from the follow-on public offering completed in February 2023 will be sufficient to fund the Company&#x2019;s operations for at least 12 months after the date these audited financial statements are issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <lbph:NumberOfCommonStockSharesIssuedAndSold
      contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c"
      decimals="INF"
      id="F_deab6a8a-3fb8-4ebf-8321-f39bbe65f65d"
      unitRef="U_shares">5298360</lbph:NumberOfCommonStockSharesIssuedAndSold>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c"
      decimals="INF"
      id="F_62fc777f-63e8-4d66-a87b-f0da3a1d6534"
      unitRef="U_shares">298360</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_7cc30c5a-347a-4ddc-9ffa-37b8c1372a0c"
      decimals="2"
      id="F_bcc89524-4a40-4e4e-a92c-9d420ca2d5b9"
      unitRef="U_USDollarShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72"
      decimals="-5"
      id="F_c2065041-f2d0-4fea-9669-8e9cb3cecf25"
      unitRef="U_USD">76200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="C_c8ccaab1-2bd3-458a-8b03-8557b629abff"
      decimals="-5"
      id="F_9b8b5a35-1b65-4bb3-839c-5de1efb9cc87"
      unitRef="U_USD">5900000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_a51bf83a-7c70-43dd-bd6b-a34f1ed77d72"
      decimals="-5"
      id="F_d019123f-cd17-48fe-87ca-90ec9bfc5dc3"
      unitRef="U_USD">2600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="C_fe3381e4-0776-4a65-882e-c5998ec43929"
      decimals="INF"
      id="F_40a6df6f-d08e-4887-951c-0779c95e37c9"
      unitRef="U_shares">2630000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_cec91faf-30a3-4e32-832f-b145d4c6a42a"
      decimals="INF"
      id="F_f0af19b4-c939-49c7-9a33-d569dd684986"
      unitRef="U_shares">3629400</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="INF"
      id="F_794c6b8f-7c2c-4a15-bb49-7a4c16d7db80"
      unitRef="U_shares">2970000</us-gaap:StockIssuedDuringPeriodSharesPeriodIncreaseDecrease>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_e460be53-bb93-4714-a2f3-98129e137c72"
      decimals="INF"
      id="F_3117f83d-4689-4e1a-a21e-bda0d44ed64e"
      unitRef="U_shares">4098600</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockholdersEquityNoteStockSplit
      contextRef="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b"
      id="F_afe7ddf2-3de9-41a4-95f3-11902967555b">On March 5, 2021, the Company filed an amendment to the Company&#x2019;s amended and restated certificate of incorporation to effect a forward stock split of shares of the Company&#x2019;s common stock on a 1.38-for-1 basis (March Forward Stock Split). Adjustments corresponding to the March Forward Stock Split were made to the ratio at which the Company&#x2019;s Series A Preferred Stock were converted into common stock immediately prior to the closing of the IPO. The par value of the common stock and number of shares authorized were not adjusted as a result of the March Forward Stock Split. All references to common stock, options to purchase common stock, share data, per share data, and related information contained in the financial statements and related footnotes have been retrospectively adjusted to reflect the effect of the March Forward Stock Split for all periods presented.</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_f44d2d7b-ea07-459b-a1e9-f5acf733498b"
      decimals="2"
      id="F_43b7e888-ca1b-4a65-b972-c40b5809ad69"
      unitRef="U_pure">1.38</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-5"
      id="F_56b710aa-cca6-4390-937d-2ddba93950dd"
      unitRef="U_USD">-86100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-5"
      id="F_25f4ba8f-eb43-4c98-9178-2bbecc9327b0"
      unitRef="U_USD">-42200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-5"
      id="F_902eba0f-322d-4708-8d0c-6e4f0b588d62"
      unitRef="U_USD">67600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <lbph:WorkingCapital
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-2"
      id="F_7ab07614-a80c-408a-883b-a3c9b369422e"
      unitRef="U_USD">61100</lbph:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1befd146-6464-4f1f-827e-a4945f1fa132">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. Government-sponsored enterprises. The carrying amounts reported in the audited balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying audited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and depreciated on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;straight-line basis&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; over the estimated useful life of the related assets (generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9966dab8-f3b5-4022-bcb9-d2650d18a5da;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). Property and equipment as of December 31, 2022 consists of computer equipment.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;R&amp;amp;D Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;amp;D expenses amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s board of directors and stockholders approved the 2020 Equity Incentive Plan (2020 Plan). The Company's board of directors adopted the 2021 Equity Incentive Plan (2021 Plan) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. Under both the 2021 and 2020 Plans, awards are measured at fair value and recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.447%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.405%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.34%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.808%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,566,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance became effective for the Company on January 1, 2023. The Company does not expect the adoption of this standard to have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia, have contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on the Company&#x2019;s business or ability to access the capital markets in the future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_8eda8b1f-df48-4dd7-a184-e555ec0d7653">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the accrual of R&amp;amp;D expenses and stock-based compensation. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#x2019;s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_0049b4a3-8c00-41b8-ab53-13b3394a701a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and invests in short-term investments with the primary objectives of seeking to preserve principal, achieve liquidity requirements and safeguard funds. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held and the nature, including the credit-ratings, of its short-term investments.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_787e532e-1d42-41c5-a9f4-4411f49bffb3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_01567c0d-9e01-4494-ac79-3c26b432fb4b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, corporate debt securities, and obligations of U.S. Government-sponsored enterprises. The carrying amounts reported in the audited balance sheets for cash and cash equivalents are valued at cost, which approximates fair value.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <lbph:ShortTermInvestmentsPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_13b40ecd-fc58-4a3d-88f0-49767ab994a4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term investments primarily consist of commercial paper, corporate debt securities, and government and agency bonds. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying audited balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lbph:ShortTermInvestmentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_16d4d2de-da80-471e-9203-2760f178a5b2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and depreciated on a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;straight-line basis&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; over the estimated useful life of the related assets (generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_9966dab8-f3b5-4022-bcb9-d2650d18a5da;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;). Property and equipment as of December 31, 2022 consists of computer equipment.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentBasisOfValuation
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6b656442-cc31-4992-92d5-6fe1bb30700f">Property and equipment are stated at cost</us-gaap:PropertyPlantAndEquipmentBasisOfValuation>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethods
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_d5da7131-d32b-4134-b34b-eea765fc1f75">straight-line basis</us-gaap:PropertyPlantAndEquipmentDepreciationMethods>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_dff02006-cd88-4a9f-b084-06afef117c07"
      id="F_f862b3a2-17e2-4637-8fce-fcbc92f8388f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_66d8e89f-10de-43dc-ac99-3996864d0c4f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;R&amp;amp;D Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D expenses are expensed in the periods in which they are incurred. External expenses consist primarily of payments to contract research organizations, outside consultants and other third parties in connection with the Company&#x2019;s discovery, preclinical and clinical activities, process development, manufacturing activities, regulatory and other services. Certain R&amp;amp;D external expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its service providers or the estimate of the level of service that has been performed at each reporting date. R&amp;amp;D expenses amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-5"
      id="F_c5b1b62b-3f07-4a1c-ab03-ef1372b5e22f"
      unitRef="U_USD">34600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-5"
      id="F_013e9cf1-5d59-47b5-9dca-948656c90ecc"
      unitRef="U_USD">19800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_7beb4532-ea57-47f5-960e-91ff0975af74">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s board of directors and stockholders approved the 2020 Equity Incentive Plan (2020 Plan). The Company's board of directors adopted the 2021 Equity Incentive Plan (2021 Plan) in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. Under both the 2021 and 2020 Plans, awards are measured at fair value and recognized over the requisite service period. Forfeitures are accounted for in the period they occur. The Company estimates the fair value of each stock-based award on the date of grant using the Black-Scholes option pricing model which requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected term of the option.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_58aefbe6-bde4-4dac-9e98-f38abb73dc64">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock and potentially dilutive securities outstanding for the period. Since the Company had a net loss in each of the periods presented, basic and diluted net loss per share of common stock are the same.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.447%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.405%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.34%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.808%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,566,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_b0220280-634c-4cfe-83c0-6e0af4a4bd9b">&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share as it would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_278" style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:61.447%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.405%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.34%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:16.808%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock awards, issued but unvested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,566,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4a748f73-8881-44ab-8a19-7b222ef02cd3"
      decimals="0"
      id="F_a63e7c0c-3342-480b-83eb-edd5eeec123d"
      unitRef="U_shares">2395748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2e064b44-0ba6-4451-b69e-017e6f114799"
      decimals="0"
      id="F_69621482-b785-4429-86f0-e8dab27b9557"
      unitRef="U_shares">1421756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0b4cba7f-1def-41a7-8c96-7470a5736a61"
      decimals="0"
      id="F_9a79de21-31c9-4358-911f-a2938e917159"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a865a91f-b26b-471a-990b-888ae5f1a037"
      decimals="0"
      id="F_c3ec8be5-362f-454a-b030-3d6ace97b25c"
      unitRef="U_shares">145189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="0"
      id="F_e8618b12-ce30-413c-976b-2d34d6931c2c"
      unitRef="U_shares">2395748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="0"
      id="F_b0301fb4-ef9b-4f1c-bb4a-bc3502f4f2ea"
      unitRef="U_shares">1566945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_bcb652a9-f64c-432f-a6e4-5be89be504d3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Company records uncertain tax positions on the basis of a two-step process whereby (1) management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_5057acd0-52ee-4f40-a6ec-5830fa8693e0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources, including unrealized gains and losses on short-term investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_aa222aa6-836a-4d64-93ef-27636a00ba3e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, to improve financial reporting by requiring timely recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. The ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. This guidance became effective for the Company on January 1, 2023. The Company does not expect the adoption of this standard to have a material impact on its financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <lbph:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6fd96ec7-0c08-4419-aabf-fcd03e28768c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2019, COVID-19, a novel strain of coronavirus, was first identified in Wuhan, China. In March 2020, the World Health Organization categorized COVID-19 as a pandemic, and the virus has spread to over 100 countries, including the United States. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potential impacts to the Company&#x2019;s business include, but are not limited to, temporary closures of facilities of its vendors, disruptions or restrictions on its employees&#x2019; ability to travel, disruptions to or delays in ongoing laboratory experiments, preclinical studies, clinical trials, third-party manufacturing supply and other operations, the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, interruptions or delays in the operations of the U.S. Food and Drug Administration or other regulatory authorities, and the Company&#x2019;s ability to raise capital and conduct business development activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.231%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2022, Russia commenced a military invasion of Ukraine. The ongoing geopolitical turmoil, including continuing military action in the region and sanctions imposed on Russia, have contributed to further disruption, instability and volatility of the financial markets, which may have an adverse impact on the Company&#x2019;s business or ability to access the capital markets in the future.&lt;/span&gt;&lt;/p&gt;</lbph:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_7d407b7c-6ca1-4b5e-8d9e-f77de3bdae83">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 3. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2014; Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2014; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#x2014; Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.597%;"/&gt;
        &lt;td style="width:2.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.030999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at &lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other Observable Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s cash equivalents and accounts payable approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_43f74d9c-93f1-49c3-93c0-86d45548e612">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the Company's financial instruments measured at fair value on a recurring basis as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.597%;"/&gt;
        &lt;td style="width:2.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.109%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.792%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.030999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements at &lt;br/&gt;Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Quoted Prices in Active Markets for Identical Assets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Other Observable Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant Unobservable Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments
      contextRef="C_74af52ba-c383-42f9-b16d-f0ae6869106e"
      decimals="-3"
      id="F_8a08638e-bc26-4f99-9d9c-28b4c506ee3a"
      unitRef="U_USD">8784000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_2387a101-f4f7-41ac-81ac-f6f8c20ae797"
      decimals="-3"
      id="F_dd8e23c8-1939-47ff-a189-9b7e97622963"
      unitRef="U_USD">8784000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_5baa7a2f-9417-41f3-897c-6e8e7fb9c734"
      decimals="-3"
      id="F_edd17cb3-9d8c-4eb8-8caf-8564f9cbf56e"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_bac860ed-4260-4d2b-aaa0-2cf0b6ff87f9"
      decimals="-3"
      id="F_1f7d2bd4-47dd-4118-ad75-435dc60518ca"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_b72f156f-3735-4e2b-85b3-f2d14f32ace8"
      decimals="-3"
      id="F_766219ae-273d-44dd-83eb-96c3fe0eb836"
      unitRef="U_USD">19429000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_605c1392-d2f6-4361-a5a7-62e125b3d648"
      decimals="-3"
      id="F_c2172ddc-624a-4dc0-9094-06d700775089"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_53b98a5d-b6cc-435d-a362-2f3c9ec191b3"
      decimals="-3"
      id="F_8ea33051-7a29-433b-9a8c-8b4e1e021939"
      unitRef="U_USD">19429000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_46857555-d570-4cd4-ae8b-3c59794bbe00"
      decimals="-3"
      id="F_b682ce13-c694-4305-8908-ac58610e9194"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_d0e46809-eb85-4065-bb2f-e5ee4eca223d"
      decimals="-3"
      id="F_0a491216-1911-4484-961a-99400c0efa30"
      unitRef="U_USD">19737000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_fa63f794-52c0-4d53-92d9-a98e8d59cf61"
      decimals="-3"
      id="F_f5be2c55-eb95-496d-b4d4-ed067884d2bb"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_9a38ddbe-fed7-4742-ab7b-2216e168c7ab"
      decimals="-3"
      id="F_cf570bd1-e907-4136-b283-7f4b2b2ac10b"
      unitRef="U_USD">19737000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_53dd140c-ac6e-4f56-8b33-5aa2379a8262"
      decimals="-3"
      id="F_2d70113d-eee0-417a-ae8d-9bd028076b54"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_cac615bb-7672-44e1-90ae-9ae47c52b057"
      decimals="-3"
      id="F_c60f43d5-2b49-4cb7-b5d0-f9aca648841a"
      unitRef="U_USD">18639000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_1f18a6a6-d98f-4e05-b791-6e86ed836955"
      decimals="-3"
      id="F_f98fdb4f-a3e9-4989-8e9a-f589d954185f"
      unitRef="U_USD">14759000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <us-gaap:ShortTermInvestments
      contextRef="C_701bf585-2e81-4356-a0ca-8b96a608fa6e"
      decimals="-3"
      id="F_f2e71be1-c7c8-4334-ba3a-947b469c3322"
      unitRef="U_USD">3880000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_2ffd1420-ee39-450c-bf5c-212f9be25ac4"
      decimals="-3"
      id="F_bafaf735-c10b-4fc4-823d-c16c7bbc37f6"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_5321ddad-ab6c-42a0-8350-64694be7656e"
      unitRef="U_USD">66589000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_379bd6b7-5319-4b15-8167-d1c5f35d5101"
      decimals="-3"
      id="F_16a372c9-b4ea-4d99-bee9-ba055e97ff8e"
      unitRef="U_USD">23543000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_27e2ac14-7028-40bd-adb2-ee9d7609e0b2"
      decimals="-3"
      id="F_03393d5c-39f5-4246-85cc-65dec26826c9"
      unitRef="U_USD">43046000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c563b15e-dc26-4b32-8128-0eb744b0ea45"
      decimals="-3"
      id="F_fee677f1-4376-4f07-8d6a-9cb61e2ce07c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="C_6f3ce05b-630d-43cb-8922-6a4a7d3fe473"
      decimals="-3"
      id="F_ed051866-69ed-4966-bb24-3893eb617de2"
      unitRef="U_USD">36014000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_d5c63294-9633-482f-83e8-25fa79adec30"
      decimals="-3"
      id="F_076baad9-c2d0-4651-ab38-5e841312b876"
      unitRef="U_USD">36014000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_48d2c5e1-2f02-4441-bec9-1183eabb3c33"
      decimals="-3"
      id="F_b4a65d2c-9e0e-4a77-bbef-f19be1f964bc"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_543a9b51-1efa-42be-8dd4-628dbc709107"
      decimals="-3"
      id="F_303de350-5c0c-4c99-a436-1ab8ca26680b"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_8be4e204-080b-4434-8ee1-a698bdb48ced"
      decimals="-3"
      id="F_52f69e1f-0721-46a6-b8c7-244201fd6b4e"
      unitRef="U_USD">13987000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0e02f99d-7c5e-4870-8e5b-0f199407f23f"
      decimals="-3"
      id="F_61136139-deed-4624-8755-df12338401b7"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_5c17c66e-3873-4eff-9ad7-cbee76e03837"
      decimals="-3"
      id="F_1d362645-970d-4a19-917e-ebe591112c3a"
      unitRef="U_USD">13987000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_3eeb2093-348a-4291-bc28-b0dd5ac681be"
      decimals="-3"
      id="F_90b2d449-8f13-42f8-957b-7ec4bffed888"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_78f4b339-ebd9-40c0-a799-bb28950ec2e0"
      decimals="-3"
      id="F_d9fa82b1-d53a-4856-afe2-18105d4730de"
      unitRef="U_USD">14017000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_b6f25d12-90a1-4bda-b22f-fb58f13cbf4f"
      decimals="-3"
      id="F_a43e72ef-7fac-4d06-a239-3e04d0ed293f"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_316ea6c1-7da7-4c8b-98b3-6abc844f5486"
      decimals="-3"
      id="F_fd4b1bf7-1d80-45c1-8c43-3743f3339bb6"
      unitRef="U_USD">14017000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_ba895260-3a97-4fca-9f2e-da37a4f7379e"
      decimals="-3"
      id="F_47fa8261-f187-472c-b44c-6affd407f325"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_31b36330-7551-4a6c-b015-e29fcadaa3ae"
      decimals="-3"
      id="F_4b026786-0205-4322-87cd-aa52d0b83bdb"
      unitRef="U_USD">12375000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <lbph:ShortTermInvestmentsAndCashEquivalents
      contextRef="C_8c2552fb-8de3-4abb-af54-8eaa29d393c8"
      decimals="-3"
      id="F_4bdb5c98-0a86-4573-970b-d1e945526308"
      unitRef="U_USD">9559000</lbph:ShortTermInvestmentsAndCashEquivalents>
    <us-gaap:ShortTermInvestments
      contextRef="C_b7cb4cfe-7014-4ddf-b9bf-2f0c02907348"
      decimals="-3"
      id="F_c0f0c3a2-c458-4306-bc2a-27134717fdfc"
      unitRef="U_USD">2816000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_1cb02383-4a83-4256-897d-6beb9cf7f359"
      decimals="-3"
      id="F_fc1cc657-1fb0-4ddc-9525-26782916e4be"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_3c49f5ae-d55e-4b5b-9f2f-02286eeb809d"
      unitRef="U_USD">40379000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c"
      decimals="-3"
      id="F_c86d2a94-7efd-4562-af07-a4a76447c453"
      unitRef="U_USD">9559000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_2e2350c3-4151-47e7-8025-d36e129778e9"
      decimals="-3"
      id="F_47260231-9a0f-4d82-955c-51bd725f4600"
      unitRef="U_USD">30820000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_341fea9a-781e-4a09-8de8-80cfcb42280e"
      decimals="-3"
      id="F_3bcc8560-e045-49d4-971d-7c9a9f0f5aaa"
      unitRef="U_USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_5163ca19-cf4f-48fa-b852-e17d69568cbd"
      unitRef="U_USD">76393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2eb7269c-8261-4586-88b9-33b4fc7d8b5c"
      decimals="-3"
      id="F_76ab05af-68a3-417f-b50b-4d2d5eb73743"
      unitRef="U_USD">45573000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2e2350c3-4151-47e7-8025-d36e129778e9"
      decimals="-3"
      id="F_f5e41188-4bd4-4d1a-b9b6-6792c3f28da0"
      unitRef="U_USD">30820000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_341fea9a-781e-4a09-8de8-80cfcb42280e"
      decimals="-3"
      id="F_db4700f7-1811-4554-a039-f3b4273d5428"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6a95be45-1301-4bb1-a6e8-17c26cc9b510">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 4. Short-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes short-term investments (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.927%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.66%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.855%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the maturities of the Company's short-term investments at December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.526%;"/&gt;
        &lt;td style="width:3.369%;"/&gt;
        &lt;td style="width:12.567%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:12.567%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.915999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.915999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the Company&#x2019;s available-for-sale investments&#x2019; gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at December 31, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.316%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.440999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.497%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.440999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.497%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;More than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;More than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews its investments to identify and evaluate investments that have an indication of possible other-than-temporary impairment. Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost basis, any changes to the underlying credit risk of the investment, and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value. The unrealized losses in the Company&#x2019;s investments were caused by changes in interest rates caused by changing economic conditions, and not from a decline in credit of their underlying issuers. The Company does not generally intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost basis which may be at maturity. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_205b4411-89f3-47c4-a0f6-7f858089bc07">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes short-term investments (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.927%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.66%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.411%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.855%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a"
      decimals="-3"
      id="F_a3b865f1-6860-4f97-8fc0-2fcd56d65063"
      unitRef="U_USD">18453000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a"
      decimals="-3"
      id="F_e17673a8-0c7b-4620-afc0-5951fc94230d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a"
      decimals="-3"
      id="F_7edf47f0-3e9b-4cb3-b5fe-1cc54d226c9e"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1e8da0f5-7411-4acd-b359-d2226605885a"
      decimals="-3"
      id="F_5d080a96-48a6-48c4-a26b-1f671502050f"
      unitRef="U_USD">18438000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_19a56b19-bc29-4a5f-814d-f48fd55911c0"
      unitRef="U_USD">20090000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_5c4b96ae-6ea6-4774-8196-2bd0a88d46c3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_8a35d6ef-6058-4e6f-8669-1f9474ce696c"
      unitRef="U_USD">353000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_05c0a772-481a-45bf-b15c-0a73a5751ac5"
      unitRef="U_USD">19737000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_e295726f-339e-4617-b0bc-5c4ca78954c4"
      unitRef="U_USD">18963000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_dee7d528-1f43-417a-b552-7c7e6bad0067"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_360b707d-660a-40f7-84f5-9c84f2420473"
      unitRef="U_USD">325000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_535b696b-6816-4603-a063-7ad8e03be067"
      unitRef="U_USD">18639000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_ac1d8ebf-95e9-4e70-a361-559e5251668f"
      unitRef="U_USD">57506000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_d67f71d8-f4ca-4dfb-af8e-a3a6da53db73"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_ab446819-d3b8-4a7d-95af-d74ce0e6bef6"
      unitRef="U_USD">693000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_23d32ab7-3bca-4c36-a1ab-abc12e0fe4af"
      unitRef="U_USD">56814000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8"
      decimals="-3"
      id="F_3d3da5c7-6d3e-4932-bbe4-1f2036cda9f3"
      unitRef="U_USD">13987000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8"
      decimals="-3"
      id="F_029531d5-87ce-4cea-94f6-cf2eea1c6d5d"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8"
      decimals="-3"
      id="F_4975f906-f5fa-4656-859f-0fb6a77f10fe"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_115b4147-e78e-43dc-81da-9e776c6fefa8"
      decimals="-3"
      id="F_794607d0-67b3-4d1d-a1d3-df5cde8ba516"
      unitRef="U_USD">13987000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_ff9fa20e-94b2-402a-bc28-b9acc5e68663"
      unitRef="U_USD">14117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_96a420b8-d708-472a-b1a3-13a349cb55d3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_9ff0e18b-ffc2-48ca-a338-a639942c6aca"
      unitRef="U_USD">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_a7ade63f-6df2-478d-aeb6-90aa1ab1095c"
      unitRef="U_USD">14017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_20eacc02-902b-4865-aa46-9f6735b5e426"
      unitRef="U_USD">12439000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_4aed97cb-2002-4a8e-9a0a-ceffad136968"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_0581a0ce-bbb9-4173-8b5e-0b99b6876ef8"
      unitRef="U_USD">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_47fc3fea-473b-4f37-8298-7f4884b1baa6"
      unitRef="U_USD">12375000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_e9b13534-5218-4f16-80d6-bc376a5fe9fc"
      unitRef="U_USD">40543000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_19b8dcf1-0d63-44e4-ae53-10a185238b91"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_8a107661-b173-4bf9-8e54-5390f4ce98f8"
      unitRef="U_USD">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_ef7adb50-19b6-45c1-a81b-e90162698ee1"
      unitRef="U_USD">40379000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6ac94bf3-a119-4b14-a533-1b59156e79c3">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the maturities of the Company's short-term investments at December 31, 2022:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:35.526%;"/&gt;
        &lt;td style="width:3.369%;"/&gt;
        &lt;td style="width:12.567%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:12.567%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.915999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.379%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.915999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one year or less&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due after one year through two years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Total short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_576ad9ca-0d86-4e1c-b56c-01ed54d7e569"
      unitRef="U_USD">49139000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f6ffafb2-f858-4a5b-a64a-f5247b52cdde"
      unitRef="U_USD">48834000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f1b33219-2136-4b67-a56a-f5cbd0413dd1"
      unitRef="U_USD">8367000</lbph:DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_ac623938-b7c7-4f5d-81b2-9270e98533e5"
      unitRef="U_USD">7980000</lbph:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_537272df-2e26-4973-bcf5-0030b0d818c8"
      unitRef="U_USD">57506000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b2bb8a59-0ac2-4944-be31-b3c07afaffcd"
      unitRef="U_USD">56814000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_1876ab94-95c9-48f2-b1ac-12decdd4d070">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table shows the Company&#x2019;s available-for-sale investments&#x2019; gross unrealized losses and fair value aggregated by investment category and length of time that individual securities have been in a continuous loss position, at December 31, 2022 and 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:22.316%;"/&gt;
        &lt;td style="width:1.253%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.440999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.497%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.440999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.262%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.497%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:6.633%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.642%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;More than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,111&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;325&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;693&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="28" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;More than 12 months&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="8" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Count&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Government and agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_962e9c2b-6893-43c2-a52f-d0bcb1daace0"
      unitRef="U_Securities">8000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_79480c9e-114d-44de-9222-74d2cc0e353e"
      unitRef="U_USD">7934000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_6fdeb8cd-090e-4a98-8e0f-180841abe3d9"
      unitRef="U_USD">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_6799805b-3180-4317-982d-5d5206c65c4a"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_57b335ea-899e-45d4-bba0-091c4119205c"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_4d3fb288-8934-42d0-a88d-75c9a8dcf584"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_3b80f7d9-13c6-4944-b5d6-b9439ee948fa"
      unitRef="U_Securities">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_858392e2-dd3b-4ac6-a37a-6624242a44a8"
      unitRef="U_USD">7934000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_9519f058-65b9-4a77-993f-c530aca0ec5e"
      decimals="-3"
      id="F_d3b39957-0f72-44d2-96e6-4928509ccaff"
      unitRef="U_USD">15000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_24342d37-5c75-49c3-b725-4e4a083ac12e"
      unitRef="U_Securities">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_c9c13200-f40e-4f4c-9ffb-cef972337629"
      unitRef="U_USD">7626000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_6bf7c4e4-2727-4351-b311-c9dfd030b3f0"
      unitRef="U_USD">43000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_db697ed1-b6f3-4ca9-b8ad-0ce211fed39e"
      unitRef="U_Securities">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_f91d94c6-6784-4e2d-9067-329917bc40c8"
      unitRef="U_USD">12111000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_6f6418d2-7756-4dfc-9d27-964b84cec899"
      unitRef="U_USD">310000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_ebb23e72-062d-4b76-adae-a298434c2885"
      unitRef="U_Securities">16000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_9c4b6e9d-4fe8-4a3d-87fa-6e687727c987"
      unitRef="U_USD">19737000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_9ca04336-7e27-473c-a5c4-84f1d23ab4e3"
      decimals="-3"
      id="F_77242bcc-5b59-4018-862e-b930b6793027"
      unitRef="U_USD">353000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_460ab3b6-7847-46b8-bac9-3eb6a41ba659"
      unitRef="U_Securities">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_7795df34-554d-40a9-a8a8-0cf13827e8c5"
      unitRef="U_USD">4511000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_e0885294-1b25-4148-842b-7a55bfe48716"
      unitRef="U_USD">37000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_18f6829f-6dd8-4664-8bff-36e06ffead92"
      unitRef="U_Securities">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_82ab5254-7fcc-4eef-8898-7f56a5c2c64d"
      unitRef="U_USD">10653000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_5d92c8c9-4524-4b63-ae9e-0e2a3feef888"
      unitRef="U_USD">288000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_c2008a1e-9ce9-4abf-b593-0c6c92593730"
      unitRef="U_Securities">9000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_e78d2fb1-415d-4867-95f0-f4c972582d3c"
      unitRef="U_USD">15164000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_708a2984-e296-43ff-8866-08ed7b02f589"
      decimals="-3"
      id="F_83d370d8-3c95-4080-889c-639c1a9efb6e"
      unitRef="U_USD">325000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_a3508a0a-b944-48eb-8698-1a3eb6004bac"
      unitRef="U_Securities">18000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_e420bc7a-5509-40cf-8253-9f9b901c637a"
      unitRef="U_USD">20071000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_48bae4b1-6eb8-4f90-854d-7bf9d8f48695"
      unitRef="U_USD">95000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_efd49a06-75f2-4eee-aa90-ad37e715e846"
      unitRef="U_Securities">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_bbc1f98c-614d-4f27-8a0f-f552ffa232c0"
      unitRef="U_USD">22764000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_cae916de-badc-4592-9968-f36be4106348"
      unitRef="U_USD">598000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_e860893d-70d0-42d9-ad04-18fd25114b76"
      unitRef="U_Securities">33000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_7bbc41fa-d292-4e8b-a1d5-37d4944ab5fa"
      unitRef="U_USD">42835000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_679b1a2e-2bb0-478d-a9e5-66b1bc3bdedf"
      unitRef="U_USD">693000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_8f3ad40a-4853-4ea2-a744-a8bf88f85eab"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_c0c755c1-1cb5-4635-98c9-87d39dfc9464"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_e0b6b9cb-aa07-4ddc-8982-09ff7449f8de"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_f6764844-2c87-41b0-9417-2c504c56120d"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_aae3d294-cd82-426e-a669-5a552a56300f"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_6b9b8199-2721-4425-8b74-5b16096d8dd1"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_ff3f43f4-f145-46bb-95ba-b520d976fdf1"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_f6b98466-f59a-4f1c-be55-25fd4ebc4145"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_b846d527-268f-4a88-a431-c7de28a3105b"
      decimals="-3"
      id="F_8e7a611a-f465-4e34-96a3-f1a5ae65863b"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_47f37a4a-f679-4276-b9e3-fc3984aac34c"
      unitRef="U_Securities">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_74305995-4b14-43ce-a34f-77055dedb9d0"
      unitRef="U_USD">14017000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_7c73ffae-1193-4575-bb46-d7128ab52025"
      unitRef="U_USD">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_e1c5840c-254d-4681-bfdc-5575e6a032e4"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_b2aa38e1-e9c1-4708-be8e-ceabb3388c80"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_89e83f5f-98f7-4f50-bd83-f7a14e9b4364"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_85e4a373-a763-43d7-9020-eddea4304ead"
      unitRef="U_Securities">10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_c0fbe7fc-b240-4104-9fe0-842da12f8da2"
      unitRef="U_USD">14017000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_a3c9e7e2-a04c-4b02-9cd6-19f4d103cb11"
      decimals="-3"
      id="F_0b5c9a7c-a56b-4ee1-860e-5648ed5102dd"
      unitRef="U_USD">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_12f1b1fd-def7-4418-9527-6aad13594d6e"
      unitRef="U_Securities">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_d83d19c6-6432-48ee-9353-0cc1fce8f380"
      unitRef="U_USD">12375000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_cf8ce472-2b51-41e3-83f9-7426795e2898"
      unitRef="U_USD">64000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_02729902-2fcf-4737-8ddf-210d45572230"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_948c8fc2-7930-454b-bb2f-80d03f6e10bb"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_6f9650e1-6fed-4c9b-9fce-8f13f000355e"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_4f17dbc6-590d-43c9-ae22-7cc9f58736f4"
      unitRef="U_Securities">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_eb1fd3ce-7214-4bb4-909a-ed1a94458105"
      unitRef="U_USD">12375000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_0f374945-0780-451f-9899-e3095382578c"
      decimals="-3"
      id="F_a98b7e0b-e69e-439a-b73f-7d6cb774751a"
      unitRef="U_USD">64000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_c26156b3-cf5d-4570-b7d7-e35954913321"
      unitRef="U_Securities">17000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_7a498bb3-b7a2-462e-aa1e-de92249ffe95"
      unitRef="U_USD">26392000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_a0302998-ce62-409d-b5df-3e6c17de83b9"
      unitRef="U_USD">164000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_dab012c4-3833-4561-a2bd-ad4ec679fca0"
      unitRef="U_Securities">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_7a264109-e425-490c-a10f-9c087b2d4bc4"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_6a1940c6-8d13-4b9e-a489-c8176c5b14e0"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_f9901af4-1015-4e32-aabb-859de409b3d9"
      unitRef="U_Securities">17000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_9d56db8a-2755-437f-93fa-d150fbb520c5"
      unitRef="U_USD">26392000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_ab75d1ca-a1b2-468e-8ac0-8c96bb02bea8"
      unitRef="U_USD">164000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_cdbb0ef6-b8b6-4f36-90d9-332fcd2de4a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 5. Accrued Other Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued other expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.251%;"/&gt;
        &lt;td style="width:1.946%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.570999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.559%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.672%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued consulting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued computer related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_d8d00fd8-2116-461b-b8b5-c01a94b2b0b1">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued other expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p id="bkmk_281" style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.251%;"/&gt;
        &lt;td style="width:1.946%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.570999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.559%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.672%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued consulting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued legal and accounting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued computer related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued recruiting fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_117950ac-e3e6-4b73-a230-879b0c5c3a4b"
      unitRef="U_USD">254000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_1aba0c04-d494-408f-8ee3-c274e2cec49e"
      unitRef="U_USD">97000</us-gaap:AccruedProfessionalFeesCurrent>
    <lbph:AccruedLegalAndAccountingFeesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f529fcda-488a-4b38-ba47-bc851a9480e9"
      unitRef="U_USD">127000</lbph:AccruedLegalAndAccountingFeesCurrent>
    <lbph:AccruedLegalAndAccountingFeesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_7b159a57-592e-42a4-bd91-2a890e9c47ed"
      unitRef="U_USD">7000</lbph:AccruedLegalAndAccountingFeesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f1dbd704-2353-4304-a0e4-802de0b134bb"
      unitRef="U_USD">34000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_60421e3f-5864-4dab-94f3-a399faa6f42e"
      unitRef="U_USD">168000</us-gaap:AccruedPayrollTaxesCurrent>
    <lbph:AccruedComputerRelatedExpenses
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_47aac980-b67b-46e4-843b-dcac324944c5"
      unitRef="U_USD">15000</lbph:AccruedComputerRelatedExpenses>
    <lbph:AccruedComputerRelatedExpenses
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_f5f88fe5-eda2-47b3-bd0a-fc5aa85fabea"
      unitRef="U_USD">27000</lbph:AccruedComputerRelatedExpenses>
    <lbph:AccruedRecruitmentFeesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_7abfb0be-efad-4fd0-a4fd-ba0705ad9d24"
      unitRef="U_USD">0</lbph:AccruedRecruitmentFeesCurrent>
    <lbph:AccruedRecruitmentFeesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_1b0cdc32-3e4f-4fa4-b4c7-5c8ca8fced52"
      unitRef="U_USD">30000</lbph:AccruedRecruitmentFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_55915831-39ef-421f-8b29-ff7629e4a9b4"
      unitRef="U_USD">60000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_5b05ab63-7e7d-4a03-9ddc-95c8de57f386"
      unitRef="U_USD">23000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_4bbc91db-0a14-4cc9-b2e8-3be426609c3f"
      unitRef="U_USD">490000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_f2d48631-d142-456e-9b38-7e5576427a1e"
      unitRef="U_USD">352000</us-gaap:AccruedLiabilitiesCurrent>
    <lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_ed92986f-250f-4363-9a7e-864b319adf91">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 6.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, the Company entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;SM &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sales Agreement (the Sales Agreement) with Cantor Fitzgerald &amp;amp; Co., as sales agent (Cantor Fitzgerald), pursuant to which it may issue and sell its common stock from time to time through an &#x201c;at the market offering&#x201d; (ATM) program under the Sales Agreement. The Company has no obligation to sell any shares of common stock under the Sales Agreement and may at any time suspend sales under the Sales Agreement. Cantor Fitzgerald will be entitled to compensation in an amount of 3% of the gross proceeds of any shares of common stock sold under the Sales Agreement. A maximum of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of shares of common stock may be sold under th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;e Sales Agreement. The Company had not sold any shares of its common stock under the Sales Agreement as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Amended and Restated Certificate of Incorporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2021, the Company amended and restated the Company&#x2019;s certificate of incorporation to, among other things, increase the authorized shares of voting common stock, non-voting common stock and preferred stock to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Voting Common Stock and Non-Voting Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,585,950&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of voting common stock outstanding and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of non-voting common stock outstanding. As of December 31, 2021, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,440,761&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of voting common stock outstanding, excluding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares subject to repurchase, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,629,400&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of non-voting common stock outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock>
    <lbph:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_70566aaa-8ddd-488f-8329-70945439bec9"
      decimals="-5"
      id="F_8674f75f-0855-4935-822f-b7bcd13d818f"
      unitRef="U_USD">20000000.0</lbph:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0d4f20c8-e119-4763-a167-6957a1d2975c"
      decimals="INF"
      id="F_68f90197-f1ff-41cd-b133-b53a62f5bbc9"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_355af628-daf1-4971-8c16-cbb53131df03"
      decimals="INF"
      id="F_347fa91a-4758-4e6d-8e5e-7aee174e4ac7"
      unitRef="U_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f36635ab-29c5-4e22-a6be-fcbab49127d7"
      decimals="INF"
      id="F_95eec1ab-11e9-488a-a439-b651872e3277"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_542f2c4a-2e6b-42f0-8322-3069af427f7d"
      decimals="INF"
      id="F_972b591e-8b84-488d-8c93-58817244b58e"
      unitRef="U_shares">13585950</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c8378fee-8af8-4c6c-9f01-c15be4f76329"
      decimals="INF"
      id="F_561706d7-7284-4390-b52c-5e62697c30ce"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287"
      decimals="INF"
      id="F_93136c36-a9cc-49bc-94ec-6ca57ceb2935"
      unitRef="U_shares">13440761</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_5cd9d80a-9fb9-4fd1-afa3-6bda02dbc287"
      decimals="INF"
      id="F_a012ccda-d9c9-484e-818b-d26b8a9a4df3"
      unitRef="U_shares">145189</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0d1da38c-7079-4f7e-bcd1-165773ea5f87"
      decimals="INF"
      id="F_7aa8e67b-9369-4340-8d12-bdc8fca0d250"
      unitRef="U_shares">3629400</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_266c1cd8-db99-4676-bd17-02dc454270e3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 7. Agreements with Arena Pharmaceuticals, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company entered into a license agreement (the License Agreement), a services agreement (the Services Agreement), and a royalty purchase agreement (the Royalty Purchase Agreement) in October 2020 with Arena, which was subsequently amended as described below. Arena was purchased by Pfizer in March 2022. The following section summarizes these related party agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Pursuant to the License Agreement, the Company has obtained an exclusive, royalty bearing, sublicensable, worldwide license under certain know-how and patents of Arena to develop and commercialize LP352 for any use in humans, LP143 and certain 5-HT2A compounds for the treatment of any central nervous system (CNS) indication in humans (excluding the treatment, prevention or amelioration of pain or any gastrointestinal, non-CNS autoimmune or cardiovascular disorder), and LP659 for the treatment of selected CNS indications in humans (pharmaceutical products containing any such compounds, Licensed Products). In January 2022, the Company and Arena amended the Arena License Agreement to add additional 5-HT2A compounds, and in September 2022 the Company and Arena further amended the Arena License Agreement to expand the field of the license of LP659 and provide Arena a right of first negotiation to acquire certain development and commercial rights to LP659 products. As consideration for the rights granted to the Company under the License Agreement, the Company will be required to pay to Arena a mid-single digit royalty on net sales of Licensed Products of LP352, and a low-single digit royalty on net sales of all other Licensed Products, by the Company, its affiliates or its sublicensees, subject to standard reductions. The Company&#x2019;s royalty obligations continue on a Licensed Product-by-Licensed Product and country-by-country basis until the later of the (i) tenth anniversary of the first commercial sale of such product in such country or (ii) expiration of the last-to-expire valid claim of the patents licensed by us under the License Agreement covering the manufacture, use or sale of such product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Services Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.269%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the License Agreement, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company also entered into a Services Agreement with Arena under which Arena agreed to perform certain research and development services, general administrative services, management services and other mutually agreed services for the Company and receive service fees therefore on an hourly rate based on an annual full time equivalent rate agreed upon by the parties. Arena invoices the Company for services provided on a monthly basis, in arrears. The Services Agreement will continue until December 31, 2022, and will automatically renew for successive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; terms. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Either party may terminate the Services Agreement for any reason, subject to specified notice periods. Payments for services provided under the Services Agreement are recorded to research and development or general and administrative, on the statement of operations, as appropriate. The Company has significantly reduced its activities under the Services Agreement, including as a result of its having&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;hired &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;employees or contracted with third parties with the requisite expertise, and the Company is no longer substantially dependent on such services from Arena.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the services expensed under the Services Agreement (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.555%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.49%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.953999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;188,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of related party amounts related to the Services Agreement in accounts payable as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <lbph:RenewOfSuccessiveAgreementTerm
      contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36"
      id="F_a8882813-0e1b-4cef-ac1f-6dbb72c41d24">P1Y</lbph:RenewOfSuccessiveAgreementTerm>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_8a44cabc-f7f8-4ad0-a5e6-0d06df86b111">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the services expensed under the Services Agreement (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:52.002%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.555%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.49%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.953999999999997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36"
      decimals="-3"
      id="F_791f9ede-27f1-46c8-b55d-23275bd7f5ae"
      unitRef="U_USD">93000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed"
      decimals="-3"
      id="F_2574dcc4-4aa7-48d0-bbcf-42af23275c32"
      unitRef="U_USD">930000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36"
      decimals="-3"
      id="F_361f76ec-bd7a-42f2-8732-798ee45e0d10"
      unitRef="U_USD">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed"
      decimals="-3"
      id="F_eed6ccba-2a57-4e8b-960b-5bd2bec36e07"
      unitRef="U_USD">94000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_e8180cb1-d339-43ce-8382-ffb65f743b36"
      decimals="-3"
      id="F_d8dae182-e616-43e8-883a-1d86d3fff94f"
      unitRef="U_USD">93000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_408b138b-5567-4c0d-8740-e0f77b39b6ed"
      decimals="-3"
      id="F_1126dde2-e2ee-44c6-af14-dec6efa79101"
      unitRef="U_USD">1024000</us-gaap:OperatingExpenses>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_d29e8ef9-ee88-456f-b2dd-f017a70b32f1"
      decimals="0"
      id="F_97ff00c7-bb3e-4250-8ba0-4dfdc3d2abaa"
      unitRef="U_USD">0</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:AccountsPayableRelatedPartiesNoncurrent
      contextRef="C_288ded8c-213e-400a-8676-efb385f835af"
      decimals="0"
      id="F_fda7c4bd-7750-4abd-a594-7b59c5ebe4c9"
      unitRef="U_USD">188000</us-gaap:AccountsPayableRelatedPartiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_f9c969b7-8b14-4d81-9bed-d07ec6eb044c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 8. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, the Company&#x2019;s board of directors and stockholder approved the 2020 Plan, which provided for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, and stock appreciation rights to its employees, members of its board of directors, and consultants. The Company&#x2019;s board of directors determined the exercise price, vesting and expiration period of the grants under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's board of directors adopted the 2021 Plan in February 2021 and the Company's stockholders approved the 2021 Plan in March 2021. The 2021 Plan became effective on March 11, 2021. The 2021 Plan is the successor and continuation of the 2020 Plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional awards may be granted under the 2020 Plan and all outstanding awards under the 2020 Plan remain subject to the terms of the 2020 Plan. As of December 31, 2022, the 2021 Plan authorizes and provides for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,694,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, which amount will be increased to the extent that awards granted under the 2021 Plan are forfeited, expire or are settled for cash (except as otherwise provided in the 2021 Plan). T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on January 1 of each calendar year, through January 1, 2031, in an amount equal to (i) 5% of the total number of shares of common stock outstanding on December 31 of the fiscal year before the date of each automatic increase (determined on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock), or (ii) a lesser number of shares determined by the Company&#x2019;s board of directors prior to the applicable January 1. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Recipients of stock options are eligible to purchase shares of the Company&#x2019;s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the 2020 and 2021 Plans (or collectively, Equity Plans) is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and, in general, the options issued under the Equity Plans vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_c1171003-0a4e-4fc3-897f-9cf0a00e25b7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period from the vesting commencement date. There are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,299,251&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for grant under the 2021 Plan as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Award Grants under the Equity Plans&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.322%;"/&gt;
        &lt;td style="width:0.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.947000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.071%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.689%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.192%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;873,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;548,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,244,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;270,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,055,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022 included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;736,434&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; vested stock options and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;319,413&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; stock options that are subject to an early exercise provision.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used for the stock option grants for the years ended December 31, 2022 and 2021, along with the related grant date fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.328%;"/&gt;
        &lt;td style="width:2.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.212%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.164%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated grant date fair value per share of award granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value of Common Stock.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Prior to the IPO, there was no public market for the Company's common stock, and therefore, the estimated fair value of common stock for option grants was determined by the Company&#x2019;s board of directors as of the date of each option grant, with input from management, considering the most recently available third-party valuations of common stock and the board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Historically, these third-party valuations of our equity instruments were performed contemporaneously with identified value inflection points. These third-party valuations were performed in accordance with the guidance outlined in the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition to considering the results of these third-party valuations, the Company&#x2019;s board of directors considered various objective and subjective factors to determine the fair value of its common stock as of each grant date, including: the prices of the preferred stock sold to or exchanged between outside investors in arm&#x2019;s length transactions and the rights, preferences and privileges of the preferred stock as compared to those of the Company&#x2019;s common stock including liquidation preferences of the Company&#x2019;s preferred stock; the progress of the Company&#x2019;s research and development programs, including the status and results of preclinical and clinical trials for product candidates; the stage of development and material risks related to the Company&#x2019;s business; external market and other conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#x2019;s business conditions and projections; the Company&#x2019;s financial position and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock and preferred stock; the likelihood of achieving a liquidity event for the Company&#x2019;s securityholders, such as an initial public offering or a sale of the Company in light of prevailing market conditions; the hiring of key personnel and the experience of management; and the analysis of initial public offerings and the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;market performance of similar companies in the biopharmaceutical industry, as well as trends and developments in the biopharmaceutical industry.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;After the closing of the IPO in March 2021, the Company began utilizing the closing stock price of the common stock on the Nasdaq Global Market as both the exercise price and an input to the Black Scholes option pricing model to determine stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities similar to the expected term of the awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Since the Company is a newly public company and does not have a trading history for its common stock, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;life&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The expected life represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is equal to the contractual term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;348,450&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock awards were granted to an employee under the 2020 Plan, which vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two years &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and had an estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.12&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share at the time of grant. During 2022 and 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;145,189&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;203,261&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; restricted stock awards vested, respectively; the total fair value of the vested awards was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. As of December 31, 2022, all restricted stock awards were vested. For the years ended December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of stock-based compensation related to the restricted stock awards was recorded in general and administrative expense, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.852%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.692%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.503%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.953%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, unrecognized stock-based compensation expense&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;n, which is expected to be recognized over a remaining weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company's board of directors adopted the 2021 Employee Stock Purchase Plan (ESPP) in February 2021, the Company's stockholders approved the ESPP in March 2021 and it became effective on March 11, 2021. The ESPP initially authorizes the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;353,339&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock under purchase rights granted to the Company's employees. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, beginning on January 1, 2022 through January 1, 2031, by the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;of the total number of shares of common stock outstanding on the last day of the fiscal year before the date of the automatic increase (determining on an as-converted to voting common stock basis, without regard to any limitations on the conversion of the non-voting common stock); and (ii) such number of shares of common stock that would cause the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;aggregate &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;number of shares of common stock then reserved for issuance under the ESPP to equal &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,060,017&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares; provided that before the date of any such increase, the Company&#x2019;s board of directors may determine that such increase will be for a lesser amount of shares. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP permits eligible employees, who elect to participate in an offering under the ESPP, to contribute up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible earnings (as defined in the ESPP) towards the purchase of shares of common stock. Unless otherwise determined by the Company's board of directors, the price at which stock is purchased under the ESPP is equal will be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair market value of the Company&#x2019;s common stock on the commencement date of each offering period or the relevant purchase date, whichever is lower. There are certain service requirements for an employee to be eligible to participate in the ESPP, and no employee may purchase shares under the ESPP at a rate in excess of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; worth of common stock (as determined in accordance with the ESPP). Offering durations under the ESPP may not be longer than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and the Company may specify shorter purchase periods within each offering. The ESPP is considered a compensatory plan as defined by the authoritative guidance for stock-based compensation. As of December 31, 2022, the ESPP had not yet been implemented.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_41221969-e7b7-45c7-916d-09ca02aa8b4a"
      decimals="0"
      id="F_6ffb6235-d8ae-4fb6-9c8c-15682d4cc453"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_997cf810-2610-4985-8384-a99e8aea8da6"
      decimals="INF"
      id="F_e2b6875d-b1ca-4ea0-a6e1-6fc29dceaf5b"
      unitRef="U_shares">3694999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7"
      id="F_e8e67fc5-c577-45b6-a53f-5478f792ecdc">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_029ab23f-75c4-4df0-bc56-b2d487ec48d7"
      id="F_f2d38108-6c04-436a-aac8-cd13b35db353">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_f5f0dc44-7d37-4e54-8447-edb5ba753a90"
      decimals="INF"
      id="F_55f80d8f-bdb6-4dc8-a72f-95e29b1e22ed"
      unitRef="U_shares">1299251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_ced83f2e-e66e-4ce8-8975-5219c03fd8ea">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A summary of the Company&#x2019;s Equity Plans stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.322%;"/&gt;
        &lt;td style="width:0.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.947000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.071%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.131%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.235%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.689%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.192%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-Average Remaining Contractual Term (in Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;873,264&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;548,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,421,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,244,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited/cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;270,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,395,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,055,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="INF"
      id="F_0984f106-18be-4ef4-8726-67d16be0a24c"
      unitRef="U_shares">873264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="2"
      id="F_315ef729-fb8e-4703-aa46-1c8ee22f5a79"
      unitRef="U_USDollarShare">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_76c0819f-9885-4686-b0fe-6c11ff7e48b6"
      id="F_fa0f01d2-e2d9-4a48-b320-a894683d7463">P9Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="-3"
      id="F_3ee216e3-90a2-4f4f-9985-9aebf63763c7"
      unitRef="U_USD">174000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="0"
      id="F_b65ae777-8fe3-483d-bc38-01554bb5c69e"
      unitRef="U_shares">548492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="2"
      id="F_e6b49516-369a-427b-be89-10128e59b592"
      unitRef="U_USDollarShare">10.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="INF"
      id="F_d002da67-a6a6-4fe4-9dfb-847485083178"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="0"
      id="F_20643da0-9b9f-46b4-ad78-80d9041f9d8c"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="INF"
      id="F_45e23751-d147-4d02-926a-971fc924f676"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="0"
      id="F_cbc00b32-7362-491d-a43e-79744afb597a"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="INF"
      id="F_11382e16-7673-4e13-b3e8-d924ff123c29"
      unitRef="U_shares">1421756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="2"
      id="F_407f5d5d-d5b7-4dba-ad71-a0ac58bce60d"
      unitRef="U_USDollarShare">6.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      id="F_bd960da3-2466-4a55-b433-8f1b31b8b807">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_f1c08c81-4dc4-488a-b6cc-2eb8ec5e6d9c"
      unitRef="U_USD">1272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="0"
      id="F_cd1a3ca6-10a6-4d57-b7fa-9ca75de9ed83"
      unitRef="U_shares">1244802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_a328bda7-1e8d-4daf-9641-734e8e1e73a0"
      unitRef="U_USDollarShare">4.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="0"
      id="F_f9518bd7-a7fe-4f43-8e0c-24cd76a38902"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="0"
      id="F_6ddd4bae-0e2e-49c2-8699-ad97eac66c5a"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="INF"
      id="F_b48f97a1-f2b8-4ac9-bb46-b846b385b17d"
      unitRef="U_shares">270810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_470b6504-c895-4d34-b411-cea5c53ac977"
      unitRef="U_USDollarShare">5.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="INF"
      id="F_46033084-b768-43d4-985e-989b78750ef5"
      unitRef="U_shares">2395748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="2"
      id="F_45a76293-c456-4337-8ab7-5d64d4b25c04"
      unitRef="U_USDollarShare">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_5d2e1838-b5a5-4536-8f8d-ac818a0994f9">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_014ecd3f-7794-4b59-8f8d-2a731343238d"
      unitRef="U_USD">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="INF"
      id="F_4838cdf6-fedd-4a84-a84f-4291eb958c35"
      unitRef="U_shares">2395748</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="2"
      id="F_df6c19d0-75b3-443d-9053-76cb4d02ee82"
      unitRef="U_USDollarShare">5.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_e14bdb5d-a5ad-4578-aad2-8b96781f88d3">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_15c52bbe-38ce-486c-863b-ed1f93926fea"
      unitRef="U_USD">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="INF"
      id="F_a135c804-c316-40c7-9087-5ca09932d159"
      unitRef="U_shares">1055847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="2"
      id="F_eebf85e0-631f-48b1-a8ad-7e14cf7a97ef"
      unitRef="U_USDollarShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_e56633a9-34de-4444-ac9c-26c03ebac5b9">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_bfefd9ef-f9d3-41ab-9426-b56973781006"
      unitRef="U_USD">48000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_980e5964-6698-49d6-bacc-0b50e634f80e"
      unitRef="U_shares">736434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="0"
      id="F_385d1da9-d77d-424a-b558-ccb4632c1f0a"
      unitRef="U_shares">319413</lbph:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_0df87d8f-a115-4108-8bb7-17c709362933">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the weighted-average assumptions used for the stock option grants for the years ended December 31, 2022 and 2021, along with the related grant date fair value:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:54.328%;"/&gt;
        &lt;td style="width:2.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.212%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.164%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.123%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Estimated grant date fair value per share of award granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lbph:WeightedAverageStockPrice
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_91c7077d-c0ad-40dd-ad13-5e47270b94cf"
      unitRef="U_USDollarShare">4.61</lbph:WeightedAverageStockPrice>
    <lbph:WeightedAverageStockPrice
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="2"
      id="F_08c9646e-ae5a-4d3f-9d5d-7d9e827f4ab9"
      unitRef="U_USDollarShare">10.90</lbph:WeightedAverageStockPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="4"
      id="F_1732d59c-6b4d-448d-a219-d20cac024dae"
      unitRef="U_pure">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="4"
      id="F_3cf70e06-f879-45ae-8dda-7de82ca39a10"
      unitRef="U_pure">0.0092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="4"
      id="F_997acf53-92a5-40d3-b769-cb74472ff656"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="4"
      id="F_4988c02a-0b47-4732-9fa7-dfcb41915473"
      unitRef="U_pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="4"
      id="F_e7f69852-eaa4-4458-96a0-552be0416f34"
      unitRef="U_pure">0.7528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="4"
      id="F_5e9c99d7-f9e9-4067-b960-3774a0aad412"
      unitRef="U_pure">0.7435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_8f10d4c4-cd9e-4164-8ad8-68984d525952">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      id="F_5e4b543b-0fdb-4cf4-8178-7d4e1c0af8af">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_7e407f7e-bc9f-4656-bfc8-e9397acd07b0"
      unitRef="U_USDollarShare">3.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="2"
      id="F_cd8a9172-96b1-425b-a3f4-76ca390e0f1c"
      unitRef="U_USDollarShare">7.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d"
      decimals="INF"
      id="F_4b94f79f-8446-44a4-b25b-23d9305338ea"
      unitRef="U_shares">348450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d"
      id="F_a9a9c5e3-ef4f-4802-80c2-87d806b359ed">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f3f38f3c-0e13-4518-80d3-a72bb118157d"
      decimals="2"
      id="F_68614df7-df72-4816-a57f-0330dba72da0"
      unitRef="U_USDollarShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_15377397-0660-4b11-971f-4f76f43bcec3"
      decimals="0"
      id="F_44d9735e-3bbd-44a3-b1c3-2ef10fb6f04f"
      unitRef="U_shares">145189</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="C_a6fbcb62-1dd5-47e8-a5f0-a9811e2e702b"
      decimals="INF"
      id="F_21891a3d-b8bf-4f0d-acf7-d0e1b0e9411d"
      unitRef="U_shares">203261</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_15377397-0660-4b11-971f-4f76f43bcec3"
      decimals="-5"
      id="F_9173cf75-2a4f-4a3a-868a-af91458d2e3b"
      unitRef="U_USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_097b4d4d-1926-4a4a-8cc2-59de0584c1ec"
      decimals="-5"
      id="F_4bfb3ca5-7574-4d23-8f42-fa6c4ac4284c"
      unitRef="U_USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8fb4ce3e-c646-46e9-a87a-ec14ffdb12ec"
      decimals="-5"
      id="F_3da1fdd8-b2f0-479f-b23b-04f49f2740c6"
      unitRef="U_USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_2fb8cca4-765e-4f7f-8bfe-c63a94e82264">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the statements of operations and comprehensive loss as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.852%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.692%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.503%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.953%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,016&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_35559507-1949-4257-b3c7-aa78f7685bfb"
      decimals="-3"
      id="F_94a7af3b-4b64-4594-b128-c5f445a8f449"
      unitRef="U_USD">1016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1111d63f-8f4d-4079-a133-a11d3aa8b573"
      decimals="-3"
      id="F_f0a87771-513e-425e-9578-d1a5fd643103"
      unitRef="U_USD">561000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_aa114e73-9d3e-4367-b67d-0376849d85a2"
      decimals="-3"
      id="F_188399a6-49fe-4881-9b59-76484375f60a"
      unitRef="U_USD">1641000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_351fd3fe-1bac-41ec-aaee-86835367c6a7"
      decimals="-3"
      id="F_9a9d4400-9f07-49b7-a5c7-2d40ddf0a6e9"
      unitRef="U_USD">1406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_b3692e3f-d716-47a2-b575-c1d346c84aac"
      unitRef="U_USD">2657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_00ca5002-a5c4-4d07-a4bc-371e98708d6b"
      unitRef="U_USD">1967000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-5"
      id="F_a1c7667d-49b1-48c8-b2cb-1da370b2ceba"
      unitRef="U_USD">5000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_ac1153fc-5d71-469f-9f27-36dd276b78d2">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_092f0ada-7a1d-48a7-a337-44d3d7397cba"
      decimals="INF"
      id="F_a0285ad1-fa85-4f00-8a3a-eba2dc3b8056"
      unitRef="U_shares">353339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lbph:PercentageOfSharesOfCommonStockOutstanding
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="2"
      id="F_35f04fe2-d673-4383-9032-ea47024ea155"
      unitRef="U_pure">0.01</lbph:PercentageOfSharesOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_092f0ada-7a1d-48a7-a337-44d3d7397cba"
      decimals="INF"
      id="F_da1466ec-9c03-4764-903d-c020f4281014"
      unitRef="U_shares">1060017</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage
      contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701"
      decimals="2"
      id="F_bc305bab-7b18-4d79-84c3-f17a1a22e6de"
      unitRef="U_pure">0.15</lbph:EmployeeStockPurchasePlanEligibleEarningsContributionPercentage>
    <lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue
      contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701"
      decimals="2"
      id="F_5e732b4f-3733-47bf-83f6-b542e5bdd542"
      unitRef="U_pure">0.85</lbph:EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue>
    <lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue
      contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701"
      decimals="-3"
      id="F_2359d4e9-9afe-473f-b57e-878421f10347"
      unitRef="U_USD">25000000</lbph:EmployeeStockPurchasePlanMaximumSharesPurchasedValue>
    <lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod
      contextRef="C_7302ab2c-5265-4951-b1f5-570da21cd701"
      id="F_da16ad97-2fab-43a8-a51f-da630ab8f450">P27M</lbph:EmployeeStockPurchasePlanMaximumOfferingPeriod>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_6a5dc78a-b377-4cad-9289-f123d05dec81">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2021, the Company entered into the lease agreement (original lease) for office space located at 4275 Executive Square, Suite 950, La Jolla, California 92037 where it occupies &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,681&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; square feet. The original lease became effective &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and continues through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;June 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Rent payments were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per month for the first year and increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% in July 2022. A security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; was paid in June 2021 and is included in other long-term assets on the balance sheet as of December 31, 2022. In August 2022, the Company and the landlord extended the lease agreement (lease extension) through December 31, 2024. Rent payments under the lease extension are approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;33,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; starting in July 2023 and increase by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% in July 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Previously, the Company leased certain office space in San Diego, California under a month to month lease. Rent payments were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per month.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rent expense totaled approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;394,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;198,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for the years ended December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The below table provides supplemental cash flow information related to leases as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.55%;"/&gt;
        &lt;td style="width:59.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.1%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.51%;"/&gt;
        &lt;td style="width:58.656%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.676%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease commitments are as follows as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:2.791%;"/&gt;
        &lt;td style="width:73.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.676%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2022 and 2021, the Company is not a party to any litigation.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lbph:AreaOfOfficeSpace
      contextRef="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1"
      decimals="INF"
      id="F_e398e0c6-c9bf-4556-90c9-710690a9a5eb"
      unitRef="U_sqft">8681</lbph:AreaOfOfficeSpace>
    <lbph:EffectiveLeaseDate
      contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"
      id="F_806151b3-5c5a-4c10-ae37-79c7c6ce3790">2021-07-01</lbph:EffectiveLeaseDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"
      id="F_c4884558-e294-40be-b499-e283ab585052">2023-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:PaymentsForRent
      contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"
      decimals="0"
      id="F_5dc0a5ab-e2f1-4c5f-b6d2-cac698ff837c"
      unitRef="U_USD">29000</us-gaap:PaymentsForRent>
    <lbph:PercentageOfIncreaseInRent
      contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"
      decimals="3"
      id="F_183b1fe7-22e7-4db7-8f26-5ffbb9856619"
      unitRef="U_pure">0.045</lbph:PercentageOfIncreaseInRent>
    <us-gaap:SecurityDeposit
      contextRef="C_e8b05dde-c63b-4937-aa2c-b60f69be55e1"
      decimals="0"
      id="F_05db194e-c353-4adb-bf94-afab5e442a0b"
      unitRef="U_USD">33000</us-gaap:SecurityDeposit>
    <us-gaap:PaymentsForRent
      contextRef="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3"
      decimals="0"
      id="F_d9e29378-1fc0-438a-b721-59e2fb7fa14b"
      unitRef="U_USD">33000</us-gaap:PaymentsForRent>
    <lbph:PercentageOfIncreaseInRent
      contextRef="C_c3e0656d-aaae-4ab6-a09c-f6158595aae3"
      decimals="3"
      id="F_42ebc7ac-36d1-4a44-ba76-46a2850f4697"
      unitRef="U_pure">0.045</lbph:PercentageOfIncreaseInRent>
    <lbph:PaymentsForRentHistorical
      contextRef="C_a0ce3cee-05d6-48a6-8a3d-b586eb18dbbf"
      decimals="0"
      id="F_54b0bbc2-c59e-4d09-8a83-2aa0aff7ff64"
      unitRef="U_USD">1000</lbph:PaymentsForRentHistorical>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="0"
      id="F_d647d827-dc16-4387-90ca-92a332d0e941"
      unitRef="U_USD">394000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="0"
      id="F_e70a5cde-a4b3-4a76-ba94-568c0ddb987d"
      unitRef="U_USD">198000</us-gaap:OperatingLeasesRentExpenseNet>
    <lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_96b73105-4033-4801-a6ad-f89c3300333a">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The below table provides supplemental cash flow information related to leases as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.55%;"/&gt;
        &lt;td style="width:59.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.48%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.707%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.1%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_b98f572a-a2f7-40cc-80b7-a8e1f4a4d53d"
      unitRef="U_USD">370000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_30c8bfb6-830f-4121-a1a3-f63a5b355f30"
      unitRef="U_USD">181000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_1e5c0956-dca8-4aa2-bc20-b9e21ed72c62"
      unitRef="U_USD">554000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_bb2f9af9-03c2-4a72-be32-7d1ca70749c6"
      unitRef="U_USD">679000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_96225eae-e616-4f54-b0f3-4eae9de352eb">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:3.51%;"/&gt;
        &lt;td style="width:58.656%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.957%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.676%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.202%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;521&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;382&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f35b6184-5aec-4c0f-94d1-41758bf09e5c"
      unitRef="U_USD">736000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_b90954c8-2190-4c66-809f-321d4959e120"
      unitRef="U_USD">521000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b82f0d33-b231-4dbd-9e36-607ac7573f05"
      unitRef="U_USD">358000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_0ccd01ea-d40b-42d2-ac09-a4454d17d0ff"
      unitRef="U_USD">339000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_2a04ae07-8fc2-4942-8b1a-c0fd4c2ec144"
      unitRef="U_USD">382000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_3d69dedf-bcf3-49a1-89eb-9e1554bbe7f8"
      unitRef="U_USD">185000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_da8cb555-cf2b-4677-add9-67552f9fe6d3"
      unitRef="U_USD">740000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_cd581439-a149-45d0-b5cf-31f4f22eb21b"
      unitRef="U_USD">524000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      id="F_35b4a6ca-678a-4825-bc22-928d3f1531a5">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      id="F_b5c211ce-ec8c-48cb-b0c0-bdc9222e5611">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="3"
      id="F_8c6f730d-666f-471c-afd4-46696b74401a"
      unitRef="U_pure">0.098</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="3"
      id="F_365ffbae-4b4c-4213-b299-6481e1202ade"
      unitRef="U_pure">0.090</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_bf628488-ddad-440c-9803-5e2960747efa">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum lease commitments are as follows as of December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:2.791%;"/&gt;
        &lt;td style="width:73.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:21.676%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_5087d7b0-1241-4541-a147-7e9f2bd089f7"
      unitRef="U_USD">384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f262606a-e725-49ff-a56a-2e40de919f17"
      unitRef="U_USD">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_49ceb6e2-b5d6-4e2f-bbdc-efd69e2627da"
      unitRef="U_USD">784000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_1a232378-2f76-4112-b7c8-4f4f5606acae"
      unitRef="U_USD">44000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_56522d14-af8c-41ce-957a-a86c576f57b2"
      unitRef="U_USD">740000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_3f9c41df-d6c9-4e4c-a166-9dc03e69e8fe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 10. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the net loss attributable to stockholders before benefit for income taxes by region for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The benefit for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Benefit for income taxes at statutory federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company's net deferred taxes were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and California net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and California research and development carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed asset basis difference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The deferred income tax assets have been fully offset by a valuation allowance, as realization is dependent on future earnings, if any, the timing and amount of which are uncertain. The net valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. We will continue to assess the need for a valuation allowance on our deferred tax assets by evaluating both positive and negative evidence that may exist.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we had federal net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that will not expire and California net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million that will begin to expire in 2040. As of December 31, 2022, we also had federal and California research and development tax credit carryforwards, net of reserves, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million respectively. Federal credit carryforwards will begin to expire after 2040 unless previously utilized. The California research and development credit carries forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sections 382 and 383 of the IRC limit the utilization of tax attribute carryforwards that arise prior to certain cumulative changes in a corporation's ownership. We have not completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with authoritative guidance, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% likelihood of being sustained.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions from tax positions taken in the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions from tax positions taken in prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions from tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Gross unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022. Due to the existence of the valuation allowance, future changes in unrecognized tax benefits will have no impact on our effective tax rate. We do not anticipate that there will be a substantial change in unrecognized tax benefits within the next 12 months. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Because we have incurred net losses since our inception, we did not have any accrued interest or penalties included in our balance sheet as of December 31, 2022 and did not recognize any interest and/or penalties in our statements of operations and comprehensive loss for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are subject to income taxation in the United States at the Federal and state levels. All tax years are subject to examination by US and California tax authorities due to the carryforward of unutilized net operating losses and tax credits. To our knowledge, we are not currently under examination by any taxing authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_09051c03-2e82-4be0-87eb-1aa05ecf48aa">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the net loss attributable to stockholders before benefit for income taxes by region for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_a3848440-17b9-4c67-8bd5-7b38a8061497"
      unitRef="U_USD">-43945000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_252e9f2a-5f4b-4bb0-8fc1-2779c6e2d73b"
      unitRef="U_USD">-27797000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_5fd3e412-382a-4b93-b6bc-ac9bfed0593d"
      unitRef="U_USD">-43945000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_7ea4347e-b732-49c9-a65f-f7981647110a"
      unitRef="U_USD">-27797000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_0d3131e3-8c3f-4441-a78e-8e3dbd6c2040">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The benefit for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Benefit for income taxes at statutory federal rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent differences and other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;679&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,437&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_e6396088-6f91-4a47-ad19-54e11061a999"
      unitRef="U_USD">-9229000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_54904210-fdb5-4c8d-9ea0-4a040f8efd3a"
      unitRef="U_USD">-5855000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <lbph:PermanentItems
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_dcfe9468-42b2-49f2-95d9-500a8b2e9161"
      unitRef="U_USD">524000</lbph:PermanentItems>
    <lbph:PermanentItems
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_a48f0a5a-9692-428f-ace4-a17adff06d89"
      unitRef="U_USD">97000</lbph:PermanentItems>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_40ee81f7-3e38-4ace-9a21-514fab419b51"
      unitRef="U_USD">1688000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_9a8cf084-3b5d-430b-aa0b-c0660e7c9f74"
      unitRef="U_USD">679000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_71c625db-99d9-4bcc-83bf-48b1c2e563da"
      unitRef="U_USD">10393000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_54c853f4-25f5-42a7-8832-f39ff89908ff"
      unitRef="U_USD">6437000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_bca2741e-f55e-44dd-b63f-14104000d766"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_a97e289f-457c-4ece-84dd-0f0b1ed2d098"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_3041303a-57f9-4bfb-ab27-128793c10ae4">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of the Company's net deferred taxes were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and California net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal and California research and development carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 174 capitalized R&amp;amp;D expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,970&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed asset basis difference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_971ae643-6dc2-4ffc-ad89-c839321b5eab"
      unitRef="U_USD">8512000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_71f45fb4-b411-49e3-b33a-e287ac8f32f8"
      unitRef="U_USD">6376000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_df4e8626-dfe4-4345-a40e-fab827ef62f2"
      unitRef="U_USD">2528000</lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal>
    <lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_4ec18208-6c0c-45d3-bae6-4862e72af406"
      unitRef="U_USD">840000</lbph:DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_7cc22a17-bc2c-4804-8990-0af4a4221f59"
      unitRef="U_USD">404000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_deab6bdf-e692-4682-8e72-8f50efb108b7"
      unitRef="U_USD">343000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <lbph:DeferredTaxAssetsCarryforwardsLeaseLiability
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f0d5fdea-0f5e-46b7-b8d4-190ead31cbbf"
      unitRef="U_USD">155000</lbph:DeferredTaxAssetsCarryforwardsLeaseLiability>
    <lbph:DeferredTaxAssetsCarryforwardsLeaseLiability
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_afb36e4c-c83e-416c-84d3-8863b3299f72"
      unitRef="U_USD">110000</lbph:DeferredTaxAssetsCarryforwardsLeaseLiability>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b0250b5d-f012-44f9-b7de-6da9340ec8ac"
      unitRef="U_USD">6318000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_e5697be6-9f2e-4322-93a0-a95f521b404d"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_3863bbbd-d4e6-40f3-9187-b267794454f0"
      unitRef="U_USD">491000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_999e8249-03ac-4b97-82c6-0c9904ae8893"
      unitRef="U_USD">301000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_66fd2420-3240-4233-bd52-04018854790a"
      unitRef="U_USD">18408000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_bf56dd2c-b791-45c3-97e2-144ac2872497"
      unitRef="U_USD">7970000</us-gaap:DeferredTaxAssetsGross>
    <lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f62f7437-1ee8-419b-8131-475982172b01"
      unitRef="U_USD">-155000</lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset>
    <lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_b68a7b89-2663-46fa-874a-4b79b81b0a4c"
      unitRef="U_USD">-109000</lbph:DeferredTaxAssetsCarryforwardsRightOfUseAsset>
    <lbph:FixedAssetBasisDifference
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_b3b3a59f-9096-4e03-acba-326cbec6dd17"
      unitRef="U_USD">-2000</lbph:FixedAssetBasisDifference>
    <lbph:FixedAssetBasisDifference
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_4ae65d6e-869c-40bb-a226-b819753e31a0"
      unitRef="U_USD">-3000</lbph:FixedAssetBasisDifference>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_0b892086-45b5-4769-80c4-9f5d6ef1eaad"
      unitRef="U_USD">157000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_4bab4f13-ef32-4fd2-84e2-0a300e1eb565"
      unitRef="U_USD">112000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_0dab0ca2-6008-4fa7-9561-f58c7bebbe0d"
      unitRef="U_USD">18251000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_d3cb63a0-b2ce-49c6-b878-1ca520bb799d"
      unitRef="U_USD">7858000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_527a9334-2d7d-46e6-ab9b-785a0b412813"
      unitRef="U_USD">18251000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_dba83398-654d-493a-ac49-2cdfe655e3de"
      unitRef="U_USD">7858000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <lbph:TaxDeferredAssetsNet
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_8ff16f34-3e12-4de4-875d-6d7dbaafd840"
      unitRef="U_USD">0</lbph:TaxDeferredAssetsNet>
    <lbph:TaxDeferredAssetsNet
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_3be09535-f6a9-4faf-aaac-6ceb0f81d620"
      unitRef="U_USD">0</lbph:TaxDeferredAssetsNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-5"
      id="F_467b5286-99da-40cc-9484-6e536caba34b"
      unitRef="U_USD">10400000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f"
      decimals="-5"
      id="F_96f54c0e-3243-48cb-bcb0-ffb76b62ceda"
      unitRef="U_USD">40500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_db5b19d0-862e-49e9-b69a-8b019f65a709"
      decimals="-5"
      id="F_7a812b6f-6d43-40e7-b12a-9410585369d3"
      unitRef="U_USD">1600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ff69ec20-3f4b-4a85-a2bb-0b076ba7b55f"
      decimals="-5"
      id="F_30d07590-d41d-4afc-85e6-8d34bd95b650"
      unitRef="U_USD">1900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_db5b19d0-862e-49e9-b69a-8b019f65a709"
      decimals="-5"
      id="F_36d5f79d-397a-4a69-aeb6-5a8f261d4f9b"
      unitRef="U_USD">800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <lbph:PercentageOfUncertainTaxPositionsNotRecognized
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_0c2e3a6b-c0a3-4b7b-8d97-e08e181fda2a"
      unitRef="U_pure">0.50</lbph:PercentageOfUncertainTaxPositionsNotRecognized>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_39db5a45-b0e4-4f8c-8d6d-21f97d0c295c">&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table reconciles the beginning and ending amounts of unrecognized tax benefits for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.508%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.475000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions from tax positions taken in the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions from tax positions taken in prior year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions from tax positions taken in prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#160;Gross unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;703&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_96dc5034-e439-4c46-89e2-b06af8b99eac"
      unitRef="U_USD">345000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e"
      decimals="-3"
      id="F_4c5d4995-5363-4aff-9820-80b2599f50d0"
      unitRef="U_USD">31000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_0ce57072-18ac-47f0-aad9-effc60a3fed6"
      unitRef="U_USD">359000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_1d5d966e-3920-4d3a-868e-0590ac7d2949"
      unitRef="U_USD">174000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_394b9ec8-8792-4898-9293-7af977187447"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_c6c9a546-7472-487b-a673-0c4dabcee4a7"
      unitRef="U_USD">140000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_4c55829b-96b0-4a00-b94f-cc707cffe91b"
      unitRef="U_USD">1000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_0a1f4102-a010-4105-964c-01b01645be73"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-3"
      id="F_f1e2815a-530f-4504-8884-85503b89cd8c"
      unitRef="U_USD">703000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_40404be9-80f7-4dc1-b501-800029d9ebce"
      decimals="-3"
      id="F_b04fe307-5b18-421c-9573-900c7a681705"
      unitRef="U_USD">345000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_149cb0bc-9ebd-4628-bcf6-d7051edc3551"
      decimals="-5"
      id="F_6e201100-e4f3-4e60-968f-7e33313d356b"
      unitRef="U_USD">700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PostemploymentBenefitsDisclosureTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_b01c8c80-5a48-4c8e-a45b-7c0b2e440d68">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 11. Employment Benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:2.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.315%;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective in June 2021, the Company established a 401(k) salary deferral plan for its employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company provides a safe harbor contribution of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the employee's compensation, not to exceed eligible limits, and subject to employee participation. For the years ended December 31, 2022 and 2021, the Company incurred approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;265,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively, in expenses related to the safe harbor contribution.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 12. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2023, we raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in a follow-on public offering. We issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock which included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. We raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PostemploymentBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="2"
      id="F_dc3efedc-b21f-4ca5-ba9d-338e7c99dfd5"
      unitRef="U_pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      decimals="-3"
      id="F_dc444a1b-ae32-41fd-885c-e1124deca3ce"
      unitRef="U_USD">265000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="C_5caf6dc0-91c0-4b3b-ba66-cc1f5bb731bc"
      decimals="-3"
      id="F_4fedab0d-3a2e-4be5-90c3-11458aef7b34"
      unitRef="U_USD">119000000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d"
      id="F_afb8465f-7a43-4029-b8e3-d0e8d3dcaa22">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Note 12. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.133%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2023, we raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in a follow-on public offering. We issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock which included &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock issued pursuant to the over-allotment option granted to the underwriters to purchase additional shares of common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. We raised $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds from the follow-on public offering after deducting underwriters' commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and issuance costs of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b"
      decimals="-5"
      id="F_5827af8f-81a8-4d78-97ae-2a19f1325ed0"
      unitRef="U_USD">23000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <lbph:NumberOfCommonStockSharesIssuedAndSold
      contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12"
      decimals="0"
      id="F_4eceeb5c-0bf3-4000-91e4-98d51e3ca3da"
      unitRef="U_shares">5750000</lbph:NumberOfCommonStockSharesIssuedAndSold>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12"
      decimals="INF"
      id="F_613fbebb-65b7-4789-a540-2d8cf2b94bf0"
      unitRef="U_shares">750000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12"
      decimals="2"
      id="F_21b270e1-11fc-4dec-b747-a2c5a141eae4"
      unitRef="U_USDollarShare">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b"
      decimals="-5"
      id="F_2d3f4506-64f3-49db-aa45-dbb327fa585c"
      unitRef="U_USD">21200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:CommonStockDiscountOnShares
      contextRef="C_7eb219cb-8457-4d8a-97f7-e3b40dbb0a12"
      decimals="-5"
      id="F_c1b41d26-d412-473e-a8ea-19ca8b046c72"
      unitRef="U_USD">1400000</us-gaap:CommonStockDiscountOnShares>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1a00012b-31e0-4fbb-92a1-83ef81b5033b"
      decimals="-5"
      id="F_2aee2b5b-8584-49d0-8d18-5b8da360d2c3"
      unitRef="U_USD">400000</us-gaap:PaymentsOfStockIssuanceCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 2C>CG/M@V0;/1&], GSE;XM8 2F7 G _RO&Y.%!?: ?JA?_ U!+ P04
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M@6 M26'K8(!:YIO 6C[#VO]>U(UG34O>;(BTCJ:E% Y/O'&GHY@3]M4**"T
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M#[W<V2(_:8P:O:"%V41YD4<6IGD\[P.WA<(HG T [U@Y]-/R$_ Z<;THIPX
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MV;5PM!K2Z .;RKNAG#84E/O@\%9C7[BX<PMI])\RNLCDXDIZ[86=BZE37IG
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M&W8:>;7L((2\7Q,6FFPZH 3%(XWF/]Z. G.\!H<Q8B:0?L# ]0:Q(PY\-S(
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MI@%XOW*(NO2#%NB_2W_Y7U!+ P04    "  4@F)6G<ACLR0&   6#P  &
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MT,UTURRLJOQ$M5"6YC/_6M! C-H=H/VEHJ]CNW &-B/VY&]02P,$%     @
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M QQ_U,=96.X"!06%67@4<[:G%O0MUZU#W<QZIRX(RM2KC'T0 RD7&ONHOKI
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MJ(?B,-\KYT"+O(Y>69@BOK6UH]!LG?2]D+9SZAW_UO#>/3S7,*%!]&QX[.R
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MWN"N]?UMW"^B:],-N'01]VGZN<8?&/82@/>U@W^W"RFP_TNT^!=02P,$%
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MH<TH<7A#!3PX[:1^7VB"/9E#S?,S@VML*U#BW27*T:C!W,H3=RQ,BB'I:=C
M;U TJ5J'VQ#1L9^&8^F=S05E^_474G"N9(3E])KGU*[O9(F%@N0B!:.LX(J.
M M3"4 XHN;;XM4'5&(&5LW>0F8T8(.=3PMGOU=.SV84J;5&D//[W:OYB]CS]
M1!*GLU+=6D"GR\BFN+&A)NJ(LQ(=?)@?=,M>:WA^.'WB'M-KUM2;7H]IU#V_
MCA3"D_J8U8Y. <9/)J.VO7!4;4,7.3(-O.U[/; 8/R2-O)-<ATDQ0@/F/G #
MA"#P&O%</>9G]/')(&7ZP_@VN=O4'='Y :)S(4K^^MXL?$.M!_XY5=S=1@<9
M%SI$YGN&#M8G<]I[&'.S)B,?IMR"W)Q[E$-':@]+ 1W;X8P1/UK6VE<H&]M"
M N*KI='2?(%]=WD!K^BY<1NC. T,R)LZ#V-LG:GWSB^-I6:#$(YE#:4;S@^!
M6.#7(9OPPW2V:^QQ5Z1C!\=DY^NW0_D0J6.9<L"5IS9+ETR]+C06W&30 I5[
MFX@=-J,72I?#]R4B#'K1MD+\DVPX-97Z;<9^-X5HH>1Q $UJ$>^21KC967"B
MR4Q/N.DS75*L;K-"RH\G,$."* B<,\%)VZ?.V"*IPH@TA?V#3G_:.?WI?]Z0
M^:TT_M^1^2]U9.;=N&M^<#YU24GK7R@OO\8Y;];0QJBBOV+(]9"R O C9%=X
MP*7 AG('?@ 5(3')8NVPV(G-)R=M%^BZ]G;1U*Q)R0E0Z@UQ-&ITRW-8DT\U
MH FB5%7#,9*<EK9,B6R[GI,QI&"\:RZ93P=)$\ZXR/923ZG%UWXG/K=%PVC0
M5= S]99^Q+'VG%N2Z?_5J<G8?N$$ \FD!"3!^HVM,C/(L-8:IM]Q3SU]@N:4
MTL54F^V$X'_"94XF]=!^23W@VYO8ERBC3XE\%G3!(*5UX1>/1KWX?@G+8! M
ML=]FW\^8YOG5UC4HTA<4&&L[33M]^^COR--DUCU(TQYQFD:Q]]''-+5T7=M@
M<-+3R=,7YY-G9\_5?')V.I\\.[]X] G1 8&%6(KBX(B-P(,H1+8$0VVXXL<7
MSI].OU/SL_/)_/F+1S^X&@C9)WM^<3%Y<79^J,B>=R/I^>&)\@=I9?R@O^RI
MX'[]\@%6ICYHS!?XK9K?XE@J#1RJ?@<SV5WLD$S&XGC,8)*F<[,T5.P1V7WS
MW63_;0"6(24O(6@ >1I^LJ/%46>L&.Z,E SWS6UL5)S2-)2 H3W KV&/+#(W
ME!1 K&WV$QL)R99I7BI,+DR])9X.CJQINY;"GGTEHS*5EJ0$*WR<92N#[5 #
M]RN70:$]8"A5YUDLD#QDZ$/T\$B)N$#$UM5*)L7M9CCMKY&1#?W4U5;)F.[G
MH+J%!K$6/ATG-%+9]8VS)1@8(\;8B(4HE<34V+L_&.R-#$TP+>^4@E-+M+"W
MAILYR(<(M&3DT/7'/K0I"G=H=6L%C&.3?M]U.!7I4B.9+=Y)<E\9&AO@B^'D
M,QN,"*/-BW)T(<;^Q0;.G7!DB52FI!ZVW_45S V'G^Y[#K\O6IC0]^D&=4@E
MN7'J$<>20ZX 8#](G/N';=X$&2S[QVS=8&0*V\%UC*E1D)QOC2EO<"-A.*>6
M[BEIG8S Y^U%DX'094>^N?*@PRN#W/N;JBY+I<1RJUD)XC9"#:\W,?ARP.,K
M<O?1\:&=4FG7@)BT:FB_-%4.#P!#JWKKI@@CF[93M*4V/?*-Q_,G>\2--[@O
MA+A(\#5JODDCP^VW%A:YH(HV$'-[$*PVV5HZ625\M6Y_;X?C9"J/3Y]$S*$!
M^' ;WKVDRXZTC!B<"H-38G!*#/9# W50 V5: XWV7)X;1=JOJ&83W3-+A)NF
M,DL;SYN$P5(X/R&D81M.PAFXM&I0!"E8N[2C8!!U'*&TO;_4\V63:7!0FH?L
MQ:6VJN24#V!6,!JV1!R,HH>+/>YEXM(!)3V*[2P9A_ M)<;2T2T&<X)(ZC[_
M;;P^6-9TEW3FOW2OIC]XH#)D-!4Y2&2\K'E(6;UY..6P#"-LP7& U@6L..&(
M-89. 4<N,'E=A70OJNNP]BY-9=9G34GY.,5+7E2A4'7;BE)2+D0'#8CFP #'
M[;L]<W#>,N\N=<P/7\GX)!C=OU/I7>4(?/:.8/]#DA0(_]Q4U-B:7T@;\?W5
MS>N4&%_=?%9_=3-^.IT_G?3N6'WHW;&:IGM8?Q%!3>(0DSITO42IZ_4NT@4A
MCH"V)'\6K*4?NOM6G> +IP<J7HY>]N*[.B"^Y\)4MWPP61 ,H+,.TMW8RROC
MW(VB?YMK#?DCX.RVC#%0[@WU[U2F+G?7QM]S$S"-6Y%ZY+9C'9897,4QF!NY
MS8:HICZ-R720"V;PIE5CY6[I C^7*1<D?TN)98(\</%G77'?5?KA3X>0F#O3
MWL%*M^:XO]O6>Y9:LV"(^H?0.Z?NNKURF*Z64F>I'K^Y>A##NMLR\\-W7.@.
MH,CI<XK6!*>C3O-5E,A7VJH4'O%BHMY\_-N'MU/ZA!+>T>B#1Y)R9=#!T_2=
M]0T 9JOIZ)Y&UUWS#N_]V #G0 <8KSDK;;O7L:G_H_,PHS\!DQ#%/O:L%G4W
M,CT8#T%5XD/&Q=!;;DJ;M?<$%'/!8QCY*P32$S>AYR<GBJ'!VR$.TJK/%4_T
M;TA1T4F2,J/>TT[=A(=VY+0D1NG87C<Q7',ZS[C/34(*ACROD4N&+K.FWJ6L
MC6A*!AOGY0=(RWM\O[%W/S"WP3==PX#.M"K<@KP-BUVYX_L:6T-Y?=<XC,ES
MIC>VYOM-=(&(PC+D).+<DE)FZCIU2Z)8PKWI63>)22W)&-8GW'&@.$^.Q?<T
M.:68]*J >(U:[G;J+%5C\6HA ESN?)@,C@C/]K'3D;)3OL%<;@JW,R9$?E0J
M]8E;#V\M)O<E11<UD&WL.)-/-YY1]M E&QIF"EBQ\PX'IZ&&^9 EM;_4! )A
M(N/9*8UG=_<&IH1C17] VA4IDYBH)CGGEDJHB#QK=HI,1J0QE%-G9]=>;F8
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M!]K_?N<DI*U$T5Z(S[[[[OOLNV.RT^;19H@.GG*I[#3(G"O&86AYACFS9[I
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MW!B%IP+YS/@FE\J\ON6JA$_5BFN##C<:CF[9I.#Z^'1D4 B1CJ8MX$4#Z!\
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MH<L5$>#Y7$JS^2 !W=-Y_ ]02P,$%     @ %()B5A!M9+6P @  ^P4  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&ULA91M3]LP$,??]U.< D(@(9*X
M:2FEC50>IDT:&@*VO9CVPDTNC45B9[9#NV^_<]*F12K=F_CI[N?_^7(W62K]
M:G)$"ZNRD&;JY=968]\W28XE-Q>J0DDGF=(EM[34"]]4&GG:.)6%SX)@Z)=<
M2"^>-'N/.IZHVA9"XJ,&4Y<EUW]OL%#+J1=ZFXTGL<BMV_#C2<47^(SV>_6H
M:>5WE%24*(U0$C1F4V\6CF\B9]\8_!"X-#MS<)',E7IUBR_IU N<("PPL8[
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MTVL\Z'Q!P]CHU@G(G+(W?5@%2QK^75<_$.*,MM]%Z 5)X@WBS+F($LC\Q+F
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M,I-NNNGFPZJYZV#'RE(_[%YG] ,$-1O0_$0IN_W@#=J?-,/_ 5!+ P04
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MBH4M<P$T,DYI8GN.$]@I99DU[)NQJ1CV>:$2EL%4$%FD*17_QI#PU<!RK?7
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M"R"T <[/.5?KCEZ@_OT8_@=02P,$%     @ %()B5NZC!=5. @  3@4  !D
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M5&TO*E6E[5ZL]L*$@5AU8M8VT.[3[SB!E%.CJD*] 1]F)O]\MD?360KYK%(
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M!I'-NV(QW.ND6JN$UU<_ZS-LC9+JMA9%:FZ/I&;<V-)$7/FNEJ.AS%50YG8
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M<(Q]+B&0^'K&*QS'$DG$\:T$-:HVI>/A]2OZQ[SSHC,;Q/"*Q']% 0\7QM0
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M,)4&XO<M(?SU1C90_7O!\G]02P,$%     @ %()B5H *-=*N @  X08  !D
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MZ/0#'JYK0ZTW5E7>DV;*HL/Y98G?(- N 9_/E;+;C3N@_:IE/P%02P,$%
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MDB@:LV*B^-+T-C.NL%,RPQB;61#: +_/.5>;B=Z@:H_[?P!02P,$%     @
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M+%36@+[G4IKGB0W0/ML6_P!02P,$%     @ %()B5O>N=C)F P  ,PP  !D
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MN+W&\[?N&_:R]YFJ)1,:!2P0%EP-L6]5<W]J)D96[@KR( U>:-QPA7=.4#8
MWR^D-$\3>ZOI;K'9'U!+ P04    "  4@F)6^;;+YL "  !#"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6RM5EU/VS 4_2M7&9I *B1-TA:Q-A(4
MH4T"K:*P/4Q[<)/;UL(?F>VT\.]G)R$K-!14[:6Q'9]SSSGQ1X=KJ1[T$M'
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M <H:F/VME/@RL0=T_RSI/U!+ P04    "  4@F)6+=>2H]H#   L#0  &0
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M[:\CQFU"7E#W&^K^4>II%#%S%RD22Y$1C=RY4/60IH_ S:;7">!!EA*X)L]
M91=_]9Q!FZW_?H=_/\8=]KH-#!H#@U<PD$LFY$'TP1Z6LP.^'^'VG&[P80,^
M/ I^!U$1_@MYYXTSW ?;0=^/.  ^:L!'_[O1ZQOVR"X?[>W@H>/O$._'M$]"
MQ6RWR@7>]JNRBBH2FJN]NC^;T:903\OZM#,^PP)>U=O?,E7UOZ$2CZTB*<0H
MZ5P,D4A6%;7J:)&716DI-):XLIG@1PA($X#SL1!ZVS$/:#YK@E]02P,$%
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M&192[&B&"I9DC7!-Y$I(F)DW+^EJ:[^NKBY4U&'@N&T@[9*@%PQB?]>V=U+
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M!1(#4P/D[VM*Q7-#35 7,F=_ U!+ P04    "  4@F)6R_ 2V3(#  #P$@
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M,<S;((@,4,X Y7A6")FX#Y8GS,GL%1YIEB5)FF(S.ID$'4RP>4M3^(;5,&_
MP/) IM^;:WRU\0IYO@ZP-7VN0K"1XI6(C12?:T#"\P:,+ NO-I8'&-@J8+4#
M^<-YH*;"G"2!5<6\86\PCF09AD MAFLT39'92>$37A_L+4F2+ LC@(4=) F&
MP-N((Y@#\( A2>+VP8/]*-[L4_'V-Z[Q+U!+ P04    "  4@F)6EXJ[',
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MJFN:6[?O0?ZA>+7_BF?_!=*7?P!02P,$%     @ %()B5KP!UL'@ 0  ["
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MRU^6WSM'-]0%YP _-SQ^ 5!+ P04    "  4@F)6%-1QY- !  "M(   $P
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M<' N>&UL4$L! A0#%     @ %()B5IPG:,'N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ %()B5IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  4@F)6I6Z/JHX(  "N-   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ %()B5@M:B-FE
M!0  W1@  !@              ("!T1   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( !2"8E8_#-]00P,  *X-   8              "
M@:P6  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  4@F)6
M_41@^S,$  !@#P  &               @($E&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ %()B5LAE3./S!@  I#0  !@
M     ("!CAX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M !2"8E:F%=@W6@8  (@;   8              " @;<E  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  4@F)62\;KYCH+  "^&P  &
M            @(%'+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ %()B5@K@T3%P$0  HRX  !@              ("!MS<  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !2"8E:=R&.S) 8  !8/
M   8              " @5U)  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  4@F)6:T9:&XD&  #E$0  &0              @(&W3P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !2"8E:6$5_8
MJ@(   8&   9              " @7=6  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ %()B5LUQ3I)R!   ;@L  !D
M ("!6%D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  4
M@F)6AV("7]<'  "2$P  &0              @($!7@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !2"8E947/F_CQ$  "<S   9
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M970Q."YX;6Q02P$"% ,4    "  4@F)6> []CV42  #\-@  &0
M    @(&]C@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M !2"8E:B($ . 0,  $\&   9              " @5FA  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ %()B5M"EYTVZ P  [P@  !D
M             ("!D:0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  4@F)6" !^$ 0%  !&#P  &0              @(&"J   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !2"8E80;62UL (
M /L%   9              " @;VM  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ %()B5@CJ3[ZS @  N@4  !D              ("!
MI+   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  4@F)6
MW8N/ZDP%  #>#   &0              @(&.LP  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( !2"8E8+$,-8# 0  (0*   9
M      " @1&Y  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ %()B5GQI %0[!0  'PX  !D              ("!5+T  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  4@F)6+AJY2#4(  #^-@
M&0              @('&P@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( !2"8E9=97[(QP,  'D/   9              " @3++  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ %()B5KL4\9A
M P  B@P  !D              ("!,,\  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  4@F)6[J,%U4X"  !.!0  &0
M@(&GT@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !2"
M8E9S3'L@$@<  /T_   9              " @2S5  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ %()B5HDQY.E&!   JA0  !D
M         ("!==P  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  4@F)6D9Z(?UH"  !-!0  &0              @('RX   >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !2"8E;HA+^J-P,  ,T+
M   9              " @8/C  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ %()B5DT;+!(=!@  +2T  !D              ("!\>8
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  4@F)6$=+]
M_MD"  #?"   &0              @(%%[0  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( !2"8E8-_H+7%@4  &H@   9
M  " @57P  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M%()B5H *-=*N @  X08  !D              ("!HO4  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  4@F)6^^]_@DH#   J"P  &0
M            @(&'^   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( !2"8E:]QIG<H D  $A4   9              " @0C\  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ %()B5C7.=CR3!0
MJ!\  !D              ("!WP4! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  4@F)60><OQVP#  #""0  &0              @(&I
M"P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !2"8E;W
MKG8R9@,  #,,   9              " @4P/ 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ %()B5M6<ELTD!   >Q,  !D
M     ("!Z1(! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !2"8E;K@QDZ,0,  +\(   9              "
M@9XC 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ %()B
M5BW7DJ/: P  + T  !D              ("!!B<! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    "  4@F)6N@?SW ,#  #B"   &0
M        @($7*P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( !2"8E85'SM\^P,  *X2   9              " @5$N 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ %()B5D,$F@JA @  M08
M !D              ("!@S(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    "  4@F)69DCGAD8$  #4%   &0              @(%;-0$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !2"8E;+\!+9
M,@,  / 2   -              "  =@Y 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ %()B5I>*NQS     $P(   L              ( !-3T! %]R96QS
M+RYR96QS4$L! A0#%     @ %()B5ED=JH.%!   !24   \
M ( !'CX! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !2"8E:\ =;!X $
M .P@   :              "  =!" 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( !2"8E84U''DT $  *T@   3              "
M >A$ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     _ #\ ,!$  .E& 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>285</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure -  Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments</Role>
      <ShortName>Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Accrued Other Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses</Role>
      <ShortName>Accrued Other Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits</Role>
      <ShortName>Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables</Role>
      <ShortName>Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Accrued Other Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables</Role>
      <ShortName>Accrued Other Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Fair Value Measurements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Summary of Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Short-Term Investments (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Short-Term Investments (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails</Role>
      <ShortName>Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Short-Term Investments - schedule of short term investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails</Role>
      <ShortName>Short-Term Investments - schedule of short term investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails</Role>
      <ShortName>Accrued Other Expenses - Summary of Accrued Other Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails</Role>
      <ShortName>Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper</Role>
      <ShortName>Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Employment Benefits - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails</Role>
      <ShortName>Employment Benefits - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lbph-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Subsequent Events (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  lbph-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="lbph-20221231.htm">lbph-20221231.htm</File>
    <File>lbph-20221231.xsd</File>
    <File>lbph-20221231_cal.xml</File>
    <File>lbph-20221231_def.xml</File>
    <File>lbph-20221231_lab.xml</File>
    <File>lbph-20221231_pre.xml</File>
    <File>lbph-ex23_1.htm</File>
    <File>lbph-ex31_1.htm</File>
    <File>lbph-ex31_2.htm</File>
    <File>lbph-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img8619836_0.jpg</File>
    <File>img8619836_1.jpg</File>
    <File>img8619836_2.jpg</File>
    <File>img8619836_3.jpg</File>
    <File>img8619836_4.jpg</File>
    <File>img8619836_5.jpg</File>
    <File>img8619836_6.jpg</File>
    <File>img8619836_7.jpg</File>
    <File>img8619836_8.jpg</File>
    <File>img8619836_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="568">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lbph-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 568,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 121,
   "dts": {
    "calculationLink": {
     "local": [
      "lbph-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lbph-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lbph-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lbph-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lbph-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lbph-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 473,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 8
   },
   "keyCustom": 38,
   "keyStandard": 247,
   "memberCustom": 7,
   "memberStandard": 27,
   "nsprefix": "lbph",
   "nsuri": "http://www.longboardpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Short-Term Investments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments",
     "shortName": "Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Accrued Other Expenses",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses",
     "shortName": "Accrued Other Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Agreements with Arena Pharmaceuticals, Inc.",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Employment Benefits",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits",
     "shortName": "Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Short-Term Investments (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables",
     "shortName": "Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Accrued Other Expenses (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables",
     "shortName": "Accrued Other Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Agreements with Arena Pharmaceuticals, Inc (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_f44d2d7b-ea07-459b-a1e9-f5acf733498b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Organization and Basis of Presentation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Organization and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_f44d2d7b-ea07-459b-a1e9-f5acf733498b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentBasisOfValuation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentBasisOfValuation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Fair Value Measurements (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
     "shortName": "Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_cac615bb-7672-44e1-90ae-9ae47c52b057",
      "decimals": "-3",
      "lang": null,
      "name": "lbph:ShortTermInvestmentsAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Short-Term Investments - Summary of Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails",
     "shortName": "Short-Term Investments - Summary of Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Short-Term Investments (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
     "shortName": "Short-Term Investments (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
     "shortName": "Short-Term Investments - Summary of Maturity of the Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Securities",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Short-Term Investments - schedule of short term investment (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
     "shortName": "Short-Term Investments - schedule of short term investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "div",
       "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Securities",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Accrued Other Expenses - Summary of Accrued Other Expenses (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails",
     "shortName": "Accrued Other Expenses - Summary of Accrued Other Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
     "shortName": "Convertible Preferred Stock and Stockholders' Equity (Deficit) - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "lbph:TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_f36635ab-29c5-4e22-a6be-fcbab49127d7",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_e8180cb1-d339-43ce-8382-ffb65f743b36",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:RenewOfSuccessiveAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc. - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_e8180cb1-d339-43ce-8382-ffb65f743b36",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lbph:RenewOfSuccessiveAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
     "shortName": "Agreements with Arena Pharmaceuticals, Inc - Schedule of Services Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_e8180cb1-d339-43ce-8382-ffb65f743b36",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_40404be9-80f7-4dc1-b501-800029d9ebce",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lbph:WeightedAverageStockPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
     "shortName": "Stock-Based Compensation - Summary of Weighted Average Grant-Date Fair Values And Weighted Average Assumptions Used to Calculate Fair Value of Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lbph:WeightedAverageStockPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper",
     "shortName": "Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_e8b05dde-c63b-4937-aa2c-b60f69be55e1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_e8b05dde-c63b-4937-aa2c-b60f69be55e1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SecurityDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lbph:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails",
     "shortName": "Income Taxes - Net loss Attributable To Stockholders Before Benefit for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_ae4e10a4-7b24-48b8-9b2e-e9fc787a4e9e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Provision For Income Taxes and Income Taxes Computed U.S. Federal Statutory Corporate Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Schedule of Components of Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_149cb0bc-9ebd-4628-bcf6-d7051edc3551",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_40404be9-80f7-4dc1-b501-800029d9ebce",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summery of Beginning and Ending Amounts of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lbph:PercentageOfUncertainTaxPositionsNotRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "lbph:PercentageOfUncertainTaxPositionsNotRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Employment Benefits - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails",
     "shortName": "Employment Benefits - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Subsequent Events (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_1a00012b-31e0-4fbb-92a1-83ef81b5033b",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure -  Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "lbph-20221231.htm",
      "contextRef": "C_a9ff4fbc-96e2-4d81-9ac9-40b28d6c7d7d",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated By Reference Text Block"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lbph_AccountsPayableRelatedToStockBasedCompensationExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts payable related to stock based compensation expenses.",
        "label": "Accounts Payable Related to Stock Based Compensation Expenses",
        "terseLabel": "Accounts payable related to stock based compensation expense."
       }
      }
     },
     "localname": "AccountsPayableRelatedToStockBasedCompensationExpenses",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedComputerRelatedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued computer related expenses",
        "label": "Accrued computer related expenses",
        "terseLabel": "Accrued computer related expenses"
       }
      }
     },
     "localname": "AccruedComputerRelatedExpenses",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedFinancingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued financing costs.",
        "label": "Accrued Financing Costs",
        "terseLabel": "Accrued financing costs"
       }
      }
     },
     "localname": "AccruedFinancingCosts",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedLegalAndAccountingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for legal and accounting fees received.",
        "label": "Accrued Legal and Accounting Fees, Current",
        "terseLabel": "Accrued legal and accounting fees"
       }
      }
     },
     "localname": "AccruedLegalAndAccountingFeesCurrent",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedRecruitmentFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable within one year for recruitment fees received.",
        "label": "Accrued Recruitment Fees, Current",
        "terseLabel": "Accrued recruiting fees"
       }
      }
     },
     "localname": "AccruedRecruitmentFeesCurrent",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_AreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space.",
        "label": "Area of Office Space",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOfficeSpace",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "lbph_ArenaPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arena Pharmaceuticals, Inc.",
        "label": "Arena Pharmaceuticals Inc [Member]",
        "terseLabel": "Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ArenaPharmaceuticalsIncMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_ArenaTwoThousandSeventeenLongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arena two thousand seventeen long term incentive plan.",
        "label": "Arena Two Thousand Seventeen Long Term Incentive Plan [Member]",
        "terseLabel": "Arena 2017 LTIP [Member]"
       }
      }
     },
     "localname": "ArenaTwoThousandSeventeenLongTermIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid for Amounts Included in the Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued on conversion of convertible preferred stock in connection with initial public offering",
        "label": "Common Stock Issued On Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering",
        "terseLabel": "Common stock issued on conversion of convertible preferred stock in connection with initial public offering"
       }
      }
     },
     "localname": "CommonStockIssuedOnConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fixed maturity securities, available for sale, due after one year through two years, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three",
        "terseLabel": "Fixed maturity securities, available for sale, due after one year through two years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Costs Policy Text Block",
        "label": "Deferred Financing Costs Policy [Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_DeferredTaxAssetsCarryforwardsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets carryforwards lease liability",
        "label": "Deferred Tax Assets Carryforwards Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsCarryforwardsLeaseLiability",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets carryforwards research and development state and local",
        "label": "Deferred Tax Assets Carryforwards Research and Development State and Local",
        "terseLabel": "Federal and California research and development carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsCarryforwardsResearchAndDevelopmentStateAndLocal",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DeferredTaxAssetsCarryforwardsRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets carryforwards right of use asset",
        "label": "Deferred Tax Assets Carryforwards Right Of Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsCarryforwardsRightOfUseAsset",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_DefinedContributionPlanArenaMatchingContributions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Arena Matching Contributions",
        "label": "Defined Contribution Plan Arena Matching Contributions",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanArenaMatchingContributions",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_EffectiveLeaseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective lease date.",
        "label": "Effective Lease Date",
        "terseLabel": "Effective lease date"
       }
      }
     },
     "localname": "EffectiveLeaseDate",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "lbph_EmployeeStockPurchasePlanEligibleEarningsContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, eligible earnings contribution, percentage.",
        "label": "Employee Stock Purchase Plan Eligible Earnings Contribution Percentage",
        "terseLabel": "Employee stock purchase plan, eligible earnings contribution, percentage"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanEligibleEarningsContributionPercentage",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_EmployeeStockPurchasePlanMaximumOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, maximum offering period.",
        "label": "Employee Stock Purchase Plan Maximum Offering Period",
        "terseLabel": "Employee stock purchase plan, maximum offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumOfferingPeriod",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_EmployeeStockPurchasePlanMaximumSharesPurchasedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, maximum shares purchased, value.",
        "label": "Employee Stock Purchase Plan Maximum Shares Purchased Value",
        "terseLabel": "Employee stock purchase plan, maximum shares purchased, value"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumSharesPurchasedValue",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, shares purchase price as a percentage of market fair value.",
        "label": "Employee Stock Purchase Plan Shares Purchase Price As Percentage Of Market Fair Value",
        "terseLabel": "Employee stock purchase plan, shares purchase price as a percentage of market fair value"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesPurchasePriceAsPercentageOfMarketFairValue",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_FinancingRelatedFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing, accounting fees and other fees such as printers, transfer agent, etc.",
        "label": "Financing related fees",
        "terseLabel": "Financing related fees"
       }
      }
     },
     "localname": "FinancingRelatedFees",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_FixedAssetBasisDifference": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset basis difference",
        "label": "Fixed asset basis difference",
        "terseLabel": "Fixed asset basis difference"
       }
      }
     },
     "localname": "FixedAssetBasisDifference",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "negatedLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating right-of-use assets and lease liabilities, net.",
        "label": "Increase (Decrease) in Operating Right-Of-Use Assets and Lease Liabilities, Net",
        "terseLabel": "Operating right-of-use assets and lease liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingRightOfUseAssetsAndLeaseLiabilitiesNet",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_IssuanceOfSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of series A convertible preferred stock",
        "label": "Issuance Of Series A Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock, Shares"
       }
      }
     },
     "localname": "IssuanceOfSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "lbph_NonVotingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Voting Member.",
        "label": "Non Voting [Member]"
       }
      }
     },
     "localname": "NonVotingMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_NumberOfCommonStockSharesIssuedAndSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock Shares issued and sold.",
        "label": "Number of Common Stock Shares Issued and Sold",
        "terseLabel": "Number of common stock shares issued and sold"
       }
      }
     },
     "localname": "NumberOfCommonStockSharesIssuedAndSold",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lbph_NumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities.",
        "label": "Number of Securities",
        "verboseLabel": "Number of securities"
       }
      }
     },
     "localname": "NumberOfSecurities",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "lbph_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_PaymentsForRentHistorical": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Rent Historical",
        "label": "Payments For Rent Historical",
        "terseLabel": "Historical rent paid"
       }
      }
     },
     "localname": "PaymentsForRentHistorical",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_PercentageOfIncreaseInRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in rent.",
        "label": "Percentage of Increase in Rent",
        "terseLabel": "Percentage of increase in rent by second year"
       }
      }
     },
     "localname": "PercentageOfIncreaseInRent",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_PercentageOfSharesOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares of common stock outstanding",
        "label": "Percentage of shares of common stock outstanding",
        "terseLabel": "Percentage of shares of common stock outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOfCommonStockOutstanding",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_PercentageOfUncertainTaxPositionsNotRecognized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of uncertain tax positions not recognized",
        "label": "Percentage Of Uncertain Tax Positions Not Recognized",
        "terseLabel": "Percentage of uncertain tax positions not recognized",
        "verboseLabel": "Percentage of uncertain tax positions not recognized"
       }
      }
     },
     "localname": "PercentageOfUncertainTaxPositionsNotRecognized",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lbph_PermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Permanent items.",
        "label": "Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "PermanentItems",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_PostSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post split.",
        "label": "Post Split [Member]",
        "terseLabel": "Post Split"
       }
      }
     },
     "localname": "PostSplitMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_PreSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre split.",
        "label": "Pre Split [Member]",
        "terseLabel": "Pre Split"
       }
      }
     },
     "localname": "PreSplitMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_RenewOfSuccessiveAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Renew of successive agreement term.",
        "label": "Renew Of Successive Agreement Term",
        "terseLabel": "Renew of successive agreement term"
       }
      }
     },
     "localname": "RenewOfSuccessiveAgreementTerm",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_RestrictedStockAwardsIssuedButUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards, issued but unvested [Member]",
        "label": "Restricted Stock Awards Issued But Unvested [Member]",
        "terseLabel": "Restricted Stock Awards, Issued But Unvested"
       }
      }
     },
     "localname": "RestrictedStockAwardsIssuedButUnvestedMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for lease obligations.",
        "label": "Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties Policy Text Block.",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental balance sheet information related to leases.",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to leases.",
        "label": "Schedule of Supplemental Cash Flow Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A convertible preferred stock.",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Preferred Stock (on an as-converted to common stock basis) [Member]",
        "label": "Series A Preferred Stock On As Converted To Common Stock Basis [Member]",
        "terseLabel": "Series A Preferred Stock (On As-Converted To Common Stock Basis)"
       }
      }
     },
     "localname": "SeriesAPreferredStockOnAsConvertedToCommonStockBasisMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options exercised in period, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share based payment award, options forfeitures in period, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remining Contractual Term, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual term, options granted",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Contractual Term",
        "verboseLabel": "Remaining contractual term, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual term for option awards granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Granted Remaining Contractual Term",
        "terseLabel": "Remaining Contractual Term, Options granted",
        "verboseLabel": "Remaining contractual term, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedRemainingContractualTerm",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options subject to early exercise provision, exercisable number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Early Exercise Provision Exercisable Number",
        "terseLabel": "Options exercisable, subject to early exercise provision"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToEarlyExerciseProvisionExercisableNumber",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lbph_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years) [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_ShortTermInvestmentsAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short Term Investments And Cash Equivalents",
        "label": "Short Term Investments And Cash Equivalents"
       }
      }
     },
     "localname": "ShortTermInvestmentsAndCashEquivalents",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_ShortTermInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Investments [Policy Text Block]",
        "label": "Short-Term Investments [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsPolicyTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_TaxDeferredAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax deferred assets net",
        "label": "Tax Deferred Assets Net",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "TaxDeferredAssetsNet",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lbph_TemporaryEquityAndStockholdersEquityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity and stockholders equity disclosure.",
        "label": "Temporary Equity And Stockholders Equity Disclosure [Text Block]",
        "terseLabel": "Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "TemporaryEquityAndStockholdersEquityDisclosureTextBlock",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lbph_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity Incentive Plan member.",
        "label": "Two Thousand And Twenty One Equity Incentive Plan [Member]",
        "terseLabel": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_VotingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting Member.",
        "label": "Voting [Member]"
       }
      }
     },
     "localname": "VotingMember",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lbph_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lbph_WeightedAverageStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average stock price",
        "label": "Weighted Average Stock Price",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "WeightedAverageStockPrice",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "lbph_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.longboardpharma.com/20221231",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer [Member]"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r459",
      "r475",
      "r506",
      "r507",
      "r516",
      "r520",
      "r529",
      "r573",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r284",
      "r459",
      "r475",
      "r506",
      "r507",
      "r516",
      "r520",
      "r529",
      "r573",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProFormaMember": {
     "auth_ref": [
      "r180",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pro Forma [Member]",
        "terseLabel": "Pro Forma"
       }
      }
     },
     "localname": "ProFormaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r277",
      "r284",
      "r312",
      "r313",
      "r314",
      "r435",
      "r459",
      "r475",
      "r506",
      "r507",
      "r516",
      "r520",
      "r529",
      "r569",
      "r573",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r277",
      "r284",
      "r312",
      "r313",
      "r314",
      "r435",
      "r459",
      "r475",
      "r506",
      "r507",
      "r516",
      "r520",
      "r529",
      "r569",
      "r573",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r180",
      "r285",
      "r542",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r180",
      "r285",
      "r542",
      "r543",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r562",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Other Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r528"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r106",
      "r114",
      "r126",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount for accounts payable to related parties.",
        "label": "Accounts Payable, Related Parties",
        "terseLabel": "Accounts payable includes related parties"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable, Related Parties, Noncurrent",
        "terseLabel": "Related party amounts related to accounts payable"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Accretion of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Payroll Taxes, Current",
        "terseLabel": "Accrued taxes"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued consulting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r144",
      "r471",
      "r483",
      "r487"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r98",
      "r419",
      "r478",
      "r479",
      "r550",
      "r551",
      "r552",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r557",
      "r558",
      "r559",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r168",
      "r169",
      "r170",
      "r171",
      "r180",
      "r214",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r321",
      "r322",
      "r323",
      "r341",
      "r342",
      "r343",
      "r344",
      "r353",
      "r354",
      "r355",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r461",
      "r462",
      "r463",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r85",
      "r86",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r120",
      "r140",
      "r160",
      "r201",
      "r209",
      "r211",
      "r227",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r357",
      "r361",
      "r383",
      "r528",
      "r571",
      "r572",
      "r611"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r137",
      "r145",
      "r160",
      "r227",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r357",
      "r361",
      "r383",
      "r528",
      "r571",
      "r572",
      "r611"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets",
        "totalLabel": "Total assets measured at fair value",
        "verboseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r217",
      "r239"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r61",
      "r218",
      "r469"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Fixed maturity securities, available for sale, due in one year or less, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r58",
      "r216",
      "r239",
      "r464"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "totalLabel": "Fixed maturity securities, available for sale, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfMaturityOfTheShorttermInvestmentsDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r139",
      "r509"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and investment securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r38",
      "r44",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r105"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "terseLabel": "Net (decrease) increase in cash and cash equivalents",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r160",
      "r183",
      "r184",
      "r186",
      "r188",
      "r192",
      "r193",
      "r227",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r383",
      "r508",
      "r541",
      "r554",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r115",
      "r124"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r249",
      "r250",
      "r503",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockConversionBasis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of basis for conversion of convertible common stock.",
        "label": "Common Stock, Conversion Basis",
        "terseLabel": "Common stock, conversion basis"
       }
      }
     },
     "localname": "CommonStockConversionBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDiscountOnShares": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount on common shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.",
        "label": "Common Stock, Discount on Shares",
        "terseLabel": "Discount and commissions paid"
       }
      }
     },
     "localname": "CommonStockDiscountOnShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r557",
      "r558",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Voting Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common Stock Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r528"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, value",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r147",
      "r149",
      "r154",
      "r465",
      "r472"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering",
        "terseLabel": "Conversion of convertible preferred stock",
        "verboseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "negatedTerseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering, shares",
        "terseLabel": "Number of Shares Converted",
        "verboseLabel": "Number of shares converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of convertible preferred stock to common stock in association with initial public offering (in shares)",
        "verboseLabel": "Conversion of stock, shares issued"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r267",
      "r268",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r3",
      "r4",
      "r70",
      "r71",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock available for conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r517",
      "r519",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r225",
      "r244",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r225",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r225",
      "r244",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r225",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r222",
      "r240",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total",
        "verboseLabel": "Aggregate fair value of unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r223",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "negatedLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total",
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r221",
      "r513",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Summary of Available-for-sale Investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r224",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r109",
      "r119",
      "r545"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred financing costs",
        "totalLabel": "Deferred Costs, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred Costs, Current",
        "terseLabel": "Deferred financing costs",
        "totalLabel": "Deferred Costs, Current, Total"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r336"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "lbph_TaxDeferredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 2.0,
       "parentTag": "lbph_TaxDeferredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Net deferred tax assets",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r94",
      "r605"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Federal and California net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r94",
      "r605"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r92",
      "r94",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Tax credit carryforwards research"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r94",
      "r605"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 3.0,
       "parentTag": "lbph_TaxDeferredAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation Allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r88",
      "r604"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "lbph_TaxDeferredAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r94",
      "r605"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "Section 174 capitalized R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Company Provides Safe Harbor Contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r42",
      "r199"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r289",
      "r317",
      "r318",
      "r320",
      "r324",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r155",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r183",
      "r186",
      "r187",
      "r188",
      "r190",
      "r373",
      "r374",
      "r466",
      "r473",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r155",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r183",
      "r186",
      "r187",
      "r188",
      "r190",
      "r373",
      "r374",
      "r466",
      "r473",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r69",
      "r133",
      "r151",
      "r152",
      "r153",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r191",
      "r231",
      "r274",
      "r321",
      "r322",
      "r323",
      "r343",
      "r344",
      "r372",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r419",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r376",
      "r377",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r264",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r377",
      "r432",
      "r433",
      "r434",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r376",
      "r377",
      "r378",
      "r379",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r264",
      "r278",
      "r283",
      "r377",
      "r432",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r264",
      "r278",
      "r283",
      "r377",
      "r433",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r264",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r377",
      "r434",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r264",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r432",
      "r433",
      "r434",
      "r514",
      "r515",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243",
      "r245",
      "r246",
      "r266",
      "r272",
      "r363",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r513",
      "r563",
      "r564",
      "r565",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r28",
      "r43",
      "r96",
      "r172",
      "r173",
      "r174",
      "r175",
      "r185",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Total",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r161",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesNetLossAttributableToStockholdersBeforeBenefitForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r330",
      "r334",
      "r339",
      "r345",
      "r348",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r163",
      "r178",
      "r179",
      "r200",
      "r328",
      "r346",
      "r349",
      "r474"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r326",
      "r327",
      "r334",
      "r335",
      "r338",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "verboseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Benefit for income taxes at statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r602"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "negatedLabel": "Research and development credits",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesAndIncomeTaxesComputedUsFederalStatutoryCorporateTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "negatedLabel": "Accrued compensation and related expenses",
        "terseLabel": "Accrued compensation and related expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Maturity of the Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiry date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r111",
      "r122",
      "r528",
      "r555",
      "r566",
      "r607"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock and shareholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r138",
      "r160",
      "r227",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r358",
      "r361",
      "r362",
      "r383",
      "r528",
      "r571",
      "r611",
      "r612"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities",
        "totalLabel": "Liabilities, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r43",
      "r116",
      "r127",
      "r136",
      "r146",
      "r148",
      "r153",
      "r160",
      "r168",
      "r172",
      "r173",
      "r174",
      "r175",
      "r178",
      "r179",
      "r185",
      "r201",
      "r208",
      "r210",
      "r212",
      "r227",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r374",
      "r383",
      "r512",
      "r571"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r51",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r180",
      "r190",
      "r214",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r321",
      "r322",
      "r323",
      "r341",
      "r342",
      "r343",
      "r344",
      "r353",
      "r354",
      "r355",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r461",
      "r462",
      "r463",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvotingCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock securities that do not empower a holder to vote on corporate resolutions or the election of directors.",
        "label": "Nonvoting Common Stock [Member]",
        "terseLabel": "Non-Voting Common Stock [Member]"
       }
      }
     },
     "localname": "NonvotingCommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r201",
      "r208",
      "r210",
      "r212",
      "r512"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeaseCommitmentsDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Right-of-use liabilities, current portion",
        "verboseLabel": "Right-of-use lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Right-of-use liabilities, net of current portion",
        "verboseLabel": "Right-of-use lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r412",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r411",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Total rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Net, Total"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "verboseLabel": "Accrued other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesSummaryOfAccruedOtherExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r125",
      "r544"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Future rent payment per month for first year",
        "verboseLabel": "Rent payments"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.",
        "label": "Payments for Repurchase of Initial Public Offering",
        "negatedLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Financing related fees",
        "terseLabel": "Financing related fees",
        "totalLabel": "Payments of Financing Costs, Total"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Series A convertible preferred stock financing costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "verboseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of short-term investments",
        "terseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Expenses Related To Contribution Plan",
        "totalLabel": "Pension and Other Postretirement Benefits Cost (Reversal of Cost), Total"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefitsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
        "label": "Postemployment Benefits Disclosure [Text Block]",
        "terseLabel": "Employment Benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureEmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockDividendRatePerDollarAmount": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount per share used to calculated dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Per-Dollar-Amount",
        "terseLabel": "Dividend rate, per-dollar-amount"
       }
      }
     },
     "localname": "PreferredStockDividendRatePerDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r159",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Preferred stock, liquidation preference, value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r528"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, value",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from contributed capital"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering",
        "verboseLabel": "Net proceeds from initial public offering (IPO)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock, Value"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from Series A convertible preferred stock financing"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r136",
      "r146",
      "r148",
      "r156",
      "r160",
      "r168",
      "r178",
      "r179",
      "r201",
      "r208",
      "r210",
      "r212",
      "r227",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r356",
      "r359",
      "r360",
      "r374",
      "r383",
      "r467",
      "r512",
      "r525",
      "r526",
      "r552",
      "r571"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentBasisOfValuation": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).",
        "label": "Property, Plant and Equipment, Basis of Valuation",
        "terseLabel": "Property and equipment, basis of valuation",
        "verboseLabel": "Property and Equipment Basis of Valuation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentBasisOfValuation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.",
        "label": "Property, Plant and Equipment, Depreciation Methods",
        "terseLabel": "Property and equipment, depreciation method",
        "verboseLabel": "Property and Equipment Depreciation Method"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciationMethods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r123",
      "r470",
      "r528"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment",
        "totalLabel": "Property, Plant and Equipment, Net, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life",
        "verboseLabel": "Property and Equipment Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r129",
      "r422",
      "r423",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r420",
      "r421",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Agreements with Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Payments of related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r87",
      "r128",
      "r619"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      },
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "R&amp;D Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r72",
      "r121",
      "r482",
      "r487",
      "r528"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r133",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r231",
      "r321",
      "r322",
      "r323",
      "r343",
      "r344",
      "r372",
      "r478",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r410",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r97",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public Offering Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued Other Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAccruedOtherExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Short-Term Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Net Loss Attributable to Stockholders Before Benefit for Income Taxes by Region"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Benefit for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationExpenseScheduleOfStockbasedCompensationExpenseRecognizedForAllEquityAwardsAndReportedInTheStatementsOfOper"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense Recognized for all Equity Awards and Reported in the Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Company's Financial Assets Recognized at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "terseLabel": "Schedule of Services Expensed"
       }
      }
     },
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureAgreementsWithArenaPharmaceuticalsIncScheduleOfServicesExpensesDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureAgreementsWithArenaPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r286",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted Average Grant Date Fair Values and Weighted Average Assumptions used to calculate Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r524",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy",
        "terseLabel": "Segment Reporting",
        "verboseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r546",
      "r547",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "verboseLabel": "Restricted stock award, Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock award, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock award, Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Restricted stock award, vested",
        "verboseLabel": "Vesting of restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Restricted stock award, vested fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Shares, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares, Options granted",
        "verboseLabel": "Number of shares, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Estimated grant date fair value per share of award granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Options outstanding, ending balance",
        "periodStartLabel": "Number of Shares, Options outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per share, Options outstanding, ending balance",
        "periodStartLabel": "Weighted Average Exercise Price Per share, Options outstanding, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options exercisable, vested stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfWeightedAverageGrantdateFairValuesAndWeightedAverageAssumptionsUsedToCalculateFairValueOfOptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of Shares, Options Vested and Expected to Vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price per share",
        "verboseLabel": "Shares issued price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r112",
      "r113",
      "r118",
      "r548"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r50",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r160",
      "r183",
      "r184",
      "r186",
      "r188",
      "r192",
      "r193",
      "r227",
      "r255",
      "r257",
      "r258",
      "r259",
      "r262",
      "r263",
      "r267",
      "r268",
      "r269",
      "r270",
      "r273",
      "r383",
      "r508",
      "r541",
      "r554",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r69",
      "r133",
      "r151",
      "r152",
      "r153",
      "r164",
      "r165",
      "r166",
      "r169",
      "r177",
      "r179",
      "r191",
      "r231",
      "r274",
      "r321",
      "r322",
      "r323",
      "r343",
      "r344",
      "r372",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r419",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r191",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r4",
      "r5",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares purchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r69",
      "r70",
      "r72",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock issued during conversion of convertible securities"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r69",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net, Shares",
        "verboseLabel": "Purchase of common stock by Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the number of shares issued.",
        "label": "Stock Issued During Period, Shares, Period Increase (Decrease)",
        "terseLabel": "Number of shares exchanged during period",
        "totalLabel": "Stock Issued During Period, Shares, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r69",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Shares remained to vest",
        "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r69",
      "r72",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Number of Shares, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r69",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in initial public offering, net, Value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Common stock, subject to repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityDeficitAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r4",
      "r5",
      "r69",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Purchase of common stock by Arena Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r57",
      "r528",
      "r555",
      "r566",
      "r607"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance, Value",
        "periodStartLabel": "Beginning Balance, Value",
        "totalLabel": "Total stockholder\u2019s equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Forward stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r398",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r398",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r398",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r398",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureOrganizationAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Convertible preferred stock:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r17",
      "r160",
      "r227",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, Ending Balance, Value",
        "periodStartLabel": "Temporary equity, Balance",
        "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Temporary equity, liquidation preference, value"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Temporary equity, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Temporary equity, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Temporary equity, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Temporary equity, Ending Balance, shares",
        "terseLabel": "Temporary equity, Balance (in shares)",
        "verboseLabel": "Temporary equity, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r1",
      "r68"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Par Value",
        "terseLabel": "Temporary equity, value"
       }
      }
     },
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r266",
      "r272",
      "r363",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r563",
      "r564",
      "r565",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r168",
      "r169",
      "r170",
      "r171",
      "r180",
      "r214",
      "r215",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r321",
      "r322",
      "r323",
      "r341",
      "r342",
      "r343",
      "r344",
      "r353",
      "r354",
      "r355",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r402",
      "r403",
      "r404",
      "r405",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r461",
      "r462",
      "r463",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r510",
      "r517",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsScheduleOfShortTermInvestmentDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r468",
      "r517",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government and agency securities [Member]"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfCompanysFinancialAssetsRecognizedAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on short-term investments",
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r325",
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Reductions from tax positions taken in prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions from tax positions taken in the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions from tax positions taken in prior year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummeryOfBeginningAndEndingAmountsOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r194",
      "r195",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r182",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r181",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.longboardpharma.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r531": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r532": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r533": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r534": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-07)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0000950170-23-005832-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005832-xbrl.zip
M4$L#!!0    ( !2"8E9L]9LA.P4! *8K 0 0    :6UG.#8Q.3@S-E\P+FIP
M9^R[=5R<2[<FVEA(T. NP8,&=TD('MP]!(?@K@TAN&LGN$MP=_?@'IQ&0Z.-
M-GXA>^_OG)G[G7-GYL_[FY=>-"5OU5K/>M;JJN+MAU\/:X"7LI(RD@ X.#C
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M/5)R/V-_N3PK_(#U]#0F"/LR[79\_<B5,NVG6P:$<O'.03).!2V^%5=/R0>
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M"PV_7A:]#1"5I)^C=#B+CV8Q[.;H7O*N/"H;JF)=)R _4QN59S4I84=SRD1
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MD<GK:SKA9N2L]/);C7?/*2^1&XJ*!T5BK<HD'.Y+@&WMUR^+& 6CSXWOSA\
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ML')[><6"%%FNP\W$(%_LJ&MPI#H+7MTJ.T%=,RFDQ#D8$<D.>I],ZVQ$]6;
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M+Z-["<IS'@#4VQM11:3&*C"ZUE7U>_.\P?52\A6+=9!Z590,R:<</4JSSQL
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M\603Y;Z"3.S5N8T;ZN8^@B"$P1'7UYD87$FJ=CYXRYU^L=/E>K*JF]=R0%.
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M&O8ST"E$;.SF76K67"[? \ ?)<.NE<3"C3A"8\#\.]OMR0.@/Y#<I/UTZ %
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MF=FB_[#U[T9&60;X_[8NZA%QH%N4%-"S4EGO[\,;H4',VZJG&)&J.5S>C'@
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M?O.U-LJKCT-!6VJ1OZC#CA_3CM;NY/TXR.UZ.3HB7E81?7&AWP,\9&.D7$"
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MF!,P'>P8I6)).)$)N^H.&1!^^S!>V[SKXS_DNHEDU:#GJ;?!D?[VB>.#[=X
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MRK?B]31K="CH!_\_[+UU6%3?VC<^"(I*(]T"@M+=*5(B+=T"PC"DM,3078*
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M;T8I5Q<Y[T<41P;L[;Y 9D 7E^)AD6+,8"RDOP%\*"BA5E?/4HP^=OATZD?
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M;7/U^T.3V%=I+'FO/JG&O]T#<J?UIT>K*2/$>VLY060V/1GF#EYY5ENFCN7
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M?%)&#5V^8F#8T?U5T6EW#WU.?/2-A]BZDO<!_'K!]KQQO2EB@C-/?:[[];3
MGND*H\^5:-%(@54K'WP]J5"OMK_4CE>;-H$[ AJ?BOO1W@N4/7&RQZ\Y_FZ*
MI09#;XA+[FJRN2[)+' B(U5 ^#7<?5B@G'YZ. ]X*:^_8/G1*SWK*[__)R*L
MEXB]=\[$7:E]GU[+H%*%.$Z$Y1'[KR.]?N;!C4XU(.'L(M)>[D56<]Y!H_.Y
M?(<-P 0\GLJOW0TKT?<[<7>_.Z.04VU6V:ITWE=^*4@XS-B-@]Y_]^::%(0=
M\T_7G8-GBPL[;%W!K@.+36(SY1F\=F3;.Y><VT)*A6=SF@70%B7(2TCNI^^-
M09U[>*C,/-;?B6J<GWT*Z;?F[/;"HPZX$BQT4X)(!RM5QG7N4( MJGV)^_#*
MR+A\W0#&QM%OP@ _;@&!LW!XZ2 .%=*XM/SB]&:FKLN(;SECX]R=QG%A7.?*
M&NE1R#HXASSHY']A0YKN$JY=9\?$\3+16GR@P9Q4Q,QW02MN>^")]'6!2YF8
M//?\C3&"[$",HA]F(]5QH0VIIB0;40Z7D@0YF'J?Q7XC&37Q;R=.C-^P.A@I
M[/V!,F=Y(P0_"ZE..C%@-!P_$66Z-\AZDK;ZH2-0@IZ[B(GCH4AR>*<XGB?K
MBGQ>>.<-_=C)K EY7O2;MC!H#E4)7A3S^D$PP_3AQ*GKV,EX!CQRP;+N2;N-
M^)7'@I5JB<Q]>V]-<YGX&(JK3AJS]ZV9]:-.ERUJ@VKITR_8=^O"07YB;OX1
M7'[">#ZR%9F/3A3?][Z<V&B;/& ]WB%W: 05-V@^OY/R0P*U0'WIJYM=#QEU
M1(GN4>?%<$:9+O.YC4.!@:P#B<F5<,RG#*L-L>=(JLL>S0NLGC3>K)8Q7MY)
M6/5D#CO(:9 B!/^-^>=H[@\56#7Q2A.&!@C'[B7&21'*E1$<(\M&NR 1N60>
M+<5"[06Q+#O7]^,\[SD9YMWQ.NU(S&GNR0TK KR(,P9B*@&(Y,-%_AXJ_DK$
M7F_ R4,1\<(A*G^&/) [:&,.H^C5U[ J.E+/0+1X :!\S[[8FH6;%JRL#8':
MV8K_K=9?8?Q*JAR8*)0Z;O#RC*\6T<GC\!F/)60<WUPU;?O!HXW 3!R=RJE2
M7KDE!>9"=KHHF<"E1ZB!S@+F]$[&;C3'Q?%'Q($G8+R[&> %0Q;T&'Z=%I0"
MBY1A-5#*H*^0!%YGT8J,TG_HK3&EYIOX5&TO(WAZ@+D]=U,*B_PH7U;=T,R.
M6MJ:L:K;J"^2]79 5UGPTY@\<T<1"PDNG_EW8@-DTT\PQG8<L'$DXDHT=YMC
M[^@N?)5[FB#ZG7 AXF>$W\.1PI-2(RQD[TM$?-R2)=ET6IDN?;JZ/K!.=4&F
MW.=UPDL) ;JHYK"CZ#E^A>H:I*.#B#WMD',Y\,EK9+\K<6T?.?RM*E)C4;TK
M>?&LBQT/:='>*S/!;LW*6J-P66JXI/?)D;Y]16X*7^ZJ^5GC^INZ)1)]?PFJ
M@K<;4ZPVMJQW 500>4ILQT.S&.8!"?H]M-6?F(BY9M/V-M(K P2CVJB-4XOP
MJ]'2&J][BAIL^TL@2)CV6A2C.OZY1-FI,2?C#XY9:B>8W@Y98I@8C:?H],&Q
M**N("="Y;/-0O^.-BD&*6ZYT5Y/AJ\ ,ASG7SRP+G!0^7D0D%^H[&P=H5W((
MT9X,^)GBV#$.!M)[H@M539.#I90R=[2Z*Z!.Q3>1J4S/C4T!D\%5?;_U;D"_
MJ:@;+[<I&0FE1]Q?#X',N22Z>P 4W*XFA&8[AKCQ'[.U,Z(EL/N& <ZVUSWE
M$<P=WIA-09 NL>=C3LQ)<3^B*!54PF87/\BL:1G+]=%M,Q5T+!-NW[#!FPQ!
M0AXSR]*.O/5 %EN6A#7"BCB6)[[T5CO^-=_\/R7L:&?@D?!W4P>:5DS:-=X"
M( &3*#-N=KU45(A4KD'HM8<"Y%V +WVRS:KKXZ2MV B'C(\+Y<3(^/QV<\0$
M-"$OIRL&-#'H3I1'+ZR1-S[]P(+;]7G5N;#\YM VL)&Z1]1. QF7;\FQL/4Q
M/;%49U$1Z&Z>MR1+6-P3-B ]6!?O%L!_537ST1XE$\=BP:NEZ.3HH./:H\N;
M$*F4^+$\U(G.H=!*J\B<OE%C<'#=*W]M]7I\@7M1D$DN4J2*@$^G%I+E283T
M+;R2@I<NKA?;4+:<).0Y%LC!YQ6MXLX5?6F"[):D8V14#R718P4S<22RZTNE
M8.OA^48+.H,F,(N$1V3\(/#C[3B9UZGX90EK^A\)Z:FFIH 7?E::?&?VN<4$
MB)*O=;C-7(!.&BX!S()T*8"L@P31YO\J'$3Q3SC(OP:RHMDU6@F#_\@4W5G/
M29=;P!\9($#"W?D'>P3W4?.$?M]T93MG4%W]'VN%_+.$D[QJYQ\HDO^@&TJ3
MUQ;0,O->2L7'=VF_VV]^X^-NH7^X@T>W@*GRRYT[M^>Q]QA$\"+9YN]X7.9D
M"7[+#9&-Z81$&W)+%'$R<3*#:IOL[XPKLBL*M9'5VFA7EE? 7P41 !F1U)%L
M<WQCQD\0.8B\>9DYEGO>O"2W /V%6\##F_=Y\ZJ%UY>_]IAE?Q?_^Q4\WCQ-
MEO/2/LH]T3V_1%0\0HXAQ_=R;(C^J3 KP3MEJ0MOG-GFPGYZ[U[+'F5_E_\;
M17U>7C>YY2%*GN3.2 TK*TG^O3^1-G\<*)BB9K< S\FI/WXG_WKR/UQ(\ ?L
M7O=7!;MKY4->5H!L79MX:('#$)OH9C>'(,D- =)%G$H\(H%5Z@:?.+H?Y%]L
M\.6'*;WLZGFKYG=YFR:7_0W2]=*"SKV[^^B'?:];GO_PDC59JDC_RQL)"L88
ML\/*?H'9LU#; MX!'613]PABZ:CCFZ%E*73&J?#$_/!X-F&W)+8?O\N,_SX7
M*2KQX3DIN:QN@>D*.^6BIQHB,7@E1;*I8FS7YH#UJ8&894%\F0@47R0?^AF-
M$^O'DW4TJ%:8A'.R;$<&EF7ZL^F:'1"HGY<5*-(B678B7/REC+B"HY].UD=,
MHR/RZ^N(>])OQV\>(66E[5ELV/>L?:V!#MMG_LKMVVUF1YZ1&;O6\WL:GIRP
MMB<Z5Z\2.PSI$^4GEPQXMA,@%XHEM4V$YMIS@K3NYJN)]_7%!4RJ31D@T37L
M9%NCVV1!OFS!H(*MTS9+RQ,0T)P_(BMI4IZB>/6Y!JJ[O. [%X0?BL(-Z5&[
MH5(+\>R)/U533WY!EV[HI1:*-_@XREN%^'JL;A]A0)C1V4*N##>&E[:=!GSD
MZEW]BJ6V.5R4T?@M260470(5+K#5[7#GV^,W*Z[T9_FWP[<^ZE=N)GP<&@39
MR]N3[FO,,1O3Q7(%/!S>PMXU,\&B]Q9')(:+W+=8H<8N"\[=VE!0?*D@^NZ1
MA7ONXR$60^L/!;'$MHMK%+'R3)Q^*.,SGL1PEXR?@7"_+59'Z,P,CZ86Q''1
MG1ZENNNP2<3#GF^7#KAJ/'6 ?<4_YLEN'S='J;0M=QZRG=RRE+5&0?CC'4QK
MQEYN8,5/UE$?$B("@H4O![NTLL,O-R\,*L?5-4"B[Y9TEMZ-N:?+',=RXEU^
MI<8WJUL@.6\:0E>KG^(1%3O='JJ^; IW6TL>&E[WG47E,?OY(7=%@%+H,: 4
M9H>^U<I6';:LJI>UVK_>RQN_.^W8,T/'S,(6U8#FAVH\;8Q4ASI"%[5>)2J"
MBBDU1)K.FAJ2/<)C'A#T"S?$AT4W=E>UA)35A@%6RL3PD59'*F,UCTH/<B=Y
MONC.S>W5*)0+9K_''/MQ8[LU&H]NG==KI/ZVQ/L^DE]Q_+@)0P]CYNGXNOLN
MO8'NT4@-&\ IRH[_A_8\*F?0C$=1V448X*<X]/[X%6&.E9!6L(BHHZ-=^<*
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MRWWG_820ZA4C&[_SBY4?Z1JYU2F/LMD<L^H*%L0>/ES]!O3^86JWM$88HC9
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MI)\Q?IRAMBXS^(D(BL?/9;M*/N4L5\9U_:&U.DRKX0_ W?3G<1^2DA-^AS3
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M<023]":%>1/"3CN%RPB%<_80(7C1)M6I;PMK8O6!\O1!&_CGB!J.[,@!L:F
MF\>MZYTD9\^KC34_<<09<8!U:L!WC,R-Q\]/V'OL<R93Y7%3U\2!S8V_E"G
MRT2(=!D.X]^O./R]J68>],XRN_3':M/X#!ZY5R&'VTM-BYR*V$MB#DN\< MV
MQY+QB^W?9ML1'R2FO 4\Q:=HSNR"Z</WFI/2R1:=,-B)T8ODZ5]SG@@(C,AX
MFQ\:$:1!;3QI-T@-'@6ZWZQA\);F3SP#:MM72UW"\9X!%A>!5=&F 7)MGA-+
M4J#T(OBEXK1H>Z6Y&$-/!RBJ=0;K[%$KXLYXUTU<9Y&41ZDT_K0LF3Q+ZUN2
MH:A.P_2RPU]H_/*HO0<43+5G4>50 X-PY3F^<O%MI_#$J#7MQ%5K;>N5X=MR
MICBF3I9SZ5\6@.0Q@'AB3FN:+FP4\L:9DE1OWQOY8NNL1E9T;5&_S&7--C W
M]D9Z.V\YEHBYLD%(),+B$P36<ETT64N,SX8KOT:18%\ZCMA4\;Y@!*H4L8_?
MG. C#"H=B@M#95J+_X/4-"WP#+@KJ4\HD2ZS<4FZWF@-+XJSOD$C+X,CONFL
M))CVQG=CZ<DD:Z=.-^F\(\A_"BT8?4HIZ.8XI2.D,(\<\K9:;!+[*)2%^6WE
MO9#J1YZU*&"W)RKO&H8WG>?[L[&P2,<-#U1%-NVI/LBNA;#310J!;IPLHP6=
M#/VBH-%HG7OG"%2@7\RD]QF (DXC$7Q\N>3E\VX!1+^:5/Y8,%$6\B8.-2'
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MG9\!G2;/ +O**NO<1_-1B=V+^Z1;I+OTOS+H1O=F4OITOWJQ0>^;GP'KE<^
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M W6DD3KC>O;TS5$?8NE=8_4,_4D 9?FOBE2S ,R_,N$NAT-$==#'.BJ6>R%
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M_*OR^EN05=0Y,=M6U =Z"]7O_.#7KGV]WS"(UN<X[L7VS]^?0>:TXE5G^0C
MEJE/C+-\J&D%BJX)BPN$XR[," Q<?3PS6Q>2%&GM@68>.B.+"45@/HX0;CUC
MM^M=[33-U/'N2>N[BJ+K:F4RN8I1A@L@UKU4$@O78DDR:A2FUR80_1O^&7NF
M1&@=;IFM<&!ZW9#>0-6[524KCT(*_5RL0U2__)#NLQQ?L2\2"J@7_:*?P\[7
M(BBH9BK86&M'"4Z ^/&ZTT>?6QN^Q8F(=;G'TL+'UE,=]4>5P&U79T('"Z>V
M&F9Z^T.<&B?+NP[K[Z*3"FPLAN#<RS=C1&\W:>16Q5.L^S8E*8:ES6'A/1,P
ME[&WQJL>2^&A" 3UVME*<]P)5M@%.R@8^%%Z?KYY<0"&IG2.S==1^?8;"QW5
MSFD^Q\4[#=)Q;Y:.3HF28VGI(@K%WV\.<SR(";!+BAQ\3HD_/C0,2H<*]ZN?
M+=H>FOH@I]Z!A%>[/D0?$Q)B*](IA0:_'?ZPQ?6)WT]>%9E(XK55\ZQ=Z^<R
M%8PZT]?@FK/.@D.!G?WR#W+A3$K*K+8%YAS8]9.^$D&^8N_"UJU@G::82_*3
M=?[7RL9KLL[WPJ^,[1DML@B)HF^@NRYDGFL<0PZ?#6'E!=;M]%63TN7;ES<Z
M@X6BX!Q:,MP:]Q^DCJ5<R!<-B975'W<6A;(PAO\"85GU+$/BY# _"328PMV=
M'E_DIX/4J\OOR@%SW$8K<D4GH7CVO,$HVHCQK!L \[C7FE#,ON%CF>[NXHT.
M]$,<DX/OP_L-G%6_<?7Y6GB6N]Z/X35%O>4<TN,:.SI&@SNJU2&$8(81I&(T
M@0HJ$HIM#4X_534V_]9M+94O6#37$Q@H6T CNK6]EV7[$58JT(?ZQGOQ8V09
M98WM]9U(Y<($SH6["#V@L<>G(UJD:G/GUEO#%^,N;-L"^L#8 \I?LM$/?,!:
M)E4<_;A@Q@]V= >R#WZ#2)USIP\%RJRCPAN"L^\E][21RT9XVXP/II6GG@'U
MXK/V:!_CEQ[F+2FLM@:T679"NGT5$O'@]M,>9=Y>[38G]7Q(TY]P,CEZ]%'(
MU&W6K&L-0S6+*,9.#R>PZL*/W+1/^BK8MS*P(]_.J?O^>LH)].DQ7J=A<L5[
MS#<I;7"!Z74?[>.#^THPI<#P^2^ Z\PX3R.>>\8*U%C9'HJJ#D6LA%*@*\K,
M7':@[;F,VK*+3R)XY,NU+LC%(4>4C,3UZ-CQ^\HS/P.8 %?E:[MX!^?C0<;L
MPA*!3D9(:D8&.K-?:DF!AVWOWMF)7CO6^A[=SR=AO,=NL(UO"9N=\N;4/30F
MF:IK 9%J<]J>=3.DP$51"E_+8V^=QR!_)5;G'AG3 DAX;E3!K:D9^V0_6$P[
M'Y93@-D8M?U.5=L;I_."($0S"^,H U-T973,;J$=LTE/N!-^3KFPA$)#Z_+B
M]_;.W/6Y_$D@N[ ,T#)4#AI+.-Z T+=%P/RJV-P7.0NCTOVR<"X$-MU?ORHV
M><Q:UM>QD6XUW%//KZ,J^EM_$-<>9Y@RQ6[G[85=Y3G+@+C%&%'8Y3, #=;,
M@:]G*\!?KZ/*EKYU+6WW"C$!(J);,4=+/$!,M47V0Y+4[Z-_4[:)T.482R>?
M/?EAABA,%HKQ=#*N=?;G7C-1GW4-%+8"<8XQJ*"O2\_\MDQ+,(CR'B!0R3C%
MZDUEX\)U4/^;(1OO.ZV!OECOU"DPA5Z:J\S<(?;7B4HK''T?3RK@N#CM&2"\
M*XJZ6>I#8>.J4P_6T48%N?/]C#5*3CZ-\.W5?TM.[!B;8#Y M>[',O#$Z6D[
M_6F.9OHRFGC?A? [Q>_"?' :12Z.D8F(80^#KVR+@W3H?#TB*ID/_"NX2WS\
M 6 '#MNE";X!S)DW4D-MYH2-H3409!Y!YT=+9(%.%R* RPSP/F5DY;0-7.M3
M9E[KF=B;L+F+O!])8A I_1 *^>S_2K,S1KX;*^W:W;1=?7T"R4O:P9L4EF\.
M 3XB@M%Y-.J?YJ?2=((,BM1P!&=Z?\9CR#GL,DKJ%(U)X;GY0+PJ0T65FI5?
MOD!9!##(!UBB5.V5>H!UD!;_)4AZT$X@YP20,+#C*T+>?\#TXCT9&T%9%)]6
M8>GKZ-QLLMHU]">GE3335R*E%JE@HC]+-+TTI?"\$U[K'^'(D?$GW1IZ)VR\
M:29$)2+U%R]T&E'QMP.P>=5NK2\X8_,00!:A/X_5)4UO%-]F80R%;;*+,^DN
M'>"4S*^IY"Z)]>BD7K[CJ-:71^&1BU+R>Q^9[\K,'73KV$)E(0N=5HZ#/.%F
M Q6NOP=69#)0!_H"@Z1EK7!BDB^P:H3T\ 26LS 5<AKGVYEL3C'JZ!)=P?U*
M,SE3 8Y]87,Z.&4R]"'V>ZN>YCM+?A\=_*3%##9?9_AO%,SRL>%J5[7J[J9<
M>D3_SI^21GXECTH<0(VH@[ES+/+SE?PK7Y&#3S&_'+1JT^6=O=C';FD2WYQD
MRX-9 A9H$%4[]3PXQVG!K2SJL-D7_ )I\)]^!\U($PL[_&:COI?X/4*9;RH-
MZ#N'(T/JTINBIHKM7]LA,E.$-,&K@[[)$4Y @7;O,9Q_\#VA(+&4H=BUL)\T
MWX_[!)VF-NSX_&')3.?3&WIW8@/*,+!^8<@)+Y"-5C=C9W5Q$;IJ8-F@AC:V
M1U8V%I7MV<!*+-7UD!T*\'7%T\G0][2;L+L"MG"]/N_&SQ.H,OXB&W5,'S\4
M\J%D1WGL@<K):#-AF=N6G'&S(+Y4T93R6KP:=-WV;E-Y%2K-3%>5^YL<JG"P
MGKP@FVAXLA[("[?/JX.4[6D\?74XR@X68]%LR'@&J+9,2Z8*0O$2GZRNO]50
M_KQ5]FMIKG!HU+ 7Y]K7?F((EPE6F7%&3+%3<M4.Q>T9AT-E!G$C<Y(%7/"[
MFS:RH[_8PM%G0+I#!CFLV!)B,(JQN"0_2^-EHN!E3- 8QJL9J239MSLBZ+/&
MJ%2IUD(UBQD@+@ 6]<(,<7ZQEZU37W34$]=4HO;+D]T=,M_.$%G&).+T4].M
MDW?;F(X"OO_M;M[_BD*MNF(#9.[OU><O+C.QX?]>%[E::MIPG,AIF#L.:K3T
M[$'Z9N&T_!I@.X</1=UHJ^QAJ40;='4ZZ\P]\+%WTW)EF[I5ES'UEL$[1=BE
M"F2) M95$!I#^ZKS/97/=H- ER**Z0(Z#1D;=4)\A)$;YPKNX5LANEP]1;)C
M3;>_(W.I,*&,W6ZBLE#X;G$FCP4J85['7OK4"O4C(1GE75%WN[1@)+I93)0'
MMN:SRBB^%3OTCW_T#^;*/7@=]IF3*A0"L>6=#$]#Y09(X<C0YTN_Z_2RJ& )
M1.9,FT8LPVRM B.W1M%X8K&\[KNX--=VJ#^5^Y-B82HLG+$WE<#BNU*MBLOV
MH'LZ-S&A+\.QM^Q.':3)DSS-YL?-?^8V>"B)[VR".%@$RP$YV,>1!DQ93'_Q
M<6@J-Y9=H<LZN?U=3YD4W>A^V[A]>1I ,A;*_H,]"5($RI^^]#D26E1F,])'
MRT8'X& R2,]SFHPB10XY&&?'CGW/U!>YS,(4F7S"BL8$?ALOL!VWR7L&F';F
M+"V4$:=24Z:ZWO;6?+-<EE3MC?UX9*$. VYXYV:_^!9WY?TAVF?[WP6GE%M=
M:.A,?]+G#C<DD@Z_T]FQ_^DY#VG#G*&\.)4Y67:84$7*A/5O>(V'M'KEN^4,
MJTV7LY>5K8YXM<@;S$7P!%V E@?:E=JDZ 2I(BKQ'@TVGMI*#O2M\E:9I6=X
MEVZM:F/V_V35Q0G(!$[(P8N3.S#"<Q6>/%T?JZ"[M:B"1;4@Y0RG\GY@<@I=
M==)2X&^!1<\>=OBWD:(-J%4)PYB_/&<G]AOB3'0[><'QNLHT04"#()DX&EGF
M7N(DVNS%'H\))/)\-R3]25'9"B,]6!Q3;;KZY0$'Z/$7R9:2J=Q02D2:DD^+
M1L,P>I\ Y#?O6H!P4/KZVNL]B;.XTDS,E5Y'.L@?N*_5/= 29F*,[J: M.3!
MBPJ'"*9+TJ6F\JT&W3*KEHL\KMK8&N8N_NK5^V3R)H!G=I2N0T3LZ(,$-+%X
MTQYI^:!FG]^%<-_1%8A?ZWK*UEJ G$'598Y2I6TA>NL.CX24#S S>&"9=5K#
M.-2WS&@H&$E-S&?;"->>'%UID3DY,D\0W;8Q0?-MASZ5D3>Q);GYK"][$\ZV
M<O!GEH3P/A*PK+.JC[[C61XE*S/K!@7BT=)D:01\PXNP:E8)]F9N@C;X\Z[8
M7:A$*V9 C2++'&OW\$1>6[I\8"66_*0019IO#4OJT?;&F;"_"G^$3$W1TF7H
M)[KT2ZNMA%+!+<<>2I*!,\_.3\B!&L!'4WLGTL@/MM4V:Y9OF4?/JW!&#&]C
M2W-JBC[0V@:Q(C)7=JT%-IB@>\\!9H[L6.E2;=[I[;. 1$=.#/E&EI9'#C!6
M_C V\NUA#^[05+^+D'%I6#7FB5;95\S80@L#= 5WL[8+-D/1YKRM0>(BI$ 3
MEE< .M>$[MVXK?[8/M%L<.M2+XE5]-EAYURJ2G@=D_UE)2Y0@(T]VREH#-PS
M<CY6H\CD-:09*.UU&%<=N !N2U&Q/U3H>"=6!-_]1 @SZ^[-( D;$TGS^KBF
M!&8[8;^ZY%[IA7#0P_?3C+)&+,MO[^[&2H4F?,0D_UAZ]EMMAG>-8+$70K01
M;SB3TX'F=#9,DOL^>=G]1QY:3,C@\B\*I.^GIQ5TOZL;&X.F@+?F,DYU#18X
M"I(;>"W,06+B5O",<<(SD_6J/$&1(90LV+$9*];PXZT>9Q6;D-?E!>G%MOI>
MJS%51"?B2[EY<SGO,]>6E,BUD86([-G.M.0ZRRM)W<0/>PGNR%STBZ;&TGS(
M-WF6POV9R[Y1F:0$@5]W(PD!LH:J!BH*Y[+OO#6=QN? OJ*'^C -CS*WX!Y<
MCA#1=,(>_IA%VT29<0'VZM(*FD8=-2+G;T1$\^<*"8Q\Q9N8KU8/"9_(9GC)
MU9=DVB:V8KK)9T.;&YSB>$C?1EI$_H _J7+PGZ."M) Y#>16(OJ*WBUM**6Z
M%&\LE8L8Q+VYO.5@YT ##[+._5X6%AENC<&N(?,"DUI0O>Z*69'=,)QK]LXF
MTV_5OFFX>_B^,CI9L]9FYL39^]M'4S>'-)26:ZL8(>R2/653K#1VTM/1V1F"
M23A_T.S5GFZ:E1QV@+U*G&CAMOB^3<EFNZ9(79. 4G#'EUN4XZS@IJN=9\ZY
M%&36TUUJ5+>5/(5E(L+]&GO8<<<3^I8TX=U;<@&SYDH$-^ 3-B6*3:J($=\6
MN/IUZG&\:>//N"D%G>K/K/.[E=_C5:#4LYXBA4 "?=#QB,X@6O62F>".[A95
M\->3K-<:C1&)?P01'NJJ(];-X6]5D6*LQ?%;8*%%,/#!A4;P$S9(1Q,H6Q4U
MF;BC>^PB.9GF3TVA6*N^_<$TQ*5[?:=%MQ6EW &RSVZ_*C.78*I!9L9?^^,3
M-JOM-U?3B.B,E!CHX>RNF-"#]<W^*,!=^(&@H_6L>?^N,B2K9>;+9<%D[5*I
MEV G>BNCE;&<Y^:.B+MUV?LLYC>J:6G"A!TH5XK#X\1&T7B\KA344W,J>N)=
MJ/HU>6%E;[RUE"HZ$:?'6;^#^^*A<,YL[/<]W 9+"S#QQ57W)(W$C8?K<Z.$
M^>[M==D *^T+5.SHGY_#,BAA/TI,W)J'96<]!9NU*O)-Z9_2G<E/,[;-N4[#
MW![JL.40BB2U8[!(,S@E6?:? 2@%U5"X&4H#<_B]R7WN;OPBF:[;3(=AK-B'
M@W>O![C\#+<;U((W3$(,-H9@VIN]B37TK03UB948T=L]U'YR2S?5*:$N3LH1
M6I-?%U!8RJ#:394V-V!^<?+)RT?] ^OM5)-C-AE%P<T/3$@C,4J*. ^O %T9
M'CK4FY@1J<'^QCNDD2A]>I?EW&PZ^IJS>MIOMF(WY8Y#_05P>#ZLOZJ&/X_P
M^Z.*E%.?.&U=HVMHI,@SB/J>'HQ/9R;UNET5()KAC__'1@+5^= $8T]8^C2<
M[82MUIU-NGEQ'Q6G5K5B=I5$#_GG0Z'WNU=9M\X+^_I;=_5MQ;TX,KPM5#'N
M>>3GAMA-,V2;MOY$^S?A&/S@DT7 123EAFCB5UTIGS*&7'M0Q7AY\E,/[JB5
M>P:]F6[<P'FI_3@#W1_C;SY=%3.][5FY/?*[R\#!<IE1TW,F/=>0>?<4EWE\
M 3N N[7+5ZE+XBW.#R?5O"-9L218Q(U[R%06][&&P4&>[LZ5L%RC*?9:@2GS
M*5#Y"7T<\&?LC?(.)5L"G*J6*E=WPYH^8/?D"7UMV4:<NOH9$) Y\C0/_C1K
M+%^&'ZJ[%1BA;MJ?TF2J>XY2I!&9 .R30#YMU2(,!3T#-NB 'EYV?:MCTAY<
MM%;<&_Y5SBNDP4+2R'ZZ)YU+&C!%B$LV!.0A%UA+M#YQE2ZNK*@\0]U^D<]%
M'8WHY@)'L,$<6[=U*<C7 FFS-ZYIKZD^NXXN/)CCZ6>=>@;8V'+K]9-02XI;
M^)G)<TSX<A9F<+VL*"UG26K@O!GR5IGLD]WI'7&[C(J.O2G:GY_(75GPOW#
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M9J7N%#>CBO0_UG*A^OG'<*>.]4'%Q@LBIBCM[[%B,]'--WS\N.C><EW@TQ;
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M:U&_#GB,BS3N*II#T:K,7MCF3M2(]+'F[I]8Q9O]7A8;5O34O28J$,WZ,SY
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MJ.G?^VV)[K>">);Z/O8/M:L7K7JV/'USJUXS*9RM",9AE\@E0XB'1,UQBAI
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ME!O+J>>XLVIQY7'%1->>,K7I<V(_1NT<A@Z'V:U>?E?=M:)*C?JF_$3NG(%
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M&[3HA4!=(!O:+68-,74MV9CHAILF,O7/<\6VB9OQ8Z7&+&,/W'\MK^G( <O
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M+BVOK*ZM;Z#W]@\.CXXQ)Z=_X,(!\'#^+?TI+LHK7+CX^'CX1'_@PL'U^*,
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M<K\]_^WY;\]_>_[;\]^>__;\M^>_/?_M^6_/_W_G>:W^BL??!2N;P[^(CE)
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M:^A@Z5,=;67[LD;5\MYS5[XN,Q*<D%8V.1B2*](5RJ"YT.3>_K1QJN3@Q/%
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M=1#F04OHY#9I1^)VA.:6G\A\QTTSY<*BI'7"GVY<OFUE+:GEVU%*(@6 O&=
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M$3;3[!XLAK/C$ZIQ4/5(L=E43;FL0<DF!HF?8J0R\/K17;:[_NM+3MZZI_]
M]/[3/N'?'=Q5;\\!^*G30HN90DNK_K)3Y4 -5&H[4/_QQ.4_3JR5V@-&W)+$
MDL1_>?8RX@&)(J<B4_ ?=8+_\FAFIRPGV?M_>4;S7RO^<92N4L<C:E%F;(=9
M&V_@SX[T7ESW'\<">Q H#1;8TIYL.8@QNO0!3_<W,["R_@O_@:T7GF\3_H$%
MJ,]2D^*3FEU/;_UG+I>=DYU---""TC8_$1D.@YI*8P$-O2J,FWGMG^@4DK$
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MTN_!K Q. IQ6-3 D678U,_Q\N6K4&P1<*\K'TMWOK:&C(R%A)$[+<;V:_+<
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MWP*X<LE31UMD5>"MQHG22M^=.UL*_[I>WK!>W)GY_DN,T]^LA;9#[*<=UUM
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M[A?"I CP)7MC'&\5",?)OWJ.KJV+R#-<7.B@$]+XZZ#'F6:WI4Y4U+[DYPD
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M8.08)O=F.J>U-J7+*-J<A@-#;&(,RUO0V+S^LG(>.>2/WW%OD2G+GI\,?U5
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M[EY7K3-D.6 W;YD\?>TA;Q>JD7L-]M%B7LDF&_9T='N1OPC,78+H ><>[6W
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M"H(AN$L<#^2U\[_EXMM)?[=A'MQ;RXB6%;I;@>R]IKG/ITSO!/Y^]7WQA5:
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M2) 4T>&FL.ZSAJA?98&T\IQR:ET:;!S*#)>7%HQV$3Z.=>6JMT9$1XN_I/_
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MC.^]V#BM\PDJ5O,2J[GO;E:15G>N[>L/:KQWGJFG^*LY4<X]CLYZ'AR&$7:
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M*^@A-:,.H.B40K6US5D+U$]#1 -Q9N9K$=AI8M_Z<LGGIGU#\4<AXQ/ (2/
MJ;H'C" 4(\!>5 >3YE;U!,)M.CNC*"J@4;@M8<2WWQ($%#,]#D+XRD(YU,4E
M@A+F;3>"9C0AO\*)5$+L!-?B5UPOAQC]P>%H?:AW::&C.>4Q?*WE0<.\)Q#!
M=V(8V%M:LJ2,.\336E"Q-O:[UL5->.*J@ 3JT$7:;EZJ+D*#)>A$QMZ<$3?[
M&'J_=7X]4Y,=41;UQZW=S.A7+S[$X-93@#4@@#(?#>_+?C GX#G.8SY](OUR
M%"M3\?N /=7^V=!$5'^UU/O'V-(2Y8*=,_&D?<$^^O?EH_?)0I:R"4K96KH
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ME%6./0GK-Z\W#C?>LET\CXT,59!'>XBO;&15XDP#$",S117Z*O<M$[TW"(3
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M+&+F3\:^4RCXM[]=<6.SS"*.MY$,;0.5FZ7?OON7-J.;E'83.;5$.&<V-3L
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M_W8>Z,ZU<^U<_S87A/SI_P!02P,$%     @ %()B5MN^.@ 0$P$ .*8! !
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M,PC F"P!N&APJITIE@ P$("C4 *P= .,@A, @WE<N"H'HS$8IT\ UCD(0)P
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MLHZ45O^OH'-2M33^/_1IU[G9GE66!JVK63]M%[_18T53459!Q<?-Y$<!.RB
M]K:GL]4TZD>D"V!S%R LW>\)0,Y&TE6V78.L0+FJLX$O!92N]YU3Z[P+MI[W
M'SBRF.R(I8;BJ==$%M'XEQZ.?A?EU,*SIQ3(&KV0(:\QL4CNBJ99_XZ4H#59
M/-,H7F"C$DXKGF^?C\9-E.B+]R&GC)9CEHU:Y6:Z^=*FY/TS_2@69HVYW%O,
M9+).O4OIDS5V[4N)<CO4]6 CV;D&/_=]U>4)JL$2HYF#@L2"*_P;T0O0UGMH
MEY ZR;S('%#8CX9^=V\>TZ=]"[NS<NM4I!)-HC4-N6A$Z'<8![)>\MHHKYW'
MB<RTHJZ'33=5!./C SDVO@/II0Q&L(TG)BPV+ ;&CYK5;;*4@%(4#V0]9$T1
M?M\!G&^[Y\TI%&,.$L*\%"1!L3MGH=Y(;<40@%,X#=2FE6EP:XWY>HI773*Y
MQ2$/^;QMBM'5YM:+I4<^.7(=RAS[Y&C(/KBI7QC"/E<,E7:[PFX].W&L"!9:
M]^BO@W)0GZPL+4T^1&_L/QQNX,+RMT_?<*B:;JA&?;X4>7=R*^8PUU;+HME]
MB(VKFB^^DS]/$134>#8+*XN>U$9[5NRFO&5W2:M<-VU[@G\\*-@3Y,M&M3$=
MH*2^B,"E)S?3'B'=<>FEC0O9;.5H M!:>R(<RSRST;06#9R"??_J=8X U)DJ
M>LYL6J9B1O?MX%%XL2$E#2?4B6Z+64PL62OYT:-'AM6EIG+6UG)\;NN.XDT$
MH/1<1C9T]"9&/[+.%@5Z8=;P:J9\:[,WF$^F[]S=EA*;K\6A(!F2Y@Y5*9+%
M.='@C@-057+X)')O(-H) 7]T37>C1=UEV>>*,Z"96V7KXF)V)(FTB.W0=:&[
M+]MFOD4U9T< ;!Z2?J.6>V/[];/HR@4.KZVMMW'WO=L&I[@7.S.8*FBY[2%T
M%8V4Z\DO.YWGIX2L'KR("(&U>SZ1:7+[+FR%=/F^A](/\Y>HFJ@ 15H*83R+
MW+K91O;,WUA2BEQA#4T,O;,S6@' >H_9IV"/:M"0%_/(?@+PO%@JKDA;C*&-
M6OYU_W*^\'(6A]?FNF\P1 -VK1([3_M]"W5'UM>ZLTU<BL-'282/\GMM C2R
M#SBLO9YVRE5S/I6I ^N]SS .XZ494^'&=J(0M--?;]K&S]^TK=)\"GR]>PFH
M!-AX/WU<']V_YZ>+S&M<F&?&'K<UB(7=29%?'!-WOC]H9^!Q[?M"@?*=*,Z,
M1X 2[P*DK9>:-G*.>61+R1W#TLK^-=-\'NO>:8YPJCC]CL20]VG/L,039(J*
MOX%$%]AG<I =]!U1,(=M;66?CVVXN)ZNJ']6;S^:>\!<;M-8\-0(NXFQJ. I
M*:6X^!QY-LIO#H#9GQ+KW^F?I[X,O"8UY&B! /03$0@1HL8%3>(_@W=^ 2!%
MO8A#VC4B>.V!G"25;US=P*L?P4^>$N=QZU_0S+] [,.A W9WJ4?2_H*9KM\7
M;);RB1RZTN_:R%Q'QA\#4S$:\:X8%RV[5/=^64UNF>,DJ>G(U2^VR]LD)3>D
M[=/]^Q;J2B+=?"Z\IXR-U,AMWU\LYAM,ZY.\9[UCZ/'CS<$GST'#%+B:I3J:
M%SD['^;1N)GV2&?F3JU^/-O;C+(VGV;(5D+4:AZPN#+X<??=H!6-\=T"H?CH
MCRH1 @4*01$"F:2_T_\9_>I,HT7=!&#I004QGZ;%301(??LC4A3^U9F*%?X:
M$=N1W?I/R;ZQHJ2!$6ZQI&W0%86WLXN%03'A\?.&8P^#-*/BLX)JR<H3'_X$
M4&.&][V2,<^::GYD482^6=2G=9 ]H*D4-M<S/FT=5X,TO!_OBZ;P8@3*B?XI
MZ8QR#!IOH/LV/1A3K*1W%8]GZDM":G8_9OVR^:/NQ+7A.?=1ZF</RI2S0L/Y
M]RX96K8F7L,$WLJ.H&GY0Y_T6O,T[8@B_^\O3_Q/)J9?P-I$F@T1G_%2($Y<
MX2OE)/D:C 8D/^FOH)K]A/4D+FR7 !PMB^-[5=D]_C-"D9 *VF;X*6@K\B *
M=J_(SLT2&Z:+7E[]LI5^CREK.RM)&TU&(><EVK7^;+)F$H1Q5Z_'@%O@['9'
MC\'V8YY<S/L#$UP]#8]+5;]%)O%HF@;&JZX$J'B?O&B@PO(;8+6(P9=+/[.=
M/_*\8P&+T<YCVFHQF^A;LS-059;<^VB732:,(TJ_+98.ZMUJ>7[(=E1)$<4_
MNJ=LA-*"B/4-6&G>N1H]$A)CPG=>#I(\.4( B/B6="/C+)X,^ZRU@:\$/S#A
MQ/VMWVE52ZSIX&H-KJO]UMW A8,BEZE"9/Z+!A T#%4\49M/354Q>%[_O:E<
MBN#9(<EJDQ8)X5;:Q$\^:ZK<GC['%M"-=EW4X'DHK0:Z?3X0)RNIN54XJ\.U
MGUT2/:)<$PK 7C]@<^_J6#G4REN?YZS30PT^YV;%N+2"J5L_6FSDJLODN/)6
MCEYIOR0)Z_G!-)Z\#,"*ILA(&KRK3I)PYN@..-,W,^\6/6J4=.[XJ&XV--9P
M[(%6>70HTZ7HGF2A3$X!P\^5U&06JQVQ4UL=502 %L]D7Z,9_&XC2054YQCM
MTJ*@,;CO&3VJ6!36>[5JEK)?K^W'R1J/*A] @P@%EV?$U%D0,08;E/1 'YV>
MC_)3U$HV&-G"@;WY4F [0GE=[R[U/BB/.-T35Q$JW[4C/N5--#GD+$X"BT#9
M?_>8.;G<L6@T9M-0EZ+CS'%'NWCP5:O_34M3SKV#CQL+&<WS;%C(_JO/F.*M
MUA/)YG3VL7+C<G,:[O79D1;5[N<O>2P&YG0>#1> ZBV?<K!Q U@MC'[S3QW$
M8$H9S>C!=XX9T\DI7E7<^8 L@RZ[!N.UJ\>OKF8JOCUKFP(XYQX_A!D,^7-A
M]5&:N0OSM.T+];>61?(B%,-3CDQ:?\1+U#ZQZY"EKO4YU(0^M,B+/%:'W2 F
MR!UP*B(';8B4!;\>YO%5G4<U3FWQ7Z>ND!>Y5RM:O-HTGLZ$+00WFRTU7(:1
M8>9?@*TRR* L^D-U1-1O7^7:Z_EP_S-+[UT6-L7>[THUNU:3T_7"BUJMH//8
MLL6#%OWS:PIV-</E;/E.FJN#X;"7,S)I1<VI<F /[E<D39;^D]P*&!/<96X>
M].5P9"J"'.ML$U59XGT1XG!-HD8K4%V S+:/3,R'2V=:%L_K/SFI &H5#VV0
M04_$GLJU1:6.5WTN_3QG'6LO+&+X24@VS%BUC;Y)#G$Y;/\^!MZJBV"V2W%I
ML:!$*>?.CNIG8R,-QS*COP\'GHGO6#:[EBDXG7GVA[P\0@>;BR9K3TD.5*&U
MF]8,S]5URW24F'?X9%=46>FU/MB@SMY_><6@;_:</C^9',!!A"R;&'$-+ 9)
M  #L0:LO31'WQ8J4E99%C7031[\76Z6:3]4_;?=4CI.)4/&YPF;V#3&4;?U:
M^S'8%$]=+AG3=PVAXN>U)\]M/C9T#JDSKO:_[;_</,#"BK#"1J,GVWP/-C70
MG>W["O ,Y";SR+;PQJ"*]':*]A*5#//9*9%&3WW+\7Z<"!K4ID]TV>0VCGFL
M!G),B0UUO%?KY^E)=6?Z@\A P#7SOD>6%F'+FW%QJB"]D1&C(9(_Q;[?Z5^G
M>PD$H*O9D9AT@ Z+[2=^71S\RWS!],:3 /"<@/'5ND302)QZ?ET>_&7R^5=(
M9R(I M#+CLX9(?YU'E[3'/*-&BV@?A3 8+?[;KIQ-NOMN7>T'6_V7S0?;QR.
MECVC6V7]T1F@+.@5>\/NC7G6X$BZWL4$_8<RL3<LLB/,3ET>UBGW;%>(^.NE
M^']'RON1.ZM*K7%Y7=: =%BG)GH,*#=RSO$$1!E3W_^?74CP!!0B],;*_]]8
M0[:&QK:E0)Y[/$N#F(V)[A9?_4(F/3L6R*MJ*M +,E(]BE-E+[_+)6E<-B%5
MJZ?9L:)8R/'9&"K&X]0MXER;.'9 3N<HW#ZG, QCX([W3!VV/2DL4,N]1QK5
MX?A&A[X#H/Q(RQ\8K,K%Q=BTZ.S>_@AZNR.%,J;\4!PG7_1E(TFBY\&S:!6D
M3?3C,T5W2N-E'[Y:/,E2Y1@S!KU0LL["FFWH5H[OF5LH.!DAG41RJE_R?'[U
MDI2_\+P6]UX5<4C^XNCD-I\1$2 F*?WG>"XG$[/7R)@NT2R.W#2T]EU0V.T
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M7VU\$K7("^:#UN[?P= ^ARF^=V38\.7J8S8H'^2\W;!_EXWGZ6N^(]MBG_Q
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M:]MWWF+ :XX;^P953ZF#T1ML<R(=O1FL5L(>N]\0K/AURK*%/FWBROI'+M+
MBC!Y5E3U)C5JLIVZEXNZG9C"E1"#EI:I'5 R*G[Y\_CWAZ^0SI>B-"K&:(KN
MGENF&9R5;B8&.<NL D3L[B;9]?$&;ICB)$[^<H93UL:!BGN:3J]@#5WX8PFA
M !:.AB?!0VXS=OX2V%QO)((6>V.RJ<J7-MS)O]^E8.,H>*8W5_WL8Y\$C4J+
M'<D/"YJ,3N+=A^ZJS,0;.;5310$;^?%;"FV(!R8;ZFVAX)Q?,#>G\(:GYT%3
MED_BG=K2D@X9N&^=UV2'KFQS; #[ZG,<!U<!G.$KM3C-M(5$;%__TC/8)'F
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M2DH^7L2FE@!8<77BXZ>'*(>XE;")M &>XC3W>K/7IPLFQ4>:+XT^.'^IP,:
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MB-AVT'/NT)6'^^Q,GJ$ AH&HJ1GD55H#E*X=[6.MP892S!P^XP)A5]]\4"R
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M/KZ,^9OX1\UF@!0J)8!J!@7G1/>XIP1%V@QL\04)4/Z<D_BCK=V9X-_X'W2
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MD];G^+3+;85VE@MO+%F;H;-B>(N-D6+N/=$G0%NGN:[)R<Z>O24K6G$<Q/R
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M='EUO=PIPMY03<N])+'Q2?:8%V)$#0=5)<VOP+$)J+IMIW55027%L 0E@"S
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M=\5B!*PBHN&RSE2^<#.>D(:+4-+6XYUUD[&W>W::^CJ7:KY7*%DU AQ^'&$
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MJGPG?EM\SDY2P=F83J?RMLG!G'DT-4X331.XB9:VJV//G3:V3638REXTEOC
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MLKE9&FI)(TTJ2Q?Z<0OTL,>3XVVQ!=3%N&Q$["AI]J#W91(S8][+ZQ$GM#)
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M[A00KLG@*#?>FX_28&(AF^A*SS&(IT\YK6':'2]_[RWKLV[\!)\C]+/,9J)
M$0-5U1FXJI/&8Z?Z4BQ#(O449/.@K#,YD]K06>XQ]6C3ZM2MZKEK"KPX691%
M'!9L.BSF/<-@5"2T#Z2<LBEA2SAPN4LU,,TL*=;)9<#7R2A;VL@,.'81L^>H
M7)H$MFBH :,X.#'VQ79C3^QN4CDHIDE-J/I+QCN7?9=5%PA4:03R4U=*-L)8
MUX@ VCJ@!SI2\5D44GNX.%DY2LJ$A^'2#143+4VA*>8RJ1L)_O)W_^P#Q2:$
M 5JQ^A$L.6^\(:X1!SOME2.F-IQ#4NBZ9 (]/ BVW+E-!)R#'8]LF"SC XIA
M,\6,])M/^9Y<]8F%]!^E# :R5-Y<NR_Y,\J20)_[BWS]#_)A6',%I@]_9 Z;
MUSSSQ&KL,B(SZC7MP$=SLU"X+A+6EW?:+GKF7 XA0;M+O]($@WX%V#.!6A%\
MBA&8,W179"XQH#2@7/4K# =P%OCOKZ(Y94 $P*.W:;Z@$,O#?@N?B(! &Q3\
M:.=76FCXKXAU17)GS2@8@G'7B(#1XF3K3.O,_Z0Z5G^JPX/G!U$2 7WQ8X3S
M9Y"T(!>=Q,3Q,7NS -;7?ECF5Q188]$+<I8NP1GX,9\UQ%^"O_2WH'R7^_[4
MP54/X3R@KM+^/C"58Q*!QR?.=APWT!!\V[>4)?]M6?!\K(]>5\=+_X//E\I4
M[Q*&%PXYD_XGG8MSW,^E9)&O=#C"$0Z ^LV((P_@MY^PO[2NC.?7_'/G<B9Y
M)WD/1A#+"R>=QVFL!%_E+6DXSB#MMY[]F=W5JC"),+_):CP>!O75I#IC(/.0
MK>^O[>;]QJKKE"*K(L=_31TZ'^"\/+DJECYU)KNRQ>-J N^+9.?306HE^4LE
M!J2CWV T1,"/YU-IFT1 >M(6I+%=32<O)75/ <Z??=G5Y-WKDGY?.FT+S\T_
MQ[-G3@H*=\CK+'O,ZASAD\N^JX] T9<3 3GPPQ&[1:\!@_PG?!T?U0*E93NY
MA?$WJ\![0X3COT=N+$H\%2,"&A#'(Y6*AE5?IL&&V?B\5B+@G4$7(0DV!_XU
M'^C+_FAK[&P!5N5E3NEM ?_O(EKY%R+D+Z*^7T3Z/QLH1H3<MB-AM#["KIVN
M]63L@AL!0FS,Z)C%Z9DVO>?U<1S[:# E;'%%08((&*L*) *R=K4W\ST81[[
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M[NG^F9(ORC_3UK+1_R&1$@%G1&L?H 9= T3 =OY$#_,_?O_PB%6/9"K,C<Y
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M/2#NL FCA!CLU+7FG.A57[:_^8+$Z>>%^:]'T>1LIR** &A.W*]],H[K6.J
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M5W+N8I8-8=6\[BY&4J H=H<'$'%J,PS0-O9R"-E+?7YP,(C4+6NH+84)K5%
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MCC[$M.^=*?O;).2YXNH&(QNN[ JFIT^.YYZ4A9.I)W\QX!WB(15H(>D@A9L
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MH_;;NTNT7?-$92+KHT]),I20J3S7!*=#N@K$<1]W_GDE_:W!]P[,<<A7'#8
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M0'TJ1%BUUXVGYA?$5X5W&BJ7,@MU!VA][G'O>J+@E&2Y=>\P6-C(1!,E \O
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M?]1W'8,.!S&UA3*)^5AQE&'V>F%.?^'&T>=NN;+/$6[NKR*C>*8;/>Z2A!
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MY2S'?&,8JUW;]G0METUD:'I9Z[M(-7//*V=<E"V#;]2I-.8.04P=F "#:9'
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M+2886\V:T3L6D?![#>$];GD+:9(G3XEI:4M_X2OJ9YX(HA5LSX$_,Y;U,U/
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MK/K@,WU49SY%Z:?[OV-7_7ET&#B-&(@5@4@&0C_IPEZ861PYJEJ'JQ3+H9^
MBQ*A]-U$_.B&YXBF:%,),1NIE*;NU8(IUSQJW&,AF'Y MJK*NK0T2)+K]1B3
MD8[E&K)S4:=2EZ)+T'&<;#NTM>9R2VRC?1I,ZO3Y<+^$=^+P,\91Y*"R>#[?
M.RLY49OATQA^5=#5FTD7DI+36>\C:7R)FY@HMSYA:S,H]!2O9$Q'S\?RN[I^
ME__6\^J6"/_#P)=WQ:Z*,TIOT"Q*3[2S1<X3P% RJ2B8QF#66(Z?9(2)85.%
M[NM%O>B^9&I%Z[LTF>%[LFR_$1,1)K6CH\*%81? ED\G#D+ZJQ)>L*4Z"F7)
MC'4S3F=QQ1K+N[DC'8*A]"X#%ZQEN)I0U8%>G+EZ$0\7U763-1IK:A2MT/S!
M""H-<=[Z$'XAI]WCHW836G 4CA9O,Q? "1JX^1I48VIV?-U(>[2JD\-;TDSE
MX L[42^,FLEG'4<_4):81;^2;4;)@E+-P6'MTY;OG:M'73PGBUY'CY$-Q\A8
MFA:DNW#^[@LP<DPD05I?%&+4#P/+4+A<GU<H>*BPF4SL]0*0H[=='YJ'-+68
MYK+02L$'OG8<ARW3.= 1Y<<$C;C3(.]MGFD"KIL35B45#F 7O>QYC4HR*"+9
MW=G=YU!(2:,#\'XJ<\,*COJLTV+LB8<P#YUA6U'EQVK5F_,.<?4^HBL09J>D
MM7(3/G!LJ\1V_JGI&I-,(G)._G$,*"BO>OI+&U%"]572%;)KOV,KHG_/F*<)
M%P6V.$P8I=10_JH8Q(NB]1A,90-%_#-KL>GW&D7?[B")N3_MM@9=.GT[229G
MGX)W]'<0&RHU'J&8)$@4_3S5H#.46@_[&$T?(?6,N=G%@7P6\U;WM0.[Y07=
M!= K=<YHW0_?CZ>ZQ3L\(BM@5WUN>H'100'.44QJ"!.R-7W\XK^L;Z @T#IP
MJUOK6DUG)V_?%!$VF)C !CAA=ZO)>G/ ENI5OAC%S-#@7F+MPX[YZIVQCEPM
M"<$[IHNZR7L.K,WL8E957R0?KRS?NP^ WB^$/XU:%(OR,C^5\KHQOC_W4@"O
M84XTOS[G? 9+D7U1<@G"^K=7=@/;V@^S"'F5GG 3;A@MCOHXUP<5@X7=?#@P
MS]!1+?-,]6CM7"2<$M,J.0E#OOGL_:ESFP&[A?[*=-O,I>?X%4OV!4J;%0$?
M84QL&_R"EX-E_MS7?*S2H(M*@XC]QG5;D:W1;W0]SF',;WIY[UY\,V]PL.PK
MDY)3!"6;A*\UL8T(B$@NYJ_?U>^@[5][&HA\FBZ5K*363O-N0__?MG )] _1
MKXNS4UMX&+Z23J"6RR (B<_G0)H.VU'/.8#6ROKI!!9A#1X:+W?AP+,0.!_>
MEGX4,/5'8='XCYMT\$MQ"6LHL U"B.,Q;9K8G_[_'-+J9'8.2-F#=N+. 61A
M4*:O9!3FR6O(2D37V2X,J\6&2ID\!P:8HTZ_0S %B-5TBD4<33+;\:+C.>"%
MA]:T2E@N4=!>YR+NV 3'6^/!_5_#A#2SRL3".(=SH/C5]*][ (M/8*5MV$_G
MR#X"<0/]BWR2[MD!2*C7Z^<('4:2ZGZ#K2/;/A&'8U)CR 2>UF >8<G_,1J1
M/&6CG5[7B9Y1N-:J](VTX%TSU\1TU<:W!KX?<4;UCRUL69'5O]KZ)X@MP(3"
ME1+9D\0-OVP3WZ4\*##Y18#>7W?@W7X5[U>VM-J&9%FZ?A;O%\V\V7]*XO@7
MPF7]JAM#Z6L$L[\*E_>K=G0H%?Y1)OP7"ZG. ?Y_4U:V#7 @*9GA;GMM]4I1
M* /QPIZV36 0/F+W%#Q9@O64_MWS>7_S45%5 )R@J!1=?W_R'W(N_CJ^B7^<
MS_O?.O6T9*#(0C7%;4EPUN_*QRUO@#6H_@*?3BM\]ZZ^M\$Y("=,L#KZ3^R0
M_K=>:_2\(>!.\5+@(\KKH5IQ@7)$+V&"/MS@*QN(ZLA*(^(U!LZ&CN+OIH[\
M9$[,_N_2'CQ8N-I6Z9/]99NAE -S@*)7QW1DYJM0MQE7D&PFS+R]M'/=/U]^
MJULJ<N%,1BZIJ)KJ=, /KYI$5(I>=.^#UEREQ4CXDI?:0E2X6Q-)[*,:?X7A
MG=)]K41^ASOO6Y7'-;^WD')KGP.ZYX [^&O)R(^BLW@8 D*#"=(;%>XU,JJ,
M#]430#K9ETG<4.!],TL+F*ZDKY1X]7:9D&.54/"GHDFX.)'HN>!MT>U !V?'
MEL7K+BP=3ES;$^N0J2D+(:&\&*\YAQ4G%'R+?^;.1VO1Q=YA./N\S!V?L0GX
MM09&)P0"@7%.]LQGOZ]Z&'N?5IOB0D28?ZU.C*?SCC%7IE6USZVQS8KZ2Q$=
M6TN]9/<$7;FN0W]+RZVR&0CTXBD"]SY3$U,8*1%1[5KIJ7HXHRC;RQI:RQ[_
M8+EI_BP%8E$CPY W4=E&NQ*2HY:71Z JPA[W;*Y['?[TP5<'2?KPYB4&ZV=M
M7NKF.,LRWV8+0_7P"$.M8^W=R@II3\3.>R0*Y+=O=X6:A=\NAN96GM'F->*W
MXBUFL9BD-9Z:_5S"#9/P)_;9*3GUH*S5D0@FQUSRK/1U[LSLR3_R4_Z81E3!
M '(B\-;(IWKHX]'7)5FCPHW:$\0&S-TA]_H*P*:7;^1WRDGY^TGV<!,VB_RH
MS:67X;#*;9T70'<&F2/<JSJ\G1!S$KHN+(J K-5<:I^C ^-<F>.H:?ZMRA\]
MF_6&&XRRP-6(SIQ/JQZ=R5EW_)SGM.=6/M>6:\\QB792A <QF*H\(/SDM'7M
M*4G0))9D?*>"+42LB6/"3D20"3SRV%N@Q*Y8GT] ANWF8B3WQW*9N6&ZEP;+
MS8OL7/+ML(NE!P-3&PH8%];<"\:Z4VNNQ5ZKG:*BI83W+U['SFMTG8YMXM\;
MBPE"1 6? P@/:Y.KPN3J:J'$P[&/QOA%&#A>CO>^L1 D9"=35N$5>R--^7AY
MXM!U%((PQDJBC@X;2Z$("(-@B$5*YXQ%N)&AVO>\S<D4LC299\;'"L ;F=L8
M3Z=2+QV4>ACU-G<Q%N20)\]9SR/(4Z,\YIKF;]^6<A*ZEX.A7SR[,]#!>FU8
M2B]K!DS?3I^0\+:ABEHTURJ!HZ(*?1<B:,W?K-RCZ\!U_<H)12B *H1-G6I5
MHTS:'@VYS!B!.M,N5NGR'S 6)]D:!-R]E!NH?$3X1;9PS_+M8J1M+@:R &/I
M0A9&46-6V@^K=8C[=&=6]8G>MGUZ)!9DG?C*U?+C C +D+IT=_VX!MT.B1_$
M(Y^[F,H%.+71?-N9/R)OVS+L";?>IX8X5_Z(Z'#%6KY(^>M1;EZN&!VNCIV@
M\M5XMT65\9LU?J=JHZB.XCLO/PAUU]SPC^B-'G$46<4O6?X;/VY^8.]":ZI?
MQUB:H+;BSI;#''+FY?/TU(0]HWO+%6E;@#(6SROK6,8<K&X5FH@:G&N":CP,
MIVV8=.Z7 %MR^%T+M+ZT,7&K4304.)[ SW!BG !6?*2T D*)@;4>3JN-G?6O
M?W7*49-NM]#A=SP=TU14TC!^API:.,;8G"SGYF_HL/*@[1O?5#.5U#I1MUI,
M7NE@4JREZ@Q]<XT&GF)*^3C35VIGD:3-$Q9"A1'6GY>W/ M &K"X:@C1+'<1
MWGMEZ&Q6GU_ZD/0)_G?^G9 K7AIF:.J5+@BE2*JDVG@EL_*FBY&8H9_*:P=M
M(:]\]?B6\4>:O2D?Y @CW9R.3,HCBPO!)$AAIBJ8'631Y'H1Q&$T9BZS\IT9
MH$"DL2WPO9.4^Z7;]:4)V) LFZC/1&\N.+9-@B1@O]^53SUXV,8U2Z&\,DYM
M8J=:GJ_.5\]T5]_"HMDP?25<!X(F76A&<[4H2Y&F&]^.F?825<TU-+P99V:K
M$[%(<3^&,L$?=^B^9NR+8QV&ZZH95?2*C<4(WG3HN[Q2Y,Z1'LM<M91V/U+-
M>I#D(P:""&R",?$WW;35F79.@*!"2MZYV+ZX'AJX8.2^Q6O/\9[=-SOV>2G(
M$B.E@'0(<]JH5G7*!*_/M\X:S$243Y^E$4>!+8CLR;0F_/VRQ->,ORH 8 %H
M*RRL+B R$9'J@"1.I0_DYPCRR<^<,32P%4,_DJ-2X4JN$F@F[TM)\4PY(0G$
M$CIF8)^A@T)?U84:>+\=;[VT-?9D-:+FXSVNLU)A'\7Z KR?J1#T!U$U4!6!
M,WM;<=RH,V@@5K[ :'T8;FQ=KE:@KP+2"@]YY/#Y764V2>F-1=IE.$T3S3J4
M5.8RE@FE5E++9.,*O2I /:*K*]7"K"HP&]UM]H#L>;=0]L*63.6AR/.&D2T7
M2JXM[<^SQ]1%0^Y#0;M+AELN XJ,#]C3K B_8N^CJCNF)]KM!#NA5"+>K"='
M\GZ>WFQJJ+/LSS.RYLRO:ESCII(4?[L-KP.ZEY+V:K"@#*_G9Z7TSU#;N;9%
M5A):$27Y):32L3,R.933-\O);YB==J@85?G>^TZ1FSLZEIRURF09A(@7$%2K
M&+F5I)VFN[F@'+?T8';S&EG9@53*4^(X@?^_0N67"I5_M$/;?[K@Y!^^G/>7
M_(3U^,]-'OX,Q6A_R4_@4=W/;1Y^PG7_S*/&A_=<W//6A],!#1\,VUC:A7B4
M5*X*?98R]9_9,$S$<"W<MNMJJ;L,.B3' _F0$GB2>#&[]AO,JZ'>9Z0/RQN5
M;Y^1S3'+C520*F\)SS#;,NOB-D6'+@UYOTDWU8Z<7Q@)&H_DO9Z2.O\)E<MD
M&\_;K:_/G:W[3[:A^'=;5*AJ57IN7$Z/(E@RO##5\=8$Y?_C@)$!Y'0-ADG:
MSDNGH,==]3P'CC<<S@%OL1^'C"Y)GP/8@VH\2$_&\M5E^CXPP<CMG ,KQ;"S
M?3A""7OCZ!S8&X?C3AQ0)>NA  *"(('A$3S>G(]&?C0N_#.!UA_^)P ?!+">
M SB/F7, KO;CW!\EY!R0MCL'=CZ= U?^*UA8\1)+-US=Z]D3MF>1936@&5P9
MKN/E_G&0MM,8+'.X?>(>KTS[RM64,5DJ=N)[R?#_"*;_"UA04D 5SR<7R#NQ
MMZ[6=C^<^JZ\?U!2]S?JRY+17$';+F%Y\W015,^LY]MIOGF3XR?5_TBA_D$6
MY%#XK]5%?W" NXTG<2$M@7!J4H[P@['PE<<KUSVT>O[!AMPQ\7@QHOP$)V.7
M_X5)Z/].Z_B5!:TYYM9J#]><B^TQ#S7N?PA768MZO&'US_4L_V_IE\Y;N=0Y
M/JZG+?9[YOW@178G4TNKKYWJM>FDPCK=,D)G13(\7I(C E@]I$F0A$4$PGI'
M+7/-33]:3<=/!TQDQJ@)?J)(.2=96(LI.U6Q32/!E"$$B3%NK=;(1"_Y7.\O
M<SZCIK&.>Q?"HRNX)QE#5L6>D@Q6ZN]NL\A,&X0E9E57!Y#%J/%=5!Y]JQ?R
M "#;M6UNHO$9,KXQ+L,.KFZ&7G7F$Z2T]6$ML],TJ"?U%R@W\&?D?ZM"Q)\W
MY_ZU6_.>L0FR=/H^DK)CP%\&A*9+7F!VQCB(!&PGLXPFY#@<5M@QUDY%% 7K
MVFN,++>)#EL1;J9*/J\8YW_9^+G.[_#_:>].@YHZUP  G[!:EHM@631(+*)"
M(<H.0B!89&LLBR#(&A%98HR(J*B@!XH0!)0"!:Q%!!'0A$UV)9)"B6 0V301
M62([@D" "P1RDER8VQ_W=^_,[9WI^?'^.O/,^6:^,^^9=[YWOK?7C=^8<DTB
MG6ZNI=^.B>_K+23[]<V;6-XQ1?()EY&GRJP>'2L.BP<\JD+W;+<WFM%M!T_3
MUTVQ$B ;F2;X]C[M]%AKGF&W"""YI)@*I;@KY?2R(4(=UK0@<MS7YU5V76O[
M%%6)X?%M^MKM3^(V**(;WOBJP^IOB>$)0DMVC%<^KI"7TFQ4EO>T<*"#YF3T
M/%D_[8-Q,O,:J='I-25@M^ ))O(Q44.N85$$Q.L9@[(\YJ3E#=,UEZ;E?=6$
M"X&^"0>H8H_3ZX'ZG9)AXC/?ZS(PTHN34SZ\GC$.>5BS;ZXF.DWA:#TKQ\G@
M3$.-U@[=[!%'[V^LHNE%%UZ <[D]T Z6];ZS0G4B49J%=.J^Q)L(0O,E]79R
M"-OT45IR"NAG>9+ #9Q=3&,H'Q=SA >.=BF<A$YRT17D&I?M@RDX*W?GE]X)
M-63$\8B&Y6R_W IDDK3TK@ MP2.(>.#5@DJ,(1>,+ZU]X(6K2YR4[6A<T%2^
MDY_LD.%J[ZSA89-\,2ITKU2L]4^E E^_OAJDT>6GG $"*S_!:.C-L_TN1YXG
M[:S(@\3YIQPH,?L7V;=I)PIVH[RYYS:__'?& X1C5*W2YKTR']:C<#^/UPV&
MFE?("HJM=6.<%CE?U@B;:Y7H#QM69RV@YVL&9G4[EUII-**%1F.?GEK0_)*4
M'7 S7E?*E7E1X7#)B6@4;SE>P!!^5[HU,/WA-8JLSBTP]'ENUMO I,K9U!VS
M#"#,S1L_L%E"6JN* )[<.S"\ N+A1< G(U>I,N4L01-]>60S4\1V.JQN;&:4
MS3PB%#<!SO; "$8P@A&,8 2C_P[=&94(^.&/1T0WQ[*&D.S_@SOWFQ<9=ZF4
MJX<"JKOG&8FU$8$83[-CCHK./95W7K>IG=,@%X6[V:!^?4'^PEY4\.7A(AZ9
MM6P=V;7X_UIFRXC::#7RPQ^Z?Z5M^\$+ _Y1NW\CW5KR7L3;SJ)D(6^*L ^_
M#1-P7_UVP?2&K.^,F8(Q?KI:[:!JARX]XIO'1[(D(O$_]-B@C 8@5;9)VL?&
MT8#GE,]IJO$8NQ'WPO+\:GM<==O9NW&1#>I:N5EM'0L!P2,5DM %KE<SJ @A
MZ[GRQ87G%P-L2:,GWI]V]!FV><-\AOKE08>YWUQS>I2<CLD:^FO$N BHXL2O
M@$#,5]SRN(I^TX?4_C;#KG-ORUUK6U-I5$5F)49C9?P%.T&H V$%)3?W0+9<
MSH_NC.LJ)830L#J'X\DL7*YOBUQZ9J/ MY5IBW@ A3[98"8#O$);038M>"P\
M 50-QSB%DPJNTMMVI5[/*K[7JY="G#C6IVE$5<PQM "KQ/)H<B  B;,7:KND
M/^>@$)=0\F69#$']J+R[9\8G7&7Y.GHL\92G_<<WAG[!9!O#FPN/\Q62L.&=
MTJY<3C)-9Y0N[ZSJQ]:;IQE$A*3N(CXI^HZBI&]F(.9UO-\<K5![7961UD_V
M>$</P<OP4"ULE4)_+JUNXY:ET(/6<#2S$W$/*AKV5C\_9BXMGCY=QC> L#FC
MF="1AMXSC8NHO(-N4PU7$G7(3BJ8N:$\^XN(\<C.ZPP@)GIT01;R%12M=$E.
M#^MR]0+$N&]30(TBBK]ID7*'?WNL]LDL^XEV0\0:N2MC,'(Z0((7/HH^L$KC
M98Y9OD07<">IQ3X#_?A?@C2]',O>YX21?I<RG<$F-L4]BK76YTY]Z1F3CVX!
M:_X1][1?7I%V@K)O,BT"D_["96*PPS T2"DNR>[U3N1R?*J7U2*R!=QMK0U)
M]F(0V-^U_]G6[?D^N,F")L<6?G_O?5":N?N/:AF\=6=+&7[+5F^W(K')HB\&
M')$WL^.NE&T6QO-!@:4S%YDJOO:R2Q+^8X?W7')G%=>R:>$'&+,O-4E2'[&(
MXMS]9!\E!0O<2Z:<;Y1@4!4;R7,PX?38:&P-*;>V8F&"QV1=ON:=9SMP!5GL
MG *.K794$SDFMC'-H/)*:6@6GD;L(?S)^AF.OWSF&AQ_V9XN"&U9J#]^:2CO
MQ,OW/RY)$,[4A:"55L[LE9.FB\6::I=2P>V$-<5$OH=;7D(P*=4JR02[RMK<
M>NPJ9VT=?!5[R,T#K*L1 >LBH$X$T#N$QB")( *610!)!( Y4)C8BK(#G^@B
M A[RP_D0?<P!YC"'.<QA#G.8PQSF,(?YWX?_N^F[7A !3M9\-IFS4.M ?MBF
M#E5)87\R\7)>-D$?G9%'VHF5Y,@T3,0=1M]]AZC_SY9[KPSF<,B0EF+[D"%3
MWHQ_L$MX(W#S342A\MED@"K("14!UI4B@%.[=;]KU1<1,,5"\5?I(YY/\F7H
M_5? Y5D% 1_/+80E+&$)2UC"$I:PA"4L_[Z26C)@WYPQO"^PFP* 6=Y%?WZ,
M/!S_V\"*^O\%4$L#!!0    ( !2"8E;4Q_CSH/,  -<6 0 0    :6UG.#8Q
M.3@S-E\S+FIP9^R[=U14S;8OVHB 2,X95) <)&<0D21""TB&1B2#Y!Q;07(2
M$!"0)#DT3<Y)4JM(#DT.3<[=Q 8:>'QG[_V=???Y]COWWC?&&_>/6[WF&'/T
M6E5SSEI5LWYS5JV;J9LE .D+935E !86%B#E]@>XF04H K#OW/GCNBUW;R^<
M>S@X=^_BW,?#P[U'>)^0D. ^ 0$1,3DI$3$9,0$!*34I&04E%145(0D-+34E
M+3DE%>4?C6!AW]:YBX./@X-/241 1/F_7&XZ 63W[OS %L7&>@2X0X:%389U
MTP-@ 0"P<+#^HP#^7K#NW.J(BW</_S[![0-UI( [6-C8=^YB_Z'U[=W V_N
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MI)9F(!%'NGZ>$W.,H"JT+8S*V^O!<?[=12G.NR0OQY*]HE2LE\CZ7#3M)K0
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M,LD7] *\2RH[6B0^&L1>-X:Q\O4,7*XI['6%&GZWAQ]\>O:XU9:VVF-^M"[
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M=@X89V5_;3?XO3/2>3:*?:>;[MRE<3#PR,#E>JB=/J2;6698;T-++$BX.?%
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MQB:8<Y4L?%1 -X"/T4IARY7\%&?NQ=?H _0)QL&Z0RU/3W2KKYPYU@3]8KQ
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M#@EV]$$5-8L#"91!QIR?/GSE8DW?Y,4H%6S3URVD.8!Q^G)M<_?Y5AP'2#D
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MT,3^RI%BE(>]@V^0[86)IS=P>\)\A%D?"=<32S^;/HIP3L*6S516P%3S3/#
M1!V<T2JMMOTTORH75$0L1@Q"XHO8VQ*JDN(R2Y"8#7K/)S4+Q%V#>72:5"NU
MPY^UE (-C\Q?BPZXP;MG_.?GVRE=$J +"1W-[2?JO<Q\=<C>QL7+G29<BP:=
M8/",L\*!B5Q(WB)&84*^UE.?KZC/M[-+_)(L'JBST,KK9/53-+2;WQZ*/+*I
M">T\4D ($H_#5U:CLQB&]P-<2YG\#<R.^::"%]$&V)TLNR3C\)Q%,^.M%*BK
MIX@7\L%:O@3V[ V@G,LZ?5&CQH[-LJ$^5$C3I32OP.<LHFXGGLH^:IG-MN%=
M;2UV0I9P_ '+:"./?IB:\LC9]M"!,R;NETA1AF[+F1T,:;;NY!.-P!FL!==X
MJ#[6_;)[)'@YC?<M?IEYO;95 #G#(\C4!ZFWT\?AT[\R K==K5SH=81@.&C"
MW_4DAB9I)X/]Q4T[=@5RKCU']*9,ZGTB>?7>G!>,>"C[Q'AP]BY7JJ?(FNFQ
M:.*]U%*B.NY7L@RX 63<@H</_YI(P/OGM$O7/^&(/R+YK/^UO3/N^@*/4RG'
M^5_/X"2$ H^ZVBP?D%,&VMX9H-JXID>)=4!4BK:I9[+BRWM=MDXA_-,R)9"$
MYJ64GUQS9(.<0'('^I2&BN\L$1Z!CP@8NAT9Q3\%[[8HS"<].#DN\)!F_C :
MM7S2YF]8,Q$@7?"]W.Z3[%KM&+!8'2 H^-)Q1CP&.UMG-*-@YV+OM*UXD^#6
M_WD+SA2,&R47--DB'E=:)&"_292DM>>GEH9.1BVW\A3[%!E,BAHX>9I*S-IY
M+UHE6%0_^"U61DY\ TBMD*+?M_O U#I ?:(ZHXLG:694/+F.4''GM>\Y+,])
MT+-H,3;=_#4TZ)8G&VA?/NEFTO3Y7B4FMC.1AZKI[57RMRU>MAM [?M7IX["
M-E<LVV4#HAY;-->&LS]W%2A%8RI@I(HLEPJQ( 1)9:V5IOD#QB5V(N/V<0BB
M*E&-4?%^B7>B63+9TY]O@0"LU[>X<!7X-?\E35*#)/0!>J_,-. %2B\$F:24
M"<D=3[I4[*'1<ADQ*$'PG@J1Q1?8O4BM38_K+]N-"U!RMB"VK+C@W]V7HPYX
M91;U:4<J-"Q-M"-\KZ)]H&C;39P^JOA\5:GO6=@2\\G<A :'6LVP1XN&.+!>
M79U!-87V08RY%N4;++WM0L3J.=4G;9T8FEIO<R7*U_3_LJ?P\L_#E&I11IR
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MO)/R2[$JI%F88\JZ J'6 T+7_J;5)6\V.%;Q=GI1C^,K8Z.GVI/"36\M/L:
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ME>8]YO*AX0 .\ K/T)ZIM1I.C9MX )3S6 O#A=FIFY11*D#+]4EHCEN9*-H
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MT-4NP\-OHTM&.B"R,;QM=Y9%&9QWH51V0E=)AJ.+8<'FF*?>RMLD;7XX 3<
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M1_#OUUSQ_[?PW@@15.!,5"0&9# E<G3]Z,?T6S_E9^97X9>='?>)U5<0[OM
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M\TYU/OH=R8^'!"\S\!A2%B?4&. ,4%!<\0$%8F'F7T<WC_Y%U_ZW3FT)\JN
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ME-5%F)O?Z_[%W2F](8F2I,<D&REY5*>*0D8I.B 9Y%,L+^TE5BX?=NUIV%B
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M.W?./FVZKLI?_O-T\3+01=.]^\IC;,^I44)[_*=EDCG[_G.[ ^.E*D$ *->
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MRETH]H7FY:0"T^&!V*4)J_MK#"!5=DID\+XGY[<&3M.E1<(9<W[Z\Y>< \^
MO,7>QVD.EJ/!;N]L%%?CED* AR^,RWB+]O9/KE_!K)^&S4R^F*;AXICX(')?
MGCN7WO<6]F]<I>#<03Y9KMNUERO8:K%VKADO5:-6WB)<AI[5+#<+KC6;UF(
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MI).X:EW\RP/N.WKZ^4M>W,B4GZ%%3)N/=6@(.SRH-H3-FFS;PPGAQD<!F_3
M;?T?\[M)#_TS#8B#0F48:YLE"DGU852O7!_R7D)5!ISQ]"3:V(,GCF&.?O4A
MD&8I8"OT76:!!9US#;, \[.@_/4XX:\'DAY%$46E98*%F?C<)=WTPT%+P@I+
MYE8"\]NLH[->VVQ799ZY>6>HPJ[^,HMXYWT[](G&^]STK_WYDY%^4.?S;0P
M %EX6#99L=8T#-<6:1.5[]?GGA]/+9"T]ZA,/GO,!]NOU]%UT<+!V?*<@/$H
MUXX9688*KN\G)W.OLO[>Z_5$5S;>JHL3;;_F:>=Y1M!O:#..TF'%"5A"7WC]
M:X>8P;F:".>3"9_.3]F6GC)>_?VC3M '^F_3S)L:2FNV>EY_X-EKL9.TF;W
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M[/:,!&=A%Y=#OO9\:]R;[1=V!4UKB4=0,I12 ])Y]\)T^2AI]Y*[FJK.GJ#
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MP0 >S.>>YV  S3GA%U+[X$:!FQN^0DGR3T;&T%8!\YOMYL/M3#1QO>*A @8
M5; 8D?RM16F ")V!>MA>7YG]8TE*+F3_:4$A\-N'"V[\![=P@Y<IRG83OF,
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M>-2OCV_H)QN 2A?6R+BSZ"EAEDRW3/'&X8J41_>J:AJ;):BJ"(?X"1<CH@$
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M/I8]L2%IT*Z&%\$]>^JP8$U0606P]G#1A0O$#?0A6Z:)=W:6=I<KY>L&UL1
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M, T\6W]"4*MG:1^&\U.[5!97Y2>IL.A8W"D-G@ M_73V!2!S] (PKQ3[KZ4
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M?O?;PC4@X*M!%8@XH(%R/O [^M>/PGG\[BC "07\/C?M>'B$ @3>HX F\YN
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M91YVP-0+$D62$\VHFV>\G1T'NY?=$S%TVM6J,F8^*-)7X<^/+A]RI.%'/:
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M+\&96"-'9%/WU^! ,]:R847K/6:\WYWXP/0WP,I D] S*O4OBGP=QH:?F1,
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MDY!)_Y"3!OV1;T%MAUZR/Y9"D(CED/4,%( G6]]X%\3A?P5QWEO*R:"VS=O
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M%4X6/<GF!R&,<&)WTW.K=3\UA=G#$SY785.9X_D+#=%]W"-+KSP8]J[VHV'
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M)II:'$DE8E]J;Q+Z2$R2[%N0*D?^3JBS\5,'GJ)LUO_P@?L[Z'N%7.$J(%#
M3Z[*5ZO,MT\U;V5_XU9F?JL J>Q5%<!QD,'<-Y[,WQ;D35! C.PF7/;@_:U-
M?=2NM6OHMZ(XWH^0?_NV#BGVBZK_PMY;Q\6Y+6O"32! T$!PUT" AN!N2;
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MJ#54(JK2GKP';DB1+;$Q-Y>GSSIP![%$.0ZXW0)VS^ '[1X]'VU-$9(=O;>
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M>7H66"7../P(IR)YMKAN3M<)HU[00XO@Y75XVI':%,R97Q>$@X)!=\P/ :T
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M0_OB9?:$CLJ"G'CL7^@?Z_7I^+'BM(BQ*2)0ZEID=?$XS;1PP;=G8*\FQWY
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MPN[*VA'V*N>SZEB"!#8A%"VY$4U5#!38DQK\T&23T"O^O [/Y<*2_;>UL;<
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MLPTJC-:/RP)!^Q'ZXE3[XD.0N(2-@'DKK]QC0C<TIL9[[GH?.5'ZV'B-$V4
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M;F!]+B19<1H-6,U9]7YA/5G#K%#^3;EU-/?88R>^&=JT]!MA]Z3.86_NZVZ
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M\ (U][B,+S<]U_$-6#]L*Y9JK<R<:IF$$4/!&>Q).SJ];!58Q['UY4(KX\,
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M;C_XSM<BOC86M&9=[32ER+N=G2)4M(89;+G?I%&YH3Z-+0Y_'N\MQ-#0\OD
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MENC^5=,]5!;LUF$EC,CX@*OO0XS?(*.IV,%FF!X[=:!)GS<]@:;;ZVSEL5Z
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M8)7DVVUD.2I5+$#R?D_W,B-U-P$!ZX0A\MQ^OD"C$E'K 76W==SO/E,H%20
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M@7"OY:1&<*)&&S\"Y=W'H-75'FU.<>"O7V1LYW4^==!66;!DUI[*#&.T6X/
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M@E:8GT&+WUZOT?GGC?+_2K';^?M-_[I_V![UVU5<<(R0FJ@Y$?K!J-F2?75
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MD$XC,7*W%I>,MS_8!W),3(]_5O4DS'_#(IG-<>=FO2[6BZSX::>"YQ);-Z\
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M)A&B1M3G!:CW10X]35ZV>F@>DP7E!(S(<@*J;9_?6>]@@KO]-M;)]VFY^NL
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M(Q9BX/Z[LV)\,A:HC]64L3)RXIMZM'*0-')TK7!G7*(&"6)Z\"3@/<D70;G
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M:[>7=;25Y)P\Y9[T>7O-;Y-C,?P\HS^*L7VNZ45MW'1W^:=;@IC&*R2=/R,
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MH$]N(["5Z36Z\ H^!5Q8,4:^4/:WOH2(2H4V;?.T0WPY]P3=MQ!FQ*D(;UX
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MF26Y;"[SQNC;S[BW<!- /W-;]L[=(Y5(K8BA-XLUGQ?;[V)DH*I[8-,]BGT
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MVOE:X:<[\I6,IM5+E\PGDZWU:X&JZ)[X^!K*(S6YWFA(U<;Z22^GAMJ:E*5
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M[PKO4N#+96U ]=NNT0SR7]^]OVO;7"8-XE0%60OL?7*P9*Q5B-\27ZE=5U]
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ME*PW+PJ2C= .Z;HNWOD'8#[TR8CY*4 1[12P33O2&X?Q3WC]D4=WH_V_CF@
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M$>$E!A$^S!K\PJ"*2,'3":*_]K>]41YK&1:!867OK^6S1"W -][F&X=<C5J
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M;O_DV,G$6S;GVY7\PWII3<OF\]A3YIKEJO!1RDKQZ$B=<5*21&0<Z<IM#OC
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MVS^=4%!>7$-%34M-3<O&2,_(]G^[G#<!F*]0O:1"4E+< %QBIJ!DICAO X
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M'^4LGD^4Y+; Y9#6!K.Y=E24[$1%K9YQ/K/=S:%MX!5;;O^U,_;=PRV+;&@
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M47%JWJ.GK-J3/S+_0G^#'69X70242?IVOOE_<9PCNW(5">#IH-P/003;1F#
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MKE(:UV;G%\K5KFOT$>G*"9$9#7Z= \)GN\M,SU\_QDF>T%;N4$*1I,:IKG/
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M[2'<X@#9O9-U<14W*&%'.V75_^+LE606%8+>$H.]W$TV"LZ$M<',I3.V8UU
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M2'CI\%TR*XK'Q=DMFP1ZXZ?=QB-?.J?":*P5+S<@%/:6Q747JZ7()Q 2T4H
M=@(I_2S5QF/#BP25QEF4'D89Y'#*:<\V1D/S8%?QTPA?NEZH?%:^A/ZAS2,E
M4#',[.0Q2?H17KJ#=K_W<K>:^I\)#;%6T)3IZQBU:CXS+:OD@4Y[Q]!\X>+@
MIOG>O2)3BQ2C]H&/EDD8D. V@A5FAP_^L.6:.X+>L%&U[A *5=*1ZM;2&*>0
M\VK&L*K*$"Z)I+0>#Y?D"9YLT,-Z#HQ#; 5SSGX?TX23!1F)F#P7R[!P*5>3
MO]]P-(>N56+L <_?W)EAW\-MG@/45CZ"G1C%FF\ZO*H/I&W!E]S5%L3WOC7L
M?N-7P)Y]'[F26]C8R>]V[<\;OS1Z5BVQ3*N;KW;RCV7KHP8=LQ(+[CSP9B>L
MK':V8RH1[9%UF0'@R^:3LLI!]2\"^\,$H*#:XDWE^09'XE.2GO/L3!@Q8+BW
M(-C-)7^E2[S$4K%ORG K"M31J'>:G6Q"&IJ?41$Z_<9^#O!]WGF ZD>$)6A[
MS(*9NFAY>0U">(,WTG"KW 7'68:A2&U--4@Z6/@WA)@<%('Z/#PT*+J/7?4A
MK-DZ$F+G8(BK<D#:R?'6UT)#WHK;CLFVO%W\]Q82,CQLLPHGB@7,>V&2/.5(
M.2.@\0&#%D^66'JVH?/90Y<)-LHF]F:_](65=S 0[#4:PGJ1@%+^T8B,.QAG
M$O\#?MT7?ASV@2R3NYJF^2<Y): 0G"FKS?0K;Y%R0NB](8P2[]LZ$?Q)7MLL
M2&##$/O"V5VH+EG^2W(?54+<>]MAOL8[+9W<GQM^;L;/8(^BGG@KQ"1#/I8E
MLD\D3S\Z-* EG;2>*:,5+)F*70ON-UC2=($,L689<!Q]W2P<?=:CI7U*%%^2
M#E,>)-\Y_;& 'G#GT)=$RY>=3J8CDSE5W\XN"-*,-Y:<%C^!7]Z ;X'./HK7
M^@<3?>S#GOI&95CNU"P_4/1O-(SP%G36T%%Q+5V^"%"VO(\(2IWDJE@$B;8D
MESAK> Z@BY_ZO.C";']0XDYDN/A^Y3"<MZ;&X)0*IW?R)KCK>LA9R]5S@(S-
M,(+\4H^LMZM*5B#' \G2>S)@.UMU_@T1KG- ^/N^TUWQ&;+^ B.H>=P+ @V(
M;DQU:G"H#D+BMX/I\)!1.VVRN-KCF%S#X$7Q+K#3#E<XV*G'G*S'AH/S#0J]
MRP07U/OUW+8] G?7E'+1?'UUL#8#Q2BX?5YO6<:,\8%#"Y(FRLPF;%<&/<Z&
M00S3!#MUP1@Y]SK9.,7HQNB( T8%$_3(ZV\-95DJA3HXF/'#,3.!;[A/&\KG
M@);8*-LKF '9NE-FZ5>5XF[E6J6J=YEW#RB_[Z.,29"Y5%5>_#E 8\ A7NEE
M&?I1VB/XG-IO(@K(?3_ZEI1Y]]W&03)1>VAI](_6C<*H7-H67'V >I\Q*ONG
MI>6N ?+?G?W\[P)/1\',M';N6)^W#'4$F]0?@WN7]2U==H.C(4!51P(+[D3F
M/N%F93C2^OZ 31MQ:3%!I)RRJ9.K>/4^N]@M;(K8MH>]&!:I99Q-(_KV$0'Q
M"4'_MF_\09NZ%*$JG'&N+&M_8NT<X%#C9)"<(:"M>())16DE$!5)\.YNK5]-
M,0]<XK]XK<N8JM.2082JEE#TD#!!'A$TE^=;;JGM9&K4N[J(E['%%#T(],BV
M:<_]FXSK995@[:Z+ _&QJ$3AT%%_Q#H:?AT$M:-1/]0=I;J=#.A[H[Z?=,*A
M!X&(-%OAP9U&>K)E3<14JO# SL.1K2S;VY[UA]T$R$\!)H)F5119,F?#U+5V
MFDB=]";@I2>P?Q'.OJ<=#7[IS@-[@ .9XU0A.5W!-PID-%]VR\=D4-J&X[5G
MSP'19VR]3 C?^4@UO=8[X<#1Y-&B]Y\7H*Q-?8HHB%*[G1>#G.C)P_5V:&/N
M^]9J";AQ5+'!*%K+;>/W2KTA'M(,KC M+%H?AU4%J*/L?4;,S)Z^KW34B$I2
M!:%LQ5<,HC'EV[GXAVN'G<8QQR/+#_C,;N?'/)KTI#@';)CUF\Y0PT7)*H17
MZ'R20INE]W!.OO?-/Y6^I5^^E;,H'G!W:(*?D6@6,)%I[5'G !:Y"<7]0OG)
M-'C\UVF#ISIK6:D;5L_+19_G\LZSY4W,36U5=DK9)YP#G(Q3I-@[F8/#G?D/
M&_XB6M15*\\!H<Y#<GW<#VZ>5HS<YZT>\Y4ML.ZXJ]8A_H[ N:F!A!I&G@,8
MH3B>U\9YR>)6/UDZWD7-@AJF&W+G?5O>$G);QNI!V=;:/Q]RR(7JIR>Q7[EF
M/\.^' #Z"%<C63V.U:X8J5 Y>:2=PC@\F' C;VT"T5%?+R7U[&A]#BKFZ1F@
M5CST^_#.Z!4LT0_FPS\<$5&1O&X#ZT.HLX]M!-,&.[F*:U@\JK8Z**\QYSKR
M[)@B[#>C;$]_J2M I[E'BNO%OTU5?HUVDY(JN:X8M_N(#FC7*;<*H0UVY, C
M(D0(81%H\-8.VY/VPX*M"): )'Z=3H%A V+4:9H#J2;(L=B9LW3,I;]S48>]
M25C)6(DO1H/OS'O=X&[3O!>/B?A87D?OA+;42IB!2.]M?S47\U?8;/&\&1,!
MW)Y2IO8LZI.J"E[LL$T9F6EOC7A\HH'UIOWS-2[Q*JL(9<+[B"7,<RQEFZV(
M4M>)+.1O[0X=O$LYC21,;&W+NIY@V.CTV$<^5!NJI[4YX;7'?/P,0Q?\*IB'
M?!/7.)/M5Z5_QYI=K_IEV:L9+J5K+).@@/"%VS-&;793;LXZ:\BJWP5*/G>6
MN1Y#AFL$J4NJ?+?[OL-,OOT7]MX[JLFOVQ-_$)$B1024(D0%I(M(E18; B("
M*EV(BG0! 8$ @2!=I @(*!UI4@/2:^@HB'203A*1&D@H(9"03+[WO7/?=F?-
M_<U[WYGYS;I_G(3%.NL\^SEE[\]G[WUV9HBYG7[)B1[!.K(R\R=,!#\\0VH$
M<A,;(4$+O+:4H=G:VB]ZME YLCH*>8P.,4Q8+D*\!3LB0G/-B#LH4H"L6P9:
M_Q/4M/C]>?6(&==KA/+[0EVC;TO"NF!<!C@-3=GV\82<V [:=CNM"QN$''U0
M5W;W+5C75!\;H@).T-350JLYFSI&SL^'5"#,OS$NN6I7\-+"C>&-ZG7C*3?G
MTYV\0E%R%L+3K?8\EC,3[R?F-%1!+BFHP*+PF,LM 7Z1\^-X$'8117;,SEZ3
MSMI["G&>EXYQ$P\+[J_>L/MUHO<XR:[5DAA&DB:NHPN*SN2B:9 P8?9VYF-G
MMK<7BY<UZ$VKWCT31\E%M?AZY'LN0Q$G(WN?" FPL3LJ9>7'N1"YKF2A.,*L
M_ 1X>W_)0<Y1?I;1^"3ZX>09;^1 R1I'&&V;DP-HUJ.S:J5.4VS4K32[:OO5
M0*V6!9_GNQ^Z!RD(GJ5,A:-XF"W^9-?I]=3EZ%<'-1*<AM4F]XJ/[0*N^XA;
M4EU/*SZ&W=.R>)LT/[,.C\<L0^_9J4GDAN;K[I1 7*0#KJ%23D--]=R'IGJI
M0#8+41CUT1SNY'PKG;[T._PAQ)$LC4-&-<N@#JJWN)Q-&K_%F$CIRI1]UQ(^
M&:VLGID^&?R3TMLJ-0)[/B\RVFSYU 4N.#/79C'\X9C9.P[UO<]]>#.85/?-
MO)%E$X.)I>4/YZR55"3?%RDMCCK7E :X[&6'3'^!R;B56*PHQ3NG&"XX%==G
MHN?!,H(M-PEE[A"0J-T(6"NTX5.^,X@[<'J!=?.%NK8;1L R@'!6IW;?-??H
M<<AFE=\QE0$?<.5"C[/,PPX<5/Y!HXZ7OCJGX^]SOKAE%:$\3Z+I<./O"%NT
MS-5E@S$7F^:JC+NZK"5)3R&7H3,$86$CEUOM?NNK9;]]WSA[)BZ!;KM_!5F0
M[FG:A/<^$0[J:34%A4-^!SI'][E/6=M+#\K$J:9T"R)6 NR%V/6O^H[,^:B_
MY8\M[0*DEES *"26.;\C>8(B4YW ('!+[_(VXUC4&EF9I$$LL1B7W@-%6BLU
M34Q,:"5K*(U]0$FSW]DAW](HZ2QZG:NKA.=T[L-FZ6LK=4TZR77H@M5$]S-]
M2+X..S0]"35]V"D0D&B9O,'[;N$K_^11JJ8 69[X$;<]KW=TK&?=LL:&9ZU!
M[=L@ZQT_3NLCO!2J-1&OU[&SDMHH]X;B4&" Y(J-UEA?:H),":/!K_=ZFW"%
MD648ONDZ9N&;&ZW1]><GAY[*O9>[YM3^ U&5;C6Z0L'\PA^X2C&FJW=P:]1<
M*U$<!^FMP.G5Z5%I]:X*"ZRKA#I.I96YAZ(&GP<\D#6CH410*?V/Y4@.TH8)
MO#,N1$@YHLO$;RNVV=Z]6-?.YU;A=*69;J_IWJ'Q8 R$6=T%;X.UL$*^V5#8
M8NU?JJCQOSJR::U[F>/>9,Q=P\*80LF:AO<6+NO[PBLE/5Y?IJM74 VB"B,6
M$.O2G86?2@;$!&*&_ A:G@K$IM)LO<L^"%?DDM)$0YJX@0?$AR15XA9**!N;
M1T3>\Y?Z:%2.2NA^XR7HG0!5*7.C&2AZLCO>8PW=Y\:].I$I9-XU40M_9G-Q
MD5VP?3E]LN@A3WBR1V5488/_PL/NW-">AZCEE$;9:8LY5LA/:_T%=J]0L3#D
M,\; 1R;+76X1@<S$?8R^Y>V/KJ4PW4]:H(^?+1=M(>_RA 2$CB01[5E!F2I$
MM<_:;(BHZO4,%N?7BMBB+VYR;;P7>+/>CZK;XDS1#''=; 8]F4QXMG0NB(NY
M]-:IL&E P."9%/_/*&-Y_OHHQ0:W4NL2Z^\S'.$( _'<T*ZGLPVOWK_R\]$.
M@3D=)<NV<A$#:GXJ0O?T5:\=JX 2]'C% !*%9]=TPQ/-I@TA:I\:$TV&?['2
M=6.M\NB1BV;=[WX"?;NXU0UY^^W$1XP+7']4@>?E=F>!]D>1W@;,#@**,PAY
M-0@0O0=OCUS8EBY+8>&0[FWBFDT=O?J=4ODZAF7G89'_W"OKO.<-\AV_/;J?
M+JX.US188P\%649&6"R(F-V@__/UI6Y=/ZGERX%E(#V":1Q]V%4+T.M5;;)H
M&;XX:5 3]Z.QOM<JDFG1+X$!ZA-$!19+%AB:GZ*E7(0?\"^$IF([9JR=SUBZ
M+(@!*0^\8],Q0KMTA  >Z^EMM9\7,^=OIS(;ZIZ+KUVR50]F6F-"?*#0N$#[
MG=939":\PCQ?2TLK_NR;IVJBH]5J[G)OJ$#]UCMZ?]94X# AZL!R$4[F?HMB
M[ 7QW$+Y6P[<Z@P4SB#72WOUNW.DSR5!1%P)*HC/KK(7:^J2?7_I/'VC]TTD
M)DSK7(+N"I!]DMNTNY7VK. *\ED<C87O9FAX(7ED$GD:D2/2G3.7V)E-I)4Y
M AG\]]O TS9MX.JZ\/R)YI,E1ZUJWLR>]B\SC0>J.-^)Q-4&W+@8I/$@2NM:
M_C]<#N5X]Y4>I[OB=#G0_3SFZ2PM0-XM7RR%./;^007K]LJTXZXAO7JCDEV6
MUA6^+W&R?T3*8A);+@CMB?DYLU<'X2"1D!J[M[A1])E<U)QUC^.3NKK8V_4U
MG7+QKT5Y[6-G21/PM@!9<V(*!FN*CD7:$0P'0%.OG,W#^56T37J1"-ADS5K@
M"1REYG-O #S7;&Z^1]/\]VOS"+262SO+S1QAX]M&8<:\@+\I8J^1>\7#,*Q0
MU&[KP"]+\5P3CR4/UMW+MZA[7N[N?$K "XU'HVTYCL[?--_K5W<49DK>%3^F
M$3$=$Y[W*4B@-JWB]Q_?U2.?NV6X@;E/B2ZT-['KLZI>$Z=+$]]>I;VF4E9'
MS/M#<;HF1R6_ARO93.1&]<:$*""N?Q>=8DOK?=?B_X;B-0M)JJD+=X$#CAY(
MQ?<%;N2+SX&7H>OFE7B.D&J25IP^[GN%W/9S+0'E7UA;=FL#SSH-*5D*R],"
MLG@<P0HO'7@A1#O$.EQ4E64F<@+KN@\$7T$JS>=$Z#<@JBY9#3>&5']YQ^N-
M*0OTA#G0-JK9-QN>K;AF#LR1I2'^1XK:&J&6<I'9W44ZJL= ^IBF4>8)#PT'
M^I6%G[][>]Y1N@)/5B./)M_>#Y.<#JA(FDJ@ G8+LT]9?<OI"2>/(I\3.3^M
MMUXD)A4X-@YVS5D:)BV-F7=/][J^U$[^KF+W['LOWXJ:J1OI>.#H?E8-8WO$
MV%Z_RBLJP.W@$W%O#%6G'U]57&1N# ^](N*R\8B L"*VXQ,[(,=@G 'H0;ZU
MRE4__>+$8$_IK6F5T9(&%8##VH$>;4"4FNP$,:Y0 <9=6:$ILVF'>:7*\9S@
M/L*W,WR%#Q/ZO%\WN2K3CSUKW)I)PRA'PF2IP/&=(:^3;W[5X$W?5F,O=]!,
MU/A7T4R&A$6;RC9WZX>XA79K)=KD))-=1P/%H!B#M$XJP "3=V^Z/;S\E>1_
M@JV-(IUDM37*:S3?-$B4KBFIVR MF@O'G;(DULYE.71\.DI=Y"@480$.Z0F:
M1VDP"1R$$( KCTT5C.G)#RCL]"V>>VR9^\W=79+Q95>LL8\+_;#SD@""8Q59
MN47FWND@6'.'O4(PP71J2!H3*:!3>=MR]$\VCN?PLL]\>*5X*+<X==J-R<%#
MZH1VQ>NDB)NLSI!,>)W/H3V96YA@7QOQ.]VJ/4G0M_$>7/@Z*.^MGC4=R1[Z
M%@,.;ST[907C&&4O0O>,Y<9" P>XB;7B2[$BYP,6T_<0;PJ(-)S)P%,7KOL<
MYVZ&>?!]84I)';AJ,)_-,9XJA<]%@;!-)"<R-.)A2MN9VE:QM_<<)O!E"OXW
M?GVDYV9T%_16-KB["R):9N&,X@ZY!&AC*8'(QD!@B1$D"8RK R_F@G8O*5-8
M7H")Q6"4*[S]#GCEGAN9^R<<_XCNL$PK\!$5Z)BE37PT?.C# E&B@@J@/]/8
M00-M)%XJD".'Q#U\2@6Z#1G7:G@.'E*!DYX4%CDJ<-,&OEA 6Z*H7,J993*W
M#26TAZ;O]2.H ,]U4/&8Z9(!66:0*-Y[Q!Q#&SR-@R(9]U]"_I>0_Z\(67)'
M:KOD[YZB_;?C!X&-U2NO&]8<F-*$]/F3D$__Z!WWI]X+?^X-^I?>GQ%]67\K
M$^AOI &.3#XA)>%_(Q/\[V:,?L\BBEST[\R;T=_/&$W;.$EM%_Z'WNB_9/PO
M&?]+QO\+9&SZ"QEM:#*:EM%$ ,,=MV+@9UJ583=PLMVK,MDMN+E@M57\S^[C
M[^[;LMQ2" A\."I6!@3L_V=EG^@[>5W@R^;XCIP^B?:)A3_+FDDGZTRFF>(9
M.PRX+8\^]'Q1CY^6N+W#R9U1O+9RCOUJJ98?J,>-*+G<$0-&'8UI JFD'B&9
M,9=I 4%-->48F_A)X*L.-JNQX5+K')XQK#KKC./5U=3Y-.>2U1U671=_EKX8
M(N=C^S"X/4<8A6D\O# 'RG%C5!'PD?E^1K?%X+.(.]&0\0<(9S 8EI+U!;E1
MAP;QDK7 4Q;A92+S(F.8#T_+7)+5B^LW?K)V><\R.A&S](@'N"U"/?' 'Y,U
M?;*G[!-40"N=[61[?+=4W@KS>=V*4XQ Y5H7)C_P!S&DL]$MJMH2*VQ6%6$T
MLO7)X;*+F-7P !^O9&>]XE(NX1I11(6V.#:H!3(]-]W2H0&9&TZP'ZI>=V8#
M]W@33)2^"@=/+QA\/*UPCL&8.4C*GM!#=#F+=2&==S(BWJ "U;];JT,>#PN>
M8&LW%+DN/]28 .;'SOPQ;%L<T413D JTR5F7Y#IX!PJ.O-AMN3JO)JCZ0S1X
M?IJG0XL_6O+S!H . FM0 5O:?MGOW.(@@T;(<G@+-!7HM);#=7]:W>?\]GR+
MD,/T,Q2X*C*=?;7VVO$)Q@U,0!%E%EEW>^$<>[Q7 4P-YX*<>I550]MG.A^D
MCFNF??E]*S;MD>F\T.6C#$U>XKZ9BVF7)L/0GHMNK,4:>H U.L ,D]73I,'8
M:0$)VZU7F ,9U([L$N\(UU2]L8D)C!*GUS%QHQ'_7Y;CR/41MR-@(LF.F$O1
M*K.DM%RB D-L0* =O)V-UH$>'T%I?84\.K&&-'*'I,!QM^ ' /D)%4!DT'C$
MC4;$F 5P5\(A^_@?&8C_+_[1'>@?V+NPG1 W[;D"WO4P7=%%#+K])%$>&)'N
M!S!28N\"1RS_3$=1Z2 W_&M-"7PR;^&0KDSU.UZ;_-:B[LA/GPID\P/D 9H^
MHNFPKXP8QB/8*OR0;3SPT^32)/G4 N4ZF!>\OJQ'6T[7DKTS_\>CJO_+.:Y1
MMXSTA>^4&^OQ/'BIFN4$I$9M.V_%6/1\9.O:(=*;Z3F__+Y=_28HMR3PT0 8
MXUU6,CTS9T%D-$^=\&)/*'T37-CB=72_3E:Q>@_RVSW (TY99F_7OIS% N$B
MK,_JVF?X)5S2KVBW:**!O;N"GTPXBD,NB8*JEX?@*[\00XF0S(7*?7)>+B']
MD./HW'O6_S^OM@0O^IVF ]W80Q\6"\!"0OF!:S:CD0Z[XS^AROW_MT;'[MC4
ML'YW/ VQ?F5%58:0ZYYU<>)24N4L7;IA8J(NEX1XR9>YB1PW6]!'=W?!Y@#E
M/I3V;\>A>2TOW@2^,V9?OT)_GH)S0C*IP"E-$6<PIV+15LW)HN.B<8E.T;?=
MQ9XP>L;NM>#LT3^*<%2@*SE><2QQ9?*TM,^9+TI+ +[!<RCJ<!6'=3 D-$^F
MN!'%^K7!^9*SZ:V;DYI;;/%WUKXF=J?*5#N-.M6Z2_ )+!L=.9\AH?=#%&:/
M<KN\)3:^;%+,$2DQ+%]&Y-Q^!4@A[DK-)Y!^]'L)E'PO1SHL1-1F8[KD[FGC
MN@42R27\6X1RG&BM]T" >]P!QLE@YV*C\.MN/2>WS6OS:FR":[+-!)>QM)*V
M3>0+,$MWEK#^F#T5\#4&E]GIDI[_U.M&A+O^TJA2I>E>R](2/MD#GP/>YE&F
MUH7? >>^2PI\-&&R-E4SXJX"76> C8MAW4OZIFIQ_E^\^L^J!QXKL:*,MEZ:
M*!.KCFN/O3U<;7_LYIT[&E(Z2[PEI&&(GURR2WA5%?);NFSW8.SA<DR-?[^
M0)&T K==V)-0K+SL3<CZJA%,C(@M(S(^J*II;DX@79^M_.8F,9C0<C7SPRY"
M94R!5*:TF#^7-Q';5:'[KDA8<P_>H<DUINZ"/JDO=C\L+].>92"ZU#G3/.X)
M0V",M!![)L=4=8,+<@W&WXW.CUK6WX'8[)I,H"YG1SG\6,F[OC:?'1U54:.M
M74D9&)5Q478CJ4N<V?":!@9732/\R.$FK1%K\2U)^_1_?4R3#D\[[\P0-*G
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M7WS[>S]K#?IM(5&&4!GX;_-1.$[0Z4<&KK<C5>.7:;(UJ**NX4V=MO3+H+Z
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M/=_[HDH7H)^!K#)UMF;#8\,TMM#K4G. I:WEM0R!'NL3,6;R96'MMHSQ'[E
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M8LY1*>5[F;LS0Z?LG6319V Y$_5L@)[N>AOOXJ/WAL=,W/XBV7PBXZ]3T8%
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ML)-+SW#?G(4/\:/@&Y!G,$;B00[,&W>[D9+&]5/7Z;?4^K5(&==%^\]K3+]
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M\IQB9VYRO!KC[IPA_@+A/%U4>[6(D*RV +_X"P].R3NTXLL@(:M2DHS#"1#
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M]@]0FGSZCU4(6L!W%O_@2\S&+T?GY<U/\SS80P?]E&SA-[O&@.S=.4GI1O!
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MVLEEJ"*ZA?;E%/_JGO>*8ZF=[LVB$G-T-')?_>VWHB29!VSQ(6*3(->4$\>
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MUHB1V.OS&''F$[YJ@A0Q>^QE4KC9J5ZHZT<=M-R<]_$093.:''K36_,L%T,
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M74]F\[,L(KM7H\2=D2$ "@QJ4(R,5>CITWXH+=]>\SSKX:8S>QMC6NM'X:B
M!9H#;WZ9=F]6=Q@-\7QU0BDR7>,:#IUH)-37/"/%EEZ#X @*(+:&'.!3"G_[
MO#!U<[ W'MU\UZ>--E*C(XRZZ4X.$7@#<?KX9]CO]1J]B@+ F"N61S;Y+\\,
M7")_O<V9[A2\*$('"),Z!C K$5VA-[WE.H%\QX!R-.A:Z_16;YX)V3?I>DKS
M* [>(@P3A11_(20LI=T\[#DW-:"R6LJ?#_S69&'U#%9107-8]OX8T,))XOL(
MM",D(<&SSFG>WES4J)GB!2H)$' EL2,7&S^P5:YGBZ%HR^HL!D1ZP*%#$5I
M 7<$U@ QM=LFXI+P:=X9N'$@J4(JL_.A/NT*E3C<6&:%<HJ%PS8\..\> Y;&
M#J*X:/9@OSC/#CG;;ZP=SEQ1&]1UI&,@>0SH>CU>\FI3$DMO\GB(=!&[5*5_
MM*$M2LILW$WCHCD<(?X&;Q$A2>%XVX<WFEC]?T 9O 3]CM2F#JON'K5SO^C4
MJ 7>W(;?!Q(N *- +@L<=H3Z=H'/N(*$+0-%7T'XA?&^V,[EZ]:O.F%.00,
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MW)<R$M0>D?9+NC2FJ.WJRI>L/!H N$W?)L)#?9\B5&2D0N.*<. =W"GDI]9
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M-_5-'DK)W\.%_P"E;._\7W((R[T*%H"&'@,83)ZN6 ,%DK;O/1D+.GPCTG:
MU,Z^7YVT_#Q2+Z'V]3[ 7V$/]H89(:1YQ2!0<W5P'\-8@-TT;SXJ6UTSHEF
MTF"!)#$1/M67LZY$??/V&/CE,NI#22&4.^OO,SB>WGYW/:*9]G/!8+/M?\)6
MIEHL'KB=:7,,]TY$ R]7B%\2W7;>V0@)G2=\G=9/)C&-8?7?4>;D#Y5%3;$+
M9^07Z'[X,-46[_95"WW3%]/XW BKW%BQ<+;C%O'?+@&_5W\[7)X7 T5:O=<,
M2;7*U$O7=WV9;-/=+?ZS+TR"*$FZU50W>@&;11JV;STG9VL@QG-U:QUQRQ>L
M ?XAD/WJHT+47%0[[Z<9:'KB]M=-^I C7_P# @B.SI# *5;2VL[U\;[T]!9M
M.R=2W%:F<17LGVW12C8J@)#? +E?Z+ ?5(QMC1Z=A7D=(# F[.[9'(,[_DE.
M1RQ*AE]B^WS]'[4XQ]&;&8&LQQ]"U7+GUFVS9E5A6>Z<1AIC;5$WGC&GB^.1
MW6S)QP#!!A\J];Q,&//&OD);UY41O)TUB3UX.K$,+G2IJQ@!5!.3ZM,9 K--
M&6XG3."*,&PDKB4,"<R$XFWSR8=>*ZMA"PR[8J9B:LS2UP)LF[@/3;VQ,[+_
M!N]-?@,5)EZ#:E1CNZ(NCUYM6_ P^TC4W9Q<F6M*W:?-,R J4_HU.<@9,.%I
M@E5K5?C=TS+^_ "Y^;[D^\^. >=_T(5\7#0'3&M0(\P_+2S^"YJQ.'>*+X;K
MR6H7C/#'5]$!@MG:X5.!+8Z:M0))E179?#@A5ZCJ>#PT[F73-&TTT-0^<@/,
MJTD_4TT25[T%XH(JT(.F,^VE1/(XV';:E=-$/F3N(^/!P 9V;,!0+NY*+5UC
M_VS7/:;35\2/1)?#C.F@=C@["B,]9D'8 >Y$4AG.'7J7T9!;>WIUOM<$<"XB
M:N"SQ'RX9AO6NR,E!B[B)SBG=JNI,M,N-I,IZ\KV5999NVB&JTHJ_.O7I*JP
M,D]+H/1H8:FV\6M]&OEOO*IP!H^TG[\(? B0(UBM(EJ;)E,PWNW2[NJ&F# S
M;X:*G56%T7ZCO;3^@$A%Q,\4-/B]XYG!-ZT4H<_#X-OU8[;]9]D;47='C%(P
MCP'?PQ7=_MUQW4^-?5'^Z-,UD\_(WH1C0-)"A<36&"ZF@R)(4,+($WP7@4SV
M8>E+ECI?;,"AE\IOG-JU<W[V2:OY>].M;3%.*;T%_]'"(_9X4@H6WA5T#%C,
M0%3HMYN<]@ ZXQ:>-A@$D]]5Z]9;-GY^U&]QHR!\QCXR=S7<5TMXE^1%?M=T
M=R<NFWL8)4>(!L4VL:KK/I+FM15MJ!IXGBH4WA*N,CUUDC;YY<]C0"<X/M.J
M!1Q%.8M#E;\:V4^PK'$;)0U7Z^K^=-(B0?:8J,"%CKH7]I:4(C2%UA /L+Q/
M_-ZLC'[W]%KAV<7?\I0Z(\0S:4U'#[JJ4;0&(DCUEUU)(YYORY]QN>@O[-4_
MU(I[ZM!//W+Q(NU7=5IG(A@V7:>.X*B QPY!9;&5RU^$!0TK Y+N)UDCU4Y9
MWV>O[>ZF#Y<:!SDCIQ,P#@6=27:+O%U/GQ(PPSRUPP?W[X"K.XMJ"B^=:/K*
M) 4X/=V\*[4A$T$1KL0VM2!.K/$\+PX8#Q%^<?&C+.O96XA"%5 25(H82(^-
MV3HD*A,R>P^5.&<[/.6ZVFZ\1UNY:[18W2-D LCGN'\7.Q3,.U"JV)UPO_U1
M=2/D&DQH9%Z;8^Y7RYUV^\CKT8]IU$7DIFN [+#A!895+*50",Y%XA9K+/[T
M$76V0CPUAI;\  "5_B]%GW]N]>+X0_,BD/V8Y[[TE8W;]<_TO;WYGT_5^6B)
M@(DZ06L5#HP:C'V3X'6PU":QA^>1/B:H]!6:+6*DF7*FJCH(!_>)V[9#+0W"
M:(\FTDE2PUZ:DE =% [V*6JSY'[OC=G2G44P@6%U ZR[E;\_2)?WQP(?JIWG
M,E,053&)RU:L(L 7YW2LLK[@\B>=MW=%N/67'!6(,H3KH7$*,L*0RRQ]>U_L
MY M23_<T:19$;$J)+:57^N @F.B,1:.S"7:V/0EQO"_G88>:WYKZ&^>)Z.2(
MHB"(R>#VUC*$B?L$5[)EXC*SZR4]R ^'ST&ZQL;#A46[*23.9F/K7O.W,#ZW
MAJENPKQA &%JT8I-4#)RU>>K6 [2N&:L>//A:FWV-H-GR=*U'KFO)SJI4%>D
MF7'1#A^,U7ZT57#+)D3-H?N99GW1G@Z^D="ZP*,I*=,L,T69QGR'="<EEQ7.
MS!F(UMV%N>EP7&]_^\J+T!$\EJ?W*#XQ.Z&:Q%F7"+G^^''\6#J("HVGF3J/
M =C;"XG/H3P$Y3V=1;7@N%&%\]_T_3X]&NF=>P=&@S'*>.00< J.OX=%;%9C
MMQ?:' 6?]-<_.ZT@;/M )&Q_<N4UWG3(XA']JC6B;&'S0P[L&Y"Y9-_P?#*Q
MW2K^RX; 9WN%]DEBT9K /BT.&7:GE':(B_E7&X)_)J#YR\5WW$^6,FS9Z#>^
MY"8QQ]V3NQS[Z-MU#@;-L4:+ P=-8=M6S+<5]1Y([+2DN?)LL:S^BA;PN<@I
M@@3F& #TJ,H<KT<W<7MD:BSL3&_W+_1FKA@,?-L]<PK>.#",ZB+8?:3.!/W6
M$%0%2]MAZD 3C:I)YK\"7%_Y F+$LXE O0B!1.4?=0$IG]:E[E>-;PCGO_+(
MMWGJ(?M!.$;8 "E/Q5R12=#+=0W6YZLG-I<D@&Z9?0%L\)?=Y(NT.EV@2I,X
M>02S1YHV-J&CJIH)(G:^?2C_:_)(C%/MHO_:="-D4;,\% -\,L\^6BD57=]4
M-[*4ZKZLXNH\FEF_2/W^("OJKXA>K1OT-PR#&&4PRUWVW+MX+[*TT4ILO%I=
M#DT$,KH%V&IFL$WM$R\^E=5-#?CXXYH;K=F_GQ&PJBVQ-H:AX5$PV7'Y2IE"
M:W=>*\5O-!*]UJ^1P-M2&!F">$KKPFD(F-X?'/<*GW[T,_G R 4CV&=\^-N(
M%I<D0SUJ3>TGY^BVR,LCMD!OX>5KVO).UN>O)S^]?^UY)-NHU7=*-9$+&D).
MIYR%9)\E9T+U'_B@DUR\5;V9UXV+EJN"')"[5,+PL)"6-A.P0!VK2NAE;.D;
MK'$/QA+QP/M#T)+^F&?J@$69*?/P*2CW>9]ZOED-Q3'0S/(&B NT^ ;&@ LC
M0+)L+_J%N1R\]&G,C96JI<VY8+20]&"2T@FND-FZLU3"=(><JZ[O[+Q(%C&I
MD(CQJ[7(6#X)K1<3Y!43K16/:!;*)*YV 9DKV&)!K/X@6H]TR5^=@@[B/D."
MPDV%[ (^FACE,(==I)7"!^.B7J6@Z CTCB/YR:%V<QQ#U7J/N=MOEB+NW/VF
M[\0"U2"ZEY.N4W]'(FP =69D8-I+?NI<8WV\9IG^:G!4RM Y9X*E:\PQP!4X
MPX8W58UYBCJS46<2#SU]OJW[[L3.F=0IZ]47:8)V$^ZBV4']4M-P9^!D>0>0
MB116"K4CU"-U,8AXU6^OVY^KO+S\X5YTV[-K'5J. ,8/)\(U"O YY QU%:)E
MT*F)5L<+H_X:5UJ9EE$V%:^2'ESY](WFFACSO92'$]W3U23V4#0/(L]Q3B(1
MZC9PDN/FNX**EDNY*8>!5&_R,&3<-9Z>9!Y2MH/_]Q3S E8G+8M^B>UO>1FZ
M,=A[JY6%?\_+P/\M+W/EGYF7$6C'_ZUPHRB%$Y*N>7J8/^_YBOECL>W5[<(C
M?X5U$&>##WV$NI0OM)=EYHEP1=CT=642O>W>SM3/YKUC0&Y0TQVSB>J.I-JT
MM I$QC& $]%:2+/NR(2M1#XA*3W(F[EX@NMPUC\0%)RR9%>1,)R>^R<G=Q=I
M^/;L]3MV8L^05+!&VP5B+FNONBM3B,//NU;&ZU5>7TIWF?YTS> ''12QY*FW
M@7]*:(2@R?)I.6O(N L4X1S2#F'_1./E4R(*G_8L"&)%E(8!.6"LG_NN#B8]
M=N,8\ !QPH0E:C717]<%-3K5$ VKETOW;C\&7-H')R"$&CBQ$KJ58PT^I;KO
MW'^:'9[INR1'G\;?]8W-8W-_AD&^GBE4RJT] 'NN,_9##NT)U"7J@GL)F[*U
M:@:?!#*XP9U&46<]RA"2+DD7*+U1T<R;#*(J_$R'^.*KUG%.13>+-JK?H7A9
M/^]_,((.\)%138OYF1=*%I\OPI^$C#C.KI>]'*TD<'\X<UV/V3259GYNYG/I
M$N4T& U_(L(T-#^AA9-.B8==7N>!0\8N)//VO54!UB9EZ .>UR3G-XGP6C6F
M6*BFSMW,C'C6A\]S O9*G"_?R"13Z5.D&65"CO1_V'OOJ*:C;%_\"Z@("(C2
MI$4%!01$17J)J#21+B U*BH=1#J$A"(@*$1$0$$(2!<1$4*'T*.@TENH(8IT
M$DH(IKUXW_O==V?FOCMW[IV9.^NWYH^SLCCKRSG[E+W/YW/.WN=8("W(@?.+
MY<5$O:0*;,":D\+ Z89:1_9$?7.N"X2'84_'9,=AJ6^3U8HM%:_9_PE$^,=?
MC0SLAP^D%LS,GNN9O+3%MX(RHJ>%U:,3N&M;=:0D$>0,LSY:E0= I9'5*4HK
M$!3R,:KB<8["2-&'_@W%NYL3M@%C:FKMKK%ZPHZ46[;]['2.,4+C*LP\]>91
M%UHP-@XN?Z=9D62-BAYC8@[Y(,I5^ 3NV^R&DI+JLDG8MP/GK_-&:ND2C)F3
MJ5+ZR3LH'.=DZ1W<UO)0]RWVW.29]B\LA]A[.@8:Q6QG&DSS?,N6:L9&$0O8
MZ:M5G7AR6N0MN*2CP1K+;=\( ACS8'J_FVE2 "98[>3IXS1=8 CLZA#?0!:=
MBW^V[KM:H@][$D4M95D<_O_0F_"_OA5N\N8I3_.26R[K'QW)5Z_\VQ-[-[8M
MU7_G!A5(!N3?.=3Z;\40_^NYH&R1X9U0*3\QMPM?,)'L_I9B8PE4*/%'IQSO
MH^UHB#FZ_>L':D\!(6:*J8NW'OXJ&(*&D L%"FLVR ;;6U_BBUIA]W]5SH7;
M#HP&$;&3!OL,)>.4#SYN9HV*E'M&MB7004"(AYP5:F.!U:$4CI5<1]QV*IG/
M^I=[,_^$9*=>OX^Q][<Q2Z#JNN*<>#:LT<\,/+V/!4FC/^Q>Q N=SA>?N/ \
M>B']TV8?UF'>CP"/[4XIKJ6:[%QR<2I>2-9YVC&U#;+OI^70A1% B(KFDY+6
MD1V!HZ9F-ZQZBG'4KZ$&[30>!H"O[>)""GN>QQM\?"9\V[?!D)*",-?(W.G#
M*I*B"7VK0X1&*R(BX2R__$&7CY56E,G):!W#9^$YQ;EBF;OG']ZTYV+GGOFX
ML[:I=5W*^4QC5]^] OB7+<3D$U+/(/QN7SS]+H=@(=[;VEY;VOC^G$1<*+O3
MDU\Y<EO&%K08^@6J!UEVWC>9+IF^8DZ$%9X;5J@VXD=-3U?^^"%)#NGN%)N+
MV!^VNQI. 9,S2(ODB1(HE(SFSY 0BEO1"$+J0,N*KFQ>383_> IUK1*CC"WN
M=O?%!$.$H)K%2_;!R5 C @-8]0]%>Q":<:CG>I,(A<=TD <!$4#W]"F7KJQ[
M/K-PS'O]Y!V$6(GU2+SU\4UN6"Z\[3CXWNSAI9PSPSJ*Y.@>_+6AYP.K%Q^_
MEY09T[_N^X*-RJ+/LFXFL/9KC'K$K%U"B@B,H7P38!>'=UK;NO,#'SXWJPO0
M_/3-<X9^@/[%'M&&X.LMG8+:$C%)WO;#DP:%Y">6[FMOOA]>SF8[="=2>SB@
ML,#YQ5\_SOAO?QQF"\:OH0F/R#%!*DS,TO=ZFP'8C/3?$$H?F+E,^"K2>RC1
M8B#NBNPR+PJ 68>(DOS(.^]#;,V& [@B+L\:-#XU\<BW-M1]NGGP,OY_.Q$%
MDYYO#X,)(4CJ0[2)E_RM(:_<?PF(S],5>]!]KB3W%J )G.G2C-KS+(?U@JJO
M8YUZIK'+0C5TNPNZM$JQK#&QI!97+==$VGY:CG=.WQPRYE:Z:MS-[?$T?,JU
MCS7J^T2VKP%<K<+\D?;_R-[_!6]*/.V[<N)=E-=H/5AL9V..@1J(YK]V2?CW
M5?6^WG-@GBD/6ZF+R(<'PS_]S*TXP[2YD^@CGK8Z:F.ZZ>YW7;PJ^BN7&< E
M-0&,!^Q,-;F>J-'OL;M2[':^9=SF2N0-B9RN9I,(H^))!RRV@_NC5!"QY.8@
MN$&HYDP-:WL4-MO(V/*/C_-973.5],XC[ $;'VYH!;&J*V-6" J_-Z?-:G7J
MA=*=><,]FV<1"U*!!Y7(8X&4*] [.KQ#<!QH4+Q@;&/,=WWO7!X>O"'17@(]
M1WB/H("IFB-07[Q#7<"$S=2T\[0CB$QZ?&AU]TYXL+3 QNWC'VZTU-O.PSEI
M9NP"JDEE.]?@O%AXWB@YO\OY$"V]A6=J16-Z*BPH)M]A/?B.5F^"F9[%2(%_
MJP1]9"]E;I:+S #HG,U$(M5X7A'<,7N0"E;Y-'=]]>86\K3.5R5$RVP[[^"K
M>6\X!DRP 6&/*!R]FKRB2];#+04W?73ULOAYP'9UZ).:]2I8A':'[$KH8Q;1
MQ%L88M;^*R#,YTGQU9.)PACY\$:)5<QSDY"'J:]?%ZQ/K'6?X;-(_C1"J(C=
M1A\@!YOV5SO(5*_)F<5ZKY7?=I1WRP=8[*LMA]/Y7U2;L_ZU6?3?!;O\66SS
MC^..\JB?[:YWOM2<;0]8G'X"WNXP;_;!S@Q]K7)/?[91"MDY0Q^9I;J1"Q6&
M9PD)(5[-W?D/9DPZ/SRT!;?6K8?_LM'/IZA\T3KF-NHO2SP$;\H^UF*P+Z(U
MG&_E1B0A]=-.12G3X&F'K=@1C-L"%LPJK]])>OE]K?L25:[KXFRTSKF6%N/@
M0><1N_K,^RQ GS-WA#)AHRV(SD;X+G)7\:<A1VA1MVK]LGL-NX6QGL"_]M_I
MT**,0FW/KRT7H?:U9+N\@C*1:8_@J^6H1C$>C:IPSM$DV;&24BM;KVZ4FWE,
MJ<6$Y* JG;^QOB(V@Y1,G%^&>&I\N/V:ANR1L!V22-M1;>M+'$7S0S5\;$YX
MEDQF9]BT$LHG,FBISC6JTIUSM][>L ^5N']4N0-_>FEH:OODK/(#N)".[$WJ
M><)41NJ%7O@Y.7?/G+N^EN &S<P1(@- !,S&MX#J1@+5@:O"R7R[WV$]^Z%=
MN1.(!/OT4J+BO,*JO6W,191[CG'Q!$_7SUO29 .X59=+3'NW7TCB+RL$_ON3
M[CN%@A^V [.H6E\K'M%%HX519D^0?!5OJH?61M9'/3MJ+K*ERO;='M"#FA#A
M\\7)#&"N!")V@AQ(6'1RAW,%E%[-4/4I=+G+?F !;@F/DD4+MYP/H= Y[8@/
M0;%(SKPL S*DJ.'5.B=_0KX5HMH,@:-_AX\5+\6O_J2HA1B0W,C!GC@(Y^0<
M(+%KGF: #%=1?WX9+,83::LB)R!O;>KZ9K%1LHPK-EE$K+&EHO&BSC[J04+%
MZA9APXP0_\@K?:9G6C<'MY>Y[ @=_#3]&1RY*#<P?.M.BJT;QC[0+_NO%??W
M/Q4+^!^F/SX2#7SU/W$D:B(]$\F_T.2/E^Y:&/3';? :D;+O^__X1*!VBQ&K
MX=7P:ZY=LT^/C#O"V]5Q&133"O7-'^F@K)X^0@4%TE,!/4E6!\4&>8ITG]WY
M#/-%+AQVK7 N7W:/4FQ#/ZHDZTQY-!1O[$Q&&BOY?X\9EU@-S]PYGC^802C,
MW8>554D,_.-+F[H8 ,$")++$ #BWO86Z,ILFRWDHAM[FB MV+01.I45U[?T1
MN2-[3&.WO^;#*!IWANP?MG*"L#OA<S(I?LHAJ?591 ]^\_V[LR=#[-^6:P_T
M/N[H$# 9*JW2N<\ XE;&P"A5$,^XN";\5_/&@G??;M53NL O=0H_]1YA>K<C
M&SY_9&;?X%1Y\80P0LOT %YB]GO8'30()@ %C;7(>[J[%SJ\J+8!N;4\NR-C
MVV+FOZHQMFC;-GL0>H',.Q=A3X&,I5XGC#[K/5THH_D^D*L<+7^^(E@G9CT&
M8J)?(WWTLF57SS!R=A'!QG>%-[Y,&.="&:GU?;5M6E4.2JCRD- F1[U5C&N1
M6&S]M'5]TN)&0!*XZ6>RO@DT!N_[&,D'GRN$',DENQ!ZOID=HAX?^&$A%<O9
M*6F%T)E#-&&>5S)IGP<7%SP13;AA!K)WPUHWY1PDR^5]$>"[0<O9Q\XTLCEC
M^X(6E;!HZQ9V*B\!N;H[QP7B" &;.FCK3/FDWV')7+BLXW[*=][%^8"2()%;
M_TR_@^)*Z2KN7!G/ZX(-U48EN*OBQ% [N K<,>G+2;8<X^K,R'ST5HLR41DC
MB?RNP>+\]JU0;MZ-,*NR;]I_D[#-OZ>'QY_U /D?<;*2E47()!E+ -]3+QVQ
ML%;8,78HEN7^8EE'YW]@8F^5<HG+R$1AM'[V6,B6(<$T9TRDL*>;_"5HV5\J
MOE]Q)Y=[LJRD_+9[4=J=V /.!FJ<VD85!X@_NTT,NK Q9/^V\T;G7^P]=-;7
M<5V]',9+*CL9<:4+#0J\LO^-3AIN/&M!ZQ$;+9_JO>8\.0>.US"+#!CP+<8T
M!(&:&YZQ2<7_XKUM=DN]+Q;,KD ]A,8*K69@I_(77FR>[#.OW]APSI1A8TW_
M-]X/EN:L T8-T6Y OEJ1$L7?L2^I17+1F65H9L6V)?G( <O]QWM/;%LO>^!,
M T_U[@]RU4@IJB]:34Y[?=;H.&_8GB<)312*;)$AG]W"K9<6&LR7^HC?##4U
MF#C%_N->X,^0;="5I9LP3?+TO&*"S5BY:R#OHR:05^'[';G/C\Z_Y2DR,F(
M&-O4#8@0N9'4GN,=2.6C:+ME."L0O8DJ^*XC]D(I1G-9AH9[!C1E^"?;6C$%
ML2.DE[6A 8DT,\&;F>.8S[$VB"UX2B%Q?JL#^1'33O$6E",'0(Y,ZPOV=31
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M:K]S_3/5^5!0;& 9Q8R<J*<VL*JZ+3S3L3=VINA'E<;K^F"#H?!25=NOZ0P
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M'7#ROEFJ$RR. 72\9P#W$;^DP7MV: : WX;_<<8AZO<L.A<'<=G@OBZNVFH
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M_-E\"[(\:Q.8U$XF4D[ QIR/5%4-PZ2,WX3$&\\$3-\1YR1F*G2\G(;FU7,
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M[D2Y^;XN)+\=.;_3G/MR-[;[NL(['U7];[QBT>\$5"(/+C0JCF/F@SMY(QE
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M8LT33WAV!7^&)Z5J$:,&Z8[49DVL*%X6;$"]4 VR/>^$_9*'SQ3B22X(W/?
M0P%B_X% 1ZKDE<Y,+I',WR^=/7N/[PVOI0D06MP-PEJU,X!]Z[$MM>YECM<^
MB9MDY[G5+QZ*YWH>L3S;:I8LB)304H67CR^EN@>-CNE/6.(ZE.9<_3"F*#P#
M0,&[?0&H+@U)-2MR<SXSB(JXK.Z=K9#[^AC/:<MKR06\%E8,H$W399)@:P&]
M55,FTS=@\Q)D9657$XV)%7L>QOF@"_J$:2GXB$$H'/(@^3ZWM$W#D"5I_D9=
M,M8*E)G' 3!K&3'D+;]=ESQ_7NJ"?&7-@T5==F*I9P_\OEUY'I-1U^F,B$YI
M1S[+>R'T6>JY@?T:U0F/Y@UA-Z4$/]XITQ89>X.:ZHE%Y+(_A[U@0>N%WH^A
MF$,5B()OT@6=E3Y0;CPZH]"]R(;4.PN<;M83UHBSY/SPZ?AWOI5+/&\2XS;7
MN43M?,ZZ)F-GE*>VKN$L@'6C11E6#[FO7G!W4)Q(>BD-Z8O//O:^=N^V_??]
M][^=>V?*\37L?)J-]H\7QT6?'(U"6$;(L%[K)1H\+H=*XBC3=W;.2J&JGWX^
MB6T?_'2)OOS>2/G3-*P?R>VUDU]H@D\ZHMD_>4T9&\O]VGMZ2'TM<Z-\7;(N
M6?UVROV$UGO/+QR\O9()[/7JT^J:Y.8K'F>J/JHV.7HC\Z=YHX-^YIH-'Y_T
M,:QIR&Y76&T7_&FF4%OS!=&U(&[]D/O3M:N"22HJ._(&7.1,LE^YY2R=4^+#
MV\B8SH'7+"LBJ=25#=_$PPJ8#HC U1[.EBRUXP@2]SFMW3G(FFX!-)QXH.IV
MOKM0D H6*J>(]9G0C<  WOOP6Q4>%='HN5?+HL[$+ GT_R+M/<.:VJ)HT2 J
M2HO2I2L@(-*KM"@>F@B(2J^"2(F 2 L0"$6J%(4C*%4%1+H"H1-*J"*]=Y)0
MI 022MA"$E[.O>_>[_Y][_[-WNO;67//.>88>ZTYETNTT/%D6#<6S.;AP#&V
M-H&LT)M^\#/)=5=F[=);(.NNQZC#LV_AXQ"FHV3#V])PKZ+L8J=XL?0!2Y>1
MBVH,$)O#23+E#]V$F5UJBK8T3 /3D0 WPFJP"!JV379K?C98PH3@ECGHILWL
M]J+#;\#<L)S9BS ?^Y]37Y*P]]T4&G5"Y;; 4Y7;>;=&X:KTQF6>)!N[!ZJ*
MBR8_8P2+Q8M GJ-V 6T]X/,+@#GY(4I\/!.]K6A[!G+O5R^\J;OU)?5)W^94
M.:"(#7I#O2$ZB*FZLGDR&O?)I3;7&B=0+_,:P@O:NL5TVG>XS?>V)"CX4<^8
M=O?M&7IQT&M3Y$,$Q;P/-H[=BZ(*&',XB!)5L@OM#!3>V9F<?Q."'_*]*RB)
M-9T?[^2U:+Z8^NSSMF7(F_1",>\OIPJ56)":3S8JQ'+\2O]Z9VJ2]Z.9DT3R
M#*5$\]Y7&)KT>21 B^%1[>2.#%L74YGD^?C5.WU]>XZ%A.0?/5H<X+$(01@G
MNYU>^FWI&[=_7[8:8.EB+60]M%>9MXUEJ2U_>.]PY< Q'U&M^E;9E),ZP8O<
MB%=NW$LNYXZZ(^M]V9RN#_1\Q7?SKI CW F@8(:C?.?K6GU*AMR2?K4]JU40
M!D4>0!:?I(]D%1$82%'C;>Y, N''#\=VE>;M9;!J#'-VBD:-1M[MFTG^WQ&>
M!2Q[.]LX$3[1]]G&O_KNL_+XWVC1H%[&E6Y2!0%;G->3)ZAHDY^I9@E%C8WO
M]/F=]()OASQBF#VT%," D[0O$8\.,QP$B1:994N?Q2KPNQS]D1,Q0P;'G#-N
MB2 ;J??$XNZJBV3--#6R(=9+P^#37P,9<3,IL'VK+V!1'$-V_0S,FYXBXHZR
MI3V' \>5DSIU&49P7TB?64HEMJ1DK8@J[S%_>.V?/*T9=S;+""V9DM,:,@9Y
MFMGID#T)BK#'>UT#V&2M6B;KP=JLJ/[3 N&M4D0\1=%>/ ZN6PS4W*N>\L\N
M;!V7%3GPVGV$L;]S;>./.[U)X@IR+]61E2Q;AG#=RE,<W:GJF!OI]V],.I'_
MTY8<&!)8[%%NA0Y]%L""+_PE*(E?4%<_B5*[$2%-\_%DU&U  S.@ER=*Y$Q)
MOQTM>7X<K!Q7G6)\?R4U*>\R\-Y7NBVVQ>A9Z:*>:FOM:V<G5!%8[;@;%/BO
MI2K6,7Z)D^!5LP#-NS'NWY NAAI__1VV0W=G&.DPKOFD<&N.)0_I]5UGSGS5
MV4IF]57\GY K)A+T3TE5@D#WJ1GP9*7RZQ3O9%Z%;]!:6=6LU^7XW6OTO]4>
MPS9S$O&'B$2'JT3NA'QTDV/\2V4M9[4L-V3MQP=]!958-4[L,N&1E87I[+KU
MI0']TCF75 N11-#A&2@2PH.GWH$)D(T]BHV^V895VSZ-=6/N?28D+S*M)34B
M(R."3.K73&"^7];7H;\.W8  XM@+E%QI*U8$LNHU8L7(@>[4':BQR29]J";\
MF?+.O.^XL\$E)6]EGDMUOHL[^ P>.?H;+]@JA=84.76$J?8X<KT@".2H)@2*
MI2WQ;7)<<OW RL/J-R'XM;4H@(G'Y9G 6K,^B'%P0V:RES^'Z' !DQ^+.*\I
M2>S1@AI-5GPCYGV10J(R!;9^O__UVGI*^=KCX-4T+0GZ/P&;1D\#I*&FH\\4
MME1)4U<E^D,_6<BG;.180@K(-H07;2ZERQY4\7'O6HIDU-)24?O^=?%WS'&)
MH.WOE:J=$![R5=RBCI$L&"@SFJQZ<J>NKL'B7>1DQ+#(@J4S8ECST;E1!P0.
MG)H/;J&'D]0W$LN]? K6\&9)U9_/0!Y/V2YXPB#8^FARV(MC6CC<S"W5O88N
MMV1J!)_>W:=!T+94+%!&C/X'T"CH^+[]SI.]0U'A^SC>QEDE*:WK5<$"MAFV
M:E@ 9B^/#U%X=X]<E@E47,G&I";BO,UK^WO I@WN]!$ ^^DC]S.04(M^I4>3
MROM@%Y]OMD6]<]Z_UHV'Z_GNT6#=G4%$F:!/9@_$+IM.MB""_90"IP@S'>O&
M4A?,S:[?$255_=#4(#:W"]Z>@E3[(WC<3U*^FK M\=5*BU<.A?MT1F@D2FJ$
M\&(U?6@W+;.*<U%O$)53<@/UPG\YPF>.9AK5/K-B&ZH2V[@.':-/;JM_J[]
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M-63?RW\4/5:$Y!DW O6?[8VA[A.\M2]2Y\Y#WY*81$H?GJ]^A7KZ^X$*HOF
MU9W^C^-\^LI>G#B@*AM?2[DQ;CKI'_Q54JS0B.O/QQC7ZW?[=K4_%)W2 Z=F
MQ-1.C5R-)XUIN_9<VSN$02DN'\E8<T/M.&&+>GP_-A>B2\D/"/6HQ'"KY_R\
MY\7SZF'<*]'41Z";U6<@IWS0,@RRLC.74N C5CLW.3WW-<5\;ND1CT5OV\UW
M0@]+,]KYV;OAXK@J?D?JF"/2N!Y]9V_W-ASL\HJX8#V/&D8&W[+1V5A( C_T
MKVH:28H*L5R'),O0F-V+,] \HWW(R2BUKRG=41:A/?4XB%-KZ+)0#"CL'M&/
MI$#(^%GX9Q^F@2:=.)2Y(<ZGC/:9/X^TXV9)>^WK\%_3,A#06.*!$AZA"FUF
MIGDT/1\1&RH<^7E?U/O4S%" 0\)9'VXY8>/8*QMWTI,@6.&%I4A8&Y3.IFV:
M3>0E_C*Y'VK9BR"8.5Y8L@4&T$O*]7&_Q[WQ;(/?>LQ==:SO@U\9@WS@GMDK
M++WMH:W<:/78MS*-+B]C>VS-ST &&>;MHCG/=S?N'%5.4R]OX%B,' "7TDW5
M_4&E$..YHIH'X &^RL"HT',0QC_AE\B/  AN^/QF4#T7BGM,N:%B3&/>MMG]
M^K\&9;$B4K]RW$2F6K/;J;<)]8FUIPF:TL$N0<4VPZN&8O%FEWQGKG9LST5H
MLPFKDCFLFW%=$@B)QZ@](/4,)'K0=08BL>;_#]Y&H?STH=UQU0<U*C2;FG#E
MVH<.N_/FFE2>*I3V+<\KUG!%XL/]86;WIN>K&FI,QV#XP4-P*F(E2X1ZTT%9
MBSH,HB%NJ>Q\7,\36CZH!4>M$"\4-L5%U0).K5X0M90_F3Y*(6QR;;GW:; Q
MV1(K= 7HN29F,&=D<,U\YMRK!2PJ%H@LH6D]2$]".#=LP'#<^W.JX=O'/_/6
M?OUV#73JBTMRDH%ICK0?"''"<"N6>#I,J#W3@]8QN%0ETT?!(:-MV9J/OYK2
MLB/HWZD<555->V(>.<O)%<PCP_W#9QUK$%%4\&:33 '&J.1+ZX2,<1OIG_3+
M"3Q]L#-0O%_D<D78(,&A]\FX-COLP;2-@H"%@(I8PX%?BXH:@U9[.UF2;I8^
ME@??7Y6C[!.!8-04=RUSA)M-W0[0LGW:E&4QJ0RMX4A,Z2KTK=Q5H8],0>*%
M. +*EEG(=X@R9<7TI&VC:ZYQ]&JOBAD$%Z$K;;/<W<O@RA9=K.D5\I,)Z3WD
MF$NH8< [-^;+8J3H=[9J[9^9\V?U*'"14^M[1>Z\T4ON0>R+UF5?_GH+=TCT
M3O,+580>DSF8,-1H<;0B%EW<HWDW\Y4MI8&]L4 TN7@^B] 6S;N>7Q*^\'-+
M99O$QY>KMS+?JW I4#*5426_.0^]A$JF@5+$$EJH_3TX6_"O,L]=8YQXV[D(
MS3V2(26[18/HLO*;-S/)M76R@G<?MN._UN#^N;9'U>!<GGW*'2UY!V-"KV[^
MRC#^TS/,HLS6?2_6TI?1BD[]3,P1P'8'16IK>8;KY/(9R"U76V)-/T]:9U7S
M6>S*Z^+B(OAXB>.],Q#+7X[JO@3>[=$2-R>0AIZ"._T.>*X*.[G7T?8F: Z5
MT:$<6F(Q-*1G]R9P:X;$/YU)[1=B(&L1Z3&^Q+BDPYD6TRIH$)M2?<CG ZL;
M.:!&3=96J:^4EA:1 .QPY&M[J^(Y6\-6H]GS;I#F#@O-@';E-<3/.+P61N@B
M636]$R4U,:V?T1.4->5AGFC$=T0O<$F)CD8>!,-YW?,9VSQ9Q T).]+0;\:^
M'H$9O^??/-S[5;)=GT)%GOBW!81'M<FWN2/B+1RT*46U6N$]3&^]))!9\\;!
MUY*&>=M.)AERBW/<QMJ,GWT2BU75*2__'%5^:=-\A!DB #-9[LFCD0KO75EI
MKV_)]?TN=V+O1YBHLO:VAOM2?R$NP^\0(3B55@PE_/*NTK:5-S.4'\_G^OR6
M CJ].SQG01)J';'Z<88.X"5/4=*IPNZ.S AWGRN+L+R_2F^M8Q8;\L(Y'0>=
MZ4,>19P<XZ;?'"Z?H_ZBWARIA1FCLEV+>582/OXT7\PKSOJ;3Q('1(K(CH3Z
M^.%$&1^9%BUH,&]OP7T-7>8:#O'?Z3ZBD>V<A]-X66R%K!WED^:34BL'7:WD
MQ?Q=,>GZWQ<B^A@J@E7)["_V158<>6P_N;#+%%V>L;JXKI@B27=P!NINH[MW
MJD4=M_'*C/463QS3*(.6Z>P=]%2V<T@O! @EAVV>&I(?- &V!'T'HL!;KXF6
M!GR%8V6_J\9]EYGIGN6Z#ZM&IT\]-&;.)]P^?G[X=WO;=*ZM(TCH*L0M-P3]
MT"PH@.U^&*->^]Y^O#,#BO;(U)T2K..;@HZLN@JBJN6XCZ9EJ<.O>G!YOHH9
M*^@\&ZMB^OA8H]!L9M<H3(-4FVE(Z!X8QMA;[$/_L4+SY(FD\X4+(FM.KY(?
M &%%LUOAG,3NC%3.WYE"[M43RK96LR9ZO J[K.K/7Z"&"&>@)!1_<8*TDO&Y
M4QTOY\UKN/JQ*86UI\_3?[R2W[XK@(>WGL+@6@3*1J>7?O?CS='Z>.D\'A=4
M_Q)[H I%SCA,1]VOHRKO#.0]T.=$R4/"\JRF#&6<S!^OR&NT2D8>#.\,G\IW
M$W$K1UUSRPG*3-(J2_O/QVM/I;^JK0M[9]S5'YQQ2=&8AIY:P6JL*?G:%P ^
M3$],B8+]X$O"@F,GHP9:$.:PW9B=[XEO6\D['AD@J,#^^?GIR=.//,?)BPQJ
ME9941JT56[Q+YQ(?T;BH>1!:U))1_[+@8]I#3A?\^Z21"RPRCK,DH5F".S=O
MY5OM5IG,]8'7N(!Y^W\73';<7KDDA9J# 7'5)&7CI=N$WVF#RDDJ6-+4';JY
MZM>L8V&P%<MGI[=H]-$2FQ_':Y)=90U C8EZG[AGUZ';5F:5<N'6G!]?&VP/
MP:IH[ MG>G&;W3/#@:UU7";?Q/A8LBAF?^2=P?GO/3"\ 3@RG)GL1NA]$ZX&
M&[ $BKZARL*"?45]%^UTQ%7**_7&DN=!K.J6$XY,3S"I*>'*\\!\.V_=OYE7
M-Q_/+6U:C 8K]NV@7Z*LZ2,4P +;&IT(<#AW^"2*+[_+!I7@PA ?/J[<>DSR
MZDA\ZO^ZU';B'5T_Y\$R&A$KM2(T[V="V'NC?#E 6M&HF6WX=7'@C(K I@@K
MJQH'73&-.( !Q&>8OAUAJ:308W1FR3/!3VR[QW3OH]S?>*WM+5,6,F0$[GNJ
M#+@93]<"1WP&2O*:9GTF;/>N7H\%VQ 0@&1X_BL2BJ'E:OWLO89Z!9>(C?/T
M@*4?H9=42)!N:[<7?W@*SQ04B7X !>^XWW#+,]11B/C,J@\?88BG"1;UE]-4
M;M7XCR['O$_H\H/E'75H/]Z%K"[*4"#(ES1VJ^BH^=]"H\\7)#"(Y7%[?ST#
M9^24N,MPX^'[O<3C94!"^E ^?!A/;\0[H%(&K5/ ^:+9##CH_$A,<8B=6>>(
M?Y>_+S&7K+IF9OU5)6436+,Q>W,9+(QW?&1V]O)Z#%=;&A0>]%B@R1OYQ45A
M-#9SGM*2:#J[?NG\]P/]TJ476NA7YTOX [KA&Z<>]BS<I+H?$]X?TJ9XE&8'
M<*52;%UA$O1X62;J[S,0F,Q7N!TBG9(T[M'4$N]SO3EW[2 P;*E8F0AI1X!G
M@5 25MTB_U)43Z]94PI/36XB=X3VIZJV%FZB;6<^&VK<%]/Z8OEI?429L>CS
MF*1Z83;8,!+.0HBVB A?G.:6UM2YC+1%LNW1@7EX(&;&=$=N^##"'IHJ 4"P
M+%"S\8*&2:7FFRI!+TW^-#(DTE!1#! I(#O08CS!MFM\<>&/Q?35[Z.8W*^Q
M'HD;O].]F9Q>,> <K:D3QR-SU&&J@EN6J/1SG5W?(8/-;0>^_\YP:7U#TS(D
MJF="S([Q6@W+C$1P;\@5009B&695J&89+_EM%G#&8IF4L^;V1VK6#:)_+,0T
MI[1%5J'^ZT[![>D !IBPK:$/I 6+N+)1DB[\7<,1CH3^JJ0SD-?V]S9,<>VK
MU?.)3/(W3=11T#U'#D]>K38TQ>3 TFI/2>UP/6WK>ISUC4NJLE\.BT? 'R K
M>=K71LBZ&"%NSZ;D#W55%=J??QJ+K4*EWDB8$MWV^-,=),71TB(VE-I*N #T
MQ2#F;\ +0SS>_MUMVR"Y"R$@J/Y*7#R<GK41F_MB&LM50LCK6<<\'C>LO^DB
MJC:T_EH^K]TEU>9X+QHE2<G3YMDZ6-H4E$TY[N)>33@*LY[]]KHW_^-W\WY2
M"?VF$ .@;TP0C[M=*RTH'F=28_^N,,4N,F>_-_TIE28D^U6)^I1HMS/0"(N_
MRO2C)=MNK98$3;;OL-7D>BG)/_=VI3( 9!AG/AK,V7_[?=?%3Y"3'J;\=X>#
M2@SMD)]"G:$^;[/V$FKQSM1=6=9[7AR960&%W^1#N@EO15@#4QH$H*JD>D"C
MD$P/?"HPQH@H?TB>D IBUM/IN7SUATZ]7=!Z*Q_U<EDP1[@8L85%%"HR>W>K
M?(4]0<.<%JN<G8C.8(Q$OY!TNOR)#T?[R4"OXU49^+53S66@O>[T-(Q%YE$^
M]M/[NR<Y=0C&OXZD"P3[S"XP.PS=O206I>7W./*]A=$J6ZK\WR#T<S?.P_J4
M%MDS$!,[R18UZH_/5%R"A<B?Z^FHWN;]L;F<^+>8>GD8N^W%W;5TB]!Z^-;M
MN\,-X_,*N84M;M!OX%>W[G91FC49/ AE6+?8EB<8J]@$E2],#\Y SI2YHJZ7
M<K\8'J8T5%5K0K#]\(!3S>1P'%7;AZQUNR:T+:TC=5T1F/[U7V,>%C.X.2[U
M/,Q('S+'^TM71+E<2+',H,/,0.#R]F'5]_)#3L#G]$XNU[X5)MV$</CCEWU4
M,O6)M]"G;CGMQS3N^.+[&>A-60\^!5&-CT7@2ZIHK#XJ"JY!V"<K^O#<S.6%
M)00P05U""F/=YX5+!-0M/R$ZE/:NUQ,WDKYD/$TN&G.:26KWON&28UE#0RH=
MY*5G  OGSRSYVW-(U,PQRV!M&FPOT<D[O.-5.:(F+]& )_3TFZ9+6>)?A"[0
M\15P))43PY%$?>-T2X.-C*$+6?)RU7,SCT6TZG#%E=#-MIF;^U)5L\L&]0<B
M"KJ( +X>'F^[AE[.^^@\/L#WU*(?:TTV^^*QB=62?9IO^KY\0WY!R6#>)5 D
MS4 06WA9DSV8D(W-[/%AAM6TGU2FNY5YC-B)#64+M,WNRIA/7+C^BFY^.G*L
MQ8_**+\R;\QU@+8A!ZG6+'L^>9@FUMT!<S&_>S=976*XZ-62&* HA$;,X=#A
M/$!HR7#XMI]7X#4KS8SH0%=]UQT.053+=.5_)8E?/)2$SO_Z#G\?]+KH9[O8
MQ0N@$)^=Y5,MF/@]0ERLIJ-7L3&E'E%X(<_06V DX6D<G6'[><M?0DA5- 7<
M#JG-2"@"PCNUU'M>_/S8(1BXJU!IJHTDR>X,$],[!<4!/PP8O#G7I;B=<?*Z
M6SF>X7?2Y[]O0\ A?^^3)B8P9Z#8PM$BPZ_^];8"OU-X9$3/KZ9Z@DZ;L;TI
M[)A\M'%HU^\\-Y+7IP_L_%SMC! %J37(K#Z&DH\71HD2E[L*Q!-]QO9V,J:.
M3> ?Z?A2)ACH1RQ':1)0/&8-B"/(=MN89-=M8;?0OR-=G((4,.T\V^U5[\Y
MSV13LH30V:W03@?QEE3#J!/7K*7U%7SR32$ID7P,Z6:$]@? _E1ML^TR50U*
MO3%R^_$ >GKNI:\N^%/S0'Z@G81FC&90E7^Y@&QO'O^TLNCXX:*?Z82LC8C"
M_-S"[>2U5&P[WO9_M[JB^U*,*/6IL.&T-#D#/5VVJ96@<_^_*+E.W*9JT12#
M_Y0Q]'^MC/SO/9#,J5PPTX?$GLB K]LJ9R#HN,R/FW&A$DZL=T6O^&8=*)X*
MDT4VST"7PNJT-&<A0"E)78*^YPR$2:5>I>%?OM<9"/'\#(0M*YX*OP"(= FR
MC9$5$5^ZM>.^Y4[5A2[<=LN_GSYQ5$E*!!%K3H7A(MXH<-U&ZE$:@FB^Y<!'
MV,W':+&-&XQ]/E7)]\R^'N?K59;W27/J P?=!RR":3-/8<3'W]YYTL=_OFM_
M(S*!+G/K3A5G#266RCZ[J%E6M-3R\)X*/H1J?1+I< ;2!;G"W#J;(-%*,*4*
ML$G]V"$0OM9:?<&QY$A[O<$T<;DF*#)<84O>4UMT_'FF6>+5<_;W%?5.Z40E
M=^[VD[<G)#Z#;P/!IPID3<#U>^_W35[>_I+>5)F3H]]CO;N%E/'#RNUN%'@,
M'H YK6"WK[6E*&P(OF1CHW=:=6.8JG/_#.:G>>==P/ ,I!/V\PQ45XT@/DVF
M&5!,PQ<CY7^KXT.&M<*E.]2C4#$.T$R!E;/!R+.K.M\/04X6LDDMG%_A=PF4
MH00LTR6D@ K<)];QT6L>P<_1"Q9K''3K@I<IV=J"9.V?D]+^81?5>HJ9;.V-
M%#/?8Y\=W,3U,<SE8TQGZS'3D4<#]H[_$%9MP@M>^G&,_OKK(#\>R!+BRD'7
M#]<%GF!\$N>>AB 2#C\&2#B+=N'W^Z]J!?Y8M=18$9JMPNRAH0*/IW5')B\6
M,=DN#&I\$G6/[[C;^PZ,# GCH%O+ N]T$,8[3Y!U146 IX;4=B"8_^>PL' *
MHK6/1..SZ YUH2X65B^A+MZ7O-]R)?MC78>F=GZ%1.]*O4X$[:?&M54?HZMB
M>0^@ZH()]69SYN*-[P;6W$H>4L;WIK(0KHXQ9Z YK^]5,5BCJ7>_W P++19,
M#/M\GCC4Z(+<MAP$Q@,JN(P%J4-\BPH&+9G(1OL_?R[*W:,&8+GS?_1V&K4:
MTK#I9^7GQZ^]L$W/!,-B0BD<=$. $.8X#L7WIZP(YF-4/U9>TYC&N3;/L]!;
M)E3AU\:.H"5Q>KA#ED8JVY^2@%#>'=L&JUZ591WT]Y/IKV9W!7T*J$-+H!$R
M0\#*J=<YD2_V!M4+73M&0[]>%RV7= @B(9%4.H ;@_JA;,KJ#BU:BGD.YAB.
MNM3Q*STE;JSU8B((PC^MA<L'N0NQ*5WS][FZ.>II W^CFBEN_FST7Y(VMHE7
M@CX:<".H=N1?"I^A\HP6_,S:/N<Q^[:O'<&*ZQ/L3$U8IB=S$Z-XXA(.W??<
M$@)U PL+_VC1I_CB[6E^@9UCV(DFS-^?D)99&_=&)GA=E!XW;P[&Q=._.R<(
M(FTZ#/(;<D!Y;WV5Z"Q- C$X:4D>/J*SL^RJB@Z_"C2Z<K8E*L4CZ5GAV:G-
MMZVWD7&0F,#:1PQQ,%.2'&".$; 1T&-A--K^;F<H-+_A87;I#H./";@B9#F!
M+%D(F]9M&$,.7%(V5E]Q-O#F?J7])D0H9.IKA'8X+0HX 4/*YVEQ_:9;"S3L
M]5K;($-XCT(1,52N&H+=$CMR=*660"Y9:_W0(!_+4&G%GQ;FE[7U_3-8@#;V
M/F"4NTR(G]\=,@JN=M-N7+27:2/(=FB+$TCI7[9"Y)K&#@LE/;S'#>,[MM0T
MJ7?^ Y=]+UF2.>#X=>N*HQ7@P&?;(/ \Q6#]':?P*H+3$?ATJ@YP8Z>J!"NP
M F)%DP7F28ZVOT>-D'ZUSP5GE3>?/F)(!_1)C@2&-\K-8:Y*LT=>%LN"QE-5
MKXZ-KPDP[JVXU!>%H"3=/U]:C]6(?Y[XU/K&^P?J<GVN6O=(5>(C;:ZRL8+\
M1&=8X@#ZT5M@]<#9D*=%'N77^(@@-4W#%*G)-M>]6)M=I%_9$N!\#<GT*6E_
M(;CZHINX1H,WTJ<;49./WN/WO!Q: 81KZ:S=,.!<S3*YJL?AHK;ID*X+>J5]
M#F!?0<2JUVR%\X[@QO8<%/D,^5/N/9D___[$PC$>\D(H-D]B:O<HV11]96'+
M\G%PC=TU.T75*H;$HUL2]+(/"$.?"F"!+(QSDQ?3F;5UY@TS'65S2A9S4DQM
M]F,IR53V^OB"*?W8?Q^F!7^=?>$C$NAWK.XRUUJ9"#K(YPT?AH!1UZ'TYM,M
M&CZ(D!L&7(]_-[O<BWE$UPZRM,4(,6PZ7!QU'O.W#43^2'XKJJ<'9T_:[\J;
MI 4MY^J2*.4#ZAJLIFNO:DO[6LS1Y>=L VLU-QZ@<ZI964-/ILM'[_*+)Z,N
M B)8I0ROJC^OEMY*P.-%EOK>]ZA+F M;.,8B7N3'"8*G*@*\A-"^5EM<@TV2
M!5D/HP\7AW$.^;J@X.'D-K>VN#/05<U[-Y%8(?#][UN/;Q28[*NGE8TX\?O:
MFT:WL!? &.ZEZHV4=V=D\]64\[V-L*VZ;5@Q)T'?1?8XY2-+$WO*9 H"/E-B
MM]R61:P>/+,4W0],40@K*Z4%)KA]^5*>(5SYJ[Y'L/#<<1J[:'>8JF#TID.,
M+DC@IT,8KBHB[P+PH1SA"4O727W2.O/S;]J#%2^':!"N-82%!MQ+;)0<JB#
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MB2*=0TS9]@F$?^(4K,*RR*()?^>^%4"+=<] 6C)%5M-'2G2P',L,N"ZE6%L
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MO669I#JAG!K75EN[=(4[92I-:S#W]QUMNUA-#'&[=]O1.;Q?X?9R36]4HL
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MW=!:,@?==4'J&PE';W6;FZ=D9)X?3!EROYH?TK9+>LZ[?P8")"&QN]11C$
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M0N:7-NKA7O[R%9=-%KTB)ZR3^5U(4[7 B(#-(YB2]'R\P.\*G(/[2-/99W<
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M4?Z=4DP7NGT9UPH_EM&93MJ+2JW?^A^OJ/@-W_ -W_ -_WW8^?!74$L#!!0
M   ( !2"8E;:C!*9@$ " (B& @ 0    :6UG.#8Q.3@S-E\V+FIP9^RZ9UQ3
MW;<N&@0!Z2!5F@HJTGLO(M*E]]"4(IW0:P % >G2%81([X3>B_0F(%T2>N\D
MU  A.;SG[K/WW?O<#^?>^^7\[OW/M9ZU/LRYQAS/&'..-4:RL'^Q*P *-255
M)0 .#@[@W=T!P,(!"@#<>_?^.>\:WMUYG_#^?3R\^T0$!/B$)$0D),1$Q,2D
M9%04I&249,3$%+04E ^I:6AH2,CIZ&FIZ:FH::C_$8*#>_<,WOT']^\_H"8E
M)J7^O]VPOP"4A/?^W ?@XCP%W*/$P:7$P?8"6 $ G/LX_[T!_JWAW+O3$9^
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M30CD!?H,=+,SL7VGE0PCYEIX.'YKBTO*WY7WF<KC*/4A[E@:G5=#[-D W':
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M<Y5+RPW'V>>Q%0[T(WQ]\J*[[7(K(1ES+IJBT?MGQ^&P7L20;/$?E.NB:]K
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MC3^)/6+/=BO[8PVP:N+DS&9)@7IW7IF>_/FRCA38K,,PUYD?P\V]:R>W"\S
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M[Z!-,\I]K>E]7$&:QO-#*O'I6B%Z,P!@3Q6:T;F2B:'I^(,AV?_J!)3IAWC
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MQLN25?'^$Q 7;RQ6UB6E12:DDNESR@)YO#1QJX9]MQJT?3U1TPN3KRNPQ.A
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MMW7:"T;?Y=HC<1&N E/';J& 8!J:1; '+]N#"61_%%P#SQ<J,L<>?=(E@8
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MRP@;+T ,M/_.GG9& 5$W=(D !'GE3$!YHQU ^3\[;YG "UY^!2;<:?AWS23
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M+W&IQ"_VUYQ<B?GNO&VO%5U77WB5WS$:3Q0A.\PI'HEODMZ/S@UN,_!ZX2>
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M G1.TT@CP;NR2NQ(EO-/=T"E2M OR]7@<$ZRL4!&PJPI+J^J3*0P=V#I\=,
M/ 84:O!:,_%&U.L7/B"\Q>T.G>ZXS5\,7C%FM89.2,TQ-J,/[U(R7=.*^+]4
M#"M>)OJ,-IZ?VO V5PO;5S#?,2X/D/4YL'W5#LW@M'?E3I<DBR@U#6IU.^^1
M.AMZ!F)!QX8HBHQ)-M']<"F;6$\:^3'C[*VGH1!U&'^ZX46]_##MKG\?\66G
M@/SM@G6.^W73,#>6;@NK6)=A,(2.'HXPQT''T^8':"?6%*_<T\IVOICL^'UF
MP5CH]_G/L;(:M.JG2U%?.!F+7&TJE[,#YE!,\&>B%^#/.CK;CL,.D4OCG4_V
MXE<YNH6>8Y]?+W9X?:-4]T:,X)H-Q<0:&)=%.D<(75$BN#MZ<NAO@^E=%6\.
M57Y^55T6Y!55Z&.G/WR>G--FASDJ;58,187/;X:*+B2WN5V')S2;3 @$D]BL
M"&$G7"J-8Q-PY#8L]1QW"'>,R64?__*B.W'Q#8(QXOG\.VP6^X@1.:1$8L:!
M'8_YZ5=Y.Z1&T;J:YN!SHE6QBV"6*Z=0)>:3)-MGRSM?GSK<%2PO*GP5;@%Z
M&G5Y\29A:Z%8-\B;BXH[_3RN;2+Y\/-7U1.EYW33L.E8T9?%6Y-IW]@/2UL?
MG<;Z^Y5H+^#E29Q#3W&YNS^ G5B%/D\_V35\!^;V,?&QU.DFZ&D)DP<-NGA1
M-"A=K()@-<]!BU7'B:"A/@L^E4A!&UPO?FJ=M7+3E,(O$9I'?3IXPNR?\UI0
M:\A8L_FD[^<RX,=&.3AJL?TPQ&>A^)UCAMI(]HCM7<%;[T5G4AZ8+ILL>E"3
M5[X0,R)=(SX;4Z3O6Z H'Y%H@.AB]W]*I*EICRW$9:93WHC[F!,]]D8OJ%3,
M*BRRR4&7GF#32A(=W?)7FI^E[YD[6L3@+Z1E3^E@93WN07LNV:IX4E].N';_
M/)=RK/EIXAG(28Y&<$&J.-]?&8-K6$;3A:V,)K0<9U8G/ZGL5;07WS0\N>=@
M9MJQW?\E2$];QC"7%38I$M)Q[^6>S,Y;,)>((K^_ ^$>%+762(<KC9O[W-4K
MFV+)(6-;;C(U5*?K_JOQ/@]Y[S/9,N'T>X>Q0';MOHCB@B-4*G#+D9D;K!73
ML]KS%JC*]I);<3E!9H[7>AO8W&/$(]A3O]AVALX-&Q6)1=4D'XQ:#Z'MCJ]D
M10@NQC[_/W3GR'>G&1%\S-062T-(>#+FB1UQ&DD0ZV2[01^=<U0.8\^#S\6$
MI>R*CI>%.!NF%G;"=_;D!&WO#.;J5))89B8.O6Q5KAMWL@PKX08ZF)ZH22A>
MQ_*'JM#&J^4__OY=5>F\Z(V(\$ N>)[V0RT&W/A7[% 'GY^M[>VX)_'D#)/O
M+YUWFFCP*;$=/0,Y6%UF2S/'JD>>. RDP2O$N0Z:1+BC)Q6.[6+0W_H6M)K"
MP%<KB^NT%@LZLW)KE6\</?KZ@;9+T4A.]^,<C*699<T:*J]BGKI^VTJJ*D!^
M(!/UIG5^[+9VH]FMJNW*99,)[$B305(U+J8.4J*<,Y"U?F4]@6;H1S>$NW]N
M)?&A-&?8ETU7#JW6VM+( C6[ I?D).EABMM0#QB^ZUOJ.8;7 @)O;!X0=0@>
MMIYX.5U\D2 X> =(W3$BRTIQ)VAC^^.NQT_]:O91"@3?VLZH>BB2T%UYA"[N
MDY#*/G2V=8E*%OKQ1HHZ/O/=<R_3OCOP 1?=B5=5C0UA-H*'DJ32'6]!D<9U
MD^7)JN*5'WM^&U1I(KL66CTN2)%,:+F2[/57BB&Z-TXAUFX@>-:LMNS;1K:Q
MQ:^FQ,57A^+OWL+[3T_<,>PK]U$6IP7UO+N6SNG2H1T6S.C/K[1Z?++%NFF^
M6;Z>>ZTDV*E[Y!C@6HKF0;3RK9*[=QXN1CEA=F+ LCQ1'ODZ.29MF\0ZDG*Z
M">O]*!76:-*VB,9O<XN=Q[L<3*V^3>%\\<(\F@UCO%&P5^48GPC:3S>5ON7W
MS5O!9DUCU9/51GG&[#MZF-#N<O;VS^1A\A[#=:B?^20MFS#%BC/0:KA@$N$-
ML/=;NO",FT>S$Q@N[U+_\?W26(@H;.T5^@S$V*0<O#XZ?OE^LE]-]>20P&1O
MY]B^MEKK[PS[,2&1RDED)C&RRUQ@PI>CA*Q=S3MW9@TWJ>WIHE IK;&LQ#LD
M+E28"GNHUGMORL1CP8UVFH!=3$)F?S/;%I4,SYSRN9.EG+!O=/Z4PO<,U(:B
MGH*?S&5;H\*V*P5G+T]I<* ;IHN_[9K&D)&]'N@NBY'KF$&_Q4=\SLL]1"($
MMPAI'\KSWYF&&[A--=0?>1_E%LZY^XOAH_"\97!=RWAILD2L]L=0RO=*DUWY
MB!8D/GT./$^/K<!R_4Q X"77FLJW<SU*_$U'M[>7]F"\PWDS)P]7+MR]3\X!
M*H7,T19Z<K7'TOX0JJ[T.TS+_O:K3?^6S,;0NTX=%RUZ8Y&LD2F-@[TS$/?:
MW LTST/K@Z+N3L_<%)-)),G:B<<'M]*> LW!F@0RC4.AF?J[VE(9XMRWULTB
MYN@\+ ]\=]JL^(7![5STDA ;^HDIZ\A/67YLKS[W&B8%Q)2S<%]^0,G%P^D>
M'-%#<,*M/, GAQ"UBM9]T:<)JX.7EF)F?K)XI<X%60@%&NS.^_E/X4O$;NL?
MHJ5&LC?<]F2*?FV;QA8/SEHM59F,'WOY<D)5?$G)N&15_(5$)#Q9.<P:*T%E
M9HNN'$'J!<[*][%*?/[>\3TB)/8FFV)#7YK-H9\-P=185BHC0*'TDT=NM+7J
M*,^%Y7&QWXL.S#W!,7<; @J.MZY/P,;/0&&G*J=QD>[Z46Y>\14S6SDG9NCC
MS8%[%3C%I@*XUX9UL&8UE/6'H\6R55G 7/VUZ$X!9I82V=\9%'V9/3B!!?4A
MY(&@HU'5->&#-@]!_S.0X&W#QTZI0;3WE[ W"XE2@Y5GH',$N3:NB=I@->2T
M!O4FU.!N$4?^<S^2736G5E04.VVB!-YZ/UO/PD)8'K7L8B$<V)^Z*C?#/F!$
M[)>UGK$.2QFR'EJ(?2.ER#0N;R"$24Z690J#0G-3\\;2E\T>M-R>>$B=FG3S
MJQSK$(&[D3&LW?IF]3 25<H=VVI@N; ^3_U>(V3OB72\XO-42O(WZ;1PONBP
M"L_;I9# JE-FY5O%!^\&47P7)JT.H5+(VEH(B6SQV"W8,\VN]3@=X_1L;\W7
M1<_S1<D7M6I\LPSX]?V=B Z4'FX@9%,2%9HN,RXD:>78,M'VR$)-O##B<2./
MN/I=ODZ!4_.GBQ=*=''85L6K%;B7\"0KXX63-CUDJU2&_)-.)ZK$R^K.4UU3
M2[M9Q1MZ^A\<&K8@$'3OC(7,PVNAX<55,RG=[>;?UT_3ZS#V/I(,V[)AWZR8
M6I&+35L<%D_JW&C:KZ\Q5(JU\6NHVO7$3^&4CE3%XNIR7UHKXCBC<^'76AJ!
M,Z11R\JN/\9"^Z%AXD(<&R6DZ(9@\[K<_^+MO<.:VKIU\2 J(DWITJ(44:I(
MKU&4)B)-0 A-J2&$2&^A" +2I4N7#D) >B]2 HAT"!)Z0)">4 ,$^+&_[_Q.
MV?L[]]ZSG^?>/U:>K)FL.<<<\QWO&&,]<ZU!8\HF$O]%+&?BCWH6,>(5)1K7
MONO1&A?5E"'CZ\%'ZD_B%:C0!NV!G?E=YX!RJNY)I=E?W<D1BP[N%G/,@[?Z
M+0SR_=IYR8CWRLN$ZK^HTQQ\ ==\:N.ITK'OZZ'SG'6;OWI$HQTV6T?0G>\'
MOL+Q!,V@ZQ$9O '22C\TJ<H#?YC?.+*R')P%1$Z[]J[J[M>AUHS6T.$UK1/S
MD--D'40IB]"K6K>6T8JI'#]W?0\DP\1:"VGT<T*>\/O<,=I[=#J,9@Y) #XF
M@*S; ,VH^#1"D4!Y=BMV8&108VS3P:'ZU=X)M+&O;DNP5'N'\7DWRY&*VUQ"
MJ)2<S=6J1+YX8UT_VH8]Z85$K)UR;@[PW>3Q.<#D3"5"?Z!H?L9&::BJV?J@
M:WY4_ %J9+XBYNYH8)LT\,.M3=/F0M]!-S<<(;_7? )9Y@+F<J8N][RA3G&H
MG?14)Q">G2E2V;L9MM*D-G\JJ8D3[CA]MMW)4KT<5SC=$\W>]C-1*^22)M\#
MRV\#BQ\]VXZ<NRS+X]>D"N7GX/RKYP"R79E?\>B<6PW#DV8NR.U[C7.N99J\
MWARZ2MY7BW"'WQK,VE%XDR66Y61G'RZEG$GUPB?\QHNY)0H#>;JM==V@!R7I
MF@LU004$IF^SM\_&QUCD'=94;2SLDH.T-F4MYG;9VW:,+<WG79!<X05")U/+
MU;^=!P7*.(I.OH#W8#S-M0U'T/+E*H.*09SFTUK"%,V[O/$R-#EG9.S";14(
M6U?SNSZJP,# 8'FR9E$U@M)")I/'5UL%X+BKFLUH_W1*51+CFF8"W>W'#N&'
MR>$,1Q]Z;V&DKOHV*D^@T2V#;\X!%2(&CA6MHI&EI4M(EY:38SN/38:-E+)O
MLG=Q6^^*53B0"Q:>Q4+)KA L>R-6'R2PAJC;J5N[MN:%CS/ ;G_[><:^*OPV
MQ:$85D, =[LZNC+\8'J08+%,(R2^DWH;$:6V$C&?PA61<_\>;_$IJ#2@*!Y;
M-)I@*.QV7W9]PA2#V)QR[K7-#MN2>YL==H]T0Q,#.G4+.=L?W(UJ>M.<>1!]
M 8"L<T"S,W&QC+E4(.FT/7/P'/#,8E'S"/@&M#EWRGDW.D3\E8N\5Y]6QJQZ
M7G6"]:N<>&7U^SU]# X/I1=WBCD$\90*7'AV%!(.Y8F;!J7@>Q\DT61\WC2F
M3F,[A3(45:^=W//6A,)@\*0E1$J7_BN_+P5;9BEH,&:BN:PV>=JC&&L_RU_C
M)V6G/]H3%MM]-7_.$F%.MQ0OU;/9R+Y&!4<UN)47_C;@4JM_YU+WIG;G;!JY
MK +D'TSX-J@[.&3 KO2:C9V9.X<5W+]_E+XO&@&#/-/C=><WQ4>KN(ZVG!Y/
M;Y>=\8+7F#)N[U:%LKY !XAWU6*Z/\7>.3(!]K6Q2_%YN1;&87/R\TADWBC$
M,:9@M,HA40?OW\5:3AU6D Q,>QM0:>3ML\GH_R*:0=UG^WSZ>=*7J8T'\FM;
MAK=^P6H:X4DP-YD9"Y21;];\NLFE*;6484$;"#:][/+[Q/4F3PLYCI^;Q@GT
M!DI\VKDI(09^K6.[Y<Q?ZNKOH]TAW"6QP[8UJO?CCZUL![3R=5>K@M]?K-0]
MY?QJZ2+D2$ P>C"0J.<\WWH#8X<NSZU05!7I32_-O:'"+B4>J3K#QWMM+/Q]
MPJADCE$^1Z[=B%N\R>C&\+ =!^?(P5Q-7*Y&09]7OC3E1(87*BB0(>*RCF@$
MHJN.N-Z$EPOLR"#!,6PNA[B*SV2KXC6XJK2?GASR]312;RR^)8G_2*-M"M(H
ME?GTJK]]\.GVA(E@\Z %3<I8#DMMF .$QXH^J2G/UQ0L;Q!37N@Q:#*6B.<=
M+Z-D<A*K!)=LE(N*]!Z13$U@JL5:V5Y!9DG&FB2.G^_*[P5 A-!X VC1E0<9
MAO/FEG2#<A'X7LEG%BY(*\6TV'"CNQDI=LW4SSR(&M(-8>XPJ?72:%?DH4Q?
M-)M1;8#+S'7YAY8IJ)5-B,O$ZX1<D ?]3G=?5*";2A'R):'(O/4F:U?WDSIH
MOO(,_&!_LJD@J0[(?QLV2":7ME+MN;"J43)+&]Z,/EP[WIXH&F6;NL7$F-\\
M"_8N/V'27KW(8Q0*K!8R@48$;5>KJI'EJYN+MD+Z&X+]=;JQ+>;1'V>H+Z&#
M5KK"P65T'B&Z,,;7\%)#5O541R_)(BG6&&()-?W;E[MSU9Z+NBSYKYX]C$LU
M:I7\M;(4'@R+*'@AEB.K++3JU.V#:&TZ>S%S<_HQ_B&59(>71'K!JO,3USPS
MGQ:*HC)&I8<V'WNXC$NE%MX=YHTK\&+ZX=C+HWN& D"S!*"631-M9%;XPTZY
M\DI'WKC&6]@ZB7Q)([.7.=Y3>)_MN98\/ZB%M*?G7G5-%/K7J(;\A/4AU'DD
M%;L?X2OP%;TX9 VT'GV1,E3SF=QULMQ8,O[!(UZY&QZKIC9O+2!I[9%L2E%=
M,8$/C''D ,O%%K(AK3$4\OY0@<J\*;@E$[<LE>;&=2L/8J9_H&Y@>:!>P>SU
MQ[Y%"-(H[4-DPS^_/L[F$F=]&3F;8Q<[A"K$Y-F%-HZ(/:'YX]9\-=W+Q ^8
M'/DUY<)^KJ=/QU!%+#EV<2^?SMA);.N(BS2.6!=^F/!9\.. S%*.(D0\"V;L
M>$U&7*6%<X.0%J\XI!FY/3HS(/#&6[<F!W:D4)J7+BXLL=/58\@KGPHI$Y!=
M#CX')!;-((:WC-R[::CZL,)L=DRX-7V)E/'W&+V@],CX%S5?ZWE_V/]H%;&V
MYI/BB>[74[B%,,*!.@AB(29\^\)946OLBLOR"N16];/,RJM<?0UREQZ&^SL?
M1DGC92*+(^=7JQ:1F4>O#NZD8KFDQD;6CJ<:6U>F\E,YBB6C$&R^[ 3O#LY=
M8^&\M?Y"\=Z1A<ZP[BN*IP4!9/*><H[H:G'A" [:9GQ(IXG:BUJ&@K"JN8I.
MWV[RV-DGM6Z_=OVMCE3NO%N*<(S#"FI5TU!0;Y^Q%QQ]CK+2XXXU K<^Q38<
MV.^;$<!&SV5H.B!O G#KIC0)GS!-:@?0/%%RT>7MZ1"*"$^;N(DH>\(4=CD:
M*WNH+JBK4SY4)BXV)K37B=M\_SR7=JKI=ZY^\KMY)HRJ7-H^'ET8[:6 ?'&X
M3S0Y!SQ$6YAT=6ULSM@CAP^&]^3[= F]"Q3;MQ"J8V/K'R<)E1HGW!H'4L\3
M=]@;:X4S2(5['CPA[65>Y'$!18!H]LRNVQF)YR<50D36,CC.?C1XPQ[.0I2&
M44<1_0\\;YP#G/FNRGAYR(YI&)[JI"/=1W$R%BD&RTX5+<VR-7,7J5LQQR0<
M[_SMV'6B/10K\^L;+O!KHT%%,$C:\$=R].%FCSTEFZ5SS$B172N]W!VL\/5U
M4[;6))/*H.HC\1E)_:J*T&6JVQVYP[?:%GDI*[PX9 PBY97'?(R86EI'6]<,
M#H+TT^PO,NI>H=-8^3XEPF$!AL#[:-1HYQ^[A\BWJ$K+&4.LBIKP/;\.@552
M'MR]2SDWO%<B/)3VQY(F)IA$0<EB(V)1)XI;;YQ>D)'&88(+C4KI+31J.7+U
MNEYVWD/!X02X1M)1C/RC4[N.,1JC6YQ,A;-_;-[3$0^E<"\T*G"X, !1VX_5
MBC-KUH6I2*Z7BN-T8_W:S6H-M^U"OUAHBW.]^BBNZ#4>4LB*5/O"Z5!]$1E5
MSJ%@LO/P<&'$8]>%7J*2NV#.9 >+'3^$#7*[,ZB2,BB4^=L5QP'G#+FNM;N%
M:7JJ=7W6KCI%?$ZZ4;_WS2X,@KE)%K>KA-]*. =<JRGP@V)3K;^2G=A)9:"G
M9.-M-DHX'GFUT .WP@I*$:^'B8:X<T"; @N:*.DIT$+WL#-)7^9+6Y+$SG-N
M%UL,&1\!0$;Y:&E3GO]':I[B#%38BF+7]2QFI'A@NG9TV+UUV;NT]N29;4KM
MYA6:KJLXW@RCA[5&"EE%/#_LL<#[W*%G W(5G_FIOI\#'@RRO>G^< Z /BZU
MRZ2LML8=9#D6$SCP!5';NNBNX9;07.I>X2WZD/;/U-3#@3L6  1QG_6E]W4O
M2$V(8N?XA,G^)/R4:T8L$\/5CI&?Z%SEPKTHY_18NW^G01]/;UA#*QWS'5CN
MY!X7$47&EF&'2CHQ>F)31!#NG&BA.7&/:N+)3>?5'*?3%3'L8U91S?"&WZNL
M((,W\EWES7A -MB/SG94^9I_[.L;7-[YTL3OROI11H<G?O=9"\$@VT-GL?VP
M<HW%MP7QY&XAIN%RACM7OR8/##5FQ0Q0>+D;JV"TU"*#>%9)^(:7-<#[Y$<K
M!&-R!"HG^[UJ'ZD"=+0[M1=4*78^JDHOK9"&B-/I\3F&+YN-?S^HC*WT&^&T
ML[B>$*0\;O%40_M!$2;'ZO.0_YA]-?]UV)5\;]XH7SD/OZXY )$7AYYK-TH(
M)-BI.0B*JXG7+=.J\R=]ZKU1;5PD,/7HK0$7SU=G4#L($W:R4-9^JMX6-[4>
M^#Q3BR6])FO![X9">"'X^TNNH@2+!,O(@.B8N, !+XM.YC<I2A8;KQW D/J1
M+]\/ZS=EF#9)LG\22+&:P?MPZO7C_<%(A]N)/J;KG1\<WKQB:R()-Y+\]"UT
MMILU&$".+ACV@TR972?RXR2#730I9Z:@OK3HB4[&E*Z!DM@.P5ZN'P:UC&N(
M"A*2IY\C3I?+*#D_&8AY,RMDHE%AN8T91XLTF-@.K>$SKL<+9E=[%Y!/L)3X
M_E+C&;OL8_'KFUR"5;Y/?;7<K;D;U?S?BGQC5XX[@?QV:Z4K]>5< U)9-N%]
M\W+8N5YFS)GNP/)_J-_,8(ZL9$[[ G :J!N\)5V6>'U$YX!^$^IK'5;2&-4"
M]11V8!FX;UX)8>Z@WPFU?-J+*5EX*4H2\?$+^0IIWF,=;!S,06GP]]VP>V4A
M"A_^K^ZJ(\OMPJLK9RX$I\\W/^DX')TR,D[M<(5]X7ZQPSZY@)R^<C3(EB$S
M <3*&SP;8VQGYWT6][RV)C0FLJM]4.R'2:IS0S>SU.5[K!ZD2 OM5XKO[]<L
MSIXT3TX:W#*J>FDGMA$[:=IGY6V\O:T@8N>>20Y#7!]^<\U!KL-]^5?&#74!
M)<<AD0'G(9*POJ2N% ,B_R_<AHS&M*3U;U-UGX/]^P+OW/S?[+3\UOG)6D%!
M%S=2_^S>*R_'23"8V"W@P.G'5K:ULY;4,0DI*%TI7 4QNS2"@G0\.,X!';5&
M"251UDR\.D]M<WOL47*!599T >!M22EQ4^$P([%S *78]I4U#F!+!F9D:9:U
M&*;-Z?YQ:Y#*85YXP&,)CV["A VN57F[MFS[GJ2> R#8DJ2'(W*9E+X<4^Q!
M9=%(HB26G4P/ATHX3;X;2PZ$)3N8+H2+W%5^&<T%A;7= KB6UAH0AA=,P"_C
MP/#@1" N1M0S?TM#4=^_;\+[$3V_<^_EW>F)&.T7KXQT(%7;:^> 0;-DL5TV
MC7MU2L62WDY=Q9@)-21[0S%[9C#"TRIO!GJ(J4GU_&+G5:6K..%VV.?PYF(Y
M2\PI-7<YE+U>?^CV&B6 \'8T0<YV%6HY_25"64PQ/(VF EKQ%\(C\KEWE)VN
M,N.@@[<CK5/$(/H,UM<M/](6DJ^])6\[N'QB\!K/NU!/<,-PUA11%YT66-86
M\S0]CPFRV)FOY>7*>'3\\F6>HN:D!L)'?/6(90'/W,,3FGT."$$/CZ8V'[:F
M]T<'MS*XP(,S[H]5IPI3S1B?9DL$4'BZ*E%0VK_\ROTX4=J4AIF,F3>E'6<6
M>:'\R\1'-7B&E@1G1ZC=)C>CCFGAVV<QNZJ<W]@R/L@:<"E!]KW<XZ!8?:_F
MEMUT"SRYKEJ9XZX@8^3Z5!\LZO 5OCMH'W[#KF'1X\UI-<5*!EQH12\,;!FK
M-2>9=&"NJC-)ZOZZ7]C?EQN2085K_> 2GDZ[K05SN -WE#,*:*,52;/7I5AH
ML>CE=IDW(%6BH='HCD&*K1W#QAR[L5RZF/SZZA.1$R.%]!?KW^;H;E]XI6#7
M3,JU%-#!1$CU_<MS-B?: ;8\S!VY[U0'+JWP#Y#9!V10$#YE4A,A<.1O&8,D
M*)L@7##OU[?D@L@HL'.0%FO^]4)2V_G=#!75KQJZNC55L5NLEY/;6</]?]')
M#W19$X/@Q.<XMDPJA*%"D"!VKH_2L5&#A5['\(GY)<WG^X4),M0.J4:])DC[
M8Y#0K/50IP7#O8G D50U>:$,I-#!7)]S9=RB6W +!UXHT&8^?F0OW<:">:.:
M4HTU,+9K]NXT.8K^BAXIP$GCC2%1IQQ^Z7<&VSA"P94D>T:^/Q=O^DFO5N1-
M;"E*X*'FC)54MT*+MY+X^^R$V'6?V8-:W\X^L2ZUF5Y8'PZ%AJ>@JVLG^K(V
MC0HV;UU%(M<GZ A62Z/BZTHU8V)'XFP!VFXYG=@[7_U?.+'*N70YGI$3(E_/
MF]&:S1K^=M+,F_VI5M!G([]E?8_ TS3D[]##?H/2;5"\??B9E(Q(^'O]:(VY
MHZA\2'B1CKB-;*_$:)77Q:+XIG*$+OB%IH!"$$ LB":39F:0NOJKNH!72E:D
MUB^)0 KG4ZR'?,!>4717GZ"%"FZF[ -1X;AZ(@27F*1_.&=#JRQ2(QV/.O''
M2.L4D*Y!^VV_>!AIU(,-2K>K&P\XI:/NBFCIZ#]#5\&@NVX3)J[R5KZR*G[P
M1>'-=$;OJ4&Z(XBS>/5.V\=NYDXH"[/99RGNN#3J=&CZA *GT7HFE0L-A4(,
MMZ2,; _>C.<GYLPB$3;LZ7L.F-W,M,/>RY8R$H%TV6\W_D8>V=+]*-?C7)0V
M72W(GFRQ&3VJ;EGY#":JC2P27B%NW0WQ6"AMF9XH+LP^.W&8I>L!W06%2)\#
M[*JJRR)2W/*^>-P]H*$Q?C3+=$.)5J.P)-LCY[;_SZ"WG>]VJ4&3)32DB(L_
MO\]'K1B,[;]"R"],01)G8<\\,&:S-1+9V3N:MV-5+P#@6''/P(KL+=FM_9)%
M%1KI7IXOS?O>S<2:D\A?X:B1/'*U/,98(^6#\(95;S.;B8%N,RP-&^1XI=,=
MKW+ >RPVH;BV^+RAGHX[,JUB:V?BNL\UJ7WQ(E>\ESJ0<LK6E*VR8:3D]1B=
MSM6#DTV'BCM7&*@[K_O[.P:HD6::R6;7'#??S4X9AK4^2; HO^D<;V7#/Y-;
M5GH\I7[$?@Z(5N"T]95MS33(;.^'E!DKU7AFC6E.YL8YS(E^WSF\)-5&:Q'U
M>$6RK.7^;Y;,((3@YQF"Z8ZW_%7]F,?C\3Z?11U<$6 <S>. :V1%Z\:=OG2C
M9FW#T)!.-^TU89\#_1%FH#@7"K$8\&*.0"W?BT42E0E.<S1^Y:1V;]?\,&Z*
M^Y:UH3&71&3?@BF=I'\IBQI?I!'X@M+(*4,7LU_G ,"6:SFZZ(-;5>RR6W!1
M8W&Q*]2T>2"\&\BT9\8.?:+7A!M?R:0J-L(8UA2Q&DY%!KW\T/*#_)ML>9T3
MF11 WS6SBY\1)Q2ZT&_0L:+%(C@ZC=%D6 T".S/>Y]MXT\%]BM:-<%Y?J=(O
MIE 6T597JBDC$@<,K5\5O=#CX?&$;W6#)]<+8O=J0LIF$"ZC0F?\8,)JD[A+
M[=?N*J/2PA9#\U22P9@T&&^T,=N!W&'(&1_P&O%I(UXB+O]K3=,NX\J+YCK:
MHZ([/\*;M1^(]AQYM UXX\1'/"3;C_U"XUY)GMVN&HI,2)UN%PKV'5O,5>]9
M.K$\)M7"[=U_/ .!NGJQJ@ C._6,*XRG!\!*WC,F&XVP<FLXG8<UNQ/ZY 4N
MIP/./C*M;N-=Z)-WBT0ZR,^M3C?#G4R.VFOYH!'_4#;SLN3[/2@%$J02N[WI
M)+A_U(B(;OB@>/LI^S^@84H;-O=3%R:);)I$E2?$QH:KIWISU\Y9%?1<1#K3
MV'_4PE03!DV 3KJ/QACD5XY7_OD*Y(!63E"18A@_"L&+IT.EK'2E(CE@T(43
MVQLS,RB71N]D5,-7U, '%&>7<_W+N @8=X0-/<G&F$$\H1O+^Z%)&-_8;LH*
MJ?H@)UP*-O[AP%OU<9IK*O^([L=N0$31 #;-BZ/ZW6>BTP31+\?X[CN&X)BR
M#JS82']&L87 9-5'SQB-:NN(HAU17AV:Q [2V_XTKME-9>WG ,92Y#Z(XS&V
M=R-VZC&:<[1D[GE%6I]4+'<,TW<JKE[>;4 [M5M<](M2FM ,C@8\MQ&E@>1#
M.YT'$5]^&C/G?.RTNJDFG/2K^^ZW1HNO]A912@!7,6TE .($2WAN1D]41CW"
MJLV_K3_)_#T4X9M,A-8.@<8+1NK\F%3H_1CDG@WW-L]ZL"B=+?HDWHSN(26@
M#[+<Q1/#H=RT8B\F#D02=0/TMK+U@8HE*HN/./(LSI!0)1E]U^CC:B3]ZB/J
M[+![@'\_FLH6S:+E=.>;+;XQ9G"DJJ@2'Q=WY_:=%E@(+'.N_>#1B>M.NP*Z
MS[:R?1TIV1G-X '$)@7+"6*[1EQ-)#NS;3=<33C18.5@CSC'J%<9AD[7N"B!
M$UQA@'T,_P<0BQRG4#447CO#FBXT9#:MV  ;=JL1K-*X<7/9=I?HN,6^&V:=
MBJ]M9ZG.#-G:A)=Q5T_\\G"9C$IP*Y*])]!]]S:#8C"L/ZB]?(#^(\F,MO'<
M^Y8[OTVE8A=<H.'A,9>X\]7L"P*DN9R^<8<N*1EJ;=@_9&1S73*0_DQ41[MJ
M1GA%!VY771G>0%;E%'YS%/S>)_X]F9AG?X>?);W$+5;S^>:2%EG.L'%(E]FM
M-5\2G&D><M7KYD1>98!Z**?D_4LJ+%RRLJ).RDS91=PQHX7S33YX@ZX4>!"1
MKM"VH2! C#_20O,$MC3[( /LK>6FJ/CT^]& E1S;$G63$\EFO#X\>+FU'G>0
M+%'$$]\0GSC<_",%8F$_PG E0JG^W@NWE;0W587_L0YA*T1';X7,["EU./\3
M+CLOA-+'^7CO'NV)WWJ?@!:/V*]X1*,BY1?QJ$R$P_AB2M=KL,DT2D>%IV</
M_H#FQ-J'?ZJXHT7,$,,;7>)PX=2)B>3T-77G  .6WCN1YX!YI24@[CI@&-=Z
MG%#V9*1U?"*FUU4\(QSV3\1H)^H.H!M"7_E<CP6Q[/?SGYH [+LPN87839U_
M\50- _8BXQ"'TT5'S9+CT,G8396GP_N-_).EKZMJ*F,2/BOQ:>>_Z^EU<([I
M!FB156F;BF1YC':>41&F7.=]W'53NV3D!\(P_5&?#QSSEGBX?^(:VL(J2,=N
M^"^]Z[>S,ZMB3,]9-15L;,1U?\B^\!,WQS80C=8I4I:*ZS(Q"MW/2=,D%F8\
MQ$C67 R2^_';JM6UE8T-P_O>/C*+3_QN-!\(Y@7/CJO@CYQ%IIWJKC.S3P,3
M:O85*/ Q^)IH<:*,TD'BEY,W&H_G.<VU7\G(T3X+HMZP9 M@OMD%<'$Q"+7U
M8T(\R9HF&M;C/XYBA*]]@\OIIVB]YIBHA=0<14F*LGW9NDTMI6TT1^-[?[5U
M$I,P%]8$N6ST7AL\/8NQ8US/QT#Z[BF\"LI3@MR,[EMF>MOE:U+?!?!J9IB_
M8 UA.?<2Q3-N'+"S&";\.$46:O)P9%2C:HQSS"'W(TIBH#.!-?FQU.TK%E%4
M>N/[<W2_SP'T O;[P' F&85D]LV$Z /$&8,:;'MIYS6$?O8].=VS'W-"&T5R
M;O0D>PS_ZI6\#(-$^>9,'1Q-<.E6'F3+0:P/8I4P8#B3K?/#I_=NPW4 ?X>O
M8+L!UE[7T[\8XO:;:Y _M$":Z$YSLMS\O4D4.^8HW'5MB=;:>@0YGK.G+8ZB
MP:K[OB1I7FC=%YGPR\N1DZ/$-I6U23X<]$1R1PU\G"UQ+#IC.)&C>D>H!**:
MP<\>"J;E\QC$"W\OG7HL-4\7^&X[\!&+:I[7:'%7TQU\3C>'Q-!^O^YS''6<
MF)=REG.!.NP<0,X:NA)[B?3HT630[7, ];+Q89>K[PW"W((P T)V5,Y*HACZ
M>56RLRO]#5;6@NU[E]%=@9_3US-"8OH![F,&(.%.S>O?D!TY:E@8A_P;\WQY
M^3(L$_4M]_NO#AVDV2*H5<3U6O@]>,3BQUE1,I=6HT5JP:-?'MV!/+J, KI1
M !ZCG/L!KB\-&/"BJ(P[N/2,Y'/ M=;WYX"%AV-E-K9=20?Q;K):=]Z<+%W1
M?"2R;=P=K"!EASD,=DDN10 /@'1027<)C-N'AI3GL2HDG4FTQI>OEU^BX2M+
M*QV:"@)X_6*X4E5Y&GQ?"!O%FBD@-OQH^:5^]P^&L")SZK=N 3YDSW:H> \^
MUM0-;XDWJZB 3:BJH.E. ]ZRO^J3%]Z-<TCG8++OJ\4\R$JS_"IP?8BL4ML4
MOM :/FJ\EG*6BM5@D;^Z^VR4$^T,]SZHRZMZ>PZ06&2YL:8=*'1M-5BZ1 UD
M:RBX%(M=Z;">4RUOK1QQ!2<U<[@BQ]M1CU2;6F>5@RTINS[NM]?<(_WYNXRW
M@H!S(#[.YSU@-J.R2T&BPVV**8:LH(5R/[;??Z9@9<Z]/OM:CK*P7RCTY-&K
M-8Q"95%-M.N5TG3QIB?4S,^Y;SK<%[I,W=:[DZO3,P*X'MC\&+#OQ9]&\%ZD
M(6C*W2F ^KU)TH06!E8WE7]O) <L/(_)<OT&E#(I*.=*\>ODG]R; Q 2M]#Z
M <MSS^L3[VLMQ*#O\G5,W[A'.M@BJP@VQ57-FE__.GLG6J[&:'H%A_';_F)&
M<0XH,H)WVV+A-SSTG]R]^PK.8+&O@SX"O:,X&FT2/LNS)1W:*]MWK62R.PH[
MP:+K<=N&^.J2!F+*P@A1]FX.'%:RFMV?LFG)]_R*182Z@]2@@-?K06XOE0Z_
MF^L'<[35\.OK,F,IIZT'XOGE<%='.*5.YXAL;LS9ZLUG5B3& 1W<C&(DZV(&
M@00A.#-A%&O0V<]H]L%H/#+QG2><*FS*$-+Y3D#A-;7I6"+@(]F3=[V\*:,$
M%3RXTR@_$%LL[Z>1V<ER&+Q?5.5\-_J2,GR<_F%?]8Q%1,+ 8W,9DMY+_O*)
M83MJ((@@S8GLMR2\K='&@2E_W0E[_(E@SJLMR0IFJUU>D]+KM<\#H\CE]#:?
M+**3\C6\J5 A)2IR,N7#L)C(+X+[;1$]L[I5"Y?>W[JK_.+%7--U?QJ-DE8&
M\!J3*1/Z]HCECJNAP+*ZFB1L2D3QQDH-*X.%RMB+LMS).?&\KD!CQ8I4<!>%
MF*R_+-NE1Z_3V&@?RJ04+5+)[\/)H6XB)LCW2?JB[;7/IY[RY)BS9;39@((
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M3O)K^:G]70#K5:9WW0RY7UWW?V4^K?9!_LH?+"8:#FJ*?SMI&4E WMU[UJL
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M3/HLG+58MO8+$R\?5Y[=. 6?A:3[G1$AYP!BN,J?AVG1/0<$H_'=IY>:0.<
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MW7"_@AK+8>+P_2+M5*.,4@-*[=YU3)@%9 M3$0<^%0V42!*VZ/!3NK15SPM
M#^_Z>7\.!="&X@*P>#9U 6!%/*^X !@CNS=R[B3*6[EC3P4,U$;2A_LL,LY
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MO<5V%WQ(HU>F%B+?<]"_9O67*ZQ.S*\#FW)^?A;K\">/M8+8ZA>Y.*2Z1>E
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M;#3Y.S>R;J1Q%LC*GWB]6M]57]KC>!@Z][05\(05>"W';G7?Q+!B#ZI0S&^
MK#8V/AUB6/):4/M5WPMW!=?Z!)W 3[(EL*@(ZT?X!:)"7;.L3&B'I(EQ6HO5
M>)U7XI.]VY_K'US5S/2<;7YS :"$4AIT--2&PH6(G)Z*,0H#-?Z<*X>#317F
M/6\&NO+"[6B__Y(1%7EP-=@Z91]G#PJF_NDEM^;F-4VM/;;]^)J&.QC$HJ^H
MHV/VA"O'?"L",G@KNNF.QX'%GF(<-'F[*'5\=]W>$LFC1:G7I;(1(/=;66!^
M"W:]*!VM,<UT@)UEXL?=Z9F4TH"VG&M=B[:P#"F+L__8?:EP'NU2$ZX'Q/U-
MH8C G8.BA/^]9]Q4,WD2)-1QE):*[W&7:!+@[>*/D(!\S;P'6'BW9@7L +*:
M$O)51XF8C;N3\,W1+6U9GJE!E9?,<C>G8VD&O53#-0R@K^#)M0?GCOP5AKEF
MNLG5Z0VGN*-C5TB@^D^H$)WO'=,1KT*DE']X(^9&TY>\.)*KY YZO>QC+"?1
MKV-R"9% @AU5;++96L-93<ZA7,!G#G"4L4J"L\:>:G')M;CB^P=5Q80,M7$)
MC?U^*^/N%?U:QO0AYD^@/)+3'U1J>N,^Q::^92H3$GQQLOTFWYO&!=Z)H2W^
MY/??HZ):).5[_V31!S:A^;.@U,,I1W(V1XNELC"RU&KJ,+W7PVD*GN7:#)3$
M%W>@Z"]G+;+3H#DB5_R$NZ)>*\Y\7A4<[H&=2+^#9%A8TLWU8>'I&4A7:P_R
M$'I[='ZC$2(YJ^=;&,\<X[>8Q"7P\*/8L@1?;\^5!D=TLY3&SN-DA$ '*+TP
M-:]F>VD (DBK=R<$6I,<N@E.Q*]TD1'U=J3T\+BP!H?#+^#B&&3S]T9ZBB%[
M,KWODKDL1)04/C-VOID:9L>[IZ$BJ&.F)&@3Z;-2:]=[DFJC_)0*\BWSIWEQ
M<("G"ZHQ8#^XAI>-S#=O8YXT4N(W;O^S +_7;Q=!N^ASDV11.LYD88#[=RB[
MC(+(@#4U7NT#D0M[,U#T\$2P& RB[#3W_GJDKR)"I3/"$:QU74FDG^]^:/06
MDOJ>4[I.X8V<H'+0H<D1PR[$53!)QKZW%5VPN+?*@^Z)%G>C@D.MS'M>,/N\
MWEUZM" ]/*#&.%]_CHSZ9 =,5@/S*<;]AKD=YLQX\]^[E[ED@C[M._*Q,C0
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M?%$[@=TVT<'L!@S*+/@'+D&71.2D$V(93(=995L?6WO"VO7O%VN:3?[[4P>
M[%^SW/]5:Y);4%G*)YQT3PAXV_2\3.J_%,0*[" .FF+BM8+(<U+K!6OVG7Q=
M/WGWXE\9*NK8"K/4#3=1^L2VIT'T_:3G:#9S@ "DL!F/.VOB:P'!"N+H'SA$
MW[X!;#;&4W><Z5C8D)R5:5DQA9!SY!;XL;LAY9X;T'S^]3$L:\"4I)5!A@-,
ML#G3G,I=LUG?:(@7+;SEFDD[14PG9LC_4;71HC.7^"95K"U0\"E-:W4^.W97
M@;I#4:INIS;T &?W+/F,5J[? F/A6!4_\]N>036,;YO;,[G^2YVTWG2Z6_LL
M74UBJ5,J[;JYS@?!1*A]:L-^3?)GAX^4,=>^N[K?4Z9L=&.8R\[>H7=.:LQV
MLRAXU&(-@3$CI\3&=].HL;AMPXP6A)$/E*&Q.KE*SQQ"L&B=Q5JCRGSYS&]@
MC&MW^$^@L!B54N K <=X1I+/^9*MK 4W=.U)(@!'\-J.$\6Z6<;'.W0]D0YC
M7HV#M'(*RP'>3@YFY'0?.2)K #QU=F[L'Q44HX>*0,8%#O1TCL$GUACPV43S
MX)I]-7??G=@EW]_[$\5<\)P9'V0"^4Y.A\UM&V<EFG+LR)1Q9!<8<JBM/DQ;
MF!OW=%YW@.4Z^YM?B&Q9ILE1XLT0QQT+"Y0;M>O85C7#_C9.57)A.$MMH.O9
M=@=E61*J+;3U1K-_= @Z)5,A*P7FVIR':#F,WMVE_8'O*T8N^RPOK\VX8B!^
M_<,#>XA(1<:)Z@O ^]26^^/\;,")5V-+54ZO4Z6N1W^G8&2,&,NQ/#5ASR<(
M=:)?!8I//,;CNL9\7?L@BGN:IRJU&?5YAG>>O\BVH'@O W7Q1GCFY<FDF/9Y
M+%F?0K8GQ$\.74;-%!B??I)9.D7>K3D5%-5> \_P]0=17Q\-9O5-ZY#,)HE0
MH-)"CAV4P736^2RBKIH_$_I\[X'5E+ON7-;7>"KJ%]-X1 >E>4=7?,,?\^;I
M0GBM>]EO*W,MNT.U/2F6/@;RN$X1_7J^UK8>("0/F0JQ=C:)GCP[J3D]1JXU
M#_G[W6#*B-%/R0?SE3DEU6 "2D]@ A7S;-0MK-.$$.V=E#_!URLKIK)WM[95
MP/M(+YH?=?&W[1)C[4@H\IVQ#=GN5#%S%P &-GIGV:+<@FGI"7EA=$!3@OW[
MF<5[CQY42)_-.BC)'$>HK]S?4*&6A/'HZ/#4^Z^M(5+.U%@BJ1G&PAPY<N&9
MW[:MK/++JFIS%Q2I">XE_<4$*@7@<R8M@@ZC_DMK1LH]>95;714_?G6FNHF!
MN$A(.>*#J4D(WZ:P^DZZA*?K?'6!SR7(<$G+@[H6,0G2+S]\%T8)*@35(W)+
MBJK\__P9XEG/0HX4<\TV?<Y6CGBS9)!T9&EQY#JFE["[KVN,3&"/;$]O0M$T
M@0+H(SG']L_<U+0,FT "[<CVLL6&@O#ZF1N;;(UKH:;9C_#9"$<\UY/Z($4K
MH<YS2E/!.8W"N-KJ!S<!(HU7X8UOK[U_(WH]H-E^?89^##KX=&CWD/%QZL]E
MSM/G,30R%%+=#.QS)>QOI-G9[Y8N>QB$IALG"$Y-I9BC6\I4Z2I-93WC9"27
M!IN3+$?U6Q)GA$S/A;ZM8/'P?'?\GAF2%I83A:SCRO8+95%QYWW)[5H7Z_+$
M'WO=/5TI//"IO!Y^9C?DED16=EPQL&CVU?SOZ'MQMR6OY8A;THKL0?OBQ7#B
M)@KR09K.&AS'B%FM8E;^4P4YUA2/!@E+YF3+&C1ZMU?#>NW '#W5N%L[-)5#
M051QQ#)6,[N1"728$C).C4?G&7'&2E6,'?.WAV[5S*:!KS%L^9OH?0M4T@8O
M6*)G<N>,QL4UJM]!.*9N.CY2^/$_V'OOJ*:?;6\X-D!I F*AJH!TD=Y!19H(
M"$IO*B*&$$+O$*5*;P+2E=Y"1$KHH?=>):&%W@()-;3DY9Q[SSWG_)[GO><\
M[W/7NYYR_IBU9JWOK#U[[YG9,WM_]WP&?#+)]*+R!L4A8[_JH0?\;68-5\I$
M_'2L'0G0=P#S;3 /9G&D$M,U[<M>R%I"U'H)!9^,;U?F]:&$6J#7C=$$E3O>
MY'QIW*U.ZU3M('J.<M</>J::J7Z=KI_#.R8^:Q$"OZ\WW)X0[WMU0G^LI!A2
M["+(N_DN=%6KBV:BKZ;[E_1MIZBO>[*?NN!9&]RM"HPC<GJ,-3:/Y"+ W&F7
M!P<XZ9L)'([JS/R\31S^G>(CVC*I1;QCH96(BN,&NU_;!-.%@I:O"\'.JYJ[
M'\>PPW)I'&B\VISOY764RUGP%UN.GV/%%=H(\8,\FK)W@G>RJWJL[L^<O*+\
M=)4[,D^ZA&\7D_&E^)1#PA^,N5(%8F> VJ!,E>0+.PXLI;R?WFG21^]@W_BS
M#CP_!-.V>$*#, FR%$RBHI!DH)5';E)IQ !'[)8]H(>A\6+Y1MJR79K'6!8K
ML[;)5CW3UA[VQ_@OP_'FD:PO\3F,7.YHH*+8B:!743JC0JHBQL5]'-72H@A.
M?#V('7[7\)13\YY]G\3R9?_/M6\<7??D#"PP4/^\)^?NMYV1G-X\&?C^,+/3
M6XC7DF&OCKW&LUN<]$Y=F^1/0M<V3RFS?KL7;K=&*]DGMZ$H5K[-:'6NDP&$
M$R<_HY<6N!F1.E]ZK;ANZ[B:%LCNVTAL$?5+W4TSKW\M?$</2=8T6HU+E'Q6
ML>VU4;H[/=&R3:^*&^]Y=MZM%FC:0!M_ 1EJE3[R-@PKR.L^F7/%,=B.@IS[
M=H=XQ0*$;,,X$K'0E=B\"[K9<'<(AL4^[0%]L:,SI7VDSC=7)/+3:GKD[@HC
M]K4>"0#27UY>,D%,%(77'H:>JA$;6W8<G;K'-38WLWC@92A-T*)[0N)<A)/2
M8!V_=9:[+NOUG@]@E]I:]^*(X\[2 )69WL[.#E?M_M^*SFS\LBV^5_ J<1CM
MH#4/3$I8R*FLBS.B4GC*.#&6E\.^..DK!VWJ1<I+$^$&2!V-$^,R32E5_5F3
M]6P$$BB^HT1L:LE-3BU7Y]J:-&K"]H#G4K;=EB#IY1E!,]S^32@615RD?-FJ
M+S?8$"CD8'NEKU;VUY?NSI<B9.S\C"PL;%_=LS#FB )WD]9850RDPFR#[5[8
MZ\IAE,F[\=*2 >&TI ,R^Q(*%4@=F;V60F!F.1'5RGNBS.@U"_="^Y( "HFE
M<9A>_KS-U"60R28)("1(9,7FV54VY*6OF;./%A-%;9AF#YY%KTFBQ.N1**66
M+\NJ'WC6V5W/_>2+4ANF;FT%[R"A=.T<K3TY)F7JZ[F@<-K&H-.-J8T67\%>
MDWG;ET=O^-9<MS@[!)/R;I]*1)VLUX6.Y9CE<?W2V!H\Q!'<,5^SR*;1"?7H
MVDD.M_]^6&1%YI^(B^2$>#_!&/9Z)/VHLXH;4C)9].6$+_TY+I)-P J;>34/
M'KTI4G)??N%8!7*(ZG @ 1J WO\@,M+VG\$L@O6%(B""YQX=V<:$<2 <77SW
M9U7"_ 312Z6T]/WI8P[\=^I"@DW#$CRH<-X7VI:QLT"<(0'06I$3\S=K0=9
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M!0S"82W0+C.".I[%-U0D?OMT.MEDUJOBF*7.]]'XO7%!%S6(\<S.!%&^KT8
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M@[KC+EH3/GSVA:<DI766NDYY[HROX]68V'Z49H,4H@Y1%3K/*S5 R_QHT7G
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ME%[.SZ_>-*5-W;]MNT >R3O2UI.NX=6CZ3S,N_T&%C_B7-!E?M,/,GV8XN2
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M_Z+S+SK_A71 $R2 56VM//=\@'%Z5O[:L55$??$:Y\1AJ4EXG6WA+:^+4R2
MF]1V: X)0-6"%R4&PD\S*O\-+_K1Z8MSCQ=$ G!CD00L '0JCD^'.>"]FA.,
MB64YJ-5C1K3:36FL8/';V[)IQB*ELBQG<^H*^V.G_#Y"343.ZO$'^/AB&B+'
MHZG?1C;C/U7&%Q<U!8(=J@*"VMOF6&)?^ZFFDP!_Z(4=UZO(H+AJ_"=$;PA1
M]C'K+TWK'VM$'@LR=W_E86\#R+Q!K;J!+J+2!"8=]"Z4]_!+]WN_H6#61ZH
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M1QN5X]\VPQ;7QC0.<\@$EEV]'V[:=1=AI<O!%W VZ+KXD&;JLQEY:U3PL62
M-_E<O8ZSCZIFP^B#;Q9HB]X7<_<NV5W+-]U1[:;E@#DV2 YAQ2V8Y1$!=9)%
MP(-$NO:#&G"OUB'5M?"?IF77M=0628 G7ZU4ZFRSWF^7I(E9ZSUW+V9]MJ0
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M'28_":8?O:1]CC?>EKLU#Z<BJ"J#GQG9B+J/DR=N.O$7HE18+Q8A9,.X>UL
M5.E.Z!?*Y%P2%8X5=<F3W]X(EP;D%QCQ>?=-;]^Q@X&Q3IDCXEW.%F$-5(-B
M*9.694-"=T<F,=&!R09??0KJQW[_.BF$>>:0 .%RRG/L8>:"2+Q XDOW1^B^
M R^/=L&MVY\LU0RVRL.=4IVZ!#<L) CD!B-[0DQ II+"PZ?#W>NRN3=C!&*E
M5:AN475+<UQ>B5(R4.!U#]; 0R+V!4'J7BT0Z+VTK+K/]]U_DP 4J*W;;VC<
M-T8FKGU3UBT,2$BMM)N&^!PKY'U@%W/W%BTBW^;-S?(-E1AST5 &TQKA8+"2
M:IR0"K%M>)_:0G>XPJ 6^7-(B'YF4;TZ7/?7MVP@P.S3F_>^Y*R:B2$/O9U<
M'DTHL'8IQ.?;K G\ B+")YC S4I,(0]X;EQ D,=6\<V%AQMTB^GU".F"=^W0
M)M,6YA$NPGGISU/?LFG2J\-=^[NGWQQ#X";I1=D$R^=X5>Q5B7@(O+_&I3U+
M5+6PB:^XI%%TB86Z6N#1;2J611J_V@BG%E3LZ<6)XKE!.[$CL5DZ2- 0DWIN
MD+C>&69*G3PU]J(?S1Q &IZ:#\L+_+IT:R ;/(+HLW,<ZBT8#E2K,1Y(>7VL
M+BBN#3Z<@"NMLS.ISE_&!S<QIR"Q%,N&X/M5Z:MJ%&E)WFV.T(BO+/Y='6+)
M%L'#)_.);3"6CIN)\ZRZ,T^RY;N/;#&'$.%2XN$=CDH?:F^D\IN?U*KQVCF5
MQ$-):..FQY35J[3AAH(-H2U'A91][:PMGZOSM!0;QNR; PZYYF2U]:7CAU-/
M[$B CS?5&.(_F.:W.]K;2[Y)7=37;E:DCF(Z9<,G!&=65.%-)^C4[ED;+J5/
M/D_[',+^<&YFLMTS%,_$#RG4B.G(,'@(;O"R@"1U[\KXHL3E$VM^=-F!P1]*
MTLH]#ZR'B#*#I\K6N!Z,X]JV1X&-A(&HRH2GB;IP1,^G&VH-W_@HI&2UKC(B
M%Y3'Q:"1"MS(X.:!>5E^&./;V#Y$!]<HITHLQ6W>J6ZU3M:RF0:=S%)#\G$#
M0@U4%*DZN.8Q/)&08D&.TIX+BS*LWX8-%(L]PU4&XY6T*DO3S3A>5N/0:*/?
M-@R\<2^J/G0_-4PMBA[XU(JXZW:QRDR!]543\F*=438AG3*,^63Z*?MFK6Q?
MCVPOJT874[I#HVSPY95T4//'PDBR\;IM1$GDR>QI5[IS=H8@/Y"S>*]\6&L=
MA4(9]W1W'@LM^"(6!&D;T\E=,_0K(GTXT>MPODZY+M:+7U-_+GT1:G%*C1D0
M'UIGH\[0(<3@=MO,V1K*_)NO,L+*(=2-X2I-D6\I:):MNRX#/*9K 0P6/$,:
MZ]1/5$34-T:\3H^=^4^ SXOS9,!YG</+DRW]:(7"6=%UK+92\.M20DX6]<.#
M%;,,PQ.0H;%69:)!PIN2YG!\PQX5RQSOP&CX$D&TC>TN7K(#<JUT<%^0=M/3
MOKPA5",HP>B>7IREV5L&H% DJZJLMH.%R)#NK_T>GFKS=;3\P]AMNT ->=]A
MAG"!S!&@."Q[L6():>#CLNDCF$T(:W.[92X^Y*V,B5!J-V:PH61>L\J)W$))
MN/+@>4R/#)7G& %8:4"<^2L\:N!%*2$.>C/>BPM;TW:M.GX,Q4U7^"U,2/<[
MP#/5[RHG@SE4V7FHF4]</M-'PL1Y OHPF(Q?U+V0K5VGMGYK>M9,Z#T6KG\*
ML\\,Y:_#_Q%FD798XR\8D-K_D2X/[XQ:?_D_@QCPOWJ!2_P]"DKVQ!_.(V7D
MQ%V-4XU=N6(T49D0A=,@ =2MVYQUE'TSH9+_33+=?U'YIU\-^S^JF(/_/A-1
MO9B6S5T7W4YD;!BRF_F(W7IJ!W*\%%%2\DB-HS!R;"@X.<^8(:$KCY J=2S2
M^I9?)V@G/'8?F#7'Q/^[(F-R9VM\?W@ 2_^4MGOXNO;J%1T2()"R".JH/7+*
MOZ58^3-M=LI7DIB_G)9UF&Z@[)EWRF-F<A+KFX%Y3* LHB?K4M3&99V KDZ?
M-?VU4<<I#ZO!22PQ Z/ZU]K!.$/MB?^93I^LZK9<>NA^%.&E#/R0ZTRQ^6]J
MV&)NMT/RXZQDUZ@9#WG&#7;<=Q>++8UC:.#?U-"&6MM;M/NJ8ECVNAU/_G%%
MS.-UY%3B'@EP[6^K?^:=?3T2B%+T6-PS*(8V?QZ#5@NM$6_\30W\5A99I3C&
M,E+NN]NU"C<\E_[2N9/H:#%RRO.W=2*JV0UJ#RV4SOMXMA(W9%YZW@.Y'G$1
MF4?0^9OJ647 %G&.!'CMI#5T,L"=66])O$%3=-8%/=?27VM_IR_M?^GK_Q)]
M;:(;7PQ\SOAV[KSZ _?$;:#[P]!SDR6"5%1TO(ORH6;6_E&P^IU"(D-)9635
MQI/G(G7>X%#Y,5-Z*."\O1A8(2@O\]._&OZKX=\U#-XY_WXM=UK;<)>@<_">
M!$BWW"EZ_?**11GWZ2Y[/!\Z%W-2.C%<//28:L>2.$]\[2%, CA ^7QN  8>
M*&X)+:G&L1_>VLG[U_?_X>]'),"$^OE9T+G;FP38R/ZWN)35O]V3-+B'?]5Q
M*X/&F]ECGA+\D-687QXF1V^6XOI;S;1@9Y:;T]ZAW6/3T5L6KWM\V)'0<'/<
MF<=YHZA/S,9UXJ;!\KI$E!3?269$-/$RNS$VB*;^N58=XSQ\S+EBKWZO9M6C
M0I1%G&F#6MK8;IJU?B,'!BO2M/,4O/%:,E:#.G7G"2W*^MF'2-8F[_9+@5US
M[_')"\:U;&&N!@\RRTX5O:#YJY6),KDI9S'Y:BFYI;OC4"YD;;T[)+^@0GT+
M[+SQ_[#VUF%11M&_[R@(*B7=H-*M=*,@.1+2C70,0PH,C2#=("#=(L* P Q#
M#-T@.70/*3U#2UY_OW/N/>>YSWE.//?^\?[YQM[OVNO[66NOO7=T)3IF;5>8
MCT%GT$J)I<:M4M?_0$ZM#*]T8 8\LXT8M:)\ASX0@5?7M2VUW$ ]IBB[;UY>
MAGMA%3I?[YTX:NV\4F<I>:WL[4(3;E5I\KK 7)EFE"F7!V[WM/3;ZH,4I[T/
M>4PEY;KZ7\WRS8*4( &*TGHT,T5'M#QE=K!3;ZMQT^W0 '-I][)ZJ"VA];MO
MR;;N6XALT1D;J_&O]'@&B9G1^$EE,7]VG732N!K4C8IV],(AW%^7ULX#;VZE
M?)YR%M6)/.6LE".'=&EB2JZDQ5H=,_1:@ 2VT6)V2KAQQZ\ ^%D-\GIL0X^\
M[;5+./ORBFO%."NSP4"]C&Y$NH[#G5(R!2?&*=])Z61#SD^.DV@(,8D!&4<K
M]@6?W+2]Z'1RA*/4=4S\[OQE/RM2Z%+]MY6Q*C1BS[?A +[_BJ<TLH+8WOA5
M1IYKH%E#^DB7FU)#PK11VI.=YB']^2?K'#@<E)0SW8S$(XQTJO:-^M-/J/37
M>KWS3 E3-W&7"XA5;0$/!95 \;<_,JE7?:(NK#GVT1Y"H_F,UC<B6+WMR+N7
M*PZR8L!/,W#.:75F_6@CRR8XP&I9IGN?6TEM.T5#59SO2*L=51%V-5*E.K@C
M\E--$BKI:794M.#=:D&>I5?X[59]3O&'L;H,0TY:=INYB3+8_)KC &8080BY
M[C/GQ8J6WT:#/QFHSJA_F7YC1"!76VR9)7_(+SWQY*/NHU5")G7>/$ZL;/9Z
M&SE$\*2'NDROR<07*<-5#Z,-7[B(4TZ.X(I<ROM91B,]'3RGY[*V35_J7;4
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M1'URQC-%&?7E($_9A=-]@ZD_RS<Q%ZU#07>M=H2R#S ]S18T2(F2;M>OI7-
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MD5.\]7K*^1,Q7YJ><1Y<OVPR'UADBX@<3=,93FO=Y=?D=7/#YZ!,;G3Z?[(
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M"'*C@IAY53"+W6= NRYK0/&LGL&E.UJ"=Q7F2O 'ZNBRCVF?#V 7GSVS-6O
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MK7I\O4_70D1<6U\;[OC@$0Q3ZX<"'58S]-@^VD[HV_'0YJ9;$;NIDM(^3=#
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M$5^T<[6?< ]P:IZ@_RT&;*B%I0A_J"-MB'OFGH!<!9L'\&'L"JH0YJ1C+OK
M]!9WT4R"B 9GEZ^;OIZ?TW?=IT->!^"7.^6)-MZMW .^Q(#\_4%[0_35)'VX
M1$]]M0?H(L!Y3H.BQ<SYCJ-/'^#]^C^QB0E+3%"8Z]H3D3\P=4D9CW?'*SI
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MSB;#=CMM:7Z[9 \\(5$L,LZX]T?]/<#EV.Y-[Z$5WJR=\[ZX/GT&F\;$6\)
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M9P%O4(=>8!(M^ 2<CP4X151<F2%9FC\?:O+K16V12C_NC[_1/,?'WQM,JLE
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M;/ADW=4<M(VO^J&"BE)8;+RAT6!:CNY0!?\O()UC</V< OH7,*NGQO+^A2:
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M(E:[,8_4^16K>O!*E*/JS_*^$][4[S!6[,J0#:TT,(A%<4_JDX#E[51[1.A
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MW"SU<E^B+SCGSYM]O[@YY>$>^U/Z+4PX+JQ%<T.57-VQW$(;N<:OJ"]JHS)
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MHQG.S8&(*8&J]$-JS%;&BZP2%1D'GM;1'[A<$OGUMSZN[;SPNJ]BU]&--UK
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M>$FKJ (QNM&;F&.*X.[N5:_Y4))PPWE_R!!(&[8VDN1Y4D=J3R(WSOM5.<@
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M#W:)?_#2TN/)F:7D4T**@LT@6NW.N=+ZN:.?+^<^I;(JZ)D9"0CCALAYN 4
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MERB.D\.^VS2DZ"V=""#LD!PZ1@F2YF0F,LVSJ:4\$)>;NN]/C\_[1@,Z->2
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M;6TV5LU70";"$*",\,X$J^QIL?&;'AY8L<-6J)=@QG61B ?,&/T7@&S?[^+
MT(]/'RZRQ$]K?%X#U??2%(@5&\=_X*IGM21[HTW@K<(QA>R.O6'"V,:*XF3L
M@\0/%\7N[<V=N+H+\U&GA1XT:>8L 6%C*2/G]'JFV*W-!%(3>=_CM@;M5H@]
M[[>5)Q?)J_G)HU[E]HF&%^:][(,!"]=?5_\"FG??H:@_'^)KM*'+EGGF,_7:
M3DW\LW*!$SLW/R(..-UE)P7'8??0V=C;I(QUW-K%K/H=5HQZTLDKI9,A@DM+
M5;FU6T->^6D*B<-&D\G>I8P .%6"9^5WOR -PR__ J)!BC6KK[/STQD1X%0F
MKG3'[0=:YN"0S%Q<FQQ^K@,GQZ(2+TP5G?\.[635B(E8BO' 6?-^7L>^O?PV
M<L_$+'T;^N31,/=#A_C4'G<C0[;+S"-E\H$"/)Q&D9DSHK2NW':%5,\R2&D(
M\L7ZM&SW=*$E_L&?'/P6+Y6*$*<"TM=^W90PF?(D4I$D5&"0.*+OYN"W)D1P
M#OCFLWB3#DM''8"0H&*8*!: ZI3!Z.[UA<#Y!]DE!KKN+S3K,^HV-N7/KII_
M';,L*D]5XVZ)4S"%WOVV3=[Q\5SI$,G)^/I& 7V4T5&XH57A+!-M0_JQ%R\4
M2!T)""/F"L,CH(+TWW!*S2LW$PVRZUK36L;I+]0(<S5VMLT<?V[-VXQR#=6>
MN8O_4 48NNHFG&+Z%P#^JO#L-A1ZL/"<(QZCF?,XRZJRU*47]=DKF2E9)"?&
MZ\7@='YV"@%\B<'LUB%*0FA'W]L<;/[P\Y:E\_*?*[V0DL<U;JXK61^M[CMY
MLT$R7(^(\C7Q3KJ=V;VMT&6]UR$#'!R+QY+ZAKIQ1V*C9%2ZC:=T1=4-W6.3
MP59L[R;%*3_@5-#M."AZ,D<I9]-:JZ^;7FG)C7>H22E-.*;^]7>AQIP68]HA
M>FT-4S\Y]7=A6L4W\Q!O;[3$0+9Q1D&%R^4M)H3=:GZMW*O-VW@C9\_2TAL:
M_*KG*#=9 /_;>5*,+16,OQ#&O"34:>^+LOP+8-1YW=K%T=78>,<X@S> @Y9,
M;"0VBP=8S_HA;5AIKBYXQI8<)B%=Q/!I2UB,=V[$\B,R>7*FP:U#C,FU2_4/
MH9D;/QO+Q'4^3/@3 J>(7O\,$FI7CCGZ-08AO:I:8ZZN>Y+2%_UM NARW E@
MHBECXQ",1P>U=5Q7=?K>TO! 4WF#BE+5,HL-F]>F>FZ"G]^)!R0Q3)<YL\:0
MK-KEQ@+.*:EO29AM1#/I(>N1B5/;',K\)"*QP!O:HKU:93 ]=$BA,C5IFOC6
M)+\"H]R'4(YTA:DJ-7GPI06/9#Q'1+;)N/\%^-[7[I>,?Q-L3("&;BY%8J6G
M3+"&*,JX2YNOR*\>IG$#IG,N\M;KF;<Z@_Y MQJ4 >TG_N@@>J*;J#,I5TLT
MN,[8=EWP%^!D&\%XPQ5X*$J##;&X>OQJDJXC]OOXJ?:^D..,[;W337G< #)4
MKI"R[%=2(@?!(K S F0(=O1WVF7-83=.B)C'8_1NZI75H5<[-:L56Z]8#I[A
M)#\75IO\-C>XR&@J$^P982^$S* 3Y:%AQ%,QZ:?!NPW*>-.PF\D0#MS=.M@3
MC$W1[N'OX$<8.FX42G-F48#,#Y.KX4$@87C?K3"79K!A&,2($S9DQ"I?.&,<
M@MG17660K15%S< K,X]?<D4?JE./: ;W-!E,J9D?%0%]>'*I*#]+%L3G4RV<
M*SXWL#;[;KN?L>':T;I0\VIN7=!S\:4(M033\1:7@_>$@TWP+">%JT_(D1^&
M,:\H+JFQI03BZ*U8[;5-7B?IV<CG3^;.Q;&P=0FV?OT7 +>-A#T7B=G2JZ'N
M!+JY2PFN<5_NVC8S,V=9$[C.Y"O],+;*+>\E0%]D*S5S_G1"U=U+N@?-5J:R
M/JB>=B[XSOCNF]0WW;)K$^F?"8W>H6\H@7?PSA/S,"%]%F5QPITR%.6CU=9]
M[L+WV^#Y=!WQ9)EA6BII9-X?E]L(+J2632<XI!(O?J.2>FRI5 LAC<[905]G
MUR>SI>84*UX;29D_U?HJOGS50^8]EWUID_ROG)'Z[\Q*_4^9N9( >B(I[I=>
M@L13_6E=6<>KF?H?WP*I;Z U+@+<;Q*TV_2M)78XZ6'4&)DH]V*&"\.JY;WM
M_ G_!HX?2G8A=Q0G7CDKD\#,JZV$GKWV3W;8'/5G?J?59<M9$A2N82IV*HZ$
M"96-E\X>E>V^Z28-9ER!*=:G;*>X-UN&$OPF43)F]^.'.76'C% <Q#XTK.A'
M[B.=*U^D?PZ+%2C\\>]^2CXM(,9Q+H$D,$D#ZW*9 XN,#1"4;*W/SBR'M#9*
MK8$@\XB(3,EZ_.EQ;X\5YF#^?WD3=\0CC<ID>=C83$*B8 JE6$.-YEF?N,<-
M<T>9KD^U4@EU@*D!P%2=?Y[%A/^AUQ9O5YE-B>H@A+$&I@QQ1K%:4VSHS']>
M\)3.7M*7G-D;8Z;5:E9Z-=++SY.2&,31*U+4T*JW_*FMTVQ>7[A34V -<T:O
M-OZ"=IK!]6U^L^)_ON77E!J#CSSZ'2<U10%Y:]+N$V2HGF%^/W%WZ<C/.R"F
MH?.[_R<A0K_&]I2VRR4/#<";2^7^G"A,0ET<2*_"$B)_GEZ=X??JV_#/C(N9
M+W>7GQ6GC+4 >(NYR#;)<G__WQ#)_V=C]?F/]B ;*_*;U2]59YP]^6=!(G/6
MW<'B*B'']-CZU>+X2 +J[V$/=_[S#<[&@8IJ2T\EXBP_NNMWEC)W9N'_\0+<
MT^Q%AO*$3W%7W\8*O0V[VN+N 6J1]:/CEY:5O;[4.QAW9NL>KR]L\>>%I/]7
MVZO_OVCT[ .O7@,UW.*_O9 !.?ANAO^A-GJFPL;?KQQU61 FTKPLQ>[E9F=K
MI?50\IUXKWV"C-R#7096Z839T=/*[>-5PX\6ELLP<FQ%)39UP>U7$@&DO7"V
M.9KG&?W7O*5T5DMK._)R]KPM[YZQH>$O=9^KXJ.01!%%#4NNI4T=\]7-0Y3E
MEB[9>0L_GS\:(C8O?A,5L:."?!%"W(\_[G/$,#6XP0F20EU[S0J&>Q:YR+RU
M\B\G6;;L5RQL33>.I-&D!$8TM 5T>)_&9G@DL$Q6A*#T'PJZD0XR""-'SW/4
M7(]KA($:CJ;O)[C;K8>,3X$Q+Z0?&?O?490QQAHBOT(&%V_X.L,NK6W6>0A<
MVVL0:@WL'46G#,^H-1$='TI9\=](I?P%D%UM>M()9+"\5]+_D.T%DE_[Y7%A
MRO615*@W'HQ/;,#X^9T*$P<[9CC>]ZN6VC0\D)/BATEF/D/KPI%[_H-:&IEQ
MW9GK+ OA<IGTIT"0W5Y8%/?&L(T,9AK[/*3T &$3BBANC2FW:"D0'A>?('@N
MR,$?_W%4S=B0ZPC8(F83@3P)ZZ)#=WTM@[#XL'QV80DJ^^Z6'^1^Z:,7\F>G
M42?+7)ZJF(KX^?P=8#-6 JG'RBY]6Z\NB'U6]N9=<5]-?BIV3A(')>T>$_?F
MB(77'\O9../M=3%C]U$A#(>+=24_A@[UV[N_U%L233<SP=+CO\5Y\A4_74D7
M93E6R7JZ3?C*BM6"<S"$Q>KU#0F&L,SCDVH91+[[0NHXRXUN"F0PIT\SQK:K
M4DSX^!O3']9H^^2B:>%@>JB_X4*=+ZM ,[D\9#%#!]FP4'MTE+=- ,I7T^6F
M\#) ?VHZ<P(ML"J_NZ&:PPD21=DU=>OSK6-=GFI=-[QUB-QD[]WZ,+'+/ZYG
M;T:6ZIFJ8^<M ;-;Z$:^=G[+D,>75N/<7IS94E\MW?I,N!.M^1/?UOY3<AJS
MZ6.5F=SKZS+)7\JQ-Y)M,SAZ%+G!AEJXP:)OR$_(FCCB03XTKS2;-T-N_)TV
M6<P'L5,9JO[[6F#^GBG"YGG&!V7KEE,>_E)'G1GMS=M\Z^:J-'\L>3DLNG9Y
M:4ET)B7TG-#*?2PA$7;HGPS^^\4K&^2ZQ'\!+:)/DE?QVT!>69T#?V)<!?%2
M#<1UN)@O/1([U5&""E,T^U,E*U@/@\[.EB]SM<*\J1<.+1G:>8O&R0_%Q%*I
MAI:9_D1"![!ZF+@!&Z5%>&3['-L^2W.XS:XRY0$#I$R:.E6Z/9>X-IS0OOU1
M;JT*U_9;P@+T4O^E88R'U(H@)$?A<,A9!!QV@Q1V\K.NX5FY!\KP(A)Y[GF8
M.PLU1-:&;SIO!]$(K@B8ZPIG7J2/9W@^D!LP.;D?>[_@^.%6"1=HY0G6<K.;
M%@;%1B*&W_NP&W<-E^JW_WX2"=Z5;5O_"Q OR&JI-7P.=RH!?\=&!%-!5X;>
M$D5\TO$A2--J:6K(=Y+.]OL4(/%XI"PUY?UIB1B95P]YQYE-216.%;W8C&*]
M]@+76![X'[)8C95AHYXVF1OC$9?<SS,%T(8286CGLZ<](H,9/8A7L=9P/=/I
MVACG(S:&L]QZ,$^#0K9:C\Q'@Z,>MKULNS<L40-);%A_4PQ1E*B0Y+6_&1S>
M-"\LQ<YIF#EV!9K[Z.@L-'["(VG)WE><E4Q&7FP"W( 3-DAFFR0X^D*\*Z?H
MMW_+E[2^/[<LCE<7'^)V4Z0LH'O?/6Z-_L@9^*;.( E)&0F>K74U8==BI!D6
M:BTSZY29G$D%3RQG3O9M(_TW'3:]7!22PI6HV^KG:C0+O-T1@=H7OS.RTQ>^
M'L"CQ-.\V>(D&+D85O<\\>5Z"LFN-F*R2Y+ZUDAMOLQT]=:Y-)E_CV-% A_<
M'1P8H]@C^]1W9Z4EF2G^ <) *Q]F@6F-_PF[C^'IRRY9S/!5L"81-E@RGSWB
MC903WDGYG"KSKLPOX30>_QXQUQZ^,]&J;Q+1/@<W>CR?8\%UJ*Q8AZ8?R)@*
M&NS;K'!Z:5;/Q3YP/$(DM_OEL"XLF*8+??SI\RK"=M7\X"[Y=I/+[R1?+UH%
M&KUPT=P1\3<1%_'Y OB9UX62<J+=KPH8^U&JI8<RBX@G9S&?&L34&BO%='@2
MUM7BBY@41B>UAW6/^=!342_1;,&L;@KZ-X,9X[T,'Z>'M[4_D;I1;SG_L 3X
M39@MPO"+H%&]WM#G1HG'9X_S\=PDO0X8"9W!!+ :Y:S=%L\PO>WX\&1]\ J,
M$;U0;M<$C7S2-RU:@ HRL!4V \"^_B:R[QG:Z1W2?*//!?+8#.DU\^@41;=:
MS4DJDO8__6Z^8CM5ZQP_5NFB47A_\X.0[AT):3W)5!HZ^Q>YB:5;_3,P)>P.
MTG(LA-BY73.G\NOBQ^S\&#_]A9\UE-DU0=01_H#[R9$;]\E'>?B5*I"<@!_Y
MA.@^J+]V2[8B,WV*L'L=7SOQ>[O/\-IQ1LX^"B)9MH4@(F1!%$Y!8LS#P]>?
M1W-&T"4[8N(O()V53%QK;^3&(B74^!$Q/D^L7<"K-/11, .VH\]H ME-N)IG
ML@.?*=^7YVI9J-Z%.%M-NNO)%*2PO4L<F60%A6KXV-"C*1**<4:M7]$)[^5M
M\DJ7#9VKK2T2XLI7F[0:@#T#LUK-R\4>'QE)4_7POO_8()=D)]0I;DZ\WDEA
MX4T]>='^)=#'/JQ>LE$L% P/?$NI:@P212?UKY.W-Q?H9EI'6T126ZY"XYZU
MM0+"B!^-*6B^S:]\$\ 6/WLGL6X;.XQ*7XKT)1Y':!9\+MG.F$A.T_,$-A "
MO3]H6Y%QD&4=X+$19J*UD$?#PQZT^Q.;(91Q3##%LE'Z=N?D2LT3Q6EGJKM_
MK-[;YMIW/9NB/[R,BBSY"W@_9H@ACQM*$^XPLQGD4\F^TSL=AM?/0]CSXW$B
MY4O!99C8M.1? )L5MIWIG/+H\",NZU6:<0<T6TG;D+=$[.[=CQ&D$<"4<!5.
M>>@PLOO]$8C_2DV?,M+GXT[DY7W:F@\!2=<T",.TG3_!_J^VV!H4(9W8!71_
M;S >%ER%+>K/)LQ!*M,XOR&]E3S31^"FO-I&4'E2!N.$.:<+T\K]5C!S[4(7
M "NB%T*M=I%=G )]'[G H.]WW36K:G1O',?&76M*]'KE-[2&G1_)&.F39[3R
M]-277?=XH76EJ[G:QD6-J!=ORS++@1@+=']*<8]Y]R/3J8M%;1*&FUQZU"YV
MRWI:1 K?[1&8P'\:),"6OBUXK\?5]W2IVRR8%W(#;)K#T1:J30_60L/0%NMC
M8 55)NH5'5 573%#O%S<*S1I99-X0@^X-*>7M!I;8+P@%<X^P,A I-,"CT^F
M64O<_]B"[YY\1( ?RF/%EF8B)1J%H*A"YK#?04T,9;WD9H@C'V_0<P>S/BO*
M8M*.)V(-QP\+V)[%9T061#MVAMO.%*/7ZJ)\$QBV-13S:I8*(!(Z+".IU3<6
M3>YD,@PJ/7M<:$.B4IP-YF@JXA<GM94%UM.^$T/0Q?EECD<O;&3#+76!5R]L
M->)A<47<+B#YN1_C=TE.XOU@YMG=N5\_>".9L_*=;5#F(GQ^ &9@UO>1DU#"
MBY??\?/O>NE=*6.%??2"[KN=1\P=G>08Q?)B&#Z3K#9YB!]?:?X\^7.)'OSH
MI</%E%G  %)'*HH.S1Q6E=AN8-^B1H,WP 3UEG&!>07=&32GXM4J'=)L.T\+
M,G.=89P8CU@<N +RFR6_#CD!Z?=KJNG**__!0/LX<SF!O<2<9=?X84FV.-VC
MU;*]$4$=C!XRNGNN><)0=>[5UT5?XY:6^2/39ZFBK>9#AUVR_=T?T@("PT8C
M[ PWK(Z9NCBQIN78R"W3I&=*W-,X7EA&0U=XW:%^I=7XC/:L]KI]OCV)\O%T
M1$JK "P"R&+GT\T,4BC'AG%2,OF(H6IH%K%CE=B0B1CRGYK\+U F9MO??];M
MC/0:K)ZJ5">%MM+H.V_QS<*;9W$R')4S/Q !>4_$7,.DLF7' U.H#(!&/*OO
MWN?HT/_HXD779J&.A)P1Q>*&X$X%5?:!Y.J/-XS?Q[[*[; ^# PW%?:ITF,7
M492?71.J!L>-)I(^VZYVC@?D>+;BEXHESH=BV&50OY/<8:*%V%C44G\<^5XT
M+_IZ,HO%BD'SRC6CXJ$5P_8#8]XGMH\(PG+J.QC_-SS@5O?S+V"S>4;X5T3K
M(J-A:Y>;KD#F@$6TH-=$YUC'$6M3]]YA/X/]*' !6X(>L-U'[)85[C?9',I7
MKEBZ^%65CS*N5&_Y;K#9;WS3Z?S:Z]!7SW]2ZT]X!_>_Z=@KG7WT*HP9HS^>
M;Y^Q/J3.1%.OHF.C&]X</4P0IB4[I/\2&X*T*4*Q)M@H/L;&J:/33RV&+BFZ
M:Z0KO"4T>'1X B(#W@O\!72H,6BN?CJE2X;,X#S1?P&/L0F?_@+ A]-KAJ49
M9(L7K;\9PI[X4&ZW,]I<6?)PL3F0 $:PZ<@ZD@.$JTR^P.Q]S)U!YK I_;:8
M5V=\,+O'\<J+>6V4O<_2TED3E/OE_;HW0]Z;2*=VRG='P]<>X5^,E9UNIS]7
ML'"+']327]&1'=V>.S=\K\2Q&-*8,)Y]DE/2-VTQ11G=S.1H##YS3^$GV]YT
MS$T+)7PC^%*9:!^#M3&D_-/^(1N6TNEZYI)I9$W_4N<O0,>9;'E[\V2$C0PO
M5B7 ,.I& 'IF!L=Z^^SU5S FP#% EY:TX[F]*U&$3,%&\#6Q"8?M\<C(GTEQ
MR!K.9TE(&#DGI:_7K\0VO_1T7G+?]UJ-V>#C[ K3N&?T^,@HL()/#5[&80D.
MN=.QPOENG7HN!,EZ)=55P8+U3GB@W.KQS9("BGC53T;39J<YE7:,L0I)4J(G
MI61>.4 X1?E..&EWIJ(N+E=4E[8;.Q*OPRHG(X[M22*5Q<S!/J,/S6WQ(?C^
MVM@(E"$ECK3MEA75"&TO(.=RC(*4AA"6DO&N9 TR'T\?R1ULD^%_NT/Q^H #
MA-F+@.E[%+E(WW N\2W .ZJ.Y/4TL@>YLLDC4!^;GEB3C(@]K#Q]]-2=P&>#
MHI,S"+PI!P^ATQ$ISTQ=S6B:K]4_TX (-N@Y\\*R6CZ1Z#$<B_?<L2ZY):^E
M2?:^SL[.06S^#!O@,U:3CH#"UA&E)S3PDLVD'=M4/N--ST$N+JPQ2ID.V]%S
M&1+MZ_$S@-5X]LBC^LC52/NQEP[%G@Y;9Y;UX)MOL@1AK,P@DP*,Y;!_/N$L
M#"Q<$#4[V&Q?NOZCOOC4X, CH1#J3EI.=N]Y_8"_W>D]P-NR2)!@&4P1#9=7
MBH+X^%PQQ:Z8CP;P]D?@[R1P!-S##Z5C()%E(SFK"U4F^PNHA\G_9CF):A;F
MM&!)7YA:]B77MNK-XD]]G"T SM=^UC(*KR=9)I^W2R;SP'>IAU*J8YI+DY0R
M"SN[Q+ZV-D7JW1,Q53*2,W/C>G@F39=7;HKO[;33NX@V'1+V1A$F("$*LJZ2
M==00Z<S?1M;6B E>N-HLTLY5Q4:.5$$^+_[@A=-MQ9Y#X$C1OKE)0)/LI-RE
MOP!$L/>AZ13W*OW#R=HY!NMO@V9W\.,)"? B;-\%DT9IP>>XYD3<W*J/=[["
M(=8&!\PUP#0EIY2'NL 85GZQ(H*]DD>RA@PP)TQP>*TM]NWZ+&+/8@:.=3_.
M'NO/SO]$4224;V]6=*44_(TX'G8J^5%$A8PJ]5:L[R.NZQ*[>*R@:NR,_8UK
MK.R:N^1&@SL;"HAC'\=8[18Q=PLUL^V"#^=U.@M=]%A_BWDWJ7NH^?OS;G:6
MQEV-MTK5'1AC8,R;\<"XY*F7YWUW'<4)Z2ND5J0O)XUAG;[C&RG!T"JOZ0-&
M:@V?RD_&3C$.U..%9&XI9E[0[6DB:N1?0&RP"#8+0@)U6=%!WWRBB'"LMAJL
MZ16>3M5+_U!,S),J' TJNIJU/ F:)/?E8 UBW.KN5Z9TZ;J//J]9*/GU;+TE
M,[C*FT07_\$(CVOL/;?B> X*O"')3AUT:[^-T'S-.>D5<^H-D])(JS1CT_((
MVLD_]8CT4ZK0V4Z7:=J@CYBS2<:EQ7X+NB8O5OT"BFSFHZ:S]XO0__C@W9R[
M6**8-N5=K S:J<=T_=Z2>QGZ5;CP-XC%N*"@\XS[Z> \ICI@Y?<=N[L_'CV2
MI1^%<B*3PD]@HE>*&MY(:X8#A1&^P)*V.52R@?[[Q"<Y'XYY>]R]1XB: R_"
MT5']-LSHFYK/^PT'&9?!Y4?"LRVM@<#XGWH*U0EBT.48WECQ#/[<15?EIK^
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MZGQ&@BO=_VCT,,4C72#4MX7ATN&\P2+:>'V0&9S')C8G2OKQL<? 8V.1GK6
MV.0GRS"R._9^8PJ^"!4<1*)EBO67NK>GJ,'?*%IDF+1)?OUTY'[L31C62M;9
M:T*_B^-H0'NT>L/SYR2^=O'K/;0.'1#(^*1H:5\M1T]9VL#5<X_I]^N*-CY%
M<[3D8,=PP5Z<H2W7YSHS"4O&/8LP_M5%@Y#^,&$BCZ;J#%G-)V&;,&&T1O?%
M,CVJ["+\C61<I$9WIFE]R^A9<I2(ZKQEY/N]*C:+CUE29'P6"\FSSD8>F2B0
MXKA[)-?'ZAG!0DC5F6*Z^OBL_+U0N@UX.@7!LR;A'[> UT^81AYSBD=_.1^'
M>HBY,?*@@>F10>7SP[E\?J'?*5/HWGYIK:8,.^HF8,'.LGP! "H*89];JZM-
MR-F#ON,(Z3+/#9NR3;;1#QN$MN'5#P=^P,8B+IO/?_X]U'*2%#^@GN>I+LO$
MEZB+S]KO59Z<OM!XWQ3YX/V;V9Q(%OE7K(N:?2WWOG:O.DFCY#X$G7\25-8[
MI:U]4%P?S&@SWW4HJR;\XS4HE3#US0BW_-91_]RPMDF MHN7$W(>O!,F>".U
MT%T/L6N,6RO#2SJQE+=1,"BDG?U&\A3V#6"Q>7\F^HU\B72%,D%0[+!D<)YR
MR3#)!2\>?]]:SE=16JU00^Y_$8SF*NER$$)D!27&:74[<AU.OH=CI#G1S9N,
M,[1;'W^4W"_7YUG_-*7?_CW5KXZA;Q'G&30HS?-7F/!KJW_7"@<Z/W*3:>GG
ME\QT<TBTR DX2_\"I8)B*Y&?I%$T*E$3TD&J%'83_;E[$U"*Q3=)G7KVFP])
MN+7O1;;IFT[885NJU>^+0R+F@T/<TYD51V$<W"?[\T0'T\GZZ5B/:>2CZ O[
MCXHO8K>_J"9Y]]RC-?VS[#\IE.1QY9<^%16?Y15EU:Q8HDIQ,#:KMU!;LZP4
M5L\FQ$_MU!B"L\1+;RBFP-#YD6T0?A,@%==#^Y5EA*\UUFQ.9TT -^(O*M]\
M5A2M$<(<;S"+$'(2'.YD?IAL(]^K5LXWVJ/+*%I+UU#5VXA6&]\,S4MD<V89
M?)DA2JE\#-BLBF^.D54&N/J8]#IH('7F62N"8?2L.^?E(?-#-#1-"1^EKED"
M64)I\;[';O]\C:_-^4HA;G 2,[/.L!-XIT.M!"-=$_OQ!V4"GY<%)S\NR+ X
MOTDSC+/8;4F4#IA@WV*&\?%[7<BC+=I>3N>W3OS-Z'#0L^]^\GZ+)*V]GC39
M)L=,*QG_\QTW'D/HP3R"3B$@4G"9)?IQQB=$0ZJ1AO0$2P-UUN%F*''?IR16
M_-G[+$\!FZLDHWAT]8=,;4_U3E?(]_0= ]9MSE3_=I#B:BJAP1?WUZR$HY^^
M>$W[X$;[<)-G^8PG^5K*"!,$(LD/7_,ZDS]+&QP6/_QLBY9,9T"VN+11KFEE
MO'<F?][]%K"([;)TGZ_OE.#5K*VS0$R6"J;YKAQ2S3A81!C[_>K=>EVW:3/[
M%"<52.0 P'_Z-%@'H\'36.BE?W728\P4]Z]KHG:(DMN#:Z=O8'?X)77#MBC#
MJP#9Q_X7PV^?G54@-_)M,SAI<+1W84N@I\U\YCR%U;VNKFY"LI6DVR(YI%-?
MM#\14_4!EDPB=?1YRHIM,CA0%^=6S?9U<?K2^<OT@[YGC6E]T8.)&R%%E-A2
M!@)"IEAM=]4 'ZO&$J^,ZX\S[LU9%?3>+%_D\12AK,W!]4F$4<!88WX1U@4(
MLBF_$<.:NS_O7\!876P[OUP" T_5-A>9A1U3X 49P%]V/7/NW>I3C&!GP2X4
M!0Q[D>S? E!CQEP.9AUN"RDPB"5OO%/Q(-RQ?5$E:X/_A;?WPU_9V1%%$"$7
M'[TWYI[.ZZJTA@L&1K;:R]11XC:G@QSJPHT-7MI08AIWZ>]>[8MO0:*;&S1N
MH,"#+$R?5X8JY8%^?OZ5S]X,Q$%HV6@(RMSTFE.J64\I^,88*=$ARIKL3]1B
M0ND5,[<X8E[@%;<LE''<ASP/-_@Q,<B#5]PGW<ULTC3[TD72_LMC_IWSB#1Y
M5$&P8+JUS/@IQ;INV=:X@<9,$C$\XX$  IJ8S?A!"9]>6PHY ; (*%O+C%Q!
MI4,]/MJ(669D52R%CRSV%ENK$CN\D&,)]XJMM#!G\:4U9SG:Y'DL /9_-*N'
MX>W2Q]/'U51[.23LB76V-BWK%_>8/^I^(6S"G?!\PSZJ\<W4H>K:YRG6,=Y<
MM&0]68A 0M+3VEG_@61^)(<&BWI![&957&AOPL.7#YGNK/D/&"MZ>.8+EL'2
M3C+8S\T=0F]B<_RF*23S+VOY$F$*=X1%&H#\(5[=RH]RNU&#C1=ZP^O?)]W$
MRR1J_%1F%.JCY->]>:T:7C[G!(9E5R;R-5;=8_T:&Q:,HY+\D4IZE$R-*$<^
MFU\YOREK3R)([=D=L&1CLU'9XNX-??^3L1;<V[[$^S&^&PPOL]/I,HI:.)22
M-Y5*)L<_+L^Q"-5CQ7_PB>'+Z5N17T3^K.@_K3E+7CYDE%[R9<CM9CMK)\]L
MN[_G>RTQ9<*#))%_7&F2=KWZBVDR&<["'6CTID>^9BS(CYZ9Y^_;^19E&\D&
M9#/:J_7$L?R@/.*T, 9TF'T6(W5=>X9[,>YFQW4+>.85YRW0?#IIUC)7$)JA
MV1$A"?:(*1#I_.K)T(T."T6Q#6.%UP\I3Y",3),.+8K.Y\TI/'2C\GASZL:4
M2?L$'DQ=!*"7[;2B@+R-D4A]1/ _P9 6R%H:V%O 3VI$J94FM;$J0=5UR]O8
MT.R1<,&_>)88E:<O[76@ZV0TAE[^,^_KXSI%SVZ,3:H69KL^PS)%WA^W[87=
M9]:*Q/FEB#PU_*D3A!GL$LM"'R&*.]M8ZM%+I11S-C3G&0RUK5\OM4%Q>H[+
M4QM?:J+OWD+%SX!G;NP+,-55371=? ZIPOF&\G3-G/KQBL:XD;JB;TP@0\YR
M:9Y"<Y&.-KY!#/3>%N,]M,-,0&UFF+!/7?++R6TT:6"NF(5/FC&7H:%!.X6Z
MMU0LA;>P2TFE_#T18B.A/'2O&FHH]2A]G9=4NL N%294ST?L]^Y(X'(UPX1%
M:492J@9*OS,$IAG(^;S()>OTY4IY!\N2Z3!]-CA6(6_G^MDB@\6K_'":CV&2
M]YEM/Q,?\UV;H\@?<YY"'F$36QH9N6=&0AR_\_6OWW?PGWX>FA)'_I6,22[9
M12[QQ%&4/>R3<U/R(9]E_MSNV ?<DW"MR>R&1GG'-SI4/FI!'/<M>=]D&_V,
MK<5[BUJHV\@8A9F,,V,D)5\8RG#KJ^_= IR\M&)_.E\ JX!11P^LH:L[A(*R
MD( F]]"JY@G!0R?YF;+EM<T9L$6]L+"L)YEP:C2Q5$>*YJKL_41ZCQG34B_M
MD>X,JB84[O?XOH>G1\_TMOP'>3;\S[H_.@,=+S^^\C'[\L9%==[ER.&)2?-X
MC0F95]B!;%VP6H,R/?+^T9(#;8J%=2+X3[_Y/&W._#NE1 ]FX(37X(9E[Y?Q
M[1.M\9J:L9R@/R)G>-,>.<N+KXB):0*U7J@E0Q4MGFM4@P-F,9X=U3;S#M.9
M15[A6FCE7/3E"PE+AS0++TX=/FG:3^\V&\W\?*8UX02G+W&@!8R,U21^>DWL
M,/[%/'SB19(0*56VH=_F_!<+BEJI&#FJ>SUZN'%EO]S+:7W2_&9GQGIHCBHD
M^*RP0@"#&QW[GF#H(.M\/02DL.#_N?;!O,();=U][B\0W[7,A"J/S\K\ZWVF
MRTMO[&V>-N!0\?06(,/P2-9\DKEH7D43BHE> _:&824L\VR-1=$L/=,X\#LG
M:@D)*^@+]SBFV9JY6H8')"_98Y#!0.ON9=!$"W3=@:ASF_C2L886>;+<6A/3
MO3_&_Q2[5/*L>9 47<1,?'*OYRWOPA+F6S><="?C1,F(N%LXB3*QLJ;U-;TW
M+?W@??58[ 97!H"0F9VVG*M=Z 0#60>V199"]=/3E_/,W]0)*Z_?2.O7)9IY
M8;OCQ./PU-?& K1,(]LA'_T,-"OI\C,E*N;9:T\T"S.FE>-Z?/DS/_JY2+Q[
MILT>#*-L J,F><\BY;I3BWM&Y>#%#_%BWR/U8JD?YD2^>YD;TRBNP[)J>F][
M!?1&"[Y.%K1"X7;S1-&N69GNCU<M\5IQOSFW>MGOG][WJ%(\@B.JJK-_)EXV
M O,VG,)74$6P)UDF(]8%B[IEB<U*]?I5^H8##[6X'"AD3])]$ED)F?%^!M2N
M\WYML@[A:5$:+#T0,TH.9;)Q-Q+KL4DB3GYU*>DY0L__@?SE):U6'<^9:8RK
M8/3<COP,][]?S>C'+2M.XZ;CO*Q1BA:^(6M6?*(OR!*3?4G8)NVQ?9/M\FV\
M=JB##)%Q@\XK'^-=OG>2F<0'CT%:\K,A8='5_O^<\<7:6.A]8%.LT<B#YG^,
M<FOBP^)ROYL6ZRX^]I?_^"?\ Z^,M8:7B#[DG4.&;56=-.P;L,!N+1W2S2@V
MX2YGI."[\MA WA1\=EB]0-QK3JLNVRW_-8&WD>:3%;UW'_4_?WK6B]"L::>S
M)6NM^IHFW&C-F)4=O*I#1*JX[[TB.Z .F,N5Q$[UQ;,KD]QP7WE=@O'8I,9P
MERX-NNXAZFW&)R>@A"NKTE+W361OXQK$B6"*;P$]C(_"+I3'%W 4!ZKD\P9P
M*$\):TN/[MG#U9B;%!W[WTG+"/&S+GL1@E;K=D;ZIM'#6KLE&7-E#?U)EDE'
M\X@MLX%2Y]Z?Q]HO-]3E\+]1=)1;:V,(\VU]'"OR9=89?)7'SHC'BGC2H0*,
MRF4S\]2K@]08O2 +]1XAJVCN;B81I@<TW28UT]'97@/7LM'7C!_<#F49^(_$
M(QU%!&EB!^Y/3_L^2J$9HF4=3:^H$1*M]48W&SO0('UJ@P,L?"'$R\-.A5V^
MQ7+ P=YG4.:61W0#40O/TB/V?I((R3\HJL*8"612&MK168>ZEXD?QO4Z%^IV
MG5O7M:6H?>S;1_')6LJ0;@E\VA A:+E>RPR$K'&CY;IS"@V]4B?D$-,9<F,5
M-3LU56T!6:$/@E+Q8P/XFJIZF?#,/S\/TGVRGUDK% Q=ER\%(ZHL:VI;ZBL;
MHP[THTCEETUXM^NKYY4&VFPWDZ44&C[.;I_M]/J9+<A,NU>O%M2-NTGH[C6E
M+N_;)*O]L@E.HW+.#67#:PY+H?GR2O?GXS90D/->&V?+=$TTN>T5M^=$WO!Y
MLJW#\OB^EI;R4%7GW^_%A9(&;)_)C.V _OAZ_6L(&IOZC)<S9\1.E(LWY=N*
M0364!L.)K%D<CK^LS4A>F1Z3W(N/>>R[L1-6@7V'6ECGR<R&.GA"<_1&J+-@
M@GK<EF%:=4^BF5[$\XRBD[3=-.(0PB_*>M$,+<(E]+K8UZ6V-/KP[^:3.3;N
M>+KE&]IOM47H/@8$L/.+Z'3&- >]KB^&/?X]E6P2B96N,%CP^CJZ<$!]?MP>
MN]SWB=PO*SC^NM$#?R1!C=YF,?>SG2'L$8UP)PJSTXU>A)NGDS3Q9+RV_ZR*
M;?K<_<63K(OJ'GLPCL=6/ZEQ3=%/L2MV;]XDM.:\9>(H:_+-9>(X56).$B^'
M%+9T0<_HI,:"0X2VC1XSM4X&Q*1U3L_# ]UF1F$R4)X<AR*AAF4W[;$:TZ$8
M<"4Q^S\=HF?E7CP%8?/1:T10'Y-OR/+F4J,5+QD6.EAU[6_?!!ML)<GFNWK'
M]B<N@?:NS6]F?L"844=%.5[?9!M&G\\(M$KA#LMA.@7[&?1?__P1M(Q-5]]=
MR*VN&FB7U?9NV$QO&24L]4I;)Z@D#!%D^+];5W-(7Y_ZU.C9&.X@51Z1D#"I
MXTR.J*<OONCL[#S('&T3,\',7_5,=$E2I%HCQG1T:QNF>>/^T-RLYW0CJ76T
MI89R_UZWFV^)'Q2BV;N(_5R[AROF[%)[@P7ER[1[CHS8=+\T!^BE4,HDB5(!
M>3!N1!O>]XK+PU&>JJB5\)HR)\5I00-ZH]?*N/ZZ,>97]*QUJX>B(0,J6SI+
MVXXL[AU,OT"YV/>M:+G.)^N'[$I!8)F_>2ENUP=QE;T"EHECN>_-WEK8D[>L
MNHTPZA$4K:>;FV#XUAE456LSNY.3="S!AV?>_KTB=N0'W&%F6H&A'DM5PIPB
M^+W O_ZD&'?KU9&'(VL-%?]JP4)R/PO;^)Q"6<V&Z7Z,21I6DQN 1S1Z7@FL
M?'7>JS=^_-.KJUOG06?AF)[<JRI.=.*LNCHXP'1KC?^A".V??ZE?7M62S4LM
MR(R:^NEWJ8S57@J&1U*4U8)-F2;64X'+QX(+LGRTR@V2QNM&.DZ&-HA(;AP/
MC 0MF?WC"[CLL*4L=U^91?:#-&QT$?F[GY;SH6D]T]J73:V%Z( F^^3DBYB#
M^:7$S:MJ.^UZZF.#X-^-;GQ]ID/L+F(,I7&7X>WMP E;1O),+93R3' Y5KI8
MZ>*C8$M3W:!ELZ5]T*K4"T(H%ZZB "'0?L(U$@%"%>$H,+P?&VHFCNR#(LTF
MB%OUP(Z6! +J=6-43J*]ZKF_-C_%QXB)XEXILW=#6[BLS7-#S>/[*/;U1^9X
MK9R8%%C"9CMALRX#0>]=WI$>I]=F.E\+[L[XR/Q)%PYI>3MF!"7?K>=_!$Z2
MSPK\T=X=0D#[(#:P\_?U?B_+:2R,ZXE=$EU0T7JDIU%0CWM+_<2_X<)ZQ<#H
M3PG>GYEW\*.6%NZ929UVWJ_H  &]"GJ,*1P4N\]]'&KB#!>Y*:$73D);!J$:
M=EQ2:4*!6GC4W 0J$TC7IH+>,A/5"9A1<31>P\0;KJ(T!AGK*6;%_! YD@Q[
MON(JT867XG3O-T!"\EJGO \P;*![>Q?:U*F)9V<1R1J&7?A[(>$F_+*Q.1'9
M7%2+0[+'O3^M@;VV((!#+9@=>>6V_ K]M XM,]N"(.)^1UIISAG\%\&9\&'F
M9^;2UX>LX0 '*(A<T/N-1O'NG4<PKVRLG^@ILCKW^;H('F*=$Q)UBQY((.>7
MM+ALNT1^ID,<X@-O 4$M-LET+_;5O?P-9!J<B+U"Y!]%68F;'')M]@4JF(YI
MUC,!VN.-"L(D'^TM\_]4++;SZ1YF"V4+]*PM&S66VF'=['XCN4J_.=OXE%.'
MT\4]>FYZ4#]<5[[%=%WW%E '=G!P?T!;=8.I9^F9%>I^OKDI"_2KCE=Z=+82
M/G]3=@N(! L@\&_RL+S//%\+Y12S_FX.R(F]Z*IDW;R$<[8M;AZ]E"4UB [+
M>-& /H^PYW9#8*1YWHC-;XXO&?<#^T)JWO?_?MOEPD7^Y#-I0]S@%RY/98QD
MDD]]J-,15J=B_]\Z,?!W2]#)W_"G6E(AN\SU4J4/(#"&7B9T,!1":'^:TB+^
MXJ"IM<OFRFX/3_7<K'XZ0C.DX#ZYI%'8 [G*ALV?/W^).)'AIK3]GY.Q1B6;
MEGK/6\RGIT<%ER\LK01&<#T]RGI.O310Y]S:.S"8/DM8BMI!EJEJSF#9[0HQ
M+F!Q);3,-V/HC)JM)&S@@$AA;)@F(4M2VZ&T_'*>G^HGL;Y3)_485M![[0!"
MBXD#4QM(6SK8#EL_KPQ!A^3:N3[OQ.8,6;=+_B*?;2.:8TM;/9!#$]3SH3KE
M26N[:AN2UFFB!_@4WC,!CW%&?12HU\V> NW=MX# &Q;C%VCJB'G2MCQX/E3=
M=FQ^-[6;QC5![N&82BF%:8(CH8TU'D$7WU,Q,3+DC=2U/JI&OR+8=/PTDW)O
MQ,_4FS%G9R B)G?DV9BW KF#U?/$%7%9J?@ A9ESUXG3:]^7I2T&ZXK,UKF*
M63VHV@S_GJT/T= Z3J)#@,B]*$FSWM2%*HPX],[Z%,+7F*:MXSO3QL?7G:II
M&D+C!_F4WD3FP5K8-+D^67MXYQ(XC/2$EY ]A$0>U3S4: ]6$8O0V2O\YM.G
M*>!;-O\J#,1TGXV%FO[+SA,8-V;* <UL.%D3XZ;'X^"0TZ+7 BG++[D7.9=L
M$5688?BK@N/KPT_2PB+UN5B:"0'$8UM_NGB=J5HR(F.#UE(?ALU* 2%GONO?
M?96A7XS#FV3G^2(^Z4BO@8B7O8R7/_# E$LPD0_5:,Y_URT1!400!#T=M&YT
MZ8UJM7G0Z___QWW-O$#8I\G30+3@>>2:^XR "<D'LZD"L2]!FXF1K/%_1R_M
M66?C[GNVZ#$%9-0TU;=+O-:8</?CYR4_F'>,+C2.E'<[D/]U[.#8-EI/H%O?
M.?3Z11)?M8"WU?-['=1GJE]]'(O@)4KNP[;+(P::1G;*]:FL=9,#/2_ 3'S4
MD2E K0A2QE4":$#R+8#XZ(_J4Z&49_J&^O:V+-Y.M2;5)OT4]4\N4?IO3-I"
M"(@;+?Y(PQ!@;8SEM2P400E3+MA+.LA]>B8NRNM D%[6Z^M)E#]1=8SW[MR3
M\Q+P.J*$@VE#0F:GTU="PS#H1&W:W4A1L2[S4*B)M*.>6OO8V^J5AKV4(3XX
M$$IT[%7BCX_Q@3V@U)OWBM9#C/T*>0?-LR5U8M$.D=S/_4KQ&O^!S0JS\UL&
M=RJU#__3)^O>#^/D*BGD_N1]Q!:U3$4+9?U4+)D[RC:N8U&C$^_5=9Z! GV_
MZ&7,=2_)VWN<VO9IY'HS$!M:08RN. Q=5S8U9B 8)WU,T$>9N:)\&5L#7X%$
M^CZ%%="$3DD--D_@'AV+!@.W1-TG]T\4:]SAFVWV5P?&:)[$-5^AYJE:8C_)
M1?BS8_R1WPSRY\"3BV[>!:*>(47H&M=K;V'FPYDP;;ZCHDF<R)7.H-A.6*TJ
MA:'$<E&AH<FBL!X/"X__S^E[+3=KVVTEQ#%J>?]T8",H'*($E&0%\XSJ85?%
M!UDR7@]BD_M-AF[TLA$<[KP8KOIN/<1&;T<;;2WH=.60,G-<!J?5MP]":?%&
M)NN11S^><[T%<+NMKUS1IV)JOQ6/+!A;!QL(7X JJ736H_)N ?ALF.M"IT?K
M@W;@E9/#O 52A%)6N=7U.0IS46@^C(DOXKWY'/00<?H0:?-;4#P'<J@@\037
M9GV4!\30>E\;8^W:S,9A:FBIG:\O)G,C_!7>EON?G'_%9,&&)K#OT>_SFHZF
M=G9N : 2/1CBA\E\S!XU7,IMVM(XEZRH8D=[8[T^LMS3>_G53!YXQJ. ;P0G
MH?<:@S!I,!L_\$DH]4ENCHF_FH);([:Q^#?YB'@T)*>1MRSG^H*"_?H/OC1;
M;8',Q;]#C9N]!+@^SK%<D&MPY.Q"0_468,0"Q@YKBTK(8_<1U8A6#+R#YCSY
M @+"$)X&"T>X$<//FI;3:*XOG*,/M**[58FBVMC&>F\0R%L 4N?D^X!!&S3P
M0\'-3T0:"G0>CS/IQD7? M;,O51Q07[TMP ""CA:$][9@\J\(;D2QI$\OP6L
MEURV[4R.NQ[(G;O@G-KA\V27\"=7TB"*-YQ+;Y1S,J_AX;> L!)RS&#7!6B_
M=DE(]8)G S*-2.,GVY"/7X$$0OYN85>^W )J0,<X]M/?J=OI[(N38).;N81;
M@'Z*(+&>Y-80&'?PS628;'@VCE.7M]P!/KFH_.@6D.^H<ZF.^X.[R_ 6@%=Q
M2'9T%Z"MBMG-$B*M4K%=#*&VBS$?G';'ZU6N5R?QK\TB0Y+1SD=(KQ]Z/-]-
M36B'[VI!YD8N$??;6A )N%B;BAVIF8V=[A(M8IIN,JIW>UO[%P!_@P/'F?-R
MS$2!;!$A$D*=:YXOZ-UWHU]P+6DR)!@5K9LY>K<B'ME=.V.]J^:9,3D50LL9
M;H/L.XTJ=OZ]."*^:VG=OCLB(*;T_0+YNJ%:XWP+R*Z^FKP%6$_NCF7W=%5#
M/%]6=*=#<$2):%R?F9&O8NO=@I8/AF!V@1/06P!*^U^D=D298'!@+9YQ"?A[
ML>J,?7;6*N<E\&S R-&_3\TD+A6.I59<IWKKU]R>0=NX@S/:; B/1LXWE0GC
MB-]Y-M,%=_8I;/PSL&.'Q$M_1&G-2.%J%1NOOLGX>T!74'K1A -R"S@&.X^N
M9VF^LY8["\_MJL?AJ^4K!!7FTMZYF I5%ABR-"M6\\K2:F1/KP5L>:YXA>3=
MEES-;E.YN[#0I/JHX+?\NN^-Q ]K&A_E]M[)XM\W=G7C""?0%_UV1KGN0T9^
M66?W[8[H\E-@6HZ6$\T%=7''(8OO$G GE??P":JZ6Q<WC(E>4QQW/D:6+B3M
M%-"?&"5EKH.YM'MGW<7%%T^O)3KE,_NF'<&.D:+QLV/989RR_]L?2_VW#RT&
M#<.)F@]*39$WM1%OK?V&!I_>*'L?M5Y_\**7-G_F$Y&:>Y-3&=(&7Y4COIK1
M>@:&R:%^;>U&OZ9-_>1R!C.RZ9K*PSCZ! )/Y$)N ?;/*8'C C(ZS$%-,8T@
M+4/X:V.U==5Y\9Z,YR<49Z(.3*;1G$,A;[&:CMAAWU,15WH=O7FN__R8,O*M
MQRLTWO2HT%4+OJ1M BO#L/E5EWN5R**&V(P,-*LGXG$95IKLNX_ZL5S]6*UK
M R_F=\M)I.[E*@6@W;&_T9!_DI!7I#!7]_(1;^;!S_C=I2XC'(N]^[Y3M.79
MR:'@&'@MB*#UZMEK*;KIM.15Q!!&R3I4Y&HFBC("6GYX AGS)SG_1^,_9\PU
M)2R7/:=O$_OL"^9D"Q0.0V .O1"A,/=UWJ>&M.[I9B<?[3>YQ^-*3HV_H8H=
M+.))%@:>7LBM3CE5)URWAUT1T?J#2+$O62]OKC/)(D8JYZ*OIZ"* ^<F+E58
M@O?-W@+3\:YHQ=>?/CEK3?RS%BU?ENY3;RM-75>NG#;_X&E5L01*JE[8DWM>
M*[H+DWTM=[FG097O4#$\LMMFQF9R_BX_1H+3KV:I9E"=Z:7$7K,$J5*_,I=2
M;A_=ZSVUPQ*2MH3ID>F4XEC#<FA$0PF]SJ(&K/KLU]B'<NWXS,*BL(W:UP[B
M2;*:PK4"/3J+FH$VFV[Y6GT>XYJ+PL9DM8(Y(B-J!^]T7G0PO%QK0_4V%)C%
MI>@\'4O<=)&0$2BW54O<=5:L-;A)NN$@^U%1E^B2+LJ8R"RKN?%48#@_18<T
MG'UI]1;@=@M0B,@R)I576:0/IF5LW7M\SH0D0JJ\ZRA*?9'#G'A6>'ZMP7G!
M<#R\6W%%%YK#^5F65-Q!PH*DV8*6(:TAEY[\,$NW9TXC6C_N0P3L9DOBJ<9+
MSKTHFVE'C2VGHTD6H @S0>9742"/MCWA6K/@/4_*6OW**9Z:O0<&B\KWSD('
M,L>SXIAI.T#19:\=Z!-SQ(W8-PBCL9+ &J=GF'AEHE?4$]H9W&0.Y5S-8W!'
MWFC]AVH.:&GC6)U?S2F.D--/MFA\E^"P9-M%%TD=G'O:=^/]#2W6QP538NQ8
MX)/SKV-3VDY/H%?%+WMXW0H?^^<!Y;$'8S#Q.Z4/P11821TP4J/:\E]?9(7Y
M>D N*8+W3/"K$EDHOBGOC%<G,4;4APEK%;O%7OEFWP(ZK.;!B 4X\?>0SR1-
M_A41/M@*"IS[KB3H%O 5">-"6!CI=+:]')>_'G[VV9 )^_Y+Y@#BN>F/ L+$
M4X%+\#<>3*/QP:(V&:%<I2*-MIA\9CWN/W=F^H^D;G .KY<,,V5>/83J ,B0
MP$ ?[6_7%C!R].L7L["/J 5Q-\7PK8#H-;8)DQ%GJNPJ+R(_>B'=_C.YT\IL
MS$&7/PL35))IO%;*QR_LG -Q2BW8:#*$;#T@X6HN7VE^$4=K5S:&>P630OD^
M'W_CO,X@QC= KZSN)HTA0'XZQHUSBAPZO,P<FP)B&.X$<V%CX\XGSRG7=P_K
MKSZ>_XKTS+R^BC3.O)O"</'V@EE^M3F1V=FV^D_E7]JO1*@@!JJ2[F?/Y;A'
M%$SO' *!ET9K" SW3(B9I9'O6EVR!R3T]$96$=XGUH\]F(1)W-4] N/I^8*M
M?K6"8D_O>M@691AP6?5$]PVKY;DR-5O\OO\7-1-VC!..*. :<O W7#BTHD:/
M'N,.YK'LG8H1P]7N9]#?E$L28RH3W59"EVD]'4.="^4<>U$Q1:5&G+'+W'.:
MW^NLR]7TFE1#!2)]!..5INQKG\Y:&H^OL1+N:J:.ET;^SP/X?V78]54667\J
M%DL2 8[8KE"T\&95&BSY=](PF#\I@=P<-T+RH$2NQ8<J8 18Q1:3^M3F9"8U
M[&C>)&5LS%B^U']BF6@"B&RI]TFKL/,2BK@Q+/M\U7OXQ1,XCI7,\E5TYW/"
MNK_%N?]5ZW<E6B%E:W7#CL0AT?GOOB$D.?GA2RV(TX2QTW3F5Q_E11CSVU[/
M(* F]/MO0WA_36PX79X&O+NRK*>XG"$N]UHP0;-X3[K[#E;^Y!\4Y\>]GZF5
M"W3FGRZ=]!.\!3"O5_IS;-6<=H[^O'$ 7B':K\/U,(EK)F2;)@?GY"*;/6R/
M;P$7 YNXQ X[4"W[MU)Y@^?>10@1/N16Q78W:+Q-S+Z.O_O**E%V8KIUX WX
M>U"MQ1:&]V ;IOT:23)=94>J0C7S1Q5=A27[A7UW;6@[3FC$+E-;LW.OW"@?
MDC]_$NF[T1N)?==J-6-=']EP?,CW$!0&@.MOJ/0_<77?0[X=YT251+M.M\Z+
MJA"38<44=RIV7-?X8'KIYD<EZ[DS%I<Z2_0OAF8N],/%EU2YC[J28\.?X 1E
MY26'])A!PAZ] GNLGOOP/"%+RI?^-Z0^+77:DM;I]=[N+W]SR[_)] E,+C.P
M!%*%[W*XI'-FR2?/YU@.Z]E/LD)=THIBO"W(Y?2=?R#[[[75"HT6VY:6-(QO
M<:BF[,OBM'H\XI_X,+XK5 *#6!P9LS/,J7I<6NFI&E4">9#>L_6VI9K;%8+=
MP6W^V:D\F06#EVH#]L4"T2$<9*,:@6((3DANR&\)CD"Y(J"HOAVKFGS,CYN.
M? 'K\?P%Y7DY!:O0Q+ )A:GXH]=*G 6S$P)*%74_!C%:21'G.WMJB6?Y=K3D
M)RNQRK,%!2#]A(I:MGEBI8 <YL+"@?72U0H%Z,?EGA1/K@V!GQ4**3G,>P=*
M7$HE$9WU)@D3=/RM/CZ3WWU&2W4*5*7?Z3Q?D ^KK#0YPA9<Y^=8<&7TCHZJ
MQR#M/\OJC(Z:DPX\N_;,ZZUEX^L3$2")*&.;KTR,#UY#M$#*^#9L1IAW?>D(
M<M^7CF6(,O2:JQQ/JYBO-5=@U,?-&U8G0%F,XAH>4Q5)CJ @W 5FTH$B8C6Z
M)U;!B$"V!^*\9&,C'3F&XWJG3\/I(B) F/I\049_OAK^&]<:*=5G;O^J(WN+
MX[Y\SPRMOD7,(7WRMJJ)@KZ;R],1!@X?,@<U_ =;>QTEO$1]S3D'2_#.7W,R
M ^I*L7IL'RLZ_DY1Q=0H?\,P]D3F:HX-'_^-<=0W(-;]J[.@$CFDW*A"JBA8
M&>&HT03Y!X^4_B:[921/32+OGO2NSOC@X+1XP2/N8<>IP%JBZ#.ZFO+D,&J-
M*N-Q#XB^ 84G2"I=&;\CF'-P^_W2QUN JK1R$F'@0$-'_F&.2TT<>^JD_8FI
MI(7$C<[LE$\2;<;RV]W/\,S*HOEE<20O8(Y7.WCF+M.DA=BA#;2]1@'79V"0
MSAG5XG]$.$%#X-E_V*"MYH^MC%E!F,<8^](:HAE'99BVX&($46\=WWZB9S0"
MY;U8C8U%O+(;PX*OE6%Z*-MB*(2B1=F2\C144#Z%$(O_HV+/V+P>I*^OPFF0
M=2)8+9F-VL%2)9\'H&9IT;D^W:+734GI3NRK']["]<]42> =II+L>VL:!JB"
M(/=$!F/\C+F1C=9@G+@) 3-0])EF@+9J\W']A2]=IR:'Q'JX;ECEM=P^>] M
M8+5JGKLXO (KV%;GM!ZO/!EGTF]$<SE3_!]Q:$5!]#6O7;V^O7.=--[K:,>:
M>5;T&#4;X'T:#RPU)@K?,[>,+&U:O$&A5@[[4>Q(A?R1=>/(>\Q'^R3GWWU!
M@MJM<F\QL6L0("<#3?>59!GBZ"8(QQ%Z"VC3G3GYVJB-KS*QS]G]FGPM<?Z1
MW//1.TV<TAWDC9:GX^ZQ6X\<V;,*PWF\$4?GK(.^SD/^.M%[!2MJ7A?9%0W=
MA8 %(7UZ@^"KOTP86X0.-K'OFEO5IB44EHECX#12<'WDULDUOVP)?]!Q.,1U
MMZ+/A/2.+?0D>:'V)<508_KIT<=*27%O=U8XF$!Y/A5W<7YWU!6$2-+]A%/-
M.Q9A8^]RF2NA_637FS><\\-T^6B%^30I#-/5M8+2BOZ>FLTQZ39"L4>[/VSW
MK ^A'F=]6J%T5X,S%*A[H$TUNLS^YYU?SW&0J&2<<WMP5LK(6.H9+AS%\QU'
MF[,KQA6.NNA!!"]S:XH)1V(EBFBNBYR*.H?@J^+55SKF5&-_ C;<8\ED-6)U
M!:9W]]35YZ*SPSBH_E=\D":-SO3T2^/M=2XW!GT=(HC^]ADH;/GQ>"B-),N$
M]+VXRC]5H'Y7_<Y$A50I\!5S7!TO69!.A3K?&=3?6D?&6S;G6L6+")EBCFAH
ML[P%9/I:@4H.@?W[)G74D729OVUTDL$+(XEFH%^VIT5;(ON9I.PG$R>5)UY1
M/'V_$=U(Y)6DTPW;SJB;SH!8P:%WA<K#W^/<8 F2YBUF=!].J]\64>,9=::2
M^KM& TL]FNW?,')@G"A)WS.R7N-G<FEX"9,+U6, K;F.C O= L93)1=*RQ21
M^CQAI4YG=ERO6F'7WY7\K=I()UO\UB6<HQ=JFP]BEM05@[DNK8$1$\V$BW]=
M[J1*'\9U"X!PW@SBR'9AY5Q(RSJ:1R<)B/<(C<-#C8V=@)K2H.GQ+42SPY/^
MJX#HZ88;C?,JU&';FGG>BC$%5AT8JKJIBTL\]JDO@V#@=&=[GZ<)0 Q;^[>
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M:F'.J=DI\V[^E7C1@G#Z_\&_! G(&8!(F-\.LQZK&@!2U'E/AS:M?0$F6NR
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M@G1B=_&UOPC0FDR+.)L%NXTMNXY?LK"F,T#)I3:&0]84BK"]F'?8;]Q,V-*
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MOXT)Z@'42949RSZY(CL^"F%9&\IVF+X4-I(HM(0QX/'8<K:@SZ5428XW*=R
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M+&/C^]A0$+Y]IU>?' \0AIC/A?SUM59IZ).QMRO;$I>TO[#JYUHLM @H4<:
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M]':?Q6W2[LWQ,$E!4/2^AI_U-W<GE_%M\_@]DV_1/Y4U^6?X)K-3ETPFEUJ
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MGVY\M&<@+(U!BY&A=,#9*CR.#BCH Q]P2D^X,O%'1%@2A'O?SWV(=GSR(V'
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MM.KK%OAP[5Z4T]TP*[W5\F[?MXZQ@.U5DHGR0:6M!+L/YQ<ZX*'8G,_^B?F
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M@.Z>9YY7QZ<#VZ9T?WE)2!,H>SIG%2!X>?Q[Y9I;N)Y_3S__0H&&C_WK63J
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MWQXB[%;RK$9L=L:K$P$^S6KDVV^HNFG'E0WDS'(/2W[SLI9MKL_A:"0PI/.
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M@A] 288ZA/5H"8U6LP.M0Z]^@EFN65\0#;(0N4=8UBPF7$[AUBL[],OCD;$
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MZX??4A\TXGM W'6&E S77 C;;EB-^R)>!B$N4]?34! ,;].;EX390(+V7R'
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ML!UF1KU!Z9;V'H1Q1[OS%J_'EB'B*XBC?H[IDV/*WNCN56_GIYN. ]@%]=4
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MG]-[SL]^%3Y<XKCMD)0K<RLM+!.N'?FLYAED1[/E/**Y_@9QQX(,+.57)WZ
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MV4!I ;2)RCQ2KE6P+*.D^K0J+NO1]8A8Q*J1.?7$QFSIMQ$9R1]&,)(>#2
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MI'O52:CZX_8]:_'$/34L4824[.JR"(ZZ(/EYT7>4FG @1;8=L-[$@2Z8I=,
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MY?SB='.UT8'*?FBK,@#VX@)6DGUY_QI>K>B)1.9QX6C0W5U%8[4TZWQH7Z.
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MF;;4L&/S.N2G+Y=6FTW>GKS(&+,J+>S2-MF3DJM1X&^@DM40RE<MX6LI>O.
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MJ*N6?B6/Q@X#N97G1-99,)R'IM;O+1L $2U\G#N+L*F>,\#3K3@/18F%]C,
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M.*_S9=F [HN?(V:W"Q2C>AO?T<[1TQ5\K[8C'O-+J8VY_LEV+OS.@^Z$F9U
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M^;VH0C"M6.YX-*Q.T$I(>/(F/(/IP_[-B%\*N S 6CMX64QD&8ZSP'>O=27
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MPK-Y&ZD*6_&@98%)WP$K8-09 -A)OWEBD_/^#;ZWM]]*KRV+/W"2\<J$ -K
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M]=";?JH36R N"BW1L=>. 1G#P'=S^&E'?4-2(,,/\P\><]^B+2QLWGD.;%G
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M*>STZH)_#47<2OIKLTN]#K%/CJV'=^4,9DU>\50@T*RE+G'F1K!;O2Q,A]<
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M/$'3U:^5_+('N9:\J[,;66F1()'+C3R"D6.Y;E Q;1-S 22XTX]WLH950R?
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M4L:P,XK&?6RA1=.'Q4SPK"W?'B"/GHN>L2L+T-EZX87KA:RUP_LI(.BZ=5B
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MM/$Y%0+?IN7)@<XUX'O26.XX#)0W(;"1L'8-.-?A5RH>(!CRA/1:/HG]2*5
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M9MTGYE^I+3C)%!^+!1)<Z*F>TSG<^'[BO&S2IM'0G"QAHMHNO=%7LDUL$.-
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MY?Q3I_,7>J+PL1_IPMZ);72M[VX7+G7L^6P/3$S8MFFU@JXE\X"1 0Q>!US
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MX[ZTJ-G(EA>?'K_5VD3@VH<)G&P^_('B(I[6#7-K8%SX#"+Q1OG'6GF4M(N
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MA<&C= ^CGR$]TBM;Y/;8^1!"'@5N8Q^+9)JR0\W:EU/UV5,1XULK+W7S^0M
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M^Z-Z :R1M=N!)$U?.#EM?>J9+%\B%>Y&#A]S[S=CKY"R55>34F4&VA>6FK*
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M3]- G&P\DI0F;"(%>;*H$<\[5,?9U96QWL M+V'24H$[6B9TC)IKO5B?1P[
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MJ_=&\5H]/+,JE0;];;^4FXL;?Y5M9*4Q#*A]7&MP^3GK6Z]2W]9RSJ&E@NG
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M[(GYSEG\!DD$A)NAMZAMVKI>7 4E&)AW\6@4'3/.1G6&#7&X*-PB7\147=?
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M*[[>W/M#+]MN/66IH\L?TTEBPN<!SU(TUX_5U%MLJ3-^/EMNJXR>*1GTDGK
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M^7<S(1Q9"8[(P1Q#KC :N6FE)J25GH7+'W5FS0$LDM_W%7%M#T#Q [O @N_
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M%J)Q7X:4/. WH._I%MZ]#4/]:C$?SKX?#$9)X<[T%"I<:S@MN\9995VN#42
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M$P=IJ>?4MH*TEY=WDYI6>ND7W7W*^_.PKBOQ!#Y975,K.I.8HF%N!T"9>*7
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M1&M<M/:2,#DI>B3$Z+3\]SL$J/Z3.&8NC:^MB]U0:7FWB]!TQ)RFMY+G/=Q
M88K31?286W$7IDI5WX"20@N3K7X%7!^T1YFQFUL7S[F\J9^?OK(@E[\A")39
M9M/T(G9]YY(A3\AZ?%I!Q5WFOZ+RD.\Z^.7 !XD%;X#.VSL>C<=C (4J8"(
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MIXKLYR 6!I9)9W$,G](H>Q$(_(9JE!WV<Z "$Y"2A)2920-(0:FW'<'37%/
M'3CNU'3^X5%'"?%\N3-.<@GLF,";]R&_:E3_5[%]%1V^FK;)_PJ7_.]RR@'4
MX]WU;OK@U;XIHJ]RDAX&UQ OAI+X](QYVL1^@HI7P+?QS6<V<@5%/T9;6I;J
M 7R$)9&PF9HL26BFMZ+P;Q7J;U9;/0>#%/ 5(IFMKI!!5LBV[13PS^[,)N)+
M[:05*/NG-0!K&C4IJX* 1D")\%3>.*A!N+#J[3UW0*+$JF>EJ&_\4C=^)L[9
M<6]Z50CKUL]3BA5"R63CUB&AM1M>V'/DW(N/[2O@=.H5$"CZ/HSJDZ/,S^9
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M?"J'"3&Z(>?7A+*R@FMJ]9X&"2^TX*@%=NUM1S.OL]9#;?/.94.IO0=.\A/
MCP-%W_ZD1V>\U,VWJLG]I TEEY7^AN@K\Q-3\B-5$,>:"<?'K+%DLJC _*G<
ML[)<9\O(*(YD.7P"X4@$BT(;!-U$#; '37?#FPUO1>8NNBVU-[UXSB;5D=T!
M1M&V:^]_^E.3;=<0WT=U0)BD,#_^<NC[V7ZFB2!NX)K;Y9PX9U8_Z\J*=K44
M4OXA:$OAHF?=7RHJS9$<I:K@3OM0Q9[0(X*UH'[Y%O?^*Y]QBIMS [EL.7-I
M)/%71%E,2]*B3W_OHZ&^"./#(F]EZ :SF.#>_90@*PQT928EYS>PLJ/6K&_/
MU)$V4?@@*RPK4%Z^N&X'^=HH[2JO*11,+"#*Q=1VDF#M0QPI-Z/:Z E/16&.
M[=!?SJUC^8\[_<_ .CC]HQ0^(...QB7N@JQ^-0 !8(+M7[+X\B#/%B4KK/$\
M^?(!HNWR?#C>L?T,LA(5A:TFJ_WC,K6\;Q8*5CB/\?R8JO0>#N^]Z"9?+@*?
M1GD;\XX)QZ2#']Y5..'[,9W^^%-T!?!-Z,ZUSX2]?U+/?>EX!IT 3RDA5JJ[
MW:P]N6',-'G_-3]7=?TLI[_D$\OW"I!/-T':*KD5N+[*9V0HK=[OFHX-8P3*
M/T,VLD2<D1KIQ )^^.&E[EMGG373/YA6V(:()9?[YR9U^^[,0YB<6&.KD(XV
M%OL\TW)E_,0"[N>807_&@(++ZU\=#!X0NEY<*S;T;G1[<9ZNXUA?#BZL1?8;
M% L^>J05<+'M?T4X"9BHJ&@L.U@95@Y6)I#A>=X]MW0U>(-*%3! TYC;A(%E
M!,2KYMX%!HQ@.@R^G'CY8+GR-:C"@'EG?'M+ERB-8M=E3(QD=947^>T]TUK>
M^Q3,_"X")CHH!YU:Z=_G;TO;ZSGJDP0. V/J?J=Y.S19I9=DWI%T/EQJ7V&L
MDT_6T^,:?)_<O3-N? *),F*] D(*FU6N.88N"&]%X)Y&M9I_;LVR'=ML6KC&
M-X>,H;O3+Z5NZ1A=G'B=)EI-)7V[$!9B9I:;%5O6G]W^[#X9E8':=WZ <@G1
M/PB/3YC<5G[[J\GLK]OA^M_<ED K^A]W)^TLHGW&/>I(WNQR26N23=D?MOO$
MZ^HM^M)$WI<]EXN6\,4-P,:W&]&*W594D\+6:E&Z9/S+%%&-U'*[BT(/Q1G@
M\Y %RE\?MA6Z..RYF>S&3Y395NY%L5]^!>!*C%JWF1]T_XD#)7$ND19-/T7+
MMXLN=.YVV,P P3[9^Y81Q<M&A@=$:CVQ8^ W28>UV-VQ2,[F,#0Q[" &$E.W
M>15[6(S^"\-D[3S+E=QF32B-CPP!$[<_CMI<&Y404  YHB#DU%70#AZO>>=\
M1G[\JP>!'6-N8X@B9M4PR=Y>5](E0;^A- ^%0+!* Z'J$FNB[?L6;<MAPOOZ
M'YYV68&ZKX!?[D<WBUM)XU9,8YGN"R;:FH'^6<GP3MR?L3/L;&'2$1:A>5^:
M- 5HHU1%&3ML:_G%S1\U*2U? 9E&H--70+MSZB;/,Q.I'YQLZ7RG<AG/S8(#
MEW$,].Q8T1Z\?&B$7W-1?I6<C4$*67;L2 WG4-9M@(T;3#I4+0X[(I)<%H2)
MEC:>.C12M-[<Y@=YV)F^[6)QZO,2L2&F[-&AMRW4ZSZG]NAM-MO/U28>,&<?
M-GF8;N8MHSR+]<@<'E0#]7W@^!EX'[\;N9"-U<:M80A4B3V!?9!^*P*B%55(
M-WMP8GSPZ;G8+Q8]78@UP*./8;OKPS$O-_VCSY? 'Y3GR?K>+6$'4]E)POGG
M7#V2UJ3=,:05+5?B9M6*GU^&@8;+1OUQ/J(?&IFQA]#0T%+7@KADT"U@A!8F
M<?>P-N,CKA&EUM0>QI#A.\@?.[+:,S].F>'L989#V>.=O$48<EJ(P*+](W!L
M3>S+89@QIF6S!NSPTZ*DPBH/$[:'(7B;[-D2(1]:V-PH'S&UA**7H@H<;+4E
MY_?B+RJF;J_)=$;D=[OXW&8JKY7L"]AIO<=8\*#I05#!C.DO$6I(2B_SCN<3
MQYP=#[,MBPHZ9N?)"V5+U(T(CP:0A-+\D#42FG00&K2C"G#/$%$[-NSW#NR\
M%CP^_<3=[?@F$<TTD7MRTZ3SA;I)44ELBCWD5HX5C+@_S,S&A4%T'\DT'@Q6
M],/WB(7AX_ZI_K/!2PQ($.P\EB#'O'VCW[]CH(+/F&Z7\"=J!!IKF1<\%JD+
M8[$8T49R/,Q,"/1Q)A\/;>^RMT"<B]&_CZ*#^A[3F"YX9PK=E.L/C<'L@U^H
M+[5)"!=WUG,XXZJY -N":\[2G5?O?2PM=)%6FE*"M#F93KX<(#N!Y+]%HJ;J
MY<EM&I4?X>,4\_8>WB1.?A>I:0S#U_NJ:!&IVFCBU+H+L1H52.LO_N89 *AZ
M"Y1Y!;ANK5R^$8YF@&MF79EN9YT^WIK!.BX!]IVM,7QLS$SS$.5,W2^-G7CI
M$_&$0*)#Z!<V6*B)#1<$;YY*(3D M?^DA#-3VR9GQ!>IX.1CE EW\03=DDK?
MEQW%J'7CE?YGE5V]F1DGMHXD#3G+^Q9"+:TWU.%,X7#'BG\=TC\L'E59UELR
MRRT_+TU*B/5?3*?RI)A#40/1=/^D=4<24<B> M%C?^9AO4<_LHZ;[']286U+
M> 4DN"9H\7-W/_W3^GID^;],(Z$@R=;*FW5ME;4'$D<;3">;?47@%O9.Q2D^
M58F^*31?=\5JL7>1N,:"8;D:H<^YLQ]B.RG-T"NM1Z .+KI/B=@@13MEW8A=
M46P%!E =:$:"ES6N?(QF-Q9)3>D37-_]LLS:%J1(@.AFTM<T^+ !^R1J>OVK
ML7&,KM\JLXZ2:J06)9 \9147.G^Q\N!TM"<+G@ZG',N!ULY ];>_QJ2BZ0K1
MD"4(=.T45'G20H\S#>XCWB:.ES/U&L;=AAMLQ05>,1T8GZ_3/PZ^ G+0ZWW/
M2U*3GCSD7R[\]B0AF061N7[PUWXY9&JR\ EA/!'R+)+A9@_0K_7^*#$;H;C;
MMF.=3OVP_-R,T!8\4-)JG?LF:=686&WM?R2E_/__\!N:+5-'[%N1BBT"YAXO
MFT(7'1$Z2=W-/)>#/*G?6A3I5VT;6:][K=8RI]_(JDF,^-U]>A*ML;@1+1@_
M.=J\*!0/XF$D(%1B6D@0V_M&;P]-G>NZRH;W0I#^ >:+*330E[7FC>?Z2/10
M^VW N-!1;I$M^<;8U)I8J=YY&[</=,V(Z(JHBJ1(SM?_.32WJBX2QB?(3-Q9
M!)ZX*BJ/&/'R:?ZLK%BRF56H,-&%D///?25(?J\?D]O[SC?;-C:O=(PMNEL(
MCOG6<4RY7$\#U8 "@8>NZ3C)YY$J4^4 E8\RG+,_&/R^[ /9\![%  U8S29$
M<&/.<6K]ZRN$S'JLX*GC1#145F)E-'(LR\\UM=BLX5]MOA=(* 2<H/!&K1M*
MWFI.F67>@SUG=^1> 6YI$NB.$H10R2G3QJ!UGD/75-R0+8Q+A@?HDAPT=<,[
MJ#IX+,--X='3<0]T@^T8((.3#[!8L/323CVYT?_^AB? .M[ CN*JOIDOQ90S
M=?8/JIG(B?3^U55ICRF$#9L[( PP8HQCN>]]TPNU[9T]ACEHM B..6NPQ146
MY"Z&+?2P T^5448\^L4##;I$BQV<P\DFD(0A;'\>+'>::X*L3!\CAX=>>-6>
MV+,'QL;S]./>#S\E8_KT6AH.L[;E57?;W;[-C:W,@4M_@+<Z:QE$M*=5PJOV
MGZP:U-B_4T7BS+4R5;$5/WKC$Y'F&& _I%(NCJ['8\AF+0<QJ_RY%IP\48%V
M=:HS0%/$\T96U1(^^(8MZ6;@%.D7_ X'O (1)F"/Z?H_"/[_3 D8/$83"=5B
MUB&M,-X!2 ZL^U5W[J2HLPCO]K:"_DSJ@OUQ9?RJ5"M==%_P*2:O5N&]-+YV
MT+]ZQNEF?A#?2P3/^NT#78,W'/HP1(N.'Z>49^@;ZC3YN2%GW/R*MLW;*=?+
M'<GES8V' NQ*UV7%%F)O57M3. "GLRUXTYOYFK<T.+[:?Y>^N=U_ES;XA8S(
M@4B1'1ZFS_ O/KNTV*__5]8I_<LOIH4#4&;^*X#BK5]KUL.;TN#B_.F&,W:=
M!S1I?(W_UYW\_AV]>Q0:L>38N_LOB1L'0$\6(^T@^93HC#53BO2K_#KH++3W
MULLV'-I;.&Q.E\J03S,8YP:G,2-/LE$*4M]/^AO+L68GWLE,+E27=KEN5P]V
MG&Q1M'F40WB6/(YI&\*'B>-.AV)Q:2C5GYU/Y2SHUWWH[&WPU!M;6E(WIDY,
MWW"_%:#]$NR;H:28,Z]_E]0MOOCNIY5]/A=AEB<6!KP#$:4[F:,A<ES.PE[(
MOMD<-3]=F**PT-:%'$I3T5*WEU6FIYI%B '9*+X&ERSCB9XL<L:/79XVT,O%
M>+?V7 T'4123$L/:$-Y[&9^[AYF.MXO2ZVWO3M4F-_EJ!JL)Y^>UD(* F<&9
M=1-&>S?O L/TEI<8_46(9WPU2,C18Z;2"'^;1RMAMOM,.[/U$ZFG.+6GWV1C
M4A[9*A[?\&N_<R'$(2N!CC2T?TD5W\#D"X\[5%U=7%Y:,5H!I;+?U%7%9 H7
MT=^O1TTP[H=3!#4SLV*/=9L$GH0[7L3(.XR%[@>*,@9WU[-,?3L5*29NZ;I)
MO$B.BTO8][?2Q8R09,Z0+JN V!!I3444,9M?>MH07Y"B^#OV\Q:OMY0*IZ'1
MU-:F0@>2^UE;VTQ]T<A5R,(R-Z7K&AOQ0MD@6Z@TH[7';YB$,'$@^K4U_GUP
M6+5?\&@SMT,/Y$]\]G^.[\NC_-/4?'L:.LIW&_N1[%O(FY)-1"^\.=Z47,LS
M:R.DUFI,O7:HXY9B:RRD<6W+]15P.*="'WRU;Y_7>K$E_Z$_O6I ZT/_[;3#
M#%9=4,RZQU:*'<4L3$]0S^(#QY$W0B?M!#)%!E)FQ_H*1>=2F2WISCJ<8'B?
MP_-?0+3FUUFB6[NG$F5G8Y:X 30^VG9$K.%F9P\WN5ESU%]$^H4K[U<LA2%[
M<Q\>!GF>X, 6MD!\H<Y3P=8M*'?]R'JZA+IHL,*)Y)R1Y[*4.0T7DS>*'>>W
M86V>L@X]NI$+H&N-'E*T'?T&Z_O2<O;\G!%_4P!LW.374'H<G D^+^PPJIL5
M#W;99R\_63&W:#5,PDU)&XXV)6:&YG^D_U5;_,6?46QV8R&@LV__]I.L4J$(
M#DC"?+BPE[Z'T-_*SMP?B!R3$VMN-K;&&:4"XO'A6[2U,)KZ(!.GW)#(C=52
MQ4RQ/=B_P:SK >H!*19YWN[LZYA$KS3=^[5<W10N>'@-JTQ_Z_ 'CM=^=F;T
M3OSR 1EYS4/@^#/V5Z38S4ZA'GMW)_\^8,BZ2W(IDG$SV@E*FW'D@_%=OLM.
MS!3&L.U4I< E>A]'TZUXAB4EFI4Y1IK#[3 2M#;N4Y(=[K#KINB!\WH;[U7C
MU;ZZ%63#9)+$W-QC8+^N.5P=_J^A"9:&)&Q: FU."J7#V2Z*Y@6?T,C,M P_
M (&L=AC643B#^2MC9=0Q=)<T20CT,:L'S"9[?+9V9X-TRSEA&1<&-4+'@L1V
MX-1$J%Q];=8Q7&&F0XNV8DJJMMHRO)<&_/5_-KS(:8KO1N *;[I7]8J;*BCI
M.#SMF/_A:^?7J:EIR\RZX*!PZTUM^?Z-1$RD'%F6QO)TO)IF;%@U7?W*_%_[
MV?,OHVKQ]UG(\@=*_Q/J#>5CW%3) HCPP5]80O>7;1FQ:6J45D(L=##\Y<8-
MMW!S^D4KH'!7^AQC49CR@TH\WNK$K%-&7I)400*2D)./U_<&H2$FX=#919A\
MEK":DZ/>V2I,Q8)\RU%R4AAG)3P)D.ZZG]I FQ$.5E;7D;[?\6=X!4R1$ZC<
M1NDG">XT9>$+DY;R7ABCWV,Z!HDX,&L;2NZ0BY8;=>:HM)$.<*%4$#!YU3Z\
M$\*)Y3+TP7K'C(X%NCF D9A4LN3?#+P"_H!%6^*T@PINA>(3M2U_];Y4ZW'_
M/ +D:/[&ZQZUGX#F5A_S:L>IQ:DT1YAF>*H';W]15RFJ:K869IBU3B"Q[4?-
MTE#)T-]JYE:>O;Q_AZ_]K0V6S[S<S4*XSZ- (D=;:@Z>K%.,D-]YF\=Y;T!@
ML"N>I2 X,T4*IDT[?DB])G-_,W)2I5"N<6HKV*O6T-J2PI:Q$2FW\36,&H5-
M=OJJ+ ISE,?<3%$VAL(X5:(3\2_N3,U?K@O^'FM[;%J<6X1QT]B6.#7QWE+V
ME/;[,0H4 2);>!#AZBZ:?EYB(*GLEI407*<CU!;^''^T:JH<QE#"]>^(E9+]
MRYT5%?X3C!;'J/W3BB'[7^4&(*]_U1ZD+JM\K<-7TY90^ZR7:_6.-X9D[I3!
M1.XAS(>#YE&$M,$3UV[,N=)"K([.:3%AMB23JQI*-?..%-AH)(G4:J-:M(=&
M%@6QF5]:[79G7^05KY? ![RCE9$YS<AVR^.6#"M;C C#Q_&V*9#ZA<45T2^P
MF>E9IO)VU,>ZR'(*N#I,AF?4CQG-](/82474VV5?@IR. )&_/HE+"+CRD;MP
M57<+4^< ;B/6^U%8CU X;=C#L/U@F*E87$()H)N;>M%/K$$;\C-$BZ73+/.'
MIJK1HD%+?MLTGI#/=:1$KV\V!0.N* '6Z#8D%:6Y*0C)],?4P!N\NXFYQ&(;
M-J,=@@91.BY \/F^Q&!Q>2CUL8L.13@<?O0XP8BD+EVD[KAL1 #"7=B."+!H
MD R77%P/5R$)MY^WE26P<@1N_!P=<%"4WR^B26E=#PN]279O8OJ]@UE%+D$^
M"O\AMW30QP+KS]*PNSW9\:VIIR;G [RS^B"/&E=9;"ZW!5PRO.,</J8/@2$O
M!J,M;$-XV.*GV%,I4X)Q\1@2I5W-(_MB^YS]C?W]\4[Y^..A0#8&OI9:L2ZI
MLP,[Y#-<?<KW[46< N=PZ.+-)*LT=$6B?C>O3^+-*Z"S)@R0&=9]3MXSY?'U
MXE9Q^K,M/COU(/(<SD^HR.8!XTU#4L?".Y:0V3$+N=;;ICCK-YIF%;=IHD4(
MYF%AP%(/?L\Y7-DZ=[Y;C,!_$+XBXMER#UU#JB!8E((/$V># 9>.P)#]**^)
M;Q(&;-TL4V1*H@QR5FTO^%W>FX^:/G3&L_V(A$(9@<"NICGK#2Z3MUO]1IA+
M-1PJ[M,BLNW-WB;/EO,-<0.M@A6<TBQS45+UA#;ZK[]("_S>K[GL5KZ!K))]
M6Y3=6M=L ;0N^F FX$CV,^S9P2/[T]7_A%R2%<E%I9!ZHOEYX*UAF\O12=#D
M?"EX;3H+CKN]+28ZD[KL:'&CG(5H.]X6;"^I7+X":&3S;%<?/OZ72/;_>83G
M3)=B%A-3W6:;J^E,\X:^$QRQLN2#S^8?\[HN^QO$S2M$]WM96!EQX<?F. B[
M0/9L6%FW5K%J'3M*PM^YW"3>"ERNR7-"'4;-]R^E"US^-/^" MEIU<,>F-L
MRY];XH9[2K %]ZS?O@(4WYGA&LX;#B>9X,(=9GUV+4]E)I7C]^2;S/X2A-XF
MS:+-5]E^!]F4N<90T%Q.! =Z0.T3;XX?B(UHS(V/YN+\*5D?S&NOY4V3I)LM
ME[F.#K"E#5-AI/$+(O+4KMV84(JA63EU^H8(L$KS+P?&"^$.+BW+1;2*X!<R
M\'K-*^"MG!_,?E>31XNOG:K-WXC\WN 50"0(F6<YAH1R2,3$S5GVLLS6WQ)S
M2\;B3E3NR])47U#61_$\RG7CUO6'Z\OUJ1.0SKN@$/=*63DT6X2RS1X=Z8UC
M>[EN-.OFA"$NX8-^[X'Q%XZSFU1K_L3"+019>?,WPVXI9_%N]:=F+U%/J!*&
M>EGL.LV.J%X!3#MV&5=1;X8FBJG7Q;0H"E\!%8;4_;:F"/ARZZ&>PO]'>V\9
M5%?7;0D?@D. H &"!0X2++AK".[N!/>#NT,""6[AD.#NAR!'< GN;@<+[FY!
M0KX\3U?WK=O]UNU^;_7M^F[5_3&J=JT?N_9>>^ZYUEASS#GE !5$6/S4EDM]
M<%FXUN&^!T\ P8&: [0YYL/G/\S7I^? V-W).BE!Z1OS]$V5).X8$>.T\P_A
M])?JVJ:,;\ ^$Z-VRGZS>OMK_GQ+WJI>]/SZ[(6<I?R.5O5SU3]:4@S0()]M
M//(N>MV-?7SNO'P3&:$1RA&-/A>"6;3:>CLP1"- '<TC?"I@&_S"#Y1J30AT
M^O-JA;@\^_K:^C.B0=%_.,/XUG^$>Y:.M%BKM8(HE@679W%;$E-=[ ?.'I'H
M#KJXG*.ES&]Z9^JT_GQ?]'9*E8R#D:[S57P[]X@C'N?HDLG>'!X'<MFE =>M
M]\V32*I:X8,8F&_^GOZ-I$/S%&0G]T50GPI<G%?E'?YN675EB3%Z$LB]_N3I
M#FVVU.@[V7IHYII.W+C<YN+PXJ>!)5S/7&=M&)/A@_"/"^$E8!-B.?6F36G_
M"&K*.;KB% B26"&W-:WKC8YTWY7?T$V,#)*0PI2KI_.B>:?^AX;OU\BZ;H02
MM' 7J=-E4^7UKB'H:,V<!'5R.-3?GJ'-7L,UC1D&J*9,:^W\2:RVJ$"[W"/>
MOI0"7WV2&$<^$$$:NE_.21A<7^[)[#:9I Z([EV/L!<ZU4J#:1ZA*+VK"\B!
M(C^1;?N9[91 /Z3>_7"S)_3>%NZM0(\X&_NX0C[)E&PGS\+=@-Z/.0N57",=
MQP+L7OM18Z9/[>FY\(%XCLR-,[$8C=T_R50'U1[M389Q/XCS^38E(-#O"E>*
M%PE838A>=BR&!7H_'(B\3:%](6/EP/C9I]+F\2/U8'VOHFNN.1K>ZF1392NM
M:GNR=7-MA#^).6^) JU1\.A7"W\7\(V V]#34'=JGN=[>U)4"946P7F[R*-#
M7[?;=#QB1;P"$@-](5M BIR<JN(&2E%?P1X$9S%*D OZ-(P8X3: YM,7<&!>
M!X,A[L7(SOJPR5DJ.RO:YRDE%XH0C\.P<VOS,5HPE\*N?<US%TA^4X0")[TA
MO<4% SZ>>P[A1)7->,@2?(CQD'CLVI^ B8?\!X'C07O]X6/7-6V]_+6)U4#?
M4(Q-0G*I0V1\Y&>RQ<>;SPTC /<,ZLCCQA_;D=5>+?W4+M;@YPX;J<R,F;Y/
M66>N4YTPHX->;[/[$M<U#0A3C<"$F&>;_/E,.8W;81*Y+G,4 ZEVP"E.+VKZ
M\YVCYR(@:/W9?9]*LE*G)XVH/?&ZV!E0LT(BJT[,'*_X_8:/B!U)!G5Q2T9?
M#-\&47#JF/K2QI;IP"BFJ]$"#>W$[*%IO,"\R?L&Y?KML=F4[2F5J>)< P&V
MZR1>8$VWD=S1N(=#^+#]&=L>L9^2M33?<R;,%_)<P3]VEA)X#[27@XO\+HWD
MKC7?PEG9UYOB,WC'1FJ>8!SG1KHX)#'V%GI7O0A]5:H;PS,493_72%VGKN[8
M[%^ZL,]=Y0NO-6'-"J??P42&"0>VLIHROSD3NS U;D>^Y.%OK2-52%ARPQ8:
MT9T&@633WW,.*W"J7/<#CW68U8N]4^PS3&:=')AR7:X'/>BM!]_K_@:LD?UM
M=-:OI;<N[S3->3CX[EE"@*M GXEO#\J3J@W]2R:;&[.%]0WP2=<'RQ,*,C>2
MM(+8A#+/1)79!PGJ"= QT3HUYZSP^):USFWXW?3J J5#:\KE?.=U.0H!Y]C7
M</*=N1C !C_05?)[O;^ 0,R<^^TK7+(O+ZD7&Z[6H=67K0*AGYRN8PV,!9CT
MED3@:V-SI/ @X0+RH-1B(W*$*X[5#UI-/9LI=COPBB+HI3_'S\BO'E9_GK1Q
MQ!C9:7>&J4E&"/00^ S\?N.Q' (=(Y MV:=!_[Q:I<YB*(&<0FFU&1BP],<L
M8<M7155(.#5CRG1&2"-N.R6<[[9SF>)+5'U<-FL03N\'DDJ9#PYDP];TQD*R
M?RQ<D2/,E'UJ6U((LL<QD 1K,;NN:S&K?7<,,I1RDXNC=<[D2X#^,8BSF7V
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M%]O7,UQUAW5C/+D=]9Q[Y1@RTR3F+Y:?<]L1[52ZV0R:X]ZJ>O[LRM(A%@M
M/(K([SO5XOX'4M387D180]^^R!TU[M T5$PY9GA#(21WD45:KU<4F749]K&K
M0[X/XJI_\F5[DD:[,*BFR!CMF:*X[U?VH$B"V?M(X4 ?'^X0:X,R2MP. 7A=
MSUW[?H@U'O(?O")4^I;8/^U:N9>L,#%0;LA0WL5F0D=W1YBQPPQ-U#NS30\N
M6A3#MC=86O9GHMN7>V(>9GR^7N=*K%IW+SMS$HX\)Q2#N >=E4BM^ /.NZA_
M%JQ93?S5<"]I4$X:DR[&*&+0V/\0M WM6\CAMX?'X36LE_Z/),1_*KGP?PN1
M?U9T^ 60&IXZ/3DA]<\D1J)I&DOC-O?@,$BRZ[JI*LN2X,%O>!BF86S^I5$;
MBLU9V,:#X%4+/;6%H2=XTD5[4PXI^QE5UYM+9OW >PXXMBX5RBB*RTZQJZ84
M55^DWN-LL)+H".?QLHO+RKI@<.2;G+ZG:J$XL<J)&HE](CGY3&G^I) ES1XJ
M2/T66Q:XRQKG@"4/S8<U;M&P'^W(K'1>GZ,P^XTDJ6.Z]M[SFD6S6TM!MUS.
MB0ACO+X#4UT2E*]V96.!5>^,BUC8(>ZTV:GIZ3_#KDD0ODV1.04X!NK>MA/X
MH.MC^8%1:08&\A/]]1@A8FO-"B;%[W%/,X(!YO*EZN5^X$7#!KA ,O+[1'=B
M(O^0-T<"@.8KO^H[C=^ #XOW\O>4#X:9[^K!]&+'RUD;ODK[NWGXVMV:[T;6
M043;BTK-#1'?]5,,&18B*-S/MZ)4O64'5'L,LNQ<0TMGP3& S1<&9YB+.;ZG
MWIN+V,]H87+Y^G,T);!0^&OKYBD.L@X9=[<HX[+-X-X%S'(J(O4G\/)8$B>V
MP;(">0 OR@!J,4!G>KL5D4#A#!GI79#/)$JB2,44&@M:KX,Y&7\C[D3/=+@P
MDJH'U@UYD7#A>'[ 46>>8R"=F)"B:H_1>]S>44T84F[.!G%.^B8+@%@QZ6S"
MF3-\XZQ:9X)>\1>#,[T9>R;CF)Z1GTK?MKE(/IU3E07H36VEF$H0<[3,'I.\
MBC%Q(=^HI:^ />:#@OE>ERR92"EPC6 L65%%H<69WVQ#=_.>!J/*@UZYVJ;;
MYURO50/?"AM<3,A_HSX@.U&;=BF:96B?LFM+>?,;8.G)\HS>:HM\#.]G"/_"
M'^MX"K]K]G-Z,S7UINWBT"YR>RP=@3V'&<H/JY;WERC-<R2[\YXN=V4;X'-"
M!#QIH$"OS0FDW&,IZ/3,F,J;AIJJ:\M.;38A6AL$N083\ABX*/3'I,3E[$\_
MBT3&K"+WR7BZ3[R!0UQ]X(Z<I9W+ZC^?8KBI=9K]B@&AGK,_4D@N<._+L+E#
ME]S+O5(A4ZH>NFX :XZU<@2?DA?$UVX+,Z?,_T"9MYZ](D$9?'/W\8&ISI%9
MKMU8F$-OU9UPQ\UY,WY9N&BNH#V])X-_JRW-7[SUO8)-BO@7T% X@IWW3M]0
ME@R%O#Z_B]12B#F+LL<I6UEC:J<V73GC132#?88#SBVSF L:5:Z))7PW#P<9
M_#G )]?5!C^H@8&P.AA0R?<OI^'_5/#\WP-93RXX'.Q#05CNK&<+MIGA4%WN
MZ7[O^:RV>^M-XG>8K<)F^*2)OW.10#!;M@A-H7G/Y6)+_HZ%T-@E_\[ZLL%,
MW+1)7FJ3\6IK4_87;S4-=X^M=+G?  A>IL$V(N6'*F\+*H9 TE\%X6U:8#XX
M"*YZ&@#1$U5K^Z;BY9XEN'Z_6#?%Z!)M?D7G<^4S@UL26?>IA*^_ 0>S[KUE
M4Q_VOGD/CMY#0HN,NP2%Y4*)]/46LK$:PP:VL-<O>.,S>STO2[]:X4'[\VNS
M[++T@K,4/4.]_31 8RE9WJCE#P=,LY,89ZK#C)B?\]9$O4BKSKP9^J>UM]/
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MO7%ZN!J^D!@*AI_3_*1X*$,M+ZCQ;M77G/K1E,-0VDE%]V7V:-2%B\?G1UR
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MS\D08SN*:'5?AK6L4B#ODT+2)OY0FZCBM58Y54QM&(SL?&4_A<*%T1\':,>
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MP5=D0)?CSE@%LH(M :C G#!=<4']FMF7*2")+1>&^&'G07Q4_,(<*$IRX5Y
M=;Q]ANM"%2<D?[#+8Z3VNUW\$'0SL:RR[>6DS0PTF;JYR/=49 3T:DU/^A>;
M60Q@,/=MPDE7_9YVNR!A,GN,2.,F8N=.A]*FK1:$IH?0R_#T5R(^4EBJH4*M
M=WWWD]3E#_W;@D75Y7 US%C#H&3U'>![O4VP1JEHV\F?9;)X"KK\9JQ;I*>K
M#Z6^W=LF2<FWY#E5M?##04 ,8(</(FDP^2#)E+V)5*9W-<@<8Z7B%LM-WV(0
M%Q[1@)WVEO\&8&UG.K M+NY3ZD08.Z2\V7NY\S(* V54=,Y&E@P5!R3R&Z#;
M5-<P;8$(=\X:3NKB#N51,;?Y1/[.F3)6JF;F$ ;1VKY>F3%O_Z)Z7QG1*\;)
M'5\H?/6'1+.@8G89^>07,VZU+FGX:YD,B'G(O[+TI8ETX[Z=\2S8YW9$0K[W
MV'D@VO=+LQ-V,99 BPGRXS%[%<+'+V&1)0UI]-'^=G\K6P#KN5V/+UVQ#>TM
M5SKXJVK;<Z\+HY"+;<>CO%<0B$N7SG1H':<Y OZ<+%TBJ*9EQ_4-UPM7R30G
M T>RC.RRQKILV[!:C8/QY-FJ"7/AGWPCVFJS?\@4&*G@_:1.E:KNF4724R(L
MVC_,/[6KR:RRV&R?S??:/Z^I@;=JC^D%T.L5XFXV^[BV=&].;W;.5Y'D1A5.
M/JKH^=/K+J-5BNJXTJ+*Y&>B6AL,#G,*_+/TAORH5""W*IF*TVEJ2_26@-A5
M&01G5^?%%_BY2&Q^\F<0_R1^9@S50%=^#3.']<!@B((WB[=7R^&WEG70$X(!
MB^KEL>V74QGJ4.,.D:(JKIV]/5-T$I2QY=V;)+\852MU9</'":(>=U<WGQU7
M.;W.S@=6D-JB=O-X-<@"6F]X_*RO?H2U-D+D>/$BY V\+.]IL,2J+OQTR2=*
MU+HM@C&!=_NY?*^PV%-K7?YQZ^99]I.=J2KH#3QUF,=8L75KXS@5:A[B/?G'
MYDQR*&82HBL<*JD_I)K6U[2E#?@^]4 AWZ#F3;TL_^8U]LQ4,;]I8?[;M=5'
M<U>"$[=F]QNAZJ88]N>$BJRX@!=489[OKXK_50<360!I=K"%;[#;LQ56AT/,
MKSA]%[68DH%BJ$N65<OO%N8C!7W=C(_OVYS#>6^G:U5)SMAK^E/DEJ+DT&B[
M-;A_ LR?HHS_2U517;8C*[4IZQC1H?[\%#V<3R,7W,RHJ-^,,/Y6J.FAET27
M2Z\;7OF[0JC4*7N RBY=6V9?1)MF?Y$\_1^-5;2MD^GCBY+3"*79A]T 5_SZ
MJC/LL%AUF,/-$S]!TA445(8_]S/Y6_&F<T5MK#YI0;2ZW./RL>1ZJ^U]^<.K
M;U5[Y<%XL68]UXWM,]_Q#<YRY%W$[2D"_C?JB/]X;_@7>AX7&YL%F16G9L_9
M[+B;6Q[U=JC?N'DF!NF-_YCC+C)V-*/*.!\W4 YT8#]Q=^5CSRNW2JDFC_-<
ML@W_W"*[3C+=0L Q\UG;4E$/.SW,4C3,QB44GZVJ+G4$CG<MS,'=$2.5%R:Y
M#-2G+MLUBF^/+*E!U*;LGY^?''G<LN?3BW:R@>ER,(M]?*;$NW&!X//%V@.J
MAB5)>OD#*8I))^*1LF5#!WBRB:)3N&"F^Y9Y<A(F6NYDY;[1K^ML_Y(.I!9A
MT#K7D2=4[E?GK?J/P!F0L>I[C=:L93\7_VV\3RY'FSKLW)VV2^3F]Y3>QY'>
M@A'HD2.=&7?+8IM?:H$*I1X7JU-\*/F>%2LR5;'D7F/0WI<77S>^N* *]4X"
M!L2%*WQ"@"W3T,7818Z77\W3-KPRW.)\O'M1!JY_.:XD\G?MA2+G!*KG?%GJ
M^+@WW !NA4 "[9^SOI&@*UQ3SL?)&[6<Y<T,_T);:];.,=0HL3\$NQ*C#M'$
M7UUH!V+_?D!C$HS%G/CE&I4J ^+P;8RIW+_$U.$;]58+O8V"#1'VY[/SE.>Y
M$ O#^8-D/RNEVGOTI3>3SF9O4BI:SE+4^SM;>Z7IJQV,O$<2XS9;8M\&.KV(
MU?G$PT-4]0+8,/:NQ/[)2NZZZ)$1<MT)CS0Z0B\:'!CV(>V0"U_]=D1SID6;
M<>P]T[37KHMEEN)F/\!T7,B<G"JWBX'/S_+NG+"\"S^=;] ;.T:M.I\W^:;.
M W"-4=)Z>C1M1M!2BV!S#Q8K65<)RE^J 7(&>'6,T!%W4U8YY"^V/L:6B3'9
M=^+1E\SVXQA4$L==/!SX'&@1KOR*0'*+[\6.G ^!=$TVV.>%!J[Y/ZY'3E^I
M$_2 G J7OA:E"%,H,_>3AM,]+ =S9X#MO5G$9&B:019\$R:+6)P<%-/*-/C2
M5$>2V5P"? >50[G"KNR15<EMXV3ON$VLRH1(]53UC&N%IISUKEE,^MC$\E$L
MIE]CNM/\),VW<^<[NTTU&@!=!)6_0J_==U.@S?:\$Z^NS(\=$796[=8R4>1O
M[4]"0QEUVRCKJQ'.PUEY/GUTF8O:X^M!H7U$Q-I;R&[0B")U!7'@'XKED!M=
MU*HQ(#H;=ANB>K0;BSNR"$^<;6P0$R]?^<D/C<TDQEMN'6B(&]0?S-P97<%F
M8)C6V\ZV<MKN>_U 'VWG3CML4N6'^2L"&_A+J@A=_(6F[YE<VPW9\Q=:.C*\
M:/1H.F,C%];X#[;5(^L.VDHBW4;NJ4JX+8.VBYS#&VXJ'I)4,^*<LX^JZF;&
MK:S'*ZO:;E9I&;PUSHL7@.[WER/2A;O<\_,]I?LT9%';]G*=/N%//1*&%X0Q
MY]Y+41/OGPWP^<RR<+I8AYFPDLWG$[P9>1_W"\_RYT?C&5"0L/_+J2UHHZ(>
MUVD_4*,H,=.]SRP+I][3*K3D9[*W$YLDS%C5&7ZQ^';-2+R4KL0-ZZ'\[O+Y
MW5B4BV54SWI64YTT&^<V3L<U$/7GU)/NNYT%YZ.G8$]Y3T^Z*'([&ZV1A.)P
M.H(Y9/7"2#";R,J"O"OBA9'P0X_KN%Y(<=O=]V47Z//FR($+T'Q^BA@^UD"O
MYZXC 8$#D</-#6\77@\XYRPR8=3?-^EVJS;E^11@'%/V'^79%S$#4L<]E64!
M-@[(3:/X)? ![G]7 <^4;2"BGMLE .5"6W3=U&>+BDDFIR<+WZ?]J$I@-QW*
M]TO5;9CARVR&-B;QPV9:).P-.NX_A.*SVLY<_FQAJWSG%Q@(-UVVDBJAP-I,
M<S;'F5.5T4%D^+GP569&7A@/9BP7(K7ATN;2M/%_J-)W21^OD1!;@Y1[':VW
M+"$ZY!T4Q\&J/%BNL*"?+\:F^>+E_((B>4/.=!HZ1!$8_6B/$C/Y_NO$)4/%
MBTQ?W>G-0 J;^J:%;%D>'@H/K."JC.+5\%RUC_*-]R;P=0+VIJ B*V#V?!^5
MU7G9%6&%*35:3_Z[T+S!.A7<MT*XB,3<#"G'DD:OIMK):J\UZHUN6\2"Q&:R
M=.>0.:AO?'+AH&Z,\1<4Z14=:@-M;='"7(&,5U(1C)'*_9GQ#65J6;[ +B>\
M^N\G36);GX1[C]^WJCNX!H(VXN7V#FV=1,LLWC9H-4MKCLIYWFFCS*XPW^M'
M91HEJC5XZ[E9R&D-DF2E**(BG&==HX^)M4^K4T.WL(81X,G(?7V.*;XF4$*Y
MS5KF+U+HWM.^L?/ME3:3\&@&JAVQ2X:SBG0XLON19-)K_E*YT]V)'8_3B*-!
M)O5]6Q(UZ&AKTQ</'9Q[_5%GQ4@Q"'J'T3D4J,?1%UW4<JJZ K$!B7E6]$=B
M3%IX]P-3Y*1^ ^AC8P/O6WT43[R&,B$2!MJ'U]NZN+B_ <^2?:W.7E3D)!?M
M*_[(5I9+5W=R E_$&=IPP]<5<*3'MM&Y&*>]77\6B!W)R$_;?1S0?GU"JHR/
M?]19'Q%*Z[B0JV\ K*^%(7C-3&2VY;&#\S50A@2%J)LH!V:)=5I/9?9.=V\D
MG< H!&!3B3?<*6J'5@G<=UH#=N5,Q25.X%FB]*C%PW0!+9YHG-\ ?S7WN96P
MUUWK%!*K$MF^I8HT^50ASFXR] U?>>,*J5M%W\=$+';/Z2,9]N$9TO8,KUN!
M66QKZHQR^.J8":]ZD?O!WMY[SLS2(!>+J&E2GGZ#S=31B42([NER22%H310B
M<**6@1M63[+4+W/"+H7&O9,\1X(R,6\F6[9W?5-C-YC#37]\\/[ T,JLJ3G"
M"<*F^AQ<R\MYG3O$0WI08[YS1I^[9E\->A"VL_.WXX#.GF%]M6;U-?=&5UPO
MLT]RS*&&9RJ+>*4G525<SQ&*1+Z,%@I*DB-PPP-HG]&TDA6O!;ZH)"\!XV8V
M)'< "#]ND1//,="DS2TJV(2;( ><U1_JDEAL?@/:%&DA[KY-9/E6:P?4 K.]
M3@,]^RLJ9SQH[[+J69:DQTI)D9ULZCB#IXJH@@:;O5MW/Y+OQC&L'&\$N88$
M4BW3D[L/X\8DTQK3R\SP_3>RM#@1',/;DX/#BOY4BNQG0Z_!M2Z[Q34>H3CY
MA;(5?@'"E]M3MJUP8C'PS3.1<_(=?/(([IQ"?K.#-WXMBI[EZ@5]Y8MFO9GC
MI#Q2^]R]ZRB8!U*$?A]U8HU.)>"4J'@C^><ET34]5%QB-!LK5?MGWQZ -(2I
M ,$O&W3>OV8$S:9*0K%7#!PH<64X5I\(M< 6^X5#W @T>QU%?P..C"':T@V)
M;]H(#7CY.C/8LTHF$#O;2=02A7ZS9#Q+D"J$A &PCXPW?/I<UI*65*V)A')Q
M3Z4IL (*V7D/-,^RYA2F_20Q4UO1TJ6<)>W$WUTGIVF5Z.(A?9""[I&"=!P[
MW;4OE&N^=TUYB302;T2CVO%5,G<U=:HW-#/B&$D88FM$TS1A;S3O=J-P[PTI
MR5,>\CWKAP>+K+/5VO>X %,WK9^*L "]C]T<\3SP9#0FH"7O51HN("?T8 6*
M)"'=4?65O@-5JW+E#:=@A=VY:%MPO,OP"(T,+VJ*X&4/0-5]?8RU\TH!>I.I
MI*@"$NE'S1)8[N0>W&F350Y>][1@3!DJ6GV-W,2*A'L?))!?/'J:;!*2Q%P,
M35WA9N.(@C.$(*9/V4DV<S/QY7ZH8=(:3<UP5GN7CL/P>%6:&F QFAZC @2?
MR\D!-3L94DZ+CG,7AA]3Y3)>E'SIKA$+"\,4_1K609LMJ#97W-PZS>["=Q-U
MW<_&I]D/)'I%@6ZP<=4C_TVF;&FH5!'M.=$"AI6OT]-PH+G\T-(3E'U>'2B'
MQ(':F5ZAX+6HT8)I'WE\H0UKL?3H6E:$YR)?AY@@9-5T#Y%B\F<MPN=D[*0Q
MXWJ!@CG2B7JZGEOH%.!=^N'HY"4T!\LZ.S]JOC%%+JF1?.!831VFF%>27[1W
M _[K((>Q.X5!;B!:AIO!1;U=N,?*T-ZHY9$4 0T4A$X[NTK,/<\:M/I\PNPB
M+1X/\"(ZN*$,/H**5.? )TP%TTG.QK8Y'P>7GA+_G#3VB]B^UVRK@4_:&,=*
M148.5X0=[Z0TU_;-G99]._H6]!;.-58Z8D5"7-S=:ZNE:/:F9-(S=6F]<&).
M4YUL'^&Y)ZB!7+E](TR5OUCKYFN1(%Z; 9B9\':O7!SNQ4#DK-A&V']]#W*?
MPVRX@;#N!(FZ!MJ4.Q$NS8]0Z3]/%--.*:9P ^S^RT&.S/\3FO+?,?KGPYZ4
M$,;VQ/2D.T]@/?KLB GX7>X9\6EP W#R=0!YYBCS6A.R3W"LVQPB'Z)DTVD9
M%(H_T[IAC>VH%X1Q/8@7F-D7[#&W1JR_VG8X3?K,>NB_6;N.^,,7(_]=E:8&
M,KLS3"B3IHHR+'SZMF(/)XE6-K8V R\ACA@DNJ8R&N]5Z@,K<WD'U=I,G'?.
M4:^*ITXLIZ'W@?.H6*52NU3F/^[&T3-87[F8AR?;I!&NOB3),4EPP_2\K#"R
M;;2K-%DV7L1^CTP"7EC^+=7[C%(LR^-0@(@NSM&)X=_*G@=(%$V%/\T/1R-,
MD@] XR"E2NTB2>X#UA;VNU/6 TSN\:\8_T5TJXMGK(^8./I0+\\WND/8Z4IS
M"Q2__@8SB5$7($EBX[S"@T5AC5F*VY/?_:NF''IFY=\6'(B-NSR87[O3]V;2
M,WKTH7*,A_CGV18SL'A96Z191(B71_G)=B!XY7?2EAB6!*WFJ-VU-!AR8*>_
M?H%SD":4%?&2VSJ_QDZ2"4ZC1B6I]):+JP0$DI"+)?V64I_:PG2FY[SB*39M
MWFJ";84 @>/<T]I6R4SQUM$S&Q9I-L)H >_5_A>J_/^&'O_? '8',\5U00R&
ME8-13\^ORW%E9P:=4:PQFEZX_0/+GRWHS%)32ERQ7R55Z\[#Y^77_TTW6@*?
MN0H<"=28;!NS<YZ= $:\&6&Y;;(.:MQ D%_Q#4$$C5)[!9 M>M=R*RO/$5AS
M3RG2$GR#5PA@(EWJLQ9GIL?E8F26R&.A==9TM#JT,4G/K#MWE3#$C(LW'JT9
MHB4!V%1+U,D@^[>4%#/YLFJ16EYGL@6]=%^CN-+8&%FHB!JU,K04A0FX-Y_I
M+#K0FSKXCL5>'*N=_)7BF +G2;/_"X*+?#YQ/744Q;Q1#KT]4#=A?UU*_%3J
M>5P(%(6SM&PPXSH"4FJDZ.K-2=_@LPRT+E'#D'CWEZ84-_ W %O_4TK_]P\M
M*C;9RF$^^ (1V ][K_G&GBV;V-?%FHK+9=P/_H(D9IX?/>Z0.E)+&M7->>/N
M$@T:N"H1)3*PR>E8B1%D[O4 [!R-KLY.CZLY^19QRZ&W3WVYFVDY/J(;O,(4
M#R#^.=W&V-@^]K&GBO#+5D-<VD4,!JCHB %SZ^;77SJ3F[J?(8^]7?TI)YJ6
M<X+$PE+8?5(H_1L G3FD;;FO55%3GV,ZF+@JBH&;Y0?G:BN"[I$D+%&KO>7C
MN_'UILE#A8:OR;873Q.)0<"C6SEQWM7)JK[R5<=TQ+B#+9+EL/C<S/B#W04M
M!1U #G"U77D@$O+?A#VG"^2'-CQ)%W5?L4VLCK.LYEHE5I6FH=E&UP=J9!>+
M[R2SV8F5-/J8/:I(-FE5<,PU<WOFSG9%(B?W3H/KU9)Z?.)?X;SX6\LJSL-Z
M7%BYGV%DL*(&3G1P9W=7),(@H CY(.#F?Q2N<_4:SY'(7B2MN!R><J&3-.3)
MEZ!I)4R.P^4AU&,RZ]6JK7OZ"]*0,"O:[T*?5/[E\TN"&_A.;C' R?'NLY%$
MNF>H$ <5;K/CE=4XP6CM%?4[PTFOK9EJRWKPB _T]&T5,)[ ;:'+2B("QL\A
M>N\JD_']$LMH74P2O!@A:(:/X19<R:GZVG#:*_0P6!:"AH:UU10]X/^,9B#Q
M<Q:^A_T3R-'RQ<\+-2=E/QL9"X9N&H^O6G**MVH$:FR0@<4LSX3WLXV-T!'3
M(&U0V2)R(1B,7(8D4VZ]YTF1<&WL4\N%N"Y_OR'3[J0J>06,3[:FUDB.>R1!
M&=XW T[SE5?E^$Q]41>194SAYNTEWQ >?4&KA"@[V*8&778WU]7:;QB*+8XK
MI(M_=C'+??>];OMTMAJ)E_9!PR%9T4',HS[Z!>^A\(!HB%8H);(%,7V\,+FA
M/,7YPPVG:#)W.2NHZYBZ2U(),'H&ZBW*(?]0%KZB6$C4PI.&R<D%Z.P7OWW8
M7T% ')LDDM)!I<;$K9HS+KB@@8X.).^=#L]/,_L6EB;3HHFOD^YNS><,_<&+
M\EK/:\J#9$L/1-J22:N>+1053RKBJLV_*16B?2TN<G:9AY9K/./5SYBN50_'
M<-B(&A2R9G9W/4F=HCY]-=<$_TO)*U'$85?7^%G*;$5 +W+Q> =X3)NF7N5
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MQQV\/H)QJ@+S74A=:$OZ7777QO_J'>E/F9_,*V8O2 NO'%W](Z:[@BCV6-G
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M '!7:DXP,D(177D<+G=1SF!=.6P>[93V 9!N"#O.1XX?-=XZK7&[Y!:6%-T
MMR]3#(]KDQ#8HAFFJ%":WE1$ %L8^R8D.\]R] --EO<U35G&8CCWFA+=V*BP
M,BX#M7I))(C#$PTN&$-&#U:DQ\K *G;Q]QX/@(T9U@6>*(NY!IJDG]W_ /3/
MK$4,F=FB_[#U[T9&60;X_[8NZA%QH%N4%-"S4EGO[\,;H4',VZJG&)&J.5S>
MC'@ M#[B4N/#H*DO8RGGK&EJKD?H] @GK@T_\@!BM,,3:)'B2<+*VCD</K_A
MGC("F@=EB@NMI_<C?W(7)7ZE4IU;1#O_\3=%WG]2M^I_6]W_5%?S^0$@>O@
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M2ES0/\E.U=B,LVYK\23JZM#**A+X5XJ8(OJOGH'"XOW[&:BD[#\K!\Q3/!8
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M]73[M5:O[8<MC;7Y/?D=+AJ($0#VX((+.)[:>)_<EK:6QM9#S--HO"[LI$C
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M%72OM#?P^\9"]U5>_>#VQ18S)YWWD<VOZQ3'-G2SVI!NGC!KJFR>@5#;-B3
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M0TVY28:IZS/X-ZHK4]#'MW_NG5RW\R;=% J.8O4TX'%=GI\>(W?+CW[;*)?
M)?EBM<2/*_=K[&-H6)$@C0KZ%S>%E=X03W,8I9BB^!M@M=[B:R^1>?;@&HKY
M5]'T("?(JE=:SV8[IP\'-7D_!13)V),N# =W4K)KN3N)?A15[EKOT$P@W7L?
M/#RYZKOPB3[[G4Z/^%2 QBT@(7YWNNVQIW#!]EECY&?=H S>%05Z^*S5F;U>
M4]]#=Y& SS(4JVE05]OS;^D@++"%$6I9('8$J[-O?J?'=0X!:I=N=+\]1?TG
MY3DN<G?V]LME_KLH" ,FVXU#@$3OK,-T9L=9 )T2C1N.6(!RC0R]LD4/O_C*
MZ==45=%<[R0:S",[5O=TKZ0@(G9%6'2=-OF;R1&ZH@F5#FRE-L^V43Z8S>/W
M4E3B:PU8M][L'![I?=QHOP4\=HL]!;4H**>O W?%J_:YP?;%CK:H)@RJ-/B?
M6OHL,+_72J(G!]GYM3Y)XHD^MGE)'LFPO)N0.'W1O:H%>K"WI*Y/GZWS1+QC
MM].W&^#N?!!VI?$3A\Q3$?&^M!#H>DK&%FSJX)"O-_,CFHVVWBSL1?('6BH3
M^LI(7ZRSMW[*RH6>KQ C@9Z2!4"A $-*B,7T\4[3D&#)M >]GS8A94Y2^!N#
MQVWX3&6O5XP7.)?T/7GA>^L-'L4C[XX,EG4BQ1!4VZ;W%VBX I,I;_0#'I@T
M3-9B<^LTVK4;/0(*V2Q&UL1OMSM86X>+%;L<=MK*,9"8 Q4Z26D\*ZO\?ZD[
MG850@+T"/SYF#\$3#V*MUANT$3L])9HHLT@87S(6&V.3[GB %Z3U?:\9#&#=
MNB&=JKG6ZR8[CC, .KH9HNMYB??5.-6[ORSZ7)WN2)<=JQ6HILU!8STX:?1P
MUHVQW>6& 'X:ZEX(5"^JU+9E5_RA&5-%^",(9K-.2&+$RH^+?<\W5L@."^G2
MV^%-/7%L(\1.V].#5A<HE/8U$S-](TK948+"J/L@C%CL7EQGHU> SB3O8!'K
M2OW-4,.D=&/O$[F#4Y##^FMO%3Z_^@7M"@S_02"86,2U:-E-5DF((<5XKOMD
MSW];*+)F+8<_#C.6?LN<B3XLXFL!2#YU_\WQQQ,C(C=&643-9Z+&[N+AVB.,
M+\^"W%G7_50>XE!45C7R/2+51$<+.QP)S<"Q+;]2@!\H5L+OYA7>4G3YYF2/
M%AE*IUPX>I#<Y/GA(FLGU[<@ <:UG_C>NH"LHBL)Q,L=OF3VD&91:*GEU@UK
MU<2SJ9="/2*;*PFDF75>:\\T8OS>M+V8D_DY0T*&$T6'5*3ZEND&5O+K/E$F
MLR*J[8#(US<'#3_?6_DT:\,JX2Z$4O/:M[[2^ %.-6@9O9D5ID I-GXX=_VT
MLI[?_CI:LZG&49#F?!CQNI0^B71IM:*_?74]L.X[]7W=V44]UH0\V@6#LLSQ
MD=)E!1Y7IH=/NIG?&+YX2$\LHR:#PGC/1Y"5';81=2)\\'"K]]6$-;EV:TN%
MEZQJ;7/U^T.3V%=I+'FO/JG&O]T#<J?UIT>K*2/$>VLY060V/1GF#EYY5ENF
MCN7 C])#>U5Z+87U\MZ=%#TN=ND"LYI2D=!#68+E_\'^.U94@$;Y?@6>UMI1
M7I>XC%=OL65\-= 9-C,)=DTF)9)]W]__7G"$!V4CG129?+;$>S/:=F>.BMVN
M&"Z2=^;,/H07C0OZ)+!695JJB-UY840?'J+%?'B.-$'D=-WP3?$D,8PM>7%K
M3JRVO(V6G&21]M_3"F-HJJ=2[+/7D<I4DJ#!=;MS]/V7",<\%4'EVK.+\W?/
MH\TDT'2R++"QO9H]\13,/<!D3^*76C=TUE!TQ0\O[VS%T_MR_,6NE)4Q-(M/
M?"Y1&8C/N?:N#HCI )[GU5=!%X87P!AJ8&EJ^[U=["#SHM)<5UE9&]KMGO4)
M%HW)YK+^#V'VK=;::AZ88<<7ZU>,\",I^-O8_GQIEXE^LBZ+MDDV=G.\,I>>
M<I&H 9]8%S]T4>;<WW:58Y.O: 6:(]HZ;@%XEA4 "#]?;Y^:/9GTTQAOEDQO
MWO-0>G8[YEXF'K4<&\L97(U@-&I/R(YY+V>TB^HOE,DY9*5@-Q&$P'A;#VGF
M=\2.*U5,J/<S]@Q/Z%WJ6R,YH\']N$(?=Z;/G3H^N%"H-8X_)?;CJBU2P*75
M*BNL@WF8:<A5MI-'J]S N[^-@-66BA<.6_B:^NA=:]WCI15'__.P\!M2+5CT
M]>/RNY!VNNW*I4WI9F;P+K"^\CY"\,>LA\YO'UY&,V2WF/ZZ+O'Z\<@?UT4C
MS8W"C(Z9Q6_0=>_B[3GP/"GXZD[CI<!K_V3PJ$CK2O]FN?8M($@#>>?RO;R+
MR7\ZW\F@S/E'/GL1;3?@W@/)_P?([H+;("UD7BJX@VD920FZ!?1:_MF9Q]0S
M@@77J(/[(MEA)__8=^+0>.\7X-&26\"_I$K__ZG^/94RTAP<)A4'U;P%?-\Q
MNA&6/>TQN@6(KYQEWK0/B6]2&3FL$6B5@#N9KM1N 5DZMP"X$.06$#5V"\ L
M1BC<!%K\:SH,28%R'>JJ\FZ6(^A[JEN 7>TM8"5^#&ET*HWHG:>-4Q_/D4RG
MX^<DH-J5>A*=6?9&QBMQ-'_;0YIQULI.-MCQ==7:*;X172*<*I&W-=P&5P:X
MG]K8D[F:0/.<:A4E>J!-0@0]LR[(DSQG*Q9G66\^NS\JI6_0.Q>2X<F,?&3S
M<Z?PQ,#0J6V*;IT^4CG^T0GI6LHRP$.K8H\RTILRHDN!T- YKSEM9).*O'\C
M86R]* ?X]%A5VH':ZJ_ 'BD<'?%E7MX_?OXE_D?Z3]A+=MRU&5C]*O+._QU%
MY4[_?%)&#5V^8F#8T?U5T6EW#WU.?/2-A]BZDO<!_'K!]KQQO2EB@C-/?:[[
M];3 GND*H\^5:-%(@54K'WP]J5"OMK_4CE>;-H$[ AJ?BOO1W@N4/7&RQZ\Y
M_FZ*I09#;XA+[FJRN2[)+' B(U5 ^#7<?5B@G'YZ. ]X*:^_8/G1*SWK*[__
M)R*LEXB]=\[$7:E]GU[+H%*%.$Z$Y1'[KR.]?N;!C4XU(.'L(M)>[D56<]Y!
MH_.Y?(<-P 0\GLJOW0TKT?<[<7>_.Z.04VU6V:ITWE=^*4@XS-B-@]Y_]^::
M%(0=\T_7G8-GBPL[;%W!K@.+36(SY1F\=F3;.Y><VT)*A6=SF@70%B7(2TCN
MI^^-09U[>*C,/-;?B6J<GWT*Z;?F[/;"HPZX$BQT4X)(!RM5QG7N4( MJGV)
M^_#*R+A\W0#&QM%OP@ _;@&!LW!XZ2 .%=*XM/SB]&:FKLN(;SECX]R=QG%A
M7.?*&NE1R#HXASSHY']A0YKN$JY=9\?$\3+16GR@P9Q4Q,QW02MN>^")]'6!
M2YF8//?\C3&"[$",HA]F(]5QH0VIIB0;40Z7D@0YF'J?Q7XC&37Q;R=.C-^P
M.A@I[/V!,F=Y(P0_"ZE..C%@-!P_$66Z-\AZDK;ZH2-0@IZ[B(GCH4AR>*<X
MGB?KBGQ>>.<-_=C)K EY7O2;MC!H#E4)7A3S^D$PP_3AQ*GKV,EX!CQRP;+N
M2;N-^)7'@I5JB<Q]>V]-<YGX&(JK3AJS]ZV9]:-.ERUJ@VKITR_8=^O"07YB
M;OX17'[">#ZR%9F/3A3?][Z<V&B;/& ]WB%W: 05-V@^OY/R0P*U0'WIJYM=
M#QEU1(GN4>?%<$:9+O.YC4.!@:P#B<F5<,RG#*L-L>=(JLL>S0NLGC3>K)8Q
M7MY)6/5D#CO(:9 B!/^-^>=H[@\56#7Q2A.&!@C'[B7&21'*E1$<(\M&NR 1
MN60>+<5"[06Q+#O7]^,\[SD9YMWQ.NU(S&GNR0TK KR(,P9B*@&(Y,-%_AXJ
M_DK$7F_ R4,1\<(A*G^&/) [:&,.H^C5U[ J.E+/0+1X :!\S[[8FH6;%JRL
M#8':V8K_K=9?8?Q*JAR8*)0Z;O#RC*\6T<GC\!F/)60<WUPU;?O!HXW 3!R=
MRJE27KDE!>9"=KHHF<"E1ZB!S@+F]$[&;C3'Q?%'Q($G8+R[&> %0Q;T&'Z=
M%I0"BY1A-5#*H*^0!%YGT8J,TG_HK3&EYIOX5&TO(WAZ@+D]=U,*B_PH7U;=
MT,R.6MJ:L:K;J"^2]79 5UGPTY@\<T<1"PDNG_EW8@-DTT\PQG8<L'$DXDHT
M=YMC[^@N?)5[FB#ZG7 AXF>$W\.1PI-2(RQD[TM$?-R2)=ET6IDN?;JZ/K!.
M=4&FW.=UPDL) ;JHYK"CZ#E^A>H:I*.#B#WMD',Y\,EK9+\K<6T?.?RM*E)C
M4;TK>?&LBQT/:='>*S/!;LW*6J-P66JXI/?)D;Y]16X*7^ZJ^5GC^INZ)1)]
M?PFJ@K<;4ZPVMJQW 500>4ILQT.S&.8!"?H]M-6?F(BY9M/V-M(K P2CVJB-
M4XOPJ]'2&J][BAIL^TL@2)CV6A2C.OZY1-FI,2?C#XY9:B>8W@Y98I@8C:?H
M],&Q**N("="Y;/-0O^.-BD&*6ZYT5Y/AJ\ ,ASG7SRP+G!0^7D0D%^H[&P=H
M5W((T9X,^)GBV#$.!M)[H@M539.#I90R=[2Z*Z!.Q3>1J4S/C4T!D\%5?;_U
M;D"_J:@;+[<I&0FE1]Q?#X',N22Z>P 4W*XFA&8[AKCQ'[.U,Z(EL/N& <ZV
MUSWE$<P=WIA-09 NL>=C3LQ)<3^B*!54PF87/\BL:1G+]=%M,Q5T+!-NW[#!
MFPQ!0AXSR]*.O/5 %EN6A#7"BCB6)[[T5CO^-=_\/R7L:&?@D?!W4P>:5DS:
M-=X"( &3*#-N=KU45(A4KD'HM8<"Y%V +WVRS:KKXZ2MV B'C(\+Y<3(^/QV
M<\0$-"$OIRL&-#'H3I1'+ZR1-S[]P(+;]7G5N;#\YM VL)&Z1]1. QF7;\FQ
ML/4Q/;%49U$1Z&Z>MR1+6-P3-B ]6!?O%L!_537ST1XE$\=BP:NEZ.3HH./:
MH\N;$*F4^+$\U(G.H=!*J\B<OE%C<'#=*W]M]7I\@7M1D$DN4J2*@$^G%I+E
M283T+;R2@I<NKA?;4+:<).0Y%LC!YQ6MXLX5?6F"[):D8V14#R718P4S<22R
MZTNE8.OA^48+.H,F,(N$1V3\(/#C[3B9UZGX90EK^A\)Z:FFIH 7?E::?&?V
MN<4$B)*O=;C-7(!.&BX!S()T*8"L@P31YO\J'$3Q3SC(OP:RHMDU6@F#_\@4
MW5G/29=;P!\9($#"W?D'>P3W4?.$?M]T93MG4%W]'VN%_+.$D[QJYQ\HDO^@
M&TJ3UQ;0,O->2L7'=VF_VV]^X^-NH7^X@T>W@*GRRYT[M^>Q]QA$\"+9YN]X
M7.9D"7[+#9&-Z81$&W)+%'$R<3*#:IOL[XPKLBL*M9'5VFA7EE? 7P41 !F1
MU)%L<WQCQD\0.8B\>9DYEGO>O"2W /V%6\##F_=Y\ZJ%UY>_]IAE?Q?_^Q4\
MWCQ-EO/2/LH]T3V_1%0\0HXAQ_=R;(C^J3 KP3MEJ0MOG-GFPGYZ[U[+'F5_
ME_\;17U>7C>YY2%*GN3.2 TK*TG^O3^1-G\<*)BB9K< S\FI/WXG_WKR/UQ(
M\ ?L7O=7!;MKY4->5H!L79MX:('#$)OH9C>'(,D- =)%G$H\(H%5Z@:?.+H?
MY%]L\.6'*;WLZGFKYG=YFR:7_0W2]=*"SKV[^^B'?:];GO_PDC59JDC_RQL)
M"L88L\/*?H'9LU#; MX!'613]PABZ:CCFZ%E*73&J?#$_/!X-F&W)+8?O\N,
M_SX7*2KQX3DIN:QN@>D*.^6BIQHB,7@E1;*I8FS7YH#UJ8&894%\F0@47R0?
M^AF-$^O'DW4TJ%:8A'.R;$<&EF7ZL^F:'1"HGY<5*-(B678B7/REC+B"HY].
MUD=,HR/RZ^N(>])OQV\>(66E[5ELV/>L?:V!#MMG_LKMVVUF1YZ1&;O6\WL:
MGIRPMB<Z5Z\2.PSI$^4GEPQXMA,@%XHEM4V$YMIS@K3NYJN)]_7%!4RJ31D@
MT37L9%NCVV1!OFS!H(*MTS9+RQ,0T)P_(BMI4IZB>/6Y!JJ[O. [%X0?BL(-
MZ5&[H5(+\>R)/U533WY!EV[HI1:*-_@XREN%^'JL;A]A0)C1V4*N##>&E[:=
M!GSDZEW]BJ6V.5R4T?@M260470(5+K#5[7#GV^,W*Z[T9_FWP[<^ZE=N)GP<
M&@39R]N3[FO,,1O3Q7(%/!S>PMXU,\&B]Q9')(:+W+=8H<8N"\[=VE!0?*D@
M^NZ1A7ONXR$60^L/!;'$MHMK%+'R3)Q^*.,SGL1PEXR?@7"_+59'Z,P,CZ86
MQ''1G1ZENNNP2<3#GF^7#KAJ/'6 ?<4_YLEN'S='J;0M=QZRG=RRE+5&0?CC
M'4QKQEYN8,5/UE$?$B("@H4O![NTLL,O-R\,*L?5-4"B[Y9TEMZ-N:?+',=R
MXEU^I<8WJUL@.6\:0E>KG^(1%3O='JJ^; IW6TL>&E[WG47E,?OY(7=%@%+H
M,: 49H>^U<I6';:LJI>UVK_>RQN_.^W8,T/'S,(6U8#FAVH\;8Q4ASI"%[5>
M)2J"BBDU1)K.FAJ2/<)C'A#T"S?$AT4W=E>UA)35A@%6RL3PD59'*F,UCTH/
M<B=YONC.S>W5*)0+9K_''/MQ8[LU&H]NG==KI/ZVQ/L^DE]Q_+@)0P]CYNGX
MNOLNO8'NT4@-&\ IRH[_A_8\*F?0C$=1V448X*<X]/[X%6&.E9!6L(BHHZ-=
M^<* +13TC;6TZ0U)/W,O3Z>U6;H:7EQ&TV14>:<W924\(_CXFEPIO*^RTI<5
MJE1@58C*V+ 2MS"=L/Q1%[!VY0Z?D$#&F]I9P![:L=G8K.F,,]O(K(^ZATDQ
M\\?1VC(-D%@(T-&E6]76P:,[J9XV5C2UU#3S3VMV# C/\ H7LAEB;@PDO/UD
M:,886T6$%JM,#S&7!KAEA(A1#Q5[VL!7BZ"BFI".1J5(M@SL@MQMAQEINZ>Q
MC-)O@Z ,G(&1,64_+.P&9.EJ(-Z82*TN_F2#J>[:+"!;(E[0X"6[5G.%GK/@
M@H9Q/. =B=],/SIIMTN>9($*>HKE+>#;B!\/^2+M]L"\=I0BP_OT;J,NW8A/
M\TWX^E]YVXU26.M-,4G\8Q2-FI",/R^W:@3S)O:;%U]>.\N;1:LU1N8T/=8:
M"2CQ[_N06V192T2"3O-XOS#S,1E;N%WF5L7,O+PS/4<$LZ'!H/.+U8QD'9VT
M:,98Y0(3[58.)"C+;7OG3>-4HLJE4O(X;^XT6>E4>)>!2\.#1RJQ6E$>^$)/
MTO/# .O-W/"-SILGL?MZ&()FC<V2E-WK6<Z\>S_ZN . !:XQA0OV>15<;B4V
MU#^-_)W(2XG6.Y6;_;P(OVP=@JT6*^LT 3Q27!D+:3EGLIPGY^Z\RZIW$]W5
M"^J'& 3540.G2P_+Y]7K]+PT]^E ]O-G//?-'Q"*F:[1,14X]*W7>CZ#WP)>
MPME/0T;WZ"NC51KX'3M/D\S"AQA9^LDKM0_=G][S<^<=^[7B+J1:8<&S_;L%
M*TR\$2._'KL:4E!E_Z/>UF]V])^6<$CY<_E<];=:&07G8;$^1&&OGZ-8YF;_
MD\:#OVPN59_/RI?\W<IF/OKGE_^]\:M ANKO*,2*?T0AOC@&5*NI2F!(/R/X
MKS10*/]NC0L++OU_+R4O_V_)_M83L3G4?ZN5\>)YYOWLV## /VG\42Y#;=+U
M#UA<PK^YM[O&O><?^V_.B[Z2@-<*+J=8 :P$GU7NC<E+_Y.&[#\F#'[7' 7Z
ML:US&7GG+UGJ12IW+6/%:<,'-L>V$N:B2JDRG!^_B5-X\5EFO#JLI(P -^7;
M),J0!CPZZ$0Y"/SDRJ,0Z0K5Z$[P]3(%87W6U=M*J!@1;<N(JU!Z'"HR.?<C
M$W&$8GA>U_*<)!.'"VG!]^VZU-FQ#"FL/W&2)D]8[AQ^;HU5/YL6(Q.S^'J'
M;-\FQ^Y9TI?]=PIBC/H[<STER=173W67ZJ#<)!ZS///A]R\]\,7'1M*<R5E,
MD<CSF_V7^XO;)*>Y<\]1^Z\R""R]!=H0,FE0C,%Y,"[0I78<V+,_+1PIMOX@
M$:1XN<S2,_A\\-4AURX4&T0$QD:&=[:2PP]\S>!!Y3!V+.TM1'Z!<ZZR"=FV
MV@H[T>Q^MEE +6S%UNBI]_[>TD;U1S4;ZN \@+MK%&M*SYQY3= W>((R[OP0
M<9(=51Y;^I;Y"\SZ+TFAD<%GF4=R%%%N9770MB"V*_*?HNA2;9-F4^4LK'1U
MR8?OWW-513Q)$.PU2;>_[U2?0QT($/KW#_B?-/Z*NGP+^N_[Q8]P13M6P2@W
M[S)6&=NNCX'D?]NY@G?^Z. 6X$4F$G!V"VB-_#5(?KO$\O#)\LT%[]W@H(Y)
MOP6<C>7T*8,O-R<_JZ!YO_2X!2S+1#\5O04<Y-P-\?\^CR<2*<I&EYL33P,Q
M.=.]-V_HMM3K_KJQ@_@WYF._45G]JA[U.V_9WT47W4T65[_SIOI=]ET_T/W&
MG,?]=]&_2KW]3_.(O&<C[E%P%OD[5/D>B8D4@<7Z90XR4OQWECA_J)G[?U:-
M_[T\2D68Z*@]#LH1U >/$W_C-ZX/+J8^*+\)8-+]OZNE#(VR:/#0F2R"6EWS
M+Q&=!,;_@9'VKWADIQ/B4;=,@O%.BGFQ>B]R3JB'?2C_+\K_.P_"K$"P^UGK
MV=UX^_UEK#B)NSY2_S\D[3_ST(PE.*+;F;P%X!WSLO].G_N'.?A/TX$P3T/F
M _?_&S/$_]=Y)%%8)6+Y7M&U-11M_V4(XX_]BY#U";BWXQ90#_Y29/77I,3H
M/RLW^NNX]]>-;KE_34L _E65TO_1#,2_.^XQ__W#."K#RTT48+)?3DXNIB7*
MI-K[L-_ _MMW?_E5&^\LD.*D[9VSDM(T'KD<>6>];+?U1^_]/3V3]S<O\%^K
M_B?XW^H/;T?BR;^(_?\7$P5T'QYF/IPZ<Z*)M@)#]94[VX)1O_.33>:\S5 A
MB^Q-Q]>87SM4+O_1*U)'^AW69)YO^EK]\Y/D;R(KFL@AA@S$O9WV.T<9055:
M+/F^T0<D6Z&=5\=FBL^LX!1,WDXNA]4NT,M+'0BVQ,%&-FF/5:?HB1IB*:@F
M;"^6[I>0<5KPUML)D>;V1\@U.5221C,Y5/NYM8",QGE'YH)6I"H1$1_9RI:(
MB;(5Q3RT&J,<7,PX I+HU2X)*M4"_:X6[*W:PH_!Z&XX,/:.D8?Y5<FF^LI%
M(O,G[$P7ZPI?2#%+&: T[F8+69/^30$T/]&LO;#J+[S?VHHV[!EQSUV]F?#D
MST1&=UP4A)27YWY#&/3$81B"]D#/JK&>*#Q>-,)_'\4UL%UEUO#T[9.^DDCT
MWMA%3_'83BW$=$;!2!XR^7 81&G4!>%39JW7XIAOS<:SQ?63*JZZMYTB1^LC
M5KX,F7FKY1IN#N+M\I.1,P62FH3F?0",#(1A<*X$ N+F6N6F/6U@HJ]/EWHN
M5<7POL5)U<9)I71Y<]:/1Z</T38O6>E5-!MWT%6]$S,H&#R?:RV=6$V&O*KS
M4K/4A0D[@XH#:*2;V8>_IYHXQAUG8MX"'B'GYGNPBO-J2J=*D@UVM)42Y;YZ
M=K]RK,-TFZ<]:=_I-MVA)B2614;FN0DV<Y?J+UJI-I]>!#! =O.?GS[23T@5
M>&BF'YD2Y:TRU>^)BN@-%E&$X83 M\CV4XI^W- F;-'5-,GK9''H97X&**E4
M,)'8RWWG_820ZA4C&[_SBY4?Z1JYU2F/LMD<L^H*%L0>/ES]!O3^86JWM$88
MHC9 8;S'B/88</;MZ494ZC1K;\1QD[ [0U,"2&#ZG&>*7_/;*_.T154BCCY,
MGV\^E%P%<>G88D#X2.3>W@T9$J,7WU.RM;$QN*LHWPH"(1L#&3W=9]!4"*E[
M^';7S'A-"J".1J/"9.@6+H$H\#]8UD3L];19Y+C=S'L74]6MD5C/R?DIT,WS
M./12:9R*$;[U>UML-HH^3731Q:\;N1C[['LRQ.++N)[<I]J?<K-TSW6$'"MJ
M)WSL@<GK+>;0%JHCC<E]_/&.889D]PQZ6M]-%,89E+COJ RM3C7(RBRDLBXR
MOJ NRDY$.E_[%O!>%D@&XI1GS55:TL]HV:Z4&9>I>C.?"UA+K<7Z &D<0/I#
M1WJ4L;=U%X[FMA!ZVT1$*DB_'=4$YO>A.FMZ2?<4>!OHJ;_PF&8D!4O@E+;5
MTMQ,&H@\ZTTWOI2Y!50-KNX-<Z[OS3;1>Z;4F:::)M>M>\Z0\!Z>MB!0/+EA
M0^ W</2H=<2S3C<AV([,N/GT$S7SY@7*-WJSN<E2),![?>,4]X@?!1;6C!#K
MZ'V_B/83H]WN?>GU^-#&5:5QZF:ZT6L@Y&9 0?\\W$8DEEMVM5!-4D"#*=]'
MK&#!?4NY/,63#M;$ROT6R5U6$,G.MN>I:OXL*O-LKG-!UT ?PVPFBS("R!'O
MXNFK\R5F/E3P@O8"]&5WGVSXN2W;-!]'MT@^O6N/ADY'I8JR&F$(Q<_C3 R-
MCBLI9*$8E14996XZZ71-^5YX?%5MB@)?D]AH>]([.R&WOF>JPPYU40VP#),2
MSU>Q%XMV(NQ0-Y8Y#9VU.@3KCRI:"\R!H'8I7*%[ X]6Z$K=E_<D88KDRLU(
MAP)#Y-?E3OZ"KNDS(\O+5WA#:,R8VQ;WS,T>D_@FJ#4([$A0^:[8A;7! ]U2
M.B_HD*:Z4P40>DL;AHFA@OAU)NY&_B0AKOA7[QEM%YSH$;HNMP!<EK)FJU92
M/87- ]UQ4'>RI4A]$FW\.VO;I]$_5M!MQP7124;"/%\U5\&I>XP"J>$QG@KU
M4X^WB;EJ:AO8TM _D<\JA;(]K0OUL>@P#U53$H)H@%<.,,OW1/. I3!*%J-\
M7P>SZ5)WZB]U.(ZH],*.-Y6?\8D/<+DC5-"+D.%&5)039+NS"]OXB=K9W[X]
M-D^6H6$J.]4XF H!W),'/-$O;>N)I #J+@[GF119:LWQQ'2[YAEU!6TX=6'8
MIZLWRJ]7SN61^'WW]\/F][19B22&C@3M.[>X7)"3D]AGY<?C]FT$2K-)+"BC
MTF/GQJ#P0C_VU&2[^4M.BJ@7N(7+(]B:>5L8M:=*KL0]$WL&.I9@(C)$M-T!
M5F8QK<M)X>D/1@&B[WIAURWCVPD32 _=2DCU$<#K@9-OV=H3?%K+609+'>WB
MR*7WQ*:VS&$U69XJ_OK^.M&7.-I5T]6)D6Q.PE],+S7OS-?;M[F13YA_0KM2
M9*87M("]C_B[RC& -P((G"[NDME!J((BT81"]-NZAHCYQ86D=4?,#[8/=QLD
MSRKRU1[I\^K"^:.:28IA1O@+R&6)#*W)".5"A;QME06IO([B*C0+M*]?;=^9
MV1.F]4-="@'[S<0([.4>K>06?Z!N0G#Q%I=,8K)M$<6[5_ALR!D1)41CQ0C3
M!AJN/:BDG!3)!5%S6^EV!-[0B''#2U?Y("]@S"$_CQB:.NFZ8MO)9%FL0DGO
M:SW6]I$?%DW^>Y&GT#^@[9,U^/]UX/K;&HP_':3\1041ET,>O%[Z=OE7GP:*
M1'UI*' \J?/(0YN8$YZ7B\/!738*W6+TDSS?<N?G,=!?.+#/8QC[R0Z(5*;+
M>FJ9%QD82)G3)]AWBW9$E#C*F:K? NX]GKDJ_OC90D8_;OEJ^+7 5XVMQNI3
MK2N,2:UDI 7,I0XVQ'!ZTRE98U[S+A(S<;>LZ[DU^WYEGVA?Z<']JY??$-Z^
M8@45,Z5-A&GOZ1[YD ON<\CREKYY9N6Z'C7\HR/*/*@,EL4>RM=HP#I<%;;A
M9(1OX.:;U?BM\NTX_?!\2NAKN95O]!Y*DG>&HZC7:EU$'B&K,^XIZ5&@[::Y
MHQ$V\S4E1.%GK&]EEQGVPP-U92S-DE3:&D.@M[GFC^<J^5^'FOC-<UQ%&<)@
M,&28]17U=4/)5B*9?DH8!B/:P%#J<U*,V(_'1:Q7#HX6Y3-;NL/I"?A6#W6G
MM2V.5$,N^[J^0H,IN01W9*>^[N1#KOBI(? +C_EYQ-QUF0N!JO2'=)]_5^V,
M8CE,[)FE&-XDZ_'E97A1#7G(C[$98"TQ\1D#A[T9IUY._1M$O0]WCZ-\T94B
M?#T:>CQ=SOO,KSW'7=+2C"O@)='+=QC-UN\(J]I>" B(:#*&B)![.*R$M^$A
M3;MJY\3JISEFE^>MB,"V=6ZJJVY?>JJZ-F?=)9Y^MSX6&+)OY4$$Y<%N ;.)
M/75SDYJ<BZ_J^-[M*+ZS8=<4K&5!V-('>MKS\[^QY4'9NN%#ED(/@JNV*G=B
MMW%K\Y[[07:3%1=G$M1393 Y!;#MY:2.<!^A^JN[R<+>^ZYX[%Q2<JU#G<D!
MD8XFA=H+V@M=Y6D1[]+P3E,I.$@$=O2->DO;$#;>EM.F*UCB \ '[LSL2I);
M,RYET1WB.&Q.R\165"R0&DOG<GS#.=F"DEJ7]^/3&):SJ;(4,O+DSV:^<0N;
MK9!0J#QPWM@C_>DEIJAA:^L<[CR>BV<TQ!CL_!0K!_?AD=FEV"0:5ZT\*@AU
M-.Q806_3KM2DL39!.!P8(T\PQF'F3$-H3N?WD&;5P8@#V7JI->%,'7$TW_,>
M/F@%EX8]JXE(01Z?31CK,-0*SC=R*.!J5#55^@G.0D1<8<(C^,I0<+#*MI3"
MN!,Y<POUY7TG2-"6F19>=<^AAD4="A[8'M5KMU6. .78<)M?Z]/FQ[,0;SI0
M*^UX2I<ZDE]CE*$N\GB>Q"8?*#4O_2)6E<=6E_: ECU!_5KG/'2K'TG7>PO
M]W0OEOH*K&W\K!E9;*!M(.F,G3IGD,K9_"EH[EMX)Y=-Y!<^5/SO3'XD "]L
MHS:K('(D6WY]&"DL6<$5[T=EO>D30JP:G\L"T(OVW>^0D0OJ<$_G(D_1L68M
MZO"<UFF9YCGK1A8^HBV+CQEVEJ0X T=T)>[V'6_NOZF*(8W2:*W\>L4[X?T4
M-'W#W-P894?2F__:^2&K[ES?F]-/_2Z7M#(+(3]RV.B@"B\$Z5&WAGKB'([+
M4UMIW'9ZJ7'VFKT*MEJ9#8!.8!SILO;B[60G=GIL76F^H=6'V<\ZT%^JQ/";
M\1/NIY-63%K;E.FI3=-/Z[HW;R;MK83W17R]V;1&92+A1%NKF*'_%(O2\*\B
M+T?=X*Y25'E$;0J4>;[!IF91GG(W*V'8.6SEW;Y]G/7A;+P[$SF=J)"6PI\Y
MI>;HE6@_"\34:0:HX'7MTM/*B;(34:J?MX!!YAG&:K?HT=0<8R^(B03E<F0K
MK:4XMM.EPC*N84TN?Z+#S#P+W^&"@LA!VJ=<!V;ARO;O@.GKEN\-02]4N'+#
M*#V[GL_0B10!_*.ZS%S+DZX45QZVLKOQ=]P(@G18;(PA3GK"((\ ,\YAN[W(
ME0\/[+>?HD^3/NRSVO:47!DA!IY1D^QE(Q[$$RX'[]H<')?S*W=(DG>S! B1
M\@NG9;DFS-??P_V0BSJU=^6898"LW>C$M4J8V#FMA6W#.H@7Z?%B,XE[,=(&
M)$1B/CQ@&G=+D8]5Y..=8DE65"3=?:O_E-_J*VGRTXS4^X+"CKV\T(OJ.MV-
M,)%S9]*2LGUO\N;Q)8E/^YI<.=SWS<PV,J";;KTD%IV7T81(W1$H=C0(UEZX
M>3$=M;>V+>3)!N^G#&NVHF)G=V)R2:L_PL8V%R0!7."V>4^%0L4I+ V%OC4T
MPV^*[(IGYQ=X2Q*)(EO9.258""_X^+%E9'EAR=3AS7?#4&S,4^.W80BN2U&,
MD_'K6!)66+UTE.B3@211FM[O?,1!B&).PTV1).)<ZJ9[^7:\VK(\_F2$<ILH
MU@!8;&5KBF$;BQ:R*/2=_CTJU?M='Z2:@P2UTKYX(,T[18=E#%L190=H A5+
M;7W=9$YCLD R7 \CE/7,>VN-:'_LT6.X"P4^=^#P ^(N1;VNVEO $Y$GV<"Y
M8UV9R%+65?40:S6%<BX!TLZ26"+)Z,^!A\./5Q/0+0''UXN7[^,<8*TV3<C*
M%2R^N?G.-IO6:?:,[L3&)R RKY8(UR$T%?<QWXTO>Z^&8AK,VS6L&6#,KB\1
MKEVLXCUB:.-7BB[)7NE%SH7S7@D7T_-[$ 4"97I\!7K\9HE/=<RXABJI/BX^
M.,Z+T]'<R>?+-T3B4>+0QPHK,-87!R:(KH^8$-RM'+/3(7>*Q[0/C.*"6#Z8
MT9O=$YK>L4JG;T*LE_X,;?9PSN[/!7)NVUN]ZQFRF!29+>AW=IOCQF3Z]/1P
MZI%U;&<FX 0#3&FIY<W2 .\B2VN^N"ZM;ZR?@-F,2Y'.^R$O<_?U4?TD1UXO
M+"(A@RI7FA Z7Q&P6!+YSI@G?_VDV$"E0."J7AZM8M("G0!.Q(;)CD'$$CO"
M(K!FCP^+L4L<7I$U78UQK?30UJ0VU#B90#8P5DZ#T/A3JFPH!L7*QL]1](:[
MA_1VO*88ZV./\"+7Z;SJMY@*A7 =3>V9(J89<WH*7,ECFE]%_H*3@R.;W<NV
M+LK25A3=-KF K X?DGN#]_9* R]W#W.B.63IIY%<G(>KX@ZR:4=J2'Z881NL
M5/S['$-1.26C"F2O1M!\NM0F2S86!/()17O$U&P2QLV)63;_3FQ/@NJLB1*$
M?=9+1I0!BQ3N="7+:P1=!-CQUJ8U<<N3!3T[C8#:EQY1W'OK.^2.TUU.!O+&
MA-_DF1:XU6FW0(XIV2]E8!YZ6**26D#/(K8Y^T_G%H/,M5C1\?0X29JU)XJO
MO4"]1O=KR .BA%/JV6V?R87.E9P^#:'LZ\_$,?F5_VF^!6Q#?D\ B=0-QODP
M8;V$"2OPIUMHPR*"71T# 12QRJ-:&V>]T7-2.LCX$@/@A<;"'#APY7W4<Y-W
MD4Y"=C'^L=A<Q/F<GY)/JTKR6T%:LQ,N"BZ>P^X9)H="3'D:[J*QVU[]19Y*
M\*!(_G@P+(UJ0']EL+XMC/N<B%#KAIC?![SI C^[P7IZ"X 5'^[< B#(BS&D
MUE+9XQP;D'@#=<)@5X3T<6?O@<4V^Q6;$0 \N@>]!5R1W;E9W:JW (S$[]3'
MPF[@6\"#&#!"X]Q16OR$+?KJ!OR!^.I5A/(UZB]"_O\2(?6V ?7YU<TJ-0*?
M4_P8A[HEHW 9WN")<@N0J@N^!<"!Z+< 0ME_9*6U-D0 +G(";QQ=QH"[Y+KN
M^E+$^]0[.SJB]8XR:[YS&<GC?PL(*TYH>R+RM)"#:.G%V#Y.KA:"_]#JJKS(
MIFS]VQ<%M-(G48&*YNI^*X.7C<,WEO5NT2%M;<&:)Q8[&J6[Q#&A-AM1;BDQ
M" YC,%,J9".CHRTLN39)?([GLK>Z)<2?QPKLRD&]I!2@-;^,Y>F%T\6.V5TH
MDTW^V93P!V!C, 9S95,2S8/L:H,XH,BOF(E7L_":_]E(H05N,S&S\#]SY<OH
MMN7_E3//1!Y](OO7C\C>L_HW'QEX&ER2<9"<G/7[S[_^%L&?N6C5/W'HF0_>
MI3YX89GY8)<J5[6N5NXWG#<'H(_ FCI2* Q@V]YK-.R75?0+; Z+S/Z%3;?\
M'0P^]WSN-PCZ8[Z(C8SAWTYDTA#\ H??)Y?^1;G<$<T"SEC[A6$GP$Y5K<:+
MFOQU%I!C?$?^J#;A+SG2_Z&5;;T_EM=$R@<<MQ3_^/X#P>EEOJ]H]%.D"B>"
MO*<9/-A^"QB+-OS&>%%[W+X"+^>#%_A[*D*C\4')R9WY^I$R!C"^YD]\GC]F
M1F(=SXH+ZZ*[9"]?KEM:OQJG=VBWKE,CZ<$P#W=W1]NG,$6"IGL%IDM'2)EU
MO.6I!>._UGMRYPG9GB4J)5H?&?DS%_,'.7\Y_E*J^[[1V'!?4Y*ZCR^&4,D[
M5<UMN5,6.M(Q/9%9SSU4:%#8D$+N:J\'<"&1X#PY*2N'VOF=C*#V.H/<6!AJ
MZQ.'N-J%#]2K,>]S^GQT7F#.0_0&P!")P1L39G'][Y_FQ+L__PGW3F_M@CCK
M6]-%?5 Z7HCS=A&9(S677ZN-M?H:+B^6^'%^$NJ,!>IJ?8B@#IY>WR<O953Y
MQ-J=JH*FC0V8(Q<4&/Z@+ )GZ@T]!E/TEH"(D^]WE^;E5K%DZ8$4./%H$?%T
MU.P?F V-T+=;:5K'\B&&0[3C(U]"K?9O/.NIN<UE1A\."UY,Q[>4A^[.;<_(
M%RSHB409-R;KB,S$A])PV72N"%QV^C"G00+TS0F)F746+>^F/+I\ :$JM8#S
M2=M4ZQ/#O8R!C91MLH1*A!0T0NO3/,M<>IHGF1S4T'RN1>*D\_A4H/<U.+0F
MY8#0+>5[UQ;_1^OL#8>H+1?!N;%$&@MA>QQ&TO46=FEX']PN>+I7+DPX]/.!
M.#"FA][Q+.D+L^GA[@N>-LR^N2-0\N=0L:PU=Q597#&-1BHY_1/&)NI,@(/6
MR9S*YU2Z_3);H^3*U*IF:;EN);ND0T>7,X,#[XTW;4Y>+RRSFU%W7_YW]B]^
M1Q!W+F.X=>PO[1C"AZ-+#>9]GJ:H583!Y'P$470F/_DI2RU,MM+"V8.N3,QM
M+,K<P K3>ZPIGAQ61 XC%*P1YH23@0(K/LP#-T+Z.V*/$2Z!*Z)$MP!UD W#
M'.Q(9VRE.6FOG.73SR@U&M:U4#KY=(EV26'!$9+PE;90=A%).VBQ :I.T[=Q
M\1J>)&>,%H:MGQXAMF4K80*:VK/:S#*'?2XQ;M&IO("/HF<=RO>V$S3Y7-,?
MP_<6T_QX-&.4\R2V;//J""-?FZ"(Q'".\$Y]S06M%3XDL,_)I"P>X3V(T-4*
MT-,($J76G^99QD&A*O^J\U61*"-D6FJ=])F..3-Y<=WG*EP<$83^0:]RZ(<A
M^'QW.)1_.J^QLL(];[H:SU:S_>H3%SI7[4H+J>,:,U>QQ8L82]2Q:J.@&WSX
M4I:K5ZZ;D?1XN>U4+ PVJ!Q&RJ!I7>&B<=^7CI$Q_41I!<KN6\9BO<< -PK.
MKZY\#U)P'<^TW)M)K8QT,7DD*D<Q12D,<TFRN'OOUORU,M0JQA(UTE5->,+I
M38VO9S&2%A*V<&TET;&Z/\0@$<TV*^6!8C1CO%YJU-B@2B,+A22UYWF'T ]5
M0H'+3:))81$O'F/+ XX7];Y[DT%J%$25U>&G\87;FFY\D$07504>$D%RRL_Q
M[1O^&N_A;/X/:OA#6:ZXL_MA:9%KVURZO92=M>, 8 >WS\<GPR@B5/&)Q-TA
MRN$THVR>HJ7 ,ZW:(WU@U6+W8]G"AY^Y<]T^5XF14'YCL2C]0(WC+6#%WXI5
MVWKWJO(&3#ECO5X?5*R)M,&PPF:HIR5Y.?SR7+7#E:>;8(_1T8('I0C.#75J
M!8RSF4%XJ+'GW&(5BA-ME&49@!9A.ND:.L_<WGF6)]51^%=3<5>[9L #D>!+
M*?6VF\Z)UL6O,K1M#9?TWN9S (".GJT^ -!IX<,<''?J,\JR-S)_W.*J/)DS
M]72LC*>!!3-.=^&UBNRZR)LQ-!-:0OM5OEW,U+"#9O%2^;(MU27Y_*4M+NZ^
MH!$5:9TXTRJSP/?ZE$V^:'X/13=163Q9X<;P\U'9@&KV73KV=*>1W1GO'V8W
MMX#X.ML#S_=U/&E4G9(3QA/'@\Q>0AWW9[%*2Q0(5,NSO_H 3N^5_5$CY5?-
MM+Q<NT;OSX ^\&3OS>:-1JCS3S#6LEL8#NX"$JQ0#RF%X%G%SG9!5'T>HI@S
MUV,K>Y_4_1GQU8]0(KOF6$]#\_1 Q!>06<\MI8"$=0^2C ^Y&R/&P9^MV2BC
M)@($,K&4<3W%X75AI<9U$!'>G!U<O:9^3*' "/5<ZPVVMT(QCT1BA<:7/07A
M^47NE&L;04X>3?5[BK'ZRB9/^FK7=-X\#5M]JFE2ET\2\0$T>$-T)?<*/M)1
M3&FD!<F?YE4D+<_[5.HYZ-$L8?#CJ-E]H4G^$?D#M#)H==AVR8T $&)(3;;:
MR/ -F+? V@2LPY?%]'][-&_-C)[(;/(E_MS\<&#_OE_$3U20'%+JIQ'.MLJV
MD)'?E6C^-F[93%G)<2%M/(I:+O/7>RAJ6N4O93\6>N,BF3IWSS[:^8IP\)+C
M+&ES3I@$#\1P.LW3]KP!BPM_QL<18(CDAL5,L9R(II-!Z*:=MJ:7O!ZM^.])
M)HMS8B,X_4'L3W]D.;;3('2F;P$4/"E[5,/;$+FI@BFV$]+J@-&P=LJ?3:$&
M:R%)S[1;W\I8GW^AVX]5>GXOX_MR8!427;;!RU42OE<0LMK8X#I9_>%] NR%
MA;N&V2=HZ&'K^X4/V"@KPK*J(+C_]P0^XFF^)0SX24O\Z7+-O'2>1.6"S? R
MYTN3ROH5P1XEH6FV4D3VR&M\%.C0QU,/!8+)&F$]-UK\K82#)BP.X%MN[[T;
MN8C(0$:*B$V@..%NLQ2,<<+)BU%MRAJ6Q+HQS1H@;NZG&6JNX<P5VB K52^C
MM4[-]P& KIZ]*607=-SGM,C0,:\PD8DF#;3 [R0P3HWYFHG2SXC@S2A&HG:*
MT4SOGJ2I=S9JYI3HV%RR9;F:$]3AVKS;J9)1&PQZ%H2#MEZWF8EMNP$M#[ #
MUWA/0+W(5BYUIA5EAR:@=K5<&R#%^&LHJ0!KJADL=@5:$&#'(ZQ(M-(QQW+!
M^]_8>^N@NIYO3_00" 1W=R>XNR;!(;A;T  G!T+PH,%=@P=WE^ :W!T.;@=W
M#GKPQ_?>W^_.U'WO>V?FULR;>57OCZY=M:M[]=J[>Z_^K-WKT^M7!J@^G2$3
MU4#RX6&0V*C$VVH+[1R8G^,K>'CJ[PTW2]^8>-%)0=82MV/N*#*>M]24J/%K
MH*=PI)\Q?IRAMBXS^(D(BL?/9;M*/N4L5\9U_:&U.DRKX0_ W?3G<1^2DA-^
MAS3 \?C%D^HZA9C Y-*Z4Q7=_(F>P$"BR+65A:>73[#E_&J_7V%H1IQD?]$G
MX$&Z "8\K'SFG5^R-.#W#%"NEE,8&GHWT,69'\)8X6A4+F!]-X$4L.<#,&N=
MJQ4I5^G,0#YK%;:)/3'I/OB<IJ43N&%MQ6%/0&U*2R##;4?URB-3*7J#\<?&
M1-XD;F<[I3*)?/O$XK?]KZA620![KJ-% Y0.?IX_EQ6EUH6J2"("W9DHAHHV
MK.W$D]N)8RMEQ^E'-&QH:"BU<@H/1>^Q-+]*\6EYX[I1?YYFI,"<0%C4U:J*
ML?EJ5XNR_2?DZ'&5/-RS<2L>W#ST%X!4 )R?+IJHIRG"R"&#QX-Z) NF=#[.
M6YKVDY'>(*L.37$JMY<OSHU#=Z(0%.IC![Z'Q@4VHD>;^\-T=CC"1#F*8!+&
M[9/.!B[U';]C^NF^8(I'B&EN87GXL5S9H96K+,SDK+5Y/)1Y8T,82!K 3!"V
MDV]+DRM/5M)X66IACTP/7Q7>.L@PP3'E]Q)E(>0DX26_ %5#-4G2I]<I.5#Z
MYJ@XENP[$-O#C+?6->51J3OSX??M+,8!#[=M\11M*A\>$R9/L<DM8"@?,5Z(
MW\_PQQP5.B^6X].%CC\WXF1G5V.5'MAAFQI,YI%]Q*:J+@WU$/G^ A:H.'/Y
MQWJ)&WM+\VN*-]U:U]6I^K9K^1T:"[9\_T^TCG;6QZV_@]2OLAN? 9K>N;<S
ML_^,WF'XC\(9B/X1$_DOEZ*_K?96 BQ[)3$P4_?/P &9/6LXZPK:C;4P3T4(
M:;FMF(\TB9)+ X51*<CR0H-QYF'^SVTPDJ@.Z#)K*$%:7Q3Z(',BGJF/$!#=
M8B($&W[Q!8/8)6S(WUT?;CPFA6^G=4&7Y0OI(]-:I[VJLM,>J6-1 P191TAM
MU[^3C6,^B(&]26&E&R6B;.+%;. ZMJB@N[P.TZK +%>_>=PFR0CQ:9J^$3@J
M.]4<?XT#9I91WNAPG;LD_RLOA4WIZJDZ(T:U-*56OWMMW3*S.'&EH+W^3%:_
M1G'MHX:5/PQ-AQ*+"J3/ +C%0^C^XA<<^9+Q/$4'Y]* *=,X>BL;Y?.>[J%/
MR3KG?7I^,<(32/4: I>5:%")8^5"-V?P<F%P^XI]P?OBU??N$&LVL'0,EV[9
MFKE7P3NLC-C"D4S.98<C[0L#MR2I, @/Y^^.!HQ\.K?\^<,,8CE+P9>)21&@
MBIAXVA?OL!MV0>EW#=4[,,'.#N.,E86$)N!A^!^!^V\?5?C2H(Q_;H0;>MY<
ME>MT5C_(GDU,3RVNR=JPS2^H['#%F;X>SN-HTT-\[.Q/BL"RAI]'=;H1S'78
MC()5LDT_,5AK2Z".G@07VJ::];K<*>G+3V^GGDSMNF,2^7$>0:B;KGN;WE$O
MG4<)<023]":%>1/"3CN%RPB%<_80(7C1)M6I;PMK8O6!\O1!&_CGB!J.[,@!
ML:F F\>MZYTD9\^KC34_<<09<8!U:L!WC,R-Q\]/V'OL<R93Y7%3U\2!S8V_
ME"G RT2(=!D.X]^O./R]J68>],XRN_3':M/X#!ZY5R&'VTM-BYR*V$MB#DN\
M< MVQY+QB^W?9ML1'R2FO 4\Q:=HSNR"Z</WFI/2R1:=,-B)T8ODZ5]SG@@(
MC,AXFQ\:$:1!;3QI-T@-'@6ZWZQA\);F3SP#:MM72UW"\9X!%A>!5=&F 7)M
MGA-+4J#T(OBEXK1H>Z6Y&$-/!RBJ=0;K[%$KXLYXUTU<9Y&41ZDT_K0LF3Q+
MZUN2H:A.P_2RPU]H_/*HO0<43+5G4>50 X-PY3F^<O%MI_#$J#7MQ%5K;>N5
MX=MRICBF3I9SZ5\6@.0Q@'AB3FN:+FP4\L:9DE1OWQOY8NNL1E9T;5&_S&7-
M-C W]D9Z.V\YEHBYLD%(),+B$P36<ETT64N,SX8KOT:18%\ZCMA4\;Y@!*H4
ML8_?G. C#"H=B@M#95J+_X/4-"WP#+@KJ4\HD2ZS<4FZWF@-+XJSOD$C+X,C
MONFL))CVQG=CZ<DD:Z=.-^F\(\A_"BT8?4HIZ.8XI2.D,(\<\K9:;!+[*)2%
M^6WEO9#J1YZU*&"W)RKO&H8WG>?[L[&P2,<-#U1%-NVI/LBNA;#310J!;IPL
MHP6=#/VBH-%HG7OG"%2@7\RD]QF (DXC$7Q\N>3E\VX!1+^:5/Y8,%$6\B8.
M-2' +@8M,E"UF%P:X(6I:*P&186<_#[K[W*P31V+W5CR2,YVKP"=B"I1R:(8
MW+B,TS>GY"_"+0X2#8/0E+^C9X:6V7GR(':PEIH7R%LWC/)MO@E0P\-,HMOX
M6ACW$1$= %0SE([NQPS^GO^"/#*C/3E<W1UH>M%;249_#[)4=Y44>58S9L''
M][I<_EO(D^;_2,P5PG_APQ7]6^B])-HB]T?KQ;?SN2 JXEJ?NV+M]##^B5>?
M'.3#7)B68!IP+;*V_&$NBR_W_EMYDL@2RS>,[#6AO8D%S?6IS6C\\7JC^<H%
MHO%*<3\Y[D]%F7;H^D_&27^,R0CJ27SV2*?=V$G8X$"#Q8F)H[)IBVF=\@$)
M9^ACLU/HZB.\GSA+PO$<;FY5X6HOC.=JU5_#K_J*9MROMQ?3WX315D,5=/=6
M6;H/7206EK8NE!31:O2'=YYVOS.?';)/3^-3%)_Q'SMU$%I_)PPEE#G;#3EZ
M&F>+J)>PCELT^4U?#[.X('RC+MA-B\AHLSB<>K62$YDK="I)82M.# N2P'?S
M, GON;;Q^9Q/3JEF<A1GUA(R$-U.O7L2V#<=D4*X<U_0U('^@ [5"=XZTZ<D
ML>%9=/NTS&K@A$R;:I',/9AT;ZKUJ7!;Y.L;A&(RG090KO7I*, M.L#G<]H:
M"JRTFX+Z&1 0K-PRZ_0S=?4$6JO<0/*3'5L^PUS(D7/QXWDO=\^ME^-WCA_-
M>23\\2#,L.Q@M0D^8*3*APXCGN1$<XX4]!%O.T9MO?1O&6I$AI_"KM%S(G-\
M1>U[*%]=I9N!@2&>*N;V$/3W.C6S5RS[3L%QQ*D3?:"-,.RO!4R=T3%&\R?V
M:1EB+@N6BDZX-:)+LLF3V=)6_72OY.'%$.5OBNO#^,, SGA_[^OT'+2_FEGJ
MUX#%R\PE*=T[1[B01)9=9UKCY(%HI>G8VCR+D5(W&;_'R*BNDQQG_Y.P<3V!
M%+KG@R"JE]V]+F@.S8AE]<;Q,W C;A5CN)V<Z%.DK/_$J60>88<0(SNL>?H,
ML%Q2P=*S!949[W5K-/.?U-B0H"SJB\8,[B#;@5+U"#;FX\H;?U3%9#NFWGCE
M)%EG89+&K].5;J0I\P_YH.XYRA:%#Q<Y^:"3*HNHAGS8WS8T8!NSZ'OL;!VQ
MU-D6[-69\@8<D& &V3^(6):X69V^;YIEF-'X.-O*G$1P4&.1'"'_-<3E%\@"
MV?<-U4Y;I?6CH\SDRR"*> \U*V=D6[I:.:$K2-?X#>U(X.\AE^3>*O6("B7R
M('<G+"(;,@-:'6>6/<F\WO<O>K>Y.N24MZ<)CUI>D^,9V&+G%/3^J.@I="+_
MYL?U"_"1&[/(+/*OF/Z_03UQB6& <DX*_<W[X;\8H>M/;Q_0SAIZA]V> ?4@
M8Y'YI"_Z@:4(Z4@%7]]CJ*"](:;[=&'T^%\H*DOZD^4ZF'SJ/\LFAT.ZU7JG
MG(#]J1RYXN^:'W]T*^TL]04Q.9Z7-7]U@5\.E?%ACGXBPK&_(Y][!KSV>6QN
M[UR285E[!NC^EJ[[?,-Q+JYUYJWP#-CNAXQ'=VS\8'A1:,7G3.<9L%3T@GH0
MTIZ"G9\!G2;/ +O**NO<1_-1B=V+^Z1;I+OTOS+H1O=F4OITOWJQ0>^;GP'K
ME<^ !K5G !JRP"/&X3/ K^-IQ>33I.Q=?ZK/^.Y+9YA7(O3/@$S*<''Q?R<\
M]]\IF1-]%<W[4G7\Q&2+\L#EQ2**2Q!X>OTE6_ 9D/*BHM:+BB4[F?>(!DL#
ME<Z0:><&F,_OZ^*[I\MG@/ =.+(.%X(VEK.=\!F&3X$Y:'92Y,UZSO'Z:>P%
MV9:=&1K]/IA^[T\BETW]#I-(ZB&4=K'-4I/IST"_@KOA32[(#2<^'G0EGH8>
MD!L03?_F/'OVWWZ=%__7+ V7OXL4!OPS+6[J/R'N!,+,?Y#T]S][-HBB)/HB
MDH))/L L#+"1"].N?E"U)_/I4B[GV]3W\K\7"JQ<>-T.>=*ED$V)W'4YO@_]
M0Q?%W!_Z1%(8^F"S<8K=$,+G)6R$G5)^5-;;L+#%BC*X8Q_XZT2C=J,/\-JE
M@2_P,^244*+?8QQEU#VG(=AT*G<V:7C:RJ"F1I%.$3MF&6_  LUD>,L"1&Z;
M'AW1ZNH,5>PSIHP"(9YTRU8WM-8&.MWF9&@W7@3(G:<%J6+U"'"J).,&&C.]
M6CG]0\Y_J-[2%MVC?UPV#90U#C3G+TMLD&$(?:AS(\*W\,2Z/]/$7_RFG"ZP
M/CAAVA$M"VT(O<QKF;&<21N*FS*K4<SD<N1K.5'_Z.W5@\4I+=%-P?+B3??(
M>])#Y)W2E;>G/Q:#?/(6AX'5VEJ1N7&,B<;R7[6Z+X)(9;A!;O?JT(ITC.PB
M:YP]EV;O3.!U4+1V?:*&VQ!Q^H?8H?9W@:H"/^,3&>V)J/"^>"/N9Y"W-#2=
MC=65N6D[UT>!M_;+[6E6<WBX4Q+=+-1O76]G6#Q[/A/A[SF^LPB,D9NL5L^1
M!M1DGJ+Y<0N?<QT;:]E#67I615.)1"DQDO*'*4(_ERW7-R DP65L&^74OQ*B
M99*,.(DYZ9/!FI+=? 80N_W^H^W-=7:P]_UCAE/M#-UO,%6B:ZIDV53O3C^S
M.[7+\:K:(%U<+A$5.67W:>#NQN-3M5,[$_AJ_-@@J*4Q6),@3?3Z38'T.6B3
MZEB::&S9I1P3RXW]0F\F\7RXMWDWN%-:'E3[#*AI55^/C_O=R3X]AORNZ>[B
M?SIO=BL;)F%I7F&M'QC45*;;FU=;@XIG31]TH*>;DI^>'[IE0TE'@/$&(7 I
M/KDNT]\!2"$XT_I15*-BP7!MOSQ?T<:6M;?1-^@/7/E".(N(<**9%)W7E'8;
M1AC@ A7S!S_4FE\?\:_ (AQ@.TF=GXAISJI8GJH\#@"?#NCAEN?<Y:OUJQ0M
M" &'99HVD%KZ@VI(:9V6#(#"5V,O"X-4%Z;=W-\#8NEC@QC9+AXJAZXW3*\3
M=%B>;S%9OB.!I\;<KOCX$.&9;QL@\8I7Q&,XS^B]ICA%8\?33'PW&^MGE7N=
M9/H+P/G#A.@?RF$<=_<G,@?C6&F &V$W)7HTD5LA1.4Z8)6I9K+R*BFA-O*]
M<MS8T-U*=J! 4.J*!57RBIZZY!LB2^8_&=$]F;]'.T)/6Q5%G_B@?+7&5%Q>
M]> 5)RC%0)2I-)NU+L(>QG%_$V/J561.NB2%0ZXG8;3RS(.BESMD#0OXS2UH
M0'>-_JQ&D^JMM#/6DFS=K%YP]LJ ()&_-(P0*<B[DST6<HIM,P>^5MV_6)7Y
MLG#Z*: A[C?M$M&@M-F/2?RA3585OOT957B$3^9Q*L452*HP6;[^"#X?;)L7
M=0@"74MDT72P=/L_37X)X91L=RZ+X&H:7SU8[:;PEP:X/]YTBB'>=]XT QIG
MJ('# W6DD3KC>O;TS5$?8NE=8_4,_4D 9?FOBE2S ,R_,N$NAT-$==#'.BJ6
M>R% Z_5V/09?T\E7K),) 7A?F&YE3YX!\_WX^S]5D5(/*>&_.!\>M@ROX0"G
M#-=L:&4[$H78-H&-P2EU\V54?9NC/E<&>)>6IC$>*J@P3S?S[D7O.(Z*.OR:
MP$^*I>.L2@>M[*=LV&Y$9$S[X]_!.;ZDM9^%)-*%_[-[?_^.U?I7!OB_W>O$
M;M\O.GX&_"NN^J\SJ13]?3;U_W9>3?F_/=K[_W;4]W]AA/U7B2#_EJ,"]V^/
MG_C/!/"\<&Q_)_^]PU/1H^Q%<<D_=HD!RO\!CP6!\U](4)K_>OG[:NH^9=$'
M/K'%MO_\<U/[+[R/#?W_M036^RKG?)37 /?H;J&ZS&-@:;IKY^).9MF!7+E'
MF<GP)U#?R)$?;]"!CNZ<(XC4G76DWQ%'#RJ\:PSFLWAQVC=0P%<=R,G=JX,%
MR[H<2_.Q3U&>AT4+YI3]_>,WWPA=3M46W_*C ,[M&7M)**,X'M0*W=Z=7Z_U
MD!B5UZ8ZM-1%;:HT_<A?G/:^&>:J&>*>%(UH$7R?VIO9W4YS=AKT(+*N)TI=
M"@OOUA;VM"E>L<&=EVG^V3C<6^]1E$+-UMBXE#1@TM+BVG1,.17-ZDWQ$VZ[
M7;#>GM0F$4PRWJ4G^MZ>U]BR]?O/9H_\GWG<$#,K!G[*5?]1JF]"D.:UH">B
MEC-[WTMRC&> 6KQV:U5MU"IP,"5Y:(CSH^XN>9#['_RIX_PEF.J_/]SC/RS_
M&;]U_\DLKT#^36RWG265>9@*[5.J_,M\5?TKJ:_L(V_\TUWNP#.@(,YG31..
M'I\R]AF@3/<,:"\ZE]C/R[R9!<A+RV[Y3,M+G):(1M_9,#Y>2>*HJ=U27DZI
MW!]$_X\*$VLFL>RX"_F7[9Q_-E9'_5H"B%."BVZ3Q)G\3TO^GZJF_(N)F/Z'
M'-G8S$V?^P/?-SXSA?<Y>46)R\R^=/$_HML4_]$?("XL^I_2W/^U0U^ZG-Q_
MR*+XU_ZRD)F*'OXI\)_=O5)@EOB':FK_^X0AO*!G;8E5D\<WFG6X^D%$W'+N
M2*??R:9N_W<^2X1/Y;]8R7^TBS_:=/$<Y(GP.GA9/_Y??]O,+/]JB#G^*:N8
M9)ZS,^ZOVO3_9PRTW/?!IRM%-=1//*%T6[NGZO\;QP[PXC9YI[PL, FX!HA4
MMW$.3[,<_X?-^/^O"8O\1W39Y#]D:0;0$BR/R/7SPM'_=^*5_[_\CQ:=&!CJ
MM:\]Z<,7:%+W](;'L<@3]A8.NK;L"EDW,^=@K;ME@YU*2@,38X29K]CWM);S
M0IVX!TG=VLP(BC>S)U>1'_L5^5-]&QO"U1NC1A>)P!9Q<@D]H#J$V^5"(>*Q
M25],G65KMF? 0:];5.QFN;&>J \(0ED+[_79OF1OT?/;H+VPU->"51%G)^HX
M%6ZZ9:V@N<P(<[Z&C6< @<T:.MN#T/I^(;A5T=O.;)K=6;[">ZKK>'I$W%R9
M(WG9<B!"(C%Y0"L+4QW';G]@SU;APCYD9'3S-'@0__BQM'Q[M@=\[1HOT\!)
MWV(E$$K$FMGFACF" 1"DPDT[>]"K:_\K2&9^+[4^VZ-$BGZT(-JNZK$8(@.W
M19^/S1PY\,V">!DP["!)WK[9GX_*<+2)X$%R'HZ)O0B[AU#^X"LGN=#TZ_*B
M.55+Q77D_2KJ+O?7T7;;IY@LOQ(8N;Q.7FO.M2IYVD!)_[@L*K>W 0L?*SPZ
M2Y=6;_D)KZ$]2Q.]9!MYB!I(HZP&<HPVU$V :WV6!.A<C[+('V'/) $'%7=F
M*?JY!5 JO2/:)V(Z-I8\V](F=RMX5L @E;:MIV$M2']<Q0M3/\CCGM:U\!:\
MEPGZ%-LB1<1MA\.4P&W(C"8Q]DX(0+[-XT#^5:A">Q>"(UO26ZAOW5Q0_#6N
M&R/[FCXP*'DJD)EQQ%]0!^V#QU QFK<Z,N0!"9)W%AVXW=Y$LE,)+(4E>AB\
M3H4H-OCQ-Q-4[\CGT\DH!/>=1,DA(0$HNI76#K@,V_I[(ME7ZNHL,I_H7<]L
MOGBK7(87)S)$,;7;R?/T-8&R<-S_T)D9>LH)-*R23UE-B<IOC,KJMEBKBI57
M6XO&TD71F4W)J($)B"/JX2M0$C4D*2*EW=MV^XIJK\'*_0$/4F0D&GWL#*BV
MW<,N70-XA@24;S&W:T+Y$T3$/V'\HL1W&AXG68#9+8)/MD_:IW!50V1 -Y*2
M"7)K.YYE[^S?:+@.MXBJ(@&5+C#)=.@K/>7\I:%:'<'Q<K-\Y H[8QX#!&#!
M+CD:KB#)*3E_!QXJI).K8322\4EO.IN[.%B:SL]# GX2Y2Z;J84U YF2Z2^R
MZ"A%W#P2F20@\QM?U:Q=*O*3BX$^=%2&DUG(&HXWO2R$ P$V+DF@?Q,HJOC9
M(IHRG=8@.?4S]I(2>[FE!6#P 5&RA\5.N:4T>\Z;67;#'AE6L;,D,UOW5I3-
MGC+9RNWGF!*-<F=>@NZQ>ME2U:X$<S7$5XS1545?P,'8H_#AW8R3"8IU["$)
M17D1K!X([^J8I\]6N%A-+)VJBK"JO3+6J/6MAQ. @T$)]>@G:?!_0+-W4GZ9
MH[/V5D%]DV;G<'XV*^:A*Y:Q/!>"1 CG,BX5NH#OB ?ZZP^*4(6U+F&@HGAD
MF:V.=B)+D2U_?2B\HJG=>URZGB&LV.W&)5(1\D+;JIT&OF@2/9OORH%':N-%
M[7GOYO7ULGB,JB/S4-+"BF[QDY.8LU[)X\$U&^"Y9Z:[G89X\YO8\E.0JZ##
M['7CG@$:8!/EIL# Y-3)\H6,'1R*K_DC#O)!ZH-1KI^M;=@]U0@#Q>G=EG03
MC4Q4JQL:IEG[DEXOC80ZTO+OR.7%2!.SL#7>NNRBR<C3^7J@X_>XA4/ "1LK
MWL/R_$ESY\O&; 'Q>C3"G3PR%BA#AG*[GT<^*&Q+O:X2*C5&A84B1<7)?W$J
MEUD%LX27ZK&S)])K)B(K*?V2DV?M#*'"#A2I__4*#CQI[%[N:3U]"3S%7?0Q
M ^HXNGD/VI^()M.HL=(-(4>TAD^\V]U=)/I4<=Q5H?N@73,K*BL>_CGO((F0
M<TE_532(:3-Z,'T%?GM+(_!\)4J6VMNHYX<D>1OG@$^_6*E_-6P\=P6(I3_^
MV:?0YB;1T60>2!A*HF_<C:6=$(]AH5K2V>$6VOBMB6R.=94Y30?6:5]<D08!
MB:A,U0I5; 4IYF[9LM"%)([4%XLP9S *I?*:]GW%]<6TSFD2PX3P1;4)!$&"
MP"?$SJ-\5];F*:I$G]0([Y:%.ADLX$E;+OJ &5"!OMXI3YY28.KGP*OTSXIU
MTUL=];-4_,,V3D62(JACY0\&09KV6@QB#Q;P4S=.5X4Z(NLBH_HWG7<?%J]J
MK[\/&U0NT31A!>'\"))H=E7"X0:8=Q+OTM1\@E6;.K1O\X[*U_+[*@,K6!W:
MRO>YZ8!DU!;<!"ZQ[^RD,6<5,:SA&W-:SRDCZD?SVU;&@_F&B<UFS:<8:A-%
M7-WR74/A?_?SR%81Q],)27A$)_B"?\,2"I8-8&$0-PY>&*]B;W7Z2?:.'HG@
MBF>^^LA2P*0O)ZE#'X\DN?;%$=/:L3%>!Q9E=P8;[ ?D45$>:AF4GC^_9#"8
M.^C4H/>K+*ZUNJ<!1XKR)(#J6UY\A)TGQ5Q?!GO#665@!2O[ISE115>,9#M[
M@BXWD#W.F@VZR$#E*YEOY=%L"36D9@^%  K_YGA7OBUAS&C2C>!N3,S.4OW#
M#(;9\LLB#F<)9JU4R.L8LM9*!^[$VQLFU9%=FZY?N 9<;A>Z;;!!@6#:2?OR
M6C$1Y7OI[?NVRI]3"OV#9IZGG$Q8(XW(Z<LQA&A_*&*EW4<HR2Y9(K4A@VSV
M8>5M;;UU8.KS2H2+-Z:ZSP#W)L6F6\_9",[A5YHXPL\ ],-I-W]%@^++M$<<
MKU-2W0-%HA24:N+'I68LAQBM9"RI48"M_151X1PY9)SP?<&+\_]$ :_5T IF
M=WGO;HJ@3.)N?<'=(O=F<1"W>!&9-'B%M:!8&>K715D?GPM$.DIM:X\ZO'9"
M:%W]."C)SD5YNCEV)'C;;O)S';Z]P(ZV HEOQ)9"/&K)T(B]7VZFKLFL,6SU
M#B1&8WUYP8!"[#J0%UE&%( QE,<#>#..O2Z!SQC@R<%V-3#'YV%DTO-[<9YU
M#L>H%;MNHBZ:6_DM#;>FN(#3-TE!0< UB=7%$4NJ?8B^IL]9+.\H*^>>*]?"
MLI(J=^LXV<=B(G6]Z--<PT\XHS]2SZ]@OD]D4/L>3,(#?95P5MYC]K[%564*
MQ?SFD6V+A.TH^L:X-\\ )VKX!+I?YH[KOAX5FS"-PS 3DOZL@T1CRJ9Z<)W!
MZ=$^A_@*6^O[,:Y;T]BP(Q/.V]*A(I6V1%(#C&"(<_EN4"VY=K_\3.6)\[!6
M2\T4M:[V\2836>(:35_+>W9%0>)//'%P@",!Z'SF4QVBTB<=O@U,$ILUK <A
MAGQ+_*OR^EN05=0Y,=M6U =Z"]7O_.#7KGV]WS"(UN<X[L7VS]^?0>:TXE5G
M^0C EJE/C+-\J&D%BJX)BPN$XR[," Q<?3PS6Q>2%&GM@68>.B.+"45@/HX0
M;CUCM^M=[33-U/'N2>N[BJ+K:F4RN8I1A@L@UKU4$@O78DDR:A2FUR80_1O^
M&7NF1&@=;IFM<&!ZW9#>0-6[524KCT(*_5RL0U2__)#NLQQ?L2\2"J@7_:*?
MP\[7(BBH9BK86&M'"4Z ^/&ZTT>?6QN^Q8F(=;G'TL+'UE,=]4>5P&U79T('
M"Z>V&F9Z^T.<&B?+NP[K[Z*3"FPLAN#<RS=C1&\W:>16Q5.L^S8E*8:ES6'A
M/1,PE[&WQJL>2^&A" 3UVME*<]P)5M@%.R@8^%%Z?KYY<0"&IG2.S==1^?8;
M"QW5SFD^Q\4[#=)Q;Y:.3HF28VGI(@K%WV\.<SR(";!+BAQ\3HD_/C0,2H<*
M]ZN?+=H>FOH@I]Z!A%>[/D0?$Q)B*](IA0:_'?ZPQ?6)WT]>%9E(XK55\ZQ=
MZ^<R%8PZT]?@FK/.@D.!G?WR#W+A3$K*K+8%YAS8]9.^$D&^8N_"UJU@G::8
M2_*3=?[7RL9KLL[WPJ^,[1DML@B)HF^@NRYDGFL<0PZ?#6'E!=;M]%63TN7;
MES<Z@X6BX!Q:,MP:]Q^DCJ5<R!<-B975'W<6A;(PAO\"85GU+$/BY# _"328
MPMV='E_DIX/4J\OOR@%SW$8K<D4GH7CVO,$HVHCQK!L \[C7FE#,ON%CF>[N
MXHT.]$,<DX/OP_L-G%6_<?7Y6GB6N]Z/X35%O>4<TN,:.SI&@SNJU2&$8(81
MI&(T@0HJ$HIM#4X_534V_]9M+94O6#37$Q@H6T CNK6]EV7[$58JT(?ZQGOQ
M8V0998WM]9U(Y<($SH6["#V@L<>G(UJD:G/GUEO#%^,N;-L"^L#8 \I?LM$/
M?,!:)E4<_;A@Q@]V= >R#WZ#2)USIP\%RJRCPAN"L^\E][21RT9XVXP/II6G
MG@'UXK/V:!_CEQ[F+2FLM@:T679"NGT5$O'@]M,>9=Y>[38G]7Q(TY]P,CEZ
M]%'(U&W6K&L-0S6+*,9.#R>PZL*/W+1/^BK8MS*P(]_.J?O^>LH)].DQ7J=A
M<L5[S#<I;7"!Z74?[>.#^THPI<#P^2^ Z\PX3R.>>\8*U%C9'HJJ#D6LA%*@
M*\K,7':@[;F,VK*+3R)XY,NU+LC%(4>4C,3UZ-CQ^\HS/P.8 %?E:[MX!^?C
M0<;LPA*!3D9(:D8&.K-?:DF!AVWOWMF)7CO6^A[=SR=AO,=NL(UO"9N=\N;4
M/30FF:IK 9%J<]J>=3.DP$51"E_+8V^=QR!_)5;G'AG3 DAX;E3!K:D9^V0_
M6$P['Y93@-D8M?U.5=L;I_."($0S"^,H U-T973,;J$=LTE/N!-^3KFPA$)#
MZ_+B]_;.W/6Y_$D@N[ ,T#)4#AI+.-Z T+=%P/RJV-P7.0NCTOVR<"X$-MU?
MORHV><Q:UM>QD6XUW%//KZ,J^EM_$-<>9Y@RQ6[G[85=Y3G+@+C%&%'8Y3,
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MDD^+1L,P>I\ Y#?O6H!P4/KZVNL]B;.XTDS,E5Y'.L@?N*_5/= 29F*,[J:
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M*GEBP<%$$WS#5;<2+USY:C_H$7K+@:/A<NTKO)]<%+JZ:R/QJ'&%G[HY1F<
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MCA11KVG\VU?AS4I'/5Q8XA0FKE16SB!#+E]>DB_S0RB)<.'82LVX+^=W@7R
MP^)-]S. P,A3WAY_;Y5Q\@@P+9."'I6=/>Q"H\(SXKJ:Y&"9XG?=AX?FS+!2
MV?UHI8+M]EEO5E2>_&HL"1_R,68^>>ISQH>ODT$)#UGAE(E(8R[5W1AUN6=S
M?83M_&?+J0E/:8@)W,8K>K?\<R!'TC<,;JZEM0Z_N&3Z-!W"#JK'52Z>?!(
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M!CL^(M)I)MK]0U-=QT["@85S^C?MBX54-RW>W6&0WKK NM._A/(8GXK*&(@
M'>UB(?1Q>H28 \W+XPZ'4%STFAO<4OGX:8I%1>BDSD,ZXKL,[M12'FDK(>7
M]B8_^F9Z6@3+H]FTZV.F$P+'G36QFN<M$DH>3]O9PF<Y:MY<_@LHZI[R2""R
M'AT<:U&_#GB,BS3N*II#T:K,7MCF3M2(]+'F[I]8Q9O]7A8;5O34O28J$,WZ
M,SY 2-?-@@_YH4;4/YN0\JRG:%/(7/.JPK>570>/@CF@OTD2&GG((_H^H#OQ
MVYO5-S"%#7#(<_L@.A-.BT#%=?T!\7#:'RJ.3"=/+$OH#Q.NO\]AG6$1^F5U
MAN+Z:U_)<+2]C,*\D\B)-JYI?Z.<=,=H$V6B84\7C[Z<\(B&X:1R(4%<6.BQ
MY&?&A&;FXJI,3'@08X B0@=7G"%SW%7%UWYVS*3]-E;&JZ3[VM.LU):SVJJ<
MC&\B\WBN!5*C=5XR4LPG3EWNWPRZ&2"*>(J+;T[*7OT^.9GI5?[F^@_W;SR1
M1[9MD=^KTL:I!1?I:^0HHWK%_*-\UJ9NX,4QX4XRF@[)D>"7_0&R8NZC2F+I
MQGS*]>GK%I>U3(B?ST6X'!6LF@7W(02TJ..)]_OVZ:@;S.]6_\"1D"_<W&02
MI?Q&5OOL+0A'%\J5RN)'O[K/?)UXY)3RGJ.@RQ#K52%U'J]$Y&:Y.3>,9?$Z
MWEWWLXI1+X*UQ9Q]:[2D-0R2*K^V]:A*_\+9S6/'YX6UNMC5 IBQNNQD/;I"
MNBO];-"3/BH#I8"O 1E"<K0LZ8]^_:(&9Q%E<8=89/ NP5V0NJLO3GU'>/.5
M_U,U_\_O/""-%.F*H+C!E')UCRFF7MY>9QY\P/8<XK*]'W.4>'DB58X#9LR0
MKXE++F'NP<B]RT\^+/&U+M3-*?8%?E)D7-!&V\JN4#9!;J==;<:O^3FC<"<&
M0^)Y OJO0I :R49J*LR++UP9L?9\TB*EH@5TJ5<N1JQZ:M*-V]4QX#JJFY'9
MA+AF/Z<:9@F6PZ%U@2@_?;W68JQ?U*_6QLM>!5R#*_6@U?5DF9(6[>C4'NK0
M%LE(&>A\KIBLZ(F5\?@:\RK=C]7<(9:A:&:U]O&4\L@YLVT(MXIV!1]G).MP
M(2%YNE'2 (<**U,75:LT[/CAX/<R,;\]^HW.W)4<V=_<8^5>$5J57VB/4!PJ
M?72=NV+;+E1'8\U#2D+Z[E.F_+7= =<G_.@_#T<3Y)O&TEK"(+<<I0R"4;SO
ME^O2M\;Z=7JWG)Y^_,9SSU?14\'=,JQCA&/[X5G:X2JGS)$[E$TR-);VLV:V
MC4%W<%/A<^=EA$\_V53U+9>D2Q>L+\8LW*:Q'S25Z&N3NQC=)]3CJOS?0?"@
M,R-.^?*E]*HO] \'922=OA&4L"+K[$$I<YILJ^4XHQ'8M$GA#_%5?=V;/^G6
M)"FY+S\:*_0WY+TV=0^@C^@O/7O=FS&.+KDFF1+MV1E&,.,'SX2%G9W'1,.]
M:PA1MQ0G<KWN69HO+D9+1;Y:^G,WJ/FYA>T##,W8M'WB<4Z(S<]/#GBC434_
MSH#$G5@C"]I-!G>:@$(,7^BOVY7;YP/N5Y8,$F^<'=-+#DQ+.\@K5 )-6/8_
M][*;*7T<57*MJ-Z"Y<%.*_6BKCG^NR7GG3%9S64Y+E^<4.L(4?8-](<SVB9Y
M;6VSR'ESC$I>K%MB,I(25&?3)7>22OL<*7G"E9M<C"E>.9:=G,2.3OX23T'2
MFXXZ,O=UNH983#0&EC"8M3$B',[+T8ZB,B1(>BE \I\N\+%_5<L[IUZ>-+,I
MKXDPJ.G?^VV)[K>">);Z/O8/M:L7K7JV/'USJUXS*9RM",9AE\@E0XB'1,UQ
MBAI P,P']#EC)BO;#ZZX"/-_Z/A\_?GC#"Z>,<Q/MSBD_PBU@TS9<G1-,@B/
M")-ZDHB\4NSYKB]Y:?KWSV>>@;I/D.H#LS%+AB9>"8IGUNZQO8U7S[UI>K]3
MBU"4H3ZO>=FG5'Z@1M*_\+=$$JTYNVUIK!IK,9O5KI ,CM95-?+W[GW#B\$V
M<V[FFVA])]4VM?4+F[.U2(V$)WR)!@T2L3?AX4\BVI3)('OE S&*1>0E".=*
M._YJDSEOHLIWI$&9O]EMP6=%ES7YFYQI=UV:O:6?]I9>TOQ$L<*W52:1.\TB
MSO%!G7EG3ET2J\Z%=']N7>&;'3/U9/?29>2>OQOZ"C;(+3)YSTQ8-5CYAYJ=
M)-.YM*3H9Y/A-EZ0K'#>B<&BX")0P/PW@O<F<WDZ?RFNZWO% 1=GE;J76@K;
MILM^RDX,4X7U<QXD/4< ]M5SD7QFG5_.4SY"X% 2$^Y2[*OVGYVWGAA KE?V
MHP]_IB^Q%F7MS,;?4/1ZUS'*1Z%U@7K1J[OR?<->AMT7^M0 ZYEU3C5Y3-\+
M'.<".UVID7R.?5'648S1A2V:B0EY]JTS<K>Y[R+NW/@MY^JYK\9Q*C_W9*PN
M_HM* 6RD7>S7NA_/P2&[+W,(MXG)7,-="UL%*E;L0EM'QWWS[>\>P\5_*M3%
M3N@OVR8PO;C)>J>H:1W>O"S;Q*XB46<E=K4JUMY+)E;IQJZ-74?(Z 1:E9O+
MO+[)3Z)JQDP*.S?]AAV+/:3CS)^$:>8^HA3Q;;]BHK2$N<C:(A;&L_">$32N
M1V\VOF5WA]X!A*.3K\_F%/)/Q)WNMQSD1&74F=@Y9<4:?2NW'A4-A>X,;U@>
M1NM9S-BRO3P@@]!44630!18LQ^D]^T._Q'';"K2=$W>LXI,$_>AG%WD%KDAZ
M+U]WHGY+P16#]N^W1G1$Q7G<X*9(9..:!W)R6P8.$CR'B+Y0!-3_]5NO.-DG
M+2NK2J.RU<(S;;4QR&2>-VYOO8Y:P#[)#83.;[_GUHN\^K5PBULEUI2KY0EP
MO+#C^R+B;R6DQ\69):UB0[_(9FZ>'\&A!X+4CQ"/2^]S)&UO63T_9*DPD1D/
M/Q,R-<ND=>T.J[[6_5],6=\]@4WS1-*NDL3PO(VGTIH]SL6>9JHT@9P&.T.&
M)8]*.^P74Q%WQVY7NTQ2"]0I7ZPYPY;K(ZJ!9Z[%\S_I?Y72J:G[L[R\9S[Y
M8,CVA[3EQ*&(1OOB3\5A@8 OBV&Q7_6>6T[+2,ZFP&B?38R/J\A,V]6D'Z@(
M71--NA63^>(C-:B\1_K.F3AL.FL9KC.K@[FO^UY5365=K%H8;;-*ICW'EVMG
M1BB_@[2HD^VGZ7ME#.>=[%_YN@B]+'(2$%L<^/AC2MV%PU3@%\94320_IN%S
MG:EE-*R!1(UH5-(<FL'5CO[\@!V^[/.FK."NP/+0MIG%S2FW.W0BH5$_EE_Y
M6.L+9+T^YK7+L -*J4X8+J0L#+LBOGV.X+ZM-(B.NKVH ]^P+:M-6'/]IJ_F
M])YD"J]Q8[V8]<X"<L[1!]YPX"5HX_3*R6(-V\C^W@G&+I.@;?:^"-:N6.%6
MR^W=?%CEU*4XY&7 M-W)7J&=[#4&V@6/DD$*"'F<0H?][!*N>TR<_V?V=Q/H
M#P6NHQ2+3*LS9[Y$>:"IFA4?%5\$GQ^Q@X"' O0S?)Z;M!<3OM9-NGU=S=G,
M4#,)B6H[G]AI]5&.YP8%;Y<-Y>W:0Z-^GD&!SAJID*'/38.10Q:RB_)G?N]F
M@%AIKU!M7'U[B4[=,L?$OMS5V+CQN\FO#]?<<BCT%4'$^W)@*+RA*!1OW(:5
MJ^R3D2[R2>_::M>LJ+"[65)1$74K=G;VE]'3;A<TE1:V@XTB*<0/A1!T"1#%
M=3=>F*6AY]:-[O,5O%$2XGW4P9;\1',^("'@>8*+CB-Z?"C.#F@5J'7ZB;(N
MWAF3]E,T0U>Q[&G=\7,7FL,\EM<>78_[?:)>UPU1$%$>GU(F6114QB^ES0J'
MBAJM<[%45/9MH0ND::(,C4-9]2/L>Y0[KS%K,TI;NL>5,FG(Z62\SO3?&E,'
M^([Z%X0AD->$$&#3@W+J"-;%GVT3X.0NJ:QR*Z=Z,,J@5YG(U^)VGY;R-6CZ
MTJ52NY+R1-^+CE/W3CP*AW9LNF@L8V126J8_/6L^&Q5WLG]M8>MP,Z/H#( +
MQ%RB(H<HBZ?KBLMV2';JRIMK\5^EBO$0*[#CO9QT]KR!K[P\K4+2/>6/WWGC
M#-#@D&1=QW2ZBI+>?6G'\]NH_9.D8B=(^Y42^8O--[2804OSKD^I^>F[X^+,
M=RMZ8A1["3W4X<8$N/)@S;/"5<A-7-3I;/_VG-F%Y_T\:NI2S=(^$;)E#2'1
MHC40 \E=T9#QU_R2]5*"C5 Z(E.&J0],.QJK%;NK/8C^_3))>TIN5[RF#;N(
MZ$CA,*6;TN@I^DB/^405E9$NM?^%'DD"VWLS@W%Y&]2AXOS\'";^FQIZ[![C
M+?:>=_3/&[XYKU]510&S;PCXDGHFV3G)*9- WVRS/DM"H=(<&W_,*_A+6+HS
M#)TW(PZ9]6Y4J!BKG#>8/OP<Z[C"6;<4]?:UC+1&Q-2N0@]1UO:+3_JVO$DX
MD Z=]MO5XI9?AOF-/TR-6Z#^!**P@J@H"+?*;(7/</+J]@4QC#K4@6*W:%[X
M^O-(LE_9*(\9N$IY@>608;O2YOP)Q<F]7VVYJ,R#DV2)DQ[JX+5J9U36&H:U
M+)!&?I![,/OM5%?7TAU80&^FR9B1VF4KUV'1<Q=2?6^X8^X4%EG.EA576<ZU
M(^@([LOJO>+C'+)W!6U_)$]N%5NE#3F.OV?E28JZ=;8FPX/U-XG)<L^Y7@WM
M(<?E-#-YZV6=H$^S9Q]*<+!(X.70_N;HBS0+@SCW5E?6.%==FH]U*F<C[Q1*
MF]&K]9&$?0Z;HF;RK <+"V=,S%0%;ZAU+HZ7ELH+3?:IW/C<Z,5LN1#R@,)C
M(\BHR]W>B[X(Y!,60@1#PN;H*8P=D@/W-SM#@SUO#7UU<3[AKDYMO":0<48$
MA R1'OG^@#>YNPSWJ>XJ03MC[9Z=U#O)ZNALH?T'&QN3^S3\' 48M.89'LL.
M$ 6[U)<)K[BWBOPK=!DH/R 8(*_@H*;LWV<3N)BJT;B#O+EV_G:ZFWV=,0*S
MH4P>K@<SYUZW"X "9E7#*0*S4@WV"]DGR: 0TDU5[3TSN,[@^._8XX?/0ZTC
M,^^/-X[L<IK?N<>C\'!W)^FA]N;/P$Z/.C&<C+D(0MUE4UU)H:[?.6C8/C!;
M^:URYGVT[6(,E^0YSF9.5H_F.Y18&=F9IF$QMC).K@;.,YI7'9@E)"'@7AWX
M#WL:QK>.V97O,AUXK1\7;E_Y^-2Q]65%7H#D]Q/A2!E?]U<_?TI4#F0\J:JJ
ML&OL57!A/\-YE"B\5#X;LVOYL!C1 +E8@8N=;A5&>3K):WW6],]UN!1J$G:>
MP9U!F_&</NAF[GRVAQE5_:D=Y?()/<VC;+MIQGU.EOI8^Z#;@]M;A47;+$H,
M$CQ6%8^S]*2?J IB'QQ=.K 8G0R7T<]:(['5X%.GKO65W?4TH:<=6QUB3S6@
MY[X_R:V*3Y?I8\K@OV:5^A4LS+2=HC2\KE@OQV6"RU'HJ^'-6#_>D_"+%=_E
M.7PZ)C84ZG'-:)(IO=]591GRW-<L_"AED3)N<(]C.SR=!L_RP44<R>(3X, L
M:@1OD+WT/MW*@ P2>9_,5KB0EG9(R:U0+W/WYKW![7'J+ XE51"NDU[3)5P%
MESZOU2ON>!>]+E$[0+?_:>C;E$]1(]5$8<1/-9FM7ZBIR_O7S]RQKV- -(*O
M"&V637)K5Y3UE,F-W:H-_7"K1B(A1HZ9FW/VZ*Q5K)?)1IP7I;,6Z)CF^>&?
MBHT2APF>5DZ9]45B*^P?U&"&LHP$P=;!&C\LV"[<LKAN%NO^"/+H%\^=*P1O
MI40#0LPLI[\.KNM+=0&=ZIJ3\;SF"P&KRFA^FX]D4$$X=_Q!QF76YF=Z<7%;
M)Z#5)JI[_EK443X'HO,ND6/0,*O@1@D)9C]U''M35,C$_29?$<5<RQJ]BX4E
MOIGW JS+EZ&"-F20LZ,7G,ZBM[@&FO]LC=T&Y6*/@L1E=9U;K$H1-3/Q=9 9
M_$37=7-BON.YHAO2&RC7@))PV;Z.O<DR9])!RB6T6."5(X)Q-;':YH.C0^]I
M[/F%\EWGH Z)(X%-COMMH?J\7I-=?(=A+VJ']^@DML@@U13=$KQ! ;QPVN01
M0\*4OVN(H$5\W79"[WG3T-ERAN"TG&&BTJP!GG'(]L16M[_HZQ6!@P1A=B6?
M:!#_#2L;UA8Z#F[:=-^B#_X/G%Y$L'(;O0C7OR*FQ:1'"Z)^?H>R'L*U6O'O
M]"O-_U?Z)77Y<*.K/_&]LY9YS.3L+&<XIJSYZ>IKSP":&3..;D)4+OTY3JA.
MW4!QJ:A]NT-_<XBVI2*%L?+"O<(<-B61U(1VBDV3P$[;]6.9Y*DX-UNJ'-\,
M=:&^BC%XXK*B/&7\+D//7CUMYF5UD"_U+T>:WV5JW![VM^(QH37W<^S<Y$5$
ME!/IV3M=BXO:/A8XO?:M9UN8419\3@C'8QL3CN/#P@5>K=/Q3;4U[["*TXG?
M<A-#N.MLW0>S[5!1SC8LG*%R'-HSHYJ6+[WWN$]U:^E9\>WK[6)AV](?0;_G
M7X/^?%%DH+6HXWS"&KR,6:)(7*,K4]<2U&3%A8M?./I,C&.O(RP*?K_-[7+F
M<5_8MF0[V7QC6H><-4$P$Z5PZ6FY*\>9AF.)[T.SX )#L8\6P ^FU;@5I]V\
MK[]1B\)ZL5S?W:/J54J@UH"D:E%_\ G&'BL,1Y>!Z1VGZ*L' \0.7"7B7SAE
MHH?4W01*.0I"/PDG7CNZX]VZ-L-LO9@B)G9Z<<=CYN>FDO* 4/9 C9I'L1K+
M"%)">S-Q8V6V,B1T101V]J7UQCG_YMXAH)^&P/L+>:KQ+:%$M3P?$SVI_/I\
M\\Z\*,'D38V9&!-J[@6%:*6['.#4ELJ[729G5_T./LQ.ZAPJ]"V>B"^,.65U
MO^?&->VQIPWP<].$5I?NGCV\!'K:\8;F0HK=D0=,\R4U"FHL<<F/](H"2[R#
M:TZ9A5Z4\7.*G_S$XNT!$S,T<'083ZNZ>X9B\2[ENS$.L+^ BDP6:KR.WV&8
M=%T=UE1'5]:;[NC(+][+S&;]F.HDF',Q,V44]_C(DB_UFN@/A.7(P\.,YUU^
M/=2==>": <M3Y*M.J7'5FH3=QS6Q#U_1>6A4E\09HT,6QZ_DC![6$6KR[L7<
M:QU9HYH16"6#:,1.MFGLOAM=KRH=)CYR@1\$7E%)>=IW_5UXA +'"VZ.+_<3
M1B+-+7>"=Q PO"UV'R]1DN,P5'U0-#MIT'S7J6]=S<XD0(?1-JK/)ROR;>_7
MKDFL"W61'4&SP<"<OB\(:\NS&Y:LEE0LA PH[>1FB55\0"G0F H"K8"N:5%'
M^F#J\83@.=GET'W9FT<R?.&V0FF.V2L('J?[25GI;EYP-YKMV7:*N]<RSK0\
M9(=\\"QN*B(D-AISE>;Y5#=P/E5PX0H7SSV=CX^FE+8NUG7(U;ZP4Q[[3+0S
M\'Y%UNU>.;#L.IC>&E=4DSVL_G,@&X=Z.]4V.E<:JUEA^O1,X?G\"U:/7E9%
M>31.+'LX:W+X!,T9$6_-LKTZU2((!D .HFB-:1,[97[QV'%L*U#FTZT-7_R=
M\/)U>\R>4*_BG\4)!;,=;BM0AH"TBT>;0H5H,HC>Y+'@4F5E$I/K\#5F>P/1
M5W(ME!O+J>>XLVIQY7'%1->>,K7I<V(_1NT<A@Z'V:U>?E?=M:)*C?JF_$3N
MG(% G2_?/:-AU"8UHQ,C:.U_=Y/(__+([ 0),DX..'^AUM9&(V=-ER,AW 3X
M+R^;>>.!K^AY?F8/[E-&=X?9"WH!WPUMF KZL/4#1;>8)M-D&9,R)QSH6K15
MJN/$0&MW154ZKW,JW+:;W,L^TZO^.VOI-7.$LV;1M1[*W.R%OIXSO2HJ<?N
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M>+V%F,_$!UBHX:ZPI43Q>_B-JW"I^AI@Y2:8LTMIP+TWAA4I!25$_&54EXO
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M/!Q1D'Q;SI"QH2Y5/^&0+1O]?.]!MCV;4;[!ZRP_FVP[_("N5X]=YF-7O\C
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MB?>< 19V_6OA^7G^9O5L?G?9P<K3/^J.J(MFCJ]K&-IU4W/7NF-P\6: KSZ
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M;!FU8X=$P"8C:3D!#WJ[47>X657VU3]45OS*G;JO6$_7 W=N[,6FX"Y0MG"
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M5>,HD^^>2WEY5A*L*!C^UQP#.#4@M1WS@[I*4CK+IQ4,="7%!SVH9:KC4?^
MHQ-P4LJ=4DXHIMW#@V!P&+UHAKY(RH0E:5+-=IJ[ZYO@+M$:^VIP%X>&<_&^
M$K?<$?G7;H$_BNN/'.G5K _NS8?=<]0NX=T(*R3]MJ/^2?"+Y9O7\";%O^!Q
M5I)]4)F[G*;U60>":6_33*2^#U[B-O)[%@9W#_T]56>^1=C[-*:4.1X)./Q#
M=?ZA-G=)C/V!A<.%+^FJA/UNEDUI>B(G>5&],6+DI]7/;Q)X[5)R(*X\931-
M\XKE5^MN1?WU/Z/ ]3_<HQ8 J2^EI8$ 7D< K?8,['[Y\G7WDW%R<'QT<F8<
M?STY_;K[Y<PX.S).#_;.#H^^&)9C')T8EO=6O#../AIG?SLP.DZ9UB&SNW>&
MEZW(<=?/#K\A">#?*+Q^3,-PI<O\,2^,:B2-."F!G(V9I(4A80W%?=;B*@6(
M95J.=$.0 P%C8"T&,6&2>L0.(I.YCFE[?K J 7*LPI\'.H%S08+L"$QNA(>,
M!)WA0LALW7=W7W(=R':LK9?<T,#T0^X[%G$\;.<8QQ&A/G4(<X6T9> *%H2K
MVM"/ZN3^"_;K(WQ3KON680#_/I%_JR8P\,.G+O_1R?J)Q\'46VM-]UE<+<_$
MV%W?"W@@?<)CSP=Q'2..M6<2*^9A)&UF@P6X,K]N0;-2 3W]..:>^Z.:>^OJ
M;USM&3@[V?UR>JCLNI6:?,9'^ '>UWG \<')X=&^\?'DZ+.Q]#]G1VLB"I?]
M9[ >7V+IL7@@*3%!UOB8@/X!W JMC1>T-*2/@/AA1! P"D2* V+&BUV"#>)\
M$42>$YE/%4@'*N\67U"_W[KOFHG(X*85W6=G])SLAWCC$&^\;]7FC[3M53JL
M* MBZ0CBB-@CKNU[A$K;(J'C!I9K\L"D[FJXSHD\5UURL@K+[%Z>\SQNV6X[
M,9_R[)SEM!#&\8C"T>1RJO3*<LLXS/CV<SHXAMP\O05O#ZXHK]0Y,_+8*-KS
M9=#2*">28WV,,)+,2*K2X+!-\-;/%OX>1,(@$EXT K@V:[;@T.N>7SJM\@^K
M\_ M'#PU]I-\?IYYK]/OQBVOZ_2[YMO0AVFY>V/)V7JMZ/9]ZLYJXW.<4U-:
M@K@6X@!&7DAHP"+B"6:;PHE->U5&%D+U:'3/!+%#X(#6H#Q[N9 W'8 EWC$I
M\@L<9Q/"=2F]I%A@^,H^P($F[J4)Q[.XPV-*L"T&T 2S"!4\)L($"\"19A +
MOAJ:.*-7AW7AL@9BVPPO1.@2SS0CWXJ^X[C?(2J"39 4P>:8+<%*K18E"XR\
M,'+$U#7^/2V24B0<R0',F.Y1>:EU#KQ-7.BD*X#5>A?G-$O^1WU^MU$2:*"U
M6VCM</MD^W3;.!A/TGR&,!4O3UP;N;"+4MSXDF\O):C!'%H9]WTFW<^.'1Z:
MU"7<93YQN>N24'@QB80,>>2;MDV?G-ZF=;]=(0I9EO6_/B69Z@VPUGJ?:P>>
M<7 EN>KQ:9S^.;W?XEGK%W[9S$OI!":8Y6"@>V"O"],EC/HF<6S/\DP_#&V+
M/=?1M-?]:)Y.X>E&Y)D/L$A^#$[G2"$<+PB(1YF#5JY/J!5+$D=>'$>6S:CK
MK/0X[<&?1\59?KGVSIQ/U/@[>DL'UK:RH*MM6HCVZ ?<)2Y"^D5PU(A//<>)
M[4@ZS%[I650VYU%Q7.078!:]1HWY:I-U=@>_8O_]BA[\Q_%]3J096=A?,2:,
MQ2$")+JF;].(V]%*3_EQ7E8T_7_)1+G8U_R,1[;I!(,_<3#%[_-QU(<?4R F
M!7#W9$)30[9621Z#F2[+P>'U0QP&8'X&<K\[W3%#UO"JUGN>T_;7_[P"G2[Z
M4!J53.5DE&?2R%1T:\L HDRG>/@-"J0#$D_('>/M"^J;-J8/8Z.;D-DQ<5T'
MP?[#D/A.8-N6$+836D^5Q&CN[,+K;8+LO3^2M]:O]^XE;1U7@GWMV2[AT@5;
MATM&(HM&1-#0#RTA+6[[3SU[V-<K/4::VXR LA?9) H"S_B.4[B"[1M2#ON8
M/K?AJ%<WEC3<]E;H!VU1NNO\8%E(84RF13G%1.$J-^ .%<.R[+?L'2K1B"&Q
MRZN=YT.K6^D;]@3O]1&8V"NEG?LS3WM22NZ$]Z:56O??X:U@$/?Z('>X$,)7
M<B$L<GP3":?F^8\U'</-,1U7BKAWEE2IJJ.0E(\,CEWQ7MME<.OF&^I!MN=M
M-?]'?\*[WI^)>QCB2O?S!D/LUQ;V?J_6CGX+BBKX=P=VA_6\17.<C6'XMZ_O
M.!VXX, %!ZI]X'Y_J8M!E1(CK_@(>X8:8-[!K.";N0WXG2&T%]=_$9BF9Y"C
M3S1@;_--.[;C!8P2.[!]K,BR2<1CBW >>5[DQDS*)^="U%Z F64SI>:NO5M#
M=Z2&^>?\VY8!9JEQ@8WYC/^"C31-RYA@4\%1?^NO'L_VO'Z(J!7N93]$U!HE
MJ:R2^T0BL+@7<.(Z@A)7AIR$$CB)1ZU 1K$?"?;D>M!:,]<*Y=JSGD^_'O]M
MX"H#5QFXRAU07FY@2Q8XP!)<T&DLRDC$(H](TZ&F"RS%DT_F*HU.<U KN0I4
MYT99.:K +U91_KR,YVPDC2^T%/1/X[<T9S0U=+_H1^3(]2 !YA7#:ZMTDGQ/
M>.U\(;RV- =A[<S-/),KBQ.^9#^=X=0_I?HQ$UCY* TV,_A(\F_&&)LK)?IP
M=W"HDM*@QJ5,4_(MRR_AC24MX<0(N%!.,3.,EH:0<9)IF*J3:2H-U_0:,NE0
M%U#,]F,H1JT]3J9$R; SG8!ER&DI^[BL_Y+E2_&$YWT1HP9 OB?-:I5="BF-
M3!OAJZ5@8,?XTB/4C>$?GL]$S%W??[H=HW/M_PG'^7<\S:?U83Y49_G[B'J=
MCN67_)5S 5_BL/I#UM$K"8@LK^";/Z<):DZ@,,6(/EPHF/ARN2;E()A%^TEA
M9\_UJD%*K,LA>04IX;&86K$=$-=V54663UC$8V())W+]P(P$71'2TS_R=)I5
MM%!8T\5WMK)9I^,X2(=!.JQ&.ER.I *$6A01.\9;ZYTQ D,!!8,P:)JVTJ$K
M-IBL;X!!%R7%@H3HF!2-XPBE!EY6W14$7,W.U:VP,ERJJA7+-E0SL=)X"^,!
M31KEE(^,<I0CHBX&FY(<)C&BU77Y=DG+F\)-_;A^AW=@ V7">&OK=V12PL9.
MV;_A#?!^=2O\"&=1CX/]5$HU"35)6E9&9!J"SLKEHN]Y.*D5L"CT:4@\[IK
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M(;5=XEH([QNY+N&4AGYDAY[@3X:6UFD"*I-X#VR8\[R8+:ET53<IZX;7-VU
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M.6!PA%%4?% UDEFI626"?\(E!;[=/KU[U/XW:&!7<.X50&D>QPF71=G%#RU
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M$U/=$Q"%U6Y&TUF9Z ;>248SA"-#^&"15,T])[*<II6ZY6@B]>P' 38(,"7
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MY6J,<QAENKRB2+TXHE)A_ T7==H"9944 5Y26JF(.JWJ55!U.H5$+%J=$&O
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MA6XPG4(]D-UM(<:6:I=>E#PO-"2:'FZ:C256?DNQW=*M$N1M9IP$A6!,:Q!
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MGD'4AF%4B=?R4W \GX'74SN]+T$L3!;BK1?5!@&/^DV")$C-G7HXXS7P"NG
M/7D6N&I'ELQZU_D,>)@7S-:2)<\>_24^O&N3^42;SZJ%1UCYF-Q8!U7R7\DK
M<#0G3Y\,AKO91^9?GCPZM-+IY.:?2S8W2.3R[Y\?D@!E]U8#@K)"@VCF4PXW
M,M=$95N!HYG>+1^>&U($K(0( R)7"XJ+269-,FN267_ZVUMR-<VF,ZSS!3CA
M,QET&4+Y 8I%8_=IF#P1PT=.[#B(81#1_Y2(F<[F SZ;$]'+;TX _]0WR?NZ
M9-C'Q/+RY1R9AZ3._B/;;6^(]N+)LQ.HEW-G;MZM<S*=BNE4?([4A9P+IC9
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M-)B8!\+]5DD>%^T7%G6=:[Y66_$D/]SX RY+[ HU6@^/D_?"N,6=8^H2!J;
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M:]4.^P>J0&YTM*]5!\P@I%D,\8\WV380)<FZR(\LTH .9N<<<)I!9;JDS5!
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MXB!ZVJ]97Y2#H8#; @-M+PQO3%*W@;L9N"Y"E<!F@VT2M D)\CP-C8#NY:>
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M#LTU<$(]/U#TM'9T=2'IYM.+MR!W@YW3]$N[2I(JY=COOG?$1H<WT21BLY"
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MHK8T)/<;J1WD*F2\$$$8#F"'C#U)%0UHO[9,O#(=CRUCJQ18E9T2@G@^7'S
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M6W)VQJB3F2;%(HCK?\V6T"1:)M%R]_;Y)%H^@V@1@#LDA=3R6P<SL%E<+SO
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MK2\O]A\>H&CG?=ON.OD6[23F&^.T@"^O?+-Z2Q&VSP"S?!9X.V5!<Q?0G2T
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M]$0%&[QN-BOZSN8*\*5+P>A^.DZ^JZ^QG3B95E<T>EV9X7#.GN3?[PZ;[A-
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MF(S>\GK32=>>!N4? 8">[ MA3K3;("CVT_JZ0,'XJG@VNX*XQNAR5MRD<K$
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ME;0!#9L4Z1FE UNXP-P-JZXLS\8*3\FZNV7B,(V,S=QPW!D;\Q".Y8$459F
MM%[GCGEPGMU1CQKH(=[5DH!\XS21Q#!&%\CU"MJG$R,%0S8Y70[[<^S<5IT]
MKJPJW<7:X7T6-#P-&J'"3E===H,8<91$9H=:3H@Z;^@6.S2\*X/@''H+HKM[
MV# PPGI(8*M"'&^RMB=K>[*V__93LX$R84D9"!&.IGL 3#8CH2M)AIH!+AG3
M759#JWA4 Z;X X890IYJ?@\@*1<F)PNM*>:1((--JY8,*(!'S>[X!R/V]I[!
MX^Q)EN=MTA8?P< ,I<3$S*J1=BU1D4]!9*)5C44C'/$(\9U$(35]%<3T$?=
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M],Y,D$.'J2A/ECL(%(>R2,#;"9)IG'39VDTITXC<C"_G<%_A<\:T3=NN-#-
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MMQI'HBT%J/1-5 QG5L:1'8\) VVD0MU(CZ3+?*,<55I_:1*FC!Z>\^P7A1+
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MG)"A#3[C70R%-_>6@B+!Q[9*6;PW9N*TUSK7^QQFU_XCUK&S:_].++ B2A&
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M[6CC<D4F6X>L&BV'IT?VFCOOEA[J@PN]6EQ3?DY-2GC "VU.G'I1-CFUTH*
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M^[ BCX S;!CE%V@J@:<1"DX.\-B=W/%HS);;5T5"SY'.:.UU+71SG*?>RY<
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MBV<_90_H]#7%GBXPNN)WV5TL;,#=YN<ZS3EJ7!Q513C/$P*)<QDGK,CW(N=
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M@RD;\E@TZ],-M%%XAD$W6=!3=8DNPG9AW_,3BEPU/FBJBCS$?K!Z4@YYY%V
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M,=<HE(*(Y8AQ-0"),0Q;$O)#&C"SY^"\WR!I;[10H7'#2._:143_%H?+^_R
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M.X)WK(2$M%B%"GAP?>OOZXI'ZML>MH=_M6Z;<JL8;0&GLT_":.'8HE]NRQ/
MZC:>%3-]2)]\CI0TZI!M<S)[SV)$X^^D=2*H:KTSCYC=DYL)QSV*";@>N^8/
M +;4Y[P8(C/DVWKVY:TU>8&I9&L?X)Z;/4@/9/9Q5[3[]VK=(T/#?'/P.S;6
MB\.V- G_LR,JOW],D_ /GL8#NZ9N1B)(VNG?WI1U];^I3\^^G+B-A1X+E<N:
MW:;,1>*K&4%&X7<DKL.T*O <+]#G,7$(;=E#<U(!LTUYDMT*TJ8O9HA&Z&+T
MGTSK,?<Z_O>PRRD<0V?',5$7Y2KP?1-I!,!=RUT4Z5Q(_!YL:-8AVK?HG-H!
MHF0'BTE88K@G']4?@NWF/M_#68S#5&ZV>J,!0,^JM$O5O(?!IGZ033;JA,K$
MU";[%PBBBP2;=+)61_HO,%ZB\[:;\])D]]&93H=U=> '?M"4R18/F[U@EF#-
M^JHSIB!(OO'/+S[]-!8,Y&#DDL+&582'24W$HNP8W0WM&4<,W,&G8Z^:PU^:
MJFXXHML6V)##@<)3F),Y"\57Q^1LR0F+5"WDBAL1:32-82QQ=^XX31J]2+:&
MPXTT+-+$<'N>N]B,1)[\'FY>36LC##:GC_VI>-/Q1#H=REH.AVU@-UW^.@V]
M9Y;,K >\/J>7ETZX7;,9F#YO_'!9@WI;TI,.Z S$ [*!;[ T!G;!E8MU3 Z3
M8#9IQN 4X@SYB7;._P8C;-7W25>-[9L77J\9>M R:MDJ>TVD.UIU[R>TDG30
M-@?I*9=M8KL#9(7&)C;>*#XI.<J$T.H+[/\JI0)?F $\U2V_'WJ\=Y6VL-]6
MVP&MX8X-B!N^54V!;WH(Y;8#H<$MOU_4MJ+!%)9/SICBF_DTT;[MFKH.!VLC
M%_ZSPUE)&.FM;@+3$Y[V.E^<::8?Q<G/K]>'\BA$ )%N2&/*&%**1V+]O#PJ
MEPW@9,%G-D1"#3 Z=/S(%=E?C2/]8O?]+UWT);JX)D=.AW-J1BN07H5G30S+
M@=F8.HM.Y?%#>UMM@LU"BS5;=AWSF W86P^_X$Y;$D!FH)Q+P+/%Z(EN=I2@
MD"P630D=!#[?X%=^Y(9"R[-\X".V"B=(82D"BFF#A9HM#RA":V\EE6.*8^SX
MG.!7EA_=H3G8?+U"'+WL%24.C9QO9M/-36U8AHVVF4P.D@'*G*/G9M\?@N3T
MFP.(<N3(R)Y2'&4]&NEICQEU'-VJZ8TUD!,:)3H9/>5TV8/&07@$XSM8)Z_S
M6_V&\?XTKZC$ES?GU.?>KQX<O$K5ZF.<6W HEFW+"07G6S=UD-X3U..S-W_
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M_7*(OMM#=*["']D2LV3CW)$[YB:;N5IF$ TS! 46SD*XN$[J_05,8K49A-A
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M"T&]BG*A1LSOO:77WEOHH^#G7%:+'E;.=JF"1O.V.9354<NEPEOB<#+^:4K
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MNADS<)=.(#(P'2""./>$5R#BTF+2,GO F*],STEF9W.@HWEW%KM3]NF)2LT
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MA0@*'ZHWP;*6PGHBAPM]PNF$N/:J+MF<J;EC2A;;% A?;R&>YD-S!*,)90Z
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M_</WK(X)%'<:^D1BJ =:UA/@(OQ$'L;N]-+UO'B)5S"J[&)\]LG+8I1$^=O
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M??SU7,Z&='0B'.SH5QV8.CB.G'WT9<=?R^I;=OQ3199*DG.6U-6M,O8(Z7M
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M=S_\Q(Q5UMX136CL]%I,R;4LZ\64/(E4<:9%-R=#-_)T9+,"F<DGO8+_VTC
M%:520Q2U+QZNYMW'&*+W3.X#J[P?SMZ"</JP75=].U-/HZ$H;U2XJ\?^UYZU
M!7]S=>MQL0%/ZTX H*H$.Y%1;RLL+-7._:D8>?2E$'9PT<QANS?EB9NTI-N3
MPH.&XPC'VK(3ULI'F0>4YQ,ISDP:?[5LXRM94LLV?OJ41.IUEBA>HG#-ZGNJ
MJ@A;<5R@#D'W"&ZJQ#3*7Z;K'@2ZPBH.XJEOR#C0Y_<*-2ST+__<]'_TNX7^
MY5_1![,<%\MQ\5LX+J9)),99P_UZSO\UGVV)/(\9KL(%:%HXRJM,L7C$?7B%
M*K%KJSPM_41^QH=.Y!\95:^FK/SW$'-<UR&SM)K_ECL#O]M/L=.NFO/X9(A1
M?@I0JAO69-7D(C-!%W<J#\QB\].)>7@2\01P%2A8A3<Q!)NEOQ#TL0H"<5UX
M:!66G$6,2D6=.GS3PUQ0/)E"P"+YXYH.0AHK>55XGI'0LQQNY#\?135AK5:/
M8\^05%>BV9WYAJ>GC+BV1*7$^/+0MDPN"[=:T6MLR+ZO*PZCO^T-  ]PJ=**
M<IU/N7A>K+X#GL73;Z )/' ^_Y!Z1:.KKL'UCASM6ED!T$6:'@L)\$%:_J7P
M6,?L-Z!W=+ Q&[];>!&C+F ?)@-RGZ9\6@HQT)&.$8P9-I0?P$35Z$_&C74>
M$ZC@OZV#V<^W#D3-1#P[*-Q:41_=91MB&]9" EL=!N#WJZX;L*SYF[R#>BZ^
MTL\E"E+5 3?RZ+"G&4P/RWE'NNF>; 88MGABH)T1MI.60=](()6+&[V07N6N
M9:,$-0BPXW9=D#+,3=-LL?BCMI!T$>_)5NH[,Z$#IV6.M,#C<M=MSA/*&*O!
ME#?X?CP;NW+#<UY&,M+)9$A+@GWLPL$\?Z-<OG'*;+D4_G'I2YD&M&Q#9J;H
M!@X?435.T#*M'5MEN[MX$^O6<%T=/L'+I:XH>V;2$;0Y$JV?,FSPDP0R+LTY
MA,MW&[%A"(VNMW3C:7X^HYS2>.MJ/((\)L4%MFI/TJ/4/+/,/([6]X)&E*T[
M7.N8 +%1'68TR4)+0EX>O2Y-BO \L#;4/!MRD?K2,S(-OXN:2 R=V"#*S1XV
M7HH$=+!(YT\L^->!5RR(AV%TQ:.']O!H#/ S_IND,"*1$7[&M/!2^'-3ACQB
M.HNNFA3B&IV9Q45\)V)TGM :8DC_#,>,&9EH 8WQ1=M80+%3R;']/!')F 6@
M>'E,'>/Z:%73SMPKWEW&M)(9 6?I4HX1I&%<);P-N4>X4UKTF5/?B&#0JJ_%
MB2T;5Z%N"BLAE%V%$OBJ'9Z"_0T E)*;..KHN;5N?!TE[XS:F]]6-(V7',:H
MP"!F3$X"3ZL&?8,C#2_&9-65NZ!G<N 3NMR<0;@O&NM"7YZ>SW*M\F3/A;%]
MUSQ2S[V</K$1(D6]+SYH#E7-S[T7UDSAJ4L-%\+W"7%$1T>G:T&^5O;3.UDW
MI7ORB32&LO<R/H5<#ED/D4439:21?X*#PZ1SR//APZL7/XPSR\5J.*F.#KM2
M7>>I-.?SX@F 7FJ81)//QQ2>G2F/='QKV9A=9.:D+==T8Z<O;K:9C_UMPVUY
M&+) +_=I+\0F*A+6G$ZT9(<:7BOBA;P\CS(^3FSU7K,M][!/C;'O*K)G9>M#
M$YEJT]Z0#EAQ./R2U5&@U2Q!I;!LY<,D0!^Z"AH%*&!H48P(XE##\ZQ#)&6]
M:!>BA<+;0D",NQ+@C L%+CLR,^X8TE-P"%15K<F<M3IY.%@"D?1*'LG'[2Y_
MMK@1BQMQ!:/JHI6DI6+$4F\3:V1!P@R;:4J43#]T.1\G'SEF8QV)>$"C4%*_
MT,DI,^^G'HYKKE#NH)O(/,LS;?2='@L'#I17(\)%B%)7=,AM<_Y%L6NB#H5Q
M$SD>'D6R-_2/=.NT]2>O;K+7%I7J 6C.4.C22<2/&V*D-:5;O)>O;X:E#TX<
M^3WKLJNZXD'BOB]F0D80Q,:;2_J]83)%))WZ4?8RBM5,'0P9,\<)ZSK"C*1_
M O@P(H="?Y13T\YX-ZW=!T.\H1#6XG=FEZTC;AVGX4S!>V<QX\P;((B7_(KN
M 78X*DE\"N?@EH^'-]F8C)OD9C$L[@E41XA3<9JVL8D15@P:_<M/87G=?^+^
MZBB)OO)(;V>-LV^:3RZFE#N9&S#,DD9.EQXMMECD<=V _$H7C=0()W3)(V^X
MO\'8'B7O")])A%Z5]L=^IWF'Y>!>#NXK&-67<;\=DBHNQV0]KC8-"S>E"!%7
M%%V288C4_[P!#TDRB]XE$EL8''<U"B+%6^9\=!_J7/)9*K80[$JWH:CC?!(6
MX&+FXTB_D<Y8YLYE R&/3L;G9,(.CK@V^NK*$1M%B..E7>@F30MPTC5V.3L8
M$ES\28K[Q>J;<%.VVX,&KY(W/&6:,&M_+LX]'+^"LK-KNC(((>^.SK @W5VH
M>L#Z1=)E;Q?95MY[$(]>6VKS+#9_CRJSZ^^$J8S,"IZN>GUH-F^L>.^"<85C
M.A[I^>?+<LMZ4J0;)P5GE[&XV+,!\ZQ]*E+L5V_SWO=3A9")LU*NR<@W]25'
MA5])B@/C\E:JG,4X7R-4/IQ"NYP/R_EP!:/ZM4?;Y"B U"4I)@.FF[;$7=.^
MX41C)*B/B<<*W"P"PTG;5PA*LZO <JE4=4H %F8I]^$@NKOH"(\)F<R&^I)8
M[<V4OQ%=,=#MI:=TZ$3$EBV-AZ<^;%5,SE:L_QRXH.)U5^W."0NATK?F]M9.
M@U2?&^YZF22(@E14^;EJ_U>-M<1+OIO7RU09,[H@VNS]L9.L9Z/^?A8!QPI[
M1IL1'>)89*//H:L&"Y@.1XHS:^7'PK&9Y[^8<&\:Q\^G\IU_X$36+GCD8DE3
M7/>HW/6%:U4I,Q?%#4(<\$L"I2R%Q.EN^N*,J2]L2 %<XWO'>N@B4O++533Z
M]6"ZWU\PW8NDYY4J:Z$,JU1OJ^828#C* "+KMH[_E)01G]6%(>+$DOLSXJ[L
MD!F2GR>&J++K*%J !'*QNN$"92UGRDT@"R]>0PR1G?1YBE*+22UU7(P3AVEZ
M$+U8?49.@R+JCB&D7)X7(,T$1!M!-PTG.E(#12+QKQZHAUCE9[Y+WHP']<5&
M@EQ^B.1T709,/W".+J?A$@0]^:C^]>=L#NP-2TDI57-A8$C)D"1D8X2IP+Z@
MXPW];_3I)FF%SE1$'DS,,"I1@J5VE=O %ZMO+^W\F.$0T&+8NL37?5LY&15
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M5&+(+KO< [/;N-_S[J:-QYY%V6X-2"[=UMILC1S+A-^W(&NJ8#IX,V#3D'A
MD:>7O=PNJ40HY]7,Z#U <K\.D<$PAB4(J=;22?S]BV]?K%[KK<DV?<<9.':
M5E\CB[!Z]OVWK[_[^CW8W/5YE&*8C4&2U&#^LMH4#@72&11(_J3P><5_3XXN
M/P#=IKW0%*#];^.(Z"L_2W9/V]E7;XBN Y#\Z^D$_F#I!%XZ@9]Z%?IJQ2"-
M1RG:C,%T;)J2<X9S.^P'GQ58)Y9XVX1.9:LMI9+0<^*H'LLW1DOMB/SB_6"J
MZ<*2>-L(X;(_4T C[ 4VXD^\.,=,UX9[]*_(+C<X!BT?XS!^1F976E,&W?G8
M])96\<^!UF(NNPC!9.35+<AU.'<5.<^Q53%TF[9:!\M_F"LAV?/-QW2$/2?_
M/1SD#]N/G9.@15<EG1K!F8YSYPDYZ =V$6XX<M$+VS.<4@-E5>_X/-=$ I]0
MZR$1/=NGU@TY>R=-9(#M=X-,'\<-6B33QD)W&?H\"EE(G"3+)*6F#'6Y! E+
MD' %H^H+?L[=75?-F%(@CQ52="X<E9(%ALH,%Y[KZ)!7]6USN$5S)SCZ5P=R
MZE7_IY00XG^&T"4U#\YN(ZL(RMQS*%O-=DO*<_TC(F[:KKSY$EAKRLPK,I_T
MS8F7&NN3OCCK.:68]O[([&[BJ7?9Y6;:8U_/1!,/U)I_'-JJXR8?>?$6L9+P
M$\JC#1 G "]X7QU6[_]I16:GW]-WV5W2FK'"880('Z)T8MJ5O!3E"7Y]WUS$
M:DI:*I%)ZG-H&E<TP)M5M5T?2[>(%Z>5G(P(&%95%8N*:7X^3\Z/J)3X>T,D
MW,W0=!B=\<H2F("%<Z[>/1?9V7RG(D">_]<(23+3?E&X3<#U:4X.@5?L;M\<
M@HX]UR@P#_)SW^X8S;^ ?361E?).PE.M&AG,">@Y[5%N0SKJFFW>-1JUY:AX
M)_FD)%X5JC%>3XRC:(:U)V9^\!+H_DN/QN"@#E4!?BOL%3,6 O>4ZEWN%CLC
M,BH\,V)>WT22NI!BB,S5"!+,R/2V#R%_1J=/BRFS')&'R*08(0>MJ+R&VCX3
M!01P6$*1/#M#9JU>?1M.?0"!^_M_*%;D+K\OMO7+4.[/S[\]LNU^24:$[D*G
MWBW&X259K&?9%S;]>Z B8N8$N.\]E^;OI/H^^J8"9IB@@=-G9(XS&9]$$(\,
M5II.C4T GZ$?[VD:<M,=2W(1]K.-!\%6$06,H0Y;'."H]Y+S7+8S;[SIXUS)
MLR)UV"7D0$>GVF8?MC,+3(O<%H[@;*/=36: AR\&)=VYZX6%>^:[? Z.OEGP
M.<N58U>OYLK!^DC3:LLB%OK5MT".SZJA,V@KA!8!$1C3A[C^8X9A;8U/O>Q[
M,B*V,W#&:F@KE[2<(]_MN>'8)3%)J_FY$*@X0/L+&C(HD*RR-TYOVJGB$M1.
ML%FG+"2:\M03ON4*D3H&XD[(> O_B$#"9K:-\RDM6<G!<G^0.KFS*!@MO6@%
M9DO/E6Q>35D;PX[>?%]R<*ZA=/HU:S%5H94=HK,DU2665"!KZ4A4K.IF$R+0
M,!L>WS:0S.!H-1>:)$BTT5$+\C;X3>?V&TU"LZD ^8NL/K.7K::;*7?HTN8I
M(%9U=$P-/*Y? ?.C!NA#VIWL/C&VDDER-@<:*QK?4O0%Z14*M0*SVQ:SB.)9
MHV(YIY"&)N<:_3QE\&?V/[\9)Z1-8=6K\_PK;+@[-][2CD\S[85A@'*2LJ6$
MN+A\OQ"7+^41$^6OA> X(SV],3^@17^/.P*YR!507M<L@1!F1#P5BZNTU:VJ
MT[8A_$1O5.L_X6G"Q@4F]671N\*?;/*GZ)/N@BCN^@XN0Y1%9?C,=6DR!]?^
MN(O$T2\YW\ RPXRQ9AYEP]AK]0W9P30.A;NU(+]BGYGQ7DWT832\-TA:,==I
M!@=DS!P]IK^Z$,M&\43FZ=G22;Y!GYJ *XI8ASV59V%F;O!G<+%9( VSYZ5J
M/:O82-)%X17QNIHZ%5/L%I)_P5%>1TF+'L:P:%GYL6VQ8\S+S\>C1-U81W.=
M#X)#Q5SN(;AF2W:-IFHY -Y5>CC:=!]<*!L8?5-07P%9TD:<,W6SF7E]D@:<
M0^F:QH4 8_E?B:Y/MZUUTAH&>&MY!$4HI.RD TO<USGS2/L=;]B-4,3&2^AA
M;Y8/Q',H%.,>@/$\OOA"?M'[D(?J6/5C/%O7LZUQB<:AFU'5 F>O,@CPY5,5
M,D_W:ZH3YQ3?#(0C0SN7U?%D<;-LQ(JI2\Z$3:KZPKA#X-?:!=XOJC<PFCL)
M-,BA1G]7J+$D=ZR#7B+K6VVU"4@B!YK+@?,8X:=3E1[;K]\49'[P.ZTS1 D>
MB00I6M+6+($C\^_KIGX>0Z=93K 7JW^4Y.\,G=0/NIB!]N)C'WND4L"K^^<K
M8L#A89F]DK?P6'0V;"]6GS5"'BMI]_B*O*33([#4'B^Y#*\M&@<3?=1Y#M 8
MF#4UZW*L>'FE5BUN/UAKR82/7<X&0"W7%<$5'5[$%KH+O\4-&KR-B.K:K>28
M]$LI2_JYL=+LR@B%GA;M:'!B7=]0]F0W]7G@Z-*RD_U,L3(<EZXG!T0>E)TM
MUW/2R@<V>3C7C?+MEJ?K2\Z"IG1!2:NHN>'E,OMH&>HK+QK=<C, 66VL^1)U
M_4-^;:0B)DV21Q:<.AU2EX(FQ_()E<.#S.2<R)<44S9!^@#=0$J;@,&$(V7L
M=F#_DDY&^.!N<OH@^DFG/60#6[\ZU8/7YL-":5)4RTHW'"_7+8TX=\(S/;K>
M6+XJ88=(DS@CD%IP4@XYT1;9)92*U]_(I[OFM:;REJ?1(A._N5>UDL("#'Q+
MVS5PYKC1I%W.N2R(#-_) ] 5LNZ*<5=%RK5D-,IV3DF7I*@R.]2)Y=FZ?=/"
M!8Z'LD>.0--+.VUU,_.3ZU=X&@WWL6LX+!D%5FX:)/-%JY)%*>D8INE0\7,)
M*&[I-05144_U5TP;KF_I3.O8PV^#Q'=VP_@5R=(E.3DRY"6\]'*H-_L1Y$7S
M?S+<1XQ<6A>";4&1-7DLJL<XZ3PIK.V.!YM%:WCWC$*9TB L:-..7M:\WZ)#
MF,3D<&*HX;3$US89>6.PUC8=:-%OLY0P6JRZE#33:YF"+)MO/F%J>"J/NVY^
M%C)<ZE*.^\7JAQA;CIV(F>:!^QH'8J=O4VOT;.E2'B%&$V#9A=2;EK6EQ24J
MUUZ0JK]1I.J'"U)U0:H^]2IT_03L5QCWMD^_DJM;)W9M 6S!?T,X4VU6'-&*
M&)IVX6KX]=?J5D%4Y9%K[+$M,W+S&Q0VTV@V!TTDQ\:^&5VC%A=M8IA=?P<L
MNXG%N'>4(U;,L[61<T:/?1 .,0!T&O](,*(NG[:=]B?/6?;Q-=+@/GAP2!"B
MUWFKR1#E=A6@S;!2]^8[R'MH>W*AJL9#U= F8X*T3H4Z(=?@Y&W#O7@C2<'.
MYP" 1%YRCTON\1I&U3:UJN?.<6/.;'-$<RK,F32I>PUOUF6+#9V ^H7FR01T
M<3A$.S5S/=3)AVZ$NY\I#7TM^R\JX7#!?1OK\GT4)15:BXJ3?O<VI+EFM*Z8
M?;((G[]O8^=9Q!28<%K)$(\^H^@I'KR*?5Y)&G\S+W9P5&NYC_3DY:&I,:."
M0XVUE&:Q/HOUN8I1?2M(=SATX0Y4,+P%4V(Y@;BQ!7ZJ>,_1W\=@[KF4<](6
M1!J+]V2E=,#P",4)X'317*Y:R@[2JW+0_(CJ]"J</5Z5OY]!Q>\U1:DG)R,>
MZ#R\1<AIV.8EH>58].4+, 2=/KT)X_2BX;E3'^LL:P*&)=TJ#3/Y>(5'*%BZ
M KERZUU:!U 4D:T[2KX9#&)"'6:\0?PNCBR2OH_NYPR@C7R>T*]%52E%F%X"
MH>.9X\CC^G-?C6,W+!HYBT[5M>E4?0TO+#4Y"MWB*-?K:S'*X0BDRY&6.?*<
M,&"W6BDS("47A[;-9D"NUV-G=B%$&$H"BV?XTXI])-DV3I;0MI>J$Z;4[</T
M0:,<*!MDKOZ-WT$Z'K/:P/4NOU_XGET<F,<[,"@/<0YB5"]G)%T=[B@LD'_1
MN3> M">H-V.;4O:8VTOX1I/B+_KR?W)J)#N;-=+BBA\=P&LKS7O<G[_)Y:T:
M^YWG>N[D[+32.?)86CNZ!T0R][RC4K3&<AHW*@^AD1!FL1L82$"SJ]A=>USN
M8*%(,OE1.KXT7;?5)E@FIQ5X1>(:E4I)V]?L+0'U?5;;@G'7 64+Y)LP;+0\
M:-V/;_S^/0-MRJICRV:]('/6N6P-N(-58F&G:\GP)?@IQ%^KNAA%K)E ]VYX
M,!$7'CD7V(;3(/PI#'W?5>W1=PK1%7:A$Q@&!FP?#B<AT3MR]5>Y:-DC1]M(
M)ON=RUSSZN1")( CD6>OW!BIGU[Q@KF?9>J*BV^6+0>E0"#_T;192!<#X$@*
M]3^EDMQFT'YX.P !% '+)A^+0A4C8\)\7$+_LMDT[38[I+)*]G!(])62-J#G
M4_\X(E, 1&)7>W3L\7,E)%2YII%N:H/$RZ/G&9)FSLTM]!IHP-1NA?)@I'\'
MAJ0:R"K?G+H-8QG?HR(PL B+&)9PBQ1VI-_,:]E(/CN&8I2R<&6C) 0$AX,N
M)_Z[:(TO?OHOQ$]_G5 H$8#&1H9,5RDT&+[5V?<A)RJ ^E()16E*XM7RHM*R
M&Q8/^,E']=];\=13IUM]^?K#CS[X]]8_?PC@Y1?O \H##C^8SD^Q!)>RF *P
M-1!H,:-=NY(<ISI5$<X3$3[=)>0N_^F3=KA9O6[9 W[ERJ4\RFJHOF,@W#<)
M(8>./WKZ]__\I]\SVNW(X/)+\%:F[3E)<R,9,*,-.3<*HY6E-@(")@_%*B,)
M5FL12ZQ=.$*F9\IGZEIS'3E2^LDL"#4^\GNC7D?GGI5#O^<4894CG/A;GWWR
M,F*#Q=N?F\\$L>6E?EL>X#XYHF:]P7E6H=AJSA#]$/\1I:&.7-7./%!KKLTA
MB[(^W2HRH%\;=EPYHU&5]BSWBYSV'%$1_T*^AT# YL3_*(=$ HX)9ZW9;%#J
MFL,N.F_O28"'B$H]\I"+\8^&'2Z'ZN)B7IF+^?707A( DEA-N>8\K-Z<3I.?
M97!]"M&D"2\:A26\6AS*JQG5[Y+J,M.*15!R%,Y"=T[J.;UW9U1=XBB(P))[
M?X'B85;)M,,5A[5&8FZ'Y<0*4IELJ^Z-9-%RA@0E59$$IX'W_VNT@!9!RD60
M\K<@2-DD_)9S&8_L,@**-:"<"?[K8R2$F4"P1L2N+H;C'K+X=>FCC:2G?:+Q
M-@T7<XPI,.3<8\]*#*KJ,%), LMI<UA$GJ]E+2W[]TD$98-)CH""*=Q4FU1:
MDPB+=UU"$&7T2$<K!45FJ&Z\04>4^LW]P@++)KWN!;-LTB?:I ]N16$JNQ<:
MK1ZTI?-F]<[<1EZVX=4NB64;/K&ORV.O& F'^'<=!>6A#VU=3KF*F5!JD.T9
MO/1,]J49VJ>'HN1+FW-I=_TGVUU_O[2[_BO:79=#8CDD?@N'Q-M'-S$O>6 ^
M').AC"'3XG5=R^0N&^HI-M0H@7#/'EH'(8E3XCC^...+ [F4P3')[1)]E<1;
MM^RT:YGU9:<]27PSQH$@YT"?(T] ^R: Z%RD"!S>@XG0*RV-/5*Q KO8R::6
MX)%HUR8-9]R#7C%,4_V,1+-4QB.>"7QO=Q0VK40M:0:BI95WZ3C,\-,*'ZJA
M<R9Y3BYD"+:)B=UK:Y$72%L:"2>W[.&B0BG!K]"50A^(+M'RQXQ\4F'5BT&Z
MFLVQ&*2GRGNJ;VR;*=?X.-%&YOZ:/'L2ZX5)5OACWLK+;KJ2F5UVTU/LIH3A
M=0PLJ=>^3"3/#REM7$6&\5<(,%O E3\37/E=IND@"7HZ)CC%+D&>U[+@<$^5
M%"24Y*,B$UA@O/%]N79!H3=##T6.*%MS9UWQ":TFJA%S:C:J =286B=H@28:
M/]>[:G[A6VW!<CYZ5+\>LMC$EJIR512)>!_LO)X9R[HO[-^ZNJ=TM1FME8N=
M"J^14OAN4R8@RRYF71P7"7 %R=D%0YK-^XZS@BLA^[Z+#>>-! KLSB!)P_F#
M0L&T,LF106B*SB7ZE+4"6VY<8C2-MG3@J-XFD> DCB.2;J[)R(7>]YDS%8B=
M'['807YAO,1%-_<\TQ(//U72'^9XB<W_ /4 ($+90/T0]!*>^DV5CT3RIF\*
M44-R(C28M4+=EY([3C*#GTL(I5&Z%T(\UZG^=FLMS;;O3+HDL22*3*M,D<F6
MV$B\R1K@8F,3+[#Q <@M2.U\!L7:"88NL57'N?) +9]RU00KGB^,R/F*D9J@
MG* LN]E;YWR%U&O5O9&K]9/GW>R;IM/N\AON,P(759PU)QMD\O!"J)?Z?_2-
ME:@\S^/$-TX,J'>\L X5+5QM'-3!:4,T G@#UHF =$KB;P^C5GH[XAM 3O%Z
M 0FCL5*37![9:2?R? @ZTS)5V^)>&;SD.(Q("*<Z5H]>K^A&9$#^#$>AI<<Q
MWYE\IK'P>Y(-EF (6W!A8-! +"F.41VD5Y#Q2-C03!0;NN%XLBY#NSH(8-&B
MMA[HH6I9/:QK#=(+:4KEQ2H+@J\BRYNE%L4XUK>5M)H%3C'R7BNC8KG6!^Y[
M#2P&N'FR=NL&HIYM*02XG%]X<%'<J=2BJ=C,X)7']_52"3MV$E .-'M:NFUS
M3OSV4NP N9Y;4??[KW<9$;_V^"95AC(2N:3DII=MQ6JKR5X,L2,8!*'IM$Z<
M5Z9I,@OP?M:]-[*5KM73I7\<MMP>L3ZG)[>G%=XLW04@\RN[1B4GT-'+R!Q5
M?'=V $+NX^LG>;*H<+8.X/>( A&Z0)A&J[J-?8TN@YX.T-S@E>)"Z7KL6%$T
M.U4C)8KJR(F89U2_$PX:6?R X$8U5)KK1)&#MNSF7![Z2(@B1VQ\&Q$7]L?3
M^FSKFJU!(<R 9??0-(^IDS57'EVHC 9UL@I&<@]WV1,.X"?"[.Q =U.+&[(M
MCW1,Y%V_-!>L<B*?B-DCU[RMP[FS_:)43M5TG\'0,L&.&+YHCE,CM:F?W+>Y
MR':M=I5@ %BS.CM_\58F=3]TQJ[[T&B.G.;[70]IMMC8^I#9ZQ"HMB:SZF/,
MI#![F?5VRN&R>N6$?(QW^%AUZ.@F5Q$\<*(Z5N^$7A<N;BJ?\/'=LEQ@%S9M
MZ+N)VYR??X:MNW .VH,5//ADI87#IK8E)45?B:_CZQHK)WR\A4UWB;:O851S
M3UY\VI25>@M#E/GYH/9FM@N<2'+"5?6/0ZTBUG8]/EIZ57 BWWB76X2H>DTF
M87UH-F_&+NB.3@Z^3*S6C(Q9N-3F=8_1NFBM7JP^29K2XG&;\MC%<*1(7AFK
MZ(X.SAAM,$4(7QC$:'84E=FWMY7*1_ =:'9+M?'IR!>:ML!#V=$KL-(B['UN
MKJ2;U=>N13 HM:R:H8.($M.\1?8ND"'?!N,Y2WZ[#,3D_$D+(CI7(G\E%'K9
MZ_T3IZL0,LM!FCU 84O/4]>IKQ,E!=WR+_!8XL+@G^ 1WH:.%=X$$!U=#.,5
MMA5K+$Y'E9>"<UA"VOQY4F^G^+=2>F)QJOP8@ $'LV ^!]8%G2D@-<0$T.FG
MW&DQSEE[F;.?NR/&,>#H_%WQ$%0[:$>Q7-:5GL;+F;J<J5<PJC\HM^4=U&QV
M\XD983R]"-N5Y:\5TB0$@>2P9TV,.SMR)UE0B%YHT2!E>?83<_[</?QD&8"I
MG/E&SA2)1!ET>Z/69D./34-3=7W0$&/U[?NOH4IYZF&&M\)VQ-$?ZN91J)NB
M8(K&R7PU>AH"#:5*>#@4&LW,<+#(EG-+!R^=$4Q?PC^B]Q4+^)AW'?/C/OPF
MJX^>?_Y=>I/RIN$/15+U5!WHK]6&A<D1S7+PN^<VN83YL@R@I'2BE+&WIH[@
M_A&3#4HSMJ9?OO[#1W].)\)LDL8+)-&8-BW+RDMJE7-?\,"6$N OM]K^ZVF"
M^FAI@EHT_ZX-]?&#,YX(YU"68F'GH>J[C+6U354CSY\WAD1E5-=*.?YPH)W[
MZNN@X:,DB#F&H$?NAJ-E]X8Z!6J+=5_<XR<?U5<C[L=8<,K4OF^K!D3J[V #
MO5A]UP@P/[1YQ@(M/$K!R3"(H<N<)E^Z @&"MO1H&DBWI7##CS;E\[@I"]V5
M-/1<NF/';%200+DI?[!4N4_U80%";*IM+!%:N@XC$P<DC1 JB_TJMBN!Z2QS
M$)7A,W&"=K1R!7XFP RXSTB=B#J?Z*0GG$DO[80&-).EJ;ZMFTISB).CZRY"
M[P_J4.2=7B:<J&.V)]?9Y<^XR5US<QZ(H?4/EK9R"2!=-S$0ZP4G0'\6::Y4
M094QXE5"<\7_K,NV;>Y4P<!=?7!Z4S.1A;L%OS,/$-WHQ>K[C.<M<>YK9BH8
MJM#8>+4&&IW_J(KJ!R(":$;#H)D4J[)< -_F]7TN,QOT0BJKIP-9#0$8N8=#
M.E!R@)$[,BO@ B'"4@^2?L1\Y_7=M<HIRJ:<(D>,P]D^<8GJT<H2>.5\2QXV
MVG38YHEZL:2VI132^+'LW@;H](7][$8*1U,^Z*;64?NK;@91K8V_39"'>*(S
M.)KOPNT^%-MRZ8UKKR'TQN%@"B 4 _>#TF GX0N?1Z5[Z]*[#8?^S$G16Q8@
MD7PP"LQ('R:9"/E^NK+)MM':H5$8O4<]\^(R.5ZXR5Y(QAMSQNEVWI>TJFNZ
MNL*JO!;]2*N"/T;#9=27B(O9IQ;C[@%624W:UJ]]VL#'JN/V9W!_\W1+NEAI
MH=TCS$*=>"&W)1]2EI=,<RE+9(R8 FB14\&"M_*[TQ9V^$E05_1VG*YA:2NI
MD<X@LO!2[GKNK\TIZI&"L3RIOR1\FLKAS"QYP5;R3!UD-G+;PJGG[.<XU'^2
M[M;X33$/!E>.E)5Z6,;%T4F]( Z=G(JCI803*CLI?X#*B8(T#/=L**B(GHE&
M7.:SXI7*Z* $GH[Y)5M>,NHTU(!GD!N Q-'<DOA,R>D][/&^_GNE!Q6,15X*
M,?YL*)B)>R+E$1JB3<47->.T3<4G.?W&$DIJ*Y,U69]S*PRT3^G,&EY4 $U,
M"RX5B]$LC29IQLZY4L0!:3LP"W2]HG0Q.*'=ER=8SL)>($-H>JY6/8FFJ-TY
M'-FWV#UC.9J)=-S/$X59*@5+*/1N1_4+C\Z%%]M6MTZ&2RTV=RXW;V80S( F
MTRM#,.GLSAL-6))D%D#N#$JCY;_*5&9E@X?:9<$3#AEGBEAZRQ;S5RF8V%<G
M^FF1N5X7"AJX1-.%2<@&[WZH=^5MTZ*":8>&(<^BOQ]WN#<-T^;I.<2:%/=3
MM&*>^D0KF[V;XPGVUP!^>FE&1?;)L5![:;)P9P&TQUII='K8ZG"2:#?[*PJ!
M@L1C#;G@+3]M^6ADX8O5E_&\+3*0=^$7T6P\( %>&EJ.(8$LL)! X>>X*H5A
MJD$2$H 17+HQJ52,KNAKVES_EJG95LSXJ<"">P$,BW%>C/,UC*IT$J@EG:OA
M9LYD&\PNT78U[Q'6-%434995[[S(.*J+*-TM\)[4A-2T_B,T%#%V(I0BAJ+%
MXJB'/8>U[P%HYZ@E@E.$$./>[IC)Z^&5"E!DQ[^/ZIIEZ]3_+K-LOW6C3S%&
MZ(J :<+,*J__#-3W+TK@/\M52NL3<C,0?!1I(B/$,C2^SG^:VP<9M_@7(F.>
M;.(<J]"%P?$IT5%B<(SW9GV"1C4DIR0H)8K9A;Q<G$S!Z@!ZX^QTDM?QVNZG
MINTI?JL:.UUQ:P^PCJI$BK2R%\P[JN*P*!:YD+@G3_C&0\SI&J5L%./."RS_
MK!UO#LED0#9)2.'>0W(^QNR8DMMR&PXY7V-,L63A=)ILBCKI0^R=NGQJ+)-4
M 3EAR .C'!_5P.*?^: ?ZB0QSVZ&B<1JD]XY182(]2P#Y4!IP>2?/'*34^8Y
MS.IQ2$X!I\ O0>1NF#GIUME?D$Z]YO/G&@^8Y=A^1^BKF3:>:'G*@Q8#HI6)
MX4B18Q@=GNK^<JSL33K*6_1Q3#B?V,1PF3@^E]6))2JR34=;'YT@Y3RQU<-1
M1M["^ YBCI>3LLLTNO =DP\I[?!X<'Y;3:,&&$MD<3V;:3%1[V)4S2?5^H:'
M_R?MIW.>58]Y8[J,"4(I&ASRH%F$4D7_)'H)F0-:6%_77,^U?G7$7@DW2%W?
M<8/])-WS&! +<C%5]^9YN65&I;#%ED8=UAX\X1>C2*O5&?GY-SHN\&O[\XEI
M#0[L>RLDT[1&K19C)3D9OVT18[NFT6[?5@JT8CS7Y!'')(A'UL*?EGBKZYO-
M&V[$#JT,:A6'T7FVQQ/;)[ N(('.+05M4C=_R%I::A\-*B,&@Z]'(4$<_&G+
MNSL-.QKP4E]3#*GV%1]0AIHI*V<))!Y/WYQCDI\"??!KFSS1&] FM*Y1+C6H
M2+<#HBPL)\>K&"[17:2@)$G*LPAG:C+QH BX]]9/80L,OW'O9Y6@K,D&3")]
M+XE1F_[1\=)M*OY\QRHV]$NN9![T9&Z&'L8$VVP=ZD F0&11X?:/MY>R?B36
MH'KK7P#ECV&K79VMUH&DQ%&)7TZKC N;3<T+01I]JWZ($Q@9BCBTX=8L:7?"
M6N$B,(8#,8=>EK_7'(;8_9/"4+YVKE%7=EVSD;:/<=EPHX!FV@/-L5(^%!?8
M22%5@D4N*F<IZ]CU[15<[3"Z^K/S.L!VOQY4\!\65/"""G[J52@*TT5NFN E
MU'*T"4,P6;O_G[UW;7+;2K)%_PIC8OI>.P*JT=MV.^Z)4,MVM_JV1PK+/8[[
M$20V25@@P,:C2IQ??W-EYG[A4562I2Y*VA'G]%@L$MC8V/E>N7+7Y@?&5-RS
M$18H22:5)Q="31)9#",6C*+GJ!(XH(Y,VY?'J&]D;ZHC\^RTBQ08RN( ,%>*
MAE(T= :[&C"CD*--+FK9[4=]O.*GCD"O<-7=U/K<-YC#H5./V;;#!L&0DF:?
ME .) H^\X-(&>*G$@1H1?O@&7T7'VM12[4;[KH"[*TZN^PP.6S9RA:/L17Y
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M_MB!?45(;*6]4?$3 03]75B,O9'\F9ZGX>FN"W7,8$3*[?@*D'L;3>41N/R
MJU#4:.HP(6XW= ' 3T=BU%QYO0OI:7V?[\LZY^6_(#\WSV1K\*:&JL-6>@ C
M)]<%(B7^7AX5E1S%$=YR50EP0KHJ0N*74>/Q"^L;!JM34M68='S"=>H.=>EK
MT((TL6Q.<#H<)#.ZF'(JC]?I22QX0%" P5R<,3I?$[>0(J7QB=[,02(3F[P1
MM%+@QMO3%936K6+P51#ZB*(9K< $'T.[M"P$''N4UH/SF"@_"8C#>*SWB$3*
M4)?R1IYM-@U/FH? A[[ENU!RY*WP:[GDEQMYX7I=PJ'%833F]1 DA#[!6/6
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MU:IPIZ8K$;UJL1#DK51 ,>WVH6-Y0[[E([QO;1<.7"*AC(JSV%'>/_)Z0P_
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M:3@V]?*> F\9CIJ:&=6182E7= .+I'_GE? 2F$"A-:8 Y7.C"5>3P3SN::5
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M*35NS-SJ)E84)B\J@54(W 7OW6)U$&9O-@-=V(&78X^"3Z?B3]@-.]!STT'
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M:A^#\3V35%22FR-?SZ*U':+!PP'Y0/BEO<FK?H\JFKXB+J:L42RX-<?#9X5
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M\-4]/[=AW-MATB<I>31<W1DRSN,7CH>=A;CL'%(<]$&KGZ3([+#BG8R*.>.
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M#6,?=O!.S<#WV!I3L:XG+^_$7AKJ-*Y@@Q1*'5L'W=*D39,K=&:NT*^(2)!
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M$;;>*AMI75SYE!]]#2N@IZF+LA#OW T^XY9#WZS(; &7['A;D!AWV7==@PY
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M-J9.^BW9ZC.SU2^'" ZD5GLR:D:HY\-&"\<,O[4 RGXTE4+X\+4?&0!+O7Z
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M):Z X 6@BD+8/3\"_:IA1X'!L<Q$RVZX6WNF':66RG6&B2[@S,8&<;QD&[L
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MX5<G3&DIN("V;]B9D<=P0''KG@R]88Z<JZ9]X]RVY?V(JCH'+1)*-2=:,I=
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M4.]G\L' &=FU]KOY95Y6P62_94]4BI?F,J_PC#IM4:.;PC 3HV-NE$(M]\H
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MXP&>1&.CQZ]1_[$! !E6 -*77IP8[U9<*@[!=J@9PN]L 9WPJ2!;FE9)P68
M</.9['QE? :.*B8%XMJX]##%_I:OH/8?,EQ7R)9>-%I0/@R_$NB&">38\4.N
MQPQB)OB(8*D5/ZN)-8LJ+Y92(XX1TA.;9@U/8B$*/(B7#3 _KHKB?3$D)0&F
M^?@#=65<.A$[ZDXCB9;8;"U#)$/@?8.;<<7S,2'9=7_CWE"U3/@KYF=&VZ2_
M/H,?HL".(S?X,S[YQ^+LF0$29-.?AS@?@2YTK,6W5^<",8Z/OV!"W7 Q=6+(
MKE2+07X)_@[BF-B_E,B7Y(6GS_!+1=630,?&4FA6BN994KJ+_DJ#KE]>R3 U
M/DG>IPW7>6OH0Z@O&&LP^FK..Q$NP<:47)E$W^/);?5U;NL^BT4T-UJ+N&)K
M5@X'*U!"4B.]E&.H41@?A2AVBD_\G_%#.\(?L(' 4.P)!TL9OJDRBERT&[Z0
M':NFUH=4A<\!1F?"H?%)&C=#4=5$&7].A=(YI14EP.XN7]QRBIS&_AVP?RFR
M[R9=C]9"WB?&9QI9@.H1_K 0+0,O92=($$4U=;ON$TRTZD1R%!-MGF5W0O@G
M)2>243=GK"K^3YB,F*K'\GQH8RA#^K,Q5#P5=<)(PO W5=G-EDE]*"PKLHL;
M)N:RRL:'F'%G"K--)!!VO,0(>B_,Q@5885>#H44!I1;UPZ(]'S:T^1MC-'\V
M,0'Q*V>\HBZ-Y#O+ .2R608 J>T7E)HF.UJVDPZ4(N6 0+D \D&'&V6747JB
M;%JRDNM)G0%6: B^=X%_ TBDLB4'MOBH0+?M"J'Q8OLJ]%TL^V_*CB*%["?7
MCMU"-G9!.3&^U'(LQ8!XA#:L"#<>D3!T.JCSM6;C/_G!B67 12V1],><P^&]
MRY=MWVZQ[HSY*?).HM4UA^8*Q=#O8.R7\)/CKF] 9.VA56!B[Z^UWBK%M#$[
MNB]EB_4WP!+)L^"*=@R.A$5&+4]GHO$I-A>[ "@.B;;M.>#=Q%ZAF#T*5TPD
M3&+GEB \"89]:<[V0(UJ@:)ZNDH5:+0E7%58JKW.ST3^S.098HL_>>Y)/%X=
M<9G"Z<V3#6I%K%JXEZ[=$OJ>Z$8D4Y:!(Y17-]\J='2E:3_O9229@LU$VS]%
MP8D]7IWUK6.T.R][9%L=>NS/*LP38B+5!J__/^%JPXV$"V/*'VF/> K\&_X[
MD_UGB14*QWY7S&42+='K2M"_E:R0KX0="LE5J.G>-UH.V\R*GL!DN=R"TQ-[
M'+H$8R[2N%H[+"^X(^QMP!WVSP74-FC7K NF=I-1-.1J#5QUVTG63BTD &O)
M.RS\AE/8(,+/1!P'I!J NL12<7P*KG&/R<=](^452XI2"C:ZL5.T;="@QO/C
M#12S@(1G&/GW;&UY@BW*HB+IA>P&%0UV7"?DA1R_+M4V[#-<-^31W>H4&=RM
MN-.),S:M6V1[;5NGPOX4!0DC?K YU,!NI;3?@E[8KH#,'1DK;*S$+ MZ\6K[
MG64^V2:FOY)IL<+^9V,SY[;/1;Y'-S:37I/.!#@@1(Z#0/"%%3!6S&D!0=J=
MPUW^S_H2>SG/AL1QGN*3TL4,ZQ2U<#@7\^5E%$&"U;*0I5(U=IK. $*D&=2C
MNK&VNP+!OS5;?:7$H=U6XR"O_*8*@PN$V#)!GC"+>00"I8!0_ QI'RY(/U](
M?09?BAR++ :9]G+9U'B;J1<V'^H7..%'$-C8V7J 0EO7U3 AXW*X4%JH[EZH
M7FO;+K1>0 PRC 8N=]5S27$#WQ!:95^50PU.#U>I1#RU?0K8:T7MQT""U^(B
MDE$MF>DJIZ()-8W(0]W$JN3H&J03W'K")=>$_9+@)GZ(5 DB.<5!)1CC!H8M
M=DE1+:)'P>=AY>69IUQ:GET<?461WK0I^<K9\K823Q%:O[SDP/4JXE\#)V (
MHV22>SMPL6:T 61SVX&O82,QGG3+:B>1'"?]AI*,)!%-*Y06=4=.1.3I9<F2
M>NPJ+^-@TQ$P+6@&)6M6^L1/6!V<4$YRZ2LVN!?0>)B*CIQ"C74CHJPBQDJ@
M%Z^8+@T(Q2YL !F1,YRS"]@>+0S2@!;!GHEE*32CG!4E-K<?WSH<^^XONR1.
M1'HEP^">,.X*$&1I-PPZV%:Z)[@8W#SLW2WL.%ZR*P3HO.A058 [0A=Y&"S
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MB?*0D@))@Y)V_914YC&4XZV7[MO2I4:EOQ5F/-<X>41TY@(H\$OQ2EGUB$<
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M2*Z,OBO*XO_PC#\&6?IH</DP!%A25,+? =HL%T[' 9Z AXPGG9'#(Y0!#W^
MNU>RI):PFAD _V6*)#5> Y8+EXD!#!NP&,[$:4^,_ZPO 6#-C Z 7#1%\$J/
M"@"_J#/Z;>J3$A8-?4%L013VRP2O :,L@WTC(T?W4K]8P+G745JT9&XUEZS)
MS+*NOR+PV@Z^1!8.75F 4EU>8.Y_T7X5Y^E!9#0=*T N<#@KR8VTZ\4N^A+
MF=8]F&87>,WF4B\HKY;NKX2U,GL"$%#@$P;*'S CY@NQ,WHUNG/@GE_0$>!$
MEPW<)/$^BNOB.S).5WLE)6()B[:N*_+- !.Y'$CQQ#@=;;'R:B:3-("<6K)=
M.BXN$?P)S2%8M<J*#/:(Z;5K!14$0K1Z<!TFKRF<B&YD+CR"N"Q^-$G2Q<?
M)%PN,4+TQ/@ !V$)7&NX<0,E3BE(H@]>4!']$[H!"NCOP^NZ^G66TK%P6P-T
MA >SG:T_2O:1<+EWYP5<B 5K,'US<EW%&3$+&'%67JTO@88B;_ ^ B>E#S<
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MQ.J&VLL-G>;&MGI579DIFHK""SFM%AU3)-H5/1(5"E11!M@<5\?*QR-SH\B
MNK_.O_YINX'V4:K)*1^Y&S U ?X-6\^J=5>/ZG9J27YKJ'X9&Z12"(E$1,N%
MD,,$!)"C\SF&$<?IFLO6R9-![.VV62$DH'#,V7J7.J40MW^-5$+^>H8$Z[OZ
M55(W(*EI@]CPSWI%CYM@C==]!\M_X]DK\2K;(M8LOT"^E$7+7[8<U"T0YZMY
M$+3V,WP_;&",G%P4;2'<0B^'[\N'X*EL!!F]+K!.?#?$?)Y__Z7+MCQDG\2(
MU1N>L6YZPC\)XM!:_I_]XTN>Q-Y.-A;%=]T,_-"L _Y<4'Q$E^TZQ#=S%\?W
M9\/_D)\ XD78ZZ4(?N$?-G.9M:%=@EXV4<HV#6 @":*1Z)&BE#>0:O2@E+H1
MP8^#E_WAX1X,\S&Q ##'3WY]%CS3E/+(VO).\?QW'#GV]IH:H0;YJ8YL-0A2
M6:DF]:$1IOZBPRE916:L$H!:7/;0*/@Y^?_JO@6EOWVA!N'>@/GIZP GRET!
M->AZ5= ZCRQH;TN\JO/H0R-GM-\/E(A5OPH*D;6V8E3 @F:N3X^YVFK0I&:N
MCVT+27_RK8TA*YPYG@48<'X,X0#S6R-+ATR^&\+KY5RE91[ LH?K/<EZ5UB^
MHZA]$B&6A\1#51\.%NY!;H](63^I03D;!<R^L$B1NB/@FL_=:&8%KJ;) Z/)
M^[KQM#33TNRAL7 4 -?": _"R/%FH>5KDCH&8;1#0WM7GA5M:._<T!9#R7=B
M:._)IZU5DQ_$PR'QT:, N%9-]J":V"'8R9XFJ6-03;0PTL)( 2P<!<"U,-J#
M, (S-[0#35+'((QT0/J8[>3GTE!^,12;4T^J25\A'9X^#D5EI]['7>?%/V6%
M9L<$<H_$/*WX[$[Q\>YK@C\F?=Z_>D%=:;IO-4F+0BT*M2C4HE"+0G$1PF#F
M^?=-5=?"<*^DJD/C1VKR_\X[XWG&4X!]RU]@<U[Z"0/EU*&'>MSA#]B]]8*5
MV-=-#3^M8K@_'&5GI][455;JG#C(2[.ZI][(*JL[:AL4]TU@?]"*KN]A5VM,
M#^$\ #3ZX6-5]_T8G2NO-*E-\#KJKX6J%JI:J&JA^M"WP+9GEFL=!)DK+U/W
MYXB ?[%SJ6J-I???_U4A8"C,',3W<9LW]=G^,-;EGVY*?% ,Y"HR7-UO^Z$<
M=^E-#22,2]8:/[G1B6W ^TJ<%($.O9\<[R0<_W*W]MLXK@F'>^&\HO+JQ+C=
M/K*>YG8-K]GZ%MSOHBD A0 >^!8?)FM5\)JR;FD"VD^>>Q(/VY\9+,/A\3AA
M%P[RDS,Y&3Q+ Z[,A.'F<.0QKUHY((IF)HL1'S^Y$P#1.+OT'">#M6OG::FA
M.7ZC+,3 LP+'=>P2!/8M0>"$)]%V$%AW!X$]^=*=0: N0]0"^3#8W.T%\KNQ
M?D\+9"V0U8'J-2FPJ=!4"&0[7!?(GO5P GGC/NXBD!M>LDX,;OS)#T^"%>%R
M7C>=B:.HY'O$@,:^ ?'13L8=,A1;.0@/3";&X_KC*K#%S:O,62>GJ.[V5/:U
M4ZV _^93:7FGY=VCR;O?QLS[0Y!WBMX_+<?N+L=N7P@BI)IUXJT*M3"8</D=
M"[6-V[B+4$-+J"EP->#WR]4&J2!MHZGDN1$*=Y$^*Z]'RPY63SG/A'6W"CFT
MQM  ?/?QPR!/^3<:SDU0=Z:2"YX9]SZ,*FZXL6 %@0W>;QW7%$;-YAX5&(_7
M,_F!+U?DK 'T?$QL7+ S+L(Z)@U/?<G*2W;5OGIF_*+OX6[NX8:-*2IM'W3F
M]B>.] 2*70J;)F/F8U-7\',J)NCN2+4Y'&@_,-'_!DI(QCM6E*1%Y/@V<H4V
M_(PUF5  $"7EE5&T;0]/L25N%BNX&28FD[A-46<HY@L:0%V1M)8J HV9!I6"
MOH-J38Z3DFOC][KCAF/\Z[]\<RP[??5Y.1WS,P"\R(N4K=V,&JP$4#-FXBO9
MJV%(-NX0WEQ=X5,5+-L.'F/69P5YA3=L!5-]484 5:=L^25.?A8+%JUQ6E4X
M!?X37X 9O!MC]W"NX(,2_&OT9^"X\ V(I0OUMNT*')?=[DQ)>]#S;%71)#)I
M\JASXCH_OWH$82G_)F:2 E\,PI^U?_9@".^!H?IA"T^F*?6PH07\2S82\M,F
MPT'WQF71G1MGO.(-*T$DP"=\T:T+!6"DQ:(4D3+DQW]4Q'0_XQO ?L3!R&)Y
M(6KD_./-6P$.,%B@6=&F9=WV8 C#W_[9%_A#3[Q]SKZ"V!DX!7WK'WUV)M8@
MHX_E.<@DVDY#7!PW/<<]DX$IPGBS:0QO!B9I*[<P&)"S4<8M-X-?1Z#"V5%U
MV1P0I*#AED.>&/_+#8Q&TA/+4P!H0/9T=4/\$;?0%!R0,#.^5O4E@+8!>UKN
M[V*$U@5KBAJ@4L,NX7T@?^MF-'R-A)<%/$PHQKJ6NJ+IR'!MN?!&I$63]G/8
M'+P(CBO@U?:E ).PM5%+H$]@TX685@T(0-PO@<Z2NA?@3EG3D"2^8&7/)]"^
M!B.!*-@9R&S<78;Q7K; >PB %58_G:H%0*5< ([CL@"O->#AVO":?K[ .T;
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MKS^M,OSG[9+1GW:O6=-@'^?_864/+^JK0KSECS__^/P&%&JX6["*^\S(>%H
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M9N+ ?UPGA!/Q.+?8PYSHOL'-:ZDH[LR/_%GL/SFJ!PK6Q/H],<U9$GH1".<
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M&0[R]Q"YH1CBSEG86!!:!X^\H@UBC&@DG:F1H](3P[ A^"CC+8[%8.Y5%T&
MRI01IP^VB *Z6$[KS*+/J":SML"A&.2,),-VLZ69^+*I5]D&7<AH\/MK%]@;
ML+<G9F^X-L)*GIIH7$!,>H-D+2UJA!-8,J<=\<?(/T5W^VB--'2DV-&&DCVM
M8P?*=I+>&RAL*2-+ BRJ?!L#%@4L"EC4W2RJ%I032BT2DM:(:>DB-\(>,<&D
M#8S4G-%CY, >D441,1*JS%)=8%$G3GS!G):B.)4MX,CN0I&U)#6!:D U$!V"
M)P-S =447D$.6Y,EQ9CKK<GJRD?%7NBY'U5&MV.;3Q-TX\ERX5TO C/(N$'&
MK0B7W4,O !FW._<M-=684X],8VK$N"1(!TN0M0UA4CAOI3W&ON6/>CX=3\_;
M=W[^/GGB'Y(?OIEYFTTFNGMYDX.K=W-PY'XIN,-/*H,6/-XB"C1W),;'E<XZ
MY&NGFH89[=VC/.GK#F<>Z5G)67.H70"RC\\.[6 /M_0HO21C T8)C!(8)3#*
MXS-*931A1C%$2$,1PXU AEB.#%:1,U'A+.;'V,,]/:.TC*L@A$7!<XR8= 8I
MJP@2C!!%3.#"'F6W^FD9)3Y3%!@EH%V!^]E?2C%Q$103WZ*35_&29C[>Z$)/
M6P2[0(/>:H!=(% -1,K@R<!<0#7]V\^&B6A]B,K_)W^+=TA'B>MSW^U\M]5L
MN6@7>NIB) G;X,==)46Z7\@YPM2TS^[^FHC0RC#44$S2U#2"E)#Q5]98TP3M
MM3A*U^K:)[WL7-(ORTOCYV]#3E:U;[>.:3^'USFOW336FU]^>D"N3KO&$LDM
MPD0+Q(2G2!(ID33>,X.UM40_XI.N4G9[#_R5SXK%"#?U2-6'&DX@8P>N'@+3
MDO4 ;*A8U0 ;>GYLR&K%L;08$4'JB/>U0!)+CG0C#58V-%(<90+;Z=D0(UI&
M*A.?%!N.F%0.*=($9#FF6&GB,=L['>>(3_I8;(B-&*Y'37UHZARPH4&X^CYM
M/SX_>G2RO#WHI(PD/>@!]%"X'L!'E:<3T,/)]0!=L /=#WPUNXQ?>^&G[?B#
MS_VP+X[@&Y_=R7Z%F"D<N@BJ 20[)LL#<WDNY@*J.?69FL %RYB(4L(A+/W7
MYA,J[J&-I\^N!K>'1@GMI'=MRK(@")&IO[*N*6(T>"15S9%J1$V(XM9Q]JP.
M5@ G7%0_).0OR^"L8#D%6P[0%Z OSY.^--9I32,5(=KJQ&$LTE3$7X,-IF$V
M<I&]NO-!GV@ 3K@H^@+-@L\Z(?3[-"IB$J_KNDFYT6^U%[/Y D5PO*S&TP^^
M75S&MQ9XO"><JUY0:AW.50<&=G(Y'&9@SOG&4>*1\80CIA1!RFN.E!,UI@(W
M<O],J8<DD+:N]&]Z/$TT[.WTS=:!'I>3-43VH*0=3E8O(P$%90?]!%U@0X4J
M!MA0N2P V-!=;"C@R'J,-8A@+A'#DB!94XN:VE+*&QL(KX^1CWI2-H0Y S8$
M; A*EP:<J=HO8R\A =W;(0UEFW8A^X5#FO+00Y,')G?W[*Y&-X$QY'5#$*/2
M(ETW$O$@35T+S; XRD2K:XZWVV/\Q2_>AM_TGT<NDV(C)@Z-GN^!FP<J!Y55
MSSBQ!9RJ?!L#3@6<"CC59[)C3 =JF$7&>XP85@QI1>.O1M=,6JL"/DIV[,DX
M%1$CQ3%PJF?H[^],C\7_ZBCH_.-M(OW+G1+%Y&M%NG7J/?>IOUWX2MMHQ/$Q
M/HVGY]5TMHA7T?/XY^A9XMO.YWI27>GYHIJ%:G'A6U^%\51/[3C^O5WHA<]9
M\;,=E3U<,P/DHB<4QF!6Z4_H$/3W\$'8C85QL4GT7^ESWR$2TB%J[86>?-2?
MVN^_J?X*]G0<>^J3VS>SB7LTF?X\FYZ;F9Z[ZMV%CNO=^F4F.>VHBH2N$$^^
MEG6FMQN<^5__S^5X\:GO&GB_P<V$JJ]FT\PS$WU\-_?!S^?>5>\7,_M'/N<D
M_W01[\?/VW__/W^2&JOOJQ^S()[*+SZJ-*IO7_LPMN/%=V4MO=+<7N:]A_H(
M]'(Q6P<EZ08CD7M1?Y_?CB;ZTVRYB)?_T\<()W\5KK,,5Q^PZ?#5J]:_:'VD
M>7%=KL63\P;=M;^YN2_]8=R.S7@25^"+]></[$YW7T?P&1?D+TF>AP*VU3V=
MU5Q]_CV?>0<]$XI^]56.<R_D3.&GNI6CB(Y+4N_\PXYR\U\O GI&B-B]L>,H
M^!@WQD4Y]])<DU$Q0FK.L&)JYY]"[HN?2<:+N1=,2[D7<=9\L=NZHW")?TT?
MWM/4+?$2@B9>S'X8J. I1_SQ)Q[Q]X#R[K4H3Z3)D\7<1UT/=X1XO:C[W]_0
M*'V%%&3M7Z+(E1ZZV.MV^P2_?')-/5G)SK/3 J#C,T/'O\\6:>_QU>SR<C8%
M5 14!%\+OA9\[:.LAU]F4P3^%OPM^-O3^MNG/MP!- )V 5H +8!WZI5&0 N@
M!= ">*<R-0): "V %L [E:D1T,*)M5!>8=@C#:!\&J7V+=7\[7A:+2YFRU9/
M73NJ_)_6)SE?Z+EO"YD'^VAC[IZ3F9\6_F CZ40;2<M+X^>I?^E]MNB>&G3I
MRZ(@$P<^58(6P-$^,T?[\C+>ZZ(,JP3W6H9[??0R8?#"@(7E:P&P\)EA(00=
M@(K@:,'1@J.%H /<:]_<*^@%'"XX7&"V8.+ ;$O1 CC:9^9H@=F">P7W"NX5
MW.OCN%?GQNF@!CWYOV9>_?6_WNFQBS+L?GFEK\:+^$H1-@O.%YPO.%]POD-R
MOM8N+Y<3O?"N>KNX\//J^MFS/S_\[%EPON!\P?F"\P7G>Q_GNSK0H P3!5\+
MOA9\+?C: ?G:WV8+/;EV,,Y_K$[$.7B8##C?H3G?8EM+R_+1?;/K'_1$3ZVO
M]")2*.OSECC%HXK4I(8##8JTQ$=0P9V'[Y:E@R&(^_Y56X4>9OZ52GB2@T2/
MNCP.'P'N@_#*48I$K0UBP0AD. N(6Z><%-39AMP\ MPY@65-&:)-31"C%*/X
M3HH8;ZQRHI'&NIM'@'<%2F^7BW:AIVX\/;]V\'?7W[][XO>;7WZZ\Z3O9L3K
M*->Z/M9AW^!O^NQORA(X@.SI=7#LT^J/JK1_*\-J *5[@M(L2&84\\B;&B.&
MG46*,X("):SFW BK^5%0>B<YTJ5&KL'T[^]??U.U<1G%C]!=M$;T;K!N1D(U
M@-0#0&HX:VHX: Z<J@0M@'LJ:=$#)>H)):HIH=(IA;PS"C'K&=*<<41Y)$LV
M\& ;>Y,2!<%JB1N*>-/8^!F%D1:*(\8,MLH3PXU][,0%'4E6CQH&B0OP-\4)
M'$#V]#J Q,5CHO3Q=7@0I/N'LO_^?_XD-69@D,\1A8JW)P FL .P \ 5L*=>
MV5-9 @<0.;T.(+H!% (4*L@@A^#_ (5*T$*/%CV@$.R$#68GS%/MI7$:-4VP
MB!%9(RE)*@YJFOB:"#SHFSMA4F)FG!,(<RD0DT0C8Z6*GVXH-;9QF,DG*@["
M>"1J";MA@-2E"1R0^O0Z *2&>!'BQ8(,<@C^#U"H!"WT:-$#"@TA7NP?#'V[
M5BV$O7MA;\.(H3%813BH@)AG&$FO:D2)8:PQ07NRU[G* N>:4+$J&@U"(\VH
M1TY2H6FP-9/-,</>-J[%^-/=\2\;,6AC[;L3+F1R3%D: ^IR>AT4;35 78"Z
M/$/JXI073'J*(G^AB-' D-36(<("]H'6WNCF)G71GGE<:X:$(0PQ:212AGCD
M5;!""LV\\D]-7<B(*P+,I=\^^"!S.=ZHM%J,"*NC6LD "4[_'-*KV30*MDV^
M*!T;%M\;K_$R^9HL;S/Q5;RKX.=SGS0;_4>UF,67+R]GT]7OXVEZ^]1W'NWC
M>'$1_S1>C/6DNEJ:R=C&*\<+C*?G#_0$QUHRT$K^8$+\I2KHD3,>@KB!SP*?
M+8C/&HYKU6B"9(,CGR7,(J6E0-0126T=K--F+Q77:"<I(4C+U(O=4(T4KVOD
M:V:TP0VS82\5MP6OMR%SVZXYN_OSPCM\G][L^Q#;HT^7&[ _[1^Y?>ZL%5C(
MZ74P!'$#"P$64A +P8X&4;L&69TJ61762#(K4-KP8Y@&KMW>1)BCL)#N=-A;
M6,A7)]F..SQOP"[U&1 1F+XW'+("E+$$+?3(OPU!W+VGC,"U,M<*NB&4"8<P
MP1XQ6KO(M9Q#W.L:<Q&\-GL9G]H(K6J.(R%+0XQ)&DC<- $)Z9Q,)5M6Z9-E
M?-BH5C)E?8!H@2,J3>" OJ?7P1#$#7U$/>LC GL">X*I>F 'A8L;HKJ^X=(M
M&?1:<<R803$:LX@)[9 6E"%B,->.*,U#?3.J4X+9&-DQ9 @3B"FJ8WS'&.)8
M-<PXP6)$>+*HCHXX4<=LKP%'U&='5);  7U/KX,AB+OO++1_Z E1W3.VI[($
M#B!R>AT,0=P0PO4-A Z'<*I1QDGO4T%3DTJQ'5(T1F=.:M+4C+M@_<T0SD@J
MM6TT4D3$$(XI@PRS 2EE@J&>".O$(Q9!?:[VB4'P!BZH-($#[IY>!T,0-P1O
M$+R!/0&( (C H@<0 1 !>RK?GLH2.(#(Z74P!'%#!K!O('3+7%35X( #1U0P
MBIC #3)"6Q2H]8T,E#1^KS2_L3IP9VND</P7,]0@HSE'UN+0&",H-A8R@.""
M'F=$V*!GH/;/K;QIVZ6>6I\&A-T<_'7+H*]1-?6+$\_RA-95&'];@%OLT_1:
M".\?)[P'>^JS/94E< "1T^M@".(&$ $0 7NZK[AAT,YP@ ;@O@0M@'LJ:=%#
M-K\XNG XFR]J$9C4\2F4JA$+7"$=F$(.*]+4Q@3'\#$&[>0,?LK\>?=ZF5)Z
M[^+-SES7F!F?)+_4WJ<O\\ZQRD3)$>5PVADXH>($#LA[>AT,0=R O,- 7NLU
MY8X81$4Z*]3Y.B*O(4@R4K/@# Z2/B+R_EU/EOXP\#YT+QT#[(('ZD&J#Y 8
M[ #L %+>8$^]LJ>R! X@<GH=#$'< "( (F!/ "( (K#HRP,1R D^:4ZP2=-.
M=9,VXJ1%S B)C+<4.<:9<98WUNX=,?:0Z3I/EQ,4?$3PT?IKP WUV0V5)7#
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M!'$#B "(@#W=5]PP8V4X0 -P7X(6P#V5M.@![@'NP9X 1'JF!5CT)2UZ !$
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MH9$UJO'2:T=K>G-DQ2]^\69J9Y<^3:LX[H *(D9"B6/-J #2TN>A%L!Z@/4
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MDH:27Z<>K([_,UXA60>!F+,8F:;&\=>Z3IM6WEC_5%M6-1U1 EM6P]BR.MY
MSD%/*^^?[_F[;Q?CZ7DU"]4\_C@?VX5/*HP^X<03MV$H2QFSZ,O2P1#$W?=6
MM_YYN9+.?0-[>M84 4#D]#H8@K@!1 !$P)[N*VX8(3D<H &X+T$+X)Y*6O20
MU2^.+AS.ZGM24U4KB@2O,6+$.:25KY'BF&FEK MN;X2#J!O.M=9(NOAV)F5
MDA*%1*U8PZ@RWNXWHJ0A#3_HUKM7L\LK/VUUNHF7\[F>GOO+>(<_?-J^Y9W^
ME/[T\J.>NVX+X,VT7<R7Z8_MV\6%G_]VH:=OK](EVI0Q].[-]%U\^IG[VBF2
M+*Y_J8H\]0N<&" W(#<L^E*1&P)U"-3!GGIG3X K8 =@!X K8$^]LJ>R! X@
M<GH=#$'< "( (F!/ "( (K#H 40 1,">RK>GL@0.(')Z'0Q!W  B ")@3P B
M "*PZ %$ $3 GLJWI[($#B!R>AT,0=P (@ BS]:>CC?H8] 3Q/IG8WG,#S*I
MW+^R.RT!)YY?!7US90R'*TL'0Q WT(B>T0BPIS[;4UD"!Q YO0Z&(&X $0 1
ML*?[BANF? P': #N2] "N*>2%CW /< ]V!. 2,^T (N^I$4/( (@ O;TC.P)
M< 7L .P < 7LJ5?V5);  41.KX,AB!M !$ $[ E !$ $%GUY( +#T!]I>1P>
MAFX8UT&8!C6UJA%3C4!&:HP:3$DMK?"BV1N&;KB)'PH>>1XL8EPVR'#I$/,U
M]HY);;6^.0S]I?O'LEWD:>:_S5XZ-T[WH"?O]-B]F;[25^.%GN1IZ.;FP/1?
M_3^7XS:*[KV??QA;WPT]_]7;V?DT7^7O>K+T1SDPE8QX4^8)[>#  +4!M6'1
MEXK:$/I!Z ?V5+;  41.KX,AB!M !$ $[ E !$ $%GUY( +YPR?-'Q*K-*%-
M@X*G"C&G*#).U$C47+I&8&FDOID_U"H$%HQ%BGL2/R,Q4MK&3]>&2,>M<,)!
M_A <6(DC508]OJM_3NFG\51/[7AZ7LW]1"^\JX+W[8FG5$&+(LQE*\#IP5RV
M 3@XF,OVC.VI+($#B)Q>!T,0-X (@ C8TWW%#0-5A@,T /<E: '<4TF+'N >
MX![L"4"D9UJ 15_2H@<0 1 !>WI&]@2X G8 =@"X O;4*WLJ2^  (J?7P1#$
M#2 "( +V!" "( *+OCP0>:J&B/ZAR+=KU4)?QUY?!V^D)$1C9!3VB-5UC0QI
M).(&"^5IX(&&KYD+,S%7%R\VU=N_=L7;/WG?WK\1HXU+,?YT9T<&/5H[QH#=
MYP/6[-,MS^_*\+]E:0Q(Q^EU, 1Q0^0*D2O8$X (@ @L>@ 1 !&PI_+MJ2R!
M XB<7@=#$#>D/R']65#Z4QFLL:H5PL(ZQ)P12'%9(\&HEHPS%@+YFK$VD/XL
MQWWV+_UYO'$V@YY5US]G]/LTBGT2+^NJR:QMJ^B/VHO9?($BXEU6X^D'OYJ!
M=>(I;= S"G,)^\%#BYE+",F,QTEF@#WUV9[*$CB R.EU, 1Q X@ B( ]W5?<
M,.%F.$ #<%^"%L ]E;3H >X![L&> $1ZI@58]"4M>@ 1 !&PIV=D3X K8 =@
M!X K8$^]LJ>R! X@<GH=#$'< "( (F!/ "( (K#H 40 1,">RK>GL@0.(')Z
M'0Q!W- G"'V"!?4)"J^\%B8@T5""F%4*26<TLM(3TC G:\5O]@G*P#4APB)>
M>XN8TAQ)ZQRJF94,4^&4VO0)+EMTKO75BVUCT-_T>/KSK&W?3M]LVX&.VS78
M$ F'V ^P;1 X"'"04^M@".*&0!8"6; G !$ $5CTY8$(!+(0R'YY(.N\DKC1
M'AE><\0$%TAR95&-:RH(#D36]&L&WD @6ZPW[5\@>[SY-X.>S=<_W_2+7^3!
M-R<>.@<-HV6,65QU!F\$=5MK<%FZ&H):/N/G[JL82(64E@IY2OO<_;*H#C#4
MYTY( ,4 Q0HR#D Q0#% L<<W5!CP,QRD [Y1@A: ;Q2I%N ;P#> ;_3?4,L2
M.* 8H%A!Q@$H!B@&*-8#0RW>  '8 -@*LA< -@ V +8>&&I9 @<4 Q0KR#@
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MZ!D8:UD"!RSK$Y85'2_\6QGV!6 (8 A@^#1N&":%#0<P@;:4H(5!TI8A**8
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M7"/36(R"5 R'1AABR%/3)\E'F &#>GX>'A@4,"A@4,"@>L2@@'IDZJ%T[>M
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M[,/8>??#ITB"W0XU?KE!L^.V_%,YJGEAXWCNX1**9\(]'.H(E @H$5 BH$1
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M0NI&2[(W8OE+YM=-S-7%BPXZWB<4>).!X^WTU08VWH976]!XM\:,[LWI;2O
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MU#5'ULF4OE0!F5HR5',=?,!8V%K<VU?^GBWJYVA0USH3T\)^X9;SC[.Y:_T
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M6>Q_:;4],S#J:?919R5TWKB[6GS[<C55.$\,;=-[;X+NQOWM6EN)YE05ZYO
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M-L+8<KM"8GG9+]TZ%1_VZ_+&L%G.UK/T-7UTIPWXN!3>YV*!$1)+_%"@?;%
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MS\A2J]->8!IA:G4[ K9??^P7Z5U7GON7M.YR>8I5.VLBC2'=D)<^=L>/QI#
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M4YS<VS%B0AE0+'LP,?$B";P'EV7MO^0<LY%;'LQ320)[)J5%18"!#A7!6+!
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MFWRLAQP8\"$KB)I(FF+@4M(F:H&D/I-$-5L6_E&'0BG:2.AKS.PH,U!FH,Q
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ME)]&IARQ^!HLBN7K7__PC#U#7!K"!;%H!POTD39Q02S:P0)]I$U<$ O$ K'
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M<U[>L]/SX5NW'H9I\=%?TKKK=X-P^]?X;??-R]<__KZ[7/9OENZB*Q"5P?W
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MM9N+WEVGZD(_+$*_K,F9&H!Q-G38V="/;EFT:@E,]/9,R-T 9KD'YL8+]NF
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MODS[^5&2&7Y,+;S:A1U?'B#183C@])E-A;]UN*^3P=F7%>[[ S#ACN^2H7#
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M9[3RA!\^^2?AB5<I)"-;]H0GAH<GDM,C 9+7Z_10SCI368=<97+$B%2H8K1
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M!)K4\T5'Y%\\9@FK_;D3 ^]AL1:3N>?0U>;M/_/<XK?;WU;;YB^PBB $KCZ
M*X*TN8 =-+Y$_V''!O7\G/W6;8@O5B]FL/?AC3ZV[0+N"\R\#CD'MOY[A>Z;
MSP&(P@Y[7YN?PI[-UC^ZVN@M[%Z0T(MV3?"<V_E98]H@-8'I&BWG2UD5#+;I
MK 8.Z!A$ZEG3@I@>!QGC2> ?K?M-RZG?%KV<@BV^%+C+JVU*;/_)IF2;=Z+U
M2E)XZ7"RCEP>BE%VK/=Q@Y1]6^7C9*4/O)*^KIMFMEV,YTN-MU?NC>ZL/9<W
M"!*VVWBW*Z'F2E7OV#?UO+VV;]J55KZ*0XY@ ^KQPL";O0T7"?-@5[H<UM[9
MF7^L[AIM,S;^QL "]OM2IRD[_V;MQ(MM_Q)PQ0O;AD?T@GYV?O7F8SLY]<(>
M;M]V)F&[4M3!YP!+UMW23OQ3^._@@2[JL3W=_U RO"@LOC4=HFK:%>=L+?[&
MDJS>/1O7__#:IU-I:T^P[S+7GN%=_V#-*6R-_6?!EU;.@ #^Q0P@AW$S#?@C
MG"G/VS5RA"NT<SE?=.NPMN?@YAH4I-?]X:O5'_-9#:9YD%!P1;/0<Y V$^-?
MS+;OEE<\#:NS?GM_$8\6_>E B/;O_E'' 3[V$'5[$R]:V'<M7!68W\X\;.K1
MJK]8X^&HW]4=#\$;..>W;_]:JFZF9[ S@+T7P3R'US8+@"67W7: Q0=!ZX%!
MCP#VG_#NYL?;>(:PFYK_Z9!+N^=,!X;(1/N%F#9M)P'\B9Z=SE:0*WSDT;:6
MK5^E'ML$]!+>'S[HU$-/MNYF8Y"$ 6MZ !28^4:@OV?7=N^Q8_^-Z[\#(#UK
MFB!=@-$!G : T&]OK^R!ZI,;;M1V6.#R#!C=SF _M@N_7?WBP9+#<OAUZ9ZY
M 9(&B>CU8=;*\76F\^P_]ES=[UFO2?WQ_<M>4:9[>A"AX6HN^[N]]"O:-I.)
M':\$A/T^]3HT $2W9CJ\6QT!'XTOVSKPR)Z'7<F;79@F1DV4K>OU^OM;$+L@
M'_9Y:N#63^R%V#VT?H J_@,Z$ECK![NLMDCGS_OWLU4.V12XI/.4(NF <F_E
M^)N\;-_]D/W;0_<0H</91 KDV).M_._-Y+0#<Y\WE!.(S8\3?3LB/R9N?=*%
M_J,!_.*AR(>5<OX"R,AV3HQ.>[%WH'>\0;S8S)N+:N5O\VAO<];!/=J/5"#)
M1.Q7MT<QZ\C/F_DU7%?..H-DXBW^6Q'LR,.K;W8\]O_VT/>:?7"'JQS$_G\2
MVL9(O&R;-Z):LP'RPQ=XE]IY;^:\]W:W2^/1XWEY57V1P6O9V?CRRM_5.306
M;7!!+\9+8S<XQVH7C/'YFGMCA[?_Z7QBB2<B6;,!\L1[C[@[#^ZX:7OKMH_X
M^<W]U^ ,HIB2#5=AINPIO/?"-VSYWR67+*_0;?C@IMOI'FXZ3?&';(W\1_:7
M<:- 2_RU=\UXYV,?;;'?[4Q[CW5W*:]Q@HWO@W,]W_X<_!5?]%DS]CPW[;UC
MM0Y6?&/ .-]P0H8'0*$"*RC 9?P@F.Z3-F)^?.%,@ZC6(F(^NWMD[98QV@-Y
MWWUOUX6N9KO?,:N!RP,/]J+@OTZ^P DS*]O%[+(;&.6%CPTN6:\Z_4%S> XO
M3[K0@/</_J^=^<C'8@J7V;S$))AC(6Y[+N?+V.$2^O;"PRY;RWCIL)14H;JI
MC5<.Q$CLI)>?05ZL&B&9G8/5!O*^-\N+%;J0/B:]P:.;;[T&UI<RQ&/T5=K+
MF4]2 NMTEDUE#:I>MF>K*W2VZUF?QN0#7I-YD$^393!U*B]WG#):SV *EH"<
M['T^D"9>.ATJYLT34]RWC?Q WG4_0WRIO<=F(UH%^Q"V];?QY3)HI/MO@C>F
ML7Y+S[MT+NECV"%*V\4$+X/&O!YR'VTRV=4JKC/8NK9>'=&GBLAL:H'+_.).
M=WN7OH5@=U<]W(?NPZ_A!=;SYCH1L':Y+M4ON)A\#'_Y"+L<5W.KSR9 Q=/+
M*W?3AD3Y5H_'(7G,>U\]C\OI=.QS!VL?*6^T#\3Z9*6Q#Q0NG ,+(H2=SWT*
MDW^QM<AJ/>FRROW:S, .FJV"X6OKU^<W--\F&_:0LO#X=BUI)R&-A#0B%:I'
M(DF/-SG3M\0<V,O=C/_L1K//F>W160<%IZ%(*-AIWA(,4*_I_;5>HUR9<PV(
MV9#K-?>I19/3D^QGJ^6BW=2FF_IR3;ZO_$[*PE=U,QMY2+ER(ET#IN%1U[3E
MHEVE1M7GTW&7)MME9HZ"#K;P:7-I;3OJ4[#KD+LBNZJG*X_99.X3/Q<^:6K-
M/NU]7,N$'Y_'YN_7+<ZU50SG^5M.FLGRKJLE@[O:?X2K-SMO&*]B2JZP0;#Z
M/5QAL(F!]?R6#34T6:@1;*-=]+0!![$!;TB=_J3GC0)#@V**1SL!PF-O/L!U
MV3-Z4E7,E95#@K$",2894KZ@F.:FRC'/<V'E]5IBE[M<N%PC;$F.&"<""3_!
M6I94*4($X0?L-]+5B'R\JAGZY/TT7\_D9&>5\481<3!+V_6:X8]_?+BYLP@3
M(\;W3Y\<.&_XN/92%O>!ZR"+NP*IONE7L)\G*R#31<L#B/#\E'T>R\D2VWA\
MDC7>$?<43+:GXZ.L9*6YS9%US"$F,(7MI^%':00N5,XK:UYTRX8??^N@6[<K
M=_=X]#7C ("'+W+GWYHLM.Z_2A;>W>UQX._9>98[S_">^M9_3MKF!FU3B((P
MX_QDXY("ZY("25XZA/,<&P7,:.16=ZN8M<VS][TB]&A5TU47RET1X9/LUT4H
MSP =1(-]W&6M)':["=PQ4Y4YMRA7RGAPER-%=(ZH=00[53C,MGHC$YZ795Z5
M"!>%;Q1#"*I* GK6E85CN=)6YUOLYJ%$5[K;4:GCCK#/VROS+QP6V.P/.__D
M/C0S9^OY(D"T&U$;OI$K".,C(JJC90R_V=,VOV&;4Z ^D;E!2BB_4;%!4GLE
M QI#85LQ0K8 H2R<TJJ@B!C#$2NM $WD,)*5(,126V*JGGN;WV:<4)R/:$&.
M=J/O,TZ\E6'-R'\_[6J0QWW9Y;SQA>S;]>K=&2OC1K8)E]W(014I<^ 8CJCT
M)I7,)1*%D$BZ"J2K,-3FZB"*XLEPV=\"Q9>X[*O?%WM!V IZ%>O<A_C-6N;D
M>!D/+C"&]SG)WH>H_Z]6VW/O/\L!8'F\-?+])F[V'70<=Y)]Z M[.W/03@P<
MO76]6_#; )<PB9>;G8Q.Y5IR5/*2(69HCH1C%.Y7:"8UHX)M-2S$5:F880:1
MBA8@DAB()*TIXI6QF,,)Q&XU+'S?=46Q9K><^:W+ C^(., G^[L+#GPO+\5!
MX-*TL6_:V+F1Q!DCD** '9GWHROJ9]$PQRI'2X9U<7UC"Z>8MKE%NO >]\)6
M2(I2(JL)<\XH0E]X8^\?J7LL&]MGLNTK%;G6=V2OTI.^18GO(=:U"3NU$SOK
M^W)(XYLIP7DRM-CHBT\V\>L!BK.'4PE[D-KLNP><@P&& I=LM!'+>CZY0[25
MIYR\_3EYIKYXXA /=0J4O?0MC;GU%H5#8-I[D9G+BEE!:<$.,@5!GUFS&-M/
M[K<^VO7%SBYJ;?<8*GW7M6;RR?T)S'\Z@3<WG<GQ2]/.VZ_P.#_#,7__(;,@
M>Z=^7\W  $E1_4=7]]Y2VA>$<4>/98.\9;_)7F+[D@#EVX3-[+29S:^Z.[97
MG1Q\H\JN<]*R7Y._U\R>P2V\*!_[IGK2-[B"G?"M?9LDR:,DR;+Y<^C]O'ST
M_FW]6[V5BWGS3GDE.PL/[KO$X7?A<#26E\UB#O?X;LV[[GX$!Z79GZ!]L&7:
MVK>MG4I?F+9<R-#IK;OV#[O&GEW4;:U"GO?;Y37V##_K;LNJ$\'ICYX&^YJ*
M]\_GG^[6HR@^*:H#7NZ$X_QP5Z,G%7_HY6Z9,R?";GN1,7/;0Q"67'6G/NTB
MCO8MXHF[MUPG.%#"?QL,C$2GYP71!Z7U?ULYRW[;<M9%.9TD2H+'PYC1R]A>
M.Z_6ET_GOJUK;;)-AG@Y$K^067S03?(F@-MFT0*(;7^ZFQ2GSRS%[[H38F?^
MH>T-'X*)1[3?L@O6;P?T&,!VB$<7Q#N%[WF$=F242(+V]0E:$@]O)D'[4J"[
M]Z/="W7C<D09!FK0YYN?GMS/-]0P[AR<\ CNOB^!AS10\'BGKAZ*+=/4U7B9
M?4^.)).E=+E"3!4,,5XQI @52'/'&)<"?E;78Y(YY[SBN$2D8I6?U%HBE>L2
M25D*5Q:"*[>59?S(7(]\(]<COSFG<81)<<@AJ<<LTYYJMSW:A#NP2(ILV5]Z
M!FMB@*34DU(_5J7NL!1E61+$26Z]@K:HXJ5 ADCN3,%R@O.MP@?XSQ2Y\SG,
M!C%<5DB2/(<?Q.12"L7+K<*'9U3J_(8*H231(E#I3^ L.)2G*#D+#D'^O^S-
M!7Y&9^"-?'CH&.Q1\VMTGMI=_OH$-&+A_MU @PB15Y4L$*L<  WALY,5KU!9
M,,'RDKL";_59DH HF"US5!D/3O*B1*HH#<)Y60A6&<$E?5'O0<$."C6>4\1M
M1SN2K(LZ8IS<#0D4O&I&2:#@Z$!!)2O#&,:H<K@$9*!*)+DN$34,&^.P+.R.
MD )Q)@<,06 9$"-6(RFM]?T:<@X001>R?%%0P/!!0PH)%+RXK'OR[(;UE>VO
M=C@?QGH]$5E;Y>36N.<F"4U58O$D;G(R/:&>E4VS\(5D4<.5%$5Y$-ZYB<()
M\40H+78C'I47%;6Y0Z8D!6*EI$CQDB--3,X*+9B46YU@'E+8_8R(AXX*7D8;
M<;F5BQ+FB43>1;;LPW*$)&R1L$7"%J\;6V"L)<>8>A^*[S*'2R09P(:\)+82
M)0:LL-7$DFOI"J,QJHCV32QSA90L"J0U<5RI,B?JT,VX[N=-J8J$+8X-6ZS[
M4^!WW\TDL@9!+ZW\KT^/,/5%9"LT0*FYM[GK8K+6/&EO8SR[V3QMX(N1FD+?
MJD\ET67A\PU8I0AB0OLVEUHA8F1>@NVMK=I*62"LT@I[6]WZB0,%A7.T*\#<
MQYQ8HW/.R75]>J?6:W\TDZ[%<#<\+O@BU[_W[=?^:.;_;>=7C=D.T@^3GQSO
M-*BN'^:1O,UD;>#FM6&A:^(M#*N2\,FYK"=^GLBW?H0+6D[HO!I$*J?36?,]
MC/D97S[KA"M-",^=1MR4P'E%Y9#O)HORPAA:%JH4AA["2_9DG->U1/S0S/J/
M_'&[9V#Y/N'#5ZWTI#CNR5==/_>376\3Y>-&VY@QQN&B^+9.PX-!T,_<:'@I
M/_NYMI\7,WT&XC.,2#S$2-?A='A^ZM#SU6#O?VTSU8 B\@K:U*#9Y\VLS:1I
MID'?=U,J2783:;(WOWWY_/DGW__U@U6SA9Q=]M,HYAOW":;0&6PIZ^_@P<!%
M?PM_OC_]KZ$G0+AA-[(;T(8&%9M9Y[I.WUFS/(IT]A;IIGCW5P#-*,< +N1B
M?M;,8.&Z\>-UVR[D1(=Y-LE&N<E&P51P:0C<0' _^@DCX:?7@&E"P=I0 O.M
M!ORXH@Y+(U$I"=@H0I9(YGF)&#.Y\1-MM+=K#C2X!G  &-N?7#<DZOV2S(^>
M4\OS49X?[\RS;D7\]M?-^7DSZ7BQ'T4[73)S\(>WZW-K-QEX.<*V/3F6.3->
M=$S"E@I##':O$GP&@+YOA+T2)=_ V/-R!FX6?+D@=>J)GEF_D'#J?\I)$(3$
M7\Y*$%C>5IX8.0O8;P22#11-,)G6C^X'^LS/8!U/SS8_]QXF=1EH,K9MVSWS
MF_JG)-)NG"G"_5A&L.%,4>:(Y2)'%<XILI*5F#(K">>/<;N,U?3L+1AH/IP%
M]NY2-'UROX0]%/3EI\6\G8-& VIO""K@O*O!I8C>?7+IT<[.^O%8)$L_.:^;
MJ'>KB&FN-H@7!X'%93O/C+Q<SN!SM=\G07B [("]8</'1LY78_I6TNA*$KTQ
M=FYGY_52T,":RM8_I@]!=3+^HO&#M3>?1\FV;D<@XWS/TSE(P%,/$<,@\\ML
M7)\#D.]Z^O</VUVP[8?!^$]@;Z(=5_[I74!V;VH06^T"I.*M2S,_D_/L6[,8
M&Y"@BS:\]2#M9F!8^UV/%V9?=.KI[<;G:P/XQ O[ 1V)F"#%VA;I8IC_?K;*
M")^"0ND"RD@ZH-Q;.?XF+]MW/V3_]N I1W0XF^@@[H=]*_][,SGM+-_/('C.
MX2$6 <>!V/LXT0>8)S4@;GW2A?ZCF7LSO,D^U!- SF"@9U^N1L3\RS]]IYBP
M=V!F3$!;+*R)=N5O\S5N<];!H_B/5"#) =:OKCP]]9@&H-.1Z)$[P*@PJFF7
M)=MY 59^..!4^X\%<&DR*V\P*XTDK"@LF(@:@UE9%LR;E?!6F&+'J" @U [A
M*5NS(G^14^] 7\U'#Z3\T,P^+/PT](\].1_I"2,C7,#"D_UI<@/GE)Y!WF7>
M_UR;X(&6\UTFE;=U@HVRM*8V'-J=XJK>[?2?GX/=MK2\;'>#C2MUWB-EN]EJ
M2W>./(>5G%\Q\5&YV8)LF?H5 :UO09G4/J]QY5+TV08@>,:P@%X"3:7/D*RG
MGA1U,%L;Y^ >8$YNBJN1/]K?:5:K!1R\F/H/DNBZJ6A(YY@KJ5"IB$#,E!42
M3.?($9!+DE);&'M==)4YIE)1C3@M.&(5)T@1QQ$OL9&4:%/B38_8*A?"2ZYE
MN,A'BW[K2?^;G'FG1/O+DG;P@%=NM .YR8YV]NZ/O9^EGJWQ4K^BV1O9PA(Y
M$#VKH8Q=A&[>=+,;_2<KK_]>S'"2_=?$2Z:L@>-GWVHX=B73S-(3?5,8L9.7
MTUD-(,,[<4(Z40='ZG;U .8Z /$)1P& +(5DXN8;N)G;,J>*.927N0<BRB&1
MNP(ISJCERACX]^FXN0,CJT\\J=^WZ][PO\K9W^W\@ZQG?Y/CQ8'X6AP]7V<.
M5@Q@A%^\[,*OW/*++?BQZ4A>^F//P;S6P<9>X9D0A5JIT65>WJR?RSVV%Q(.
M7HD%?U:? FA]DA]PY;CY9F<AW@Y(">B>:3N;2Y P;9?P!E?YQP*8O[/L [29
MK#1\GSNXDE;;2OY*I7L7\:2Y.M7#J=6#]<+JFM  ^2*S67\E,).#W'(I)?E&
MV4%S7AEF*U1)WT6MS)TO'[9(E()1X@C.6?ETLN.O\GM]OCC?%"%F6TP\N)*8
MCS ^WFSC;\UL?K9EYW>Z?Z6E/7;6NIF9/F8-9ZS@P$GV:2D,S&(YI/D:6WG.
MFS3>/ +NGYR&KV#9GC%Y%PSM0IJJ1-0!9&6Y%$ARXI"118ZE$HYQ_.1[=+E0
M72+NSLQ;7^O5VLGP?6.TS& [S<_:XT[![;3,FD8->[V=@O1P\.^9GVF^EAO3
MJ<LVL)#7,.NZ=#T%S>OC25L#$P'WR:N2GV8&*FP<PJ\K;-Y#Z#Y9;1Y:VF:G
MB[IC5J\_]U4/G61[JX]6K'LF36#=2SOO!K77L,F#;K;FY+IC>:L\[/_+LI3I
MNQ&:^W=8EB>6=87D1I="(I67)6):&E1148%E3G.#.6@V00Y1J."=BO4\P+3W
M$]-%7DX!+]:V_;5N];AI 9E_A7O\/(;]]T-F0?M._3Z8@6I.6<^/C89EU4FV
M1H(@B#:($$$(;-=BQRC&LY24_[1)^;][?W7:D8??D:G4^LY+^G&2_>=B8K>K
M"K(0J ]V3I^M/ [A%7DZLYWSXPT@*U@A.>Z^^2G *@!NWET17BCKNT]X#P*C
M)<]^^V[U(D"Q+_]8@&DZRKXL:B^T.1YEO\OL/YOQ6(ZR7V"%X5J36F85Q7F9
M?0MND7J>-5HOIB#%D]_R)M^#S2MAL2Z0KI1#C/,"51AP2TEP46%926ZWVHM8
MH0 %&8MTX0?'5;D?_09FGBJP*RIE.;>;=MW[F96?W*= [B]^ 3:CH_]P\_O$
M1L6H$$>;>9NU8;=GSMIY9]!L<LYV*<XS.@$$+@@G*D=<<PG F& D+5"_K'2I
M"PV_5EM. (GA<VTM@BU3^&A[X6M9#%)<%%81891RFTZ Y9L%E?<K"(7-W> ]
MHL$R-O+2I^$>@['_GXOQLNJ O 9[7S==EEF[*K%XQEVLF1 @Z 2RM&+>0+-(
ML:J"/T4N85MRS+?KT.^QBY?F7=B_OWV?UIU3S^]D\AJV,B"$'(>]G!_W7C[)
M_O389MH5QK79MQ"0V6BOD (?-P9-C<:22P6LYPCH$^X 0QB*M-1%)9P3>;G=
M-_4!G-B7+K:A=<-DOAW6N (?^.981G74L8RIG75.YP#/NW*763OOJEU"*7"?
M.!6<IFEKWS@9*5?$V1)1"C^84242CA:(.Z=4)7A1D*TA"/>&2NL1_H\]:3Y.
MMK;X#0'^FT-W[.2((_RUMV;'H4:>GF3OX7B]F-5SGS$X;=IZGN+6M[:FY$:1
MBH$=F/,<,6D44@X@E70 HRQC5.)'V8ZK,O6>,K]VA'FX^,[SHQ;?OOG;5-:F
MV]J]HZ:3VZT7W;YF(7P9,LE")!GY$'4FV];.5U6$2HY#Y*L] QO4!\IV1;A.
MLH^3[/WB= 'JX2KBM?0'+6-Z<"$#"V4RV !V8OH^$UO.H>Z#<(PO7OQI915<
MORV[#KFNXN37KA$28Q(6NT<F?07F4%X*1)SO&9O[\%=)">+PN5.EDX1M,;/.
M+2YX88"%I04!H HD<:61*PB8416'3[=F!A\,BQTY,[=SGY8U.5W74_D&"$L8
M[)8MS:A5NI3:=Y@#\T(RAI0L 5D5DH*5[UA1;>55W6=+)PQV0 S&;J_U?*5]
M@Z-:BP%NL\\S>U$WBW9\N0E2QITEN\R>W8A&P=]?X*5_K>UILQ%DZ@"'[,WD
M>=/_$JZ5_$&/]0<QA972%&E ';[7?04&L,@1E1)+YTKGBJUJOOL;S9L Y#_J
M=M[,?,GYPZ$(.6HDLO(*'56CS*1*7GHM!L@+0;[W+>.[ID(^8R%)^+M;F04K
MC: E,MI/2LM%Z=,-)*JHS'-JL*W805(K/X'0DMY\ZO*F/-WZ"29_V,?8G!4[
M:E'OS<NT@?UBI =^L8RD$DNNC?5CCKQ7&0QV)2N&>"$T-D95PK/[XP<>/9&(
M()4X:A&QC R&UNE9Y]3=\@X'0=*E"<ZL+^;P^3SCRV3B[\%ENVL:R &37JK"
M<P'FH#5]?;+ !,E"&N1$I?,<PX?YUMB3^RC>8%I]T6?6+,:^^^9BVE>YR/$O
MLCW[,&Z^?9QT; /<\*<=^V3/KTW'>U_]L*A[%CHDU'JOOA_* @6R,)5KV7*E
MS=HU*F4:R)0Y?U1]12A?D2S[#I7!Q]'Z@)!KQG!<F[T)Y<+-H@5V;W]ZF[A[
M7]%2-\8N+/Z.^>V^8>AR[)Q_2-!);_&[<#@:R\MF,8=;?+?F77<[@D.6?W^"
M]GG0T]:^;>U4^LKKY0*%-M+=M7_8->?^HFYK58_K^>7;Y37V3+OO;IN?</ZC
M7]E]P_FZPWAU0@IZAP.)?XG;C^(G3!SL:OE)B<O#/1OLYP=>;'U8WCI1SCJ!
M(,*&W$V-/3,0UX82/NO<7A(%!S](53[9W-Y$B^>D!:R\_S8,0'M6NNQ8ISO1
M23Q3I\QG*'L3AZ3U?_LTP]^V+(IX&#%V@M_"F0<EUMV'P2;]-CR9FF@1#RU6
M^HT^LW[;G(2-3_P@[+89UV;_-/DHQ>+0]*#WH,7#G;?L@NUIZ+%OAWBT9!*U
M#Q2U/B%'S>H5#>2D14G.OC1C#5#.DGA8,\G9E[)&>O_O#P\5![@<48:!,O1Y
M970*>.S9#3[BU%7"A.ZGH9_[9@6,CV">6^D;;(42E,;U!23C6@:G>&W;MP?2
M%L>]/5XX<GI/F9UHD6CQ.FF1Y%6<=$FTB((6#X*(<9KNKXYVKYX6 X3HJ^S+
MJ[RC-G.SYCQK5M^,MWI>/C'5)\U1T_P9R?O/\?#J3C_%2U$R)&5=)^6K2Z[?
M.Q*K$HZ75"))78D8UAH)K$HDA26.269XOI7Z_?CJD&5!X$&F7>3E_M3O),$.
MNNT36$C ;= ,D%1X4N''IL)SK(5RJD BQPXQ0@F21.;(%;GD*N?<Y5LM@A]?
MO750%4YNZ"Z=)%@$*ORZKR8YU(:IVQ,M4@ @T271(M$BT2+)JZ'0)=$B"EH\
M<4[;<?O !FAN_^EO@AJ'%KYW<M^P6?G.A5U&F_VNS^3DM!M8VN6R-0H6H!LH
M?*A<MN/>%A&Q=W)3)UHD6B1Y-2BZ)%I$08LGR&4[;E@?(][;,;\VF6+#AO"?
M#I?9=E_:IJ!2?+Z-%-6.D$?W3'.S7..*%\AH*1"3DB*E*4:JLI184U)=;(\,
M?4!B6C#R/[G_:NU[;^%_ZNW[CY/?>NO^0S/;C'S_WM>K71XD],TY.V3H.TFI
MX4NIR)8](IB=&. X%CVIZ6-1TTI15TE7(9QKZEN'@YJV.46E(5J6N&25+@Z1
M?/;2:KHHJZ2F8Y92ZQX8^-UW\DTMD3<6Z_I >%-?[&N#3A_R*'O;H%/*K;3(
M%G[^B.,,*>QRQ."SRMB<4[LUY?) ;=!_[L:J?O%355,K]!?2&^L$N3;H]N:N
MY_7^QN<C'WNUTWD?=>TFZDY,9NI6^\XCF>_*G;JC'WUW]+OT N?BI.#%(;NC
M5_QP#<WSDZ(\X,.Q$XH?V@D^W@:RY[4Q8QL;SGEI?3Z,4.!K[FJ8NJ,/NUMA
M:HE^U$T(4TOTF*5H(D0DA$A->E^9VDO-T%^)?DQR-LG9)&=3,_0D9R/,#DX9
M]\_&U2^8<YJHG)RIB1:)%D.A19)7<=(ET2(*6J0ZL.'2[M738H#)13M:-(RR
MB9W'DIJY:533$^JM:M,L?.+-YDH.?R\\(]D?TRCUP#Q\=PJGK/8(!<CNK':7
M<U40P1"75B.FL4,5,P0Q4G*A'*XLU]=S5@FKM,(^9]4J@UA!!5+:%<B4F!-K
M=,XYN;FEZK4<]X/DK9=Y$6W>^JVLL^USC$Q*OA:@,E@U=MSP,D&/!#T2]#@N
MZ*$J7'&F!:*DP@ ]B@()7#F44V)8Q2M+Z%8W=X;A?\I6<*0?XF(T08IC G]B
M3"L#@$3;YX<>G!ZTJ7N"'A% C\?T@4].R'B01J)%"IHDNB1:)%HD6B1Y-12Z
M)%I$08L4Y!TN[5X]+0;H*-D(\G8='\9]<Y_:MJ-,+V8S.#(6WT)D!'\M?)9\
MG!&R[AX?IZ .FSQ'BN8$,:,,JFQ>H *74I>\S!WFAP^OKAJ"_=+)B\,,G^8B
M6B=G$D1)X1\[^$H,$!\#)$T\&$V,M3:86(D,PPHQ:BB2&E=(,L:9(:7!SAT^
MVO@TFCA/'3JC%D1/X#9)+J]XE,AQTV* $O\VMPD(RL=[3NY+]7MD9>QO1!#9
MWG@M+/F /A$)_\4B#7;C/RHQDQ:72#C?OKUB% E%)-+8&::IU82Q)_3$_+$2
M08>!@((>$@(^IVQ+^68#$W*1D>>XL6)"#1$3)Z&&UX8:<E-4QAKG]7X.J$$2
M)  , " @G#.E;.G$$WJ-#HP:B. )-1R5D$L).D>-'HZ;%@/4$AU%UW]^;?RT
MEV:S$]JZ^RD6SWRJDDQ5D@F!1BQ;=B-0(X56G'.D'56(%66)I#$5*DK.J:N<
M+4S^A'ZKP[1F8#C:@&6JCQP*>AFL CMNS)E 1P(="70<%^C0A@O"\@I)@!*(
M<8.1XMJAG#CF*+6*DJU)I@=T>QVH*0-+H./(0$=JRG <&"/1(A4Y)[HD6B1:
M)%HD>344NB1:1$&+)YZQE&*.4<U8^K_A'M9D$M97GH)]:,]E/;D*-<[M[#Q[
M4T^R2RMG[4\'DJS'O0LBXN97GP60:)%HD>35L.B2:!$%+5*=Z7!I]^II,<!@
MV;WFG3YC[G1DE'TM#'7\ >U5?/B/Q3E\H)=5$5PQ66B)BE)(Q 3E2&E*446%
MR1WA.9%/T-5J:0F_[PSA/Y=V</CR*UC!9",>C%JKWYK%S)O%PQ<]] 2O-OX&
M2:(IX$A"* FAG4+HN$%7XHG$$]$H9L4U)41;9+70H)BU0@IKC)31%:74\H*0
MP^=MO6K%3$YX4LSQ"Z''9(XE?U8\FB+1(OG?$UT2+1(M$BV2O!H*71(MHJ#%
M$V>.I7A5W)ECIFXU//\\ ]O=I@S<8?'NJX\7)UHD6B1Y-2RZ)%I$08O4)6ZX
MM'OUM!A@3.B >6)I.,OP&>KXP]$#Y-'=C4^$+ER98X.*HG"(E40CZ0Q#K"BJ
M0I6,82*?/+/MU]Y._Q/,],]VIJ^W_YTN9G;5$@71]9XH-[=$J4[2",>CZ/_T
M8SS"+3*Z'3=R&Q(''<VB)^U^+-H]+[AS2EK$%-.(4>+G,E<5*I@@EE!,I;%/
MGA[WA-H]WBZKD<FF@6KW=3\._"[5V.Y?UQ]?G?*%O6^_Z_'"O-RJ7&F @;LP
M/J#ER@[\14BYMD56C'2V\H%.021W@@TL/:#=6SG^)B_;=S]D__;0743H<+;1
MDT:@?V\FIZJ1,Y-]/I- 96T703>TH^SC1)^L\^[1\^N3+O0?S1Q.FC?9AWHB
M)[J6X^S+'/#%.7S=9O_R3]\I)NQ=]@N<4$\6UD2[\K=ID&W..JPE<:L*82<D
MSU^?:MTJ;3#UQ?_Y=_BQP\8@>Q[E%W@[-:M7CR G+;JYFL455# AD#'2(,:P
M1I7 .>*65@4N66G=EC-.5LXQYYUQA:4 UP5!E=058EA180I=FM)<A^N_V[:U
M=D\OXK_*^6(&_W[U:.LKW.CG<:/__D-F :%/_>:8+>P^=/M2FV6 :OK# I;9
M9O!U?;XX[UM;Z>;\O)YW0DS"M[(%^V<\;KZU_M?&9;]:;<^5G64Y&65@O]'0
M"&M^UBQ@=YGVI[>W"KK7R<]+&R*8$,M'ZM_"/^U;N9@WRR[5_B&!+=[B=^%P
M-):7S6(.M_ANP0(,MR,X*(S^!-A?8SEM[=O63J7/-5LN4/!.=-?^85<\^J)N
MZX[KWBZOL2<JW=V6GI05^=$O[3[;MCNNS$]XSNYP(/%O<>M1E)P49?' RZ6>
M+8/BE)33$C,M7BSOZP&C7I?K^5+T/!)3YRJWXO?G[L'SN#VQ/=(A^LT1$;NG
MTH7790_\MY6S[+>)\8R^CO+C5 >1T3LBODV0*1Y:I#3@X=+NU=-B@#J,8IJG
M 'Q*#DK)07'QY>[D((Y%:4J%$:&,(,;AAR2L1*6M'%4&B\J5ATC]O3':\%E>
M!G?WKPO[!]SFZS<[OK!_A7N>M0<9BIB+>(<B)A&5W,/'CM&.FQ8#U 6 T5@L
MC?KNZE2.C.JOA=D>X/-/F"\6/M^-^1PM:($+B6Q).6*5<TAR^)-:AHVM2.7(
MLV(^[_7\^JTY"-1C^*#IX,\IZ=+TZ^2_>WW8\+AI,4"=T5%T_>?79B['?7+:
MM!?;R7R.2$0F#U]">WO1'@ WJWQ:L.*F0,Q2AY0R&EEGBLH"%"S-08K[[XKV
M#@+SRN31BULD)8_>4:.VXZ;% &6_E[Y9?3Y=^-:GM=?(MIT/Q/!-+K[DXCL,
MZ!L@X[[957&<P&L/7HFD.<U+@:@K ;P2 C"VU (QQQSW/DPMMWI7'!R\_M=D
MV4/:FM^^:SCT_;G_ZS .RX,"V>2O'$R_BY^2P_-50N?CIL4 -<^VPW/-[1F+
M4V%3%M,3ZH6Q:1:^DC5J$!VW$/[G>!CY[A2.'X<G_+I,KRPXI88P))T?3>J'
ME%:\E$B*0O.R<+Q4]/"=55?(]3"^5A9OA[5;F29ZD!J'>W8(OC\2!9B\?Y^7
MH;B!$B&&7&/Y"HF2"/'RA-C9G'-WWZR(6G9&V_^A.]\_Y-L:K,]:[R5+U]7N
MU$YTO=D.(J)ECA&G9]O[.:H660,T?3[,FO-L#F?Z7HS^WU$V/[/9+\TYO-=E
M=BXO,V5U ]^W"_4_5L_]<7HLZ_,V:V;P81TZG=6M;WL0.IE9^-S4$SF[!,V[
MF+76MSU3"SC MNU)]G7MZM_J\3B36L\6-I/9>&GY>(,&KJS/X/9S,)';[-N9
M!:MLGM5M-ITU*O0 FY_)>>:Z)FSV^]1.3.U_;[NK*@LG&[CLQ'27VCA$ \W@
M"% F;3.!JUUFMH67EW-K3K+W>QJU^4O!+V1SA>"1)LT<'G\J9_#HL#K^4WB-
M^E1Z<VMWS]#USF7T)*<_OGL&CM_H:09W)?S'(Y$".Y46:+8]_1X?]#A[6C[F
MKM*,&(=,X9LV6J:1)$6!*J-Q;HO*"K<5Y7I(R\>/$\^%7^5WWXU]W+2PC^_9
MVS&IZSMWILW@DEFWXADL^962?C1O/.FC9Y%BB1<.\CR]$, 5Y@3X'5$K@*&5
MQ4B45B$B)>96.R;D0?J^?M%GUBS&]I/SZJ>9^+3,3VXE&G[S.JZU/]N)A35)
M_5^?5 UY(-/U=O70I^]+NCB'EX=[M0$C3.P\ U$- &D^G]5JT1T$$*&= T7.
M0!1X<*,LX!T+_P2J!?!3=Z)G[D5/IBX!J)QZO[3_RE]W"@_6&(^%;.N#""9U
MC3WJKK$%.>%8'*P;+.$GK.3XZK^[=*2]XZ5/*H\J#W6U\H3@_&G:UHJ72V(^
MKXT9V]B"&;%E8JS<ML4SNVT?VN12')Q,+]8 51R2ULO&B-;<O2]B(OC=.?.@
MQ'I49<@+RM0GRE8_/(E?R$8^Z";9'%D09_#MJ?M=)VF_MST-C4>T/UN'Z]>G
M"Z(C9J3"/3**)8'\^@0R&0P/)X$<5=GVH=*DX_1X#-#I_%^3VA<)AU&)T?1Q
M&6B)<*IN2#7&\7-\JC&^J49#YH()QC BI:H0TT6)A#(<E2H74N""L&JK'>+#
MLR]^;]K6)TSU4VGKR6E?N]%,VI]#%&\5BK7MK_!+"]QT]SJ.%O8M_'9SR7$^
MJA@?2$U'*CM^IK+C>'5"9/2-+<@5#VO&2K&X.3*AM(32$DJ[#:7!%O<C223B
MCBG$E,)(.$T0+<M* P@S9:ZNHS2NI2N,QJ@B\(.I7"$EBP)I31Q7JLR)TM&B
M-%J.RJI,*.U5ZH3G; YSW"E) Q2 CVT\\H1-H%+CD0A WY.&4X;=>&2 W)Y@
MWXT-5)S)+2,4Y0*P'U-5CE2A-)*Z4LX:S*O</(]S+G8?W/-*_83O7LP+=]R]
MEX?E74M0*WY>2U K0:T$M6Z'6J65+&>E1:K, 395@)ADP1UR925(P4I"\%8!
MZM-XV&)WI"6H-2#Q?R=7VJIU42I\O:4CQG-4PIN<Y,3F2.C<(<;\3/)26"1L
M;A38;Q0S?-A*^-^<LR 5+JZ\^G_*N?W3PCUT/:Z#5$JE\$]>"K^W?%W.;";;
MOE2^397JJ5(]5:H/K*HRY>"GRO776#J3*M>/AC&CE['#+&X<&D>GRO4D[5/E
M^BO7!?'&Z5)%>D0LE@3MTPG:5)'^&@1MQ!7IL/Y'$(IY:<?OSWN=OL!#<SE?
MS)O99>8L,)@<9][Q&$L*_/!I/Y LC -7.:7<BI1;\<RY%;;(JP(+@0I7$<0D
M*Y$TI$*<64)P061550?M\+\9N]S3W?O]_$,G5K\LY>Q&_/.P:1C5B-(JVG*F
M),N'64,>&=U>.F,C<= P."BAH82&7B\:XJS"C!*,G%$<,2T,JJS$@(LPPTY8
M9_(#9II&B8;X2/!X6_ D67[DM=K)=74(RG^V<'D_0"DSM7-V9B?:^ZTF)FOF
M9W862X9Y9(2.%@X_76)-I, J 9(>D!CM;,4*@1A5OO3%451Q4R&.L12*VHH4
MY#'NF;&:GKU=28N/<WM^CQJ7FU $9='6M22I$W6:0'*() 88YJ(GM7LL:E<R
MX;#D$E1H!2J4"H?@ 1F2I)3&.5P8L145N8\?X*G4;L35I$GHI)R1XS>\_[2M
ME3-]%FQM8R_LN)F>>SM<SZRIY]%,-8B,TM%"@!32B)_G4DCC)BC#L+6"N!+E
M-A>(P<.A2E*".&%.*D8JQ1_E0;@EI/%'XRO,%O!$:FS[L,922+Z?F%^O1.1!
M ! 9%4*DZ,511R]2+L>@7!?'S$%'L^@)MR3<$A=NJ:30#@N&<L4-8CE62$KX
MH7%18%OJRI7L"5,QGAFW%&7*0#UNU))R+H[<]?/+F9R<VJR>9!=RO A")).^
M+92<Z,=4!CUA3[_!S$F*%F>]?-%NI'@LX9AE\U*B"\J-0E5E*L D6B.1*X>8
M4$13RXO<;*64'M#_TDFECY-?K;.SF35PP/NVM?/V;TLA]7XIHP[C@,&CO,JC
MC4(-?3C0:Q&$D2W[L#PN"3&\'D9)B.'H$ -G6O#<,42YXXA162(A<HI<#K!
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M;SJ;>+M77#IO+W76P:5JF?[2@HP(,B+(B!B6$6'X0O4LPU(BFWM811LIG/-
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M4%K_M^ Y^P!K%JYE6[O3MZKK!.^.8'9>QQZZ0]SA2?Q4=N\Q)?H%9K$F656
M05O<W:EQH<7U)];B/]",KI/"WS?>P!J:[JCV!W<BZSH[= <+NMN(]6F4=L<H
M08KV]!2MUAW9)$7[7$8WG4G2]QCRGW,L"=D=!FZRR<LX<E,O,P?'NBLM7_O/
M!4](\,>T63I>[(.:)W5%(>S:D!4&EFJ8BC -3S$#TU9<3^B*K]H\<GW/$WPC
MN_@C/:QWY!0/TK?:,'=OQB(5UH%^2-WUZDXB@4D"0!A.&#Y<##<#*S0]SU(L
MPS9P3UND>*ZN A[[NN5YD:6&&WO:N#"%IG)3<7S=5$S7=Q7/UX4BO"AP7(>;
MPGM:#._NF5P=TV#/ QM'/P:"X@7/W ,C#.LJ8!;EV72MT+N OWX76 ,N(P1!
ME>>XH^21D0(Z9[@'_;+)2.B?)._:8B L1W5T17-YH)A.I"J<AYXBHBBP56Y$
M(K0/44:\PTCXU+1>P_W 58)[UCZ"FCFK5<FY+$5=W8IP&)O"VKT?GA3622JL
MCBU[O^(")  ]6'1"[*$@MA9:H6?;0C$\<.;-T."*:[M"42U/Y8"]NF=ZMQ';
M"GADAX&J>!K\Q_0-7_&Y;2M!H$66[SN&Y@<=1FS-V=V%DQ16!Q06E0U0&"!.
MFX885"K0,>FD+ &9$[O[@GFF[XG 55S' V?>]5S%TSU#<7CD.8[F.J;I/'D
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MBGK3*3J9P[CP:K=GBO(/@^'P*]-;$\ZMMCH8]'^$?P]E-"ULD.8I"Y]6"]S
M516+F^#3!JY0N&GYBA.HOBY,4PUM]Q"[S,XS0,?I+,GFJ.46)>9Q$<": R1^
M@^'?)5GP^T],@!4R0^D$!7V'?S<0(_W6.8>'E=0O&8B7IHW9A\72LW;MMVK$
M9E'PY<$!-_2?WSS!JC??R> 3/E6S?KZ/$EU4BXQ<S$,OZ8>%G0N(\I<J%6C8
M@'F#2OT,K"+4K6!6<3^)P30+P;8U5>W%[R]9 09;/@<O)A(Y@LT,[#=I-*$]
M6^LA 4JXD0LAI(;+8[]JK"Y0[==94J4ECH)P@-^$ JPXF"H\"*UZA#E0T'%8
MP0-\7L3%B"7Q-&X,6YSC%/3^M)HR/H5E+QM' ,-9-5)$#11*(UY<54EM] '>
MK+S?+,_@&8A*\%81VKZY#R^R.F&):3-\*+G;=[C;X!P#/X2!XNM:!%C'+<7G
M7J@8ABN<P//"*-R(W_X(UKT'_0I,<K9"H7/@OX;7\E]X&8 _=;7VN\@Q^O\U
MDC^N.>8S0,>%9Z[HJZZY?J=GOKO);,^UPL^MB]T*\A\*Z2.!@\1KCP_-,FDS
M!@*$48!*C%'JI'2"E$K3<\6T;)7 C.>-YPRCC-G'%2>KV.5ER<$VM=+".>4S
M$&#0 F#H@H5(\;"[!=0T3:[Y"A<&")L6A8KK6H$B-$TW@:^Y@<F2 QBCZ$IG
MZ=LT_(JQ$;1-<U'&N5BQ33_488>#)%UTVQJIZNZ^3SV71RD"Q-EW-O, W.&^
M"EC#=:&8OK 43PT,1=-,R^4B<GS#/,16WJ?F;$WSALS9(S#+BEEM@B;S$5JA
M33AR+8:)BG^7;491N!U1N./'-GCDNZ9M18K#30, 0?<4WQ6&$JK"#8TPX%S7
M#P$GEY5?B']6\*(?KC&$2[&,X\4R]#%;+C>KUYLDC!+<QUC13RG[*/R\PA@
M6/B&C/KF/"X$F3MWFSN6JSL\<B/%U;@+6M1Q%<_A0M&YYD6:H5MB\ZQ6C8,A
MH>F^8F@"S)W(]Q4/KE=<<-I=S;=4P_ W-&\)6O93450B?%_EX%/7C4G^QI-*
MP(O(7PZ3YM:-\6"MG$6>&\P;#HN 42H%_IQ5?@)@FD61P+65*>98+G;M08.V
MIX#3G5:_"(3PP8%5?:SO /X&6UZ8BN>&EB8,\&=#?EL,'.'KFA?XBFM:6##H
M<A"=R%&$X9MJZ/LJU_16#!)_-GD--H\O\J_163:=9JF4B$NP0T51RP6X I=
MJ#4A*.3OJ]ROWLG\ULBQU"';^:Q>$8PK!7(9X5U@'1G,*Y@LJP&(V>\J9M*,
MR!>@M6W+!\9U7$_AEJDJ>N@&D>Y[IA]MZ/R','NK\W?P^3T,_NG+Q[NWV)P,
M@V,B>XW)&Y4^J_*BXFG9.K39M<@5S%B4,FV8R6(:=I7#)4NO5^8Q;O)8UNW
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M9- R=8MZ3 *1^!Y/?,D_[$Q(93AFN$UF>*_C%"TG2K3"!,)O<1SW'9+.U[L
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M:]3^'^2E308TK*3%Z9L;6*N:3U_7W(I?;!>L:X$G<_&D8:6:Q=K%7C"<;LW
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MZTB@>@+=&+:"ZM<(D(Y]%F4)_]P/IN_@4QBSSV-XL ],4SP64*G?PM %=@"
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MLTOQ^R2/.ZM,*)]*F1?*O% ^M0_4[R)Y2:I/6*HIGTKYU ?F4_MA%5(<G["
MJ$I4):H250="5<JD4B9U0").<7RB*E&5J$I4):IVAZJ42:5,ZL$SJ7_AJ6#?
MXB3I\-8#2J-2PH42+I1&[0/UNTA>DNH3EFI*HU(:]6%\LV(2CM@O[\XF[T;L
MX\79>3&GIK_/#PV4J"&J$E6)JD35H5.U-<S@7^XG0G[<M9@_/[U%O'OACF;+
MKJP2+48W%J-WX=%=B^KIMQ9TLO"&9OQ*U*I1X1&\[6N>W/!Y\>8G]@JN_.,K
M/POG?_K??WPU*:?)G_X'4$L#!!0    ( !2"8E9?>,"G7Q(  !W*   1
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M2Q5,:W;'P1L;B!CG>#L4_\;BJPFU-5:?84M;4A1;"F)H&'X(M2].:PT>M$/
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M+1WT%F<#D++#-F%GW[X"T(HA'WS<W._WAL$G>W=,HSW -+ID<N'D#2E *5/
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MV48W/F;Y-W8WRCYU?"FYW27'4!"7$Y!V,'%'32"BHW@A($R1"$K_<BTN-9I
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M?LKK7@4*=YJG3@RITR0UY+ICC%KAHXXUZ@BN3,J2WXO_'B&Y^^5_4$L#!!0
M   ( !2"8E9N8QA+RB<   'D @ 5    ;&)P:"TR,#(R,3(S,5]D968N>&UL
M[5UM<^.XD?Z>7^'S?4GJSNOQ3#;)3F62DNWQG*X\ELO6[.8^3<$D)#%+D5J
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MJ<X#V0MN[L/4QZ*M>Z9U(/+9T+,T5<=V!!2-&+C"LHXEHS;R6_1X*]IR+'7
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MX"!)2;O+,Y3&->&C";-QL<]___*8><7.![6TRA+Y%QQ,9TP%?\8$5(OLQVM
MQ-QJ:TJ?2R^'RV)6A:TCK9;W))>TPZ()XH'-!+I5@W4KAM)GF72=Y[F3_*G
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MAT;JL;-&T"9B4JA7.VOY;*0<")5S9^V:+5_^KH+O;BYK$RU!>D)P]YZ^)FM
M[831TFB]^IK]AR6P_N/_ 5!+ P04    "  4@F)64!4:+<V5  #&(@< %0
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MT>)&:RK,YX0?V6:BD\H[P+U:I2I4Z3 M[QS"QL( 9[-]7KQF;'G&:D\5@:
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M7\3$PJ?ZP[/VCB'\IMUB86>[:@(-*K'+$0?WE!\).MKRYI[.QAR=I.=ST=;
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MH;\ ".F:#L]N!W1N,\B#:O?QT\,RS/:2&BHO&:8*H!24+L'0U-<"'+AO6'?
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MXI7"&8?$S*5TK>&!Z:M@G<)HRSF1]FL<G;KS25WO'9!^GZ,[">HD)X\[(7C
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MPT>N*N#="%J(6A:D=)@'@,@-UM/-7 -"=&);OC"J5:#S_++&[FG*S!'UL@'
M[%UQ:]5C@*K5905]^O'3Q[<@DWQ:;=K"93'7/,FM%P8SHL<6B:HP.@*5N9N2
MDG^CV-W8@#Z%W&+?1C+W!X63O@\'/ , ]M"?J+"L**=VX^RU9RY"!$]88G,G
M/45L9Q8G^!'.^<LU3ZC7M?H.Z! @Y+# K@NOK!\V"S%,W1BVD-W:L:MQ72PS
MAVHJ)KV2!,:#!::[.$]1;/G\*OH!ETK\<1S0B1UV=W8O[EZ//<</T%85E+%[
M70-^7L3WK\X-Z%354N$,U.1=XWB.9DHJ0J9=Z_(6U3/JJ.6<K1FM:)/3":^O
M= 3WTL)I1'/A8%U=%9L W3IVC!:3.V_"OVUE99OX@?*GV'D3VDM>9?DP$B<(
MQIFYWHY<R<K*8LJ45F,$<FN(Z7B/R(L%1(I!E3,45^*#\6*D'8O##V2C.*T5
M%V#\<?13G'4MK>%4B"#C&F"Q([_E5@TYWX*> Q<?V!$7<MA;%>L!J/-.*:"2
MH.I$=PE=F#C-$;//^N:\G%T@JWJ5<[4SD),HY-7.XIYR)&Q(H79>E1.AJY*U
MA]]1/K%584H%!>:3X4L+BB(:D?6<XV\I8>_H1HLK#Y-;+\EVT$NADWY@/+Y$
MAM0V0'@:HLA%F),$.51H$*D2(-M;NP0TI@'E"K,\KR.?;<%*N15MY,V4OV4,
M;=@!K3UF3!A97$<Y93<Q(QY[[1440S+O%)%^!4]$,K67B%CDBVC&G*>0##^7
M^WDE^STXG#= &WX:6 ^KZ2W/7SD;9W\1%9OI.3=+\@P72Q#<1LJ,./3G$JG4
M>9VG%5%8C13NV=]SOQJ-$&3Z><&C$@4R!SRM=KET:L.TYY2>D4(/"\G0K.A8
M03 BR=2,U/I?SITVKQK#/.[G6E6THI9M7MW-Q%?Z(K$,8%=+XHA_] 7DQ2(Y
M?P(OP'5D7A%RA77#Z$U'Q&(^+LG)DN+(B.^(8X,CK7"9'-XQJ'&+6$<Q0<!Y
M0 LK&W3EJ /]VKG(K8-9 E[]9L*BFJ_VC>L'9\NI_IE?F&E_>BDY '\$'XD&
MQ^E4,I!FX1J-K$>@2P+ =%T!-@[ZD2&G6*2 @#WF 8_BPC'')!Q/GX-XA> X
M#U54E!GA)>@;(SET47\])<'XSCL]%II'(IYA%V.WV"%RNC+I;?7HKICV94Z3
M["]WL SGKR<+ L"+88J=A8@!P$5^!II.5>O"<RD]-5GO'&_3;U%"134NU&'>
MQFD(KQ,D\RVYQO+QTQ=^Y5,GIVZK1YDS1'*.1&FHXFE&@"N2<;;(QT]$,/96
M)_"8UV!\<W>_?4BY<<_7^>4S_U]7Y3HG1Y!>3RU A![5/>>ZGUSK3DG6SG'L
MN+5S#TDJH(Q^VX""].G'C__VXR<+[?7NOQ&@]>''3_TA#]H51SV*W##4Q(F@
MWH.$S>U=OWBOX7J[%LDUZH>@N^;<V-!U+095Z=/JU\!9?D9O<\!*XE?U[I/#
MJ9QB/: KK;4WX8]JZGM@#3CL6:#CJ#2XV$+YNC KQ R<8Q@T14"5\SPDFA_5
M=L+@_&D'6XD7H 84-51Y%#9'2GPK<\',:1"C$C&L-NU4EM]Y85J,T0VMR>6T
M\+UY'G'-CZOW_XL/EP:AW[T%(_:$ <<RTB4FX3XZ2LKNV:JY_47(MEDWT$B
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M+C$(SXC2)_N!:-AL&)Z2'E-(8-<1-V'7G@UH18-ZC@E&C &F+&2A]4(<?<
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MP[0HSX-(<K#%6WJ@Q]M5G*QHF &^]'4DC(92167>]RWL%HC?*Y\T>N-!<RU
M9,*86PX,ZH/%P9C+8VOL,ZBLZQ:8H&E;4%"#93@=E95^X $Y#%85&X9!:Y\N
MSG^X7X#4R/[LL4L,%AO,FREQ4V->Q0;WVK-AAR:'9G 0(,(05+F%P75T[FU"
MR+_,M_1.BHRFS@WZ,/@00OHE#C EB01\TWW&[?5]N6 0>/WE,+/"V34C9_0Q
MC! ;^,QC;E.&7 E^&05'BWV)U?M3E)D=)ZJ;AHFZ,:!J-MT5>M1QBVT;[+(B
MI\Y\2!AV6"2/7A3^7203\K,A9F$@5)8HN.4WJI""4>FEA4R7X,?KU$;4&)T4
MAB=\?&(R0!8KDM>&Y3R0GY&+MS,_[!]3TS+(59@BOS!%X'_=F%-40!/4((.I
M2]Q D==TF\0KFJ:X@UY1JSE?(/*6H9*THHY#!!9%844I3*H$R/:0_=4,1)IC
M"H+.>2NA)SO5?S6#&PI(7 /*$+5V-;#S5*)>9L,PJ/XQ&ZS51-PW3L2T9Z"4
MC_OXF&#@R83+Y5OV-I<=^@UK&%B7);=7(:/).>?E,4YV%NJ&D1Y1!$?+.>N5
MZ3V'@4)]Z+*OX,:@_!S\4.PAK[LK^WO>CDMG/.?K1!ZOH@B9#PI:V;:35257
MC:H$UI2)(#U^8=A <CCH)G4-4"E1&OJ8D] INEW14 LRCR1]UTT=QC,G1SC-
M3VJDE4_I3XZGE)_?JH<X3?TDW @##7%?H.3[9%4&*!MY @9U^-:@/][U\A.V
MW%6(G]TP7RRN%,'6; \=]&U/9"&R6Y(\#^B)D40^-#\XL:ER%N/7CI,CGV(6
M<!9%U+R[TI+F-/_YG_[]T\??_D>*R>S\,'H7T%7H.RVG[RZ16O<&H7]1S<GF
MF<#NPOQ&_G1N/;?&?7=I]N,<>]&+F?.MVI(4>="B&(IP+L I5J31W^&HV&%E
MZ5TGZ[K8:P)^&J7CX=0)L^B'V)^I-S5%1SBN1K>BC &QUO;<;#8DXNJ=\I3F
MB_/KFNV]AV0E9]*5?.WZF8EZY<(PXA&[E[74/U3H0?-M]A0GL-*Z2)@W$Q4*
MAT8J\#3YR<C%RB)=2I$D9L'<H4C=8V(W842O^>=.RK*5N"%P0I"5408/3YXH
M]H\Y>AM!5A.D,86]7O9D",YV=U3VM.D*$Z3I$W, ,-OU$(Y!@YQ*685/61+U
MS!0UE]2AT>,_T6 +/JJR;I=K744 +,PCL#(']]OU&HX,=#/TTWEK*+&5M2Z'
M!9'W-5FSLTEQ<)E7XK:%=>[A7WJOUP%_ .$J]'%\X0^R$*\ ](<B:>EEFX X
M;"A)BI@<^L"YB<6X71/T9+JOIDL4X4E(P@X(T4-!J$[X1/].%W.WF,DJFPSW
M!,K668Y2JQ15OC=S';7JROB^[['Q,?285FU'LMP?V2A77WG3785B!V5QQ_L=
MS3RNY0>77@(KP&S0>R%B!MT<J*;O0P8A)B%,Q5:FJ!-%GKPSI9,CN.^AXD#*
M&F?5!!_8_M;7^K'UN VZDCO?&%M+W=<F:5]D=I2D+J-L4D,3CD+P[<81&'L=
ME#\9]LQI.5?Z#/1G T53?2M3RF35#C@_[VA* :=D'O'G]TQ9C$!BT%NH6VT-
MQ0P/\O&W_TK\?#1R]\_>>O,?%SWDXPTX$3J49J"D%R!-]2^2C1DY-^=(<H).
M-8,7[/CD<,:@C=-B-0]BS*CH%@T2 #\R72X*O"1(R;<-]&%PV+\)/:6B[K\3
M]Q(ZP#'*6Q=&2XY9R;"@Y;".!3J0\/<#_C%:U-_&+/1W5AQOV&@%ECU^,,:8
MF$SL@#@S(@8@/\M_>P&<W\.)1><F^#8-UZ8=C&/$H$S1=YJ![S3LPW=J5[Z&
M!F=O1SJY4*L ?OOR?.?NT,LU3;CN_O@YB5^R)U":O,A&V86B2P1A(BF/7A0V
MC!2YJJ_A_W9&UFY7KZX)];?K)QW8HB3L@! ]*/A->4_0'36,MO$VK<Z ^OCI
M"[_B*5TD-W'TB#C^/6?9Y1PVI$=]_$0$GR1.B.!T/+EE?<WQ"8EY4YC<O4(I
M&VAKB[U*+X<@:]8D8&7F=</C7GH+'L*G.@!/)3+N >-<YMLO8_C**&?I'IVM
M+#MZ%JG^ H-16*NN2R!&.$UR\=BO+ZFLH2B5*;F***-E+.$ [BC_)T2UTS):
M0B(HNT-+L"\&*TI@$'4-E&!?EI+WXMQ+DAT\"U'K[:%UE3U1\B"<V=S2HC3#
M)I[P2_S PD>!7@80V5MTI&5/2;Q]?.+_>O)*S$B32-H S!I&)(XHV5$OP;:.
MB3&#L C@"QH^T\ EEOJIU50:JGJ>IMNUJFF4VPFWT+HUM5:O.@M7E+R#&7*)
MKC:>2;"W@QK WP9SLWP7!?YZ4$BP?ZSA:E9V_<6V:Y.<&YJF%/$SE:Z"8\VT
M8WLW@Z/B@0IHL#[TEV8MO0O@4@M=VQV@4NY$^"EF6[Y+)@+-H6,ANR8F !V<
M.G(Z,E[APG'/O>B\PE4<.)@>Z6+UC1\]"<0DE]ZK,I[2KW$&"9"/T2DE">7&
M+'HP@6\BAX-.PQK=)"51G,'1)(><I-S*R9C+NU@1/0R&Q_1 A(]$[J8M;\%E
M_&MYR*4V-J,0VTR:1Q\=CBN@/&SDR).<J 0(&;<,K'_V<>6ICM$75/Q['6DU
MX@Z H?EZ3*EH5LWMY+(2\Y5:<@TE,-:'>/5AFX*9@6W+P4Q@V,V:F1'ZB+Z9
MN9 /77?M?J=&?@\ KOGLX.@?%JL/?'S5U!UF!UDHYB]\?3NS4SJ395,3OF>%
M>KX"<[[B$U>3 ZL2)ZP$"']'(;="60)@==CPKFKX=D_"MR=J&"DM1D'?\>EQ
M93RZE965Q%0H]7H$^1)@,-2E:>-6S-):;_547:*BXCNCK?J\]VHWU4.@J,@7
M<LT%V8*#R,L,/,$)R+2/"S-YB4Q'+!*= -/,Y+?@Y\EICC#T(/).KR.^3XAB
M3L0K6#YYD?3U?^8DLKJN(OCCA9=1/8'=XOV<B]#/(S:>\)GA*,)7V\<ZGNQ<
MVO-2RFQD0Q2)8Y%Q8?(HD)"GL7V+>'8@EO%*N/3T;;B9*"I.^6=&9>4[U]:2
M3!:D=P-SR>E#=JX< =4Y<XP><'_L"\J.DW%:PA61M7/Z*);7BUB-#7+SS4\T
M+H07D5LIBY71**G+RFW3&MG8@,7E<CO@?("A8W#B?'WW/E?,Q32]H?DIU&P(
M8!QA!8C(_[-;],0<@A3;@'%AD8=N*;K8=G,AVVX:#>"0]/B%42NV"*+:FQA0
MO2JBXN!@$?EDCS3RH79&:[QV<OWSD42.O#G65 5D+60S3 ?'H#'6.A&J=GUC
M[.0H4\-&W<G1Z?P=82"T[N.H&1Y%%\<6\'Z0LXJ'X=)[[:)0'0+Y*[0@U,H!
M'W0,"(Z=)J&F>#S&2? +D\"<)@@[%I1U?-!..QCD$!1"&UMLLQ0**/GA8:,I
M0P&:0NI[QA!3$8T-+!6ZZ4MXE5R9V,=IMJXRY3W%;W5/<6&M@)I1B;G]SEWI
M?)_S()]Y&<\341K- =7WO2E9?4Y"*8)3QFO%19":DR&_#_30#N(YT.WR-HFY
M%;KVNJ/L<DH$28V145;BL8^.\C2ST[L:3C"W!W<W5LTN#^-FE>5<%K2$WML;
MG(*!KGIQZ*POA\T,#Z&@Y]T\-#=O;++8].:I.IE\=V*M1S$V?V?FS%0DROBN
MNWW:%:X0YBR(5B$4P09B+B,1=H632[<IX=]Y<]8<#=<L_I#)7_D<?Y$Y$8OH
M#MXQ</R>>6F8.D$$EG7W_Y(:8. R72[/GH7LC#XBHX-.D'(\&=C!N<RS0@YA
MS@I1O!#,.I7<$&2G%S3A"KA'T,PA[V\1=6KU531$%5&0TW6;+HNR%(YW)0(\
M0Q]\VMB<.24;+W3H;IT' 1YR'H-:HNM(@F-U0Z32-+% Z4,8*<RM/MJ3V!2H
MX*@;4JJ2S8MO_>6KS[;@=*D1V6YW$L<I0WT(6./6F('MX.KPR)UR=_0QA%S2
M*/OJK3L%;J0O+B=(@.)X>6?]LJV6E'$06DX2+23H5^8I.H]06!;.6%T&Y:FP
MS]H^EKZA[>:9*KCOC@I?CV_']5]=UR_U0=<P\4ZDK0(G].$#'0Z<L*-,%;#R
M1SW'/G'FW<EO@,\?)7UO:/0N1&?'2^PXV>V.;B2HXFT2/R;>NM@K.._2MHS/
M:'YQIYK<8A.(=/OP5^IGX*]--/TW(K6RT#%"F-,A<M3]3M)&6SP)YV",WH<;
MHSJ-!@50>$I\58K\FQQIPXFCIUW6NW!P[%UK,$>VJ9A-WV,^9AR8B@ ?2&4R
M(?VW.\T5[J*&5"2Q9G-H*L5.86;[]!=I?/ASYJ6I3/7L"H:)M'2>YP289U5\
M.P>]_';_.>8O5H0K565K%N(YW7TI^0BB> "&V9%4CS ]Z>2S^G9/#-GF.@NU
M&)/JP6'$3QVN>V6[6TX@ T \KG@@LKU9N?&%\@,H.'I=EN GY$@"RDX-0PH5
M(F*@:4I;2IC(9:5JD!D)3&'7$Q:6%>6<$1RD^&AG5<^V=U#(3I4\>!0^%(_"
M/'.7JVIQA(:G[AGANE;'CHBF;@5GA131-S.4)6;KV&5AYI,Z:_VD'*6<&0U.
M1*0-[;95G(#^!,5"%>U,4 V T&#L'^^J+B6?Z28F@.DCB]-]DP5N3AF-3 *C
MD0GV Q9@&<#(6YD@N3X*?5]D$+0P='V'EWL],3=O:6+,3>"*!MQ"8M+]P$(^
M;!1Z]6NEL*0&.,!.01\RMO4#IQ:G[GPCMRK:0<5C&G+L^T#;/*@>/9_VA<T=
MGFU$[<O-:5/.=HJB$_"J[I5B^#]HP<4G ?B&.*3HE'5JQ@,0)$#18<NM/?_"
M31C1:_ZQ6R6R;I;\,] C2'#4W+-^&<=CW$CZ$27CBT@4B$".SF)E%(OH6A%Q
M,5P6B09]?PJSI^LHS$*/B<II53C=%=/;<+&34-3=\[]]S1_XCGRCG&6CRUGD
M/7BQY!(!O/E7R"?9B!+O6'+Z:YA=Y74S$LP4FL$B(CE? *S:5"1TC1>K607V
MB.2/E KG?PVS6A<3FMR"A:08Z<G;??STL RSXZ&O"YE60  $_OCIW<-[Y21T
MU#"K*^.L9Y[5H;$/52F[7@+J^BG@XZ;94(/6J48@<@CGMH-](8MEQD(:V:=A
M0F*PHQY3+XF_W2,@LHUHX91Q'Q7H+$+5X>B>[9/;6%R^;L($+Q:X"IW>(-3Q
MJ::(D)UO4.8*S^NI&'CY7 E6G-880GX--T>?PX &9[MOG!\#T'C.585G48QF
M :,74WE6+'Y)R2J)UP90L:?'<=@3S;VP<@U U27*JH:"!_X.1N,[[WL#SSH?
ML9=N)*6N\9U,]W+;^!X,^%K-N^.>7&^+]'&R6)6I+1*#.\'RY/=Y$/!K4O0W
M+!)\%:)NR$LR$UX2GLE01)P017S\XK#!)-&%/J6JXCR] K(MOGB9_.M/V)!L
M$=$_4R^Q@K)[%;[R!;@6(YAI*S/B*::P[UF*M<;!EA*S(QK_@>%D]0(IW>LL
MZ:A<BQ)LLWQ1\K'C5S((4ZK.B/?\<.%SJ7[&?, 9 18)9]6AISQ.,[K>L!CU
MF3,:T568V0;EN]0#$#7"!"52@8 "?2W00/A[I^C-K5N(UO4, .!!4'RV'ANX
M1=X)348;^C$8<CGNK3?=9]>(JU@_E3FRXG/^I*CQI-R PA;Z'/$+[?1GXH3&
MQRKKA<M6F,+B<]D]YAJ16OQ-*KQGPR)0VYD-9F,B)CT#!2PG76&2B@H3^NH_
MP=X9<"44)V7CR ^3FQ?W3Y0QB=MAP49"<@H'9*Q\LSY9UIJ]TI2K\R!D0N0T
M<TC=R%:A8%7FE#K+)57B:?MJL=*X-D:GD-N8A7ZGEZ=8\Y1CYQB#3$PZUEHP
MOM/C".1G^6\O9L>QD$#\@J]QE!00@FXZ9L2<# @$5YG<*(2@FSX2@E3?;+U:
M0!M/L_:3\#LQ"1%]A!U#^V@D+9)0 3P,C>='+$6EGVF:,BB7@"1GO*EH J5.
M_1RVGH.95UPOB',=VL:^TJ4]N[FG-&P8SCJT5^/MI7?\><ACNF/2> ES#YO3
M<(5 5_[TD35N5S@SN0B[&2(BHG.=S:H0K/7#<9LH=2D-J*Z038H>400=0C;9
MX)WURS;F*QH5\]O-AJ$R[C&(/U^Q^.4Z6@$*M&C(C:?A,A:+PB(@@5DN;_ @
M@N# !3'8()(/\-,)3M[4Q# [<](+;L" TU1*QC:G*S6GRU<Y(R0TIBO)IPLA
M>E.7/8"C+ Q"MLW"9R,,*$#V:'"5Q&NPL;="DL7JTDO 9YVJYEHG6R>%)"J#
M![,@7G%!@ UB\ %9UHJ3O"=73Z;)4#/&6D[6JCQ9\8"3=1\^1N$J]*&V2.1D
M@K\33'#.LVV\&&,PDH]&U'!3DU+MM<U2]11!;9]>UK5% NZ)6Y%.5IE$-T4A
M62[?D;ES#A/F,#)/^2:6/(<^K?:J?H4\*PR@8OTOV@[F[V#P?HVS/],LQ]X6
M,8RK.)%?P76=@J<P"(GBC.SX_"5ZG)F,7&!:39*/]6N=LK:N;,V@2@W ^?TJ
MY_?.F-_;?'[O^IC?KK%^H^E4RZ#^I]Z#^K'+QE@3FLB*U=HUL\7@>B3)*ZV:
MG79,R&[?Z]1A%C8:6_.$1M[R)5X^Q=N4LW)/GSE7E$8W<?0($WT=^?P+KKE"
M@;4%]'48CWSZ\>-OR<WR^M9AXF]OXC%3,CX648,1/1J!X7#=$CT@5MJ_!?E+
MEK.8AXS/0Z;F(=7SP& >H."&A'H>-GQD!^:RD-_WDRT-;NBCQ_C;G"OC5Y2F
M%CK82/K<Z'^4^"Q>KN^[B?(XDXL51;K1(ADF#)!WV,/&F6SE4GL%UXM9V\3#
MD%#V1,F#P.X@Z1/E>E6 2? K$C^P\-$3N@!?MUL!X?24Q-O')_ZO)Z^$N9)E
MF5C,;":+KS!;O&:1@"9,^:L0./0:W= TI;2FW9%*S';C@KW:9G"6?>$G^7J[
M%OY$8AR!DQ9:OC5BI!DI13H*K9]T^GNO$*S:FPJ]TI2=L/1>56KW7<S8E<"*
M<O/XS7$1W\M]EGQ_0E=XUVOE)3 JD</VYT\WCO_E"W_?9&L6RXK=IQ\__:CZ
MR/:KX[B33S[<@DXGAGAKDI:;Y)K:6R8DEFUQG>MMQU8\B=HBM;="95%'XZQ5
MU=-QE4Y&NEL?=;55F.6FH6YBEDNWI<VCWW#O&X#DRD'J,)6V?[G;^N_$H#,]
M![VJ %_IBQ'C2.*(?_2ID<0I_F_EX=]1GY:B'H4!IRNEC@>\U$LW3,ZJ@08B
M*A(,IUHW3/!2UP]1C-"+-]2F3 U]3"8J444[HD(?354K4_"N]MF#R+JL1NNA
MPY+VUF_(HIBLI72.5$LH;H+)XD<GGV^:SFN!(#JJEFH@3*S!H<B\"21N<O+*
M!ZGE7' U2,G9 ($Q.3G-7=5\J/<M'JI:V0ZM!]]/* ;0UM!"_.\RM4=UYX70
M#A=_'6[7Z36&5O'\[N RQ<'(.W.X]S =>D0T#]28,V*,.ME9J*S8R">#2[^1
MU*%.)<Q'F)'(1<9O0_J@/ ONP:\[: JJ9(0@)R-*0^UC@BJ<9:?.S=#IJ'U,
M5]N4U&+08JBT5%WA<AUMN+IR _T(/G7W*R(=\JD'Z"N+ LB%;A;="*(STI\\
MS0ZT_*\NV7]'0B@-CY3406RSJ#W-PC6^6?DCGIY$[?V=O>=O"FW$.>!CJ(89
M%/#1HK#:2=68M*H'[ OP$0_24E8:&AVW2=@-@D]XF#= 9NQLRV>SE^0F1+B=
M@@@EC42+XDE14I=/0[=^K [I*@ 6:,:T99@O H4=(E]$9,7RJV_C%!-B3]TL
M:X.[LQR11C,@"SL$"RHS%V[27+RU62KD1@6!("*F 5J>;11=_M<O%$Q"S+KQ
MY0Q!ILP@B9U=/<IF+J=?R.5\EU(*>=J4_,XA/I%%T5BU5 6:/7I4!>B2E2B&
MV&=ESVY!=_2"F+IVM6M8T'5>VFY+GD.AF' :SZ716^]J;:5)]A>91'>:65I\
M+22I$?+)"@SVT9A ^WA :X8ME/\#R37<5H4ML ORANFV09U<='&$7J?Y .Z!
M-XJF8MFD%-O[-MZFH#=X#+2&FSA-E2+P\=,7?L53ND@@<9PF J%NL;*B*+1*
MN,DY)#F+!'C4VM2,?/Q$!)\ SBPXG9$<3:\'M6MDT]S>Q)_,#!]L%UC7+5 F
M_M2CR,I?:&>C=,_$4Y2%E8<EW7C>Y25F-.?J5S=U:J.T6%;6C(E<?!P.'7?!
M7[<RXL4W@(8$I?EKV"'VJ'*1[B%% )LE?]M@0<+/0->EAUE6:N1(5J>6U!AJ
MKF-%UA[/%65 ,;=F$P71Y#BN:T4(5N3?(.BPRJ> JOL4LX#/I,ADMN'C-:G^
M\S_]^Z>/O_T/E;O\+J"KT ^S]PY]O/:$8OOR_(O*.Y]G61(^;#.,KV0QWP?1
M@>+2A[O7>43^<Q-&M%-)=KGWB/Q @##44XY<%#:4%(V-^N!UYFJ=EQSC JK-
MY]B6D8/!AE'!9??;G3T)&_;NMR2?7)/UK1918D7=H;>ETIKNH.TT&-".=!T,
MH-PF]'[#S\7NZ0R<$D%2H^24E9AT7=#4C=M2- JX3H&:RZ(DW7&^@\9N-)EW
MK*#?;Q]2KOL A"=4X'=:%#DM@L1Z<,LYP^[IU*P#S<\'&U@]\S68;LY]]^.9
M1F,C+ 12T\$Z%(QF;BJ<(%96E[NID[F.W/3(=DO.8>IA'_?3NG@6:\B$XH64
MB4%Z(K*P V+TT)KT0J;;+[U7 3C^.8G3T[W',G<?4A<$N1E!@F,78,^O1 (E
M"Z0C>$AY]$*8G8$ E:0/$43J<T=_<4L<,AM>GR.@P\@[;@-![\GT/?GYSH!D
M<)9!/NYI-$\><L#]?B;=[Z3"_:YC&<<\"^=9AR.?_'*.OZ%<%AT2Q1A(:ERW
MD0_!$_I K&(@+^7LO$0_!M]X#(#&Y=!BNJ,I?]5\< -<0.I[O%GG'06Z)3 H
MTN@0"'+B/7ALK$IEGE(%F0S2>:\$Q\:"7<D*6EWUTYJ(**S=\QD(RTJUMKDX
MH2/VGHZ$I4)J6QD*G:N#1/)1M8'DRF+R0/DQ%CI,.:O)Q%4NV6(F[FT2QHG=
M/-P[&FS]PXFX&Q@94W#[STIV.A>LPN%0S-Q6PY<SMY&!GO*V\YC4.87#F5U'
M 7W];VJC^::D2) DX31'S#[KFW/4$N_"]!=(G?X6^33)N)8$(7";L#A '\^,
MP@@3DH:9@LS+@FC<&_?UN"Z$*VGA-4^+[('ZN(*MK0T(-JHTE@*]2?]J=2]"
MU\1&]>9_G4=&M98WK];R)CX%9<3FM@_>H9EX_Q0GF0"D/AF-HQBEX?0^9 )Q
MV\"=<-TJW8(8S)1@69+ T<*[X)I01+%R"/.*^+H ,$G$\O[B9?Z3\GC('SLI
MI(J@<$,HBE.5+'>2PSC$I"5 004@NA;Z_"T(7=I!QB*\D1]9:NG4T3E:V<6I
M!R3/V@/!R-3D9\("\DYS0SK_;4I)K7W+6E8$JI.DS*[;<"[B\*9/(?_=F<+[
M^)0M5M]2V3MX\0 **0 'J&Z>5W&"KHU%CE-O(Z:" W^(5Q^V*96!)A++P6&*
MJ&HF*L#M80X-I'P'.;;]3P<S9@*QO;F,LB7[PIB)2W,F!+Z],;C[($>O<[)G
M+'59)0Y52D-K@OHGOG6(Y&FC/*O;JB@HEEAB!1N$S- V^CSV"_E<CQ9ST[&/
M98LJ,L<]*@6:19S\ OJ+MPFY+M\I:"PH$5^0&B6_9<B-(LNN'!#=>&;%Z3UW
M-;V=Z]HTY!??-K=K5>2VH7Y&@Y]BQLE F.#.RSI%OA1%\JQ)_JKF0ANTG>O[
M#!Q]@\L9T3.<,TJ TQ[ XLYV7_B9MDV0_:L$,V3]78?T8(,<T?3<9PJ?NFQ4
MB;( /S /G\_\WD[Z9UY6+,$ABI!RCT#_[<^(O;<GGT\)@C(OS.=G-_-9[EPR
M5\U+%A%UU8GFX^#]69Q(*9="H1_-/.])PX=ZFW*7=*"&![Q&^@Z-BKPWYV)E
MOH8RV1>2L=.];<%2VW1,DM_? =Z,L!4[744*?$_=T[OF#?XD"@:XT2EUDV4,
M7QE(_O/'QP0#<-?@$XW2T$>%8@3H"8)W8<TJS2J+\>M2IP4M ]%"N$9#G<R#
M*?A2Z^:I,-G4F&QP+;AML G3M^5,RK?YU&!B72TMD.ZAAM:!1.PM"5,3Z^U1
MJ)IBQ$Z86GNUB*[ALS[3B":B'VVP#J,0''J@=EA)9);$16O8 OD>'HMER<P@
MO"E7D7AOZ<RVI3,VN_JG-AEQ6-OGY$ZB1?+H1;(SR3D_GF,6!N)$Q]XDJ=JZ
M%JNK,/(B/_38/?]&XB9U<^";8R/^63ZZZM:BQ\=&QHH#DK/0CW>_H\YC*#<V
M@;OVVY"=@'P6F_KD@^Y1]N"Z>=>HYS1O=]9U1JGHA?9KG4X'UE'! !H,6ZXQ
M(["[$ZVVSL4]ZH,#R=@!H23Q/H0K1NHK _4U%3%='F>>K\(<M98:0$#U5%4"
M@D[.J,_-*-4"Y:5 [HO T5MF 1]15^,C00W3YUR3MB)' ?57RK$26A7F@Z9]
ME.-WD8 U/H1>H$27,:!\\!EC]"LT'^.F/ 64WF5<U5Q&KWB[G70,?L!;E2B.
MH+$?88 9S+^%SSX =6U%YQD2Z]>OEWX[8Y@T5CE?FAGR%3O= 3OD'3#T'GYN
MZ-V3[V ]]>[)CV6QIUYZ"2CH:7<=8^[[V_56N)\N!#)G+^J%#3FT1B$/&D7-
M=:BMJYJ-05Z9&9ZC%W2MPZ_#%=!H!")8[Z(IPHAFQ;0UK !I2+;V4#/>]"R6
MTTN'7%S:N!5)C[L+BH73G:*XDA0)!*W1,LU*_%ZXYO=+'-'=%R_YA697VRCH
MMC$C,2*H$20W%KS".6.Q+UV:.5R;*#)';?*F8YKN00@Y:>T&$D@5DS--R#C'
M2;S:\PN5%-!"HF.]7/$P$O49C),5U7^N,;YL2<%,]H%>7Z5_<O->QK?\BB>^
M:HP62=UU/'64+6.BZ!.S:])DA&+MY'&M_]D7K'3>*@&Y%;)1 OI&IZY>NS$5
M:[U@=Y1Y&WS[.MO!KLJW^2BSW[%=;."IWBK?@K!L7\YR,1MBB:JT'PS/<MM3
MC]Q+S_5"/.'AL#+Z4%9&\7\_B?ZVZ!I,^=D*28+>8[<4'E3-5>/<!"F3C2;]
MQF?"7AQ%S*-DBPB^9N36X43FV#37W$Q(T/5$+[S,L^#%E#@U!F$"E-TY!&T+
MPP:7XW;[P$+_BL5>1^8%(8*41LIPQ=)QR[45PU[%-(/K2-@I+4$Q>P)TW>NB
M-EH_4U\3:=T3I1D'E!P)B';$$_J5/PYG(*_Y@D<$/Y1A/,"OE9#J:5Y48$5M
MGS\F5&9BO839DP0<N>53M_9\NLU"WV.B.?LT9=6!AAHP^93D@_14&E$G;5>0
MA7H1^XAOM44C_<JG>/E"V3,5C5 [EJK]9OH2R>=W'-[J#"'8H6;-W00L*;=<
M$R_92> 'K'HTTK>Z>1HU==E>4/<P-_+OIB.;N2SW)3L3Z8,(G2^D?#\=T5A9
MJDLIE2R#74SQ>97S1/>?V:7(_)2/3JU.E^DU-EM?=TLM<MCN^JU.()OTW-TF
ML4]ID )N]'6:;F')7T><$X\) WNQ6O$WIMN^J 81Z-"A($\VPH"/Y0 3E)%5
MB:=&('((Y:A83%?.XOD-F5>;-D^4O+N^73@X[\"C=!-S^^3V*8ZH0&?HLCR1
M%D%B$NMAG#RS_M@]@#O?O>"E 57^3->RG+DNOK J7JY3- A75"Y&+QD[(-#H
M!:AMG0C='!Z<2]%--0'+</GD:15%(>18:6]A3V$!-DG&^<Q5%Q,TQV'SAY%.
MLW65</@9/MEE; 93A;/X8^?N55D2(MR#2*R0KET5&16;\=N<"?/]_37(:\9C
M;$;/;\<Z9S>GYC 6,G(ZAZ_Z263L?Y9LK:>>)HB/'*:+50F5?6>QOPZ.@$>(
M4;(_-8%829:<_$SWU]EK03/&=5T,KX*BT-VX+8,7[@7]89@W/!?VCI!%CIJJ
M>9HYM\"KG#I<-4UD(24FL K(#_X%Y3_B-W8]66)_D)6;(EU7PGS(,5WE)/<[
M"?4NRWNN+P#N)^0!<&TT"R&=<Z.G1.BANAZWMV#(3<C_$;@KN>AV U@L'T(*
M3#$H\NP6K,Z%H+7A+(.ZL:8= NS?+KH7"' B/:24G\PJZY/+ZNWA/']7BSN%
M]<W1&*F\44Y6Z,):,V1MLQ7.QHYEB167J<I>^YS$:<?JJ3+D=I\UEL//13M]
M\]<P$PZT3<$5Y"G>RCQ%Y,Q1:NCE:D4QC1USD"ZZ=G!0U&0#F\!);P%+C+,R
MSP+JYF+,/)<R9*OFVV7S2=CLGV(6\$<NE*FO<29T[_L-"S-Q&*6 ? T,=G)W
M7L4)>EZ$KIT"^>D*IK8)8YA_4<CL,-),6EDXV(SDPQ$<SVDON7A--4KCC:RX
MOH@A$;J3"B&@6C1EHDA/1!9V0 SRLZ#KJG[U2AF7,MOWBG:&--8D9\3+VS2N
MJ&S8)]H7XI_I%K#?4FAU#W5._%#*(,N8JWS$>\32>)JY2!.W)GEA(]&P60K"
M&60<,?.L7[X+VI2%]%&M!O:1+6HI/=3,5-E+1U'YKZ.7(D](*:>TNA9@OR4I
M-T8W7A@H_#=9)ZW:DHKNBZVEK&S#+D?0R-_&)N8:R\*QN!5@AC7-5]4<*%S.
MO/&J&-(YV&$_,\$Z34(?F 0'3=&TSA8]"=Z_$H]AL2)M(L'I@5"PZPX!@TT:
M*\V7<ED<L-O3 Y%AY_-E#S#ZM(C:_A%9[_-Y R#E728I/X%;3M$$4<='$Y8M
MX(N[S..^D';459CZ'H-RO"O^3;=D3$F2")JBQ@^ICEH$UC_W5>&/+UXF<RSQ
M[!<%FES%./<82^%<B9,LZP8S9CZL?#CA\.?4!69:Z!)T;"#!*X-?^;@S8HPL
M@?'XV&*C@XGI"8TMQ\%9K)1>>!W==42IR:F"0*'2-[F2F2BL 0 D#LB.K_C1
M2\:JA+HVA+IS@EAC68J2%ZOY$3ET?K>M$H?-</D2=RQW_]?)"B)7W4E5[GPX
MAZBC$GJ:KR"EZX1^I]"G@G#?Y+UE'H#HR&50@2\%Q0VM<>X%^V<38-_TB]3*
MX,SS81,!VA9NSAN%&7<!E]4&'>M7-3FF8685C'UR*%>6)[8U/CLVW!$OIJAM
MTBO092B_GS9D=S%C*Q')MPIR5VKN]C.,0V3*P#1\<8YFS;6?Y>"3Z &!2KCU
MK73GN;^_7-Z/E5/Y+ 617F96AE(J@S860& ;0G:^H.X\=.= 0E84KCX6Y[SY
ME7 U0_8NWWW@=51Z=C>%4L(_A4@7DD+X>ZY-G@E(4UR"4^.>%1Z"(#@SFIK>
MNY4#D8YI*EN!R<7]-8YTBS)N!7=+%!/TP97#!YA!,[1I2<-*@J@N99+Z^QDQ
M!YA!)S.7S6P@77]>K 7H7GVBJP!Z*W>P* AKEJ&'@A7=$/LZXF<XF@7SU[!C
M9A@W'W)R7#W@!%VJO@=29#NMKCS'=T8"FOI)N'&;*VI;&F8(<C#!UZ&^64)"
MR<%( )LDC^+<\XV(4?GW#A+1Y^LXR0"*!%I;8&5U1ZVU%1B*XH#_*KH]R69+
M@C_],^;D8]<EP:/HOS&QAO)@U%UU-X65FV6")F^'&7!KUO8VF2KV 2=;%.QO
M0C9LVIOK^=GUS?7R^O*>S+]>D,O_]]OU\L_3DTG%D7+RHN..V%1[\3/X?L*5
M;=6M3D&263"$)>42JCV73J5Z*PMY*L*QHER**LF!\)P;O[<)Z-C9[I83P(Y0
M?*%@U_J.:"-%6UB-HM<B#C$]J5A1'&Y0P@!%J89!4YE'61B$; ME;;G^\-5;
MT^Y522;M@G("Y*<C$FLAC<,"I6+!U=)[G6^SIQ@4M0Y&C;2: 6Q2DW-NU*@L
M=9 !G72GF_^ZTSU*(#U^D"$0K[ Z7NHI7,U]<9OJ:4,F,\0.,@1*.$#1=.VB
MM2) *4VC5P$L^BSZ=U7P$X$?V#>GH *4%HWR@P&M]]A9AFU1V[X%,PY>ABQ+
MPH=MALT2LQC<9!@;Y;HX7*8<:LZ+6#J(7)$--$8^F?VGXBIO4.:?<5L,D@7_
M&*89/PI\CW5Y-#D5D<<)<9JQ\Z\V )5JRPEBOB;)28Y=A'+F9J^B%$.PTOJP
M85^?%R*5OQ\YYTI5+(8@G9K/,AF';R>E5M\6<2Q[S35W( MK$J,?>\N5:'M-
M_(83<;_D<$^WY":UX6'"6CZ;C:,KK *TL4VO5J_=HON9B;I^X;I%=EJ>G/$V
M7"JCQ<]]OKZWZ*8[2A6K+&)W#!EO\(K7O_4Y[A6/O[_)O?+"!!'VOE /^E<*
M]4Q]^<>0)E[B/^TZ.9. G(#Q(YH@;E5?YS_UX$MJ7C_5JT;/@,7-:KM> U0H
MH$H7%DO*N7"K:HQ@)HYY;^I?%F,E]7FTU3204<5GZ1U-MPPR<*"0\C8)XT3@
MZ_%KNS;^:.C_H\OM]/"BHA(94!VBX98>>GH,,4,%[WL0"")B"L 5MU%T^5^_
MT B[,^/,N"FP;-I0KQ+ZMRV-_&[;J$&0:(JNP<)*N>30Z!C@O>X@K\."Q?NG
M<I_L0 Y $G=8B0YD8B5Q5 J[H@U@>VXSV%U)5K*YFA^8PZJ2?3@@7?YY[FW"
MS&-6/#!/D.N!$*DZK5*Z8U!C8;D9X] ]XT[6/")6!7>4%]3*87K)A:CI97YC
MHW]-;4/SGMJNV):-C4,LX>D'Y0S.<VGG\'4C%Q _=,\HU^>H#N/2E!]3T#'I
MU(KB0FQ!'/+YL"0?ESS@P"2/^8*6J09_$S-2[$,89AC!X\O!E8]2]L!);[T=
MJ-QR[2UC#!ONI>_)U/2NB*)J4+(1H^KTI2R6N+T/F()72'-2J4VN\$/[F0GE
M5U<S($<C=_D,B(AM1;+BI;/DKAXGH)3.=O(Z<+ , /#H/.:J3\<#&&F,.\U8
M9$/F90 I5IR!*TWFN4('/!HHC/OATFYEVJ;!J2R.0Z^:3LH5[.;@][^^*2\J
M1M6M+Y]QA%_?W!13,55SQWA%DM)$]9+M[""FW(_E8D\&N3\8!/L),:=)]I<O
MWFNXWJY/2Z\JKB1):H1\L@*#/:1_7= 5MTT"Q+Z +"#HP,5IR83NY(N7^4\*
M&T/]+A"Y%BO\L=-KP'<;+]J1VR1^#@-NX=][*TK^Z/%GE1!SR#<DO_:YX[@%
M*3$G>Z:2Z1.B!B]<-"-R?-@'\8H^HL<JP?^>)L^A3VL.#%'3Q3\M5G?:\RRV
M?JC@2JW'EU'%K5)45%%^S@:BKGB,*<UD+I!7P']T1S=Q(M40?G[EW1\P:FV8
ML0A_R(=)Z!.GCBUDG,8!1S/_%7JAUO=R+6&FICV00)'HK@(>L)8/_)%]!HA4
MN@&*WB6Y5><M("4L[Y;P%<Y35;O)8 +0*AET%TMNG:5]I'6?Q#H[-//N^/Y*
MLW,O?9)G4G"V^Y:"!BMBP7S>YM" "76?K@G3/A^&;%.Q\82*/O'T %,4DN7R
MP0CJ; _ 7GSW30C[GNB!R+P':?-]M+HRY_(5DJ)I(+R$Z\TVD[MH&;_0*GA_
M33D/4=R0*^%0U?S 3?L B'TB^ \Q?6S_V#\X<ZORS,4#S1SH)P+"Y8(S&3V*
MPUA@N^"/Q3;8M)/[X& K<*<^!.>BVG-.E3M]T[0/#Q1G=AU'.!5YPS>$7NAH
M0W&JJB^KGW>2 V1:AWNJ/6E809![(8C1$N_,K2!&DM<Y\](T7(5P(!IHD"9N
MAI/4,XU[P3^C =)3MOL04Z!#AWEN>#XFO+<F>F@!$*17XT%G#%U'_!!);^@S
M9;_ICJN$=,AO^H @LB> ?&1YGA^DN0%12)3M2QZN.G*%@NN,:XBJ=@K/IJA$
M:%ICY9E5L]MOE3Y&&(5B <W']9YOPMT!#$C,3CW/<ZW%/ %( ?].@ 3Q,28E
M8"EZG@OJ&V>V$C3,!4WY6*ZBY6XDK=9""V*FE6(ZQSOAFA]4LF)NAQVL$TE1
M9;$XQSFQ)T@5(DWFMA3GGC["&R \K& 4X)9ELS!0#$#T"!.3A=6(H7;YB8E3
M I)U_W!$56,5=N0BFJ?"BL!L&&/#0X/"#;3D@INA*='#DF5</-5P:(?:4L_3
M4:[]K)N6=PAW1;ST@Z^G)HN+!P3:J^_?SMRT@5,E[W#!?#BP8-Z[G0PY>LB-
M*V<XLL88/>*Q.I2RO!.\.0'KWFW?$'2C!<5WV&&E02TN&C>/5EMV$ZXZ@IY7
M [UILRN 0 T?B# ^TJ3$+**A&T+2'/>-3EY*5A2P!M].T"<WCJ4S7[Z+$,)?
M40#E/K<TN> ZO)>(:'BG>*XDBQ4^,P"X_Q @Z0\>TIZ@>/H1%C;/&=&BWJ&H
M?)0/8I@/<\>B5B&3=89)KH&-ZR/MV*8\E<D%.=J:PW3&/=>%Q _\>[?H63&0
M(MT5GB8]"7DJ0RG2P31W* IDX"\3#W#%[G?KA[@3>I<D1 2E$3++^N%S/_R^
M#[;L"+8E+[AL4FO1*5N%@/\.LAO],'-@M[B?%+8_'^80&I"ZAV 4:O<Z]0^8
MN.57/7DI!>U&)@DO5ORAZ'A[ER6@49R%0;Z18Y$-IJ6N94YR+,<#G<-)O+P'
MJ5E)8+&>U3"H.Q*5@ZU&<I8?T(.\)5ONI ?MP+B#=/EEF#'L&1V FK?UV)_"
M[ EKV"!%XRG<+./+*(/0<V<T:!Q*],16@TU2)E8K3@_ /??;AQ1A+K++9_Z_
M);^G PIT3HT@.0+T^H>!QK(EFQH]$AR[ (4V(T# <3.N0NJ\J+GF!LABQ:7H
MDDI;S,AW"\EK4X12(<P$16!5W)< AR4D.J<^VX,:OO5ZZ(]X2EVC3I[A;]=V
M+;(%[\+TEZN$4@6(#-Z(3L6>G-Z'%2?(U6S92<X-O,YH9T.= =T3.@T(,H/'
M&0$N 9:):AAK="(Y#=:;M?BG!NJ-W:V,.* S#IS7GEB2I0$W8.R\LP./H+_&
M;B60P!R)\G/"M]DB2*# -#EF.Z^$*BT!_CGM3=2KM)6(+6];5JVJM@!Z-&%.
MD8<R].-,P?EP1AR&&?B-T-?F%..B$/("6]YMNY\NK+(2E^[[>FK'60T,5GJV
M*_QBL^2I%B(K)6>[TJ\]EC4YG(D*;V+]),Q S>EI%BK]%%U?MN$\+!W>O4H_
MBN.W4"..09UVY(<L1)57?RT+J25DZSR[H@%-/ :5Z=LL3G;Y_:?KW9>K%?4S
MPV0#!P9"8A:9(EY&Y/A$,U"^1U5XO]$I,Q>Y' $!!403<Y%%"_.4ZOE9R1ES
M:],9L4.^7RP2A"X(T!(ZM?]\?4QTXR7D&4A/2AY6$$7&1#EQPA^?("\M1UT7
MZB;D*#R^?Z*,_7<4OT3WU$OCB :8=W^J[U'0)$#TPR] E2BRHG#"@0O2NBB%
M"%0N#_GO?N1I5;\Z]_^V#2T@8LM0O JX#%6.VT4<I=!@Y$A6YX@19(!LIJN/
MS6%Z]6=:KS+H$_3%E3P-SMIA&K_F9N5G+XQ@4A>141;:Q6EF6*Q 6R'4\OW?
M&,"Y \VR@.P(V28C5(T7YA$E8TJR% NB,RB(#OL0TAT@XF=. EHPN .+?(01
MIHD6V6UR[(436H*7"G9' 5Z:ULUYY<R6.A(H%(Q;OIPZF0M[G18498*D4</&
MQ,H<F63XU3K<U!VQ8-.VB";E-3DC!QZ*0T]W-["@[CGREF""WM@,,:N3X\[O
M@VEQ"%+FA<%5+(L*4M' &,#*ED]F.Y_%Z@9:9AC0M%: >@'"#-H'"_A(P0)X
M?<0<2<#(M=$$B,\2PRX>;K%]!YL=9DS,K9H8.3JY+DW,E^+$( _%7IBNF^\,
M,46E;$L[:Z@Y_7*>^(4I\1)?<<P_'F!:7O$#N%7I)OL@'K&\';8!T^LS#P(^
MW^DY_[A(EO%+I)]%W'@93N(/O3-> :6JW-X%AW#1J5S,(#<EM$%OH*G('\[E
M*T:=0HEFS-6$ZH>X?]W 3U%G(D$3+6X=;I/\+:UZ2DW7#RS*5_HB\TK .9?$
M$?_H"UUOD8@"C.O(O()O&.&&"?2M*ED[$1S+<S7 JCZ*LN7&Q[I_^6BV&0FP
M4MMBN7E3.73W0&+6]A"?1P$<<V X/WL,OC'E.^*V@9^?:O]T#F])LJM?@I47
M#LQ\383T:QQQ/6/K8Q&7C)+>T91"RU_^ "[@[8FQ0+I*T,Y$AWXCJP,AN'WP
M+1-_22M?QC8W#BQ<]8S+QR%\^56BM;AM\-.Q$I_Z2H&7YZC13<?_\50&%ANX
M+6V(N9L7?N!/K/B%<:58G^4VE<*>Y\+R#Z@$@'8J=-:J*>N7@Z'W!IL9\?#Z
MP)R8B B5^XKK0<>WA@%5L.+T;]2%3B SI%+$E_[:BS@[V.5S3_DI_CR@ 3CG
M4Q9@^VOF/9:MOL*/4WTWC^Q)AC%@_6I9?6$[<3+P]%<WE82<5'Y:YFTXJN:K
MY:T#"R@?5'H5)W<U@I0NF>H+H2!?R^ B5M=ZW2!#3]I^M;*HD*X4ON[B@870
M'< AV^+<2Y+=*DZP?56M,^C +:,1"/3#.XA/+E9<-\=:YF9Q*FX8>B.)^2:.
M@ KX?HCDX$:SI/F.H3T@>Z7EM4L)LV>Y4G83^QZK$O146@-/P0WES-+BFE.>
MN-VW* A3/.!HP T:?JF(*U7)?Q*A@84O!YE+68=58AZX97@?2=%\+5D5U=_6
M>_ZZT!OZ-%2-#6O/C>(5HSHF](O3K'T>O&E(*[$6Y4>H3?H;2,R9I[+1I_=(
MH==H\@O-_O_NKJRY;21)O^^?V6EOQ#YM3(0.RZT=V51(='?,O$%D440W"'
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M=%%A%3Y]_/3]QP^Q]1;XP>[P ??\\ C_^5HP1O'GPG>N_=B-#[?^.H !,,9
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M7$5I$I![_'\L B^6A\D"?./0M6.PB^$7@'+U!Z666?"XOE#7;[E7&?ZRQ2D
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M#0^L\KO:*U463QYM@R_BM7G&*^$]#AS-A8KNAZ\^G\1P?YL'CF3?^MG=)AS
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M2/V$*HB:$80&_<]U^H%%W3!MG%'/PD?*^%/BG^PX&>'E1=C]C^793I/]\8_
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M<HPQ_%[@ &X0>0<(P[&7=YHX<C;#=C<=3-GGUC)/5P\6AB-).D61P"B4ZYG
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M\534H>$.03E\)Z*(I7H$=72YR(%42)T;_I125T3K.\(@17NT2@<BGDWPL2/
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ME-V=0WZ#R'9&-?F'<,Y-#Q[ZP6*(6/+T\&&>7H8("D\/(O;Y:(CB7=/#B/,
M-D0)KQ)8U%A!_@O\GV<K0O_^_P%02P,$%     @ %()B5MG*Q7J5 @  @0T
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M@ 0( Y0O3Z>EME?2:G>?1[NR3'MH8WGP!VD/.67PD[2ML)(?='^6&[7VEK^
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M]QJJ?/#^FUY#EQW^'U!+ 0(4 Q0    ( !2"8E9L]9LA.P4! *8K 0 0
M          "  0    !I;6<X-C$Y.#,V7S N:G!G4$L! A0#%     @ %()B
M5FI3!'6;]0  *' ! !               ( !:04! &EM9S@V,3DX,S9?,2YJ
M<&=02P$"% ,4    "  4@F)6V[XZ ! 3 0 XI@$ $               @ $R
M^P$ :6UG.#8Q.3@S-E\R+FIP9U!+ 0(4 Q0    ( !2"8E;4Q_CSH/,  -<6
M 0 0              "  7 . P!I;6<X-C$Y.#,V7S,N:G!G4$L! A0#%
M  @ %()B5F6,][AT:@$ WP(" !               ( !/@($ &EM9S@V,3DX
M,S9?-"YJ<&=02P$"% ,4    "  4@F)6S?58?O94 0!FL@$ $
M    @ '@; 4 :6UG.#8Q.3@S-E\U+FIP9U!+ 0(4 Q0    ( !2"8E;:C!*9
M@$ " (B& @ 0              "  03"!@!I;6<X-C$Y.#,V7S8N:G!G4$L!
M A0#%     @ %()B5LCO(JZI5 $ "<0! !               ( !L@() &EM
M9S@V,3DX,S9?-RYJ<&=02P$"% ,4    "  4@F)68VH', 0# 0 O(@$ $
M            @ &)5PH :6UG.#8Q.3@S-E\X+FIP9U!+ 0(4 Q0    ( !2"
M8E9L]9LA.P4! *8K 0 0              "  ;M:"P!I;6<X-C$Y.#,V7SDN
M:G!G4$L! A0#%     @ %()B5F4= _^]Z , '"TT !$              ( !
M)& , &QB<&@M,C R,C$R,S$N:'1M4$L! A0#%     @ %()B5E]XP*=?$@
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M,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ %()B5N,B.$Z91@  J6D% !4
M             ( !N"@1 &QB<&@M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0
M   ( !2"8E;9RL5ZE0(  ($-   /              "  81O$0!L8G!H+65X
M,C-?,2YH=&U02P$"% ,4    "  4@F)6ZQW=6$8)   ]5P  #P
M    @ %&<A$ ;&)P:"UE>#,Q7S$N:'1M4$L! A0#%     @ %()B5C-YR]Q&
M"0  2E<   \              ( !N7L1 &QB<&@M97@S,5\R+FAT;5!+ 0(4
M Q0    ( !2"8E:!7&TVRP8  'U8   /              "  2R%$0!L8G!H
A+65X,S)?,2YH=&U02P4&     !0 % #J!   )(P1

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
